TREA

COMPOSITIONS AND METHODS FOR REPROGRAMMING DISEASED MUSCULOSKELETAL CELLS

Follow

Information

  • Patent Application
  • 20220118109
  • Publication Number
    20220118109
  • Date Filed
    December 19, 2019
    5 years ago
  • Date Published
    April 21, 2022
    2 years ago
Information
Abstract
Disclosed herein are compositions and methods for reprogramming diseased musculoskeletal cells both in vitro and in vivo. In some embodiments, the disclosed method involves non-virally delivering intracellularly into the diseased musculoskeletal cells a polynucleotide comprising one or more nucleic acid sequences encoding one or more of the disclosed transcription factors.
Description
SEQUENCE LISTING

This application contains a sequence listing filed in electronic form as an ASCII.txt file entitled “321501_2380_Sequence_Listing_ST25” created on Dec. 18, 2019. The content of the sequence listing is incorporated herein in its entirety.


BACKGROUND

Current therapies for musculoskeletal diseases, such as low back pain, are highly invasive and is a major contributor to the growing opioid crisis. Additionally, these therapies only treat the symptomatic pain of the patient while failing to target the underlying pathology of disease which leads to further disease progression and future pain. For example, lumbar fusion of the spine is a common surgical operation to fuse the spine in place of the intervertebral disc space between the vertebras. However, removal of the disc and fusion of the vertebrae often results in adjacent segment disease due to imbalanced biomechanics of the spine post-surgery. In addition, micro-discectomies which remove the diseased tissue from the site often lead to tissue collapse and additional surgical intervention with added pain. Therefore, new treatment methods of such diseases are needed to alleviate these issues.


Current studies in the field include engineered intervertebral discs, cell therapies, drug delivery, growth factors, viral reprogramming or gene editing. However, these all include their pitfalls and risks. Engineered constructs for replacement of musculoskeletal components are disadvantageous in their biocompatibility and most importantly mechanical integrity in the body environment to function effectively. Cell therapies are poor in terms of long-term cell viability due to the harsh avascular environment of tissues such as the intervertebral disc. Drug delivery systems are hard to sustain in the environment and has potential to leech onto nearby tissue with undesired effects similar to growth factors such as Bone morphogenic proteins (BMPs) and Tumor Growth Factor (TGFβ). Viral reprogramming and gene editing have large regulatory burdens as they often involve integration into the native host genome which has been shown in history to cause adverse immunogenic and mutagenic effects on the patients. The death of Jesse Gelsinger is one such example.


SUMMARY

Disclosed herein are compositions and methods for reprogramming diseased musculoskeletal cells both in vitro and in vivo.


In some embodiments, the disclosed method involves non-virally delivering intracellularly into the diseased musculoskeletal cells a polynucleotide comprising one or more nucleic acid sequences encoding one or more transcription factors, such as HIF-1α, FOX, T, SOX, and Mohawk families of transcription factors, including the factors listed in Tables 1A, 1B, and 1C.


For example, in some embodiments, the method involves reprogramming a diseased nucleus pulposus (NP) cell into a healthy cell by non-virally delivering intracellularly into the NP cell one or more transcription factor proteins selected from the group comprising HIF-1α, HIF-2α, Hedgehog family (SHH, DHH, IHH), a T-box family of proteins (TBXT, TBR1, TBX1-6, TBX10, TBX15, TX618-22), and a Forkhead-box (FOX) family of proteins (FOXF1, FOXA1-3, FOXB1-2, FOXC1-2, FOXD1-6, FOXE1-3, FOXG1, FOXH1, FOXI1, FOXJ1, FOXK1, FOXL1-2, FOXM1, FOXN1-4, FOXO1, FOXO3-4, FOXO6, FOXP1-4, FOXQ1, FOXR1-2), or polynucleotides encoding the one or more transcription factor proteins; or exposing the NP cell to an extracellular vesicle produced from a cell containing or expressing the one or more transcription factor proteins, or polynucleotides encoding the one or more transcription factor proteins.


In some embodiments, the method involves reprogramming a diseased annulus fibrosis (AF) cell into a healthy cell by non-virally delivering intracellularly into the AF cell one or more transcription factor proteins selected from the group comprising a Iroquois Homeobox family of proteins (Mohawk, IRX1-6), Tenomodulin and Scleraxis, or polynucleotides encoding the one or more transcription factor proteins; or exposing the AF cell to an extracellular vesicle produced from a cell containing or expressing the one or more transcription factor proteins, or polynucleotides encoding the one or more transcription factor proteins.


In some embodiments, the method involves reprogramming a diseased cartilage endplate cell into a healthy cell by non-virally delivering intracellularly into the cartilage endplate cell one or more transcription factor proteins selected from the group comprising an NFAT Family proteins (NFATc1-4), ERG (C-1-1), PGC1α, Osterix, SOX family of proteins (SRY, SOX1-15, SOX17-18, SOX21, SOX30) and MEF2C, or polynucleotides encoding the one or more transcription factor proteins; or exposing the cartilage endplate cell to an extracellular vesicle produced from a cell containing or expressing the one or more transcription factor proteins, or polynucleotides encoding the one or more transcription factor protein.


Also disclosed herein is a method for treating a musculoskeletal disease in a subject that involves non-virally delivering intracellularly into disease musculoskeletal cells of the subject one or more transcription factor proteins selected from the group comprising HIF-1a, HIF-2a, a T-box family protein, and Forkhead-box (FOX) family protein, a Iroquois family proteins, Tenomodulin, Scleraxis, NFAT Family proteins, ERG, PGC1a, Osterix, Runx family of proteins, Hedgehog family of proteins, SOX family of proteins and MEF2C, or polynucleotides encoding the one or more transcription factor proteins; or exposing the disease musculoskeletal cells to an extracellular vesicle produced from a cell containing or expressing the one or more transcription factor proteins, or polynucleotides encoding the one or more transcription factor proteins.


In some embodiments, the musculoskeletal disease is osteoarthritis where chondrocytes, synoviocytes, fibrocartilage cells of the meniscus, osteoblasts, osteocytes and osteoclasts will be subject to non-viral reprogramming. In some embodiments, the musculoskeletal disease is intervertebral disc degeneration and chronic low back pain where notochordal cells, nucleus pulposus cells, annulus fibrosus cells, cartilage endplate cells, ligamentous cells, dorsal root ganglion cells and myocytes/myofibroblasts will be subject to non-viral reprogramming or injection of engineered vesicles. In some embodiments, the musculoskeletal disease is tendinopathy or rotator cuff tendonitis where tenocytes and myocytes/myofibroblasts will be subject to non-viral reprogramming or injection of engineered vesicles.


In some embodiments, the disclosed methods involve non-viral tissue nanotransfection (TNT) of notochordal cells, nucleus pulposus (NP), annulus fibrosis (AF), or cartilage endplate cells of a subject's intervertebral disc (IVD) or chondrocytes, synoviocytes, fibrocartilage cells of the meniscus, ligamentous cells, dorsal root ganglion cells, osteoblasts, osteoclasts, osteocytes, myocytes/myofibroblasts, haemapoetic and mesenchymal stem cells or tenocytes. This can be done via direct tissue nanotransfection of the NP, AF, and CEP tissue with previously stated transcription factors during patient surgery, or on cells isolated from patients. More precisely, the tissue nanotransfection device chip will be placed at the site of the IVD where degeneration is occurring and transcription factors targeting the specific tissue will be delivered in-situ. More precisely, cells from the patient IVD can be isolated and transfected ex-vivo with transcription factors and injected back into the patient.


In some embodiments, the disclosed methods involve delivery of extracellular vesicles (EVs) to the notochordal cells, nucleus pulposus (NP), annulus fibrosis (AF), or cartilage endplate cells of a subject's intervertebral disc (IVD) or chondrocytes, synoviocytes, fibrocartilage cells of the meniscus, ligamentous cells, dorsal root ganglion cells, osteoblasts, osteoclasts, osteocytes, myocytes/myofibroblasts, or tenocytes. EVs will be generated using the patient's cells which encapsulates the desired transcription factors specific for each tissue. EVs containing these factors are then injected back into the diseased/degenerate tissue and up taken by the patients cells within 4-6 hours of cell-vector contact.


Also disclosed herein are polynucleotides comprising one, two, or more nucleic acid sequences encoding transcription factors disclosed herein, such as Forkhead-box (FOX) family protein, Iroquois I family proteins, Scleraxis, NFAT Family proteins, ERG, PGC1a, Osterix, and MEF2C. In some embodiments, the transcription factors are mammalian proteins, such as human proteins.


Also disclosed a composition comprising a polynucleotide comprising one, two, or more nucleic acid sequences encoding transcription factors disclosed herein. Also disclosed are non-viral vectors containing the disclosed polynucleotides. In particular embodiments, the vector is a recombinant bacterial plasmid. For example, in some embodiments, the non-viral vector has a pCDNA3 backbone. In some embodiments, the vector comprises an internal ribosome entry site (IRES).


In some embodiments, after transfecting target cells with nucleic acid sequences encoding the disclosed transcription factors, the cells can then pack the transfected genes (e.g. cDNA) into EVs, which can then reprogram diseased musculoskeletal cells. Therefore, also disclosed is a method of reprogramming diseased musculoskeletal cells that involves exposing the cells with an extracellular vesicle produced from a cell containing or expressing the disclosed transcription factors.


In these embodiments, the polynucleotides and compositions may be delivered to diseased musculoskeletal cells, or donor cells, intracellularly via a gene gun, a microparticle or nanoparticle suitable for such delivery, transfection by electroporation, three-dimensional nanochannel electroporation, a tissue nanotransfection device, a liposome suitable for such delivery, or a deep-topical tissue nanoelectroinjection device. In some of these embodiments, the polynucleotides can be incorporated into a non-viral vector, such as a bacterial plasmid. In some embodiments, a viral vector can be used. For example, the polynucleotides can be incorporated into a viral vector, such as an adenoviral vector. However, in other embodiments, the polynucleotides are not delivered virally.


The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.





DESCRIPTION OF DRAWINGS


FIGS. 1A and 1B illustrate an embodiment the disclosed technology to use the combination of transcription factor and TNT/Evs to revert diseased intervertebral disc cells to a healthy phenotype. We have shown promising in-vitro cellular work, in-vivo rodent models, and have submitted grants to move to a large scale in-vivo canine model and larger animal trials in the future clinically relevant to the human condition. Remaining claims will focus on our current in-vitro and in-vivo work



FIG. 2 is a schematic of DNA bulk electroporation into NP cells then seeded in Agarose Gel.



FIG. 3 is a graph showing qPCR Gene expression data validating that the transcription factor was successfully transmitted. X-axis=type of tissue and transcription factor. Colors indicate the gene being tested for.



FIG. 4 contains representative viability images (4× Stitched) of Gels at day 0 and 4 Weeks. (Green=Live, Red=Dead).



FIGS. 5A and 5B are graphs showing Brachyury T expression in autopsy (FIG. 5A) and surgical (FIG. 5B) nucleus pulposus cells after sham or FOXF1 treatment.



FIGS. 5C and 5D are graphs showing FOXF1 (FIG. 5C) and KRT19 (FIG. 5D) expression in healthy nucleus pulposus cells after sham or FOXF1 treatment.



FIGS. 6A and 6B are graphs showing ACAN (FIG. 6A) and COL2 (FIG. 6B) expression in healthy nucleus pulposus cells after sham or FOXF1 treatment.



FIGS. 7A and 7B are graphs showing NGF expression in autopsy (FIG. 7A) and surgical (FIG. 7B) nucleus pulposus cells after sham or FOXF1 treatment.



FIGS. 8A and 8B are graphs showing IL1-8 expression in autopsy (FIG. 8A) and surgical (FIG. 8B) nucleus pulposus cells after sham or FOXF1 treatment. FIG. 8C is a graph showing IL6 expression in nucleus pulposus cells after sham or FOXF1 treatment of surgical tissue.



FIGS. 9A and 9B are graphs showing MMP12 expression in autopsy (FIG. 9A) and surgical (FIG. 9B) nucleus pulposus cells after sham or FOXF1 treatment. FIGS. 9C and 9D are graphs showing MMP13 expression in autopsy (FIG. 9C) and surgical (FIG. 9D) nucleus pulposus cells after sham or FOXF1 treatment.



FIGS. 10A and 10B are bar graphs showing GAG content in autopsy (FIG. 10A) and surgical (FIG. 10B) nucleus pulposus cells after sham or FOXF1 treatment.



FIGS. 11A and 11B are bar graphs showing KRT19 gene expression at day 0, week 2, and week 4 of BrachT transfected groups normalized to SHAM for non-degenerate (ND, FIG. 11A) and painful-degeneration (PD, FIG. 11B) groups. * p<0.05.



FIGS. 12A and 12B are bar graphs showing ACAN gene expression at day 0, week 2, and week 4 of BrachT transfected groups normalized to SHAM for non-degenerate (ND, FIG. 12A) and painful-degeneration (PD, FIG. 12B) groups. * p<0.05.



FIGS. 13A and 13B are bar graphs showing MMP13 gene expression at day 0, week 2, and week 4 of BrachT transfected groups normalized to SHAM for non-degenerate (ND, FIG. 13A) and painful-degeneration (PD, FIG. 13B) groups. * p<0.05.



FIGS. 14A and 14B are bar graphs showing IL1-8 gene expression at day 0, week 2, and week 4 of BrachT transfected groups normalized to SHAM for non-degenerate (ND, FIG. 14A) and painful-degeneration (PD, FIG. 14B) groups. * p<0.05.



FIGS. 15A and 15B are bar graphs showing IL6 gene expression at day 0, week 2, and week 4 of BrachT transfected groups normalized to SHAM for non-degenerate (ND, FIG. 15A) and painful-degeneration (PD, FIG. 15B) groups. * p<0.05.



FIGS. 16A and 16B are bar graphs showing NGF gene expression at day 0, week 2, and week 4 of BrachT transfected groups normalized to SHAM for non-degenerate (ND, FIG. 16A) and painful-degeneration (PD, FIG. 16B) groups. * p<0.05.



FIGS. 17A and 17B are bar graphs showing GAG normalized to DNA for non-degenerate (FIG. 17A) and painful-degenerate (FIG. 17B) cells for SHAM compared to BrachT transfected groups. * p<0.05, ** p<0.005.



FIGS. 18A to 18C show successful EV generation. FIG. 18A shows FOXF1 upregulation in transfected cells. FIG. 18B shows particle count of FOXF1- and PCMV6-loaded EVs. FIG. 18C shows FOXF1 levels in generated EVs.



FIGS. 19A to 19C show successful EV uptake by cells.



FIG. 20 shows EV delivery in in-vivo lumbar disc puncture mouse model with upregulation of healthy markers. FIG. 20 is a bar graph showing gene expression for FOXF1 and Brachyury.



FIG. 21 shows Control (no injury), Injury SHAM, Empty vector injections and FOXF1 injections on Mouse in Vivo showing effects of treatment on mice gripping time indicative of axial strength.





DETAILED DESCRIPTION

Before the present disclosure is described in greater detail, it is to be understood that this disclosure is not limited to particular embodiments described, and as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present disclosure will be limited only by the appended claims.


Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the disclosure. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also encompassed within the disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure.


Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present disclosure, the preferred methods and materials are now described.


All publications and patents cited in this specification are herein incorporated by reference as if each individual publication or patent were specifically and individually indicated to be incorporated by reference and are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present disclosure is not entitled to antedate such publication by virtue of prior disclosure. Further, the dates of publication provided could be different from the actual publication dates that may need to be independently confirmed.


As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present disclosure. Any recited method can be carried out in the order of events recited or in any other order that is logically possible.


Embodiments of the present disclosure will employ, unless otherwise indicated, techniques of chemistry, biology, and the like, which are within the skill of the art.


The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to perform the methods and use the probes disclosed and claimed herein. Efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, temperature, etc.), but some errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, temperature is in ° C., and pressure is at or near atmospheric. Standard temperature and pressure are defined as 20° C. and 1 atmosphere.


Before the embodiments of the present disclosure are described in detail, it is to be understood that, unless otherwise indicated, the present disclosure is not limited to particular materials, reagents, reaction materials, manufacturing processes, or the like, as such can vary. It is also to be understood that the terminology used herein is for purposes of describing particular embodiments only, and is not intended to be limiting. It is also possible in the present disclosure that steps can be executed in different sequence where this is logically possible.


It must be noted that, as used in the specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise.


The term “subject” refers to any individual who is the target of administration or treatment. The subject can be a vertebrate, for example, a mammal. Thus, the subject can be a human or veterinary patient. The term “patient” refers to a subject under the treatment of a clinician, e.g., physician or veterinarian.


The term “therapeutically effective” refers to the amount of the composition used is of sufficient quantity to ameliorate one or more causes or symptoms of a disease or disorder. Such amelioration only requires a reduction or alteration, not necessarily elimination.


The term “pharmaceutically acceptable” refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problems or complications commensurate with a reasonable benefit/risk ratio.


The term “carrier” means a compound, composition, substance, or structure that, when in combination with a compound or composition, aids or facilitates preparation, storage, administration, delivery, effectiveness, selectivity, or any other feature of the compound or composition for its intended use or purpose. For example, a carrier can be selected to minimize any degradation of the active ingredient and to minimize any adverse side effects in the subject.


The term “treatment” refers to the medical management of a patient with the intent to cure, ameliorate, stabilize, or prevent a disease, pathological condition, or disorder. This term includes active treatment, that is, treatment directed specifically toward the improvement of a disease, pathological condition, or disorder, and also includes causal treatment, that is, treatment directed toward removal of the cause of the associated disease, pathological condition, or disorder. In addition, this term includes palliative treatment, that is, treatment designed for the relief of symptoms rather than the curing of the disease, pathological condition, or disorder; preventative treatment, that is, treatment directed to minimizing or partially or completely inhibiting the development of the associated disease, pathological condition, or disorder; and supportive treatment, that is, treatment employed to supplement another specific therapy directed toward the improvement of the associated disease, pathological condition, or disorder.


The term “inhibit” refers to a decrease in an activity, response, condition, disease, or other biological parameter. This can include but is not limited to the complete ablation of the activity, response, condition, or disease. This may also include, for example, a 10% reduction in the activity, response, condition, or disease as compared to the native or control level. Thus, the reduction can be a 10, 20, 30, 40, 50, 60, 70, 80, 90, 100%, or any amount of reduction in between as compared to native or control levels.


The term “polypeptide” refers to amino acids joined to each other by peptide bonds or modified peptide bonds, e.g., peptide isosteres, etc. and may contain modified amino acids other than the 20 gene-encoded amino acids. The polypeptides can be modified by either natural processes, such as post-translational processing, or by chemical modification techniques which are well known in the art. Modifications can occur anywhere in the polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. The same type of modification can be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide can have many types of modifications. Modifications include, without limitation, acetylation, acylation, ADP-ribosylation, amidation, covalent cross-linking or cyclization, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of a phosphytidylinositol, disulfide bond formation, demethylation, formation of cysteine or pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristolyation, oxidation, pergylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, and transfer-RNA mediated addition of amino acids to protein such as arginylation. (See Proteins—Structure and Molecular Properties 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993); Posttranslational Covalent Modification of Proteins, B. C. Johnson, Ed., Academic Press, New York, pp. 1-12 (1983)).


As used herein, the term “amino acid sequence” refers to a list of abbreviations, letters, characters or words representing amino acid residues. The amino acid abbreviations used herein are conventional one letter codes for the amino acids and are expressed as follows: A, alanine; B, asparagine or aspartic acid; C, cysteine; D aspartic acid; E, glutamate, glutamic acid; F, phenylalanine; G, glycine; H histidine; I isoleucine; K, lysine; L, leucine; M, methionine; N, asparagine; P, proline; Q, glutamine; R, arginine; S, serine; T, threonine; V, valine; W, tryptophan; Y, tyrosine; Z, glutamine or glutamic acid.


The phrase “nucleic acid” as used herein refers to a naturally occurring or synthetic oligonucleotide or polynucleotide, whether DNA or RNA or DNA-RNA hybrid, single-stranded or double-stranded, sense or antisense, which is capable of hybridization to a complementary nucleic acid by Watson-Crick base-pairing. Nucleic acids can also include nucleotide analogs (e.g., BrdU), and non-phosphodiester internucleoside linkages (e.g., peptide nucleic acid (PNA) or thiodiester linkages). In particular, nucleic acids can include, without limitation, DNA, RNA, cDNA, gDNA, ssDNA, dsDNA or any combination thereof.


A “nucleotide” as used herein is a molecule that contains a base moiety, a sugar moiety, and a phosphate moiety. Nucleotides can be linked together through their phosphate moieties and sugar moieties creating an internucleoside linkage. The term “oligonucleotide” is sometimes used to refer to a molecule that contains two or more nucleotides linked together. The base moiety of a nucleotide can be adenine-9-yl (A), cytosine-1-yl (C), guanine-9-yl (G), uracil-1-yl (U), and thymin-1-yl (T). The sugar moiety of a nucleotide is a ribose or a deoxyribose. The phosphate moiety of a nucleotide is pentavalent phosphate. A non-limiting example of a nucleotide would be 3′-AMP (3′-adenosine monophosphate) or 5′-GMP (5′-guanosine monophosphate).


A nucleotide analog is a nucleotide that contains some type of modification to the base, sugar, and/or phosphate moieties. Modifications to nucleotides are well known in the art and would include, for example, 5-methylcytosine (5-me-C), 5 hydroxymethyl cytosine, xanthine, hypoxanthine, and 2-aminoadenine as well as modifications at the sugar or phosphate moieties.


Nucleotide substitutes are molecules having similar functional properties to nucleotides, but which do not contain a phosphate moiety, such as peptide nucleic acid (PNA). Nucleotide substitutes are molecules that will recognize nucleic acids in a Watson-Crick or Hoogsteen manner, but are linked together through a moiety other than a phosphate moiety. Nucleotide substitutes are able to conform to a double helix type structure when interacting with the appropriate target nucleic acid.


The term “vector” or “construct” refers to a nucleic acid sequence capable of transporting into a cell another nucleic acid to which the vector sequence has been linked. The term “expression vector” includes any vector, (e.g., a plasmid, cosmid or phage chromosome) containing a gene construct in a form suitable for expression by a cell (e.g., linked to a transcriptional control element). “Plasmid” and “vector” are used interchangeably, as a plasmid is a commonly used form of vector. Moreover, the invention is intended to include other vectors which serve equivalent functions.


The term “operably linked to” refers to the functional relationship of a nucleic acid with another nucleic acid sequence. Promoters, enhancers, transcriptional and translational stop sites, and other signal sequences are examples of nucleic acid sequences operably linked to other sequences. For example, operable linkage of DNA to a transcriptional control element refers to the physical and functional relationship between the DNA and promoter such that the transcription of such DNA is initiated from the promoter by an RNA polymerase that specifically recognizes, binds to and transcribes the DNA.


For purposes herein, the % sequence identity of a given nucleotides or amino acids sequence C to, with, or against a given nucleic acid sequence D (which can alternatively be phrased as a given sequence C that has or comprises a certain % sequence identity to, with, or against a given sequence D) is calculated as follows:





100 times the fraction W/Z,


where W is the number of nucleotides or amino acids scored as identical matches by the sequence alignment program in that program's alignment of C and D, and where Z is the total number of nucleotides or amino acids in D. It will be appreciated that where the length of sequence C is not equal to the length of sequence D, the % sequence identity of C to D will not equal the % sequence identity of D to C. Alignment for purposes of determining percent sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN, ALIGN-2 or Megalign (DNASTAR) software.


By “specifically hybridizes” is meant that a probe, primer, or oligonucleotide recognizes and physically interacts (that is, base-pairs) with a substantially complementary nucleic acid (for example, a c-met nucleic acid) under high stringency conditions, and does not substantially base pair with other nucleic acids.


The term “stringent hybridization conditions” as used herein mean that hybridization will generally occur if there is at least 95% and preferably at least 97% sequence identity between the probe and the target sequence. Examples of stringent hybridization conditions are overnight incubation in a solution comprising 50% formamide, 5×SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5×Denhardt's solution, 10% dextran sulfate, and 20 μg/ml denatured, sheared carrier DNA such as salmon sperm DNA, followed by washing the hybridization support in 0.1×SSC at approximately 65° C. Other hybridization and wash conditions are well known and are exemplified in Sambrook et al, Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y. (1989), particularly chapter 11.


Compositions


Disclosed are polynucleotides comprising nucleic acid sequences encoding transcription factors that can be used to reprogram diseased musculoskeletal cells according to the disclosed methods. Examples of these transcription factors are provided in Tables 1A, 1B, 1C, 1D, 1E, 1F, 1G, and 1H.









TABLE 1A







Notochordal and Nucleus Pulposus (NP) Transcription Factors








Transcription Factors
Description/Relevance to NP





HIF-1α/2α
hypoxia-inducible factor-1α:



“Transactivate many pro-survival genes



in NP; absolutely necessary for postnatal



NP cell survival”



Strong driver of glycolytic metabolism in the



avascular IVD environment



upregulates: GLUT1/3, GAPDH, Aggrecan, B-1,



3-glucuronyltransferase 1, galectin-3



Suppresses expression of: ANK (pyrophosphate



transporter)



Mice model of HIF-1 knockout has been shown to



promote cell death with fibrous NP



involved in pathogenesis of OA


Shh (Wnt Shh
Sonic hedgehog:


signaling) pathways)
“Signaling ligand necessary for postnatal



function of NP cells”



Increases expression of Brachyury T and aggrecan



Member of the hedgehog family including DHH



and IHH


T Family (Brachyury,
T-box Family transcription factor:


etc)
“Transcription factor necessary for



notochordal morphogenesis and



patterning”


PAX1
Paired Box Protein 1


FOX Family (FOXF1,
Critical to formation of Intervertebral disc NP


FOXA1, A2, ect)



SOX Family (SOX9,
Chondrogenic markers:


SOX5, SOX6, etc.)
SOX9 shown to increase expression of COLII post



adenoviral transfection in NP tissue.



SOX5 and SOX6 have been shown to be critical



in ECM sheath formation, notochord cell survival,



and nucleus pulposus formation


NOTO
Notochord Homeobox



regulates notochord development (precursor to



NP)
















TABLE 1B







Annulus Fibrosus Transcription Factors








Transcription Factors
Description/Relevance to AF





Mohawk Family
Homeobox protein:



Key transcription factor regulating AF



development shown in humans and mice


Scleraxis
Part of basic helix-loop-helix (bHLH) super family



required in musculoskeletal tissue maturation such



as AF, ligaments, and tendons.


Tenomodulin
highly expressed in AF cells compared to NP



Cells


PAX9
Paired Box gene 9
















TABLE 1C







Cartilage Endplate/Articular Cartilage Transcription Factors








Transcription Factors
Description/Relevance to CEP





NFAT Family (Nfat1,
Nucleated factor of activate T-Cells Family:


ect)
Nfat1 deficiency causes OA


C-1-1
ets transcription factor:



involved in AC development



Note: Runx2 expression has been known to affect



C-1-1 vs versa


PGC1α
regulates chondrogenesis with SOX9


Osterix
required for calcification and degradation of



cartilage matrixes (More for bone formation)


MEF2C
MEF2C is regulated by SOX9 in positive feedback



loop



Prevents hypertrophy



stabilizes chondrogenic phenotype


SOX Family
important for chondrocyte phenotype


Nkx3-2
Maintains sox9 expression
















TABLE 1D







Osteocytes, Osteoclasts, Osteoblast Transcription Factors









Description/Relevance to Osteocytes, Osteoclasts,


Transcription Factors
Osteoblasts





RUNX2
Runt-related transcription factor 2 for osteoblast



differentiation


Foxc1
Associated with endochondral ossification and



osteoblast differentiation


AP1 Complex (Fos,
Responsible for cell proliferation, differentiation,


FosB, Fra1, Fra2, Jun,
apoptosis, ect and essential roles bone


JunB, JunD)
development


Zfp36
Regulates HSP70 family proteins to protect



against Osteoarthritis


Ebf1, Ebf3
Regulates osteoblast and adipocyte lineages


Maf
Promotes age-associated osteoblast differentiation


Mef2c
Controls chondrocyte hypertrophy and bone



development


Nupr1
Increase bone volume


Twist1/2, Dermo-1
Malfunctions in these genes cause inhibitory



effects on osteoblast proliferation/differentiation


Maged1
Overexpression in bone


Satb2
Regulates osteoblast differentiation


LMP-3
Induces osteogenic differentiation of fibroblasts


Oct3/4, Sox2, Klf4,
Yamanaka factor


c-Myc



Osterix (Sp7)
Main Osteoblast-specific transcription factor


Dlx3, Dlx5, Dlx6
Co-activates RUNX2


C/EBPs, ATF4
Lack of transcription factor in-vivo mice results in



delayed skeletal development and decreased bone



formation


NFATc
Bone deficiency in absence of gene and involved



in chondrogenesis


Smads
Part of TGF-B/BMP signal transduction pathway


Menin
Enhances Runx2 transcriptional activity


Msx1, Msx2
Important roles in skeletal development


NF-1
Osteoclast differentiation


Krox20 and SP3
Involved in endochondral ossification and



osteoblast differentiation


Ob-1
Highly expressed during osteoblast differentiation
















TABLE 1E







Tenocyte and Ligament Transcription Factors










Transcription
Description/Relevance to Tenocyte/Tendon and



Factors
Ligaments







Egr1,2
Tendon development, healing, and differentiation



Scleraxis, Mkx
Generation of tendon progenitors



Six1/2, Eya1/2
Muscle transcription factors involved in tendon




regeneration



Pea3
Induces scleraxis expression



Mohawk
Crucial for tendon/ligament homeostasis

















TABLE 1F







Synoviocyte Transcription Factors








Transcription Factors
Description/Relevance to Synoviocytes/Synovium





SOX4, 5, 11
Promotes migration and invasion of synoviocytes


NFAT5
Regulation of proinflammatory genes


BCL-6
Master Transcription factor involved in immunity


HIF-1α, 2α
Synoviocyte differentiation
















TABLE 1G







Monocytes and Myofibroblasts









Description/Relevance to Monocytes and


Transcription Factors
Myofibroblasts





MyoD
Myoblast determination protein


Myf5
Key role in regulation of myogenesis


Myogenin
Induction of myogenesis


PU.1
Important for macrophage and monocyte



development


M-CSFR Pathway
Important for monocyte development


Regulatios



C/EBPα
Directs monocyte differentiation


SRF
Critical for myofibroblast activation


GLI2
Profibrotic secretion factor
















TABLE 1H







Dorsal Root Ganglion Transcription Factors








Transcription Factors
Description/Relevance to DRG





FoxO
Upregualated in uninjured rodent DRG model


Sp4
Predominantly expressed in neurons


ATF2, 3
Potential regeneration and downregulated in



injured DRG


Etv4, Etv5
Expressed in DRG development


Sox11
Promotes nerve regeneration


Rest
Repressor element 1—silencing transcription



factors regulators neuron remodeling


Runx1, 3
Axonal Growth









The amino acid and nucleic acid sequences encoding Forkhead-box (FOX) family proteins, a Mohawk family proteins, Scleraxis, NFAT Family proteins, C-1-1, PGC1α, Osterix, and MEF2C are known in the art.


In some embodiments, Forkhead box F1 (FOXF1) comprises the amino acid sequence:









(SEQ ID NO: 1; NP_001442.2)


MSSAPEKQQPPHGGGGGGGGGGGAAMDPASSGPSKAKKTNAGIRRPEKPP





YSYIALIVMAIQSSPTKRLTLSEIYQFLQSRFPFFRGSYQGWKNSVRHNL





SLNECFIKLPKGLGRPGKGHYWTIDPASEFMFEEGSFRRRPRGFRRKCQA





LKPMYSMMNGLGFNHLPDTYGFQGSAGGLSCPPNSLALEGGLGMMNGHLP





GNVDGMALPSHSVPHLPSNGGHSYMGGCGGAAAGEYPHHDSSVPASPLLP





TGAGGVMEPHAVYSGSAAAWPPSASAALNSGASYIKQQPLSPCNPAANPL





SGSLSTHSLEQPYLHQNSHNAPAELQGIPRYHSQSPSMCDRKEFVFSFNA





MASSSMHSAGGGSYYHQQVTYQDIKPCVM,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:1).


In some embodiments, the nucleic acid sequence encoding FOXF1 comprises the nucleic acid sequence:









(SEQ ID NO: 2; NM_001451)


ATGTCTTCGGCGCCCGAGAAGCAGCAGCCACCGCACGGCGGCGGCGGCGG





CGGCGGCGGGGGAGGCGGCGCGGCCATGGACCCCGCGTCGTCCGGCCCGT





CCAAGGCCAAGAAGACCAACGCCGGCATCCGGCGCCCGGAGAAGCCGCCC





TATTCCTACATCGCGCTCATCGTCATGGCCATCCAGAGTTCACCCACCAA





GCGCCTGACGCTGAGCGAGATCTACCAGTTCCTGCAGAGCCGCTTCCCCT





TCTTCCGGGGCTCCTACCAGGGCTGGAAGAACTCCGTGCGCCACAACCTC





TCGCTCAACGAGTGCTTCATCAAGCTACCCAAGGGCCTTGGGCGGCCCGG





CAAGGGCCACTACTGGACCATCGACCCGGCCAGCGAGTTCATGTTCGAGG





AGGGCTCCTTTCGGCGGCGGCCGCGCGGCTTCCGAAGGAAATGCCAGGCG





CTCAAGCCCATGTACAGCATGATGAACGGGCTCGGCTTCAACCACCTCCC





GGACACCTACGGCTTCCAGGGCTCGGCCGGCGGCCTCTCGTGCCCGCCCA





ACAGCCTGGCGCTGGAGGGCGGCCTGGGCATGATGAACGGCCACTTGCCG





GGCAACGTGGACGGCATGGCCCTGCCCAGCCACTCGGTGCCCCACCTGCC





TTCCAACGGCGGCCACTCGTACATGGGCGGCTGCGGCGGCGCGGCGGCCG





GCGAGTACCCGCACCACGACAGCTCGGTGCCCGCCTCCCCGCTGCTGCCC





ACCGGCGCCGGTGGGGTCATGGAGCCGCACGCCGTCTACTCGGGCTCGGC





GGCGGCCTGGCCGCCCTCGGCGTCCGCGGCGCTCAACAGCGGCGCCTCTT





ATATCAAGCAGCAGCCCCTGTCCCCCTGTAACCCCGCGGCCAACCCCCTG





TCCGGCAGCCTCTCCACGCACTCCCTGGAGCAGCCGTATCTGCACCAGAA





CAGCCACAACGCCCCAGCCGAGCTGCAAGGCATCCCGCGGTATCACTCGC





AGTCGCCCAGCATGTGTGACCGAAAGGAGTTTGTCTTCTCTTTCAACGCC





ATGGCGTCCTCTTCCATGCACTCGGCCGGCGGGGGCTCCTACTACCACCA





GCAGGTCACCTACCAAGACATCAAGCCTTGCGTGATG,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:2 under stringent hybridization conditions.


In some embodiments, Forkhead Box A1 (FOXA1) comprises the amino acid sequence









(SEQ ID NO: 3; NP_004487)


MLGTVKMEGHETSDWNSYYADTQEAYSSVPVSNMNSGLGSMNSMNTYMTM





NTMTTSGNMTPASFNMSYANPGLGAGLSPGAVAGMPGGSAGAMNSMTAAG





VTAMGTALSPSGMGAMGAQQAASMNGLGPYAAAMNPCMSPMAYAPSNLGR





SRAGGGGDAKTFKRSYPHAKPPYSYISLITMAIQQAPSKMLTLSEIYQWI





MDLFPYYRQNQQRWQNSIRHSLSFNDCFVKVARSPDKPGKGSYVVTLHPD





SGNMFENGCYLRRQKRFKCEKQPGAGGGGGSGSGGSGAKGGPESRKDPSG





ASNPSADSPLHRGVHGKTGQLEGAPAPGPAASPQTLDHSGATATGGASEL





KTPASSTAPPISSGPGALASVPASHPAHGLAPHESQLHLKGDPHYSFNHP





FSINNLMSSSEQQHKLDFKAYEQALQYSPYGSTLPASLPLGSASVTTRSP





IEPSALEPAYYQGVYSRPVLNTS,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:3.


In some embodiments, the nucleic acid sequence encoding FOXA1 comprises the nucleic acid sequence









(SEQ ID NO: 4; NM_004496)


ATGTTAGGAACTGTGAAGATGGAAGGGCATGAAACCAGCGACTGGAACAG





CTACTACGCAGACACGCAGGAGGCCTACTCCTCCGTCCCGGTCAGCAACA





TGAACTCAGGCCTGGGCTCCATGAACTCCATGAACACCTACATGACCATG





AACACCATGACTACGAGCGGCAACATGACCCCGGCGTCCTTCAACATGTC





CTATGCCAACCCGGGCCTAGGGGCCGGCCTGAGTCCCGGCGCAGTAGCCG





GCATGCCGGGGGGCTCGGCGGGCGCCATGAACAGCATGACTGCGGCCGGC





GTGACGGCCATGGGTACGGCGCTGAGCCCGAGCGGCATGGGCGCCATGGG





TGCGCAGCAGGCGGCCTCCATGAATGGCCTGGGCCCCTACGCGGCCGCCA





TGAACCCGTGCATGAGCCCCATGGCGTACGCGCCGTCCAACCTGGGCCGC





AGCCGCGCGGGCGGCGGCGGCGACGCCAAGACGTTCAAGCGCAGCTACCC





GCACGCCAAGCCGCCCTACTCGTACATCTCGCTCATCACCATGGCCATCC





AGCAGGCGCCCAGCAAGATGCTCACGCTGAGCGAGATCTACCAGTGGATC





ATGGACCTCTTCCCCTATTACCGGCAGAACCAGCAGCGCTGGCAGAACTC





CATCCGCCACTCGCTGTCCTTCAATGACTGCTTCGTCAAGGTGGCACGCT





CCCCGGACAAGCCGGGCAAGGGCTCCTACTGGACGCTGCACCCGGACTCC





GGCAACATGTTCGAGAACGGCTGCTACTTGCGCCGCCAGAAGCGCTTCAA





GTGCGAGAAGCAGCCGGGGGCCGGCGGCGGGGGCGGGAGCGGAAGCGGGG





GCAGCGGCGCCAAGGGCGGCCCTGAGAGCCGCAAGGACCCCTCTGGCGCC





TCTAACCCCAGCGCCGACTCGCCCCTCCATCGGGGTGTGCACGGGAAGAC





CGGCCAGCTAGAGGGCGCGCCGGCCCCCGGGCCCGCCGCCAGCCCCCAGA





CTCTGGACCACAGTGGGGCGACGGCGACAGGGGGCGCCTCGGAGTTGAAG





ACTCCAGCCTCCTCAACTGCGCCCCCCATAAGCTCCGGGCCCGGGGCGCT





GGCCTCTGTGCCCGCCTCTCACCCGGCACACGGCTTGGCACCCCACGAGT





CCCAGCTGCACCTGAAAGGGGACCCCCACTACTCCTTCAACCACCCGTTC





TCCATCAACAACCTCATGTCCTCCTCGGAGCAGCAGCATAAGCTGGACTT





CAAGGCATACGAACAGGCACTGCAATACTCGCCTTACGGCTCTACGTTGC





CCGCCAGCCTGCCTCTAGGCAGCGCCTCGGTGACCACCAGGAGCCCCATC





GAGCCCTCAGCCCTGGAGCCGGCGTACTACCAAGGTGTGTATTCCAGACC





CGTCCTAAACACTTCC,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:4 under stringent hybridization conditions.


In some embodiments, Forkhead box A2 (FOXA2) comprises the amino acid sequence









(SEQ ID NO: 5; NP_710141)


MLGAVKMEGHEPSDWSSYYAEPEGYSSVSNMNAGLGMNGMNTYMSMSAAA





MGSGSGNMSAGSMNMSSYVGAGMSPSLAGMSPGAGAMAGMGGSAGAAGVA





GMGPHLSPSLSPLGGQAAGAMGGLAPYANMNSMSPMYGQAGLSRARDPKT





YRRSYTHAKPPYSYISLITMAIQQSPNKMLTLSEIYQWIMDLFPFYRQNQ





QRWQNSIRHSLSFNDCFLKVPRSPDKPGKGSFVVTLHPDSGNMFENGCYL





RRQKRFKCEKQLALKEAAGAAGSGKKAAAGAQASQAQLGEAAGPASETPA





GTESPHSSASPCQEHKRGGLGELKGTPAAALSPPEPAPSPGQQQQAAAHL





LGPPHHPGLPPEAHLKPEHHYAFNHPFSINNLMSSEQQHHHSHHHHQPHK





MDLKAYEQVMHYPGYGSPMPGSLAMGPVTNKTGLDASPLAADTSYYQGVY





SRPIMNSS,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:5.


In some embodiments, the nucleic acid sequence encoding FOXA2 comprises the nucleic acid sequence:









(SEQ ID NO: 6; NM_153675)


ATGCTGGGAGCGGTGAAGATGGAAGGGCACGAGCCGTCCGACTGGAGCAG





CTACTATGCAGAGCCCGAGGGCTACTCCTCCGTGAGCAACATGAACGCCG





GCCTGGGGATGAACGGCATGAACACGTACATGAGCATGTCGGCGGCCGCC





ATGGGCAGCGGCTCGGGCAACATGAGCGCGGGCTCCATGAACATGTCGTC





GTACGTGGGCGCTGGCATGAGCCCGTCCCTGGCGGGGATGTCCCCCGGCG





CGGGCGCCATGGCGGGCATGGGCGGCTCGGCCGGGGCGGCTGGCGTGGCG





GGCATGGGGCCGCACTTGAGTCCCAGCCTGAGCCCGCTCGGGGGGCAGGC





GGCCGGGGCCATGGGCGGCCTGGCCCCCTACGCCAACATGAACTCCATGA





GCCCCATGTACGGGCAGGCGGGCCTGAGCCGCGCCCGCGACCCCAAGACC





TACAGGCGCAGCTACACGCACGCAAAGCCGCCCTACTCGTACATCTCGCT





CATCACCATGGCCATCCAGCAGAGCCCCAACAAGATGCTGACGCTGAGCG





AGATCTACCAGTGGATCATGGACCTCTTCCCCTTCTACCGGCAGAACCAG





CAGCGCTGGCAGAACTCCATCCGCCACTCGCTCTCCTTCAACGACTGTTT





CCTGAAGGTGCCCCGCTCGCCCGACAAGCCCGGCAAGGGCTCCTTCTGGA





CCCTGCACCCTGACTCGGGCAACATGTTCGAGAACGGCTGCTACCTGCGC





CGCCAGAAGCGCTTCAAGTGCGAGAAGCAGCTGGCGCTGAAGGAGGCCGC





AGGCGCCGCCGGCAGCGGCAAGAAGGCGGCCGCCGGGGCCCAGGCCTCAC





AGGCTCAACTCGGGGAGGCCGCCGGGCCGGCCTCCGAGACTCCGGCGGGC





ACCGAGTCGCCTCACTCGAGCGCCTCCCCGTGCCAGGAGCACAAGCGAGG





GGGCCTGGGAGAGCTGAAGGGGACGCCGGCTGCGGCGCTGAGCCCCCCAG





AGCCGGCGCCCTCTCCCGGGCAGCAGCAGCAGGCCGCGGCCCACCTGCTG





GGCCCGCCCCACCACCCGGGCCTGCCGCCTGAGGCCCACCTGAAGCCGGA





ACACCACTACGCCTTCAACCACCCGTTCTCCATCAACAACCTCATGTCCT





CGGAGCAGCAGCACCACCACAGCCACCACCACCACCAGCCCCACAAAATG





GACCTCAAGGCCTACGAACAGGTGATGCACTACCCCGGCTACGGTTCCCC





CATGCCTGGCAGCTTGGCCATGGGCCCGGTCACGAACAAAACGGGCCTGG





ACGCCTCGCCCCTGGCCGCAGATACCTCCTACTACCAGGGGGTGTACTCC





CGGCCCATTATGAACTCCTCT,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:6 under stringent hybridization conditions.


In some embodiments, Forkhead box A3 (FOXA3) comprises the amino acid sequence:









(SEQ ID NO: 7, NP_004488)


MLGSVKMEAHDLAEWSYYPEAGEVYSPVTPVPTMAPLNSYMTLNPLSSP





YPPGGLPASPLPSGPLAPPAPAAPLGPTFPGLGVSGGSSSSGYGAPGPG





LVHGKEMPKGYRRPLAHAKPPYSYISLITMAIQQAPGKMLTLSEIYQWI





MDLFPYYRENQQRWQNSIRHSLSFNDCFVKVARSPDKPGKGSYWALHPS





SGNMFENGCYLRRQKRFKLEEKVKKGGSGAATTTRNGTGSAASTTTPAA





TVTSPPQPPPPAPEPEAQGGEDVGALDCGSPASSTPYFTGLELPGELKL





DAPYNFNHPFSINNLMSEQTPAPPKLDVGFGGYGAEGGEPGVYYQGLYS





RSLLNAS,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:7.


In some embodiments, the nucleic acid sequence encoding FOXA3 comprises the nucleic acid sequence:









(SEQ ID NO: 8; NM_004497)


ATGCTGGGCTCAGTGAAGATGGAGGCCCATGACCTGGCCGAGTGGAGCTA





CTACCCGGAGGCGGGCGAGGTCTACTCGCCGGTGACCCCAGTGCCCACCA





TGGCCCCCCTCAACTCCTACATGACCCTGAATCCTCTAAGCTCTCCCTAT





CCCCCTGGGGGGCTCCCTGCCTCCCCACTGCCCTCAGGACCCCTGGCACC





CCCAGCACCTGCAGCCCCCCTGGGGCCCACTTTCCCAGGCCTGGGTGTCA





GCGGTGGCAGCAGCAGCTCCGGGTACGGGGCCCCGGGTCCTGGGCTGGTG





CACGGGAAGGAGATGCCGAAGGGGTATCGGCGGCCCCTGGCACACGCCAA





GCCACCGTATTCCTATATCTCACTCATCACCATGGCCATCCAGCAGGCGC





CGGGCAAGATGCTGACCTTGAGTGAAATCTACCAGTGGATCATGGACCTC





TTCCCTTACTACCGGGAGAATCAGCAGCGCTGGCAGAACTCCATTCGCCA





CTCGCTGTCTTTCAACGACTGCTTCGTCAAGGTGGCGCGTTCCCCAGACA





AGCCTGGCAAGGGCTCCTACTGGGCCCTACACCCCAGCTCAGGGAACATG





TTTGAGAATGGCTGCTACCTGCGCCGCCAGAAACGCTTCAAGCTGGAGGA





GAAGGTGAAAAAAGGGGGCAGCGGGGCTGCCACCACCACCAGGAACGGGA





CAGGGTCTGCTGCCTCGACCACCACCCCCGCGGCCACAGTCACCTCCCCG





CCCCAGCCCCCGCCTCCAGCCCCTGAGCCTGAGGCCCAGGGCGGGGAAGA





TGTGGGGGCTCTGGACTGTGGCTCACCCGCTTCCTCCACACCCTATTTCA





CTGGCCTGGAGCTCCCAGGGGAGCTGAAGCTGGACGCGCCCTACAACTTC





AACCACCCTTTCTCCATCAACAACCTAATGTCAGAACAGACACCAGCACC





TCCCAAACTGGACGTGGGGTTTGGGGGCTACGGGGCTGAAGGTGGGGAGC





CTGGAGTCTACTACCAGGGCCTCTATTCCCGCTCTTTGCTTAATGCATC





C,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:8 under stringent hybridization conditions.


In some embodiments, Forkhead box B1 (FOXB1) comprises the amino acid sequence:









(SEQ ID NO: 10; NM_012182)


ATGCCTCGGCCCGGCCGCAACACGTACAGCGACCAGAAGCCGCCCTACTC





GTACATCTCGCTGACCGCTATGGCCATCCAGAGCTCTCCCGAGAAGATGC





TGCCGCTGAGCGAGATCTACAAGTTCATCATGGACCGCTTCCCCTACTAC





AGGGAGAACACGCAGCGCTGGCAGAACAGTCTGCGCCACAACCTCTCCTT





CAACGACTGCTTCATCAAGATCCCGCGGCGGCCGGACCAGCCAGGCAAGG





GCAGCTTCTGGGCGCTGCACCCAAGCTGCGGGGACATGTTCGAGAACGGC





AGCTTCCTGCGGCGCCGCAAGCGCTTCAAGGTGCTTAAGTCCGACCACCT





GGCGCCCAGCAAGCCAGCCGACGCGGCGCAGTACCTGCAGCAGCAGGCCA





AGCTGCGGCTCAGCGCGCTGGCGGCCTCGGGCACGCACCTGCCACAGATG





CCCGCCGCCGCCTACAACTTGGGCGGCGTGGCGCAGCCCTCGGGCTTCAA





GCACCCCTTCGCCATCGAGAACATCATCGCGCGGGAATACAAGATGCCTG





GGGGGCTGGCCTTCTCCGCCATGCAGCCGGTGCCCGCTGCCTACCCGCTC





CCCAACCAGTTGACTACCATGGGCAGCTCGCTGGGCACCGGCTGGCCACA





CGTGTATGGCTCCGCCGGCATGATCGACTCGGCCACCCCCATCTCCATGG





CGAGTGGCGACTACAGCGCCTACGGCGTGCCGTTGAAGCCGCTGTGCCAC





GCGGCGGGCCAAACGCTGCCCGCCATCCCCGTGCCCATTAAGCCCACGCC





GGCCGCCGTGCCCGCGCTGCCTGCGCTGCCAGCGCCCATCCCCACCTTGC





TCTCGAACTCGCCGCCCTCGCTCAGCCCCACGTCCTCGCAAACAGCCACC





AGCCAAAGCAGCCCCGCCACCCCCAGCGAAACGCTCACCAGCCCGGCCTC





CGCCTTGCACTCGGTGGCGGTGCAC,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:9.


In some embodiments, the nucleic acid sequence encoding FOXB1 comprises the nucleic acid sequence:









(SEQ ID NO: 9; NP_036314)


MPRPGRNTYSDQKPPYSYISLTAMAIQSSPEKMLPLSEIYKFIMDRFPYY





RENTQRWQNSLRHNLSFNDCFIKIPRRPDQPGKGSFWALHPSCGDMFENG





SFLRRRKRFKVLKSDHLAPSKPADAAQYLQQQAKLRLSALAASGTHLPQM





PAAAYNLGGVAQPSGFKHPFAIENIIAREYKMPGGLAFSAMQPVPAAYPL





PNQLTTMGSSLGTGWPHVYGSAGMIDSATPISMASGDYSAYGVPLKPLCH





AAGQTLPAIPVPIKPTPAAVPALPALPAPIPTLLSNSPPSLSPTSSQTAT





SQSSPATPSETLTSPASALHSVAVH,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:10 under stringent hybridization conditions.


In some embodiments, Forkhead box B2 (FOXB2) comprises the amino acid sequence:









(SEQ ID NO: 11; NP_001013757)


MPRPGKSSYSDQKPPYSYISLTAMAIQHSAEKMLPLSDIYKFIMERFPYY





REHTQRWQNSLRHNLSFNDCFIKIPRRPDQPGKGSFWALHPDCGDMFENG





SFLRRRKRFKVLRADHTHLHAGSTKSAPGAGPGGHLHPHHHHHPHHHHHH





HAAAHHHHHHHPPQPPPPPPPPPPHMVHYFHQQPPTAPQPPPHLPSQPPQ





QPPQQSQPQQPSHPGKMQEAAAVAAAAAAAAAAAVGSVGRLSQFPPYGLG





SAAAAAAAAAASTSGFKHPFAIENIIGRDYKGVLQAGGLPLASVMHHLGY





PVPGQLGNVVSSVWPHVGVMDSVAAAAAAAAAAGVPVGPEYGAFGVPVKS





LCHSASQSLPAMPVPIKPTPALPPVSALQPGLTVPAASQQPPAPSTVCSA





AAASPVASLLEPTAPTSAESKGGSLHSVLVHS,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:11.


In some embodiments, the nucleic acid sequence encoding FOXB2 comprises the nucleic acid sequence









(SEQ ID NO:12; NM_001013735)


ATGCCTCGGCCCGGCAAGTCATCTTATTCTGATCAAAAGCCACCCTACTC





ATATATTAGCCTCACAGCGATGGCTATACAGCATTCAGCTGAGAAGATGT





TGCCTCTCTCCGACATCTACAAATCATCATGGAGCGGTTCCCCTACTACC





GCGAACACACCCAGCGGTGGCAGAACTCACTTAGACACAACCTGAGCTTC





AATGATTGTTTTATTAAGATTCCCAGGAGGCCGGACCAGCCAGGCAAGGG





TTCATTCTGGGCACTCCACCCCGATTGCGGAGACATGTTTGAAAACGGGA





GCTTTCTCCGACGACGGAAGAGATTTAAGGTCCTGAGAGCCGATCATACC





CATCTCCACGCCGGGTCCACTAAATCTGCACCGGGGGCCGGCCCAGGCGG





GCATCTCCATCCCCACCACCACCATCACCCCCATCACCATCATCATCACC





ACGCCGCTGCACACCACCACCATCACCACCACCCCCCACAACCACCCCCT





CCCCCGCCACCCCCGCCACCCCACATGGTCCACTACTTTCACCAACAGCC





CCCCACCGCCCCGCAGCCCCCGCCCCACCTGCCATCACAGCCCCCCCAGC





AGCCCCCACAGCAAAGCCAGCCCCAGCAACCTAGCCATCCTGGTAAAATG





CAGGAGGCTGCGGCGGTGGCTGCGGCTGCAGCTGCCGCTGCTGCTGCGGC





TGTTGGGTCTGTGGGCAGACTGAGCCAGTTCCCTCCCTACGGCTTGGGTT





CCGCCGCCGCGGCGGCCGCCGCCGCTGCAGCCAGCACTTCCGGCTTTAAG





CATCCATTTGCTATTGAGAACATCATTGGCCGCGACTATAAAGGCGTCCT





CCAAGCCGGAGGACTCCCACTCGCGAGTGTGATGCATCACTTGGGCTATC





CAGTGCCAGGCCAGCTGGGTAACGTCGTGTCCTCCGTCTGGCCCCACGTG





GGGGTAATGGACAGTGTGGCAGCAGCCGCTGCCGCTGCAGCTGCCGCTGG





CGTTCCAGTAGGTCCCGAATATGGAGCATTCGGCGTGCCCGTGAAGTCCC





TGTGCCACTCTGCAAGCCAGAGCCTGCCAGCCATGCCGGTGCCCATCAAG





CCAACACCAGCCCTCCCACCAGTGTCTGCCTTGCAGCCAGGACTCACGGT





GCCCGCCGCATCTCAGCAGCCTCCAGCACCCTCAACGGTGTGCAGCGCCG





CAGCCGCTAGCCCCGTGGCCAGCCTCCTGGAACCCACTGCACCCACATCA





GCTGAGTCAAAAGGTGGAAGCCTTCATTCCGTGTTGGTGCACTCA,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:12 under stringent hybridization conditions.


In some embodiments, Forkhead box C1 (FOXC1) comprises the amino acid sequence:









(SEQ ID NO: 13; NP_001444)


MQARYSVSSPNSLGVVPYLGGEQSYYRAAAAAAGGGYTAMPAPMSVYSHP





AHAEQYPGGMARAYGPYTPQPQPKDMVKPPYSYIALITMAIQNAPDKKIT





LNGIYQFIMDRFPFYRDNKQGWQNSIRHNLSLNECFVKVPRDDKKPGKGS





YVVTLDPDSYNMFENGSFLRRRRRFKKKDAVKDKEEKDRLHLKEPPPPGR





QPPPAPPEQADGNAPGPQPPPVRIQDIKTENGTCPSPPQPLSPAAALGSG





SAAAVPKIESPDSSSSSLSSGSSPPGSLPSARPLSLDGADSAPPPPAPSA





PPPHHSQGFSVDNIMTSLRGSPQSAAAELSSGLLASAAASSRAGIAPPLA





LGAYSPGQSSLYSSPCSQTSSAGSSGGGGGGAGAAGGAGGAGTYHCNLQA





MSLYAAGERGGHLQGAPGGAGGSAVDDPLPDYSLPPVTSSSSSSLSHGGG





GGGGGGGQEAGHHPAAHQGRLTSVVYLNQAGGDLGHLASAAAAAAAAGYP





GQQQNFHSVREMFESQRIGLNNSPVNGNSSCQMAFPSSQSLYRTSGAFVY





DCSKF,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:13.


In some embodiments, the nucleic acid sequence encoding FOXC1 comprises the nucleic acid sequence:









(SEQ ID NO: 14; NM_001453)


ATGCAGGCGCGCTACTCCGTGTCCAGCCCCAACTCCCTGGGAGTGGTG





CCCTACCTCGGCGGCGAGCAGAGCTACTACCGCGCGGCGGCCGCGGCGGC





CGGGGGCGGCTACACCGCCATGCCGGCCCCCATGAGCGTGTACTCGCACC





CTGCGCACGCCGAGCAGTACCCGGGCGGCATGGCCCGCGCCTACGGGCCC





TACACGCCGCAGCCGCAGCCCAAGGACATGGTGAAGCCGCCCTATAGCTA





CATCGCGCTCATCACCATGGCCATCCAGAACGCCCCGGACAAGAAGATCA





CCCTGAACGGCATCTACCAGTTCATCATGGACCGCTTCCCCTTCTACCGG





GACAACAAGCAGGGCTGGCAGAACAGCATCCGCCACAACCTCTCGCTCAA





CGAGTGCTTCGTCAAGGTGCCGCGCGACGACAAGAAGCCGGGCAAGGGCA





GCTACTGGACGCTGGACCCGGACTCCTACAACATGTTCGAGAACGGCAGC





TTCCTGCGGCGGCGGCGGCGCTTCAAGAAGAAGGACGCGGTGAAGGACAA





GGAGGAGAAGGACAGGCTGCACCTCAAGGAGCCGCCCCCGCCCGGCCGCC





AGCCCCCGCCCGCGCCGCCGGAGCAGGCCGACGGCAACGCGCCCGGTCCG





CAGCCGCCGCCCGTGCGCATCCAGGACATCAAGACCGAGAACGGTACGTG





CCCCTCGCCGCCCCAGCCCCTGTCCCCGGCCGCCGCCCTGGGCAGCGGCA





GCGCCGCCGCGGTGCCCAAGATCGAGAGCCCCGACAGCAGCAGCAGCAGC





CTGTCCAGCGGGAGCAGCCCCCCGGGCAGCCTGCCGTCGGCGCGGCCGCT





CAGCCTGGACGGTGCGGATTCCGCGCCGCCGCCGCCCGCGCCCTCCGCCC





CGCCGCCGCACCATAGCCAGGGCTTCAGCGTGGACAACATCATGACGTCG





CTGCGGGGGTCGCCGCAGAGCGCGGCCGCGGAGCTCAGCTCCGGCCTTCT





GGCCTCGGCGGCCGCGTCCTCGCGCGCGGGGATCGCACCCCCGCTGGCGC





TCGGCGCCTACTCGCCCGGCCAGAGCTCCCTCTACAGCTCCCCCTGCAGC





CAGACCTCCAGCGCGGGCAGCTCGGGCGGCGGCGGCGGCGGCGCGGGGGC





CGCGGGGGGCGCGGGCGGCGCCGGGACCTACCACTGCAACCTGCAAGCCA





TGAGCCTGTACGCGGCCGGCGAGCGCGGGGGCCACTTGCAGGGCGCGCCC





GGGGGCGCGGGCGGCTCGGCCGTGGACGACCCCCTGCCCGACTACTCTCT





GCCTCCGGTCACCAGCAGCAGCTCGTCGTCCCTGAGTCACGGCGGCGGCG





GCGGCGGCGGCGGGGGAGGCCAGGAGGCCGGCCACCACCCTGCGGCCCAC





CAAGGCCGCCTCACCTCGTGGTACCTGAACCAGGCGGGCGGAGACCTGGG





CCACTTGGCGAGCGCGGCGGCGGCGGCGGCGGCCGCAGGCTACCCGGGCC





AGCAGCAGAACTTCCACTCGGTGCGGGAGATGTTCGAGTCACAGAGGATC





GGCTTGAACAACTCTCCAGTGAACGGGAATAGTAGCTGTCAAATGGCCTT





CCCTTCCAGCCAGTCTCTGTACCGCACGTCCGGAGCTTTCGTCTACGACT





GTAGCAAGTTT,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:14 under stringent hybridization conditions.


In some embodiments, Forkhead box C2 (FOXC2) comprises the amino acid sequence









(SEQ ID NO: 15; NP_005242)


MQARYSVSDPNALGVVPYLSEQNYYRAAGSYGGMASPMGVYSGHPEQYSA





GMGRSYAPYHHHQPAAPKDLVKPPYSYIALITMAIQNAPEKKITLNGIYQ





FIMDRFPFYRENKQGWQNSIRHNLSLNECFVKVPRDDKKPGKGSYVVTLD





PDSYNMFENGSFLRRRRRFKKKDVSKEKEERAHLKEPPPAASKGAPATPH





LADAPKEAEKKVVIKSEAASPALPVITKVETLSPESALQGSPRSAASTPA





GSPDGSLPEHHAAAPNGLPGFSVENIMTLRTSPPGGELSPGAGRAGLVVP





PLALPYAAAPPAAYGQPCAQGLEAGAAGGYQCSMRAMSLYTGAERPAHMC





VPPALDEALSDHPSGPTSPLSALNLAAGQEGALAATGHHHQHHGHHHPQA





PPPPPAPQPQPTPQPGAAAAQAASVVYLNHSGDLNHLPGHTFAAQQQTFP





NVREMFNSHRLGIENSTLGESQVSGNASCQLPYRSTPPLYRHAAPYSYDC





TKY,







NP 005242), or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:15.


In some embodiments, the nucleic acid sequence encoding FOXC2 comprises the nucleic acid sequence:









(SEQ ID NO: 16; NM_005251)


ATGCAGGCGCGCTACTCCGTGTCCGACCCCAACGCCCTGGGAGTGGTG





CCCTACCTGAGCGAGCAGAATTACTACCGGGCTGCGGGCAGCTACGGCGG





CATGGCCAGCCCCATGGGCGTCTATTCCGGCCACCCGGAGCAGTACAGCG





CGGGGATGGGCCGCTCCTACGCGCCCTACCACCACCACCAGCCCGCGGCG





CCTAAGGACCTGGTGAAGCCGCCCTACAGCTACATCGCGCTCATCACCAT





GGCCATCCAGAACGCGCCCGAGAAGAAGATCACCTTGAACGGCATCTACC





AGTTCATCATGGACCGCTTCCCCTTCTACCGGGAGAACAAGCAGGGCTGG





CAGAACAGCATCCGCCACAACCTCTCGCTCAACGAGTGCTTCGTCAAGGT





GCCCCGCGACGACAAGAAGCCCGGCAAGGGCAGTTACTGGACCCTGGACC





CGGACTCCTACAACATGTTCGAGAACGGCAGCTTCCTGCGGCGCCGGCGG





CGCTTCAAAAAGAAGGACGTGTCCAAGGAGAAGGAGGAGCGGGCCCACCT





CAAGGAGCCGCCCCCGGCGGCGTCCAAGGGCGCCCCGGCCACCCCCCACC





TAGCGGACGCCCCCAAGGAGGCCGAGAAGAAGGTGGTGATCAAGAGCGAG





GCGGCGTCCCCGGCGCTGCCGGTCATCACCAAGGTGGAGACGCTGAGCCC





CGAGAGCGCGCTGCAGGGCAGCCCGCGCAGCGCGGCCTCCACGCCCGCCG





GCTCCCCCGACGGCTCGCTGCCGGAGCACCACGCCGCGGCGCCCAACGGG





CTGCCTGGCTTCAGCGTGGAGAACATCATGACCCTGCGAACGTCGCCGCC





GGGCGGAGAGCTGAGCCCGGGGGCCGGACGCGCGGGCCTGGTGGTGCCGC





CGCTGGCGCTGCCCTACGCCGCCGCGCCGCCCGCCGCCTACGGCCAGCCG





TGCGCTCAGGGCCTGGAGGCCGGGGCCGCCGGGGGCTACCAGTGCAGCAT





GCGAGCGATGAGCCTGTACACCGGGGCCGAGCGGCCGGCGCACATGTGCG





TCCCGCCCGCCCTGGACGAGGCCCTCTCGGACCACCCGAGCGGCCCCACG





TCGCCCCTGAGCGCTCTCAACCTCGCCGCCGGCCAGGAGGGCGCGCTCGC





CGCCACGGGCCACCACCACCAGCACCACGGCCACCACCACCCGCAGGCGC





CGCCGCCCCCGCCGGCTCCCCAGCCCCAGCCGACGCCGCAGCCCGGGGCC





GCCGCGGCGCAGGCGGCCTCCTGGTATCTCAACCACAGCGGGGACCTGAA





CCACCTCCCCGGCCACACGTTCGCGGCCCAGCAGCAAACTTTCCCCAACG





TGCGGGAGATGTTCAACTCCCACCGGCTGGGGATTGAGAACTCGACCCTC





GGGGAGTCCCAGGTGAGTGGCAATGCCAGCTGCCAGCTGCCCTACAGATC





CACGCCGCCTCTCTATCGCCACGCAGCCCCCTACTCCTACGACTGCACGA





AATAC,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:16 under stringent hybridization conditions.


In some embodiments, Forkhead box D1 (FOXD1) comprises the amino acid sequence:









MTLSTEMSDASGLAEETDIDVVGEGEDEEDEEEEDDDEGGGGGPRLAVPA





QRRRRRRSYAGEDELEDLEEEEDDDDILLAPPAGGSPAPPGPAPAAGAGA





GGGGGGGGAGGGGSAGSGAKNPLVKPPYSYIALITMAILQSPKKRLTLSE





ICEFISGRFPYYREKFPAWQNSIRHNLSLNDCFVKIPREPGNPGKGNYWT





LDPESADMFDNGSFLRRRKRFKRQPLLPPNAAAAESLLLRGAGAAGGAGD





PAAAAALFPPAPPPPPHAYGYGPYGCGYGLQLPPYAPPSALFAAAAAAAA





AAAFHPHSPPPPPPPHGAAAELARTAFGYRPHPLGAALPGPLPASAAKAG





GPGASALARSPFSIESIIGGSLGPAAAAAAAAQAAAAAQASPSPSPVAAP





PAPGSSGGGCAAQAAVGPAAALTRSLVAAAAAAASSVSSSAALGTLHQGT





ALSSVENFTARISNC (SEQ ID NO: 17; NP_004463),







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:17.


In some embodiments, the nucleic acid sequence encoding FOXD1 comprises the nucleic acid sequence:









ATGACCCTGAGCACTGAGATGTCCGATGCCTCTGGCCTCGCCGAGGAAAC





AGACATCGACGTGGTGGGGGAGGGCGAGGACGAAGAAGACGAGGAAGAGG





AGGACGACGACGAGGGCGGCGGTGGCGGGCCCCGGCTGGCTGTCCCCGCG





CAGCGGCGGCGGCGGCGGCGCTCGTACGCCGGGGAGGACGAGCTGGAGGA





TCTGGAGGAGGAGGAGGACGACGATGACATCCTGCTGGCCCCGCCTGCTG





GGGGCTCCCCGGCGCCCCCGGGCCCGGCCCCGGCGGCGGGGGCAGGAGCC





GGTGGGGGCGGCGGCGGCGGCGGCGCGGGCGGCGGCGGGAGCGCGGGTAG





CGGCGCCAAGAACCCGCTGGTGAAGCCGCCCTACTCGTATATCGCGCTCA





TCACTATGGCCATCCTGCAGAGCCCCAAGAAGCGGCTGACGCTGAGCGAG





ATCTGTGAGTTCATCAGCGGCCGCTTCCCCTACTACCGGGAGAAGTTCCC





CGCCTGGCAGAACAGCATCCGCCACAACCTCTCGCTCAACGACTGCTTCG





TCAAGATCCCCCGCGAGCCCGGCAACCCGGGCAAGGGCAACTACTGGACG





CTGGACCCGGAGTCCGCCGACATGTTCGACAACGGCAGCTTCCTGCGCCG





GAGGAAGCGCTTCAAGCGGCAGCCGCTGCTCCCACCCAACGCCGCGGCCG





CCGAGTCTCTGCTGCTGCGCGGCGCGGGAGCCGCAGGGGGCGCGGGCGAC





CCGGCAGCCGCCGCCGCGCTCTTCCCGCCCGCGCCCCCGCCGCCCCCGCA





TGCCTACGGCTACGGCCCCTACGGCTGCGGCTACGGCCTGCAGCTGCCGC





CTTACGCGCCGCCCTCGGCCCTCTTCGCCGCCGCAGCGGCCGCCGCCGCC





GCCGCCGCCTTCCACCCGCACTCGCCCCCGCCGCCCCCGCCACCGCACGG





CGCGGCCGCCGAGCTGGCCCGGACCGCCTTCGGCTACCGGCCGCACCCGC





TCGGCGCCGCCCTACCCGGCCCCCTGCCGGCCTCCGCGGCCAAGGCGGGC





GGCCCGGGCGCCTCAGCGCTGGCGCGCTCGCCCTTCTCCATCGAGAGCAT





CATCGGGGGCAGCTTGGGCCCGGCCGCCGCTGCCGCCGCCGCCGCGCAGG





CCGCCGCCGCCGCTCAGGCCTCGCCCTCGCCCTCGCCGGTGGCGGCGCCG





CCAGCTCCCGGATCCAGCGGAGGAGGCTGCGCGGCGCAGGCGGCCGTGGG





CCCGGCGGCCGCGCTCACCCGATCCCTCGTGGCCGCCGCGGCCGCCGCCG





CCTCCTCAGTCTCCTCGTCCGCCGCCTTGGGGACTCTGCACCAAGGGACT





GCCCTGTCCAGTGTCGAGAACTTTACTGCTAGGATTTCCAATTGT (SEQ





ID NO: 18; NM_004472),







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:18 under stringent hybridization conditions.


In some embodiments, Forkhead box D2 (FOXD2) comprises the amino acid sequence:









MTLGSCCCEIMSSESSPAALSEADADIDVVGGGSGGGELPARSGPRAPRD





VLPHGHEPPAEEAEADLAEDEEESGGCSDGEPRALASRGAAAAAGSPGPG





AAAARGAAGPGPGPPSGGAATRSPLVKPPYSYIALITMAILQSPKKRLTL





SEICEFISGRFPYYREKFPAWQNSIRHNLSLNDCFVKIPREPGNPGKGNY





WTLDPESADMFDNGSFLRRRKRFKRQPLPPPHPHPHPHPELLLRGGAAAA





GDPGAFLPGFAAYGAYGYGYGLALPAYGAPPPGPAPHPHPHPHAFAFAAA





AAAAPCQLSVPPGRAAAPPPGPPTASVFAGAGSAPAPAPASGSGPGPGPA





GLPAFLGAELGCAKAFYPASLSPPAAGTAAGLPTALLRQGLKTDAGGGAG





GGGAGAGQRPSFSIDHIMGHGGGGAAPPGAGEGSPGPPFAAAAGPGGQAQ





VLAMLTAPALAPVAGHIRLSHPGDALLSSGSRFASKVAGLSGCHF (SEQ





ID NO: 19; NP_004465),







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:19.


In some embodiments, the nucleic acid sequence encoding FOXD2 comprises the nucleic acid sequence:









ATGACCCTGGGCAGCTGCTGCTGCGAGATCATGTCCTCCGAGAGCTCCCC





GGCCGCGCTGTCCGAGGCCGACGCAGACATAGACGTGGTGGGCGGCGGCA





GCGGCGGGGGGGAGCTCCCAGCTCGCTCCGGGCCCCGCGCCCCCCGGGAC





GTGCTCCCCCACGGCCACGAGCCTCCCGCGGAGGAAGCCGAGGCAGACTT





AGCCGAGGACGAGGAGGAGTCTGGTGGCTGCTCGGACGGCGAGCCCCGCG





CTCTGGCGTCCCGGGGGGCGGCGGCCGCAGCGGGGAGCCCGGGGCCAGGC





GCCGCGGCGGCCCGCGGCGCAGCGGGGCCCGGGCCGGGACCGCCGTCGGG





GGGCGCGGCGACGCGGAGCCCGCTGGTGAAGCCGCCCTACTCGTACATCG





CGCTCATCACCATGGCCATCCTGCAGAGCCCCAAGAAGCGGCTGACGTTG





AGCGAGATCTGCGAGTTCATCAGCGGCCGCTTCCCCTACTACCGGGAGAA





GTTCCCCGCCTGGCAGAACAGCATCCGCCACAACCTCTCTCTCAACGACT





GCTTCGTCAAGATCCCCCGCGAGCCGGGCAACCCGGGCAAGGGCAACTAC





TGGACGCTGGACCCGGAGTCGGCCGACATGTTCGACAACGGCAGCTTCCT





GCGGCGTCGCAAGCGCTTCAAGCGGCAGCCCCTGCCGCCGCCGCACCCAC





ACCCGCACCCTCACCCGGAGCTGCTGCTGCGTGGCGGGGCCGCGGCGGCG





GGGGATCCCGGCGCTTTCCTGCCCGGCTTCGCTGCCTACGGCGCCTACGG





CTACGGCTACGGGCTGGCTCTCCCGGCCTACGGCGCACCCCCGCCGGGGC





CGGCCCCGCATCCGCACCCGCACCCGCACGCCTTCGCTTTCGCCGCGGCA





GCCGCCGCCGCTCCTTGCCAGCTGTCGGTACCCCCAGGCCGCGCCGCCGC





GCCTCCACCCGGACCTCCGACGGCCTCGGTGTTCGCAGGCGCGGGATCGG





CCCCAGCTCCTGCGCCTGCCTCAGGCTCGGGCCCGGGCCCGGGCCCCGCA





GGCCTGCCCGCCTTCCTGGGCGCGGAGCTGGGCTGCGCCAAAGCCTTCTA





CCCGGCGTCCCTGAGTCCTCCCGCAGCCGGCACCGCGGCGGGTCTGCCCA





CCGCACTTCTGCGCCAGGGCCTCAAGACGGACGCGGGCGGTGGTGCAGGC





GGCGGGGGCGCCGGGGCAGGGCAGAGGCCTTCCTTCTCTATAGACCACAT





CATGGGCCACGGTGGCGGCGGGGCAGCACCCCCGGGCGCCGGCGAGGGCT





CTCCGGGACCGCCATTCGCGGCAGCCGCGGGTCCTGGGGGCCAAGCCCAG





GTCTTGGCCATGCTGACTGCTCCGGCCCTGGCTCCCGTTGCTGGCCACAT





TCGCCTCTCGCATCCCGGGGACGCGCTGCTGTCCTCAGGGTCCCGGTTTG





CCAGCAAAGTCGCCGGCCTTAGTGGCTGCCACTTC (SEQ ID NO:





20; NM_004474),







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:20 under stringent hybridization conditions.


In some embodiments, Forkhead box D3 (FOXD3) comprises the amino acid sequence:









MTLSGGGSASDMSGQTVLTAEDVDIDVVGEGDDGLEEKDSDAGCDSPAGP





PELRLDEADEVPPAAPHHGQPQPPHQQPLTLPKEAAGAGAGPGGDVGAPE





ADGCKGGVGGEEGGASGGGPGAGSGSAGGLAPSKPKNSLVKPPYSYIALI





TMAILQSPQKKLTLSGICEFISNRFPYYREKFPAWQNSIRHNLSLNDCFV





KIPREPGNPGKGNYWTLDPQSEDMFDNGSFLRRRKRFKRHQQEHLREQTA





LMMQSFGAYSLAAAAGAAGPYGRPYGLHPAAAAGAYSHPAAAAAAAAAAA





LQYPYALPPVAPVLPPAVPLLPSGELGRKAAAFGSQLGPGLQLQLNSLGA





AAAAAGTAGAAGTTASLIKSEPSARPSFSIENIIGGGPAAPGGSAVGAGV





AGGTGGSGGGSTAQSFLRPPGTVQSAALMATHQPLSLSRTTATIAPILSV





PLSGQFLQPAASAAAAAAAAAQAKWPAQ (SEQ ID NO: 21;





NP_036315),







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:21.


In some embodiments, the nucleic acid sequence encoding FOXD3 comprises the nucleic acid sequence:









ATGACCCTCTCCGGCGGCGGCAGCGCCAGCGACATGTCCGGCCAGACGGT





GCTGACGGCCGAGGACGTGGACATCGATGTGGTGGGCGAGGGCGACGACG





GGCTGGAAGAGAAGGACAGCGACGCAGGTTGCGATAGCCCCGCGGGGCCG





CCGGAGCTGCGCCTGGACGAGGCGGACGAGGTGCCCCCGGCGGCACCCCA





TCACGGACAGCCTCAGCCGCCCCACCAGCAGCCCCTGACATTGCCCAAGG





AGGCGGCCGGAGCCGGGGCCGGACCGGGGGGCGACGTGGGCGCGCCGGAG





GCGGACGGCTGCAAGGGCGGTGTTGGCGGCGAGGAGGGCGGCGCGAGCGG





CGGCGGGCCTGGCGCGGGCAGCGGTTCGGCGGGAGGCCTGGCCCCGAGCA





AGCCCAAGAACAGCCTAGTGAAGCCGCCTTACTCGTACATCGCGCTCATC





ACCATGGCCATCCTGCAGAGCCCGCAGAAGAAGCTGACCCTGAGCGGCAT





CTGCGAGTTCATCAGCAACCGCTTCCCCTACTACAGGGAGAAGTTCCCCG





CCTGGCAGAACAGCATCCGCCACAACCTCTCACTCAACGACTGCTTCGTC





AAGATCCCCCGCGAGCCGGGCAACCCGGGCAAGGGCAACTACTGGACCCT





GGACCCGCAGTCCGAGGACATGTTCGACAACGGCAGCTTCCTGCGGCGCC





GGAAACGCTTCAAGCGCCACCAGCAGGAGCACCTGCGCGAGCAGACGGCG





CTCATGATGCAGAGCTTCGGCGCTTACAGCCTGGCGGCGGCGGCCGGCGC





CGCGGGACCCTACGGCCGCCCCTACGGCCTGCACCCTGCGGCGGCGGCCG





GTGCCTATTCGCACCCGGCAGCGGCGGCGGCCGCGGCTGCTGCGGCGGCG





CTCCAGTACCCGTACGCGCTGCCGCCGGTGGCACCGGTGCTGCCTCCCGC





TGTGCCGCTGCTGCCCTCGGGCGAGCTGGGCCGCAAAGCGGCCGCCTTCG





GCTCACAGCTCGGCCCGGGCCTGCAGCTGCAGCTCAATAGCCTGGGCGCC





GCCGCGGCCGCTGCGGGCACAGCGGGCGCCGCGGGCACCACCGCGTCGCT





CATCAAGTCCGAGCCAAGCGCGCGGCCGTCGTTCAGCATCGAGAACATCA





TAGGTGGGGGCCCCGCGGCTCCTGGGGGCTCGGCGGTGGGCGCTGGGGTC





GCCGGCGGCACTGGGGGTTCAGGGGGCGGCAGCACGGCGCAGTCGTTTCT





GCGGCCACCCGGGACCGTGCAGTCGGCAGCGCTCATGGCCACCCACCAAC





CGCTGTCGCTGAGCCGGACGACTGCCACCATCGCGCCCATTCTTAGCGTG





CCACTCTCCGGACAGTTTCTGCAGCCCGCAGCCTCGGCCGCCGCCGCTGC





TGCGGCCGCCGCTCAAGCCAAATGGCCGGCGCAA (SEQ ID NO: 22;





NM_012183),







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:22 under stringent hybridization conditions.


In some embodiments, Forkhead box D4 (FOXD4) comprises the amino acid sequence:









MNLPRAERLRSTPQRSLRDSDGEDGKIDVLGEEEDEDEEEAASQQFLEQS





LQPGLQVARWGGVALPREHIEGGGGPSDPSEFGTEFRAPPRSAAASEDAR





QPAKPPSSYIALITMAILQSPHKRLTLSGICAFISDRFPYYRRKFPAWQN





SIRHNLSLNDCFVKIPREPGRPGKGNYWSLDPASQDMFDNGSFLRRRKRF





QRHQPTPGAHLPHPFPLPAAHAALHNPRPGPLLGAPAPPQPVPGAYPNTG





PGRRPYALLHPHPPRYLLLSAPAYAGAPKKAEGADLATPAPFPCCSPHLV





LSLGRRARVWRRHREADASLSALRVSCKGSGERVQGLRRVCPRPRGATAP





CSSDRQACRTILQQQQRHQEEDCANGCAPTKGAVLGGHLSAASALLRYQA





VAEGSGLTSLAAPLGGEGTSPVFLVSPTPSSLAESAGPS (SEQ ID





NO: 23; NP_997188),







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:23.


In some embodiments, the nucleic acid sequence encoding FOXD4 comprises the nucleic acid sequence:









ATGAACTTGCCAAGAGCTGAGCGCCTTCGCTCCACACCGCAGCGCAGCCT





CCGGGACTCCGATGGGGAAGACGGTAAAATCGATGTCCTGGGAGAGGAGG





AAGATGAAGACGAGGAGGAGGCGGCGAGCCAGCAGTTCCTAGAGCAGTCG





CTCCAGCCGGGGCTGCAGGTGGCCCGGTGGGGCGGGGTTGCGCTTCCCCG





AGAGCACATCGAGGGCGGCGGCGGCCCGAGCGACCCCTCAGAGTTTGGCA





CCGAGTTCAGGGCACCGCCAAGGTCTGCGGCGGCCTCTGAAGATGCCCGG





CAGCCGGCAAAGCCCCCCTCCTCGTACATCGCGCTCATCACCATGGCCAT





CCTGCAAAGCCCGCACAAGCGCCTCACGCTCAGCGGCATCTGCGCCTTCA





TTAGTGACCGCTTCCCCTACTACCGCCGCAAGTTCCCCGCCTGGCAGAAC





AGCATCCGCCACAACCTCTCGCTGAACGACTGCTTCGTCAAGATCCCCCG





CGAGCCGGGCCGCCCAGGCAAGGGCAACTACTGGAGCCTGGACCCCGCCT





CCCAGGACATGTTCGACAATGGCAGCTTTCTCCGGCGTAGGAAGCGTTTC





CAGCGCCACCAACCGACCCCGGGAGCCCACCTGCCCCACCCCTTCCCTCT





ACCTGCTGCACACGCCGCCCTGCACAACCCCCGCCCAGGCCCTCTGCTTG





GGGCCCCTGCCCCGCCGCAGCCAGTCCCGGGGGCCTACCCCAACACCGGC





CCCGGGAGACGCCCTTACGCTCTGCTGCACCCGCATCCTCCTCGCTACCT





ACTGCTCTCGGCCCCCGCCTATGCCGGGGCACCGAAGAAAGCAGAAGGCG





CGGACCTGGCGACCCCGGCACCCTTCCCGTGCTGCAGCCCTCACTTGGTC





CTCAGCCTTGGGAGGAGGGCAAGGGTCTGGCGTCGCCACCGGGAGGCGGA





TGCATCTCTTTCAGCATTGAGAGTATCATGCAAGGGGTCAGGGGAGCGGG





TACAGGGGCTGCGCAGAGTTTGTCCCCGACCGCGTGGAGCTACTGCCCCC





TGCTCCAGCGACCGTCAAGCCTGTCGGACAATTTTGCAGCAACAGCAGCG





GCATCAGGAGGAGGACTGCGCCAACGGCTGCGCTCCCACCAAGGGCGCGG





TGCTGGGCGGGCACCTGTCGGCCGCGTCGGCGCTGCTGCGGTATCAGGCG





GTGGCAGAGGGCTCTGGGCTGACATCGCTGGCCGCCCCTTTGGGCGGAGA





GGGGACCTCACCAGTTTTTTTAGTATCGCCCACGCCCAGTTCCCTGGCCG





AGTCCGCAGGGCCCTCC (SEQ ID NO: 24; NM_207305),







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:24 under stringent hybridization conditions.


In some embodiments, Forkhead box D4 like 1 (FOXD5) comprises the amino acid sequence:









MNLPRAERPRSTPQRSLRDSDGEDGKIDVLGEEEDEDEVEDEEEEASQKF





LEQSLQPGLQVARWGGVALPREHIEGGGPSDPSEFGTEFRAPPRSAAASE





DARQPAKPPYSYIALITMAILQSPHKRLTLSGICAFISGRFPYYRRKFPA





WQNSIRHNLSLNDCFVKIPREPGHPGKGTYWSLDPASQDMFDNGSFLRRR





KRFKRHQLTPGAHLPHPFPLPAAHAALHNPRPGPLLGAPALPQPVPGAYP





NTAPGRRPYALLHPHPPRYLLLSAPAYAGAPKKAEGADLATPGTLPVLQP





SLGPQPWEEGKGLASPPGGGCISFSIESIMQGVRGAGTGAAQSLSPTAWS





YCPLLQRPSSLSDNFAATAAASGGGLRQRLRSHQGRGAGRAPVGRVGAAA





VSGGGRGL (SEQ ID NO: 25; NP_036316),







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:25.


In some embodiments, the nucleic acid sequence encoding FOXD5 comprises the nucleic acid sequence:









ATCTTTGCCGGACGTTGTTGCAAAGGAGTAGAAACAAGCAGAGGAAAACA





TCCCAAAGGGTAACCACTAGCGTTCCTGCTTCTTGCAACATTCATCCCAG





GCTTCCAGCTCAGCCCGCCCCGGGCCAGGTGATCGGCCGCCACATCCCCT





GCGACTGAAGCACCTGCTCCGCCATGAACCTGCCAAGAGCTGAGCGCCCT





CGCTCCACACCGCAGCGCAGCCTCCGGGACTCCGATGGGGAAGACGGTAA





AATCGATGTCCTGGGAGAGGAGGAAGATGAAGACGAGGTGGAAGACGAGG





AGGAGGAGGCGAGCCAGAAGTTCCTAGAGCAGTCGCTCCAGCCGGGGCTG





CAGGTGGCCCGGTGGGGCGGGGTTGCGCTTCCCCGAGAGCACATCGAGGG





CGGCGGCCCGAGCGACCCCTCAGAGTTTGGCACCGAGTTCAGGGCACCGC





CAAGGTCTGCGGCGGCCTCTGAAGATGCCCGGCAGCCGGCAAAGCCCCCC





TACTCGTACATCGCGCTCATCACCATGGCCATCCTGCAAAGCCCGCACAA





GCGCCTCACGCTCAGCGGCATCTGCGCCTTCATTAGTGGCCGCTTCCCCT





ACTACCGCCGCAAGTTCCCCGCCTGGCAGAACAGCATCCGCCACAACCTC





TCGCTGAACGACTGCTTCGTCAAGATCCCCCGCGAGCCGGGCCACCCAGG





CAAGGGCACCTACTGGAGCCTGGACCCCGCCTCCCAGGACATGTTCGACA





ATGGCAGCTTTCTCCGGCGTAGGAAGCGTTTCAAGCGCCACCAACTGACC





CCGGGAGCCCACCTGCCCCACCCCTTCCCTCTACCTGCTGCACACGCCGC





CCTGCACAACCCCCGCCCAGGCCCTCTGCTTGGGGCCCCTGCCCTGCCGC





AGCCAGTCCCGGGGGCCTACCCCAACACCGCCCCCGGGAGACGCCCTTAC





GCTCTGCTGCACCCGCATCCTCCTCGCTACCTACTGCTCTCGGCCCCCGC





CTATGCCGGGGCACCGAAGAAAGCAGAAGGCGCGGACCTGGCGACCCCCG





GCACCCTTCCCGTGCTGCAGCCCTCACTTGGTCCTCAGCCTTGGGAGGAG





GGCAAGGGTCTGGCGTCGCCACCGGGAGGCGGATGCATCTCTTTCAGCAT





TGAGAGTATCATGCAAGGGGTCAGGGGAGCGGGTACAGGGGCTGCGCAGA





GTTTGTCCCCGACCGCGTGGAGCTACTGCCCCCTGCTCCAGCGACCGTCA





AGCCTGTCGGACAATTTTGCAGCAACAGCAGCAGCATCAGGAGGAGGACT





GCGCCAACGGCTGCGCTCCCACCAAGGGCGCGGTGCTGGGCGGGCACCTG





TCGGCCGCGTCGGCGCTGCTGCGGTATCAGGCGGTGGCAGAGGGCTCTAG





GCTGACATCGCTGGCTGCCCCTTTGGGCGGAGAGGGGACCTCACCAGTTT





TTTTAGTATCGCCCACGCCCAGTTCCCTGGCCAAGTCCGCAGGGCCCTCC





TAGAGCCAGGTGGGAGTGGGGAGCGATCCGCAGCTGCTCACTCCACCTTG





CGCGGCCCATACTGGGCGTGTGCATCTGAATCCTGCTGGAGAGCAAACAC





GAACTTCTGTTCCCTGCAAAATGGTTAGAAAGAAACAGCTGGATTACGTT





CCTCTAAAAACCACCTGAACGTAACCTTCGCAGGGCGTCAAGTCATCTTT





TCTTGCCTTCGGCTGTGGCTTCTGTGGCTTTCCGGATTTGCACATTTCCT





GGGGTACTATGAACGTGAGTGGGGTATTTTGTTCTGGCATTAGAAGAAAA





ACAAGCAAGCAAACAAAAACACAGCCTCCGATGCCAAACATGTTCCCCCT





TCTTCACTTCCTTGGAACTGGAAGTGTTATTCCTAAGTCTAGTGCAAAAT





GCTTCTACTCTCTGTGTCTTCCTGATAGGGATGTTTAATGTAAGTAGGAT





ATTAATTTCAGAACATTGATTTCTTATCTGTGTGTCTGACGTGCCATCTT





TAATGTTAAAATTAAGGTGTTAAAATTAAGCCTAGTTATATAGACGAAAT





AAAATGCTAAGTCACTA (SEQ ID NO: 26; NM_012184.4),







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:26 under stringent hybridization conditions.


In some embodiments, Forhead box D4 like 3 (FOXD6) comprises the amino acid sequence









MNLPRAERLRSTPQRSLRDSDGEDGKIDVLGEEEDEDEVEDEEEAASQQF





LEQSLQPGLQVARWGGVALPREHIEGGGGPSDPSEFGTKFRAPPRSAAAS





EDARQPAKPPYSYIALITMAILQNPHKRLTLSGICAFISGRFPYYRRKFP





AWQNSIRHNLSLNDCFVKIPREPGHPGKGNYWSLDPASQDMFDNGSFLRR





RKRFKRHQLTPGAHLPHPFPLPAAHAALHNPRPGPLLGAPAPPQPVPGAY





PNTAPGRRPYALLHPHPLRYLLLSAPVYAGAPKKAEGAALATPAPFPCCS





PHLVLSLGRRARVWRRHREADASLSALRVLCKGSRTAPTAALPPRARCWA





GTCRPRRPC (SEQ ID NO: 27; NP_954586),







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:27.


In some embodiments, the nucleic acid sequence encoding FOXD6 comprises the nucleic acid sequence:









CATTCATCCCAGGCTTCCAGCTCAGCCCGCCCCAGGCCAGGTGATCGGCC





GCCACATCCCCTGCGACTGAAGCACCTGCTCCTCCATGAACCTGCCAAGA





GCTGAGCGCCTTCGCTCCACACCGCAGCGCAGCCTCCGGGACTCCGATGG





GGAAGACGGTAAAATCGATGTCCTGGGAGAGGAGGAAGATGAAGACGAGG





TGGAAGACGAGGAGGAGGCGGCGAGCCAGCAGTTCCTAGAGCAGTCGCTC





CAGCCGGGGCTGCAGGTGGCCCGGTGGGGCGGGGTTGCGCTTCCCCGAGA





GCACATCGAGGGCGGCGGCGGCCCGAGCGACCCCTCAGAGTTTGGCACCA





AGTTCAGGGCACCGCCAAGGTCTGCGGCGGCCTCTGAAGATGCCCGGCAG





CCGGCAAAGCCCCCCTACTCGTACATCGCGCTCATCACCATGGCCATCCT





GCAAAACCCGCACAAGCGCCTCACGCTCAGCGGCATCTGCGCCTTCATTA





GTGGCCGCTTCCCCTACTACCGCCGCAAGTTCCCCGCCTGGCAGAACAGC





ATCCGCCACAACCTCTCGCTGAACGACTGCTTCGTTAAGATCCCCCGCGA





GCCGGGCCACCCAGGCAAGGGCAACTACTGGAGCCTGGACCCCGCCTCCC





AAGACATGTTCGACAATGGCAGCTTTCTCCGGCGTAGGAAGCGTTTCAAG





CGCCACCAACTGACCCCGGGAGCCCACCTGCCCCACCCCTTCCCTCTACC





TGCTGCACACGCCGCCCTGCACAACCCCCGCCCAGGCCCTCTGCTTGGGG





CCCCTGCCCCGCCGCAGCCAGTCCCGGGGGCCTACCCCAACACCGCCCCC





GGGAGACGCCCTTACGCTCTGCTGCACCCGCATCCTCTTCGCTACCTACT





GCTCTCGGCCCCCGTCTATGCCGGGGCACCGAAGAAAGCAGAAGGCGCGG





CCCTGGCGACCCCGGCACCCTTCCCGTGCTGCAGCCCTCACTTGGTCCTC





AGCCTTGGGAGGAGGGCAAGGGTCTGGCGTCGCCACCGGGAGGCGGATGC





ATCTCTTTCAGCATTGAGAGTATTATGCAAGGGGTCAGGGGAGCGGGTAC





AGGGGCTGCGCAGAATTTGTCCCCGACCGCGTGGAGCTACTGCCACCTGC





TCCAGCGACCATCAAGCCTGTTGCATCCCCAGACCGCTGCCCCTTTGCTG





CAAGTGTCCGCCGCCGCCGCTGCTCGGACAATTTTGCAGCAATAGCAGCA





GCATCAGGAGGAGGACTGCGCCAACGGCTGCGCTCCCACCAAGGGCGCGG





TGCTGGGCGGGCACCTGTCGGCCTCGTCGGCCCTGCTGAGGTATCAGGCA





GTGGCAGAGGGCTCTAGGCTGACATCGCTGGCTGCCCCTTTGGGCGGAGA





GGGGACCTCACCAGTTTTTTTAGTATCGCCCACGCCCAGTTCCCTGGCCA





ACTCCGCAGGGCCCTCCTAGAGCCAGGTGGGAGTGGGGAGCGACCCGCAG





CTGCTCACTCCACCTTGCGCGGCCCATACTGGGCGTGTGCATCTGAATCC





CGCTGGAGAGCAAACACGAACTTCTGTTCGCTGCAAAATGGTTAGAAAGA





AACAGCTGGATTACGTTCCTCTAAAAACCACCTGAACGTAACCTTCGCAG





GGCGTCAAGTCATCTTTTCTTGCCTTCGGTTGTGGCTTCTATGGCTGTCC





CGATTTGCGCATTTCCTGGGGTACTATGAACGTGAGTGGGGTATTTTGTT





CTGGCATTAAAAGAAAAACAAGCAAGCAAACAAAAACACAGCCTCCGATG





CCAAACATGTTCCCCCTTCTTCACTTCCTTGGAGCTGGAAGTATTATTCC





TAAGTCTAGTGCAAAATGCTTCTACTCTCTGTGTCTTCCTGATAGGGATG





TTTAATGTAAGTAGGATATTAATTTCAGAACATTGATTTCTTATCTGTGT





GTCTGACGTGCCATCTTTAATGTTAAAATTAAGGTGTTAAAATTAAGCCT





AGTTATATAGACGAAATAAAATGCTAAGTCACTACACTACATCGTTTATT





TTCTATTACATCTCATTCTTCCCTTTCTAAATGGAACTTTTTAAAACCTA





CGTTATTTTCCCTCAAACAATTTATTTTCACAATTCATATTTATTATAGA





TAGCAGAAGTAATCCATTTTAATATGGCCTTTAAAAATTCCAAATATTTG





AGGTTGAAAATGTCCTGG (SEQ ID NO: 28; NM_199135),







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:28 under stringent hybridization conditions.


In some embodiments, Forkhead box E1 (FOXE1/FOXE2) comprises the amino acid sequence:









MTAESGPPPPQPEVLATVKEERGETAAGAGVPGEATGRGAGGRRRKRPLQ





RGKPPYSYIALIAMAIAHAPERRLTLGGIYKFITERFPFYRDNPKKWQNS





IRHNLTLNDCFLKIPREAGRPGKGNYWALDPNAEDMFESGSFLRRRKRFK





RSDLSTYPAYMHDAAAAAAAAAAAAAAAAIFPGAVPAARPPYPGAVYAGY





APPSLAAPPPVYYPAASPGPCRVFGLVPERPLSPELGPAPSGPGGSCAFA





SAGAPATTTGYQPAGCTGARPANPSAYAAAYAGPDGAYPQGAGSAIFAAA





GRLAGPASPPAGGSSGGVETTVDFYGRTSPGQFGALGACYNPGGQLGGAS





AGAYHARHAAAYPGGIDRFVSAM (SEQ ID NO: 29;





NP_004464),







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:29.


In some embodiments, the nucleic acid sequence encoding FOXE1/FOXE2 comprises the nucleic acid sequence:









ATGACTGCCGAGAGCGGGCCGCCGCCGCCGCAGCCGGAGGTGCTGGCTAC





CGTGAAGGAAGAGCGCGGCGAGACGGCAGCAGGGGCCGGGGTCCCAGGGG





AGGCCACGGGCCGCGGGGCGGGCGGGCGGCGCCGCAAGCGCCCCCTGCAG





CGCGGGAAGCCGCCCTACAGCTACATCGCGCTCATCGCCATGGCCATCGC





GCACGCGCCCGAGCGCCGCCTCACGCTGGGCGGCATCTACAAGTTCATCA





CCGAGCGCTTCCCCTTCTACCGCGACAACCCCAAAAAGTGGCAGAACAGC





ATCCGCCACAACCTCACACTCAACGACTGCTTCCTCAAGATCCCGCGCGA





GGCCGGCCGCCCGGGTAAGGGCAACTACTGGGCGCTTGACCCCAACGCGG





AGGACATGTTCGAGAGCGGCAGCTTCCTGCGCCGCCGCAAGCGCTTCAAG





CGCTCGGACCTCTCCACCTACCCGGCTTACATGCACGACGCGGCGGCTGC





CGCAGCCGCCGCCGCCGCCGCCGCCGCCGCCGCCGCCATCTTCCCAGGCG





CGGTGCCCGCCGCGCGCCCCCCCTACCCGGGCGCCGTCTATGCAGGCTAC





GCGCCGCCGTCGCTGGCCGCGCCGCCTCCAGTCTACTACCCCGCGGCGTC





GCCCGGCCCTTGCCGCGTCTTCGGCCTGGTTCCTGAGCGGCCGCTCAGCC





CAGAGCTGGGGCCCGCACCGTCGGGGCCCGGCGGCTCTTGCGCCTTTGCC





TCCGCCGGGCCCCCGCTACCACCACCGGCTACCAGCCCGCAGGCTGCACC





GGGGCCCGGCCGGCCAACCCCTCCGCCTATGCGGCTGCCTACGCGGGCCC





CGACGGCGCGTACCCGCAGGGCGCCGGCAGTGCGATCTTTGCCGCTGCTG





GCCGCCTGGCGGGACCCGCTTCGCCCCCAGCGGGCGGCAGCAGTGGCGGC





GTGGAGACCACGGTGGACTTCTACGGGCGCACGTCGCCCGGCCAGTTCGG





AGCGCTGGGAGCCTGCTACAACCCTGGCGGGCAGCTCGGAGGGGCCAGTG





CAGGCGCCTACCATGCTCGCCATGCTGCCGCTTATCCCGGTGGGATAGAT





CGGTTCGTGTCCGCCATG (SEQ ID NO: 30; NM_004473),







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:30 under stringent hybridization conditions.


In some embodiments, Forkhead box E3 (FOXE3) comprises the amino acid sequence:









MAGRSDMDPPAAFSGFPALPAVAPSGPPPSPLAGAEPGREPEEAAAGRGE





AAPTPAPGPGRRRRRPLQRGKPPYSYIALIAMALAHAPGRRLTLAAIYRF





ITERFAFYRDSPRKWQNSIRHNLTLNDCFVKVPREPGNPGKGNYWTLDPA





AADMFDNGSFLRRRKRFKRAELPAHAAAAPGPPLPFPYAPYAPAPGPALL





VPPPSAGPGPSPPARLFSVDSLVNLQPELAGLGAPEPPCCAAPDAAAAAF





PPCAAAASPPLYSQVPDRLVLPATRPGPGPLPAEPLLALAGPAAALGPLS





PGEAYLRQPGFASGLERYL (SEQ ID NO: 31; NP_036318),







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:31.


In some embodiments, the nucleic acid sequence encoding FOXE3 comprises the nucleic acid sequence:









(SEQ ID NO: 32; NM_012186)


ATGGCGGGGCGCAGCGACATGGATCCGCCCGCCGCGTTCTCTGGCTTCC





CTGCCCTGCCAGCGGTCGCGCCGTCGGGGCCGCCGCCGTCGCCGCTCGC





AGGAGCCGAGCCAGGGCGGGAGCCAGAGGAGGCGGCGGCTGGCCGCGGA





GAGGCGGCCCCCACGCCCGCGCCCGGCCCGGGGCGGCGGCGGCGGCGGC





CCCTGCAGCGCGGGAAGCCGCCCTACTCGTACATCGCGCTCATCGCCAT





GGCTCTGGCGCACGCCCCGGGCCGCCGCCTCACGCTGGCCGCCATCTAC





CGCTTCATCACCGAACGCTTTGCCTTCTACCGCGACAGCCCGCGCAAGT





GGCAGAACAGCATCCGCCACAATCTCACGCTCAACGACTGCTTCGTCAA





GGTGCCCCGCGAGCCGGGCAACCCGGGCAAGGGCAACTACTGGACGCTG





GACCCCGCGGCCGCAGACATGTTCGACAACGGCAGCTTCCTGCGGCGCC





GCAAGCGCTTCAAGCGCGCCGAGCTGCCCGCGCACGCGGCCGCGGCGCC





AGGGCCGCCGCTCCCCTTCCCCTACGCGCCCTACGCGCCCGCGCCCGGC





CCCGCGCTGCTGGTGCCGCCGCCTTCTGCCGGACCGGGCCCCTCGCCGC





CCGCGCGTCTGTTCAGCGTCGACAGCCTGGTGAACCTGCAGCCGGAGCT





AGCGGGGCTGGGCGCCCCCGAGCCGCCCTGCTGCGCCGCGCCCGACGCC





GCAGCCGCAGCCTTCCCGCCCTGCGCTGCCGCCGCCTCCCCGCCACTCT





ACTCGCAGGTCCCCGACCGCCTGGTACTGCCCGCGACGCGCCCCGGCCC





CGGCCCGCTGCCCGCTGAGCCCCTCCTGGCCTTGGCCGGGCCGGCAGCC





GCTCTCGGCCCGCTCAGCCCTGGGGAGGCCTACCTGAGGCAGCCGGGCT





TCGCGTCGGGGCTGGAGCGCTACCTG,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:32 under stringent hybridization conditions.


In some embodiments, Forrkhead box G1 (FOXG1) comprises the amino acid sequence:









(SEQ ID NO: 33; NP_005240)


MLDMGDRKEVKMIPKSSFSINSLVPEAVQNDNHHASHGHHNSHHPQHHH





HHHHHHHHPPPPAPQPPPPPQQQQPPPPPPPAPQPPQTRGAPAADDDKG





PQQLLLPPPPPPPPAAALDGAKAVGLGGKGEPGGGPGELAPVGPDEKEK





GAGAGGEEKKGAGEGGKDGEGGKEGEKKNGKYEKPPFSYNALIMMAIRQ





SPEKRLTLNGIYEFIMKNFPYYRENKQGWQNSIRHNLSLNMCFVKVPRH





YDDPGKGNYWMLDPSSDDVFIGGTTGKLRRRSTTSRAKLAFKRGARLTS





TGLTFMDRAGSLYWPMSPFLSLHHPRASSTLSYNGTTSAYPSHPMPYSS





VLTQNSLGNNHSFSTANGLSVDRLVNGEIPYATHHLTAAALAASVPCGL





SVPCSGTYSLNPCSVNLLAGQTSYFFPHVPHPSMTSQSSTSMSARATSS





STSPQAPSTLPCESLRPSLPSFTTGLSGGLSDYFTHQNQGSSSNPLIH,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:33.


In some embodiments, the nucleic acid sequence encoding FOXG1 comprises the nucleic acid sequence:









(SEQ ID NO: 34; NM_005249)


ATGCTGGACATGGGAGATAGGAAAGAGGTGAAAATGATCCCCAAGTCCT





CGTTCAGCATCAACAGCCTGGTGCCCGAGGCGGTCCAGAACGACAACCA





CCACGCGAGCCACGGCCACCACAACAGCCACCACCCCCAGCACCACCAC





CACCACCACCACCATCACCACCACCCGCCGCCGCCCGCCCCGCAACCGC





CGCCGCCGCCGCAGCAGCAGCAGCCGCCGCCGCCGCCGCCCCCGGCACC





GCAGCCCCCCCAGACGCGGGGCGCCCCGGCCGCCGACGACGACAAGGGC





CCCCAGCAGCTGCTGCTCCCGCCGCCGCCACCGCCACCACCGGCCGCCG





CCCTGGACGGGGCTAAAGCGGTCGGGCTGGGCGGCAAGGGCGAGCCGGG





CGGCGGGCCGGGGGAGCTGGCGCCCGTCGGGCCGGACGAGAAGGAGAAG





GGCGCCGGCGCCGGGGGGGAGGAGAAGAAGGGGGCGGGCGAGGGCGGCA





AGGACGGGGAGGGGGGCAAGGAGGGCGAGAAGAAGAACGGCAAGTACGA





GAAGCCGCCGTTCAGCTACAACGCGCTCATCATGATGGCCATCCGGCAG





AGCCCCGAGAAGCGGCTCACGCTCAACGGCATCTACGAGTTCATCATGA





AGAACTTCCCTTACTACCGCGAGAACAAGCAGGGCTGGCAGAACTCCAT





CCGCCACAATCTGTCCCTCAACATGTGCTTCGTGAAGGTGCCGCGCCAC





TACGACGACCCGGGCAAGGGCAACTACTGGATGCTGGACCCGTCGAGCG





ACGACGTGTTCATCGGCGGCACCACGGGCAAGCTGCGGCGCCGCTCCAC





CACCTCGCGGGCCAAGCTGGCCTTCAAGCGCGGTGCGCGCCTCACCTCC





ACCGGCCTCACCTTCATGGACCGCGCCGGCTCCCTCTACTGGCCCATGT





CGCCCTTCCTGTCCCTGCACCACCCCCGCGCCAGCAGCACTTTGAGTTA





CAACGGCACCACGTCGGCCTACCCCAGCCACCCCATGCCCTACAGCTCC





GTGTTGACTCAGAACTCGCTGGGCAACAACCACTCCTTCTCCACCGCCA





ACGGCCTGAGCGTGGACCGGCTGGTCAACGGGGAGATCCCGTACGCCAC





GCACCACCTCACGGCCGCCGCGCTAGCCGCCTCGGTGCCCTGCGGCCTG





TCGGTGCCCTGCTCTGGGACCTACTCCCTCAACCCCTGCTCCGTCAACC





TGCTCGCGGGCCAGACCAGTTACTTTTTCCCCCACGTCCCGCACCCGTC





AATGACTTCGCAGAGCAGCACGTCCATGAGCGCCAGGGCCACGTCCTCC





TCCACGTCGCCGCAGGCCCCCTCGACCCTGCCCTGTGAGTCTTTAAGAC





CCTCTTTGCCAAGTTTTACGACGGGACTGTCTGGGGGACTGTCTGATTA





TTTCACACATCAAAATCAGGGGTCTTCTTCCAACCCTTTAATACAT,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:34 under stringent hybridization conditions.


In some embodiments, Forhead box H1 (FOXH1) comprises the amino acid sequence:









(SEQ ID NO: 35; NP_003914)


MGPCSGSRLGPPEAESPSQPPKRRKKRYLRHDKPPYTYLAMIALVIQAA





PSRRLKLAQIIRQVQAVFPFFREDYEGWKDSIRHNLSSNRCFRKVPKDP





AKPQAKGNFWAVDVSLIPAEALRLQNTALCRRWQNGGARGAFAKDLGPY





VLHGRPYRPPSPPPPPSEGFSIKSLLGGSGEGAPWPGLAPQSSPVPAGT





GNSGEEAVPTPPLPSSERPLWPLCPLPGPTRVEGETVQGGAIGPSTLSP





EPRAWPLHLLQGTAVPGGRSSGGHRASLWGQLPTSYLPIYTPNVVMPLA





PPPTSCPQCPSTSPAYWGVAPETRGPPGLLCDLDALFQGVPPNKSIYDV





WVSHPRDLAAPGPGWLLSWCSL,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:35.


In some embodiments, the nucleic acid sequence encoding FOXH1 comprises the nucleic acid sequence:









(SEQ ID NO: 36; NM_003923)


ATGGGGCCCTGCAGCGGCTCCCGCCTGGGGCCCCCAGAGGCAGAGTC





GCCCTCCCAGCCCCCTAAGAGGAGGAAGAAGAGGTACCTGCGACATGAC





AAGCCCCCCTACACCTACTTGGCCATGATCGCCTTGGTGATTCAGGCCG





CTCCCTCCCGCAGACTGAAGCTGGCCCAGATCATCCGTCAGGTCCAGGC





CGTGTTCCCCTTCTTCAGGGAAGACTACGAGGGCTGGAAAGACTCCATT





CGCCACAACCTTTCCTCCAACCGATGCTTCCGCAAGGTGCCCAAGGACC





CTGCAAAGCCCCAGGCCAAGGGCAACTTCTGGGCGGTCGACGTGAGCCT





GATCCCAGCTGAGGCGCTCCGGCTGCAGAACACCGCCCTGTGCCGGCGC





TGGCAGAACGGAGGTGCGCGTGGAGCCTTCGCCAAGGACCTGGGCCCCT





ACGTGCTGCACGGCCGGCCATACCGGCCGCCCAGTCCCCCGCCACCACC





CAGTGAGGGCTTCAGCATCAAGTCCCTGCTAGGAGGGTCCGGGGAGGGG





GCACCCTGGCCGGGGCTAGCTCCACAGAGCAGCCCAGTTCCTGCAGGCA





CAGGGAACAGTGGGGAGGAGGCGGTGCCCACCCCACCCCTTCCCTCTTC





TGAGAGGCCTCTGTGGCCCCTCTGCCCCCTTCCTGGCCCCACGAGAGTG





GAGGGGGAGACTGTGCAGGGGGGAGCCATCGGGCCCTCAACCCTCTCCC





CAGAGCCTAGGGCCTGGCCTCTCCACTTACTGCAGGGCACCGCAGTTCC





TGGGGGACGGTCCAGCGGGGGACACAGGGCCTCCCTCTGGGGGCAGCTG





CCCACCTCCTACTTGCCTATCTACACTCCCAATGTGGTAATGCCCTTGG





CACCACCACCCACCTCCTGTCCCCAGTGTCCGTCAACCAGCCCTGCCTA





CTGGGGGGTGGCCCCTGAAACCCGAGGGCCCCCAGGGCTGCTCTGCGAT





CTAGACGCCCTCTTCCAAGGGGTGCCACCCAACAAAAGCATCTACGACG





TTTGGGTCAGCCACCCTCGGGACCTGGCGGCCCCTGGCCCAGGCTGGCT





GCTCTCCTGGTGCAGCCTG,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:36 under stringent hybridization conditions.


In some embodiments, Forkheadbox 11 (FOXI1) comprises the amino acid sequence:









(SEQ ID NO: 37; NP_036320)


MSSFDLPAPSPPRCSPQFPSIGQEPPEMNLYYENFFHPQGVPSPQRPSF





EGGGEYGATPNPYLWFNGPTMTPPPYLPGPNASPFLPQAYGVQRPLLPS





VSGLGGSDLGWLPIPSQEELMKLVRPPYSYSALIAMAIHGAPDKRLTLS





QIYQYVADNFPFYNKSKAGWQNSIRHNLSLNDCFKKVPRDEDDPGKGNY





WTLDPNCEKMFDNGNFRRKRKRKSDVSSSTASLALEKTESSLPVDSPKT





TEPQDILDGASPGGTTSSPEKRPSPPPSGAPCLNSFLSSMTAYVSGGSP





TSHPLVTPGLSPEPSDKTGQNSLTFNSFSPLTNLSNHSGGGDWANPMPT





NMLSYGGSVLSQFSPHFYNSVNTSGVLYPREGTEV,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:37


In some embodiments, the nucleic acid sequence encoding FOXI1 comprises the nucleic acid sequence:









(SEQ ID NO: 38; NM_012188)


ATGAGCTCCTTCGACCTGCCGGCGCCCTCCCCACCTCGCTGCAGCCCCC





AGTTCCCCAGCATCGGCCAGGAGCCCCCCGAGATGAACCTCTACTATGA





GAACTTCTTCCACCCACAGGGCGTGCCCAGCCCTCAGCGGCCCTCCTTC





GAGGGGGGCGGCGAGTATGGGGCCACCCCCAACCCCTACCTCTGGTTCA





ACGGGCCCACCATGACCCCGCCACCCTACCTGCCCGGCCCCAACGCCAG





CCCCTTCCTGCCCCAGGCCTATGGAGTGCAGAGACCGCTGCTGCCCAGC





GTGTCGGGGCTTGGGGGGAGCGACCTGGGCTGGCTGCCCATCCCCTCGC





AGGAGGAGCTGATGAAGCTGGTGCGGCCACCCTATTCCTACTCGGCTCT





CATCGCCATGGCCATCCACGGGGCACCCGACAAGCGCCTCACTCTCAGC





CAGATCTACCAGTACGTGGCCGACAACTTCCCCTTCTACAACAAGAGCA





AGGCCGGCTGGCAGAACTCCATCCGCCACAACCTGTCGCTCAACGACTG





CTTCAAGAAGGTGCCCCGCGACGAGGACGACCCGGGCAAAGGGAATTAC





TGGACCCTGGACCCCAACTGTGAGAAAATGTTCGACAATGGAAATTTCC





GCAGGAAAAGGAAGAGAAAATCAGATGTTTCCTCTAGCACAGCCTCCTT





GGCCTTAGAGAAGACAGAGAGCAGTCTCCCGGTGGACAGCCCCAAGACC





ACGGAGCCTCAGGACATCTTGGATGGAGCCTCACCAGGGGGCACCACCA





GCTCCCCAGAGAAGCGGCCCTCCCCTCCCCCATCAGGCGCCCCTTGCCT





TAACAGCTTCCTTTCCTCTATGACAGCCTATGTGAGCGGGGGGAGCCCC





ACGAGCCACCCCTTGGTCACACCAGGACTGAGCCCTGAGCCCAGTGACA





AGACGGGGCAGAACTCACTGACCTTCAACTCCTTCTCCCCGCTCACCAA





CCTCAGCAACCACAGCGGTGGGGGTGACTGGGCGAACCCCATGCCCACC





AACATGCTCAGCTACGGAGGATCTGTGCTCAGCCAATTCAGCCCTCACT





TCTACAACAGTGTCAACACCAGTGGTGTCCTCTACCCCAGGGAGGGCAC


CGAGGTC,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:38 under stringent hybridization conditions.


In some embodiments, Forhead box J1 (FOXJ1) comprises the amino acid sequence:









(SEQ ID NO: 39; NP_001445)


MAESWLRLSGAGPAEEAGPEGGLEEPDALDDSLTSLQWLQEFSILNAKA





PALPPGGTDPHGYHQVPGSAAPGSPLAADPACLGQPHTPGKPTSSCTSR





SAPPGLQAPPPDDVDYATNPHVKPPYYATLICMAMQASKATKITLSAIY





KWITDNFCYFRHADPTWQNSIRHNLSLNKCFIKVPREKDEPGKGGFWRI





DPQYAERLLSGAFKKRRLPPVHIHPAFARQAAQEPSAVPRAGPLTVNTE





AQQLLREFEEATGEAGWGAGEGRLGHKRKQPLPKRVAKVPRPPSTLLPT





PEEQGELEPLKGNFDWEAIFDAGTLGGELGALEALELSPPLSPASHVDV





DLTIHGRHIDCPATWGPSVEQAADSLDFDETFLATSFLQHPWDESGSGC





LPPEPLFEAGDATLASDLQDWASVGAFL,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:39.


In some embodiments, the nucleic acid sequence encoding FOXJ1 comprises the nucleic acid sequence:









(SEQ ID NO: 40; NM_001454)


ATGGCGGAGAGCTGGCTGCGCCTCTCGGGAGCCGGGCCGGCGGAGGAGG





CCGGGCCGGAGGGCGGCCTGGAGGAGCCCGACGCCCTGGATGACAGCCT





GACCAGCCTGCAGTGGCTGCAGGAATTCTCCATTCTCAACGCCAAGGCC





CCCGCCCTGCCCCCGGGGGGCACCGACCCCCACGGCTACCACCAGGTGC





CAGGTTCAGCGGCGCCCGGGTCCCCCCTGGCGGCCGACCCCGCCTGCCT





GGGGCAGCCACACACGCCGGGCAAGCCCACGTCGTCGTGCACGTCGCGG





AGCGCGCCCCCGGGGCTGCAGGCCCCACCCCCCGACGACGTGGACTACG





CCACCAATCCGCACGTGAAGCCTCCCTACTCGTATGCCACGCTCATCTG





CATGGCCATGCAGGCCAGCAAGGCCACCAAGATCACCCTGTCGGCCATC





TACAAGTGGATCACGGACAACTTCTGCTACTTCCGCCACGCAGATCCCA





CCTGGCAGAATTCAATCCGCCACAACCTGTCTCTGAACAAGTGCTTCAT





CAAAGTGCCTCGGGAGAAGGACGAACCAGGCAAGGGGGGCTTCTGGCGC





ATTGACCCCCAGTACGCGGAGCGGCTACTGAGCGGCGCTTTCAAGAAGC





GGCGACTGCCCCCTGTCCACATCCACCCAGCCTTTGCCCGCCAGGCCGC





GCAGGAGCCCAGCGCTGTCCCCCGGGCCGGGCCGCTGACGGTGAATACC





GAGGCCCAGCAGCTGCTGCGGGAGTTCGAGGAGGCCACCGGGGAGGCGG





GCTGGGGTGCAGGCGAGGGCAGGCTGGGGCATAAGCGCAAACAGCCGCT





GCCCAAGCGGGTGGCCAAGGTCCCGCGGCCCCCCAGCACCCTGCTGCCC





ACCCCGGAGGAGCAGGGTGAGCTGGAACCCCTCAAAGGCAACTTTGACT





GGGAGGCCATCTTCGACGCCGGCACTCTGGGCGGGGAGCTGGGTGCACT





GGAGGCCCTGGAGCTGAGCCCGCCTCTGAGCCCCGCCTCACACGTGGAC





GTGGACCTCACCATCCACGGCCGCCACATCGACTGCCCTGCCACCTGGG





GGCCTTCGGTGGAGCAGGCTGCCGACAGCCTGGACTTCGATGAGACCTT





CCTGGCCACATCCTTCCTGCAGCACCCCTGGGACGAGAGCGGCAGTGGC





TGCCTGCCCCCGGAGCCCCTCTTTGAGGCTGGGGATGCCACCCTGGCCT





CCGACCTGCAGGACTGGGCCAGCGTGGGGGCCTTCTTG,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:40 under stringent hybridization conditions.


In some embodiments, Forkhead box K1 (FOXK1) comprises the amino acid sequence:









(SEQ ID NO: 41; NP_001032242)


MAEVGEDSGARALLALRSAPCSPVLCAAAAAAAFPAAAPPPAPAQPQPP





PGPPPPPPPPLPPGAIAGAGSSGGSSGVSGDSAVAGAAPALVAAAAASV





RQSPGPALARLEGREFEFLMRQPSVTIGRNSSQGSVDLSMGLSSFISRR





HLQLSFQEPHFYLRCLGKNGVFVDGAFQRRGAPALQLPKQCTFRFPSTA





IKIQFTSLYHKEEAPASPLRPLYPQISPLKIHIPEPDLRSMVSPVPSPT





GTISVPNSCPASPRGAGSSSYRFVQNVTSDLQLAAEFAAKAASEQQADT





SGGDSPKDESKPPFSYAQLIVQAISSAQDRQLTLSGIYAHITKHYPYYR





TADKGWQNSIRHNLSLNRYFIKVPRSQEEPGKGSFWRIDPASEAKLVEQ





AFRKRRQRGVSCFRTPFGPLSSRSAPASPTHPGLMSPRSGGLQTPECLS





REGSPIPHDPEFGSKLASVPEYRYSQSAPGSPVSAQPVIMAVPPRPSSL





VAKPVAYMPASIVTSQQPAGHAIHVVQQAPTVTMVRVVTTSANSANGYI





LTSQGAAGGSHDAAGAAVLDLGSEARGLEEKPTIAFATIPAAGGVIQTV





ASQMAPGVPGHTVTILQPATPVTLGQHHLPVRAVTQNGKHAVPTNSLAG





NAYALTSPLQLLATQASSSAPVVVTRVCEVGPKEPAAAVAATATTTPAT





ATTASASASSTGEPEVKRSRVEEPSGAVTTPAGVIAAAGPQGPGTGE,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:41.


In some embodiments, the nucleic acid sequence encoding FOXK1 comprises the nucleic acid sequence:









(SEQ ID NO: 42; NM_001037165)


ATGGCCGAAGTCGGCGAGGACAGCGGCGCCCGCGCCCTGCTCGCGCTGC





GCTCGGCGCCCTGCAGCCCAGTGCTGTGCGCCGCAGCCGCCGCCGCCGC





CTTCCCCGCGGCCGCACCCCCGCCGGCCCCCGCGCAGCCCCAGCCTCCG





CCCGGGCCGCCGCCGCCGCCGCCACCGCCGCTGCCTCCGGGCGCGATCG





CGGGCGCGGGCTCCTCCGGGGGCTCCTCCGGGGTATCCGGGGACTCCGC





GGTCGCGGGCGCGGCGCCGGCCCTGGTGGCCGCGGCGGCCGCCTCGGTA





CGGCAGAGCCCGGGGCCGGCGCTGGCGCGGCTGGAGGGCCGCGAGTTCG





AGTTCCTCATGCGCCAGCCCAGCGTCACCATCGGCCGCAACTCGTCGCA





GGGCTCGGTGGACTTGAGCATGGGCCTGTCCAGCTTCATCTCGCGGCGC





CACCTGCAGCTCAGCTTCCAGGAGCCGCACTTCTACCTGCGCTGCCTCG





GCAAGAACGGCGTCTTCGTGGACGGGGCCTTCCAGAGACGCGGCGCGCC





CGCCCTGCAGCTGCCCAAGCAGTGTACCTTCCGGTTTCCCAGCACGGCC





ATCAAGATCCAGTTCACGTCGCTCTATCACAAAGAAGAGGCCCCAGCCT





CCCCGCTGCGGCCACTGTACCCCCAGATCTCCCCTCTGAAGATCCACAT





CCCGGAGCCGGACCTCCGGAGCATGGTCAGCCCCGTCCCCTCCCCGACG





GGCACCATCAGTGTCCCCAACTCCTGCCCAGCCAGTCCACGCGGTGCCG





GCTCCTCCAGTTACCGCTTTGTGCAGAACGTGACCTCGGACCTGCAGCT





GGCAGCAGAGTTTGCAGCAAAGGCCGCGTCGGAGCAGCAGGCAGACACG





TCTGGAGGAGACAGCCCCAAGGATGAGTCAAAGCCGCCGTTCTCCTACG





CGCAGCTGATCGTGCAGGCCATCTCCTCCGCCCAGGACCGGCAGCTGAC





CCTGAGCGGGATCTACGCCCACATCACCAAGCATTACCCCTACTACCGG





ACGGCCGACAAAGGCTGGCAGAATTCTATCCGGCACAACCTCTCTTTGA





ACCGTTACTTTATCAAAGTCCCACGTTCCCAGGAGGAGCCTGGGAAGGG





GTCCTTTTGGCGAATAGACCCTGCCTCTGAAGCCAAGCTCGTGGAACAG





GCATTCCGGAAACGGAGGCAGAGGGGTGTCTCCTGCTTCCGCACCCCCT





TCGGGCCTCTGTCCTCAAGGAGCGCTCCAGCTTCGCCCACACACCCCGG





GCTGATGTCCCCTCGCTCCGGCGGCCTGCAGACCCCAGAGTGCCTGTCT





CGGGAGGGCTCCCCCATTCCACACGACCCTGAGTTTGGGTCCAAGTTAG





CTTCTGTCCCAGAGTACCGGTATTCCCAAAGCGCACCCGGCTCCCCCGT





CAGCGCCCAGCCAGTGATCATGGCCGTGCCTCCCCGACCGTCCAGCCTC





GTGGCCAAGCCCGTGGCCTACATGCCCGCCTCCATCGTAACCTCACAGC





AGCCCGCGGGCCACGCCATCCACGTCGTGCAGCAGGCCCCCACCGTCAC





CATGGTCAGGGTGGTCACCACATCTGCCAACTCGGCCAACGGATACATC





CTCACCAGCCAGGGCGCGGCGGGGGGCTCCCATGATGCGGCGGGCGCAG





CCGTGCTGGACCTGGGCAGCGAGGCCAGAGGCCTGGAGGAGAAACCCAC





CATTGCGTTTGCCACAATCCCCGCGGCTGGTGGAGTCATCCAGACGGTG





GCCAGCCAGATGGCCCCCGGGGTCCCCGGACACACGGTCACCATCCTGC





AGCCCGCCACACCCGTGACCCTCGGGCAGCACCACCTTCCAGTCCGGGC





CGTGACCCAGAACGGAAAGCATGCGGTTCCCACGAACAGTTTAGCCGGC





AACGCTTACGCCCTCACCAGCCCTTTGCAGCTCCTTGCGACCCAAGCGA





GTTCATCCGCGCCGGTGGTGGTCACCCGGGTGTGCGAGGTGGGGCCCAA





GGAGCCAGCAGCAGCCGTCGCGGCCACGGCCACCACCACCCCAGCCACT





GCCACCACCGCCTCTGCCTCCGCCTCTTCCACTGGAGAGCCCGAGGTCA





AAAGGTCCCGGGTGGAGGAGCCCAGTGGGGCTGTAACCACACCGGCTGG





AGTGATCGCAGCTGCCGGCCCCCAGGGGCCAGGCACCGGGGAG,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:42 under stringent hybridization conditions.


In some embodiments, Forkhead box L1 (FOXL1) comprises the amino acid sequence:









(SEQ ID NO: 43; NP_005241)


MSHLFDPRLPALAASPMLYLYGPERPGLPLAFAPAAALAASGRAETPQK





PPYSYIALIAMAIQDAPEQRVTLNGIYQFIMDRFPFYHDNRQGWQNSIR





HNLSLNDCFVKVPREKGRPGKGSYWTLDPRCLDMFENGNYRRRKRKPKP





GPGAPEAKRPRAETHQRSAEAQPEAGSGAGGSGPAISRLQAAPAGPSPL





LDGPSPPAPLHWPGTASPNEDAGDAAQGAAAVAVGQAARTGDGPGSPLR





PASRSSPKSSDKSKSFSIDSILAGKQGQKPPSGDELLGGAKPGPGGRLG





ASLLAASSSLRPPFNASLMLDPHVQGGFYQLGIPFLSYFPLQVPDTVLH





FQ,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:43.


In some embodiments, the nucleic acid sequence encoding FOXL1 comprises the nucleic acid sequence:









(SEQ ID NO: 44; NM_005250)


ATGAGTCACCTCTTCGATCCCCGGCTGCCTGCCCTGGCCGCCTCGCCCA





TGCTGTATCTGTACGGTCCCGAGAGACCCGGCCTCCCTCTGGCCTTCGC





CCCCGCGGCTGCTCTAGCTGCCTCGGGCCGGGCCGAGACCCCGCAGAAG





CCTCCCTACAGCTACATCGCGCTCATCGCCATGGCGATCCAGGACGCGC





CCGAGCAGAGGGTCACGCTCAACGGCATCTACCAGTTCATCATGGACCG





CTTCCCCTTCTACCACGACAACCGGCAGGGCTGGCAGAACAGCATCCGC





CACAACCTCTCGCTCAACGACTGCTTCGTCAAGGTGCCCCGCGAGAAAG





GGCGGCCGGGCAAGGGCAGCTACTGGACGCTGGACCCCCGCTGCCTGGA





CATGTTTGAGAACGGCAACTACCGGCGCCGGAAGAGGAAGCCCAAGCCG





GGCCCCGGGGCCCCGGAGGCCAAGAGGCCCCGCGCCGAGACGCACCAGC





GCAGCGCGGAGGCGCAGCCGGAGGCGGGGAGCGGGGCAGGGGGCTCGGG





CCCCGCAATCTCCCGCCTGCAGGCAGCGCCCGCGGGCCCCTCGCCCCTC





CTGGACGGCCCCTCTCCGCCGGCGCCCCTCCACTGGCCGGGGACCGCGT





CCCCGAACGAGGACGCTGGTGACGCTGCCCAGGGCGCAGCGGCCGTGGC





GGTCGGCCAGGCAGCGCGCACAGGGGACGGCCCGGGGTCCCCTCTGCGC





CCCGCCTCCCGCAGCTCTCCGAAGAGCTCCGACAAGTCCAAGAGCTTCA





GCATAGACAGCATCCTGGCGGGAAAGCAGGGCCAGAAGCCGCCTTCAGG





GGACGAACTCCTAGGGGGTGCCAAGCCTGGGCCCGGCGGCCGTCTGGGT





GCCTCGCTCCTGGCCGCCTCCTCCAGCCTCCGTCCGCCTTTCAACGCTT





CCCTGATGCTCGACCCGCATGTCCAGGGCGGCTTTTACCAGCTCGGGAT





CCCCTTCCTCTCTTATTTCCCCCTGCAGGTTCCCGACACGGTACTCCAC





TTCCAG,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:44 under stringent hybridization conditions.


In some embodiments, Forkhead box L2 (FOXL2) comprises the amino acid sequence









(SEQ ID NO: 45; NP_075555)


MMASYPEPEDAAGALLAPETGRTVKEPEGPPPSPGKGGGGGGGTAPEKP





DPAQKPPYSYVALIAMAIRESAEKRLTLSGIYQYIIAKFPFYEKNKKGW





QNSIRHNLSLNECFIKVPREGGGERKGNYWTLDPACEDMFEKGNYRRRR





RMKRPFRPPPAHFQPGKGLFGAGGAAGGCGVAGAGADGYGYLAPPKYLQ





SGFLNNSWPLPQPPSPMPYASCQMAAAAAAAAAAAAAAGPGSPGAAAVV





KGLAGPAASYGPYTRVQSMALPPGVVNSYNGLGGPPAAPPPPPHPHPHP





HAHHLHAAAAPPPAPPHHGAAAPPPGQLSPASPATAAPPAPAPTSAPGL





QFACARQPELAMMHCSYWDHDSKTGALHSRLDL,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:45.


In some embodiments, the nucleic acid sequence encoding FOXL2 comprises the nucleic acid sequence:









(SEQ ID NO: 46; NM_023067)


ATGATGGCCAGCTACCCCGAGCCCGAGGACGCGGCGGGGGCCCTGCTGG





CCCCAGAGACCGGTCGCACAGTCAAGGAGCCAGAAGGGCCGCCGCCGAG





CCCAGGCAAGGGCGGTGGGGGTGGCGGCGGGACAGCCCCGGAGAAGCCG





GACCCGGCGCAGAAGCCCCCGTACTCGTACGTGGCGCTCATCGCCATGG





CGATCCGCGAGAGCGCGGAGAAGAGGCTCACGCTGTCCGGCATCTACCA





GTACATCATCGCGAAGTTCCCGTTCTACGAGAAGAATAAGAAGGGCTGG





CAAAATAGCATCCGCCACAACCTCAGCCTCAACGAGTGCTTCATCAAGG





TGCCGCGCGAGGGCGGCGGCGAGCGCAAGGGCAACTACTGGACGCTGGA





CCCGGCCTGCGAAGACATGTTCGAGAAGGGCAACTACCGGCGCCGCCGC





CGCATGAAGAGGCCCTTCCGGCCGCCGCCCGCGCACTTCCAGCCCGGCA





AGGGGCTCTTCGGGGCCGGAGGCGCCGCAGGCGGGTGCGGCGTGGCGGG





CGCCGGGGCCGACGGCTACGGCTACCTGGCGCCCCCCAAGTACCTGCAG





TCTGGCTTCCTCAACAACTCGTGGCCGCTACCGCAGCCTCCCTCACCCA





TGCCCTATGCCTCCTGCCAGATGGCGGCAGCCGCAGCGGCTGCAGCAGC





TGCGGCTGCAGCCGCGGGCCCCGGTAGCCCTGGCGCGGCCGCTGTGGTC





AAGGGGCTGGCGGGCCCGGCCGCCTCGTACGGGCCGTACACACGCGTGC





AGAGCATGGCGCTGCCCCCCGGCGTAGTGAACTCGTACAATGGCCTGGG





AGGCCCGCCGGCCGCACCCCCGCCTCCGCCGCACCCCCACCCGCATCCG





CACGCACACCATCTGCACGCGGCCGCCGCACCGCCGCCTGCCCCACCGC





ACCACGGGGCCGCCGCGCCGCCGCCGGGCCAGCTCAGCCCTGCCAGCCC





AGCCACCGCCGCGCCCCCGGCGCCCGCGCCCACCAGTGCGCCGGGCCTG





CAGTTCGCTTGTGCCCGGCAGCCCGAGCTCGCCATGATGCATTGCTCTT





ACTGGGACCACGACAGCAAGACCGGCGCGCTGCATTCGCGCCTCGATCT





C,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:46 under stringent hybridization conditions.


In some embodiments, Forhead box M1 (FOXM1) comprises the amino acid sequence:









(SEQ ID NO: 47; NP_068772)


MKTSPRRPLILKRRRLPLPVQNAPSETSEEEPKRSPAQQESNQAEASKE





VAESNSCKFPAGIKIINHPTMPNTQVVAIPNNANIHSIITALTAKGKES





GSSGPNKFILISCGGAPTQPPGLRPQTQTSYDAKRTEVTLETLGPKPAA





RDVNLPRPPGALCEQKRETCADGEAAGCTINNSLSNIQWLRKMSSDGLG





SRSIKQEMEEKENCHLEQRQVKVEEPSRPSASWQNSVSERPPYSYMAMI





QFAINSTERKRMTLKDIYTWIEDHFPYFKHIAKPGWKNSIRHNLSLHDM





FVRETSANGKVSFWTIHPSANRYLTLDQVFKPLDPGSPQLPEHLESQQK





RPNPELRRNMTIKTELPLGARRKMKPLLPRVSSYLVPIQFPVNQSLVLQ





PSVKVPLPLAASLMSSELARHSKRVRIAPKVLLAEEGIAPLSSAGPGKE





EKLLFGEGFSPLLPVQTIKEEEIQPGEEMPHLARPIKVESPPLEEWPSP





APSFKEESSHSWEDSSQSPTPRPKKSYSGLRSPTRCVSEMLVIQHRERR





ERSRSRRKQHLLPPCVDEPELLFSEGPSTSRWAAELPFPADSSDPASQL





SYSQEVGGPFKTPIKETLPISSTPSKSVLPRTPESWRLTPPAKVGGLDF





SPVQTSQGASDPLPDPLGLMDLSTTPLQSAPPLESPQRLLSSEPLDLIS





VPFGNSSPSDIDVPKPGSPEPQVSGLAANRSLTEGLVLDTMNDSLSKIL





LDISFPGLDEDPLGPDNINWSQFIPELQ,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:47.


In some embodiments, the nucleic acid sequence encoding FOXM1 comprises the nucleic acid sequence:









(SEQ ID NO: 48; NM_021953)


ATGAAAACTAGCCCCCGTCGGCCACTGATTCTCAAAAGACGGAGGCTGC





CCCTTCCTGTTCAAAATGCCCCAAGTGAAACATCAGAGGAGGAACCTAA





GAGATCCCCTGCCCAACAGGAGTCTAATCAAGCAGAGGCCTCCAAGGAA





GTGGCAGAGTCCAACTCTTGCAAGTTTCCAGCTGGGATCAAGATTATTA





ACCACCCCACCATGCCCAACACGCAAGTAGTGGCCATCCCCAACAATGC





TAATATTCACAGCATCATCACAGCACTGACTGCCAAGGGAAAAGAGAGT





GGCAGTAGTGGGCCCAACAAATTCATCCTCATCAGCTGTGGGGGAGCCC





CAACTCAGCCTCCAGGACTCCGGCCTCAAACCCAAACCAGCTATGATGC





CAAAAGGACAGAAGTGACCCTGGAGACCTTGGGACCAAAACCTGCAGCT





AGGGATGTGAATCTTCCTAGACCACCTGGAGCCCTTTGCGAGCAGAAAC





GGGAGACCTGTGCAGATGGTGAGGCAGCAGGCTGCACTATCAACAATAG





CCTATCCAACATCCAGTGGCTTCGAAAGATGAGTTCTGATGGACTGGGC





TCCCGCAGCATCAAGCAAGAGATGGAGGAAAAGGAGAATTGTCACCTGG





AGCAGCGACAGGTTAAGGTTGAGGAGCCTTCGAGACCATCAGCGTCCTG





GCAGAACTCTGTGTCTGAGCGGCCACCCTACTCTTACATGGCCATGATA





CAATTCGCCATCAACAGCACTGAGAGGAAGCGCATGACTTTGAAAGACA





TCTATACGTGGATTGAGGACCACTTTCCCTACTTTAAGCACATTGCCAA





GCCAGGCTGGAAGAACTCCATCCGCCACAACCTTTCCCTGCACGACATG





TTTGTCCGGGAGACGTCTGCCAATGGCAAGGTCTCCTTCTGGACCATTC





ACCCCAGTGCCAACCGCTACTTGACATTGGACCAGGTGTTTAAGCCACT





GGACCCAGGGTCTCCACAATTGCCCGAGCACTTGGAATCACAGCAGAAA





CGACCGAATCCAGAGCTCCGCCGGAACATGACCATCAAAACCGAACTCC





CCCTGGGCGCACGGCGGAAGATGAAGCCACTGCTACCACGGGTCAGCTC





ATACCTGGTACCTATCCAGTTCCCGGTGAACCAGTCACTGGTGTTGCAG





CCCTCGGTGAAGGTGCCATTGCCCCTGGCGGCTTCCCTCATGAGCTCAG





AGCTTGCCCGCCATAGCAAGCGAGTCCGCATTGCCCCCAAGGTGCTGCT





AGCTGAGGAGGGGATAGCTCCTCTTTCTTCTGCAGGACCAGGGAAAGAG





GAGAAACTCCTGTTTGGAGAAGGGTTTTCTCCTTTGCTTCCAGTTCAGA





CTATCAAGGAGGAAGAAATCCAGCCTGGGGAGGAAATGCCACACTTAGC





GAGACCCATCAAAGTGGAGAGCCCTCCCTTGGAAGAGTGGCCCTCCCCG





GCCCCATCTTTCAAAGAGGAATCATCTCACTCCTGGGAGGATTCGTCCC





AATCTCCCACCCCAAGACCCAAGAAGTCCTACAGTGGGCTTAGGTCCCC





AACCCGGTGTGTCTCGGAAATGCTTGTGATTCAACACAGGGAGAGGAGG





GAGAGGAGCCGGTCTCGGAGGAAACAGCATCTACTGCCTCCCTGTGTGG





ATGAGCCGGAGCTGCTCTTCTCAGAGGGGCCCAGTACTTCCCGCTGGGC





CGCAGAGCTCCCGTTCCCAGCAGACTCCTCTGACCCTGCCTCCCAGCTC





AGCTACTCCCAGGAAGTGGGAGGACCTTTTAAGACACCCATTAAGGAAA





CGCTGCCCATCTCCTCCACCCCGAGCAAATCTGTCCTCCCCAGAACCCC





TGAATCCTGGAGGCTCACGCCCCCAGCCAAAGTAGGGGGACTGGATTTC





AGCCCAGTACAAACCTCCCAGGGTGCCTCTGACCCCTTGCCTGACCCCC





TGGGGCTGATGGATCTCAGCACCACTCCCTTGCAAAGTGCTCCCCCCCT





TGAATCACCGCAAAGGCTCCTCAGTTCAGAACCCTTAGACCTCATCTCC





GTCCCCTTTGGCAACTCTTCTCCCTCAGATATAGACGTCCCCAAGCCAG





GCTCCCCGGAGCCACAGGTTTCTGGCCTTGCAGCCAATCGTTCTCTGAC





AGAAGGCCTGGTCCTGGACACAATGAATGACAGCCTCAGCAAGATCCTG





CTGGACATCAGCTTTCCTGGCCTGGACGAGGACCCACTGGGCCCTGACA





ACATCAACTGGTCCCAGTTTATTCCTGAGCTACAG,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:48 under stringent hybridization conditions.


In some embodiments, Forkhead box N1 (FOXN1) comprises the amino acid sequence:









(SEQ ID NO: 49; NP_003584)


MVSLPPPQSDVTLPGPTRLEGERQGDLMQAPGLPGSPAPQSKHAGFSCS





SFVSDGPPERTPSLPPHSPRIASPGPEQVQGHCPAGPGPGPFRLSPSDK





YPGFGFEEAAASSPGRFLKGSHAPFHPYKRPFHEDVFPEAETTLALKGH





SFKTPGPLEAFEEIPVDVAEAEAFLPGFSAEAWCNGLPYPSQEHGPQVL





GSEVKVKPPVLESGAGMFCYQPPLQHMYCSSQPPFHQYSPGGGSYPIPY





LGSSHYQYQRMAPQASTDGHQPLFPKPIYSYSILIFMALKNSKTGSLPV





SEIYNFMTEHFPYFKTAPDGWKNSVRHNLSLNKCFEKVENKSGSSSRKG





CLWALNPAKIDKMQEELQKWKRKDPIAVRKSMAKPEELDSLIGDKREKL





GSPLLGCPPPGLSGSGPIRPLAPPAGLSPPLHSLHPAPGPIPGKNPLQD





LLMGHTPSCYGQTYLHLSPGLAPPGPPQPLFPQPDGHLELRAQPGTPQD





SPLPAHTPPSHSAKLLAEPSPARTMHDTLLPDGDLGTDLDAINPSLTDF





DFQGNLWEQLKDDSLALDPLVLVTSSPTSSSMPPPQPPPHCFPPGPCLT





ETGSGAGDLAAPGSGGSGALGDLHLTTLYSAFMELEPTPPTAPAGPSVY





LSPSSKPVALA,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:49.


In some embodiments, the nucleic acid sequence encoding FOXN1 comprises the nucleic acid sequence:









(SEQ ID NO: 50; NM_003593)


ATGGTGTCGCTACCCCCGCCGCAGTCTGACGTCACGCTGCCGGGCCCCA





CCAGACTGGAGGGCGAGCGCCAAGGGGACCTCATGCAGGCACCGGGCCT





CCCAGGCTCCCCTGCCCCACAGAGTAAGCATGCCGGCTTCAGCTGCTCG





TCATTTGTGTCCGACGGCCCTCCAGAGAGGACACCCTCACTGCCCCCAC





ACAGCCCCCGCATTGCGTCACCAGGGCCCGAGCAAGTCCAGGGCCACTG





CCCAGCCGGCCCCGGCCCTGGGCCCTTCAGGCTCTCACCCTCAGACAAG





TATCCTGGCTTTGGCTTTGAGGAGGCCGCAGCAAGCAGCCCTGGGCGAT





TCCTCAAGGGCAGCCACGCGCCCTTCCACCCGTACAAGCGGCCTTTCCA





TGAGGACGTCTTCCCAGAGGCCGAGACCACCCTGGCCCTCAAAGGACAC





TCCTTTAAGACCCCAGGGCCGCTGGAGGCCTTCGAGGAGATCCCAGTGG





ACGTGGCGGAGGCCGAGGCCTTCCTGCCTGGCTTCTCAGCAGAGGCCTG





GTGTAACGGGCTCCCCTACCCCAGCCAGGAGCATGGCCCCCAAGTCCTG





GGTTCAGAGGTCAAAGTCAAGCCCCCAGTTCTGGAGAGTGGTGCTGGGA





TGTTCTGCTACCAGCCTCCCTTGCAGCATATGTACTGCTCCTCCCAGCC





CCCCTTCCACCAGTACTCGCCAGGTGGTGGCAGCTACCCCATACCCTAC





CTGGGCTCCTCACACTATCAGTACCAGCGAATGGCACCCCAGGCCAGCA





CCGATGGGCACCAGCCTCTCTTCCCAAAACCCATCTATTCCTACAGCAT





CCTCATCTTCATGGCCCTTAAGAACAGTAAAACTGGGAGCCTTCCCGTC





AGCGAGATCTACAATTTTATGACGGAGCACTTTCCTTACTTCAAGACAG





CACCCGATGGCTGGAAGAATTCTGTCCGGCACAACCTATCCCTCAACAA





GTGCTTCGAGAAGGTGGAGAACAAATCAGGAAGTTCCTCCCGCAAGGGC





TGCCTGTGGGCCCTCAATCCGGCCAAGATCGACAAGATGCAAGAGGAGC





TGCAAAAATGGAAGAGGAAAGATCCCATTGCTGTGCGCAAAAGCATGGC





CAAGCCAGAAGAGCTGGACAGCCTCATTGGAGACAAGAGAGAAAAGCTG





GGCTCCCCACTCCTGGGCTGTCCGCCCCCTGGGCTGTCCGGCTCAGGCC





CCATCCGGCCCCTGGCACCCCCAGCTGGCCTCTCCCCACCACTGCACTC





ACTCCACCCAGCTCCAGGCCCCATTCCTGGCAAGAACCCCCTGCAGGAC





CTACTTATGGGGCACACACCCTCCTGCTATGGGCAGACATACTTGCACC





TCTCACCAGGCCTGGCCCCTCCTGGACCCCCGCAGCCATTGTTCCCACA





GCCGGACGGGCACCTTGAGCTGCGGGCCCAGCCAGGCACCCCCCAGGAC





TCGCCTCTGCCTGCCCACACCCCACCCAGCCACAGTGCCAAGCTACTGG





CCGAGCCTTCCCCAGCCAGGACTATGCACGACACCCTGCTGCCAGATGG





AGACCTTGGCACTGACCTGGATGCCATCAATCCCTCACTCACTGACTTC





GACTTCCAGGGAAACCTGTGGGAACAGTTGAAGGATGATAGCTTGGCCC





TCGACCCCCTGGTACTGGTGACCTCATCCCCGACATCATCTTCGATGCC





ACCACCCCAGCCACCACCTCACTGCTTCCCCCCTGGGCCCTGTCTGACA





GAGACAGGCAGTGGGGCAGGTGACTTGGCAGCCCCGGGCAGTGGTGGCT





CCGGGGCACTGGGTGACCTGCACCTCACCACCCTCTACTCTGCCTTTAT





GGAGCTGGAGCCACGCCCCCCACGGCCCCTGCAGGCCCCTCTGTGTACC





TCAGCCCCAGCTCCAAGCCCGTGGCCCTGGCA,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:50 under stringent hybridization conditions.


In some embodiments, Forhead box N2 (FOXN2) comprises the amino acid sequence:









(SEQ ID NO: 51; NP_002149)


MGPVIGMTPDKRAETPGAEKIAGLSQIYKMGSLPEAVDAARPKATLVDS





ESADDELTNLNWLHESTNLLTNFSLGSEGLPIVSPLYDIEGDDVPSFGP





ACYQNPEKKSATSKPPYSFSLLIYMAIEHSPNKCLPVKEIYSWILDHFP





YFATAPTGWKNSVRHNLSLNKCFQKVERSHGKVNGKGSLWCVDPEYKPN





LIQALKKQPFSSASSQNGSLSPHYLSSVIKQNQVRNLKESDIDAAAAMM





LLNTSIEQGILECEKPLPLKTALQKKRSYGNAFHHPSAVRLQESDSLAT





SIDPKEDHNYSASSMAAQRCASRSSVSSLSSVDEVYEFIPKNSHVGSDG





SEGFHSEEDTDVDYEDDPLGDSGYASQPCAKISEKGQSGKKMRKQTCQE





IDEELKEAAGSLLHLAGIRTCLGSLISTAKTQNQKQRKK,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:51.


In some embodiments, the nucleic acid sequence encoding FOXN2 comprises the nucleic acid sequence:









(SEQ ID NO: 52; NM_002158)


ATGGGTCCAGTAATTGGAATGACTCCAGATAAGAGAGCTGAAACCCCAG





GAGCTGAAAAGATTGCAGGATTAAGCCAGATTTACAAAATGGGAAGCTT





GCCTGAAGCTGTTGATGCTGCCAGGCCGAAGGCCACTCTAGTGGACAGT





GAGTCAGCAGATGATGAACTCACAAACTTGAACTGGCTTCATGAAAGCA





CTAATCTTCTAACAAACTTCAGCCTCGGAAGTGAGGGTCTTCCAATTGT





TAGTCCATTGTATGACATAGAGGGAGATGATGTGCCATCCTTTGGACCA





GCTTGCTACCAGAACCCAGAAAAAAAATCAGCGACTTCAAAGCCCCCAT





ACTCCTTTAGTCTTCTCATTTATATGGCCATTGAGCACTCTCCAAATAA





ATGTTTGCCTGTCAAAGAAATTTATAGCTGGATTCTGGACCATTTTCCA





TATTTTGCTACTGCACCAACAGGCTGGAAGAATTCTGTTCGACATAATC





TGTCCCTGAATAAATGTTTTCAGAAAGTGGAAAGAAGCCATGGCAAGGT





TAATGGAAAAGGTTCCTTATGGTGTGTTGATCCGGAATATAAACCCAAT





CTTATCCAGGCACTGAAGAAGCAACCTTTTTCTTCAGCATCTTCACAAA





ATGGTTCTTTATCACCTCACTATTTAAGCTCTGTAATCAAGCAGAACCA





GGTGCGAAACCTCAAAGAATCTGATATTGATGCTGCTGCTGCAATGATG





CTTTTAAATACTTCTATAGAACAAGGAATTTTAGAATGTGAGAAGCCTC





TTCCTCTTAAAACAGCATTGCAAAAAAAGAGGAGTTACGGCAATGCATT





TCATCATCCCAGTGCTGTACGATTACAAGAGAGTGATTCTTTAGCCACC





AGCATTGATCCAAAAGAAGATCACAATTACAGTGCAAGTAGCATGGCAG





CACAGCGTTGTGCATCCAGGTCTAGCGTGTCTTCTCTGTCTTCTGTGGA





TGAGGTATATGAATTTATCCCAAAGAATAGTCACGTGGGAAGTGATGGC





AGTGAAGGATTTCACAGTGAAGAAGATACAGACGTTGATTATGAAGATG





ATCCTCTTGGAGACAGTGGCTATGCATCACAGCCTTGTGCAAAAATCTC





TGAAAAAGGGCAGTCAGGCAAAAAGATGCGAAAACAGACATGTCAAGAA





ATTGATGAGGAGCTCAAAGAGGCAGCTGGATCTCTGCTCCACCTTGCTG





GAATTCGTACATGTTTAGGTTCCCTAATAAGTACTGCAAAGACACAAAA





TCAAAAGCAACGGAAAAAA,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:52 under stringent hybridization conditions.


In some embodiments, Forkhead box N3 (FOXN3) comprises the amino acid sequence:









(SEQ ID NO: 53; NP_001078940)


MGPVMPPSKKPESSGISVSSGLSQCYGGSGFSKALQEDDDLDFSLPDIR





LEEGAMEDEELTNLNWLHESKNLLKSFGESVLRSVSPVQDLDDDTPPSP





AHSDMPYDARQNPNCKPPYSFSCLIFMAIEDSPTKRLPVKDIYNWILEH





FPYFANAPTGWKNSVRHNLSLNKCFKKVDKERSQSIGKGSLWCIDPEYR





QNLIQALKKTPYHPHPHVFNTPPTCPQAYQSTSGPPIWPGSTFFKRNGA





LLQDPDIDAASAMMLLNTPPEIQAGFPPGVIQNGARVLSRGLFPGVRPL





PITPIGVTAAMRNGITSCRMRTESEPSCGSPVVSGDPKEDHNYSSAKSS





NARSTSPTSDSISSSSSSADDHYEFATKGSQEGSEGSEGSFRSHESPSD





TEEDDRKHSQKEPKDSLGDSGYASQHKKRQHFAKARKVPSDTLPLKKRR





TEKPPESDDEEMKEAAGSLLHLAGIRSCLNNITNRTAKGQKEQKETTK





N,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:53.


In some embodiments, the nucleic acid sequence encoding FOXN3 comprises the nucleic acid sequence:









(SEQ ID NO: 54; NM_001085471)


ATGGGTCCAGTCATGCCTCCCAGTAAGAAGCCAGAAAGCTCAGGAATTA





GTGTCTCCAGTGGACTGAGTCAGTGTTACGGGGGCAGCGGTTTCTCCAA





GGCCCTTCAGGAAGACGATGACCTCGACTTTTCTCTGCCTGACATCCGA





TTAGAAGAGGGGGCCATGGAAGATGAAGAGCTGACCAACCTGAACTGGC





TGCACGAGAGCAAGAACTTGCTGAAGAGCTTTGGGGAGTCGGTCCTCAG





GAGTGTCAGCCCCGTCCAGGACCTGGACGATGACACCCCCCCATCCCCT





GCCCACTCTGACATGCCCTACGATGCCAGGCAGAACCCCAACTGCAAAC





CCCCCTACTCCTTCAGCTGCCTCATATTTATGGCCATCGAGGACTCTCC





AACCAAGCGCCTGCCAGTGAAGGATATCTACAACTGGATCTTGGAACAT





TTTCCGTATTTTGCAAATGCACCTACTGGGTGGAAAAACTCAGTGAGAC





ACAATTTATCATTGAATAAGTGTTTTAAGAAAGTGGACAAAGAGAGGAG





TCAGAGTATTGGGAAAGGGTCGTTGTGGTGCATAGACCCAGAGTATAGA





CAAAATCTAATTCAGGCTTTGAAAAAGACACCTTATCACCCACACCCAC





ACGTGTTCAATACACCTCCCACCTGTCCTCAGGCATATCAAAGCACATC





AGGTCCACCCATCTGGCCGGGCAGTACCTTCTTCAAGAGAAATGGAGCC





CTTCTCCAAGATCCTGACATTGATGCTGCCAGTGCCATGATGCTTTTGA





ATACTCCCCCTGAGATACAAGCAGGTTTTCCTCCAGGAGTGATCCAAAA





TGGAGCGCGGGTCCTGAGCCGAGGGCTGTTTCCTGGCGTGCGGCCGCTG





CCAATCACTCCCATTGGGGTGACAGCGGCCATGAGGAATGGCATCACCA





GCTGCCGGATGCGGACTGAGAGTGAGCCATCTTGTGGCTCCCCAGTGGT





CAGCGGAGACCCCAAGGAGGATCACAACTACAGCAGTGCCAAGTCCTCC





AACGCCCGGAGCACCTCGCCCACCAGCGACTCCATCTCCTCCTCCTCCT





CCTCAGCCGACGACCACTATGAGTTTGCCACCAAGGGGAGCCAGGAGGG





CAGCGAGGGCAGCGAGGGGAGCTTCCGGAGCCACGAGAGCCCCAGCGAC





ACGGAAGAGGACGACAGGAAGCACAGCCAGAAGGAGCCCAAGGATTCTC





TGGGGGACAGCGGGTACGCATCCCAGCACAAGAAGCGCCAGCACTTCGC





CAAGGCCAGGAAGGTCCCCAGCGACACACTGCCCCTCAAAAAGAGACGC





ACCGAAAAGCCCCCCGAGAGCGATGATGAGGAGATGAAAGAAGCGGCAG





GGTCCCTCCTGCACTTAGCAGGGATCCGGTCCTGTTTGAATAACATCAC





CAATCGGACGGCAAAGGGGCAGAAAGAGCAAAAGGAAACCACAAAAAA





T,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:54 under stringent hybridization conditions.


In some embodiments, Forkhead box N4 (FOXN4) comprises the amino acid sequence:









(SEQ ID NO: 55; NP_998761)


MIESDTSSIMSGIIRNSGQNHHPSPQEYRLLATTSDDDLPGDLQSLSWL





TAVDVPRLQQMASGRVDLGGPCVPHPHPGALAGVADLHVGATPSPLLHG





PAGMAPRGMPGLGPITGHRDSMSQFPVGGQPSSGLQDPPHLYSPATQPQ





FPLPPGAQQCPPVGLYGPPFGVRPPYPQPHVAVHSSQELHPKHYPKPIY





SYSCLIAMALKNSKTGSLPVSEIYSFMKEHFPYFKTAPDGWKNSVRHNL





SLNKCFEKVENKMSGSSRKGCLWALNLARIDKMEEEMHKWKRKDLAAIH





RSMANPEELDKLISDRPESCRRPGKPGEPEAPVLTHATTVAVAHGCLAV





SQLPPQPLMTLSLQSVPLHHQVQPQAHLAPDSPAPAQTPPLHALPDLSP





SPLPHPAMGRAPVDFINISTDMNTEVDALDPSIMDFALQGNLWEEMKDE





GFSLDTLGAFADSPLGCDLGASGLTPASGGSDQSFPDLQVTGLYTAYST





PDSVAASGTSSSSQYLGAQGNKPIALL,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:55.


In some embodiments, the nucleic acid sequence encoding FOXN4 comprises the nucleic acid sequence:









(SEQ ID NO: 56; NM_213596)


ATGATAGAAAGTGACACCTCATCCATAATGTCAGGAATTATTCGAAACT





CAGGGCAAAATCACCACCCCTCTCCACAGGAATACAGGCTTCTAGCCAC





CACCAGCGATGATGACCTTCCCGGGGACCTGCAGTCGCTGTCGTGGCTC





ACGGCGGTGGATGTGCCTCGGCTGCAGCAGATGGCAAGTGGCCGCGTGG





ACCTGGGTGGCCCCTGCGTGCCACATCCACACCCAGGTGCCTTGGCTGG





GGTGGCCGACCTGCATGTGGGAGCCACTCCAAGTCCCCTTCTCCATGGC





CCAGCAGGCATGGCCCCCCGAGGCATGCCAGGTCTGGGCCCCATAACTG





GCCACAGAGACAGCATGAGCCAGTTCCCCGTGGGGGGCCAGCCCTCATC





TGGCCTGCAGGACCCGCCGCATCTGTACTCACCTGCCACCCAACCACAG





TTCCCGCTCCCCCCGGGTGCCCAGCAGTGCCCTCCTGTGGGCCTCTATG





GCCCCCCATTTGGGGTGCGGCCCCCCTACCCCCAGCCCCACGTGGCTGT





GCATTCATCTCAAGAACTGCACCCCAAACACTACCCCAAGCCCATCTAC





TCGTACAGCTGTCTGATCGCCATGGCCCTGAAGAACAGCAAGACAGGCA





GCCTGCCTGTGAGCGAGATCTACAGCTTCATGAAGGAGCACTTCCCCTA





CTTCAAGACGGCCCCCGACGGGTGGAAGAACTCGGTGCGGCACAACCTG





TCTCTGAACAAGTGCTTCGAGAAGGTGGAGAACAAGATGAGCGGCTCCT





CCCGCAAGGGCTGCCTGTGGGCTCTGAACCTGGCCCGCATCGACAAGAT





GGAGGAGGAGATGCACAAGTGGAAGAGGAAGGACCTGGCTGCCATCCAC





CGGAGTATGGCCAACCCTGAGGAGTTGGACAAGCTGATCTCCGACCGGC





CTGAAAGCTGCCGGCGCCCCGGCAAACCGGGGGAACCAGAGGCCCCCGT





GCTGACTCACGCCACCACAGTGGCCGTGGCGCATGGCTGCCTGGCTGTC





TCCCAGCTCCCACCCCAGCCACTGATGACCCTGTCCCTGCAGTCAGTCC





CCCTGCACCACCAGGTCCAGCCCCAGGCACATCTTGCTCCAGACTCTCC





AGCACCAGCCCAGACCCCGCCACTGCACGCCCTGCCGGACCTCAGCCCC





AGCCCGCTCCCCCACCCCGCCATGGGAAGGGCTCCTGTAGACTTCATCA





ACATCAGCACCGACATGAACACTGAGGTGGATGCCCTCGACCCGAGCAT





CATGGACTTCGCTCTGCAGGGGAACCTGTGGGAGGAGATGAAGGATGAG





GGATTCAGCTTGGACACACTGGGCGCCTTTGCAGACTCCCCGCTTGGCT





GTGACCTGGGGGCCTCAGGCCTAACCCCTGCCTCGGGTGGCAGCGACCA





GTCCTTCCCAGACTTGCAGGTGACGGGTCTCTACACAGCGTACTCCACT





CCGGACAGTGTGGCTGCATCGGGCACCAGCTCCTCCTCCCAGTACCTGG





GTGCACAGGGGAACAAGCCTATAGCCCTGCTT,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:56 under stringent hybridization conditions.


In some embodiments, Forkhead Box 01 (FOXO1) comprises the amino acid sequence:









(SEQ ID NO: 57; NP_002006)


MAEAPQVVEIDPDFEPLPRPRSCTWPLPRPEFSQSNSATSSPAPSGSAA





ANPDAAAGLPSASAAAVSADFMSNLSLLEESEDFPQAPGSVAAAVAAAA





AAAATGGLCGDFQGPEAGCLHPAPPQPPPPGPLSQHPPVPPAAAGPLAG





QPRKSSSSRRNAWGNLSYADLITKAIESSAEKRLTLSQIYEWMVKSVPY





FKDKGDSNSSAGWKNSIRHNLSLHSKFIRVQNEGTGKSSWWMLNPEGGK





SGKSPRRRAASMDNNSKFAKSRSRAAKKKASLQSGQEGAGDSPGSQFSK





WPASPGSHSNDDFDNWSTFRPRTSSNASTISGRLSPIMTEQDDLGEGDV





HSMVYPPSAAKMASTLPSLSEISNPENMENLLDNLNLLSSPTSLTVSTQ





SSPGTMMQQTPCYSFAPPNTSLNSPSPNYQKYTYGQSSMSPLPQMPIQT





LQDNKSSYGGMSQYNCAPGLLKELLTSDSPPHNDIMTPVDPGVAQPNSR





VLGQNVMMGPNSVMSTYGSQVSHNKMMNPSSHTHPGHAQQTSAVNGRPL





PHTVSTMPHTSGMNRLTQVKTPVQVPLPHPMQMSALGGYSSVSSCNGYG





RMGLLHQEKLPSDLDGMFIERLDCDMESIIRNDLMDGDTLDFNFDNVLP





NQSFPHSVKTTTHSWVSG,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:57.


In some embodiments, the nucleic acid sequence encoding FOXO1 comprises the nucleic acid sequence:









(SEQ ID NO: 58; NM_002015)


ATGGCCGAGGCGCCTCAGGTGGTGGAGATCGACCCGGACTTCGAGCCGC





TGCCCCGGCCGCGCTCGTGCACCTGGCCGCTGCCCAGGCCGGAGTTTAG





CCAGTCCAACTCGGCCACCTCCAGCCCGGCGCCGTCGGGCAGCGCGGCT





GCCAACCCCGACGCCGCGGCGGGCCTGCCCTCGGCCTCGGCTGCCGCTG





TCAGCGCCGACTTCATGAGCAACCTGAGCTTGCTGGAGGAGAGCGAGGA





CTTCCCGCAGGCGCCCGGCTCCGTGGCGGCGGCGGTGGCGGCGGCGGCC





GCCGCGGCCGCCACCGGGGGGCTGTGCGGGGACTTCCAGGGCCCGGAGG





CGGGCTGCCTGCACCCAGCGCCACCGCAGCCCCCGCCGCCCGGGCCGCT





GTCGCAGCACCCGCCGGTGCCCCCCGCCGCCGCTGGGCCGCTCGCGGGG





CAGCCGCGCAAGAGCAGCTCGTCCCGCCGCAACGCGTGGGGCAACCTGT





CCTACGCCGACCTCATCACCAAGGCCATCGAGAGCTCGGCGGAGAAGCG





GCTCACGCTGTCGCAGATCTACGAGTGGATGGTCAAGAGCGTGCCCTAC





TTCAAGGATAAGGGTGACAGCAACAGCTCGGCGGGCTGGAAGAATTCAA





TTCGTCATAATCTGTCCCTACACAGCAAGTTCATTCGTGTGCAGAATGA





AGGAACTGGAAAAAGTTCTTGGTGGATGCTCAATCCAGAGGGTGGCAAG





AGCGGGAAATCTCCTAGGAGAAGAGCTGCATCCATGGACAACAACAGTA





AATTTGCTAAGAGCCGAAGCCGAGCTGCCAAGAAGAAAGCATCTCTCCA





GTCTGGCCAGGAGGGTGCTGGGGACAGCCCTGGATCACAGTTTTCCAAA





TGGCCTGCAAGCCCTGGCTCTCACAGCAATGATGACTTTGATAACTGGA





GTACATTTCGCCCTCGAACTAGCTCAAATGCTAGTACTATTAGTGGGAG





ACTCTCACCCATTATGACCGAACAGGATGATCTTGGAGAAGGGGATGTG





CATTCTATGGTGTACCCGCCATCTGCCGCAAAGATGGCCTCTACTTTAC





CCAGTCTGTCTGAGATAAGCAATCCCGAAAACATGGAAAATCTTTTGGA





TAATCTCAACCTTCTCTCATCACCAACATCATTAACTGTTTCGACCCAG





TCCTCACCTGGCACCATGATGCAGCAGACGCCGTGCTACTCGTTTGCGC





CACCAAACACCAGTTTGAATTCACCCAGCCCAAACTACCAAAAATATAC





ATATGGCCAATCCAGCATGAGCCCTTTGCCCCAGATGCCTATACAAACA





CTTCAGGACAATAAGTCGAGTTATGGAGGTATGAGTCAGTATAACTGTG





CGCCTGGACTCTTGAAGGAGTTGCTGACTTCTGACTCTCCTCCCCATAA





TGACATTATGACACCAGTTGATCCTGGGGTAGCCCAGCCCAACAGCCGG





GTTCTGGGCCAGAACGTCATGATGGGCCCTAATTCGGTCATGTCAACCT





ATGGCAGCCAGGTATCTCATAACAAAATGATGAATCCCAGCTCCCATAC





CCACCCTGGACATGCTCAGCAGACATCTGCAGTTAACGGGCGTCCCCTG





CCCCACACGGTAAGCACCATGCCCCACACCTCGGGTATGAACCGCCTGA





CCCAAGTGAAGACACCTGTACAAGTGCCTCTGCCCCACCCCATGCAGAT





GAGTGCCCTGGGGGGCTACTCCTCCGTGAGCAGCTGCAATGGCTATGGC





AGAATGGGCCTTCTCCACCAGGAGAAGCTCCCAAGTGACTTGGATGGCA





TGTTCATTGAGCGCTTAGACTGTGACATGGAATCCATCATTCGGAATGA





CCTCATGGATGGAGATACATTGGATTTTAACTTTGACAATGTGTTGCCC





AACCAAAGCTTCCCACACAGTGTCAAGACAACGACACATAGCTGGGTGT





CAGGC,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:58 under stringent hybridization conditions.


In some embodiments, Forkhead Box 03 (FOXO3) comprises the amino acid sequence:









(SEQ ID NO: 59; NP_001446)


MAEAPASPAPLSPLEVELDPEFEPQSRPRSCTWPLQRPELQASPAKPSG





ETAADSMIPEEEDDEDDEDGGGRAGSAMAIGGGGGSGTLGSGLLLEDSA





RVLAPGGQDPGSGPATAAGGLSGGTQALLQPQQPLPPPQPGAAGGSGQP





RKCSSRRNAWGNLSYADLITRAIESSPDKRLTLSQIYEWMVRCVPYFKD





KGDSNSSAGWKNSIRHNLSLHSRFMRVQNEGTGKSSWWIINPDGGKSGK





APRRRAVSMDNSNKYTKSRGRAAKKKAALQTAPESADDSPSQLSKWPGS





PTSRSSDELDAWTDFRSRTNSNASTVSGRLSPIMASTELDEVQDDDAPL





SPMLYSSSASLSPSVSKPCTVELPRLTDMAGTMNLNDGLTENLMDDLLD





NITLPPSQPSPTGGLMQRSSSFPYTTKGSGLGSPTSSFNSTVFGPSSLN





SLRQSPMQTIQENKPATFSSMSHYGNQTLQDLLTSDSLSHSDVMMTQSD





PLMSQASTAVSAQNSRRNVMLRNDPMMSFAAQPNQGSLVNQNLLHHQHQ





TQGALGGSRALSNSVSNMGLSESSSLGSAKHQQQSPVSQSMQTLSDSLS





GSSLYSTSANLPVMGHEKFPSDLDLDMFNGSLECDMESIIRSELMDADG





LDFNFDSLISTQNVVGLNVGNFTGAKQASSQSWVPG,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:59.


In some embodiments, the nucleic acid sequence encoding FOXO3 comprises the nucleic acid sequence:









(SEQ ID NO: 60; NM_001455)


ATGGCAGAGGCACCGGCTTCCCCGGCCCCGCTCTCTCCGCTCGAAGTGG





AGCTGGACCCGGAGTTCGAGCCCCAGAGCCGTCCGCGATCCTGTACGTG





GCCCCTGCAAAGGCCGGAGCTCCAAGCGAGCCCTGCCAAGCCCTCGGGG





GAGACGGCCGCTGACTCCATGATCCCCGAGGAGGAGGACGATGAAGACG





ACGAGGACGGCGGGGGACGGGCCGGCTCGGCCATGGCGATCGGCGGCGG





CGGCGGGAGCGGCACGCTGGGCTCCGGGCTGCTCCTTGAGGACTCGGCC





CGGGTGCTGGCACCCGGAGGGCAAGACCCCGGGTCTGGGCCAGCCACCG





CGGCGGGCGGGCTGAGCGGGGGTACACAGGCGCTGCTGCAGCCTCAGCA





ACCGCTGCCACCGCCGCAGCCGGGGGCGGCTGGGGGCTCCGGGCAGCCG





AGGAAATGTTCGTCGCGGCGGAACGCCTGGGGAAACCTGTCCTACGCGG





ACCTGATCACCCGCGCCATCGAGAGCTCCCCGGACAAACGGCTCACTCT





GTCCCAGATCTACGAGTGGATGGTGCGTTGCGTGCCCTACTTCAAGGAT





AAGGGCGACAGCAACAGCTCTGCCGGCTGGAAGAACTCCATCCGGCACA





ACCTGTCACTGCATAGTCGATTCATGCGGGTCCAGAATGAGGGAACTGG





CAAGAGCTCTTGGTGGATCATCAACCCTGATGGGGGGAAGAGCGGAAAA





GCCCCCCGGCGGCGGGCTGTCTCCATGGACAATAGCAACAAGTATACCA





AGAGCCGTGGCCGCGCAGCCAAGAAGAAGGCAGCCCTGCAGACAGCCCC





CGAATCAGCTGACGACAGTCCCTCCCAGCTCTCCAAGTGGCCTGGCAGC





CCCACGTCACGCAGCAGTGATGAGCTGGATGCGTGGACGGACTTCCGTT





CACGCACCAATTCTAACGCCAGCACAGTCAGTGGCCGCCTGTCGCCCAT





CATGGCAAGCACAGAGTTGGATGAAGTCCAGGACGATGATGCGCCTCTC





TCGCCCATGCTCTACAGCAGCTCAGCCAGCCTGTCACCTTCAGTAAGCA





AGCCGTGCACGGTGGAACTGCCACGGCTGACTGATATGGCAGGCACCAT





GAATCTGAATGATGGGCTGACTGAAAACCTCATGGACGACCTGCTGGAT





AACATCACGCTCCCGCCATCCCAGCCATCGCCCACTGGGGGACTCATGC





AGCGGAGCTCTAGCTTCCCGTATACCACCAAGGGCTCGGGCCTGGGCTC





CCCAACCAGCTCCTTTAACAGCACGGTGTTCGGACCTTCATCTCTGAAC





TCCCTACGCCAGTCTCCCATGCAGACCATCCAAGAGAACAAGCCAGCTA





CCTTCTCTTCCATGTCACACTATGGTAACCAGACACTCCAGGACCTGCT





CACTTCGGACTCACTTAGCCACAGCGATGTCATGATGACACAGTCGGAC





CCCTTGATGTCTCAGGCCAGCACCGCTGTGTCTGCCCAGAATTCCCGCC





GGAACGTGATGCTTCGCAATGATCCGATGATGTCCTTTGCTGCCCAGCC





TAACCAGGGAAGTTTGGTCAATCAGAACTTGCTCCACCACCAGCACCAA





ACCCAGGGCGCTCTTGGTGGCAGCCGTGCCTTGTCGAATTCTGTCAGCA





ACATGGGCTTGAGTGAGTCCAGCAGCCTTGGGTCAGCCAAACACCAGCA





GCAGTCTCCTGTCAGCCAGTCTATGCAAACCCTCTCGGACTCTCTCTCA





GGCTCCTCCTTGTACTCAACTAGTGCAAACCTGCCCGTCATGGGCCATG





AGAAGTTCCCCAGCGACTTGGACCTGGACATGTTCAATGGGAGCTTGGA





ATGTGACATGGAGTCCATTATCCGTAGTGAACTCATGGATGCTGATGGG





TTGGATTTTAACTTTGATTCCCTCATCTCCACACAGAATGTTGTTGGTT





TGAACGTGGGGAACTTCACTGGTGCTAAGCAGGCCTCATCTCAGAGCTG





GGTGCCAGGC,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:60 under stringent hybridization conditions.


In some embodiments, Forkhead Box 04 (FOXO4) comprises the amino acid sequence:









(SEQ ID NO: 61; NP_005929)


MDPGNENSATEAAAIIDLDPDFEPQSRPRSCTWPLPRPEIANQPSEPPE





VEPDLGEKVHTEGRSEPILLPSRLPEPAGGPQPGILGAVTGPRKGGSRR





NAWGNQSYAELISQAIESAPEKRLTLAQIYEWMVRTVPYFKDKGDSNSS





AGWKNSIRHNLSLHSKFIKVHNEATGKSSWWMLNPEGGKSGKAPRRRAA





SMDSSSKLLRGRSKAPKKKPSVLPAPPEGATPTSPVGHFAKWSGSPCSR





NREEADMWTTFRPRSSSNASSVSTRLSPLRPESEVLAEEIPASVSSYAG





GVPPTLNEGLELLDGLNLTSSHSLLSRSGLSGFSLQHPGVTGPLHTYSS





SLFSPAEGPLSAGEGCFSSSQALEALLTSDTPPPPADVLMTQVDPILSQ





APTLLLLGGLPSSSKLATGVGLCPKPLEAPGPSSLVPTLSMIAPPPVMA





SAPIPKALGTPVLTPPTEAASQDRMPQDLDLDMYMENLECDMDNIISDL





MDEGEGLDFNFEPDP,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:61.


In some embodiments, the nucleic acid sequence encoding FOXO4 comprises the nucleic acid sequence:









(SEQ ID NO: 62; NM_005938)


ATGGATCCGGGGAATGAGAATTCAGCCACAGAGGCTGCCGCGATCATAG





ACCTAGATCCCGACTTCGAACCCCAGAGCCGTCCCCGCTCCTGCACCTG





GCCCCTTCCCCGACCAGAGATCGCTAACCAGCCGTCCGAGCCGCCCGAG





GTGGAGCCAGATCTGGGGGAAAAGGTACACACGGAGGGGCGCTCAGAGC





CGATCCTGTTGCCCTCTCGGCTCCCAGAGCCGGCCGGGGGCCCCCAGCC





CGGAATCCTGGGGGCTGTAACAGGTCCTCGGAAGGGAGGCTCCCGCCGG





AATGCCTGGGGAAATCAGTCATATGCAGAACTCATCAGCCAGGCCATTG





AAAGCGCCCCGGAGAAGCGACTGACACTTGCCCAGATCTACGAGTGGAT





GGTCCGTACTGTACCCTACTTCAAGGACAAGGGTGACAGCAACAGCTCA





GCAGGATGGAAGAACTCGATCCGCCACAACCTGTCCCTGCACAGCAAGT





TCATCAAGGTTCACAACGAGGCCACCGGCAAAAGCTCTTGGTGGATGCT





GAACCCTGAGGGAGGCAAGAGCGGCAAAGCCCCCCGCCGCCGGGCCGCC





TCCATGGATAGCAGCAGCAAGCTGCTCCGGGGCCGCAGTAAAGCCCCCA





AGAAGAAACCATCTGTGCTGCCAGCTCCACCCGAAGGTGCCACTCCAAC





GAGCCCTGTCGGCCACTTTGCCAAGTGGTCAGGCAGCCCTTGCTCTCGA





AACCGTGAAGAAGCCGATATGTGGACCACCTTCCGTCCACGAAGCAGTT





CAAATGCCAGCAGTGTCAGCACCCGGCTGTCCCCCTTGAGGCCAGAGTC





TGAGGTGCTGGCGGAGGAAATACCAGCTTCAGTCAGCAGTTATGCAGGG





GGTGTCCCTCCCACCCTCAATGAAGGTCTAGAGCTGTTAGATGGGCTCA





ATCTCACCTCTTCCCATTCCCTGCTATCTCGGAGTGGTCTCTCTGGCTT





CTCTTTGCAGCATCCTGGGGTTACCGGCCCCTTACACACCTACAGCAGC





TCCCTTTTCAGCCCAGCAGAGGGGCCCCTGTCAGCAGGAGAAGGGTGCT





TCTCCAGCTCCCAGGCTCTGGAGGCCCTGCTCACCTCTGATACGCCACC





ACCCCCTGCTGACGTCCTCATGACCCAGGTAGATCCCATTCTGTCCCAG





GCTCCGACTCTTCTGTTGCTGGGGGGGCTTCCTTCCTCCAGTAAGCTGG





CCACGGGCGTCGGCCTGTGTCCCAAGCCCCTAGAGGCTCCAGGCCCCAG





CAGTCTGGTTCCCACCCTTTCTATGATAGCACCACCTCCAGTCATGGCA





AGTGCCCCCATCCCCAAGGCTCTGGGGACTCCTGTGCTCACACCCCCTA





CTGAAGCTGCAAGCCAAGACAGAATGCCTCAGGATCTAGATCTTGATAT





GTATATGGAGAACCTGGAGTGTGACATGGATAACATCATCAGTGACCTC





ATGGATGAGGGCGAGGGACTGGACTTCAACTTTGAGCCAGATCCC,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:62 under stringent hybridization conditions.


In some embodiments, Forkhead Box 06 (FOXO6) comprises the amino acid sequence:









(SEQ ID NO: 63; NP_001278210)


MAAKLRAHQVDVDPDFAPQSRPRSCTWPLPQPDLAGDEDGALGAGVAEG





AEDCGPERRATAPAMAPAPPLGAEVGPLRKAKSSRRNAWGNLSYADLIT





KAIESAPDKRLTLSQIYDWMVRYVPYFKDKGDSNSSAGWKNSIRHNLSL





HTRFIRVQNEGTGKSSWWMLNPEGGKTGKTPRRRAVSMDNGAKFLRIKG





KASKKKQLQAPERSPDDSSPSAPAPGPVPAAAKWAASPASHASDDYEAW





ADFRGGGRPLLGEAAELEDDEALEALAPSSPLMYPSPASALSPALGSRC





PGELPRLAELGGPLGLHGGGGAGLPEGLLDGAQDAYGPRAAPRPGPVLG





APGELALAGAAAAYPGKGAAPYAPPAPSRSALAHPISLMTLPGEAGAAG





LAPPGHAAAFGGPPGGLLLDALPGPYAAAAAGPLGAAPDRFPADLDLDM





FSGSLECDVESIILNDFMDSDEMDFNFDSALPPPPPGLAGAPPPNQSWV





PG







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:63.


In some embodiments, the nucleic acid sequence encoding FOXO6 comprises the nucleic acid sequence:









(SEQ ID NO: 64; NM_001291281)


ATGGCTGCGAAGCTGCGAGCGCATCAGGTGGACGTGGACCCGGACTTCG





CGCCGCAGAGCCGGCCGCGCTCGTGTACCTGGCCCCTGCCGCAGCCTGA





CTTGGCCGGCGACGAGGACGGAGCGCTGGGCGCAGGGGTGGCCGAGGGC





GCCGAGGACTGCGGGCCGGAGCGCCGGGCTACGGCCCCGGCGATGGCCC





CAGCGCCGCCCCTGGGCGCGGAGGTCGGACCGCTGCGGAAAGCGAAGAG





CTCTCGGCGGAACGCGTGGGGGAACCTGTCCTACGCCGACCTCATCACC





AAAGCCATCGAGAGCGCCCCGGACAAGCGGCTCACGCTCTCGCAGATCT





ACGACTGGATGGTCCGTTACGTGCCCTACTTCAAGGATAAAGGCGACAG





CAACAGCTCGGCCGGCTGGAAGAACTCCATCCGGCACAACCTGTCGCTG





CACACCCGTTTCATCCGCGTGCAGAACGAGGGCACCGGCAAGAGTTCGT





GGTGGATGCTGAACCCCGAGGGCGGAAAGACAGGGAAGACCCCGCGGCG





CAGGGCCGTGTCCATGGACAACGGGGCCAAGTTCCTGCGCATCAAGGGC





AAGGCGAGCAAGAAGAAGCAGCTGCAGGCGCCCGAGCGAAGCCCGGACG





ACAGCTCCCCGAGTGCGCCCGCCCCGGGGCCGGTGCCTGCCGCAGCCAA





GTGGGCCGCCAGCCCCGCCTCGCACGCCAGCGACGACTACGAGGCTTGG





GCCGACTTCCGCGGCGGCGGGAGACCCCTGCTCGGGGAGGCGGCCGAGC





TGGAGGACGACGAGGCCCTGGAGGCCCTGGCGCCATCATCGCCGCTCAT





GTACCCAAGCCCCGCCAGCGCGCTGTCGCCGGCGCTGGGCTCGCGCTGT





CCGGGTGAGCTGCCCCGCCTGGCCGAGCTGGGAGGCCCGCTGGGCCTGC





ACGGCGGCGGCGGCGCGGGGCTGCCCGAGGGCCTGCTGGACGGCGCGCA





GGACGCGTACGGGCCGCGGGCCGCGCCCAGGCCCGGCCCGGTGCTGGGT





GCGCCGGGGGAGCTGGCGCTGGCGGGCGCAGCCGCCGCCTACCCCGGCA





AAGGGGCGGCCCCGTACGCGCCGCCCGCGCCCTCGCGCAGTGCCTTAGC





CCACCCCATCAGCCTTATGACGCTGCCCGGCGAGGCGGGCGCCGCGGGC





CTGGCACCGCCGGGCCACGCCGCCGCCTTCGGGGGCCCGCCCGGCGGCC





TCCTGCTGGACGCTCTGCCGGGGCCCTACGCTGCCGCCGCCGCCGGGCC





GCTGGGCGCCGCGCCCGACCGCTTCCCGGCCGACCTGGACCTCGACATG





TTCAGCGGGAGCCTCGAGTGCGACGTGGAGTCCATCATCCTCAACGACT





TCATGGACAGCGACGAAATGGACTTCAACTTCGATTCGGCCCTGCCTCC





GCCGCCGCCGGGCCTGGCCGGGGCCCCGCCCCCCAACCAGAGCTGGGTG





CCGGGC,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:64 under stringent hybridization conditions.


In some embodiments, Forkheadbox P1 (FOXP1) comprises the amino acid sequence:









(SEQ ID NO: 65; NP_116071)


MMQESGTETKSNGSAIQNGSGGSNHLLECGGLREGRSNGETPAVDIGAA





DLAHAQQQQQQALQVARQLLLQQQQQQQVSGLKSPKRNDKQPALQVPVS





VAMMTPQVITPQQMQQILQQQVLSPQQLQVLLQQQQALMLQQQQLQEFY





KKQQEQLQLQLLQQQHAGKQPKEQQQVATQQLAFQQQLLQMQQLQQQHL





LSLQRQGLLTIQPGQPALPLQPLAQGMIPTELQQLWKEVTSAHTAEETT





GNNHSSLDLTTTCVSSSAPSKTSLIMNPHASTNGQLSVHTPKRESLSHE





EHPHSHPLYGHGVCKWPGCEAVCEDFQSFLKHLNSEHALDDRSTAQCRV





QMQVVQQLELQLAKDKERLQAMMTHLHVKSTEPKAAPQPLNLVSSVTLS





KSASEASPQSLPHTPTTPTAPLTPVTQGPSVITTTSMHTVGPIRRRYSD





KYNVPISSADIAQNQEFYKNAEVRPPFTYASLIRQAILESPEKQLTLNE





IYNWFTRMFAYFRRNAATWKNAVRHNLSLHKCFVRVENVKGAVWTVDEV





EFQKRRPQKISGNPSLIKNMQSSHAYCTPLSAALQASMAENSIPLYTTA





SMGNPTLGNLASAIREELNGAMEHTNSNESDSSPGRSPMQAVHPVHVKE





EPLDPEEAEGPLSLVTTANHSPDFDHDRDYEDEPVNEDME,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:65.


In some embodiments, the nucleic acid sequence encoding FOXP1 comprises the nucleic acid sequence:









(SEQ ID NO: 66; NM_032682)


ATGATGCAAGAATCTGGGACTGAGACAAAAAGTAACGGTTCAGCCATCC





AGAATGGGTCGGGCGGCAGCAACCACTTACTAGAGTGCGGCGGTCTTCG





GGAGGGGCGGTCCAACGGAGAGACGCCGGCCGTGGACATCGGGGCAGCT





GACCTCGCCCACGCCCAGCAGCAGCAGCAACAGGCACTTCAGGTGGCAA





GACAGCTCCTTCTTCAGCAGCAACAGCAGCAGCAAGTTAGTGGATTAAA





ATCTCCCAAGAGGAATGACAAACAACCAGCTCTTCAGGTTCCCGTGTCA





GTGGCTATGATGACACCTCAAGTTATCACTCCCCAGCAAATGCAGCAGA





TCCTCCAGCAACAAGTGCTGAGCCCTCAGCAGCTCCAGGTTCTCCTCCA





GCAGCAGCAGGCCCTCATGCTTCAACAGCAGCAGCTTCAAGAGTTTTAT





AAAAAACAACAGGAACAGTTGCAGCTTCAACTTTTACAACAACAACATG





CTGGAAAACAGCCTAAAGAGCAACAGCAGGTGGCTACCCAGCAGTTGGC





TTTTCAGCAGCAGCTTTTACAGATGCAGCAGTTACAGCAGCAGCACCTC





CTGTCTTTGCAGCGCCAAGGCCTTCTGACAATTCAGCCCGGGCAGCCTG





CCCTTCCCCTTCAACCTCTTGCTCAAGGCATGATTCCAACAGAACTGCA





GCAGCTCTGGAAAGAAGTGACAAGTGCTCATACTGCAGAAGAAACCACA





GGCAACAATCACAGCAGTTTGGATCTGACCACGACATGTGTCTCCTCCT





CTGCACCTTCCAAGACCTCCTTAATAATGAACCCACATGCCTCTACCAA





TGGACAGCTCTCAGTCCACACTCCCAAAAGGGAAAGTTTGTCCCATGAG





GAGCACCCCCATAGCCATCCTCTCTATGGACATGGTGTATGCAAGTGGC





CAGGCTGTGAAGCAGTGTGCGAAGATTTCCAATCATTTCTAAAACATCT





CAACAGTGAGCATGCGCTGGACGATAGAAGTACAGCCCAATGTAGAGTA





CAAATGCAGGTTGTACAGCAGTTAGAGCTACAGCTTGCAAAAGACAAAG





AACGCCTGCAAGCCATGATGACCCACCTGCATGTGAAGTCTACAGAACC





CAAAGCCGCCCCTCAGCCCTTGAATCTGGTATCAAGTGTCACTCTCTCC





AAGTCCGCATCGGAGGCTTCTCCACAGAGCTTACCTCATACTCCAACGA





CCCCAACCGCCCCCCTGACTCCCGTCACCCAAGGCCCCTCTGTCATCAC





AACCACCAGCATGCACACGGTGGGACCCATCCGCAGGCGGTACTCAGAC





AAATACAACGTGCCCATTTCGTCAGCAGATATTGCGCAGAACCAAGAAT





TTTATAAGAACGCAGAAGTTAGACCACCATTTACATATGCATCTTTAAT





TAGGCAGGCCATTCTCGAATCTCCAGAAAAGCAGCTAACACTAAATGAG





ATCTATAACTGGTTCACACGAATGTTTGCTTACTTCCGACGCAACGCGG





CCACGTGGAAGAATGCAGTGCGTCATAATCTTAGTCTTCACAAGTGTTT





TGTGCGAGTAGAAAACGTTAAAGGGGCAGTATGGACAGTGGATGAAGTA





GAATTCCAAAAACGAAGGCCACAAAAGATCAGTGGTAACCCTTCCCTTA





TTAAAAACATGCAGAGCAGCCACGCCTACTGCACACCTCTCAGTGCAGC





TTTACAGGCTTCAATGGCTGAGAATAGTATACCTCTATACACTACCGCT





TCCATGGGAAATCCCACTCTGGGCAACTTAGCCAGCGCAATACGGGAAG





AGCTGAACGGGGCAATGGAGCATACCAACAGCAACGAGAGTGACAGCAG





TCCAGGCAGATCTCCTATGCAAGCCGTGCATCCTGTACACGTCAAAGAA





GAGCCCCTCGATCCAGAGGAAGCTGAAGGGCCCCTGTCCTTAGTGACAA





CAGCCAACCACAGTCCAGATTTTGACCATGACAGAGATTACGAAGATGA





ACCAGTAAACGAGGACATGGAG,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:66 under stringent hybridization conditions.


In some embodiments, Forkhead box P2 (FOXP2) comprises the amino acid sequence









(SEQ ID NO: 67; NP_055306)


MMQESATETISNSSMNQNGMSTLSSQLDAGSRDGRSSGDTSSEVSTVEL





LHLQQQQALQAARQLLLQQQTSGLKSPKSSDKQRPLQVPVSVAMMTPQV





ITPQQMQQILQQQVLSPQQLQALLQQQQAVMLQQQQLQEFYKKQQEQLH





LQLLQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQHPGKQ





AKEQQQQQQQQQQLAAQQLVFQQQLLQMQQLQQQQHLLSLQRQGLISIP





PGQAALPVQSLPQAGLSPAEIQQLWKEVTGVHSMEDNGIKHGGLDLTTN





NSSSTTSSNTSKASPPITHHSIVNGQSSVLSARRDSSSHEETGASHTLY





GHGVCKWPGCESICEDFGQFLKHLNNEHALDDRSTAQCRVQMQVVQQLE





IQLSKERERLQAMMTHLHMRPSEPKPSPKPLNLVSSVTMSKNMLETSPQ





SLPQTPTTPTAPVTPITQGPSVITPASVPNVGAIRRRHSDKYNIPMSSE





IAPNYEFYKNADVRPPFTYATLIRQAIMESSDRQLTLNEIYSWFTRTFA





YFRRNAATWKNAVRHNLSLHKCFVRVENVKGAVWTVDEVEYQKRRSQKI





TGSPTLVKNIPTSLGYGAALNASLQAALAESSLPLLSNPGLINNASSGL





LQAVHEDLNGSLDHIDSNGNSSPGCSPQPHIHSIHVKEEPVIAEDEDCP





MSLVTTANHSPELEDDREIEEEPLSEDLE,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:67.


In some embodiments, the nucleic acid sequence encoding FOXP2 comprises the nucleic acid sequence:









(SEQ ID NO: 68; NM_014491)


ATGATGCAGGAATCTGCGACAGAGACAATAAGCAACAGTTCAATGAATC





AAAATGGAATGAGCACTCTAAGCAGCCAATTAGATGCTGGCAGCAGAGA





TGGAAGATCAAGTGGTGACACCAGCTCTGAAGTAAGCACAGTAGAACTG





CTGCATCTGCAACAACAGCAGGCTCTCCAGGCAGCAAGACAACTTCTTT





TACAGCAGCAAACAAGTGGATTGAAATCTCCTAAGAGCAGTGATAAACA





GAGACCACTGCAGGTGCCTGTGTCAGTGGCCATGATGACTCCCCAGGTG





ATCACCCCTCAGCAAATGCAGCAGATCCTTCAGCAACAAGTCCTGTCTC





CTCAGCAGCTACAAGCCCTTCTCCAACAACAGCAGGCTGTCATGCTGCA





GCAGCAACAACTACAAGAGTTTTACAAGAAACAGCAAGAGCAGTTACAT





CTTCAGCTTTTGCAGCAGCAGCAGCAACAGCAGCAGCAGCAACAACAGC





AGCAACAACAGCAGCAGCAACAACAACAACAACAGCAGCAACAACAGCA





GCAGCAGCAGCAACAGCAGCAGCAGCAGCAACAGCATCCTGGAAAGCAA





GCGAAAGAGCAGCAGCAGCAGCAGCAGCAGCAACAGCAATTGGCAGCCC





AGCAGCTTGTCTTCCAGCAGCAGCTTCTCCAGATGCAACAACTCCAGCA





GCAGCAGCATCTGCTCAGCCTTCAGCGTCAGGGACTCATCTCCATTCCA





CCTGGCCAGGCAGCACTTCCTGTCCAATCGCTGCCTCAAGCTGGCTTAA





GTCCTGCTGAGATTCAGCAGTTATGGAAAGAAGTGACTGGAGTTCACAG





TATGGAAGACAATGGCATTAAACATGGAGGGCTAGACCTCACTACTAAC





AATTCCTCCTCGACTACCTCCTCCAACACTTCCAAAGCATCACCACCAA





TAACTCATCATTCCATAGTGAATGGACAGTCTTCAGTTCTAAGTGCAAG





ACGAGACAGCTCGTCACATGAGGAGACTGGGGCCTCTCACACTCTCTAT





GGCCATGGAGTTTGCAAATGGCCAGGCTGTGAAAGCATTTGTGAAGATT





TTGGACAGTTTTTAAAGCACCTTAACAATGAACACGCATTGGATGACCG





AAGCACTGCTCAGTGTCGAGTGCAAATGCAGGTGGTGCAACAGTTAGAA





ATACAGCTTTCTAAAGAACGCGAACGTCTTCAAGCAATGATGACCCACT





TGCACATGCGACCCTCAGAGCCCAAACCATCTCCCAAACCTCTAAATCT





GGTGTCTAGTGTCACCATGTCGAAGAATATGTTGGAGACATCCCCACAG





AGCTTACCTCAAACCCCTACCACACCAACGGCCCCAGTCACCCCGATTA





CCCAGGGACCCTCAGTAATCACCCCAGCCAGTGTGCCCAATGTGGGAGC





CATACGAAGGCGACATTCAGACAAATACAACATTCCCATGTCATCAGAA





ATTGCCCCAAACTATGAATTTTATAAAAATGCAGATGTCAGACCTCCAT





TTACTTATGCAACTCTCATAAGGCAGGCTATCATGGAGTCATCTGACAG





GCAGTTAACACTTAATGAAATTTACAGCTGGTTTACACGGACATTTGCT





TACTTCAGGCGTAATGCAGCAACTTGGAAGAATGCAGTACGTCATAATC





TTAGCCTGCACAAGTGTTTTGTTCGAGTAGAAAATGTTAAAGGAGCAGT





ATGGACTGTGGATGAAGTAGAATACCAGAAGCGAAGGTCACAAAAGATA





ACAGGAAGTCCAACCTTAGTAAAAAATATACCTACCAGTTTAGGCTATG





GAGCAGCTCTTAATGCCAGTTTGCAGGCTGCCTTGGCAGAGAGCAGTTT





ACCTTTGCTAAGTAATCCTGGACTGATAAATAATGCATCCAGTGGCCTA





CTGCAGGCCGTCCACGAAGACCTCAATGGTTCTCTGGATCACATTGACA





GCAATGGAAACAGTAGTCCGGGCTGCTCACCTCAGCCGCACATACATTC





AATCCACGTCAAGGAAGAGCCAGTGATTGCAGAGGATGAAGACTGCCCA





ATGTCCTTAGTGACAACAGCTAATCACAGTCCAGAATTAGAAGACGACA





GAGAGATTGAAGAAGAGCCTTTATCTGAAGATCTGGAA,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:68 under stringent hybridization conditions.


In some embodiments, Forkhead box P3 (FOXP3) comprises the amino acid sequence









(SEQ ID NO: 69; NP_054728)


MPNPRPGKPSAPSLALGPSPGASPSWRAAPKASDLLGARGPGGTFQGRD





LRGGAHASSSSLNPMPPSQLQLPTLPLVMVAPSGARLGPLPHLQALLQD





RPHFMHQLSTVDAHARTPVLQVHPLESPAMISLTPPTTATGVFSLKARP





GLPPGINVASLEWVSREPALLCTFPNPSAPRKDSTLSAVPQSSYPLLAN





GVCKWPGCEKVFEEPEDFLKHCQADHLLDEKGRAQCLLQREMVQSLEQQ





LVLEKEKLSAMQAHLAGKMALTKASSVASSDKGSCCIVAAGSQGPVVPA





WSGPREAPDSLFAVRRHLWGSHGNSTFPEFLHNMDYFKFHNMRPPFTYA





TLIRWAILEAPEKQRTLNEIYHWFTRMFAFFRNHPATWKNAIRHNLSLH





KCFVRVESEKGAVWTVDELEFRKKRSQRPSRCSNPTPGP,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:69.


In some embodiments, the nucleic acid sequence encoding FOXP3 comprises the nucleic acid sequence:









(SEQ ID NO: 70; NM_014009)


ATGCCCAACCCCAGGCCTGGCAAGCCCTCGGCCCCTTCCTTGGCCCTTG





GCCCATCCCCAGGAGCCTCGCCCAGCTGGAGGGCTGCACCCAAAGCCTC





AGACCTGCTGGGGGCCCGGGGCCCAGGGGGAACCTTCCAGGGCCGAGAT





CTTCGAGGCGGGGCCCATGCCTCCTCTTCTTCCTTGAACCCCATGCCAC





CATCGCAGCTGCAGCTGCCCACACTGCCCCTAGTCATGGTGGCACCCTC





CGGGGCACGGCTGGGCCCCTTGCCCCACTTACAGGCACTCCTCCAGGAC





AGGCCACATTTCATGCACCAGCTCTCAACGGTGGATGCCCACGCCCGGA





CCCCTGTGCTGCAGGTGCACCCCCTGGAGAGCCCAGCCATGATCAGCCT





CACACCACCCACCACCGCCACTGGGGTCTTCTCCCTCAAGGCCCGGCCT





GGCCTCCCACCTGGGATCAACGTGGCCAGCCTGGAATGGGTGTCCAGGG





AGCCGGCACTGCTCTGCACCTTCCCAAATCCCAGTGCACCCAGGAAGGA





CAGCACCCTTTCGGCTGTGCCCCAGAGCTCCTACCCACTGCTGGCAAAT





GGTGTCTGCAAGTGGCCCGGATGTGAGAAGGTCTTCGAAGAGCCAGAGG





ACTTCCTCAAGCACTGCCAGGCGGACCATCTTCTGGATGAGAAGGGCAG





GGCACAATGTCTCCTCCAGAGAGAGATGGTACAGTCTCTGGAGCAGCAG





CTGGTGCTGGAGAAGGAGAAGCTGAGTGCCATGCAGGCCCACCTGGCTG





GGAAAATGGCACTGACCAAGGCTTCATCTGTGGCATCATCCGACAAGGG





CTCCTGCTGCATCGTAGCTGCTGGCAGCCAAGGCCCTGTCGTCCCAGCC





TGGTCTGGCCCCCGGGAGGCCCCTGACAGCCTGTTTGCTGTCCGGAGGC





ACCTGTGGGGTAGCCATGGAAACAGCACATTCCCAGAGTTCCTCCACAA





CATGGACTACTTCAAGTTCCACAACATGCGACCCCCTTTCACCTACGCC





ACGCTCATCCGCTGGGCCATCCTGGAGGCTCCAGAGAAGCAGCGGACAC





TCAATGAGATCTACCACTGGTTCACACGCATGTTTGCCTTCTTCAGAAA





CCATCCTGCCACCTGGAAGAACGCCATCCGCCACAACCTGAGTCTGCAC





AAGTGCTTTGTGCGGGTGGAGAGCGAGAAGGGGGCTGTGTGGACCGTGG





ATGAGCTGGAGTTCCGCAAGAAACGGAGCCAGAGGCCCAGCAGGTGTTC





CAACCCTACACCTGGCCCC,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:70 under stringent hybridization conditions.


In some embodiments, Forkhead box 4 (FOXP4) comprises the amino acid sequence:









(SEQ ID NO: 71 NP_001012426)


MMVESASETIRSAPSGQNGVGSLSGQADGSSGGATGTTASGTGREVTTG





ADSNGEMSPAELLHFQQQQALQVARQFLLQQASGLSSPGNNDSKQSASA





VQVPVSVAMMSPQMLTPQQMQQILSPPQLQALLQQQQALMLQQEYYKKQ





QEQLHLQLLTQQQAGKPQPKEALGNKQLAFQQQLLQMQQLQQQHLLNLQ





RQGLVSLQPNQASGPLQTLPQAAVCPTDLPQLWKGEGAPGQPAEDSVKQ





EGLDLTGTAATATSFAAPPKVSPPLSHHTLPNGQPTVLTSRRDSSSHEE





TPGSHPLYGHGECKWPGCETLCEDLGQFIKHLNTEHALDDRSTAQCRVQ





MQVVQQLEIQLAKESERLQAMMAHLHMRPSEPKPFSQPLNPVPGSSSFS





KVTVSAADSFPDGLVHPPTSAAAPVTPLRPPGLGSASLHGGGPARRRSS





DKFCSPISSELAQNHEFYKNADVRPPFTYASLIRQAILETPDRQLTLNE





IYNWFTRMFAYFRRNTATWKNAVRHNLSLHKCFVRVENVKGAVWTVDER





EYQKRRPPKMTGSPTLVKNMISGLSYGALNASYQAALAESSFPLLNSPG





MLNPGSASSLLPLSHDDVGAPVEPLPSNGSSSPPRLSPPQYSHQVQVKE





EPAEAEEDRQPGPPLGAPNPSASGPPEDRDLEEELPGEELS,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:71.


In some embodiments, the nucleic acid sequence encoding FOXP4 comprises the nucleic acid sequence:









(SEQ ID NO: 72; NM_001012426)


ATGATGGTGGAATCTGCCTCGGAGACAATCAGGTCGGCTCCATCTGGTC





AGAATGGCGTGGGCAGCCTCTCTGGGCAAGCAGATGGCAGCAGCGGCGG





GGCCACAGGGACAACTGCAAGTGGCACGGGCAGGGAAGTGACCACGGGT





GCAGACAGCAATGGTGAGATGAGTCCCGCAGAGCTGCTGCACTTCCAGC





AGCAACAGGCTCTCCAAGTGGCCCGGCAGTTCCTGCTGCAGCAGGCCTC





AGGCCTGAGCTCCCCAGGGAACAATGACAGCAAACAGTCTGCCTCTGCT





GTGCAGGTGCCTGTGTCGGTGGCCATGATGTCGCCGCAGATGCTTACCC





CGCAACAGATGCAGCAGATCCTGTCGCCCCCGCAGCTGCAGGCCTTGCT





CCAGCAGCAGCAAGCCCTCATGCTCCAGCAGGAGTACTACAAGAAGCAG





CAGGAGCAGCTCCACCTGCAGCTCCTCACCCAGCAGCAGGCTGGGAAAC





CGCAGCCCAAAGAGGCACTGGGGAACAAGCAGCTGGCCTTCCAGCAGCA





GCTCCTGCAAATGCAACAGTTGCAGCAGCAGCACCTGCTCAACCTGCAG





AGGCAGGGGCTGGTCAGCCTGCAGCCCAACCAAGCCTCGGGGCCCCTCC





AGACCCTTCCGCAAGCAGCTGTTTGCCCAACAGACCTGCCCCAGCTGTG





GAAGGGCGAGGGTGCCCCCGGGCAGCCTGCCGAGGACAGCGTCAAGCAG





GAGGGGCTGGACCTCACTGGCACGGCCGCCACCGCTACCTCGTTTGCCG





CTCCCCCCAAGGTCTCACCCCCCCTCTCCCACCATACCCTGCCCAACGG





ACAGCCTACTGTGCTCACATCTCGGAGAGACAGCTCTTCCCACGAGGAG





ACCCCCGGCTCCCACCCCCTGTACGGACACGGAGAGTGCAAGTGGCCAG





GCTGTGAGACCCTGTGTGAAGACCTGGGCCAGTTTATCAAACACCTCAA





CACAGAGCACGCCCTGGATGACCGGAGTACAGCCCAGTGCCGGGTACAG





ATGCAGGTGGTGCAGCAGCTGGAGATCCAGCTCGCCAAGGAGAGCGAGC





GGCTGCAGGCCATGATGGCCCACCTGCACATGCGGCCCTCGGAGCCCAA





GCCCTTCAGCCAGCCACTGAACCCGGTCCCCGGCTCCTCCTCATTCTCC





AAGGTGACCGTCTCTGCAGCAGACTCATTCCCAGATGGTCTCGTGCACC





CCCCGACCTCGGCCGCAGCCCCTGTCACCCCTCTACGGCCCCCTGGCCT





GGGCTCTGCCTCCCTGCATGGTGGGGGCCCAGCCCGTCGGAGAAGCAGT





GACAAGTTCTGCTCCCCCATCTCCTCAGAGCTGGCCCAGAATCATGAGT





TCTACAAGAACGCCGACGTCCGGCCCCCCTTCACCTACGCCTCCCTCAT





CCGCCAGGCCATCCTGGAAACCCCTGACAGGCAGCTGACCCTGAATGAG





ATCTATAACTGGTTCACCAGGATGTTCGCCTATTTCCGCAGAAACACTG





CCACCTGGAAGAACGCCGTGCGCCACAACCTCAGCCTGCACAAGTGCTT





CGTCCGCGTGGAGAACGTCAAGGGTGCCGTGTGGACTGTGGACGAGCGG





GAGTATCAGAAGCGGAGACCGCCAAAGATGACAGGGAGCCCCACCCTGG





TGAAGAACATGATCTCTGGCCTCAGCTATGGAGCACTTAATGCCAGCTA





CCAGGCCGCCCTGGCCGAGAGCAGCTTCCCCCTCCTCAACAGCCCTGGC





ATGCTGAACCCTGGCTCCGCCAGCAGCCTGCTGCCCCTCAGCCACGATG





ACGTGGGTGCCCCCGTGGAGCCGCTGCCCAGCAACGGCAGCAGCAGCCC





TCCTCGCCTCTCCCCGCCCCAGTACAGCCACCAGGTGCAGGTGAAGGAG





GAGCCAGCAGAGGCAGAGGAAGACAGGCAGCCCGGGCCTCCCCTGGGCG





CCCCTAACCCCAGCGCCTCGGGGCCTCCGGAAGACAGGGACCTGGAGGA





GGAGCTGCCGGGAGAAGAACTGTCC,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:72 under stringent hybridization conditions.


In some embodiments, Forkhead box Q1 (FOXQ1) comprises the amino acid sequence:









(SEQ ID NO: 73; NP_150285)


MKLEVFVPRAAHGDKQGSDLEGAGGSDAPSPLSAAGDDSLGSDGDCAAN





SPAAGGGARDPPGDGEQSAGGGPGAEEAIPAAAAAAVVAEGAEAGAAGP





GAGGAGSGEGARSKPYTRRPKPPYSYIALIAMAIRDSAGGRLTLAEINE





YLMGKFPFFRGSYTGWRNSVRHNLSLNDCFVKVLRDPSRPWGKDNYWML





NPNSEYTFADGVFRRRRKRLSHRAPVPAPGLRPEEAPGLPAAPPPAPAA





PASPRMRSPARQEERASPAGKFSSSFAIDSILRKPFRSRRLRDTAPGTT





LQWGAAPCPPLPAFPALLPAAPCRALLPLCAYGAGEPARLGAREAEVPP





TAPPLLLAPLPAAAPAKPLRGPAAGGAHLYCPLRLPAALQAASVRRPGP





HLPYPVETLLA,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:73.


In some embodiments, the nucleic acid sequence encoding FOXQ1 comprises the nucleic acid sequence:









(SEQ ID NO: 74; NM_033260)


ATGAAGTTGGAGGTGTTCGTCCCTCGCGCGGCCCACGGGGACAAGCAGG





GCAGTGACCTGGAGGGCGCGGGCGGCAGCGACGCGCCGTCCCCGCTGTC





GGCGGCGGGAGACGACTCCCTGGGCTCAGATGGGGACTGCGCGGCCAAC





AGCCCGGCCGCGGGCGGCGGCGCCAGAGATCCGCCGGGCGACGGCGAAC





AGAGTGCGGGAGGCGGGCCGGGCGCGGAGGAGGCGATCCCGGCAGCAGC





TGCTGCAGCGGTGGTGGCGGAGGGCGCGGAGGCCGGGGCGGCGGGGCCA





GGCGCGGGCGGCGCGGGGAGCGGCGAGGGTGCACGCAGCAAGCCATATA





CGCGGCGGCCCAAGCCCCCCTACTCGTACATCGCGCTCATCGCCATGGC





CATCCGCGACTCGGCGGGCGGGCGCTTGACGCTGGCGGAGATCAACGAG





TACCTCATGGGCAAGTTCCCCTTTTTCCGCGGCAGCTACACGGGCTGGC





GCAACTCCGTGCGCCACAACCTTTCGCTCAACGACTGCTTCGTCAAGGT





GCTGCGCGACCCCTCGCGGCCCTGGGGCAAGGACAACTACTGGATGCTC





AACCCCAACAGCGAGTACACCTTCGCCGACGGGGTCTTCCGCCGCCGCC





GCAAGCGCCTCAGCCACCGCGCGCCGGTCCCCGCGCCCGGGCTGCGGCC





CGAGGAGGCCCCGGGCCTCCCCGCCGCCCCGCCGCCCGCGCCCGCCGCC





CCGGCCTCGCCCCGCATGCGCTCGCCCGCCCGCCAGGAGGAGCGCGCCA





GCCCCGCGGGCAAGTTCTCCAGCTCCTTCGCCATCGACAGCATCCTGCG





CAAGCCCTTCCGCAGCCGCCGCCTCAGGGACACGGCCCCCGGGACGACG





CTTCAGTGGGGCGCCGCGCCCTGCCCGCCGCTGCCCGCGTTCCCCGCGC





TCCTCCCCGCGGCGCCCTGCAGGGCCCTGCTGCCGCTCTGCGCGTACGG





CGCGGGCGAGCCGGCGCGGCTGGGCGCGCGCGAGGCCGAGGTGCCACCG





ACCGCGCCGCCCCTCCTGCTTGCACCTCTCCCGGCGGCGGCCCCCGCCA





AGCCACTCCGAGGCCCGGCGGCCGGCGGCGCGCACCTGTACTGCCCCCT





GCGGCTGCCCGCAGCCCTGCAGGCGGCCTCAGTCCGCCGCCCTGGCCCG





CACCTGCCGTACCCGGTGGAGACGCTCCTAGCC,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:74 under stringent hybridization conditions.


In some embodiments, Forkhead Box R1 (FOXR1) comprises the amino acid sequence:









(SEQ ID NO: 75; NP_859072)


MGNELFLAFTTSHLPLAEQKLARYKLRIVKPPKLPLEKKPNPDKDGPDY





EPNLWMWVNPNIVYPPGKLEVSGRRKREDLTSTLPSSQPPQKEEDASCS





EAAGVESLSQSSSKRSPPRKRFAFSPSTWELTEEEEAEDQEDSSSMALP





SPHKRAPLQSRRLRQASSQAGRLWSRPPLNYFHLIALALRNSSPCGLNV





QQIYSFTRKHFPFFRTAPEGWKNTVRHNLCFRDSFEKVPVSMQGGASTR





PRSCLWKLTEEGHRRFAEEARALASTRLESIQQCMSQPDVMPFLFDL,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:75.


In some embodiments, the nucleic acid sequence encoding FOXR1 comprises the nucleic acid sequence:









(SEQ ID NO: 76; NM_181721)


ATGGGGAACGAGCTCTTTCTGGCCTTCACCACATCTCACCTCCCCTTAG





CGGAGCAGAAACTTGCCAGGTATAAACTCCGAATTGTTAAGCCACCAAA





ATTACCCCTAGAGAAAAAACCCAACCCTGATAAGGATGGTCCAGATTAT





GAGCCCAACCTCTGGATGTGGGTAAATCCCAACATTGTGTATCCCCCTG





GAAAGCTGGAGGTCTCAGGACGTAGGAAGAGGGAGGACCTGACAAGCAC





ACTCCCCTCCTCTCAGCCACCCCAGAAGGAGGAAGATGCCAGCTGCTCA





GAGGCCGCAGGGGTGGAATCACTGTCCCAGTCCTCCAGCAAGCGGTCTC





CCCCTCGGAAGCGGTTTGCCTTTTCCCCCAGCACCTGGGAGCTCACAGA





AGAGGAGGAGGCTGAGGACCAGGAAGACAGCTCCTCTATGGCTCTCCCA





TCCCCTCACAAAAGGGCCCCCCTCCAGAGTCGGAGGCTTCGGCAAGCCA





GCAGCCAGGCGGGGAGGCTCTGGTCCCGGCCCCCTCTCAATTACTTCCA





CCTAATTGCCCTGGCATTAAGAAACAGTTCCCCCTGTGGCCTCAACGTG





CAACAGATCTACAGTTTCACTCGAAAGCACTTCCCCTTTTTCCGGACGG





CCCCGGAAGGCTGGAAGAATACTGTCCGTCACAATCTCTGTTTTCGAGA





CAGCTTTGAGAAAGTGCCTGTCAGCATGCAGGGCGGGGCCAGCACACGG





CCTCGATCTTGCCTCTGGAAGTTGACCGAGGAGGGACACCGCCGCTTTG





CGGAGGAGGCCCGCGCCTTGGCTTCCACTCGGCTAGAAAGTATCCAACA





GTGCATGAGCCAGCCAGATGTGATGCCCTTCCTCTTTGATCTT,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:76 under stringent hybridization conditions.


In some embodiments, FOXR2 comprises the amino acid sequence









(SEQ ID NO: 77; NP_940853)


MDLKLKDCEFWYSLHGQVPGLLDWDMRNELFLPCTTDQCSLAEQILAKY





RVGVMKPPEMPQKRRPSPDGDGPPCEPNLWMWVDPNILCPLGSQEAPKP





SGKEDLTNISPFPQPPQKDEGSNCSEDKVVESLPSSSSEQSPLQKQGIH





SPSDFELTEEEAEEPDDNSLQSPEMKCYQSQKLWQINNQEKSWQRPPLN





CSHLIALALRNNPHCGLSVQEIYNFTRQHFPFFWTAPDGWKSTIHYNLC





FLDSFEKVPDSLKDEDNARPRSCLWKLTKEGHRRFWEETRVLAFAQRER





IQECMSQPELLTSLFDL,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:77.


In some embodiments, the nucleic acid sequence encoding FOXR2 comprises the nucleic acid sequence:









(SEQ ID NO: 78; NM_198451)


ATGGACTTAAAACTAAAAGACTGTGAATTTTGGTATAGTCTCCATGGCC





AGGTCCCAGGGCTGCTGGACTGGGACATGAGGAATGAGTTATTTCTGCC





TTGTACCACAGACCAGTGCTCTTTAGCTGAGCAAATCCTTGCCAAATAC





AGAGTCGGAGTAATGAAGCCCCCAGAAATGCCTCAGAAGAGGAGACCCA





GTCCTGATGGAGATGGTCCTCCCTGTGAACCCAATCTGTGGATGTGGGT





GGACCCCAATATCCTGTGCCCCCTTGGCAGCCAGGAGGCCCCAAAGCCC





AGTGGAAAAGAGGATCTGACAAACATTTCTCCTTTCCCTCAGCCCCCAC





AAAAAGACGAAGGGTCTAACTGCTCAGAGGACAAAGTGGTAGAGTCTCT





GCCATCTTCCTCCAGTGAGCAGTCTCCTTTACAGAAGCAGGGTATCCAT





TCCCCCAGTGACTTTGAGCTCACAGAAGAGGAGGCTGAGGAACCAGACG





ACAACTCCCTCCAGTCCCCTGAAATGAAATGTTACCAGAGCCAGAAACT





ATGGCAAATCAACAACCAAGAGAAGTCCTGGCAAAGGCCCCCTCTCAAT





TGTAGCCACCTTATTGCCCTAGCATTAAGAAACAACCCCCACTGTGGCC





TCAGTGTGCAGGAGATCTACAATTTCACCCGACAGCATTTCCCCTTTTT





CTGGACAGCTCCGGATGGCTGGAAGAGCACCATTCATTACAACCTCTGC





TTCCTGGACAGCTTTGAGAAGGTGCCAGACAGCCTTAAGGATGAAGATA





ATGCAAGACCTCGCTCTTGCCTTTGGAAGCTCACTAAGGAGGGGCACCG





CCGCTTTTGGGAGGAGACTCGTGTCTTAGCCTTTGCTCAAAGGGAGAGA





ATCCAAGAGTGCATGAGTCAGCCAGAGTTGTTGACCTCTCTCTTTGATC





TT,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:78 under stringent hybridization conditions.


In some embodiments, Hypoxia inducible factor 1 subunit alpha (HIF-1a) comprises the amino acid sequence:









(SEQ ID NO: 79; NP_001521)


MEGAGGANDKKKISSERRKEKSRDAARSRRSKESEVFYELAHQLPLPHN





VSSHLDKASVMRLTISYLRVRKLLDAGDLDIEDDMKAQMNCFYLKALDG





FVMVLTDDGDMIYISDNVNKYMGLTQFELTGHSVFDFTHPCDHEEMREM





LTHRNGLVKKGKEQNTQRSFFLRMKCTLTSRGRTMNIKSATWKVLHCTG





HIHVYDTNSNQPQCGYKKPPMTCLVLICEPIPHPSNIEIPLDSKTFLSR





HSLDMKFSYCDERITELMGYEPEELLGRSIYEYYHALDSDHLTKTHHDM





FTKGQVTTGQYRMLAKRGGYVWVETQATVIYNTKNSQPQCIVCVNYVVS





GIIQHDLIFSLQQTECVLKPVESSDMKMTQLFTKVESEDTSSLFDKLKK





EPDALTLLAPAAGDTIISLDFGSNDTETDDQQLEEVPLYNDVMLPSPNE





KLQNINLAMSPLPTAETPKPLRSSADPALNQEVALKLEPNPESLELSFT





MPQIQDQTPSPSDGSTRQSSPEPNSPSEYCFYVDSDMVNEFKLELVEKL





FAEDTEAKNPFSTQDTDLDLEMLAPYIPMDDDFQLRSFDQLSPLESSSA





SPESASPQSTVTVFQQTQIQEPTANATTTTATTDELKTVTKDRMEDIKI





LIASPSPTHIHKETTSATSSPYRDTQSRTASPNRAGKGVIEQTEKSHPR





SPNVLSVALSQRTTVPEEELNPKILALQNAQRKRKMEHDGSLFQAVGIG





TLLQQPDDHAATTSLSWKRVKGCKSSEQNGMEQKTIILIPSDLACRLLG





QSMDESGLPQLTSYDCEVNAPIQGSRNLLQGEELLRALDQVN,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:79.


In some embodiments, the nucleic acid sequence encoding HIF-1a comprises the nucleic acid sequence:









(SEQ ID NO: 80; NM_001530)


ATGGAGGGCGCCGGCGGCGCGAACGACAAGAAAAAGATAAGTTCTGAAC





GTCGAAAAGAAAAGTCTCGAGATGCAGCCAGATCTCGGCGAAGTAAAGA





ATCTGAAGTTTTTTATGAGCTTGCTCATCAGTTGCCACTTCCACATAAT





GTGAGTTCGCATCTTGATAAGGCCTCTGTGATGAGGCTTACCATCAGCT





ATTTGCGTGTGAGGAAACTTCTGGATGCTGGTGATTTGGATATTGAAGA





TGACATGAAAGCACAGATGAATTGCTTTTATTTGAAAGCCTTGGATGGT





TTTGTTATGGTTCTCACAGATGATGGTGACATGATTTACATTTCTGATA





ATGTGAACAAATACATGGGATTAACTCAGTTTGAACTAACTGGACACAG





TGTGTTTGATTTTACTCATCCATGTGACCATGAGGAAATGAGAGAAATG





CTTACACACAGAAATGGCCTTGTGAAAAAGGGTAAAGAACAAAACACAC





AGCGAAGCTTTTTTCTCAGAATGAAGTGTACCCTAACTAGCCGAGGAAG





AACTATGAACATAAAGTCTGCAACATGGAAGGTATTGCACTGCACAGGC





CACATTCACGTATATGATACCAACAGTAACCAACCTCAGTGTGGGTATA





AGAAACCACCTATGACCTGCTTGGTGCTGATTTGTGAACCCATTCCTCA





CCCATCAAATATTGAAATTCCTTTAGATAGCAAGACTTTCCTCAGTCGA





CACAGCCTGGATATGAAATTTTCTTATTGTGATGAAAGAATTACCGAAT





TGATGGGATATGAGCCAGAAGAACTTTTAGGCCGCTCAATTTATGAATA





TTATCATGCTTTGGACTCTGATCATCTGACCAAAACTCATCATGATATG





TTTACTAAAGGACAAGTCACCACAGGACAGTACAGGATGCTTGCCAAAA





GAGGTGGATATGTCTGGGTTGAAACTCAAGCAACTGTCATATATAACAC





CAAGAATTCTCAACCACAGTGCATTGTATGTGTGAATTACGTTGTGAGT





GGTATTATTCAGCACGACTTGATTTTCTCCCTTCAACAAACAGAATGTG





TCCTTAAACCGGTTGAATCTTCAGATATGAAAATGACTCAGCTATTCAC





CAAAGTTGAATCAGAAGATACAAGTAGCCTCTTTGACAAACTTAAGAAG





GAACCTGATGCTTTAACTTTGCTGGCCCCAGCCGCTGGAGACACAATCA





TATCTTTAGATTTTGGCAGCAACGACACAGAAACTGATGACCAGCAACT





TGAGGAAGTACCATTATATAATGATGTAATGCTCCCCTCACCCAACGAA





AAATTACAGAATATAAATTTGGCAATGTCTCCATTACCCACCGCTGAAA





CGCCAAAGCCACTTCGAAGTAGTGCTGACCCTGCACTCAATCAAGAAGT





TGCATTAAAATTAGAACCAAATCCAGAGTCACTGGAACTTTCTTTTACC





ATGCCCCAGATTCAGGATCAGACACCTAGTCCTTCCGATGGAAGCACTA





GACAAAGTTCACCTGAGCCTAATAGTCCCAGTGAATATTGTTTTTATGT





GGATAGTGATATGGTCAATGAATTCAAGTTGGAATTGGTAGAAAAACTT





TTTGCTGAAGACACAGAAGCAAAGAACCCATTTTCTACTCAGGACACAG





ATTTAGACTTGGAGATGTTAGCTCCCTATATCCCAATGGATGATGACTT





CCAGTTACGTTCCTTCGATCAGTTGTCACCATTAGAAAGCAGTTCCGCA





AGCCCTGAAAGCGCAAGTCCTCAAAGCACAGTTACAGTATTCCAGCAGA





CTCAAATACAAGAACCTACTGCTAATGCCACCACTACCACTGCCACCAC





TGATGAATTAAAAACAGTGACAAAAGACCGTATGGAAGACATTAAAATA





TTGATTGCATCTCCATCTCCTACCCACATACATAAAGAAACTACTAGTG





CCACATCATCACCATATAGAGATACTCAAAGTCGGACAGCCTCACCAAA





CAGAGCAGGAAAAGGAGTCATAGAACAGACAGAAAAATCTCATCCAAGA





AGCCCTAACGTGTTATCTGTCGCTTTGAGTCAAAGAACTACAGTTCCTG





AGGAAGAACTAAATCCAAAGATACTAGCTTTGCAGAATGCTCAGAGAAA





GCGAAAAATGGAACATGATGGTTCACTTTTTCAAGCAGTAGGAATTGGA





ACATTATTACAGCAGCCAGACGATCATGCAGCTACTACATCACTTTCTT





GGAAACGTGTAAAAGGATGCAAATCTAGTGAACAGAATGGAATGGAGCA





AAAGACAATTATTTTAATACCCTCTGATTTAGCATGTAGACTGCTGGGG





CAATCAATGGATGAAAGTGGATTACCACAGCTGACCAGTTATGATTGTG





AAGTTAATGCTCCTATACAAGGCAGCAGAAACCTACTGCAGGGTGAAGA





ATTACTCAGAGCTTTGGATCAAGTTAAC,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:80 under stringent hybridization conditions.


In some embodiments, endothelial PAS domain protein 1 (HIF-2a/EPAS1) comprises the amino acid sequence:









(SEQ ID NO: 81; NP_001421)


MTADKEKKRSSSERRKEKSRDAARCRRSKETEVFYELAHELPLPHSVSS





HLDKASIMRLAISFLRTHKLLSSVCSENESEAEADQQMDNLYLKALEGF





IAVVTQDGDMIFLSENISKFMGLTQVELTGHSIFDFTHPCDHEEIRENL





SLKNGSGFGKKSKDMSTERDFFMRMKCTVTNRGRTVNLKSATWKVLHCT





GQVKVYNNCPPHNSLCGYKEPLLSCLIIMCEPIQHPSHMDIPLDSKTFL





SRHSMDMKFTYCDDRITELIGYHPEELLGRSAYEFYHALDSENMTKSHQ





NLCTKGQVVSGQYRMLAKHGGYVWLETQGTVIYNPRNLQPQCIMCVNYV





LSEIEKNDVVFSMDQTESLFKPHLMAMNSIFDSSGKGAVSEKSNFLFTK





LKEEPEELAQLAPTPGDAIISLDFGNQNFEESSAYGKAILPPSQPWATE





LRSHSTQSEAGSLPAFTVPQAAAPGSTTPSATSSSSSCSTPNSPEDYYT





SLDNDLKIEVIEKLFAMDTEAKDQCSTQTDFNELDLETLAPYIPMDGED





FQLSPICPEERLLAENPQSTPQHCFSAMTNIFQPLAPVAPHSPFLLDKF





QQQLESKKTEPEHRPMSSIFFDAGSKASLPPCCGQASTPLSSMGGRSNT





QWPPDPPLHFGPTKWAVGDQRTEFLGAAPLGPPVSPPHVSTFKTRSAKG





FGARGPDVLSPAMVALSNKLKLKRQLEYEEQAFQDLSGGDPPGGSTSHL





MWKRMKNLRGGSCPLMPDKPLSANVPNDKFTQNPMRGLGHPLRHLPLPQ





PPSAISPGENSKSRFPPQCYATQYQDYSLSSAHKVSGMASRLLGPSFES





YLLPELTRYDCEVNVPVLGSSTLLQGGDLLRALDQAT,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:81.


In some embodiments, the nucleic acid sequence encoding HIF-2a comprises the nucleic acid sequence:









(SEQ ID NO: 82; NM_001430)


ATGACAGCTGACAAGGAGAAGAAAAGGAGTAGCTCGGAGAGGAGGAAGG





AGAAGTCCCGGGATGCTGCGCGGTGCCGGCGGAGCAAGGAGACGGAGGT





GTTCTATGAGCTGGCCCATGAGCTGCCTCTGCCCCACAGTGTGAGCTCC





CATCTGGACAAGGCCTCCATCATGCGACTGGCAATCAGCTTCCTGCGAA





CACACAAGCTCCTCTCCTCAGTTTGCTCTGAAAACGAGTCCGAAGCCGA





AGCTGACCAGCAGATGGACAACTTGTACCTGAAAGCCTTGGAGGGTTTC





ATTGCCGTGGTGACCCAAGATGGCGACATGATCTTTCTGTCAGAAAACA





TCAGCAAGTTCATGGGACTTACACAGGTGGAGCTAACAGGACATAGTAT





CTTTGACTTCACTCATCCCTGCGACCATGAGGAGATTCGTGAGAACCTG





AGTCTCAAAAATGGCTCTGGTTTTGGGAAAAAAAGCAAAGACATGTCCA





CAGAGCGGGACTTCTTCATGAGGATGAAGTGCACGGTCACCAACAGAGG





CCGTACTGTCAACCTCAAGTCAGCCACCTGGAAGGTCTTGCACTGCACG





GGCCAGGTGAAAGTCTACAACAACTGCCCTCCTCACAATAGTCTGTGTG





GCTACAAGGAGCCCCTGCTGTCCTGCCTCATCATCATGTGTGAACCAAT





CCAGCACCCATCCCACATGGACATCCCCCTGGATAGCAAGACCTTCCTG





AGCCGCCACAGCATGGACATGAAGTTCACCTACTGTGATGACAGAATCA





CAGAACTGATTGGTTACCACCCTGAGGAGCTGCTTGGCCGCTCAGCCTA





TGAATTCTACCATGCGCTAGACTCCGAGAACATGACCAAGAGTCACCAG





AACTTGTGCACCAAGGGTCAGGTAGTAAGTGGCCAGTACCGGATGCTCG





CAAAGCATGGGGGCTACGTGTGGCTGGAGACCCAGGGGACGGTCATCTA





CAACCCTCGCAACCTGCAGCCCCAGTGCATCATGTGTGTCAACTACGTC





CTGAGTGAGATTGAGAAGAATGACGTGGTGTTCTCCATGGACCAGACTG





AATCCCTGTTCAAGCCCCACCTGATGGCCATGAACAGCATCTTTGATAG





CAGTGGCAAGGGGGCTGTGTCTGAGAAGAGTAACTTCCTATTCACCAAG





CTAAAGGAGGAGCCCGAGGAGCTGGCCCAGCTGGCTCCCACCCCAGGAG





ACGCCATCATCTCTCTGGATTTCGGGAATCAGAACTTCGAGGAGTCCTC





AGCCTATGGCAAGGCCATCCTGCCCCCGAGCCAGCCATGGGCCACGGAG





TTGAGGAGCCACAGCACCCAGAGCGAGGCTGGGAGCCTGCCTGCCTTCA





CCGTGCCCCAGGCAGCTGCCCCGGGCAGCACCACCCCCAGTGCCACCAG





CAGCAGCAGCAGCTGCTCCACGCCCAATAGCCCTGAAGACTATTACACA





TCTTTGGATAACGACCTGAAGATTGAAGTGATTGAGAAGCTCTTCGCCA





TGGACACAGAGGCCAAGGACCAATGCAGTACCCAGACGGATTTCAATGA





GCTGGACTTGGAGACACTGGCACCCTATATCCCCATGGACGGGGAAGAC





TTCCAGCTAAGCCCCATCTGCCCCGAGGAGCGGCTCTTGGCGGAGAACC





CACAGTCCACCCCCCAGCACTGCTTCAGTGCCATGACAAACATCTTCCA





GCCACTGGCCCCTGTAGCCCCGCACAGTCCCTTCCTCCTGGACAAGTTT





CAGCAGCAGCTGGAGAGCAAGAAGACAGAGCCCGAGCACCGGCCCATGT





CCTCCATCTTCTTTGATGCCGGAAGCAAAGCATCCCTGCCACCGTGCTG





TGGCCAGGCCAGCACCCCTCTCTCTTCCATGGGGGGCAGATCCAATACC





CAGTGGCCCCCAGATCCACCATTACATTTTGGGCCCACAAAGTGGGCCG





TCGGGGATCAGCGCACAGAGTTCTTGGGAGCAGCGCCGTTGGGGCCCCC





TGTCTCTCCACCCCATGTCTCCACCTTCAAGACAAGGTCTGCAAAGGGT





TTTGGGGCTCGAGGCCCAGACGTGCTGAGTCCGGCCATGGTAGCCCTCT





CCAACAAGCTGAAGCTGAAGCGACAGCTGGAGTATGAAGAGCAAGCCTT





CCAGGACCTGAGCGGGGGGGACCCACCTGGTGGCAGCACCTCACATTTG





ATGTGGAAACGGATGAAGAACCTCAGGGGTGGGAGCTGCCCTTTGATGC





CGGACAAGCCACTGAGCGCAAATGTACCCAATGATAAGTTCACCCAAAA





CCCCATGAGGGGCCTGGGCCATCCCCTGAGACATCTGCCGCTGCCACAG





CCTCCATCTGCCATCAGTCCCGGGGAGAACAGCAAGAGCAGGTTCCCCC





CACAGTGCTACGCCACCCAGTACCAGGACTACAGCCTGTCGTCAGCCCA





CAAGGTGTCAGGCATGGCAAGCCGGCTGCTCGGGCCCTCATTTGAGTCC





TACCTGCTGCCCGAACTGACCAGATATGACTGTGAGGTGAACGTGCCCG





TGCTGGGAAGCTCCACGCTCCTGCAAGGAGGGGACCTCCTCAGAGCCCT





GGACCAGGCCACC,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:82 under stringent hybridization conditions.


In some embodiments, Sonic Headgehog (SHH) comprises the amino acid sequence:









(SEQ ID NO: 83; NP_000184)


MGEMLLLARCLLLVLVSSLLVCSGLACGPGRGFGKRRHPKKLTPLAYKQ





FIPNVAEKTLGASGRYEGKISRNSERFKELTPNYNPDIIFKDEENTGAD





RLMTQRCKDKLNALAISVMNQWPGVKLRVTEGWDEDGHHSEESLHYEGR





AVDITTSDRDRSKYGMLARLAVEAGFDWVYYESKAHIHCSVKAENSVAA





KSGGCFPGSATVHLEQGGTKLVKDLSPGDRVLAADDQGRLLYSDFLTFL





DRDDGAKKVFYVIETREPRERLLLTAAHLLFVAPHNDSATGEPEASSGS





GPPSGGALGPRALFASRVRPGQRVYVVAERDGDRRLLPAAVHSVTLSEE





AAGAYAPLTAQGTILINRVLASCYAVIEEHSWAHRAFAPFRLAHALLAA





LAPARTDRGGDSGGGDRGGGGGRVALTAPGAADAPGAGATAGIHWYSQL





LYQIGTWLLDSEALHPLGMAVKSS,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:83.


In some embodiments, the nucleic acid sequence encoding SHH comprises the nucleic acid sequence:









(SEQ ID NO: 84; NM_000193)


ATGGGCGAGATGCTGCTGCTGGCGAGATGTCTGCTGCTAGTCCTCGTCT





CCTCGCTGCTGGTATGCTCGGGACTGGCGTGCGGACCGGGCAGGGGGTT





CGGGAAGAGGAGGCACCCCAAAAAGCTGACCCCTTTAGCCTACAAGCAG





TTTATCCCCAATGTGGCCGAGAAGACCCTAGGCGCCAGCGGAAGGTATG





AAGGGAAGATCTCCAGAAACTCCGAGCGATTTAAGGAACTCACCCCCAA





TTACAACCCCGACATCATATTTAAGGATGAAGAAAACACCGGAGCGGAC





AGGCTGATGACTCAGAGGTGTAAGGACAAGTTGAACGCTTTGGCCATCT





CGGTGATGAACCAGTGGCCAGGAGTGAAACTGCGGGTGACCGAGGGCTG





GGACGAAGATGGCCACCACTCAGAGGAGTCTCTGCACTACGAGGGCCGC





GCAGTGGACATCACCACGTCTGACCGCGACCGCAGCAAGTACGGCATGC





TGGCCCGCCTGGCGGTGGAGGCCGGCTTCGACTGGGTGTACTACGAGTC





CAAGGCACATATCCACTGCTCGGTGAAAGCAGAGAACTCGGTGGCGGCC





AAATCGGGAGGCTGCTTCCCGGGCTCGGCCACGGTGCACCTGGAGCAGG





GCGGCACCAAGCTGGTGAAGGACCTGAGCCCCGGGGACCGCGTGCTGGC





GGCGGACGACCAGGGCCGGCTGCTCTACAGCGACTTCCTCACTTTCCTG





GACCGCGACGACGGCGCCAAGAAGGTCTTCTACGTGATCGAGACGCGGG





AGCCGCGCGAGCGCCTGCTGCTCACCGCCGCGCACCTGCTCTTTGTGGC





GCCGCACAACGACTCGGCCACCGGGGAGCCCGAGGCGTCCTCGGGCTCG





GGGCCGCCTTCCGGGGGCGCACTGGGGCCTCGGGCGCTGTTCGCCAGCC





GCGTGCGCCCGGGCCAGCGCGTGTACGTGGTGGCCGAGCGTGACGGGGA





CCGCCGGCTCCTGCCCGCCGCTGTGCACAGCGTGACCCTAAGCGAGGAG





GCCGCGGGCGCCTACGCGCCGCTCACGGCCCAGGGCACCATTCTCATCA





ACCGGGTGCTGGCCTCGTGCTACGCGGTCATCGAGGAGCACAGCTGGGC





GCACCGGGCCTTCGCGCCCTTCCGCCTGGCGCACGCGCTCCTGGCTGCA





CTGGCGCCCGCGCGCACGGACCGCGGCGGGGACAGCGGCGGCGGGGACC





GCGGGGGCGGCGGCGGCAGAGTAGCCCTAACCGCTCCAGGTGCTGCCGA





CGCTCCGGGTGCGGGGGCCACCGCGGGCATCCACTGGTACTCGCAGCTG





CTCTACCAAATAGGCACCTGGCTCCTGGACAGCGAGGCCCTGCACCCGC





TGGGCATGGCGGTCAAGTCCAGC,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:84 under stringent hybridization conditions.


In some embodiments, desert hedgehog (DHH) comprises the amino acid sequence:









(SEQ ID NO: 85; NP_066382)


MALLTNLLPLCCLALLALPAQSCGPGRGPVGRRRYARKQLVPLLYKQFV





PGVPERTLGASGPAEGRVARGSERFRDLVPNYNPDIIFKDEENSGADRL





MTERCKERVNALAIAVMNMWPGVRLRVTEGWDEDGHHAQDSLHYEGRAL





DITTSDRDRNKYGLLARLAVEAGFDWVYYESRNHVHVSVKADNSLAVRA





GGCFPGNATVRLWSGERKGLRELHRGDWVLAADASGRVVPTPVLLFLDR





DLQRRASFVAVETEWPPRKLLLTPWHLVFAARGPAPAPGDFAPVFARRL





RAGDSVLAPGGDALRPARVARVAREEAVGVFAPLTAHGTLLVNDVLASC





YAVLESHQWAHRAFAPLRLLHALGALLPGGAVQPTGMHWYSRLLYRLAE





ELLG,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:85.


In some embodiments, the nucleic acid sequence encoding DHH comprises the nucleic acid sequence:









(SEQ ID NO: 86; NM_021044)


ATGGCTCTCCTGACCAATCTACTGCCCCTGTGCTGCTTGGCACTTCTGG





CGCTGCCAGCCCAGAGCTGCGGGCCGGGCCGGGGGCCGGTTGGCCGGCG





CCGCTATGCGCGCAAGCAGCTCGTGCCGCTACTCTACAAGCAATTTGTG





CCCGGCGTGCCAGAGCGGACCCTGGGCGCCAGTGGGCCAGCGGAGGGGA





GGGTGGCAAGGGGCTCCGAGCGCTTCCGGGACCTCGTGCCCAACTACAA





CCCCGACATCATCTTCAAGGATGAGGAGAACAGTGGAGCCGACCGCCTG





ATGACCGAGCGTTGTAAGGAGCGGGTGAACGCTTTGGCCATTGCCGTGA





TGAACATGTGGCCCGGAGTGCGCCTACGAGTGACTGAGGGCTGGGACGA





GGACGGCCACCACGCTCAGGATTCACTCCACTACGAAGGCCGTGCTTTG





GACATCACTACGTCTGACCGCGACCGCAACAAGTATGGGTTGCTGGCGC





GCCTCGCAGTGGAAGCCGGCTTCGACTGGGTCTACTACGAGTCCCGCAA





CCACGTCCACGTGTCGGTCAAAGCTGATAACTCACTGGCGGTCCGGGCG





GGCGGCTGCTTTCCGGGAAATGCAACTGTGCGCCTGTGGAGCGGCGAGC





GGAAAGGGCTGCGGGAACTGCACCGCGGAGACTGGGTTTTGGCGGCCGA





TGCGTCAGGCCGGGTGGTGCCCACGCCGGTGCTGCTCTTCCTGGACCGG





GACTTGCAGCGCCGGGCTTCATTTGTGGCTGTGGAGACCGAGTGGCCTC





CACGCAAACTGTTGCTCACGCCCTGGCACCTGGTGTTTGCCGCTCGAGG





GCCGGCGCCCGCGCCAGGCGACTTTGCACCGGTGTTCGCGCGCCGGCTA





CGCGCTGGGGACTCGGTGCTGGCGCCCGGCGGGGATGCGCTTCGGCCAG





CGCGCGTGGCCCGTGTGGCGCGGGAGGAAGCCGTGGGCGTGTTCGCGCC





GCTCACCGCGCACGGGACGCTGCTGGTGAACGATGTCCTGGCCTCTTGC





TACGCGGTTCTGGAGAGTCACCAGTGGGCGCACCGCGCTTTTGCCCCCT





TGAGACTGCTGCACGCGCTAGGGGCGCTGCTCCCCGGCGGGGCCGTCCA





GCCGACTGGCATGCATTGGTACTCTCGGCTCCTCTACCGCTTAGCGGAG





GAGCTACTGGGC,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:86 under stringent hybridization conditions.


In some embodiments, Indian Hedgehog (IHH) comprises the amino acid sequence:









(SEQ ID NO: 87; NP_002172)


MSPARLRPRLHFCLVLLLLLVVPAAWGCGPGRVVGSRRRPPRKLVPLAY





KQFSPNVPEKTLGASGRYEGKIARSSERFKELTPNYNPDIIFKDEENTG





ADRLMTQRCKDRLNSLAISVMNQWPGVKLRVTEGWDEDGHHSEESLHYE





GRAVDITTSDRDRNKYGLLARLAVEAGFDWVYYESKAHVHCSVKSEHSA





AAKTGGCFPAGAQVRLESGARVALSAVRPGDRVLAMGEDGSPTFSDVLI





FLDREPHRLRAFQVIETQDPPRRLALTPAHLLFTADNHTEPAARFRATF





ASHVQPGQYVLVAGVPGLQPARVAAVSTHVALGAYAPLTKHGTLVVEDV





VASCFAAVADHHLAQLAFWPLRLFHSLAWGSWTPGEGVHWYPQLLYRLG





RLLLEEGSFHPLGMSGAGS,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:87.


In some embodiments, the nucleic acid sequence encoding IHH comprises the nucleic acid sequence:









(SEQ ID NO: 88; NM_002181)


ATGTCTCCCGCCCGGCTCCGGCCCCGACTGCACTTCTGCCTGGTCCTGT





TGCTGCTGCTGGTGGTGCCGGCGGCATGGGGCTGCGGGCCGGGTCGGGT





GGTGGGCAGCCGCCGGCGACCGCCACGCAAACTCGTGCCGCTCGCCTAC





AAGCAGTTCAGCCCCAATGTGCCCGAGAAGACCCTGGGCGCCAGCGGAC





GCTATGAAGGCAAGATCGCTCGCAGCTCCGAGCGCTTCAAGGAGCTCAC





CCCCAATTACAATCCAGACATCATCTTCAAGGACGAGGAGAACACAGGC





GCCGACCGCCTCATGACCCAGCGCTGCAAGGACCGCCTGAACTCGCTGG





CTATCTCGGTGATGAACCAGTGGCCCGGTGTGAAGCTGCGGGTGACCGA





GGGCTGGGACGAGGACGGCCACCACTCAGAGGAGTCCCTGCATTATGAG





GGCCGCGCGGTGGACATCACCACATCAGACCGCGACCGCAATAAGTATG





GACTGCTGGCGCGCTTGGCAGTGGAGGCCGGCTTTGACTGGGTGTATTA





CGAGTCAAAGGCCCACGTGCATTGCTCCGTCAAGTCCGAGCACTCGGCC





GCAGCCAAGACAGGCGGCTGCTTCCCTGCCGGAGCCCAGGTACGCCTGG





AGAGTGGGGCGCGTGTGGCCTTGTCAGCCGTGAGGCCGGGAGACCGTGT





GCTGGCCATGGGGGAGGATGGGAGCCCCACCTTCAGCGATGTGCTCATT





TTCCTGGACCGCGAGCCTCACAGGCTGAGAGCCTTCCAGGTCATCGAGA





CTCAGGACCCCCCACGCCGCCTGGCACTCACACCCGCTCACCTGCTCTT





TACGGCTGACAATCACACGGAGCCGGCAGCCCGCTTCCGGGCCACATTT





GCCAGCCACGTGCAGCCTGGCCAGTACGTGCTGGTGGCTGGGGTGCCAG





GCCTGCAGCCTGCCCGCGTGGCAGCTGTCTCTACACACGTGGCCCTCGG





GGCCTACGCCCCGCTCACAAAGCATGGGACACTGGTGGTGGAGGATGTG





GTGGCATCCTGCTTCGCGGCCGTGGCTGACCACCACCTGGCTCAGTTGG





CCTTCTGGCCCCTGAGACTCTTTCACAGCTTGGCATGGGGCAGCTGGAC





CCCGGGGGAGGGTGTGCATTGGTACCCCCAGCTGCTCTACCGCCTGGGG





CGTCTCCTGCTAGAAGAGGGCAGCTTCCACCCACTGGGCATGTCCGGGG





CAGGGAGC,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:88 under stringent hybridization conditions.


In some embodiments, Brachyury (TBXT) comprises the amino acid sequence:









(SEQ ID NO: 89; NP_003172)


MSSPGTESAGKSLQYRVDHLLSAVENELQAGSEKGDPTERELRVGLEESE





LWLRFKELTNEMIVTKNGRRMFPVLKVNVSGLDPNAMYSFLLDFVAADNH





RWKYVNGEWVPGGKPEPQAPSCVYIHPDSPNFGAHWMKAPVSFSKVKLTN





KLNGGGQIMLNSLHKYEPRIHIVRVGGPQRMITSHCFPETQFIAVTAYQN





EEITALKIKYNPFAKAFLDAKERSDHKEMMEEPGDSQQPGYSQSGGWLLP





GTSTLCPPANPHPQFGGALSLPSTHSCDRYPTLRSHRSSPYPSPYAHRNN





SPTYSDNSPACLSMLQSHDNWSSLGMPAHPSMLPVSHNASPPTSSSQYPS





LWSVSNGAVTPGSQAAAVSNGLGAQFFRGSPAHYTPLTHPVSAPSSSGSP





LYEGAAAATDIVDSQYDAAAQGRLIASWTPVSPPSM,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:89.


In some embodiments, the nucleic acid sequence encoding TBXT comprises the nucleic acid sequence:









(SEQ ID NO: 90; NM_003181)


ATGAGCTCCCCTGGCACCGAGAGCGCGGGAAAGAGCCTGCAGTACCGAGT





GGACCACCTGCTGAGCGCCGTGGAGAATGAGCTGCAGGCGGGCAGCGAGA





AGGGCGACCCCACAGAGCGCGAACTGCGCGTGGGCCTGGAGGAGAGCGAG





CTGTGGCTGCGCTTCAAGGAGCTCACCAATGAGATGATCGTGACCAAGAA





CGGCAGGAGGATGTTTCCGGTGCTGAAGGTGAACGTGTCTGGCCTGGACC





CCAACGCCATGTACTCCTTCCTGCTGGACTTCGTGGCGGCGGACAACCAC





CGCTGGAAGTACGTGAACGGGGAATGGGTGCCGGGGGGCAAGCCGGAGCC





GCAGGCGCCCAGCTGCGTCTACATCCACCCCGACTCGCCCAACTTCGGGG





CCCACTGGATGAAGGCTCCCGTCTCCTTCAGCAAAGTCAAGCTCACCAAC





AAGCTCAACGGAGGGGGCCAGATCATGCTGAACTCCTTGCATAAGTATGA





GCCTCGAATCCACATAGTGAGAGTTGGGGGTCCACAGCGCATGATCACCA





GCCACTGCTTCCCTGAGACCCAGTTCATAGCGGTGACTGCTTATCAGAAC





GAGGAGATCACAGCTCTTAAAATTAAGTACAATCCATTTGCAAAAGCTTT





CCTTGATGCAAAGGAAAGAAGTGATCACAAAGAGATGATGGAGGAACCCG





GAGACAGCCAGCAACCTGGGTACTCCCAATCAGGGGGGTGGCTTCTTCCT





GGAACCAGCACCCTGTGTCCACCTGCAAATCCTCATCCTCAGTTTGGAGG





TGCCCTCTCCCTCCCCTCCACGCACAGCTGTGACAGGTACCCAACCCTGA





GGAGCCACCGGTCCTCACCCTACCCCAGCCCCTATGCTCATCGGAACAAT





TCTCCAACCTATTCTGACAACTCACCTGCATGTTTATCCATGCTGCAATC





CCATGACAATTGGTCCAGCCTTGGAATGCCTGCCCATCCCAGCATGCTCC





CCGTGAGCCACAATGCCAGCCCACCTACCAGCTCCAGTCAGTACCCCAGC





CTGTGGTCTGTGAGCAACGGCGCCGTCACCCCGGGCTCCCAGGCAGCAGC





CGTGTCCAACGGGCTGGGGGCCCAGTTCTTCCGGGGCTCCCCCGCGCACT





ACACACCCCTCACCCATCCGGTCTCGGCGCCCTCTTCCTCGGGATCCCCA





CTGTACGAAGGGGCGGCCGCGGCCACAGACATCGTGGACAGCCAGTACGA





CGCCGCAGCCCAAGGCCGCCTCATAGCCTCATGGACACCTGTGTCGCCAC





CTTCCATG,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:90 under stringent hybridization conditions.


In some embodiments, T-box brain 1 (TBR1) comprises the amino acid sequence:









(SEQ ID NO: 91; NP_006584)


MQLEHCLSPSIMLSKKFLNVSSSYPHSGGSELVLHDHPIISTTDNLERSS





PLKKITRGMTNQSDTDNFPDSKDSPGDVQRSKLSPVLDGVSELRHSFDGS





AADRYLLSQSSQPQSAATAPSAMFPYPGQHGPAHPAFSIGSPSRYMAHHP





VITNGAYNSLLSNSSPQGYPTAGYPYPQQYGHSYQGAPFYQFSSTQPGLV





PGKAQVYLCNRPLWLKFHRHQTEMIITKQGRRMFPFLSFNISGLDPTAHY





NIFVDVILADPNHWRFQGGKWVPCGKADTNVQGNRVYMHPDSPNTGAHWM





RQEISFGKLKLTNNKGASNNNGQMVVLQSLHKYQPRLHVVEVNEDGTEDT





SQPGRVQTFTFPETQFIAVTAYQNTDITQLKIDHNPFAKGFRDNYDTIYT





GCDMDRLTPSPNDSPRSQIVPGARYAMAGSFLQDQFVSNYAKARFHPGAG





AGPGPGTDRSVPHTNGLLSPQQAEDPGAPSPQRWFVTPANNRLDFAASAY





DTATDFAGNAATLLSYAAAGVKALPLQAAGCTGRPLGYYADPSGWGARSP





PQYCGTKSGSVLPCWPNSAAAAARMAGANPYLGEEAEGLAAERSPLPPGA





AEDAKPKDLSDSSWIETPSSIKSIDSSDSGIYEQAKRRRISPADTPVSES





SSPLKSEVLAQRDCEKNCAKDISGYYGFYSHS,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:91.


In some embodiments, the nucleic acid sequence encoding TBR1 comprises the nucleic acid sequence:









(SEQ ID NO: 92; NM_006593)


ATGCAGCTGGAGCACTGCCTTTCTCCTTCTATCATGCTCTCCAAGAAATT





TCTCAATGTGAGCAGCAGCTACCCACATTCAGGCGGATCCGAGCTTGTCT





TGCACGATCATCCCATTATCTCGACCACTGACAACCTGGAGAGAAGTTCA





CCTTTGAAAAAAATTACCAGGGGGATGACGAATCAGTCAGATACAGACAA





TTTTCCTGACTCCAAGGACTCACCAGGGGACGTCCAGAGAAGTAAACTCT





CTCCTGTCTTGGACGGGGTCTCTGAGCTTCGTCACAGTTTCGATGGCTCT





GCTGCAGATCGCTACCTCCTCTCTCAGTCCAGCCAGCCACAGTCTGCGGC





CACTGCTCCCAGTGCCATGTTCCCGTACCCCGGCCAGCACGGACCGGCGC





ACCCCGCCTTCTCCATCGGCAGCCCTAGCCGCTACATGGCCCACCACCCG





GTCATCACCAACGGAGCCTACAACAGCCTCCTGTCCAACTCCTCGCCGCA





GGGATACCCCACGGCCGGCTACCCCTACCCACAGCAGTACGGCCACTCCT





ACCAAGGAGCTCCGTTCTACCAGTTCTCCTCCACCCAGCCGGGGCTGGTG





CCCGGCAAAGCACAGGTGTACCTGTGCAACAGGCCCCTTTGGCTGAAATT





TCACCGGCACCAAACGGAGATGATCATCACCAAACAGGGAAGGCGCATGT





TTCCTTTTTTAAGTTTTAACATTTCTGGTCTCGATCCCACGGCTCATTAC





AATATTTTTGTGGATGTGATTTTGGCGGATCCCAATCACTGGAGGTTTCA





AGGAGGCAAATGGGTTCCTTGCGGCAAAGCGGACACCAATGTGCAAGGAA





ATCGGGTCTATATGCATCCGGATTCCCCCAACACTGGGGCTCACTGGATG





CGCCAAGAAATCTCTTTTGGAAAATTAAAACTTACGAACAACAAAGGAGC





TTCAAATAACAATGGGCAGATGGTGGTTTTACAGTCCTTGCACAAGTACC





AGCCCCGCCTGCATGTGGTGGAAGTGAACGAGGACGGCACGGAGGACACT





AGCCAGCCCGGCCGCGTGCAGACGTTCACTTTCCCTGAGACTCAGTTCAT





CGCCGTCACCGCCTACCAGAACACGGATATTACACAACTGAAAATAGATC





ACAACCCTTTTGCAAAAGGATTTCGGGATAATTATGACACGATCTACACC





GGCTGTGACATGGACCGCCTGACCCCCTCGCCCAACGACTCGCCGCGCTC





GCAGATCGTGCCCGGGGCCCGCTACGCCATGGCCGGCTCTTTCCTGCAGG





ACCAGTTCGTGAGCAACTACGCCAAGGCCCGCTTCCACCCGGGCGCGGGC





GCGGGCCCCGGGCCGGGTACGGACCGCAGCGTGCCGCACACCAACGGGCT





GCTGTCGCCGCAGCAGGCCGAGGACCCGGGCGCGCCCTCGCCGCAACGCT





GGTTTGTGACGCCGGCCAACAACCGGCTGGACTTCGCGGCCTCGGCCTAT





GACACGGCCACGGACTTCGCGGGCAACGCGGCCACGCTGCTCTCTTACGC





GGCGGCGGGCGTGAAGGCGCTGCCGCTGCAGGCTGCAGGCTGCACTGGCC





GCCCGCTCGGCTACTACGCCGACCCGTCGGGCTGGGGCGCCCGCAGTCCC





CCGCAGTACTGCGGCACCAAGTCGGGCTCGGTGCTGCCCTGCTGGCCCAA





CAGCGCCGCGGCCGCCGCGCGCATGGCCGGCGCCAATCCCTACCTGGGCG





AGGAGGCCGAGGGCCTGGCCGCCGAGCGCTCGCCGCTGCCGCCCGGCGCC





GCCGAGGACGCCAAGCCCAAGGACCTGTCCGATTCCAGCTGGATCGAGAC





GCCCTCCTCGATCAAGTCCATCGACTCCAGCGACTCGGGGATTTACGAGC





AGGCCAAGCGGAGGCGGATCTCGCCGGCCGACACGCCCGTGTCCGAGAGT





TCGTCCCCGCTCAAGAGCGAGGTGCTGGCCCAGCGGGACTGCGAGAAGAA





CTGCGCCAAGGACATTAGCGGCTACTATGGCTTCTACTCGCACAGC,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:92 under stringent hybridization conditions.


In some embodiments, T-Box 1 (TBX1) comprises the amino acid sequence:









(SEQ ID NO: 93; NP_542377)


MHFSTVTRDMEAFTASSLSSLGAAGGFPGAASPGADPYGPREPPPPPRYD





PCAAAAPGAPGPPPPPHAYPFAPAAGAATSAAAEPEGPGASCAAAAKAPV





KKNAKVAGVSVQLEMKALWDEFNQLGTEMIVTKAGRRMFPTFQVKLFGMD





PMADYMLLMDFVPVDDKRYRYAFHSSSWLVAGKADPATPGRVHYHPDSPA





KGAQWMKQIVSFDKLKLTNNLLDDNGHIILNSMHRYQPRFHVVYVDPRKD





SEKYAEENFKTFVFEETRFTAVTAYQNHRITQLKIASNPFAKGFRDCDPE





DWPRNHRPGALPLMSAFARSRNPVASPTQPSGTEKDAAEARREFQRDAGG





PAVLGDPAHPPQLLARVLSPSLPGAGGAGGLVPLPGAPGGRPSPPNPELR





LEAPGASEPLHHHPYKYPAAAYDHYLGAKSRPAPYPLPGLRGHGYHPHAN





PHHHHHPVSPAAAAAAAAAAAAAAANMYSSAGAAPPGSYDYCPR,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:93.


In some embodiments, the nucleic acid sequence encoding TBX1 comprises the nucleic acid sequence:









(SEQ ID NO: 94; NM_080647)


ATGCACTTCAGCACCGTCACCAGGGACATGGAAGCCTTCACGGCCAGCAG





CCTGAGCAGCCTGGGGGCCGCGGGGGGCTTCCCGGGCGCCGCGTCGCCCG





GCGCCGACCCGTACGGCCCGCGCGAGCCCCCGCCGCCGCCGCGCTACGAC





CCGTGCGCCGCCGCCGCCCCCGGCGCCCCGGGTCCGCCGCCGCCGCCGCA





CGCCTACCCGTTTGCGCCGGCCGCCGGGGCCGCCACCAGCGCCGCCGCCG





AGCCCGAGGGCCCCGGGGCCAGCTGCGCGGCCGCAGCCAAGGCGCCGGTG





AAGAAGAACGCGAAGGTGGCCGGTGTGAGCGTGCAGCTAGAGATGAAGGC





GCTGTGGGACGAGTTCAACCAGCTGGGCACCGAGATGATCGTCACCAAGG





CCGGCAGGCGGATGTTTCCCACCTTCCAAGTGAAGCTCTTCGGCATGGAT





CCCATGGCCGACTATATGCTGCTCATGGACTTCGTGCCGGTGGACGATAA





GCGCTACCGGTACGCCTTCCACAGCTCCTCCTGGCTGGTGGCGGGGAAGG





CCGACCCTGCCACGCCAGGCCGCGTGCACTACCACCCGGACTCGCCTGCC





AAGGGCGCGCAGTGGATGAAGCAAATCGTGTCCTTCGACAAGCTCAAGCT





GACCAACAACTTACTGGACGACAACGGCCACATTATTCTGAATTCCATGC





ACAGATACCAGCCCCGCTTCCACGTGGTCTATGTGGACCCACGCAAAGAT





AGCGAGAAATATGCCGAGGAGAACTTCAAAACCTTTGTGTTCGAGGAGAC





ACGATTCACCGCGGTCACTGCCTACCAGAACCATCGGATCACGCAGCTCA





AGATTGCCAGCAATCCCTTCGCGAAAGGCTTCCGGGACTGTGACCCTGAG





GACTGGCCCCGGAACCACCGGCCCGGCGCACTGCCGCTCATGAGCGCCTT





CGCGCGCTCGCGGAACCCCGTGGCTTCCCCGACGCAGCCCAGCGGCACGG





AGAAAGACGCGGCTGAGGCCCGGCGAGAATTCCAGCGCGACGCGGGCGGG





CCAGCGGTGCTCGGGGACCCGGCGCATCCTCCGCAGCTGCTGGCCCGGGT





GCTAAGCCCCTCGCTGCCCGGGGCCGGCGGCGCCGGCGGCTTAGTCCCGC





TGCCCGGCGCGCCCGGAGGCCGGCCCAGTCCCCCGAACCCCGAGCTGCGC





CTGGAGGCGCCCGGCGCATCGGAGCCGCTGCACCACCACCCCTACAAATA





TCCGGCCGCCGCCTACGACCACTATCTCGGGGCCAAGAGCCGGCCGGCGC





CCTACCCGCTGCCCGGCCTGCGTGGCCACGGCTACCACCCGCACGCGCAT





CCGCACCACCACCACCACCCCGTGAGTCCAGCCGCCGCGGCCGCCGCCGC





CGCTGCCGCAGCTGCCGCGGCCGCCAACATGTACTCGTCGGCCGGAGCCG





CGCCGCCCGGCTCCTACGACTATTGCCCCAGA,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:94 under stringent hybridization conditions.


In some embodiments, T-box 2 (TBX2) comprises the amino acid sequence:









(SEQ ID NO: 95; NP_005985)


MREPALAASAMAYHPFHAPRPADFPMSAFLAAAQPSFFPALALPPGALAK





PLPDPGLAGAAAAAAAAAAAAEAGLHVSALGPHPPAAHLRSLKSLEPEDE





VEDDPKVTLEAKELWDQFHKLGTEMVITKSGRRMFPPFKVRVSGLDKKAK





YILLMDIVAADDCRYKFHNSRWMVAGKADPEMPKRMYIHPDSPATGEQWM





AKPVAFHKLKLTNNISDKHGFTILNSMHKYQPRFHIVRANDILKLPYSTF





RTYVFPETDFIAVTAYQNDKITQLKIDNNPFAKGFRDTGNGRREKRKQLT





LPSLRLYEEHCKPERDGAESDASSCDPPPAREPPTSPGAAPSPLRLHRAR





AEEKSCAADSDPEPERLSEERAGAPLGRSPAPDSASPTRLTEPERARERR





SPERGKEPAESGGDGPFGLRSLEKERAEARRKDEGRKEAAEGKEQGLAPL





VVQTDSASPLGAGHLPGLAFSSHLHGQQFFGPLGAGQPLFLHPGQFTMGP





GAFSAMGMGHLLASVAGGGNGGGGGPGTAAGLDAGGLGPAASAASTAAPF





PFHLSQHMLASQGIPMPTFGGLFPYPYTYMAAAAAAASALPATSAAAAAA





AAAGSLSRSPFLGSARPRLRFSPYQIPVTIPPSTSLLTTGLASEGSKAAG





GNSREPSPLPELALRKVGAPSRGALSPSGSAKEAANELQSIQRLVSGLES





QRALSPGRESPK,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:95.


In some embodiments, the nucleic acid sequence encoding TBX2 comprises the nucleic acid sequence:









(SEQ ID NO: 96; NM_005994)


ATGAGAGAGCCGGCGCTGGCGGCCAGCGCCATGGCTTACCACCCGTTCCA





CGCGCCACGGCCCGCCGACTTCCCCATGTCCGCCTTTCTGGCGGCGGCGC





AGCCCTCCTTCTTCCCGGCACTCGCGCTGCCGCCCGGCGCGCTGGCCAAG





CCGCTGCCCGACCCGGGCCTGGCGGGGGCGGCGGCCGCGGCGGCGGCGGC





GGCAGCAGCGGCCGAGGCGGGGCTGCACGTCTCGGCACTGGGCCCGCACC





CGCCCGCCGCGCATCTGCGCTCCCTCAAGAGCCTGGAGCCCGAGGACGAG





GTGGAGGACGACCCCAAGGTGACGCTGGAGGCCAAGGAGCTGTGGGACCA





GTTCCACAAGCTAGGCACGGAGATGGTCATCACCAAGTCCGGGAGGCGGA





TGTTCCCCCCCTTCAAGGTGCGAGTCAGCGGCCTGGACAAGAAGGCCAAG





TATATCCTGCTGATGGACATTGTAGCCGCTGACGATTGCCGCTATAAGTT





CCACAACTCGCGCTGGATGGTGGCGGGCAAGGCCGACCCTGAGATGCCCA





AACGCATGTACATCCACCCAGACAGCCCAGCCACGGGGGAGCAGTGGATG





GCTAAGCCTGTGGCCTTCCACAAGCTGAAGCTGACCAACAACATCTCTGA





CAAGCACGGCTTCACCATCCTAAACTCCATGCACAAGTACCAGCCGCGCT





TCCACATAGTGCGAGCCAACGACATCCTGAAGCTGCCTTACAGCACCTTC





CGCACCTACGTGTTCCCGGAGACCGACTTCATCGCCGTCACTGCCTACCA





GAATGACAAGATCACACAGCTGAAGATCGACAACAACCCGTTTGCCAAGG





GCTTCCGGGACACCGGGAACGGCCGGCGGGAGAAAAGGAAGCAGCTGACG





CTGCCGTCTCTACGCTTGTACGAGGAGCACTGCAAACCCGAGCGCGATGG





CGCGGAGTCAGACGCCTCGTCGTGCGACCCTCCCCCCGCGCGGGAACCAC





CCACCTCCCCGGGCGCAGCGCCCAGTCCGCTGCGCCTGCACCGGGCCCGA





GCTGAGGAGAAGTCGTGCGCCGCGGACAGCGACCCGGAGCCTGAGCGGTT





GAGCGAGGAGCGTGCGGGGGCGCCGCTAGGCCGCAGCCCGGCTCCAGACA





GCGCCAGCCCCACTCGCTTGACCGAACCCGAGCGCGCCCGGGAGCGGCGT





AGTCCCGAGAGGGGCAAGGAGCCGGCCGAGAGCGGCGGGGACGGCCCGTT





CGGCCTGAGGAGCCTGGAGAAGGAGCGCGCCGAAGCTCGGAGGAAGGACG





AGGGGCGCAAGGAGGCGGCCGAGGGCAAGGAGCAGGGCCTGGCGCCGCTG





GTGGTGCAGACAGACAGTGCGTCCCCCCTGGGCGCCGGACACCTGCCCGG





CCTGGCCTTTTCCAGCCACTTGCACGGGCAGCAGTTCTTTGGGCCGCTGG





GAGCCGGCCAGCCGCTCTTCCTGCACCCTGGACAGTTCACCATGGGCCCT





GGCGCCTTCTCCGCCATGGGCATGGGTCACCTACTGGCCTCGGTGGCAGG





CGGCGGCAACGGCGGAGGTGGCGGGCCTGGGACCGCCGCGGGGCTGGACG





CAGGCGGGCTGGGTCCCGCGGCCAGCGCAGCAAGCACCGCCGCGCCCTTC





CCGTTCCACCTCTCCCAGCACATGCTGGCATCTCAGGGAATTCCAATGCC





CACTTTCGGAGGCCTCTTCCCCTACCCCTACACCTACATGGCAGCAGCAG





CCGCAGCCGCCTCGGCTTTGCCCGCCACTAGTGCTGCAGCTGCCGCCGCC





GCAGCCGCCGGCTCCCTCTCCCGGAGCCCCTTCCTGGGCAGTGCCCGGCC





CCGACTGCGTTTCAGCCCCTATCAGATCCCGGTCACCATCCCGCCTAGCA





CTAGCCTCCTCACCACCGGGCTGGCCTCTGAGGGCTCCAAGGCCGCTGGT





GGAAACAGCCGGGAGCCTAGCCCCCTGCCCGAGCTGGCTCTCCGCAAAGT





AGGGGCCCCATCCCGCGGTGCCCTGTCGCCCAGTGGCTCGGCCAAGGAGG





CGGCCAATGAACTGCAGAGCATCCAGAGACTGGTGAGTGGGCTGGAGAGC





CAGCGAGCCCTCTCCCCAGGCCGGGAGTCGCCCAAG,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:96 under stringent hybridization conditions.


In some embodiments, T-box 3 (TBX3) comprises the amino acid sequence:









(SEQ ID NO: 97; NP_057653)


MSLSMRDPVIPGTSMAYHPFLPHRAPDFAMSAVLGHQPPFFPALTLPPNG





AAALSLPGALAKPIMDQLVGAAETGIPFSSLGPQAHLRPLKTMEPEEEVE





DDPKVHLEAKELWDQFHKRGTEMVITKSGRRMFPPFKVRCSGLDKKAKYI





LLMDIIAADDCRYKFHNSRWMVAGKADPEMPKRMYIHPDSPATGEQWMSK





VVTFHKLKLTNNISDKHGFTLAFPSDHATWQGNYSFGTQTILNSMHKYQP





RFHIVRANDILKLPYSTFRTYLFPETEFIAVTAYQNDKITQLKIDNNPFA





KGFRDTGNGRREKRKQLTLQSMRVFDERHKKENGTSDESSSEQAAFNCFA





QASSPAASTVGTSNLKDLCPSEGESDAEAESKEEHGPEACDAAKISTTTS





EEPCRDKGSPAVKAHLFAAERPRDSGRLDKASPDSRHSPATISSSTRGLG





AEERRSPVREGTAPAKVEEARALPGKEAFAPLTVQTDAAAAHLAQGPLPG





LGFAPGLAGQQFFNGHPLFLHPSQFAMGGAFSSMAAAGMGPLLATVSGAS





TGVSGLDSTAMASAAAAQGLSGASAATLPFHLQQHVLASQGLAMSPFGSL





FPYPYTYMAAAAAASSAAASSSVHRHPFLNLNTMRPRLRYSPYSIPVPVP





DGSSLLTTALPSMAAAAGPLDGKVAALAASPASVAVDSGSELNSRSSTLS





SSSMSLSPKLCAEKEAATSELQSIQRLVSGLEAKPDRSRSASP,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:97.


In some embodiments, the nucleic acid sequence encoding TBX3 comprises the nucleic acid sequence









(SEQ ID NO: 98; NM_016569)


ATGAGCCTCTCCATGAGAGATCCGGTCATTCCTGGGACAAGCATGGCCTA





CCATCCGTTCCTACCTCACCGGGCGCCGGACTTCGCCATGAGCGCGGTGC





TGGGTCACCAGCCGCCGTTCTTCCCCGCGCTGACGCTGCCTCCCAACGGC





GCGGCGGCGCTCTCGCTGCCGGGCGCCCTGGCCAAGCCGATCATGGATCA





ATTGGTGGGGGCGGCCGAGACCGGCATCCCGTTCTCCTCCCTGGGGCCCC





AGGCGCATCTGAGGCCTTTGAAGACCATGGAGCCCGAAGAAGAGGTGGAG





GACGACCCCAAGGTGCACCTGGAGGCTAAAGAACTTTGGGATCAGTTTCA





CAAGCGGGGCACCGAGATGGTCATTACCAAGTCGGGAAGGCGAATGTTTC





CTCCATTTAAAGTGAGATGTTCTGGGCTGGATAAAAAAGCCAAATACATT





TTATTGATGGACATTATAGCTGCTGATGACTGTCGTTATAAATTTCACAA





TTCTCGGTGGATGGTGGCTGGTAAGGCCGACCCCGAAATGCCAAAGAGGA





TGTACATTCACCCGGACAGCCCCGCTACTGGGGAACAGTGGATGTCCAAA





GTCGTCACTTTCCACAAACTGAAACTCACCAACAACATTTCAGACAAACA





TGGATTTACTTTGGCCTTCCCAAGTGATCACGCTACGTGGCAGGGGAATT





ATAGTTTTGGTACTCAGACTATATTGAACTCCATGCACAAATACCAGCCC





CGGTTCCACATTGTAAGAGCCAATGACATCTTGAAACTCCCTTATAGTAC





ATTTCGGACATACTTGTTCCCCGAAACTGAATTCATCGCTGTGACTGCAT





ACCAGAATGATAAGATAACCCAGTTAAAAATAGACAACAACCCTTTTGCA





AAAGGTTTCCGGGACACTGGAAATGGCCGAAGAGAAAAAAGAAAACAGCT





CACCCTGCAGTCCATGAGGGTGTTTGATGAAAGACACAAAAAGGAGAATG





GGACCTCTGATGAGTCCTCCAGTGAACAAGCAGCTTTCAACTGCTTCGCC





CAGGCTTCTTCTCCAGCCGCCTCCACTGTAGGGACATCGAACCTCAAAGA





TTTATGTCCCAGCGAGGGTGAGAGCGACGCCGAGGCCGAGAGCAAAGAGG





AGCATGGCCCCGAGGCCTGCGACGCGGCCAAGATCTCCACCACCACGTCG





GAGGAGCCCTGCCGTGACAAGGGCAGCCCCGCGGTCAAGGCTCACCTTTT





CGCTGCTGAGCGGCCCCGGGACAGCGGGCGGCTGGACAAAGCGTCGCCCG





ACTCACGCCATAGCCCCGCCACCATCTCGTCCAGCACTCGCGGCCTGGGC





GCGGAGGAGCGCAGGAGCCCGGTTCGCGAGGGCACAGCGCCGGCCAAGGT





GGAAGAGGCGCGCGCGCTCCCGGGCAAGGAGGCCTTCGCGCCGCTCACGG





TGCAGACGGACGCGGCCGCCGCGCACCTGGCCCAGGGCCCCCTGCCTGGC





CTCGGCTTCGCCCCGGGCCTGGCGGGCCAACAGTTCTTCAACGGGCACCC





GCTCTTCCTGCACCCCAGCCAGTTTGCCATGGGGGGCGCCTTCTCCAGCA





TGGCGGCCGCTGGCATGGGTCCCCTCCTGGCCACGGTTTCTGGGGCCTCC





ACCGGTGTCTCGGGCCTGGATTCCACGGCCATGGCCTCTGCCGCTGCGGC





GCAGGGACTGTCCGGGGCGTCCGCGGCCACCCTGCCCTTCCACCTCCAGC





AGCACGTCCTGGCCTCTCAGGGCCTGGCCATGTCCCCTTTCGGAAGCCTG





TTCCCTTACCCCTACACGTACATGGCCGCAGCGGCGGCCGCCTCCTCTGC





GGCAGCCTCCAGCTCGGTGCACCGCCACCCCTTCCTCAATCTGAACACCA





TGCGCCCGCGGCTGCGCTACAGCCCCTACTCCATCCCGGTGCCGGTCCCG





GACGGCAGCAGTCTGCTCACCACCGCCCTGCCCTCCATGGCGGCGGCCGC





GGGGCCCCTGGACGGCAAAGTCGCCGCCCTGGCCGCCAGCCCGGCCTCGG





TGGCAGTGGACTCGGGCTCTGAACTCAACAGCCGCTCCTCCACGCTCTCC





TCCAGCTCCATGTCCTTGTCGCCCAAACTCTGCGCGGAGAAAGAGGCGGC





CACCAGCGAACTGCAGAGCATCCAGCGGTTGGTTAGCGGCTTGGAAGCCA





AGCCGGACAGGTCCCGCAGCGCGTCCCCG,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:98 under stringent hybridization conditions.


In some embodiments, T-box 4 (TBX4) comprises the amino acid sequence:









(SEQ ID NO: 99; NP_060958)


MLQDKGLSESEEAFRAPGPALGEASAANAPEPALAAPGLSGAALGSPPGP





GADVVAAAAAEQTIENIKVGLHEKELWKKFHEAGTEMIITKAGRRMFPSY





KVKVTGMNPKTKYILLIDIVPADDHRYKFCDNKWMVAGKAEPAMPGRLYV





HPDSPATGAHWMRQLVSFQKLKLTNNHLDPFGHIILNSMHKYQPRLHIVK





ADENNAFGSKNTAFCTHVFPETSFISVTSYQNHKITQLKIENNPFAKGFR





GSDDSDLRVARLQSKEYPVISKSIMRQRLISPQLSATPDVGPLLGTHQAL





QHYQHENGAHSQLAEPQDLPLSTFPTQRDSSLFYHCLKRRDGTRHLDLPC





KRSYLEAPSSVGEDHYFRSPPPYDQQMLSPSYCSEVTPREACMYSGSGPE





IAGVSGVDDLPPPPLSCNMWTSVSPYTSYSVQTMETVPYQPFPTHFTATT





MMPRLPTLSAQSSQPPGNAHFSVYNQLSQSQVRERGPSASFPRERGLPQG





CERKPPSPHLNAANEFLYSQTFSLSRESSLQYHSGMGTVENWTDG,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:99.


In some embodiments, the nucleic acid sequence encoding TBX4 comprises the nucleic acid sequence:









(SEQ ID NO: 100; NM_018488)


ATGCTGCAGGATAAGGGCCTGTCCGAGAGCGAGGAGGCCTTCCGGGCCCC





GGGCCCAGCGCTCGGAGAGGCCAGCGCAGCCAACGCCCCCGAGCCCGCGC





TGGCAGCGCCGGGCCTCAGCGGAGCCGCGCTAGGCAGCCCCCCGGGACCC





GGGGCCGACGTCGTCGCCGCCGCCGCCGCGGAGCAGACCATCGAGAACAT





CAAGGTGGGGCTGCATGAGAAGGAGCTCTGGAAGAAGTTCCACGAGGCGG





GCACCGAGATGATCATCACTAAGGCTGGCAGGAGGATGTTCCCCAGCTAC





AAGGTAAAAGTCACAGGCATGAACCCCAAGACCAAGTATATCCTGCTGAT





TGACATTGTCCCTGCCGATGACCATCGCTACAAGTTCTGTGACAACAAAT





GGATGGTGGCAGGGAAGGCTGAGCCAGCCATGCCAGGAAGGCTGTATGTC





CACCCGGATTCTCCTGCCACAGGAGCCCACTGGATGCGGCAGCTGGTCTC





CTTCCAGAAGCTGAAGCTGACAAACAACCACCTGGACCCCTTTGGCCATA





TCATCCTCAACTCTATGCACAAGTACCAGCCGCGGCTCCACATCGTTAAG





GCTGATGAGAACAATGCTTTCGGCTCCAAAAACACTGCTTTCTGCACCCA





CGTGTTCCCAGAGACCTCCTTCATCTCTGTGACCTCCTACCAGAATCACA





AGATCACCCAGCTGAAAATTGAGAACAACCCTTTTGCCAAGGGATTCCGG





GGCAGTGATGACAGTGACCTGCGTGTGGCCCGACTGCAGAGCAAAGAATA





CCCCGTGATTTCCAAAAGCATCATGAGGCAGAGGCTCATCTCCCCCCAGC





TCTCAGCCACACCGGACGTGGGCCCCCTGCTCGGCACCCACCAGGCACTC





CAGCACTACCAGCACGAGAACGGGGCACACTCACAGCTCGCGGAGCCGCA





GGACCTGCCCCTCAGCACCTTTCCCACCCAGAGGGACTCAAGCCTCTTCT





ATCACTGCCTGAAAAGACGAGACGGTACCCGCCACCTGGACTTACCTTGC





AAGCGATCCTATCTGGAAGCCCCCTCTTCGGTGGGGGAGGATCACTATTT





CCGTTCCCCCCCTCCCTACGACCAGCAAATGCTGAGCCCCTCCTACTGCA





GTGAGGTGACCCCCAGAGAAGCATGTATGTACTCAGGTTCAGGGCCCGAG





ATTGCCGGGGTGTCTGGGGTGGACGACCTGCCCCCACCTCCGCTGAGCTG





TAACATGTGGACTTCAGTGTCGCCGTACACCAGCTATAGCGTGCAGACGA





TGGAGACTGTGCCGTACCAGCCCTTCCCCACGCACTTCACCGCCACCACC





ATGATGCCGCGGCTGCCCACCCTCTCCGCTCAGAGCTCCCAGCCACCAGG





AAATGCCCACTTTAGTGTCTACAATCAGCTCTCCCAGTCTCAGGTCCGAG





AGCGGGGGCCCAGCGCCTCATTCCCAAGAGAGCGCGGCCTCCCCCAAGGG





TGTGAGAGGAAGCCACCCTCGCCACATCTAAATGCTGCCAATGAGTTTCT





CTACTCTCAAACCTTCTCCTTGTCCCGAGAATCTTCCTTACAGTACCATT





CAGGAATGGGGACTGTGGAGAACTGGACTGACGGA,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:100 under stringent hybridization conditions.


In some embodiments, T-box 5 (TBX5) comprises the amino acid sequence:









(SEQ ID NO: 101; NP_000183)


MADADEGFGLAHTPLEPDAKDLPCDSKPESALGAPSKSPSSPQAAFTQQ





GMEGIKVFLHERELWLKFHEVGTEMIITKAGRRMFPSYKVKVTGLNPKT





KYILLMDIVPADDHRYKFADNKWSVTGKAEPAMPGRLYVHPDSPATGAH





WMRQLVSFQKLKLTNNHLDPFGHIILNSMHKYQPRLHIVKADENNGFGS





KNTAFCTHVFPETAFIAVTSYQNHKITQLKIENNPFAKGFRGSDDMELH





RMSRMQSKEYPVVPRSTVRQKVASNHSPFSSESRALSTSSNLGSQYQCE





NGVSGPSQDLLPPPNPYPLPQEHSQIYHCTKRKEEECSTTDHPYKKPYM





ETSPSEEDSFYRSSYPQQQGLGASYRTESAQRQACMYASSAPPSEPVPS





LEDISCNTWPSMPSYSSCTVTTVQPMDRLPYQHFSAHFTSGPLVPRLAG





MANHGSPQLGEGMFQHQTSVAHQPVVRQCGPQTGLQSPGTLQPPEFLYS





HGVPRTLSPHQYHSVHGVGMVPEWSDNS,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:101.


In some embodiments, the nucleic acid sequence encoding TBX5 comprises the nucleic acid sequence:









(SEQ ID NO: 102; NM_000192)


ATGGCCGACGCAGACGAGGGCTTTGGCCTGGCGCACACGCCTCTGGAGC





CTGACGCAAAAGACCTGCCCTGCGATTCGAAACCCGAGAGCGCGCTCGG





GGCCCCCAGCAAGTCCCCGTCGTCCCCGCAGGCCGCCTTCACCCAGCAG





GGCATGGAGGGAATCAAAGTGTTTCTCCATGAAAGAGAACTGTGGCTAA





AATTCCACGAAGTGGGCACGGAAATGATCATAACCAAGGCTGGAAGGCG





GATGTTTCCCAGTTACAAAGTGAAGGTGACGGGCCTTAATCCCAAAACG





AAGTACATTCTTCTCATGGACATTGTACCTGCCGACGATCACAGATACA





AATTCGCAGATAATAAATGGTCTGTGACGGGCAAAGCTGAGCCCGCCAT





GCCTGGCCGCCTGTACGTGCACCCAGACTCCCCCGCCACCGGGGCGCAT





TGGATGAGGCAGCTCGTCTCCTTCCAGAAACTCAAGCTCACCAACAACC





ACCTGGACCCATTTGGGCATATTATTCTAAATTCCATGCACAAATACCA





GCCTAGATTACACATCGTGAAAGCGGATGAAAATAATGGATTTGGCTCA





AAAAATACAGCGTTCTGCACTCACGTCTTTCCTGAGACTGCGTTTATAG





CAGTGACTTCTTACCAGAACCACAAGATCACGCAATTAAAGATTGAGAA





TAATCCCTTTGCCAAAGGATTTCGGGGCAGTGATGACATGGAGCTGCAC





AGAATGTCAAGAATGCAAAGTAAAGAATATCCCGTGGTCCCCAGGAGCA





CCGTGAGGCAAAAAGTGGCCTCCAACCACAGTCCTTTCAGCAGCGAGTC





TCGAGCTCTCTCCACCTCATCCAATTTGGGGTCCCAATACCAGTGTGAG





AATGGTGTTTCCGGCCCCTCCCAGGACCTCCTGCCTCCACCCAACCCAT





ACCCACTGCCCCAGGAGCATAGCCAAATTTACCATTGTACCAAGAGGAA





AGAGGAAGAATGTTCCACCACAGACCATCCCTATAAGAAGCCCTACATG





GAGACATCACCCAGTGAAGAAGATTCCTTCTACCGCTCTAGCTATCCAC





AGCAGCAGGGCCTGGGTGCCTCCTACAGGACAGAGTCGGCACAGCGGCA





AGCTTGCATGTATGCCAGCTCTGCGCCCCCCAGCGAGCCTGTGCCCAGC





CTAGAGGACATCAGCTGCAACACGTGGCCAAGCATGCCTTCCTACAGCA





GCTGCACCGTCACCACCGTGCAGCCCATGGACAGGCTACCCTACCAGCA





CTTCTCCGCTCACTTCACCTCGGGGCCCCTGGTCCCTCGGCTGGCTGGC





ATGGCCAACCATGGCTCCCCACAGCTGGGAGAGGGAATGTTCCAGCACC





AGACCTCCGTGGCCCACCAGCCTGTGGTCAGGCAGTGTGGGCCTCAGAC





TGGCCTGCAGTCCCCTGGCACCCTTCAGCCCCCTGAGTTCCTCTACTCT





CATGGCGTGCCAAGGACTCTATCCCCTCATCAGTACCACTCTGTGCACG





GAGTTGGCATGGTGCCAGAGTGGAGCGACAATAGC,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:102 under stringent hybridization conditions.


In some embodiments, T-box 6 (TBX6) comprises the amino acid sequence:









(SEQ ID NO: 103; NP_542936)


MYHPRELYPSLGAGYRLGPAQPGADSSFPPALAEGYRYPELDTPKLDCF





LSGMEAAPRTLAAHPPLPLLPPAMGTEPAPSAPEALHSLPGVSLSLENR





ELWKEFSSVGTEMIITKAGRRMFPACRVSVTGLDPEARYLFLLDVIPVD





GARYRWQGRRWEPSGKAEPRLPDRVYIHPDSPATGAHWMRQPVSFHRVK





LTNSTLDPHGHLILHSMHKYQPRIHLVRAAQLCSQHWGGMASFRFPETT





FISVTAYQNPQITQLKIAANPFAKGFRENGRNCKRWELFIHLFMHSTNV





Y,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:103.


In some embodiments, the nucleic acid sequence encoding TBX6 comprises the nucleic acid sequence:









(SEQ ID NO: 104; NM_080758)


ATGTACCATCCACGAGAATTGTACCCGTCCCTGGGGGCCGGCTACCGCC





TGGGGCCCGCCCAACCTGGGGCCGACTCCAGCTTCCCACCCGCCCTAGC





GGAGGGCTACCGCTACCCCGAACTGGACACCCCTAAACTGGATTGCTTC





CTCTCCGGGATGGAGGCTGCTCCCCGCACCCTGGCCGCGCACCCACCTC





TGCCCCTTCTGCCCCCTGCCATGGGCACTGAGCCGGCCCCATCAGCTCC





AGAGGCCCTCCATTCCCTCCCGGGGGTCAGCCTGAGCCTGGAGAACCGG





GAGCTATGGAAGGAGTTCAGCTCTGTGGGAACAGAAATGATCATCACCA





AAGCTGGGAGGCGCATGTTCCCTGCCTGCCGAGTGTCAGTCACTGGCCT





GGACCCCGAGGCCCGCTACTTGTTTCTTCTGGATGTGATTCCGGTGGAT





GGGGCTCGCTACCGCTGGCAGGGCCGGCGCTGGGAGCCCAGCGGCAAGG





CAGAGCCCCGCCTGCCTGACCGTGTCTACATTCACCCCGACTCTCCTGC





CACTGGTGCACATTGGATGCGGCAGCCTGTGTCTTTCCATCGTGTCAAG





CTCACCAACAGCACGCTGGACCCCCACGGCCACCTGATCCTGCACTCCA





TGCACAAGTACCAACCCCGCATACACCTAGTTCGGGCAGCCCAGCTCTG





CAGCCAGCACTGGGGGGGCATGGCCTCCTTCCGCTTCCCCGAGACCACA





TTCATCTCCGTGACAGCCTACCAGAACCCACAGATCACACAACTGAAGA





TTGCAGCCAATCCCTTTGCCAAAGGCTTCCGGGAGAACGGCAGAAACTG





TAAGAGGTGGGAGTTGTTCATTCATTTGTTCATGCATTCAACAAATGTT





TAT,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:104 under stringent hybridization conditions.


In some embodiments, T-box 10 (TBX10) comprises the amino acid sequence:









(SEQ ID NO: 105; NP_005986)


MAAFLSAGLGILAPSETYPLPTTSSGWEPRLGSPFPSGPCTSSTGAQAV





AEPTGQGPKNPRVSRVTVQLEMKPLWEEFNQLGTEMIVTKAGRRMFPPF





QVKILGMDSLADYALLMDFIPLDDKRYRYAFHSSAWLVAGKADPATPGR





VHFHPDSPAKGAQWMRQIVSFDKLKLTNNLLDDNGHIILNSMHRYQPRF





HVVFVDPRKDSERYAQENFKSFIFTETQFTAVTAYQNHRITQLKIASNP





FAKGFRESDLDSWPVAPRPLLSVPARSHSSLSPCVLKGATDREKDPNKA





SASTSKTPAWLHHQLLPPPEVLLAPATYRPVTYQSLYSGAPSHLGIPRT





RPAPYPLPNIRADRDQGGLPLPAGLGLLSPTVVCLGPGQDSQ,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:105.


In some embodiments, the nucleic acid sequence encoding TBX10 comprises the nucleic acid sequence:









(SEQ ID NO: 106; NM_005995)


ATGGCAGCCTTCCTATCTGCTGGCCTCGGCATACTTGCACCCTCAGAGA





CCTACCCCCTACCTACAACCAGCTCTGGCTGGGAGCCCCGGCTGGGGTC





ACCATTCCCATCAGGCCCTTGCACCAGCTCTACTGGGGCCCAAGCTGTG





GCCGAGCCCACTGGGCAGGGCCCCAAGAACCCACGTGTGTCCAGAGTGA





CAGTTCAGCTGGAGATGAAGCCTCTGTGGGAGGAATTCAACCAGCTGGG





CACTGAGATGATCGTCACCAAGGCAGGCAGGAGGATGTTCCCCCCCTTC





CAGGTGAAGATCCTGGGCATGGACTCCCTGGCCGACTACGCCCTGCTCA





TGGACTTCATCCCCCTGGACGACAAGAGATACAGGTATGCCTTCCACAG





CTCGGCCTGGCTGGTGGCGGGCAAGGCAGACCCAGCCACACCTGGCCGC





GTGCACTTCCACCCCGACTCGCCAGCCAAGGGTGCCCAGTGGATGCGCC





AGATTGTGTCCTTTGACAAGCTCAAGCTGACCAACAACCTGCTGGATGA





CAATGGCCACATCATTCTCAACTCTATGCACCGCTACCAGCCCCGTTTC





CACGTGGTCTTCGTGGACCCACGCAAGGACAGTGAGCGCTATGCCCAGG





AGAACTTCAAGTCCTTCATCTTCACAGAGACCCAGTTCACAGCAGTGAC





AGCCTATCAGAACCACAGGATCACCCAGCTGAAAATCGCCAGCAACCCT





TTTGCCAAAGGCTTTAGAGAGAGTGACCTGGACTCCTGGCCTGTGGCCC





CACGGCCCCTGCTCAGTGTCCCAGCCCGGAGTCACAGCAGCCTCAGTCC





CTGTGTGCTGAAGGGTGCCACAGACAGGGAGAAAGACCCCAACAAAGCT





TCAGCTTCCACCTCCAAGACCCCTGCTTGGCTCCATCATCAGCTGCTGC





CCCCACCTGAGGTCCTGCTGGCCCCGGCCACCTACAGGCCTGTCACGTA





TCAGAGCCTGTACTCTGGAGCCCCGAGCCACCTAGGGATCCCAAGGACC





CGACCAGCACCATACCCCCTCCCCAACATCCGGGCTGATAGGGATCAAG





GAGGCCTGCCTCTCCCAGCTGGGCTGGGGCTCCTGTCCCCCACTGTGGT





GTGCCTGGGGCCTGGCCAGGACTCCCAG,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:106 under stringent hybridization conditions.


In some embodiments, T-box 15 (TBX15) comprises the amino acid sequence:









(SEQ ID NO: 107; NP_689593)


MSSMEEIQVELQCADLWKRFHDIGTEMIITKAGRRMFPAMRVKITGLDP





HQQYYIAMDIVPVDNKRYRYVYHSSKWMVAGNADSPVPPRVYIHPDSLA





SGDTWMRQVVSFDKLKLTNNELDDQGHIILHSMHKYQPRVHVIRKDFSS





DLSPTKPVPVGDGVKTFNFPETVFTTVTAYQNQQITRLKIDRNPFAKGF





RDSGRNRTGLEAIMETYAFWRPPVRTLTFEDFTTMQKQQGGSTGTSPTT





SSTGTPSPSASSHLLSPSCSPPTFHLAPNTFNVGCRESQLCNLNLSDYP





PCARSNMAALQSYPGLSDSGYNRLQSGTTSATQPSETFMPQRTPSLISG





IPTPPSLPGNSKMEAYGGQLGSFPTSQFQYVMQAGNAASSSSSPHMFGG





SHMQQSSYNAFSLHNPYNLYGYNFPTSPRLAASPEKLSASQSTLLCSSP





SNGAFGERQYLPSGMEHSMHMISPSPNNQQATNTCDGRQYGAVPGSSSQ





MSVHMV,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:107.


In some embodiments, the nucleic acid sequence encoding TBX15 comprises the nucleic acid sequence:









(SEQ ID NO: 108; NM_152380)


ATGTCTTCCATGGAGGAGATTCAGGTGGAGCTGCAATGTGCTGACCTCT





GGAAGCGGTTCCATGATATTGGAACTGAAATGATCATCACCAAAGCAGG





CAGGAGGATGTTTCCTGCCATGAGAGTGAAAATCACTGGCCTAGATCCA





CATCAGCAGTACTACATAGCAATGGACATTGTGCCTGTGGACAATAAAA





GATACAGATATGTGTATCATAGCTCCAAGTGGATGGTGGCTGGCAATGC





TGATTCCCCTGTGCCCCCAAGAGTTTATATACACCCTGATTCTCTAGCT





TCTGGAGACACCTGGATGAGACAGGTGGTCAGTTTTGACAAACTCAAGC





TTACCAACAATGAGTTGGATGATCAAGGACATATCATTCTGCACTCTAT





GCACAAATACCAGCCTCGAGTTCATGTGATTCGCAAAGACTTCAGCAGT





GACCTTTCACCCACTAAGCCTGTTCCTGTTGGGGATGGGGTGAAAACGT





TCAACTTTCCTGAGACTGTGTTCACCACAGTTACGGCCTATCAGAATCA





GCAGATTACCAGATTAAAAATTGACCGAAACCCTTTTGCTAAAGGATTC





AGAGATTCTGGGAGAAACAGAACTGGACTTGAAGCCATCATGGAGACAT





ATGCATTCTGGAGACCTCCTGTGCGCACACTCACCTTCGAAGACTTCAC





CACCATGCAGAAGCAGCAAGGAGGCAGCACAGGCACTTCCCCAACCACC





TCCAGCACTGGGACACCATCCCCTTCGGCTTCTTCTCATCTTTTATCTC





CATCCTGTTCTCCTCCAACTTTTCATCTGGCCCCCAACACTTTCAATGT





GGGCTGCCGAGAAAGCCAGCTGTGTAATCTAAACCTCTCTGATTATCCA





CCATGTGCCCGAAGCAACATGGCTGCCTTGCAGAGCTACCCAGGGCTGA





GTGACAGTGGCTACAACAGGCTTCAGAGTGGCACCACTTCAGCCACTCA





GCCCTCTGAAACCTTCATGCCTCAGAGGACTCCATCCCTGATCTCAGGA





ATACCAACTCCTCCCTCGTTGCCTGGCAACAGCAAGATGGAAGCCTACG





GTGGCCAGCTGGGGTCCTTTCCCACTTCCCAGTTTCAGTATGTCATGCA





GGCAGGCAATGCTGCCTCCAGCTCCTCATCACCACACATGTTCGGGGGC





AGCCACATGCAGCAGAGCTCCTACAATGCCTTCTCCCTTCACAACCCTT





ACAACCTGTATGGATACAATTTCCCCACTTCCCCTAGGCTAGCTGCAAG





CCCGGAAAAACTGAGCGCCTCTCAAAGCACTTTACTCTGTTCTTCTCCT





TCCAACGGGGCCTTTGGAGAGAGGCAGTACCTGCCGTCAGGGATGGAGC





ACAGCATGCACATGATTAGTCCTTCACCCAATAACCAACAGGCAACCAA





CACTTGTGATGGCCGGCAGTATGGGGCAGTTCCAGGCTCCTCCTCCCAG





ATGTCCGTGCACATGGTT,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:108 under stringent hybridization conditions.


In some embodiments, T-box 18 (TBX18) comprises the amino acid sequence:









(SEQ ID NO: 109; NP_001073977)


MAEKRRGSPCSMLSLKAHAFSVEALIGAEKQQQLQKKRRKLGAEEAARA





VDDGGCSRGGGAGEKGSSEGDEGAALPPPAGATSGPARSGADLERGAAG





GCEDGFQQGASPLASPGGSPKGSPARSLARPGTPLPSPQAPRVDLQGAE





LWKRFHEIGTEMIITKAGRRMFPAMRVKISGLDPHQQYYIAMDIVPVDN





KRYRYVYHSSKWMVAGNADSPVPPRVYIHPDSPASGETWMRQVISFDKL





KLTNNELDDQGHIILHSMHKYQPRVHVIRKDCGDDLSPIKPVPSGEGVK





AFSFPETVFTTVTAYQNQQITRLKIDRNPFAKGFRDSGRNRMGLEALVE





SYAFWRPSLRTLTFEDIPGIPKQGNASSSTLLQGTGNGVPATHPHLLSG





SSCSSPAFHLGPNTSQLCSLAPADYSACARSGLTLNRYSTSLAETYNRL





TNQAGETFAPPRTPSYVGVSSSTSVNMSMGGTDGDTFSCPQTSLSMQIS





GMSPQLQYIMPSPSSNAFATNQTHQGSYNTFRLHSPCALYGYNFSTSPK





LAASPEKIVSSQGSFLGSSPSGTMTDRQMLPPVEGVHLLSSGGQQSFFD





SRTLGSLTLSSSQVSAHMV,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:109.


In some embodiments, the nucleic acid sequence encoding TBX18 comprises the nucleic acid sequence









(SEQ ID NO: 110; NM_001080508)


ATGGCCGAGAAGCGAAGGGGCTCGCCGTGCAGCATGCTAAGCCTCAAGG





CGCACGCTTTCTCGGTGGAGGCGCTGATCGGCGCCGAGAAGCAGCAACA





GCTTCAGAAGAAGCGGCGAAAACTGGGCGCCGAAGAGGCGGCGAGGGCC





GTGGACGACGGAGGCTGCAGCCGCGGCGGCGGCGCGGGCGAAAAGGGTT





CTTCTGAGGGAGACGAAGGCGCTGCGCTCCCGCCGCCGGCTGGGGCGAC





GTCTGGGCCGGCTCGGAGTGGCGCAGACCTGGAGCGCGGAGCCGCGGGC





GGCTGTGAGGACGGCTTCCAGCAGGGAGCTTCCCCTCTGGCGTCACCGG





GAGGCTCCCCCAAGGGGTCTCCGGCGCGCTCCCTGGCCCGGCCCGGGAC





CCCTCTGCCCTCGCCGCAGGCCCCGCGGGTGGATCTGCAGGGAGCCGAG





CTCTGGAAGCGCTTTCATGAGATAGGCACTGAGATGATCATCACCAAGG





CCGGCAGGCGCATGTTTCCAGCAATGAGAGTGAAGATCTCTGGATTAGA





TCCTCACCAGCAATATTACATTGCCATGGATATTGTACCAGTGGACAAC





AAAAGATACAGGTATGTTTACCACAGTTCGAAATGGATGGTGGCAGGTA





ATGCTGACTCGCCTGTGCCACCCCGTGTGTACATTCATCCAGACTCGCC





TGCCTCGGGGGAGACTTGGATGAGACAAGTTATCAGCTTCGACAAGCTG





AAGCTCACCAACAATGAACTGGATGACCAAGGCCATATTATTCTTCATT





CTATGCACAAATACCAACCGCGAGTGCACGTCATCCGTAAAGACTGTGG





AGACGATCTTTCTCCCATCAAGCCTGTTCCATCCGGGGAGGGAGTAAAG





GCATTCTCCTTTCCAGAAACTGTCTTCACAACCGTCACTGCCTATCAGA





ATCAGCAGATTACTCGCCTGAAGATAGATAGGAATCCATTTGCTAAAGG





CTTCCGAGACTCCGGGCGCAACAGAATGGGTTTGGAAGCCTTGGTGGAA





TCATATGCATTCTGGCGACCATCACTACGGACTCTGACCTTTGAAGATA





TCCCTGGAATTCCCAAGCAAGGCAATGCAAGTTCCTCCACCTTGCTCCA





AGGTACTGGGAATGGCGTTCCTGCCACTCACCCTCACCTTTTGTCTGGC





TCCTCTTGCTCCTCTCCTGCCTTCCATCTGGGGCCCAACACCAGCCAGC





TGTGTAGTCTGGCCCCTGCTGACTATTCTGCCTGTGCCCGCTCAGGCCT





CACCCTCAACCGATACAGCACATCTTTGGCAGAGACCTACAACAGGCTC





ACCAACCAGGCTGGTGAGACCTTTGCCCCGCCCAGGACTCCCTCCTATG





TGGGCGTGAGCAGCAGCACCTCCGTGAACATGTCCATGGGTGGCACTGA





TGGGGACACCTTCAGCTGCCCACAGACCAGCTTATCCATGCAGATTTCG





GGAATGTCCCCCCAGCTCCAGTATATCATGCCATCACCCTCCAGCAATG





CCTTCGCCACTAACCAGACCCATCAGGGTTCCTATAATACTTTTAGATT





ACACAGCCCCTGTGCACTATATGGATATAACTTCTCCACATCCCCCAAA





CTGGCTGCCAGTCCTGAGAAAATTGTTTCTTCCCAAGGAAGTTTCTTGG





GGTCCTCACCGAGTGGGACCATGACGGATCGGCAGATGTTGCCCCCTGT





GGAAGGAGTGCACCTGCTTAGCAGTGGGGGTCAGCAGAGTTTCTTTGAC





TCTAGGACCCTAGGAAGCTTAACTCTGTCATCATCTCAAGTATCTGCAC





ATATGGTC,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:110 under stringent hybridization conditions.


In some embodiments, T-box 10 (TBX19) comprises the amino acid sequence:









(SEQ ID NO: 111; NP_005140)


MAMSELGTRKPSDGTVSHLLNVVESELQAGREKGDPTEKQLQIILEDAP





LWQRFKEVTNEMIVTKNGRRMFPVLKISVTGLDPNAMYSLLLDFVPTDS





HRWKYVNGEWVPAGKPEVSSHSCVYIHPDSPNFGAHWMKAPISFSKVKL





TNKLNGGGQIMLNSLHKYEPQVHIVRVGSAHRMVTNCSFPETQFIAVTA





YQNEEITALKIKYNPFAKAFLDAKERNHLRDVPEAISESQHVTYSHLGG





WIFSNPDGVCTAGNSNYQYAAPLPLPAPHTHHGCEHYSGLRGHRQAPYP





SAYMHRNHSPSVNLIESSSNNLQVFSGPDSVVTSLSSTPHASILSVPHT





NGPINPGPSPYPCLWTISNGAGGPSGPGPEVHASTPGAFLLGNPAVTSP





PSVLSTQAPTSAGVEVLGEPSLTSIAVSTVVTAVASHPFAGWGGPGAGG





HHSPSSLDG,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:111.


In some embodiments, the nucleic acid sequence encoding TBX19 comprises the nucleic acid sequence:









(SEQ ID NO: 112; NM_005149)


ATGGCCATGAGTGAGCTGGGCACTCGGAAGCCCAGCGATGGCACTGTTT





CTCATCTGCTCAATGTGGTGGAGAGTGAGCTTCAGGCAGGGAGGGAAAA





AGGCGACCCTACGGAGAAGCAACTTCAGATCATCCTGGAGGATGCACCT





CTCTGGCAGAGATTCAAGGAAGTCACTAATGAGATGATTGTGACCAAGA





ATGGCAGACGGATGTTTCCAGTCCTAAAGATTAGTGTCACAGGGTTGGA





CCCCAATGCCATGTACTCCCTCCTGCTGGACTTTGTCCCTACGGACAGT





CACCGCTGGAAGTACGTCAACGGGGAATGGGTGCCCGCTGGCAAGCCAG





AGGTCTCCAGCCACAGCTGCGTCTACATTCACCCGGACTCCCCCAACTT





TGGGGCCCACTGGATGAAAGCTCCCATCTCCTTCAGCAAAGTGAAGCTG





ACCAACAAGCTCAATGGAGGCGGGCAGATAATGTTGAATTCTCTGCATA





AATATGAACCCCAGGTTCACATAGTGCGTGTTGGAAGTGCCCATCGAAT





GGTAACAAACTGCTCCTTCCCTGAAACCCAGTTCATAGCCGTGACTGCC





TATCAGAATGAGGAGATAACGGCTCTCAAAATCAAGTACAATCCTTTTG





CCAAAGCCTTCTTGGATGCCAAGGAAAGAAATCACCTAAGAGACGTACC





GGAGGCTATCTCTGAGAGCCAGCATGTGACCTATTCTCACTTGGGAGGC





TGGATCTTTTCCAATCCAGATGGAGTGTGCACAGCAGGAAACTCCAATT





ACCAGTATGCCGCTCCTCTGCCTCTGCCTGCTCCCCACACCCACCATGG





CTGTGAGCACTATTCGGGTCTCCGAGGACACCGGCAGGCTCCCTACCCT





TCTGCGTACATGCACAGAAACCATTCTCCCTCAGTGAATTTGATAGAAA





GCTCAAGCAATAATCTGCAAGTTTTCTCGGGACCTGACAGCTGGACTTC





CTTATCCTCCACACCCCATGCCAGCATCCTGTCTGTACCCCACACCAAC





GGACCAATCAATCCAGGGCCCAGCCCCTACCCGTGCCTGTGGACCATCA





GCAATGGTGCCGGAGGCCCCAGTGGGCCAGGCCCGGAGGTGCACGCCAG





CACCCCAGGAGCATTTCTCCTCGGAAACCCAGCTGTGACTTCACCCCCT





TCTGTGCTCTCCACCCAAGCACCCACTTCGGCTGGTGTGGAGGTTCTGG





GGGAGCCCTCGCTAACCAGCATTGCTGTGTCCACCTGGACAGCAGTGGC





CTCGCATCCCTTCGCGGGCTGGGGTGGCCCAGGAGCGGGTGGGCACCAT





TCTCCTTCCTCACTGGATGGT,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:112 under stringent hybridization conditions.


In some embodiments, T-box 20 (TBX20) comprises the amino acid sequence:









(SEQ ID NO: 113; NP_001159692),


MEFTASPKPQLSSRANAFSIAALMSSGGSKEKEATENTIKPLEQFVEKS





SCAQPLGELTSLDAHGEFGGGSGSSPSSSSLCTEPLIPTTPIIPSEEMA





KIACSLETKELWDKFHELGTEMIITKSGRRMFPTIRVSFSGVDPEAKYI





VLMDIVPVDNKRYRYAYHRSSWLVAGKADPPLPARLYVHPDSPFTGEQL





LKQMVSFEKVKLTNNELDQHGHIILNSMHKYQPRVHIIKKKDHTASLLN





LKSEEFRTFIFPETVFTAVTAYQNQLITKLKIDSNPFAKGFRDSSRLTD





IER







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:113.


In some embodiments, the nucleic acid sequence encoding TBX20 comprises the nucleic acid sequence:









(SEQ ID NO: 114; NM_001166220)


ATGGAGTTCACGGCGTCCCCCAAGCCCCAACTCTCCTCCCGGGCCAACG





CCTTCTCCATTGCCGCGCTCATGTCGAGCGGCGGCTCTAAGGAGAAGGA





GGCGACGGAGAACACAATCAAACCCCTGGAGCAATTTGTGGAGAAGTCG





TCCTGTGCCCAGCCCCTGGGTGAGCTGACCAGCCTGGATGCTCATGGGG





AGTTTGGTGGAGGCAGTGGCAGCAGCCCGTCCTCCTCCTCTCTGTGCAC





TGAGCCACTGATCCCCACCACCCCCATCATCCCCAGTGAGGAAATGGCC





AAAATTGCCTGCAGCCTGGAGACCAAGGAGCTTTGGGACAAATTCCATG





AGCTGGGCACCGAGATGATCATCACCAAGTCGGGCAGGAGGATGTTTCC





AACCATCCGGGTGTCCTTTTCGGGGGTGGATCCTGAGGCCAAGTACATA





GTCCTGATGGACATCGTCCCTGTGGACAACAAGAGGTACCGCTACGCCT





ACCACCGGTCCTCCTGGCTGGTGGCTGGCAAGGCCGACCCGCCGTTGCC





AGCCAGGCTCTATGTGCATCCAGATTCTCCTTTTACCGGTGAGCAACTA





CTCAAACAGATGGTGTCTTTTGAAAAGGTGAAACTCACCAACAATGAAC





TGGATCAACATGGCCATATAATTTTGAACTCAATGCATAAGTACCAGCC





AAGGGTGCACATCATTAAGAAGAAAGACCACACAGCCTCATTGCTCAAC





CTGAAGTCTGAAGAATTTAGAACTTTCATCTTTCCAGAAACAGTTTTTA





CGGCAGTCACTGCCTACCAGAATCAACTGATAACGAAGCTGAAAATAGA





TAGCAATCCTTTTGCCAAAGGATTCCGGGATTCCTCCAGGCTCACTGAC





ATTGAGAGGT,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:114 under stringent hybridization conditions.


In some embodiments, T-box 21 (TBX21) comprises the amino acid sequence:









(SEQ ID NO: 115; NP_037483)


MGIVEPGCGDMLTGTEPMPGSDEGRAPGADPQHRYFYPEPGAQDADERR





GGGSLGSPYPGGALVPAPPSRFLGAYAYPPRPQAAGFPGAGESFPPPAD





AEGYQPGEGYAAPDPRAGLYPGPREDYALPAGLEVSGKLRVALNNHLLW





SKFNQHQTEMIITKQGRRMFPFLSFTVAGLEPTSHYRMFVDVVLVDQHH





WRYQSGKWVQCGKAEGSMPGNRLYVHPDSPNTGAHWMRQEVSFGKLKLT





NNKGASNNVTQMIVLQSLHKYQPRLHIVEVNDGEPEAACNASNTHIFTF





QETQFIAVTAYQNAEITQLKIDNNPFAKGFRENFESMYTSVDTSIPSPP





GPNCQFLGGDHYSPLLPNQYPVPSRFYPDLPGQAKDVVPQAYWLGAPRD





HSYEAEFRAVSMKPAFLPSAPGPTMSYYRGQEVLAPGAGWPVAPQYPPK





MGPASWFRPMRTLPMEPGPGGSEGRGPEDQGPPLVWTEIAPIRPESSDS





GLGEGDSKRRRVSPYPSSGDSSSPAGAPSPFDKEAEGQFYNYFPN,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:115.


In some embodiments, the nucleic acid sequence encoding TBX21 comprises the nucleic acid sequence:









(SEQ ID NO: 116; NM_013351)


ATGGGCATCGTGGAGCCGGGTTGCGGAGACATGCTGACGGGCACCGAGCC





GATGCCGGGGAGCGACGAGGGCCGGGCGCCTGGCGCCGACCCGCAGCACC





GCTACTTCTACCCGGAGCCGGGCGCGCAGGACGCGGACGAGCGTCGCGGG





GGCGGCAGCCTGGGGTCTCCCTACCCGGGGGGCGCCTTGGTGCCCGCCCC





GCCGAGCCGCTTCCTTGGAGCCTACGCCTACCCGCCGCGACCCCAGGCGG





CCGGCTTCCCCGGCGCGGGCGAGTCCTTCCCGCCGCCCGCGGACGCCGAG





GGCTACCAGCCGGGCGAGGGCTACGCCGCCCCGGACCCGCGCGCCGGGCT





CTACCCGGGGCCGCGTGAGGACTACGCGCTACCCGCGGGACTGGAGGTGT





CGGGGAAACTGAGGGTCGCGCTCAACAACCACCTGTTGTGGTCCAAGTTT





AATCAGCACCAGACAGAGATGATCATCACCAAGCAGGGACGGCGGATGTT





CCCATTCCTGTCATTTACTGTGGCCGGGCTGGAGCCCACCAGCCACTACA





GGATGTTTGTGGACGTGGTCTTGGTGGACCAGCACCACTGGCGGTACCAG





AGCGGCAAGTGGGTGCAGTGTGGAAAGGCCGAGGGCAGCATGCCAGGAAA





CCGCCTGTACGTCCACCCGGACTCCCCCAACACAGGAGCGCACTGGATGC





GCCAGGAAGTTTCATTTGGGAAACTAAAGCTCACAAACAACAAGGGGGCG





TCCAACAATGTGACCCAGATGATTGTGCTCCAGTCCCTCCATAAGTACCA





GCCCCGGCTGCATATCGTTGAGGTGAACGACGGAGAGCCAGAGGCAGCCT





GCAACGCTTCCAACACGCATATCTTTACTTTCCAAGAAACCCAGTTCATT





GCCGTGACTGCCTACCAGAATGCCGAGATTACTCAGCTGAAAATTGATAA





TAACCCCTTTGCCAAAGGATTCCGGGAGAACTTTGAGTCCATGTACACAT





CTGTTGACACCAGCATCCCCTCCCCGCCTGGACCCAACTGTCAATTCCTT





GGGGGAGATCACTACTCTCCTCTCCTACCCAACCAGTATCCTGTTCCCAG





CCGCTTCTACCCCGACCTTCCTGGCCAGGCGAAGGATGTGGTTCCCCAGG





CTTACTGGCTGGGGGCCCCCCGGGACCACAGCTATGAGGCTGAGTTTCGA





GCAGTCAGCATGAAGCCTGCATTCTTGCCCTCTGCCCCTGGGCCCACCAT





GTCCTACTACCGAGGCCAGGAGGTCCTGGCACCTGGAGCTGGCTGGCCTG





TGGCACCCCAGTACCCTCCCAAGATGGGCCCGGCCAGCTGGTTCCGCCCT





ATGCGGACTCTGCCCATGGAACCCGGCCCTGGAGGCTCAGAGGGACGGGG





ACCAGAGGACCAGGGTCCCCCCTTGGTGTGGACTGAGATTGCCCCCATCC





GGCCGGAATCCAGTGATTCAGGACTGGGCGAAGGAGACTCTAAGAGGAGG





CGCGTGTCCCCCTATCCTTCCAGTGGTGACAGCTCCTCCCCTGCTGGGGC





CCCTTCTCCTTTTGATAAGGAAGCTGAAGGACAGTTTTATAACTATTTTC





CCAAC,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:116 under stringent hybridization conditions.


In some embodiments, T-box 22 (TBX22) comprises the amino acid sequence:









(SEQ ID NO: 117; NP_058650)


MALSSRARAFSVEALVGRPSKRKLQDPIQAEQPELREKKGGEEEEERRSS





AAGKSEPLEKQPKTEPSTSASSGCGSDSGYGNSSESLEEKDIQMELQGSE





LWKRFHDIGTEMIITKAGRRMFPSVRVKVKGLDPGKQYHVAIDVVPVDSK





RYRYVYHSSQWMVAGNTDHLCIIPRFYVHPDSPCSGETWMRQIISFDRMK





LTNNEMDDKGHIILQSMHKYKPRVHVIEQGSSVDLSQIQSLPTEGVKTFS





FKETEFTTVTAYQNQQITKLKIERNPFAKGFRDTGRNRGVLDGLLETYPW





RPSFTLDFKTFGADTQSGSSGSSPVTSSGGAPSPLNSLLSPLCFSPMFHL





PTSSLGMPCPEAYLPNVNLPLCYKICPTNFWQQQPLVLPAPERLASSNSS





QSLAPLMMEVPMLSSLGVTNSKSGSSEDSSDQYLQAPNSTNQMLYGLQSP





GNIFLPNSITPEALSCSFHPSYDFYRYNFSMPSRLISGSNHLKVNDDSQV





SFGEGKCNHVHWYPAINHYL,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:117.


In some embodiments, the nucleic acid sequence encoding TBX22 comprises the nucleic acid sequence:









(SEQ ID NO: 118; NM_016954)


ATGGCTCTGAGCTCTCGGGCGCGTGCCTTCTCCGTGGAAGCCTTGGTGGG





GAGACCCAGCAAAAGAAAACTCCAAGACCCAATACAGGCGGAGCAGCCTG





AGCTGCGGGAGAAAAAGGGCGGAGAGGAAGAGGAGGAGAGAAGGAGCAGC





GCTGCAGGGAAGAGCGAGCCGCTTGAAAAACAACCTAAGACAGAGCCCTC





AACATCTGCTTCCTCTGGCTGCGGCAGCGACAGCGGCTACGGCAACAGCT





CTGAAAGTCTGGAAGAGAAAGATATTCAAATGGAGCTTCAAGGATCTGAA





CTGTGGAAAAGATTCCATGACATCGGGACTGAGATGATCATTACTAAAGC





GGGCAGGCGGATGTTCCCCTCTGTTCGGGTCAAGGTGAAAGGGTTGGATC





CAGGGAAGCAGTACCATGTGGCCATCGATGTGGTGCCGGTGGATTCCAAA





CGCTATAGGTACGTCTATCACAGCTCACAGTGGATGGTAGCTGGGAATAC





AGACCATTTGTGCATCATTCCTAGATTCTATGTTCACCCGGACTCACCCT





GCTCGGGAGAGACCTGGATGCGGCAGATCATCAGCTTTGATCGCATGAAA





CTCACCAACAATGAGATGGATGACAAAGGCCACATCATTCTGCAATCCAT





GCATAAGTACAAACCCCGAGTGCACGTGATAGAGCAAGGCAGCAGTGTTG





ACCTGTCCCAGATTCAGTCCTTGCCCACTGAAGGTGTTAAAACATTCTCC





TTTAAAGAAACTGAGTTCACCACAGTAACGGCTTACCAAAACCAACAGAT





TACGAAACTAAAAATAGAAAGAAATCCTTTTGCTAAAGGATTTAGAGATA





CTGGAAGAAACAGGGGTGTATTGGATGGGCTTTTAGAGACCTACCCATGG





AGGCCTTCTTTCACTCTCGATTTTAAAACCTTTGGCGCAGACACACAAAG





TGGAAGCAGTGGCTCATCTCCAGTGACCTCTAGTGGAGGGGCCCCCTCTC





CTTTGAACTCCTTACTTTCTCCACTTTGCTTTTCACCTATGTTTCATTTA





CCTACAAGCTCCCTTGGAATGCCCTGTCCAGAGGCATACCTGCCCAATGT





CAACCTGCCTCTATGCTACAAGATTTGTCCAACTAATTTTTGGCAACAGC





AACCTCTTGTTTTACCGGCTCCTGAAAGACTAGCAAGCAGCAACAGTTCT





CAGTCTTTAGCCCCACTCATGATGGAAGTGCCTATGTTATCTTCCCTGGG





GGTCACCAATTCAAAAAGCGGTTCATCTGAAGACTCCAGTGATCAGTATC





TACAAGCACCTAATTCTACCAATCAAATGTTATATGGATTACAGTCACCT





GGAAATATTTTTCTGCCAAACTCCATCACCCCAGAAGCACTTAGTTGCTC





CTTTCATCCTTCCTATGACTTTTATAGATACAATTTCTCTATGCCATCTA





GACTGATAAGTGGTTCCAACCATCTTAAAGTGAATGACGACAGTCAAGTT





TCTTTTGGAGAAGGCAAATGTAATCATGTTCATTGGTATCCAGCAATTAA





CCATTACCTT,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:118 under stringent hybridization conditions.


In some embodiments, Paired box 1 (PAX1) comprises the amino acid sequence:









(SEQ ID NO: 119; NP_006183)


MEQTYGEVNQLGGVFVNGRPLPNAIRLRIVELAQLGIRPCDISRQLRVSH





GCVSKILARYNETGSILPGAIGGSKPRVTTPNVVKHIRDYKQGDPGIFAW





EIRDRLLADGVCDKYNVPSVSSISRILRNKIGSLAQPGPYEASKQPPSQP





TLPYNHIYQYPYPSPVSPTGAKMGSHPGVPGTAGHVSIPRSWPSAHSVSN





ILGIRTFMEQTGALAGSEGTAYSPKMEDWAGVNRTAFPATPAVNGLEKPA





LEADIKYTQSASTLSAVGGFLPACAYPASNQHGVYSAPGGGYLAPGPPWP





PAQGPPLAPPGAGVAVHGGELAAAMTFKHPSREGSLPAPAARPRTPSVAY





TDCPSRPRPPRGSSPRTRARRERQADPGAQVCAAAPAIGTGRIGGLAEEE





ASAGPRGARPASPQAQPCLWPDPPHFLYWSGFLGFSELGF,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:119.


In some embodiments, the nucleic acid sequence encoding PAX1 comprises the nucleic acid sequence:









(SEQ ID NO: 120; NM_006192)


ATGGAGCAGACGTATGGCGAGGTGAACCAGCTGGGCGGTGTGTTCGTCAA





CGGCCGCCCCCTGCCCAACGCCATCCGCTTGCGCATTGTGGAGCTGGCGC





AGCTGGGCATCCGACCCTGTGACATCAGTCGGCAGCTCCGCGTATCCCAC





GGCTGCGTGAGCAAGATCCTGGCGCGCTACAACGAGACCGGCTCCATTCT





GCCCGGGGCCATCGGGGGGAGCAAGCCCCGCGTCACCACTCCCAACGTGG





TCAAGCACATCCGGGACTACAAGCAAGGAGACCCTGGCATCTTTGCCTGG





GAGATCCGCGACCGGCTGCTGGCCGACGGCGTCTGTGACAAGTACAATGT





GCCTTCGGTGAGCTCCATCAGCCGCATCCTGCGCAACAAGATCGGCAGCC





TGGCGCAGCCCGGACCGTACGAGGCAAGTAAGCAGCCGCCGTCGCAGCCT





ACGCTGCCCTACAACCACATCTACCAGTACCCCTACCCCAGTCCCGTGTC





GCCCACGGGCGCCAAGATGGGCAGCCACCCCGGGGTCCCGGGCACGGCGG





GCCACGTCAGCATCCCGCGCTCATGGCCCTCGGCACACTCGGTCAGCAAC





ATCCTGGGCATCCGGACGTTTATGGAGCAAACAGGGGCCCTGGCTGGGAG





CGAAGGCACCGCTTACTCTCCCAAGATGGAAGACTGGGCCGGCGTGAACC





GCACGGCCTTCCCCGCCACCCCCGCAGTGAATGGGCTAGAGAAACCTGCC





TTAGAGGCAGACATTAAATACACTCAGTCGGCCTCCACCCTCTCTGCCGT





GGGCGGCTTTCTCCCCGCCTGCGCCTACCCGGCCTCCAACCAGCACGGCG





TGTACAGCGCCCCGGGCGGCGGCTACCTCGCCCCGGGCCCGCCGTGGCCG





CCTGCGCAAGGTCCTCCTCTGGCGCCCCCCGGGGCCGGCGTAGCTGTGCA





TGGCGGGGAACTCGCGGCAGCAATGACCTTCAAGCATCCCAGCCGAGAAG





GAAGCCTCCCAGCTCCGGCAGCAAGGCCCCGGACGCCCTCAGTAGCTTAC





ACGGACTGCCCATCCCGGCCTCGACCTCCTAGGGGCAGCTCTCCCCGGAC





CCGAGCCCGGAGGGAACGGCAGGCGGACCCGGGCGCACAGGTCTGCGCGG





CGGCCCCGGCAATCGGCACGGGCAGGATCGGAGGACTCGCGGAGGAGGAA





GCCAGTGCCGGCCCGCGGGGTGCACGCCCAGCCAGCCCCCAGGCCCAGCC





CTGCCTCTGGCCGGACCCACCACACTTCCTTTATTGGTCTGGGTTTTTAG





GCTTCTCTGAACTTGGGTTT,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:120 under stringent hybridization conditions.


In some embodiments, Sex determining region Y (SRY/SOXA) comprises the amino acid sequence:









(SEQ ID NO: 121; NP_003131)


MQSYASAMLSVFNSDDYSPAVQENIPALRRSSSFLCTESCNSKYQCETGE





NSKGNVQDRVKRPMNAFIVWSRDQRRKMALENPRMRNSEISKQLGYQWKM





LTEAEKWPFFQEAQKLQAMHREKYPNYKYRPRRKAKMLPKNCSLLPADPA





SVLCSEVQLDNRLYRDDCTKATHSRMEHOLGHLPPINAASSPQQRDRYSH





WTKL,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:121.


In some embodiments, the nucleic acid sequence encoding SRY/SOXA comprises the nucleic acid sequence:









ATGCAATCATATGCTTCTGCTATGTTAAGCGTATTCAACAGCGATGATTA





CAGTCCAGCTGTGCAAGAGAATATTCCCGCTCTCCGGAGAAGCTCTTCCT





TCCTTTGCACTGAAAGCTGTAACTCTAAGTATCAGTGTGAAACGGGAGAA





AACAGTAAAGGCAACGTCCAGGATAGAGTGAAGCGACCCATGAACGCATT





CATCGTGTGGTCTCGCGATCAGAGGCGCAAGATGGCTCTAGAGAATCCCA





GAATGCGAAACTCAGAGATCAGCAAGCAGCTGGGATACCAGTGGAAAATG





CTTACTGAAGCCGAAAAATGGCCATTCTTCCAGGAGGCACAGAAATTACA





GGCCATGCACAGAGAGAAATACCCGAATTATAAGTATCGACCTCGTCGGA





AGGCGAAGATGCTGCCGAAGAATTGCAGTTTGCTTCCCGCAGATCCCGCT





TCGGTACTCTGCAGCGAAGTGCAACTGGACAACAGGTTGTACAGGGATGA





CTGTACGAAAGCCACACACTCAAGAATGGAGCACCAGCTAGGCCACTTAC





CGCCCATCAACGCAGCCAGCTCACCGCAGCAACGGGACCGCTACAGCCAC





TGGACAAAGCTG (SEQ ID NO: 122; NM_003140),







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:122 under stringent hybridization conditions.


In some embodiments, SRY box 1 (SOX1) comprises the amino acid sequence:









(SEQ ID NO: 123; NP_005977)


MYSMMMETDLHSPGGAQAPTNLSGPAGAGGGGGGGGGGGGGGGAKANQDR





VKRPMNAFMVWSRGQRRKMAQENPKMHNSEISKRLGAEWKVMSEAEKRPF





IDEAKRLRALHMKEHPDYKYRPRRKTKTLLKKDKYSLAGGLLAAGAGGGG





AAVAMGVGVGVGAAAVGQRLESPGGAAGGGYAHVNGWANGAYPGSVAAAA





AAAAMMQEAQLAYGQHPGAGGAHPHAHPAHPHPHHPHAHPHNPQPMHRYD





MGALQYSPISNSQGYMSASPSGYGGLPYGAAAAAAAAAGGAHQNSAVAAA





AAAAAASSGALGALGSLVKSEPSGSPPAPAHSRAPCPGDLREMISMYLPA





GEGGDPAAAAAAAAQSRLHSLPQHYQGAGAGVNGTVPLTHI,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:123.


In some embodiments, the nucleic acid sequence encoding SOX1 comprises the nucleic acid sequence:









(SEQ ID NO: 124; NM_005986)


ATGTACAGCATGATGATGGAGACCGACCTGCACTCGCCCGGCGGCGCCCA





GGCCCCCACGAACCTCTCGGGCCCCGCCGGGGCGGGCGGCGGCGGGGGCG





GAGGCGGGGGCGGCGGCGGCGGCGGGGGCGCCAAGGCCAACCAGGACCGG





GTCAAACGGCCCATGAACGCCTTCATGGTGTGGTCCCGCGGGCAGCGGCG





CAAGATGGCCCAGGAGAACCCCAAGATGCACAACTCGGAGATCAGCAAGC





GCCTGGGGGCCGAGTGGAAGGTCATGTCCGAGGCCGAGAAGCGGCCGTTC





ATCGACGAGGCCAAGCGGCTGCGCGCGCTGCACATGAAGGAGCACCCGGA





TTACAAGTACCGGCCGCGCCGCAAGACCAAGACGCTGCTCAAGAAGGACA





AGTACTCGCTGGCCGGCGGGCTCCTGGCGGCCGGCGCGGGTGGCGGCGGC





GCGGCTGTGGCCATGGGCGTGGGCGTGGGCGTGGGCGCGGCGGCCGTGGG





CCAGCGCCTGGAGAGCCCAGGCGGCGCGGCGGGCGGCGGCTACGCGCACG





TCAACGGCTGGGCCAACGGCGCCTACCCCGGCTCGGTGGCGGCGGCGGCG





GCGGCCGCGGCCATGATGCAGGAGGCGCAGCTGGCCTACGGGCAGCACCC





GGGCGCGGGCGGCGCGCACCCGCACGCGCACCCCGCGCACCCGCACCCGC





ACCACCCGCACGCGCACCCGCACAACCCGCAGCCCATGCACCGCTACGAC





ATGGGCGCGCTGCAGTACAGCCCCATCTCCAACTCGCAGGGCTACATGAG





CGCGTCGCCCTCGGGCTACGGCGGCCTCCCCTACGGCGCCGCGGCCGCCG





CCGCCGCCGCTGCGGGCGGCGCGCACCAGAACTCGGCCGTGGCGGCGGCG





GCGGCGGCGGCGGCCGCGTCGTCGGGCGCCCTGGGCGCGCTGGGCTCTCT





GGTGAAGTCGGAGCCCAGCGGCAGCCCGCCCGCCCCAGCGCACTCGCGGG





CGCCGTGCCCCGGGGACCTGCGCGAGATGATCAGCATGTACTTGCCCGCC





GGCGAGGGGGGCGACCCGGCGGCGGCAGCAGCGGCCGCGGCGCAGAGCCG





GCTGCACTCGCTGCCGCAGCACTACCAGGGCGCGGGCGCGGGCGTGAACG





GCACGGTGCCCCTGACGCACATC,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:124 under stringent hybridization conditions.


In some embodiments, SRY-box 2 (SOX2) comprises the amino acid sequence:









(SEQ ID NO: 125; NP_003097)


MYNMMETELKPPGPQQTSGGGGGNSTAAAAGGNQKNSPDRVKRPMNAFMV





WSRGQRRKMAQENPKMHNSEISKRLGAEWKLLSETEKRPFIDEAKRLRAL





HMKEHPDYKYRPRRKTKTLMKKDKYTLPGGLLAPGGNSMASGVGVGAGLG





AGVNQRMDSYAHMNGWSNGSYSMMQDQLGYPQHPGLNAHGAAQMQPMHRY





DVSALQYNSMTSSQTYMNGSPTYSMSYSQQGTPGMALGSMGSVVKSEASS





SPPVVTSSSHSRAPCQAGDLRDMISMYLPGAEVPEPAAPSRLHMSQHYQS





GPVPGTAINGTLPLSHM,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:125.


In some embodiments, the nucleic acid sequence encoding SOX2 comprises the nucleic acid sequence:









(SEQ ID NO: 126; NM_003106)


ATGTACAACATGATGGAGACGGAGCTGAAGCCGCCGGGCCCGCAGCAAAC





TTCGGGGGGCGGCGGCGGCAACTCCACCGCGGCGGCGGCCGGCGGCAACC





AGAAAAACAGCCCGGACCGCGTCAAGCGGCCCATGAATGCCTTCATGGTG





TGGTCCCGCGGGCAGCGGCGCAAGATGGCCCAGGAGAACCCCAAGATGCA





CAACTCGGAGATCAGCAAGCGCCTGGGCGCCGAGTGGAAACTTTTGTCGG





AGACGGAGAAGCGGCCGTTCATCGACGAGGCTAAGCGGCTGCGAGCGCTG





CACATGAAGGAGCACCCGGATTATAAATACCGGCCCCGGCGGAAAACCAA





GACGCTCATGAAGAAGGATAAGTACACGCTGCCCGGCGGGCTGCTGGCCC





CCGGCGGCAATAGCATGGCGAGCGGGGTCGGGGTGGGCGCCGGCCTGGGC





GCGGGCGTGAACCAGCGCATGGACAGTTACGCGCACATGAACGGCTGGAG





CAACGGCAGCTACAGCATGATGCAGGACCAGCTGGGCTACCCGCAGCACC





CGGGCCTCAATGCGCACGGCGCAGCGCAGATGCAGCCCATGCACCGCTAC





GACGTGAGCGCCCTGCAGTACAACTCCATGACCAGCTCGCAGACCTACAT





GAACGGCTCGCCCACCTACAGCATGTCCTACTCGCAGCAGGGCACCCCTG





GCATGGCTCTTGGCTCCATGGGTTCGGTGGTCAAGTCCGAGGCCAGCTCC





AGCCCCCCTGTGGTTACCTCTTCCTCCCACTCCAGGGCGCCCTGCCAGGC





CGGGGACCTCCGGGACATGATCAGCATGTATCTCCCCGGCGCCGAGGTGC





CGGAACCCGCCGCCCCCAGCAGACTTCACATGTCCCAGCACTACCAGAGC





GGCCCGGTGCCCGGCACGGCCATTAACGGCACACTGCCCCTCTCACACAT





G,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:126 under stringent hybridization conditions.


In some embodiments, SRY-box 3 (SOX3) comprises the amino acid sequence:









(SEQ ID NO: 127; NP_005625)


MRPVRENSSGARSPRVPADLARSILISLPFPPDSLAHRPPSSAPTESQGL





FTVAAPAPGAPSPPATLAHLLPAPAMYSLLETELKNPVGTPTQAAGTGGP





AAPGGAGKSSANAAGGANSGGGSSGGASGGGGGTDQDRVKRPMNAFMVWS





RGQRRKMALENPKMHNSEISKRLGADWKLLTDAEKRPFIDEAKRLRAVHM





KEYPDYKYRPRRKTKTLLKKDKYSLPSGLLPPGAAAAAAAAAAAAAAASS





PVGVGQRLDTYTHVNGWANGAYSLVQEQLGYAQPPSMSSPPPPPALPPMH





RYDMAGLQYSPMMPPGAQSYMNVAAAAAAASGYGGMAPSATAAAAAAYGQ





QPATAAAAAAAAAAMSLGPMGSVVKSEPSSPPPAIASHSQRACLGDLRDM





ISMYLPPGGDAADAASPLPGGRLHGVHQHYQGAGTAVNGTVPLTHI,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:127.


In some embodiments, the nucleic acid sequence encoding SOX3 comprises the nucleic acid sequence:









(SEQ ID NO: 128; NM_005634)


ATGCGACCTGTTCGAGAGAACTCATCAGGTGCGAGAAGCCCGCGGGTTCC





TGCTGATTTGGCGCGGAGCATTTTGATAAGCCTACCCTTCCCGCCGGACT





CGCTGGCCCACAGGCCCCCAAGCTCCGCTCCGACGGAGTCCCAGGGCCTT





TTCACCGTGGCCGCTCCAGCCCCGGGAGCGCCTTCTCCTCCCGCCACGCT





GGCGCACCTTCTTCCCGCCCCGGCAATGTACAGCCTTCTGGAGACTGAAC





TCAAGAACCCCGTAGGGACACCCACACAAGCGGCGGGCACCGGCGGCCCC





GCAGCCCCGGGAGGCGCAGGCAAGAGTAGTGCGAACGCAGCCGGCGGCGC





GAACTCGGGCGGCGGCAGCAGCGGTGGTGCGAGCGGAGGTGGCGGGGGTA





CAGACCAGGACCGTGTGAAACGGCCCATGAACGCCTTCATGGTATGGTCC





CGCGGGCAGCGGCGCAAAATGGCCCTGGAGAACCCCAAGATGCACAATTC





TGAGATCAGCAAGCGCTTGGGCGCCGACTGGAAACTGCTGACCGACGCCG





AGAAGCGACCATTCATCGACGAGGCCAAGCGACTTCGCGCCGTGCACATG





AAGGAGTATCCGGACTACAAGTACCGACCGCGCCGCAAGACCAAGACGCT





GCTCAAGAAAGATAAGTACTCCCTGCCCAGCGGCCTCCTGCCTCCCGGTG





CCGCGGCCGCCGCCGCCGCTGCCGCGGCCGCAGCCGCTGCCGCCAGCAGT





CCGGTGGGCGTGGGCCAGCGCCTGGACACGTACACGCACGTGAACGGCTG





GGCCAACGGCGCGTACTCGCTGGTGCAGGAGCAGCTGGGCTACGCGCAGC





CCCCGAGCATGAGCAGCCCGCCGCCGCCGCCCGCGCTGCCGCCGATGCAC





CGCTACGACATGGCCGGCCTGCAGTACAGCCCAATGATGCCGCCCGGCGC





TCAGAGCTACATGAACGTCGCTGCCGCGGCCGCCGCCGCCTCGGGCTACG





GGGGCATGGCGCCCTCAGCCACAGCAGCCGCGGCCGCCGCCTACGGGCAG





CAGCCCGCCACCGCCGCGGCCGCAGCTGCGGCCGCAGCCGCCATGAGCCT





GGGCCCCATGGGCTCGGTAGTGAAGTCTGAGCCCAGCTCGCCGCCGCCCG





CCATCGCATCGCACTCTCAGCGCGCGTGCCTCGGCGACCTGCGCGACATG





ATCAGCATGTACCTGCCACCCGGCGGGGACGCGGCCGACGCCGCCTCTCC





GCTGCCCGGCGGTCGCCTGCACGGCGTGCACCAGCACTACCAGGGCGCCG





GGACTGCAGTCAACGGAACGGTGCCGCTGACCCACATC,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:128 under stringent hybridization conditions.


In some embodiments, SRY box 14 (SOX14) comprises the amino acid sequence:









(SEQ ID NO: 129; NP_004180)


MSKPSDHIKRPMNAFMVWSRGQRRKMAQENPKMHNSEISKRLGAEWKLLS





EAEKRPYIDEAKRLRAQHMKEHPDYKYRPRRKPKNLLKKDRYVFPLPYLG





DTDPLKAAGLPVGASDGLLSAPEKARAFLPPASAPYSLLDPAQFSSSAIQ





KMGEVPHTLATGALPYASTLGYQNGAFGSLSCPSQHTHTHPSPTNPGYVV





PCNCTAWSASTLQPPVAYILFPGMTKTGIDPYSSAHATAM,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:129.


In some embodiments, the nucleic acid sequence encoding SOX14 comprises the nucleic acid sequence:









(SEQ ID NO: 130; NM_004189)


ATGTCCAAACCTTCAGACCACATCAAGCGGCCCATGAACGCCTTCATGGT





ATGGTCCCGGGGCCAGCGGCGCAAGATGGCCCAGGAAAACCCCAAGATGC





ACAACTCGGAGATCAGCAAACGCCTAGGTGCCGAATGGAAGCTTCTGTCC





GAGGCAGAGAAGCGGCCATACATCGATGAAGCCAAGCGGCTACGCGCCCA





GCACATGAAGGAGCACCCTGACTACAAGTACCGACCTCGGCGCAAGCCCA





AGAACCTGCTCAAGAAGGACAGGTATGTCTTCCCCTTGCCCTACCTGGGC





GACACGGACCCGCTCAAGGCGGCTGGCCTGCCCGTGGGGGCCTCCGACGG





CCTCCTGAGCGCGCCCGAGAAAGCCCGGGCCTTCTTGCCGCCGGCCTCGG





CGCCCTACTCCCTGCTGGACCCCGCGCAGTTTAGCTCGAGCGCCATCCAG





AAGATGGGCGAAGTGCCCCACACCTTGGCTACCGGCGCTCTGCCCTACGC





GTCCACCCTGGGCTACCAGAACGGCGCCTTCGGCAGCCTCAGCTGCCCCA





GCCAGCACACGCACACGCACCCGTCCCCCACCAACCCTGGCTACGTGGTG





CCCTGTAACTGTACCGCCTGGTCTGCCTCCACCCTGCAGCCCCCCGTCGC





CTACATCCTCTTCCCAGGCATGACCAAGACTGGCATAGACCCTTATTCGT





CAGCCCACGCTACGGCCATG,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:130 under stringent hybridization conditions.


In some embodiments, SRY-box 21 (SOX21) comprises the amino acid sequence:









(SEQ ID NO: 131; NP_009015)


MSKPVDHVKRPMNAFMVWSRAQRRKMAQENPKMHNSEISKRLGAEWKLLT





ESEKRPFIDEAKRLRAMHMKEHPDYKYRPRRKPKTLLKKDKFAFPVPYGL





GGVADAEHPALKAGAGLHAGAGGGLVPESLLANPEKAAAAAAAAAARVFF





PQSAAAAAAAAAAAAAGSPYSLLDLGSKMAEISSSSSGLPYASSLGYPTA





GAGAFHGAAAAAAAAAAAAGGHTHSHPSPGNPGYMIPCNCSAWPSPGLQP





PLAYILLPGMGKPQLDPYPAAYAAAL,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:131.


In some embodiments, the nucleic acid sequence encoding SOX21 comprises the nucleic acid sequence:









(SEQ ID NO: 132; NM_007084)


ATGTCCAAGCCGGTGGACCACGTCAAGCGGCCCATGAACGCCTTCATG





GTGTGGTCGCGGGCTCAGCGGCGCAAGATGGCCCAGGAGAACCCCAAG





ATGCACAACTCGGAGATCAGCAAGCGCTTGGGCGCCGAGTGGAAACTG





CTCACAGAGTCGGAGAAGCGGCCGTTCATCGACGAGGCCAAGCGTCTA





CGCGCCATGCACATGAAGGAGCACCCCGACTACAAGTACCGGCCGCGG





CGCAAGCCCAAGACGCTGCTCAAGAAGGACAAGTTCGCCTTCCCGGTG





CCCTACGGCCTGGGCGGCGTGGCGGACGCCGAGCACCCTGCGCTCAAG





GCGGGCGCCGGGCTGCACGCGGGGGCGGGCGGCGGCCTGGTGCCTGAG





TCGCTGCTCGCCAATCCCGAGAAGGCGGCCGCGGCCGCCGCCGCTGCC





GCCGCACGCGTCTTCTTCCCGCAGTCGGCCGCTGCCGCCGCCGCTGCC





GCCGCCGCCGCCGCCGCGGGCAGCCCCTACTCGCTGCTCGACCTGGGC





TCCAAAATGGCAGAGATCTCGTCGTCCTCGTCCGGCCTCCCGTACGCG





TCGTCGCTGGGCTACCCGACCGCGGGCGCGGGCGCCTTCCACGGCGCG





GCGGCGGCGGCTGCAGCGGCGGCCGCCGCCGCCGGGGGGCACACGCAC





TCGCACCCCAGCCCGGGCAACCCGGGCTACATGATCCCGTGCAACTGC





AGCGCGTGGCCCAGCCCCGGGCTGCAGCCGCCGCTCGCCTACATCCTG





CTGCCGGGCATGGGCAAGCCCCAGCTGGACCCCTACCCCGCGGCCTAC





GCTGCCGCGCTA,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:132 under stringent hybridization conditions.


In some embodiments, SRY-box 4 (SOX4) comprises the amino acid sequence:









(SEQ ID NO: 133; NP_003098)


MVQQTNNAENTEALLAGESSDSGAGLELGIASSPTPGSTASTGGKADD





PSWCKTPSGHIKRPMNAFMVWSQIERRKIMEQSPDMHNAEISKRLGKR





WKLLKDSDKIPFIREAERLRLKHMADYPDYKYRPRKKVKSGNANSSSS





AAASSKPGEKGDKVGGSGGGGHGGGGGGGSSNAGGGGGGASGGGANSK





PAQKKSCGSKVAGGAGGGVSKPHAKLILAGGGGGGKAAAAAAASFAAE





QAGAAALLPLGAAADHHSLYKARTPSASASASSAASASAALAAPGKHL





AEKKVKRVYLFGGLGTSSSPVGGVGAGADPSDPLGLYEEEGAGCSPDA





PSLSGRSSAASSPAAGRSPADHRGYASLRAASPAPSSAPSHASSSASS





HSSSSSSSGSSSSDDEFEDDLLDLNPSSNFESMSLGSFSSSSALDRDL





DFNFEPGSGSHFEFPDYCTPEVSEMISGDWLESSISNLVFTY,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:133.


In some embodiments, the nucleic acid sequence encoding SOX4 comprises the nucleic acid sequence:









(SEQ ID NO: 134; NM_003107)


ATGGTGCAGCAAACCAACAATGCCGAGAACACGGAAGCGCTGCTGGCC





GGCGAGAGCTCGGACTCGGGCGCCGGCCTCGAGCTGGGAATCGCCTCC





TCCCCCACGCCCGGCTCCACCGCCTCCACGGGCGGCAAGGCCGACGAC





CCGAGCTGGTGCAAGACCCCGAGTGGGCACATCAAGCGACCCATGAAC





GCCTTCATGGTGTGGTCGCAGATCGAGCGGCGCAAGATCATGGAGCAG





TCGCCCGACATGCACAACGCCGAGATCTCCAAGCGGCTGGGCAAACGC





TGGAAGCTGCTCAAAGACAGCGACAAGATCCCTTTCATTCGAGAGGCG





GAGCGGCTGCGCCTCAAGCACATGGCTGACTACCCCGACTACAAGTAC





CGGCCCAGGAAGAAGGTGAAGTCCGGCAACGCCAACTCCAGCTCCTCG





GCCGCCGCCTCCTCCAAGCCGGGGGAGAAGGGAGACAAGGTCGGTGGC





AGTGGCGGGGGCGGCCATGGGGGCGGCGGCGGCGGCGGGAGCAGCAAC





GCGGGGGGAGGAGGCGGCGGTGCGAGTGGCGGCGGCGCCAACTCCAAA





CCGGCGCAGAAAAAGAGCTGCGGCTCCAAAGTGGCGGGCGGCGCGGGC





GGTGGGGTTAGCAAACCGCACGCCAAGCTCATCCTGGCAGGCGGCGGC





GGCGGCGGGAAAGCAGCGGCTGCCGCCGCCGCCTCCTTCGCCGCCGAA





CAGGCGGGGGCCGCCGCCCTGCTGCCCCTGGGCGCCGCCGCCGACCAC





CACTCGCTGTACAAGGCGCGGACTCCCAGCGCCTCGGCCTCCGCCTCC





TCGGCAGCCTCGGCCTCCGCAGCGCTCGCGGCCCCGGGCAAGCACCTG





GCGGAGAAGAAGGTGAAGCGCGTCTACCTGTTCGGCGGCCTGGGCACG





TCGTCGTCGCCCGTGGGCGGCGTGGGCGCGGGAGCCGACCCCAGCGAC





CCCCTGGGCCTGTACGAGGAGGAGGGCGCGGGCTGCTCGCCCGACGCG





CCCAGCCTGAGCGGCCGCAGCAGCGCCGCCTCGTCCCCCGCCGCCGGC





CGCTCGCCCGCCGACCACCGCGGCTACGCCAGCCTGCGCGCCGCCTCG





CCCGCCCCGTCCAGCGCGCCCTCGCACGCGTCCTCCTCGGCCTCGTCC





CACTCCTCCTCTTCCTCCTCCTCGGGCTCCTCGTCCTCCGACGACGAG





TTCGAAGACGACCTGCTCGACCTGAACCCCAGCTCAAACTTTGAGAGC





ATGTCCCTGGGCAGCTTCAGTTCGTCGTCGGCGCTCGACCGGGACCTG





GATTTTAACTTCGAGCCCGGCTCCGGCTCGCACTTCGAGTTCCCGGAC





TACTGCACGCCCGAGGTGAGCGAGATGATCTCGGGAGACTGGCTCGAG





TCCAGCATCTCCAACCTGGTTTTCACCTAC,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:134 under stringent hybridization conditions.


In some embodiments, SRY-box 11 (SOX11) comprises the amino acid sequence:









(SEQ ID NO: 135; NP_003099)


MVQQAESLEAESNLPREALDTEEGEFMACSPVALDESDPDWCKTASGH





IKRPMNAFMVWSKIERRKIMEQSPDMHNAEISKRLGKRWKMLKDSEKI





PFIREAERLRLKHMADYPDYKYRPRKKPKMDPSAKPSASQSPEKSAAG





GGGGSAGGGAGGAKTSKGSSKKCGKLKAPAAAGAKAGAGKAAQSGDYG





GAGDDYVLGSLRVSGSGGGGAGKTVKCVFLDEDDDDDDDDDELQLQIK





QEPDEEDEEPPHQQLLQPPGQQPSQLLRRYNVAKVPASPTLSSSAESP





EGASLYDEVRAGATSGAGGGSRLYYSFKNITKQHPPPLAQPALSPASS





RSVSTSSSSSSGSSSGSSGEDADDLMFDLSLNFSQSAHSASEQQLGGG





AAAGNLSLSLVDKDLDSFSEGSLGSHFEFPDYCTPELSEMIAGDWLEA





NFSDLVFTY,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:135.


In some embodiments, the nucleic acid sequence encoding SOX11 comprises the nucleic acid sequence:









(SEQ ID NO: 136; NM_003108)


ATGGTGCAGCAGGCGGAGAGCTTGGAAGCGGAGAGCAACCTGCCCCGG





GAGGCGCTGGACACGGAGGAGGGCGAATTCATGGCTTGCAGCCCGGTG





GCCCTGGACGAGAGCGACCCAGACTGGTGCAAGACGGCGTCGGGCCAC





ATCAAGCGGCCGATGAACGCGTTCATGGTATGGTCCAAGATCGAACGC





AGGAAGATCATGGAGCAGTCTCCGGACATGCACAACGCCGAGATCTCC





AAGAGGCTGGGCAAGCGCTGGAAAATGCTGAAGGACAGCGAGAAGATC





CCGTTCATCCGGGAGGCGGAGCGGCTGCGGCTCAAGCACATGGCCGAC





TACCCCGACTACAAGTACCGGCCCCGGAAAAAGCCCAAAATGGACCCC





TCGGCCAAGCCCAGCGCCAGCCAGAGCCCAGAGAAGAGCGCGGCCGGC





GGCGGCGGCGGGAGCGCGGGCGGAGGCGCGGGCGGTGCCAAGACCTCC





AAGGGCTCCAGCAAGAAATGCGGCAAGCTCAAGGCCCCCGCGGCCGCG





GGCGCCAAGGCGGGCGCGGGCAAGGCGGCCCAGTCCGGGGACTACGGG





GGCGCGGGCGACGACTACGTGCTGGGCAGCCTGCGCGTGAGCGGCTCG





GGCGGCGGCGGCGCGGGCAAGACGGTCAAGTGCGTGTTTCTGGATGAG





GACGACGACGACGACGACGACGACGACGAGCTGCAGCTGCAGATCAAA





CAGGAGCCGGACGAGGAGGACGAGGAACCACCGCACCAGCAGCTCCTG





CAGCCGCCGGGGCAGCAGCCGTCGCAGCTGCTGAGACGCTACAACGTC





GCCAAAGTGCCCGCCAGCCCTACGCTGAGCAGCTCGGCGGAGTCCCCC





GAGGGAGCGAGCCTCTACGACGAGGTGCGGGCCGGCGCGACCTCGGGC





GCCGGGGGCGGCAGCCGCCTCTACTACAGCTTCAAGAACATCACCAAG





CAGCACCCGCCGCCGCTCGCGCAGCCCGCGCTGTCGCCCGCGTCCTCG





CGCTCGGTGTCCACCTCCTCGTCCAGCAGCAGCGGCAGCAGCAGCGGC





AGCAGCGGCGAGGACGCCGACGACCTGATGTTCGACCTGAGCTTGAAT





TTCTCTCAAAGCGCGCACAGCGCCAGCGAGCAGCAGCTGGGGGGCGGC





GCGGCGGCCGGGAACCTGTCCCTGTCGCTGGTGGATAAGGATTTGGAT





TCGTTCAGCGAGGGCAGCCTGGGCTCCCACTTCGAGTTCCCCGACTAC





TGCACGCCGGAGCTGAGCGAGATGATCGCGGGGGACTGGCTGGAGGCG





AACTTCTCCGACCTGGTGTTCACATAT,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:136 under stringent hybridization conditions.


In some embodiments, SRY-box 12 (SOX12) comprises the amino acid sequence:









(SEQ ID NO: 137; NP_008874)


MVQQRGARAKRDGGPPPPGPGPAEEGAREPGWCKTPSGHIKRPMNAFM





VWSQHERRKIMDQWPDMHNAEISKRLGRRWQLLQDSEKIPFVREAERL





RLKHMADYPDYKYRPRKKSKGAPAKARPRPPGGSGGGSRLKPGPQLPG





RGGRRAAGGPLGGGAAAPEDDDEDDDEELLEVRLVETPGRELWRMVPA





GRAARGQAERAQGPSGEGAAAAAAASPTPSEDEEPEEEEEEAAAAEEG





EEETVASGEESLGFLSRLPPGPAGLDCSALDRDPDLQPPSGTSHFEFP





DYCTPEVTEMIAGDWRPSSIADLVFTY,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:137.


In some embodiments, the nucleic acid sequence encoding SOX12 comprises the nucleic acid sequence:









(SEQ ID NO: 138; NM_006943)


ATGGTGCAGCAGCGGGGCGCGAGGGCCAAGCGGGACGGCGGGCCGCCG





CCCCCGGGACCCGGGCCGGCCGAGGAGGGGGCGCGCGAGCCCGGCTGG





TGCAAGACCCCGAGCGGCCACATCAAGAGGCCGATGAACGCATTCATG





GTGTGGTCGCAGCACGAACGGCGGAAGATCATGGACCAGTGGCCCGAC





ATGCACAACGCCGAGATCTCCAAGCGCCTGGGCCGCCGCTGGCAGCTG





CTGCAGGACTCGGAGAAGATCCCGTTCGTGCGGGAGGCGGAGCGGCTG





CGGCTCAAGCACATGGCGGATTACCCGGACTACAAGTACCGGCCGCGC





AAAAAGAGCAAGGGGGCGCCCGCCAAGGCGCGGCCCCGCCCCCCCGGT





GGTAGCGGTGGCGGCAGCCGGCTCAAGCCCGGGCCGCAGCTGCCTGGC





CGCGGGGGCCGCCGAGCAGCGGGAGGGCCTTTGGGGGGCGGGGCGGCG





GCGCCCGAGGACGACGATGAAGACGACGACGAGGAGCTGCTGGAAGTG





CGCCTGGTCGAGACCCCGGGGCGGGAGCTGTGGAGGATGGTCCCGGCG





GGACGGGCCGCTCGGGGACAAGCGGAGCGCGCCCAAGGGCCGTCGGGC





GAGGGGGCGGCCGCCGCCGCCGCCGCCTCCCCGACACCGTCGGAGGAC





GAGGAGCCGGAGGAAGAGGAGGAGGAGGCGGCAGCGGCTGAGGAAGGT





GAAGAGGAGACGGTGGCGTCGGGGGAGGAGTCGCTGGGCTTTCTGTCC





AGGCTGCCCCCTGGCCCGGCCGGCCTGGACTGCAGCGCCCTGGATCGC





GACCCGGACCTGCAGCCTCCCTCGGGCACGTCGCACTTCGAGTTCCCG





GACTACTGCACCCCCGAGGTTACCGAGATGATCGCGGGGGACTGGCGC





CCGTCTAGCATCGCAGACCTGGTTTTCACCTAC,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:138 under stringent hybridization conditions.


In some embodiments, SRY-box 5 (SOX5) comprises the amino acid sequence:









(SEQ ID NO: 139; NP_008871)


MLTDPDLPQEFERMSSKRPASPYGEADGEVAMVTSRQKVEEEESDGLP





AFHLPLHVSFPNKPHSEEFQPVSLLTQETCGHRTPTSQHNTMEVDGNK





VMSSFAPHNSSTSPQKAEEGGRQSGESLSSTALGTPERRKGSLADVVD





TLKQRKMEELIKNEPEETPSIEKLLSKDWKDKLLAMGSGNFGEIKGTP





ESLAEKERQLMGMINQLTSLREQLLAAHDEQKKLAASQIEKQRQQMEL





AKQQQEQIARQQQQLLQQQHKINLLQQQIQVQGQLPPLMIPVFPPDQR





TLAAAAQQGFLLPPGFSYKAGCSDPYPVQLIPTTMAAAAAATPGLGPL





QLQQLYAAQLAAMQVSPGGKLPGIPQGNLGAAVSPTSIHTDKSTNSPP





PKSKDEVAQPLNLSAKPKTSDGKSPTSPTSPHMPALRINSGAGPLKAS





VPAALASPSARVSTIGYLNDHDAVTKAIQEARQMKEQLRREQQVLDGK





VAVVNSLGLNNCRTEKEKTTLESLTQQLAVKQNEEGKFSHAMMDFNLS





GDSDGSAGVSESRIYRESRGRGSNEPHIKRPMNAFMVWAKDERRKILQ





AFPDMHNSNISKILGSRWKAMTNLEKQPYYEEQARLSKQHLEKYPDYK





YKPRPKRTCLVDGKKLRIGEYKAIMRNRRQEMRQYFNVGQQAQIPIAT





AGVVYPGAIAMAGMPSPHLPSEHSSVSSSPEPGMPVIQSTYGVKGEEP





HIKEEIQAEDINGEIYDEYDEEEDDPDVDYGSDSENHIAGQAN,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:139.


In some embodiments, the nucleic acid sequence encoding SOX5 comprises the nucleic acid sequence:









(SEQ ID NO: 140; NM_006940)


ATGCTTACTGACCCTGATTTACCTCAGGAGTTTGAAAGGATGTCTTCC





AAGCGACCAGCCTCTCCGTATGGGGAAGCAGATGGAGAGGTAGCCATG





GTGACAAGCAGACAGAAAGTGGAAGAAGAGGAGAGTGACGGGCTCCCA





GCCTTTCACCTTCCCTTGCATGTGAGTTTTCCCAACAAGCCTCACTCT





GAGGAATTTCAGCCAGTTTCTCTGCTGACGCAAGAGACTTGTGGCCAT





AGGACTCCCACTTCTCAGCACAATACAATGGAAGTTGATGGCAATAAA





GTTATGTCTTCATTTGCCCCACACAACTCATCTACCTCACCTCAGAAG





GCAGAAGAAGGTGGGCGACAGAGTGGCGAGTCCTTGTCTAGTACAGCC





CTGGGAACTCCTGAACGGCGCAAGGGCAGTTTAGCTGATGTTGTTGAC





ACCTTGAAGCAGAGGAAAATGGAAGAGCTCATCAAAAACGAGCCGGAA





GAAACCCCCAGTATTGAAAAACTACTCTCAAAGGACTGGAAAGACAAG





CTTCTTGCAATGGGATCGGGGAACTTTGGCGAAATAAAAGGGACTCCC





GAGAGCTTAGCTGAGAAAGAAAGGCAACTCATGGGTATGATCAACCAG





CTGACCAGCCTCCGAGAGCAGCTGTTGGCTGCCCACGATGAGCAGAAG





AAACTAGCTGCCTCTCAGATTGAGAAACAGCGTCAGCAAATGGAGCTG





GCCAAGCAGCAACAAGAACAAATTGCAAGACAGCAGCAGCAGCTTCTA





CAGCAACAACACAAAATCAATTTGCTCCAGCAACAGATCCAGGTTCAA





GGTCAGCTGCCGCCATTAATGATTCCCGTATTCCCTCCTGATCAACGG





ACACTGGCTGCAGCTGCCCAGCAAGGATTCCTCCTCCCTCCAGGCTTC





AGCTATAAGGCTGGATGTAGTGACCCTTACCCTGTTCAGCTGATCCCA





ACTACCATGGCAGCTGCTGCCGCAGCAACACCAGGCTTAGGCCCACTC





CAACTGCAGCAGTTATATGCTGCCCAGCTAGCTGCAATGCAGGTATCT





CCAGGAGGGAAGCTGCCAGGCATACCCCAAGGCAACCTTGGTGCTGCT





GTATCTCCTACCAGCATTCACACAGACAAGAGCACAAACAGCCCACCA





CCCAAAAGCAAGGATGAAGTGGCACAGCCACTGAACCTATCAGCTAAA





CCCAAGACCTCTGATGGCAAATCACCCACATCACCCACCTCTCCCCAT





ATGCCAGCTCTGAGAATAAACAGTGGGGCAGGCCCCCTCAAAGCCTCT





GTCCCAGCAGCGTTAGCTAGTCCTTCAGCCAGAGTTAGCACAATAGGT





TACTTAAATGACCATGATGCTGTCACCAAGGCAATCCAAGAAGCTCGG





CAAATGAAGGAGCAACTCCGACGGGAACAACAGGTGCTTGATGGGAAG





GTGGCTGTTGTGAATAGTCTGGGTCTCAATAACTGCCGAACAGAAAAG





GAAAAAACAACACTGGAGAGTCTGACTCAGCAACTGGCAGTTAAACAG





AATGAAGAAGGAAAATTTAGCCATGCAATGATGGATTTCAATCTGAGT





GGAGATTCTGATGGAAGTGCTGGAGTCTCAGAGTCAAGAATTTATAGG





GAATCCCGAGGGCGTGGTAGCAATGAACCCCACATAAAGCGTCCAATG





AATGCCTTCATGGTGTGGGCTAAAGATGAACGGAGAAAGATCCTTCAA





GCCTTTCCTGACATGCACAACTCCAACATCAGCAAGATATTGGGATCT





CGCTGGAAAGCTATGACAAACCTAGAGAAACAGCCATATTATGAGGAG





CAAGCCCGTCTCAGCAAGCAGCACCTGGAGAAGTACCCTGACTATAAG





TACAAGCCCAGGCCAAAGCGCACCTGCCTGGTGGATGGCAAAAAGCTG





CGCATTGGTGAATACAAGGCAATCATGCGCAACAGGCGGCAGGAAATG





CGGCAGTACTTCAATGTTGGGCAACAAGCACAGATCCCCATTGCCACT





GCTGGTGTTGTGTACCCTGGAGCCATCGCCATGGCTGGGATGCCCTCC





CCTCACCTGCCCTCGGAGCACTCAAGCGTGTCTAGCAGCCCAGAGCCT





GGGATGCCTGTTATCCAGAGCACTTACGGTGTGAAAGGAGAGGAGCCA





CATATCAAAGAAGAGATACAGGCCGAGGACATCAATGGAGAAATTTAT





GATGAGTACGACGAGGAAGAGGATGATCCAGATGTAGATTATGGGAGT





GACAGTGAAAACCATATTGCAGGACAAGCCAAC,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:140 under stringent hybridization conditions.


In some embodiments, SRY-box 6 (SOX6) comprises the amino acid sequence:









(SEQ ID NO: 141; NP_059978)


MGRMSSKQATSPFACAADGEDAMTQDLTSREKEEGSDQHVASHLPLHP





IMHNKPHSEELPTLVSTIQQDADWDSVLSSQQRMESENNKLCSLYSFR





NTSTSPHKPDEGSRDREIMTSVTFGTPERRKGSLADVVDTLKQKKLEE





MTRTEQEDSSCMEKLLSKDWKEKMERLNTSELLGEIKGTPESLAEKER





QLSTMITQLISLREQLLAAHDEQKKLAASQIEKQRQQMDLARQQQEQI





ARQQQQLLQQQHKINLLQQQIQVQGHMPPLMIPIFPHDQRTLAAAAAA





QQGFLFPPGITYKPGDNYPVQFIPSTMAAAAASGLSPLQLQQLYAAQL





ASMQVSPGAKMPSTPQPPNTAGTVSPTGIKNEKRGTSPVTQVKDEAAA





QPLNLSSRPKTAEPVKSPTSPTQNLFPASKTSPVNLPNKSSIPSPIGG





SLGRGSSLGKWKSQHQEETYELDILSSLNSPALFGDQDTVMKAIQEAR





KMREQIQREQQQQQPHGVDGKLSSINNMGLNSCRNEKERTRFENLGPQ





LTGKSNEDGKLGPGVIDLTRPEDAEGSKAMNGSAAKLQQYYCWPTGGA





TVAEARVYRDARGRASSEPHIKRPMNAFMVWAKDERRKILQAFPDMHN





SNISKILGSRWKSMSNQEKQPYYEEQARLSKIHLEKYPNYKYKPRPKR





TCIVDGKKLRIGEYKQLMRSRRQEMRQFFTVGQQPQIPITTGTGVVYP





GAITMATTTPSPQMTSDCSSTSASPEPSLPVIQSTYGMKTDGGSLAGN





EMINGEDEMEMYDDYEDDPKSDYSSENEAPEAVSAN,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:141.


In some embodiments, the nucleic acid sequence encoding SOX6 comprises the nucleic acid sequence:









(SEQ ID NO: 142; NM_017508)


ATGGGAAGAATGTCTTCCAAGCAAGCCACCTCTCCATTTGCCTGTGCA





GCTGATGGAGAGGATGCAATGACCCAGGATTTAACCTCAAGGGAAAAG





GAAGAGGGCAGTGATCAACATGTGGCCTCCCATCTGCCTCTGCACCCC





ATAATGCACAACAAACCTCACTCTGAGGAGCTACCAACACTTGTCAGT





ACCATTCAACAAGATGCTGACTGGGACAGCGTTCTGTCATCTCAGCAA





AGAATGGAATCAGAGAATAATAAGTTATGTTCCCTATATTCCTTCCGA





AATACCTCTACCTCACCACATAAGCCTGACGAAGGGAGTCGGGACCGT





GAGATAATGACCAGTGTTACTTTTGGAACCCCAGAGCGCCGCAAAGGG





AGTCTTGCCGATGTGGTGGACACACTGAAACAGAAGAAGCTTGAGGAA





ATGACTCGGACTGAACAAGAGGATTCCTCCTGCATGGAAAAACTACTT





TCAAAAGATTGGAAGGAAAAAATGGAAAGACTAAATACCAGTGAACTT





CTTGGAGAAATTAAAGGTACACCTGAGAGCCTGGCAGAAAAAGAACGG





CAGCTCTCCACCATGATTACCCAGCTGATCAGTTTACGGGAGCAGCTA





CTGGCAGCGCATGATGAACAGAAAAAACTGGCAGCGTCACAAATTGAG





AAACAACGGCAGCAAATGGACCTTGCTCGCCAACAGCAAGAACAGATT





GCGAGACAACAGCAGCAACTTCTGCAACAGCAGCACAAAATTAATCTC





CTGCAGCAACAGATCCAGGTTCAGGGTCACATGCCTCCGCTCATGATC





CCAATTTTTCCACATGACCAGCGGACTCTGGCAGCAGCTGCTGCTGCC





CAACAGGGATTCCTCTTCCCCCCTGGAATAACATACAAACCAGGTGAT





AACTACCCCGTACAGTTCATTCCATCAACAATGGCAGCTGCTGCTGCT





TCTGGACTCAGCCCTTTACAGCTCCAGCAGCTCTATGCCGCTCAGCTG





GCCAGCATGCAGGTGTCACCTGGAGCAAAGATGCCATCAACTCCACAG





CCACCAAACACAGCAGGGACGGTCTCACCTACTGGGATAAAAAATGAA





AAGAGAGGGACCAGCCCTGTAACTCAAGTTAAGGATGAAGCAGCAGCA





CAGCCTCTGAATCTCTCATCCCGACCCAAGACAGCAGAGCCTGTAAAG





TCCCCAACGTCTCCCACCCAGAACCTCTTCCCAGCCAGCAAAACCAGC





CCTGTCAATCTGCCAAACAAAAGCAGCATCCCTAGCCCCATTGGAGGA





AGCCTGGGAAGAGGATCCTCTTTAGGTAAATGGAAAAGTCAACACCAG





GAAGAGACTTACGAATTAGATATCCTATCTAGTCTCAACTCCCCTGCC





CTTTTTGGGGATCAGGATACAGTGATGAAAGCCATTCAGGAGGCGCGG





AAGATGCGAGAGCAGATCCAGCGGGAGCAACAGCAGCAACAGCCACAT





GGTGTTGACGGGAAACTGTCCTCCATAAATAATATGGGGCTGAACAGC





TGCAGGAATGAAAAGGAAAGAACGCGCTTTGAGAATTTGGGGCCCCAG





TTAACGGGAAAGTCAAATGAAGATGGAAAACTGGGCCCAGGTGTCATC





GACCTTACTCGGCCAGAAGATGCAGAGGGAAGTAAAGCAATGAATGGC





TCTGCAGCTAAACTACAGCAGTATTATTGTTGGCCAACAGGAGGTGCC





ACTGTGGCTGAAGCACGAGTCTACAGGGACGCCCGCGGCCGTGCCAGC





AGCGAGCCACACATTAAGCGACCAATGAATGCATTCATGGTTTGGGCA





AAGGATGAGAGGAGAAAAATCCTTCAGGCCTTCCCCGACATGCATAAC





TCCAACATTAGCAAAATCTTAGGATCTCGCTGGAAATCAATGTCCAAC





CAGGAGAAGCAACCTTATTATGAAGAGCAGGCCCGGCTAAGCAAGATC





CACTTAGAGAAGTACCCAAACTATAAATACAAACCCCGACCGAAACGC





ACCTGCATTGTTGATGGCAAAAAGCTTCGGATTGGGGAGTATAAGCAA





CTGATGAGGTCTCGGAGACAGGAGATGAGGCAGTTCTTTACTGTGGGG





CAACAGCCTCAGATTCCAATCACCACAGGAACAGGTGTTGTGTATCCT





GGTGCTATCACTATGGCAACTACCACACCATCGCCTCAGATGACATCT





GACTGCTCTAGCACCTCGGCCAGCCCGGAGCCCAGCCTCCCGGTCATC





CAGAGCACTTATGGTATGAAGACAGATGGCGGAAGCCTAGCTGGAAAT





GAAATGATCAATGGAGAGGATGAAATGGAAATGTATGATGACTATGAA





GATGACCCCAAATCAGACTATAGCAGTGAAAATGAAGCCCCGGAGGCT





GTCAGTGCCAAC,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:142 under stringent hybridization conditions.


In some embodiments, SRY-box 13 (SOX13) comprises the amino acid sequence:









(SEQ ID NO: 143; NP_005677)


MSMRSPISAQLALDGVGTMVNCTIKSEEKKEPCHEAPQGSATAAEPQP





GDPARASQDSADPQAPAQGNFRGSWDCSSPEGNGSPEPKRPGVSEAAS





GSQEKLDFNRNLKEVVPAIEKLLSSDWKERFLGRNSMEAKDVKGTQES





LAEKELQLLVMIHQLSTLRDQLLTAHSEQKNMAAMLFEKQQQQMELAR





QQQEQIAKQQQQLIQQQHKINLLQQQIQQVNMPYVMIPAFPPSHQPLP





VTPDSQLALPIQPIPCKPVEYPLQLLHSPPAPVVKRPGAMATHHPLQE





PSQPLNLTAKPKAPELPNTSSSPSLKMSSCVPRPPSHGGPTRDLQSSP





PSLPLGFLGEGDAVTKAIQDARQLLHSHSGALDGSPNTPFRKDLISLD





SSPAKERLEDGCVHPLEEAMLSCDMDGSRHFPESRNSSHIKRPMNAFM





VWAKDERRKILQAFPDMHNSSISKILGSRWKSMTNQEKQPYYEEQARL





SRQHLEKYPDYKYKPRPKRTCIVEGKRLRVGEYKALMRTRRQDARQSY





VIPPQAGQVQMSSSDVLYPRAAGMPLAQPLVEHYVPRSLDPNMPVIVN





TCSLREEGEGTDDRHSVADGEMYRYSEDEDSEGEEKSDGELVVLTD,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:143.


In some embodiments, the nucleic acid sequence encoding SOX13 comprises the nucleic acid sequence:









(SEQ ID NO: 144; NM_005686)


ATGTCCATGAGGAGCCCCATCTCTGCCCAGCTGGCCCTGGATGGCGTT





GGCACCATGGTGAACTGCACCATCAAGTCAGAGGAGAAGAAAGAGCCT





TGCCACGAGGCCCCCCAGGGCTCAGCCACTGCCGCTGAACCTCAGCCT





GGAGACCCAGCCCGGGCCTCCCAGGATAGTGCTGACCCCCAAGCTCCA





GCCCAGGGGAATTTCAGGGGCTCCTGGGACTGTAGCTCTCCAGAGGGT





AATGGGTCCCCAGAACCCAAGAGACCAGGAGTGTCGGAGGCTGCCTCT





GGAAGCCAGGAGAAGCTGGACTTCAACCGAAATTTGAAAGAAGTGGTG





CCAGCCATAGAGAAGCTGTTGTCCAGTGACTGGAAGGAGAGGTTTCTA





GGAAGGAACTCTATGGAAGCCAAAGATGTCAAAGGGACCCAAGAGAGC





CTAGCAGAGAAGGAGCTCCAGCTTCTGGTCATGATTCACCAGCTGTCC





ACCCTGCGGGACCAGCTCCTGACAGCCCACTCGGAGCAGAAGAACATG





GCTGCCATGCTGTTTGAGAAGCAGCAGCAGCAGATGGAGCTTGCCCGG





CAGCAGCAGGAGCAGATTGCAAAGCAGCAGCAGCAGCTGATTCAGCAG





CAGCATAAGATCAACCTCCTTCAGCAGCAGATCCAGCAGGTTAACATG





CCTTATGTCATGATCCCAGCCTTCCCCCCAAGCCACCAACCTCTGCCT





GTCACCCCTGACTCCCAGCTGGCCTTACCCATTCAGCCCATTCCCTGC





AAACCAGTGGAGTATCCGCTGCAGCTGCTGCACAGCCCCCCTGCCCCA





GTGGTGAAGAGGCCTGGGGCCATGGCCACCCACCACCCCCTGCAGGAG





CCCTCCCAGCCCCTGAACCTCACAGCCAAGCCCAAGGCCCCCGAGCTG





CCCAACACCTCCAGCTCCCCAAGCCTGAAGATGAGCAGCTGTGTGCCC





CGCCCCCCCAGCCATGGAGGCCCCACGCGGGACCTGCAGTCCAGCCCC





CCGAGCCTGCCTCTGGGCTTCCTTGGTGAAGGGGACGCTGTCACCAAA





GCCATCCAGGATGCTCGGCAGCTGCTGCACAGCCACAGTGGGGCCTTG





GATGGCTCCCCCAACACCCCCTTCCGTAAGGACCTCATCAGCCTGGAC





TCATCCCCAGCCAAGGAGCGGCTGGAGGACGGCTGTGTGCACCCACTG





GAGGAAGCCATGCTGAGCTGCGACATGGATGGCTCCCGCCACTTCCCC





GAGTCCCGAAACAGCAGCCACATCAAGAGGCCCATGAACGCCTTCATG





GTGTGGGCCAAGGATGAGCGGAGGAAGATCCTGCAAGCCTTCCCAGAC





ATGCACAACTCCAGCATCAGCAAGATCCTTGGATCTCGCTGGAAGTCC





ATGACCAACCAGGAGAAGCAGCCCTACTATGAGGAACAGGCGCGGCTG





AGCCGGCAGCACCTGGAGAAGTATCCTGACTACAAGTACAAGCCGCGG





CCCAAGCGCACCTGCATCGTGGAGGGCAAGCGGCTGCGCGTGGGAGAG





TACAAGGCCCTGATGAGGACCCGGCGTCAGGATGCCCGCCAGAGCTAC





GTGATCCCCCCGCAGGCTGGCCAGGTGCAGATGAGCTCCTCAGATGTC





CTGTACCCTCGGGCAGCAGGCATGCCGCTGGCACAGCCACTGGTGGAG





CACTATGTCCCTCGTAGCCTGGACCCCAACATGCCTGTGATCGTCAAC





ACCTGCAGCCTCAGAGAGGAGGGTGAGGGCACAGATGACAGGCACTCG





GTGGCTGATGGCGAGATGTACCGGTACAGCGAGGACGAGGACTCGGAG





GGCGAAGAGAAGAGCGATGGGGAGTTGGTGGTGCTCACAGAC,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:144 under stringent hybridization conditions.


In some embodiments, SRY-box 8 (SOX8) comprises the amino acid sequence:









(SEQ ID NO: 145; NP_055402)


MLDMSEARSQPPCSPSGTASSMSHVEDSDSDAPPSPAGSEGLGRAGVA





VGGARGDPAEAADERFPACIRDAVSQVLKGYDWSLVPMPVRGGGGGAL





KAKPHVKRPMNAFMVWAQAARRKLADQYPHLHNAELSKTLGKLWRLLS





ESEKRPFVEEAERLRVQHKKDHPDYKYQPRRRKSAKAGHSDSDSGAEL





GPHPGGGAVYKAEAGLGDGHHHGDHTGQTHGPPTPPTTPKTELQQAGA





KPELKLEGRRPVDSGRQNIDFSNVDISELSSEVMGTMDAFDVHEFDQY





LPLGGPAPPEPGQAYGGAYFHAGASPVWAHKSAPSASASPTETGPPRP





HIKTEQPSPGHYGDQPRGSPDYGSCSGQSSATPAAPAGPFAGSQGDYG





DLQASSYYGAYPGYAPGLYQYPCFHSPRRPYASPLLNGLALPPAHSPT





SHWDQPVYTTLTRP,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:145.


In some embodiments, the nucleic acid sequence encoding SOX8 comprises the nucleic acid sequence









(SEQ ID NO: 146; NM_014587)


ATGCTGGACATGAGCGAGGCCCGCTCCCAGCCGCCCTGCAGCCCGTCC





GGCACCGCCAGCTCCATGTCGCACGTGGAGGACTCGGACTCGGACGCG





CCGCCGTCTCCCGCCGGCTCCGAGGGCCTGGGCCGCGCGGGGGTCGCG





GTGGGGGGCGCCCGGGGCGACCCGGCGGAGGCGGCGGACGAGCGCTTC





CCGGCCTGCATCCGCGACGCCGTGTCGCAGGTGCTCAAGGGCTACGAC





TGGAGTCTGGTGCCCATGCCGGTGCGCGGCGGCGGCGGCGGCGCGCTC





AAAGCCAAGCCGCATGTGAAGCGGCCCATGAACGCATTCATGGTGTGG





GCGCAGGCGGCGCGCCGCAAGCTGGCCGACCAGTACCCGCACCTGCAC





AACGCCGAGCTCAGCAAGACGCTGGGCAAGCTGTGGCGCTTGCTGAGC





GAGAGCGAGAAGCGGCCCTTCGTGGAGGAGGCAGAGCGCCTTCGCGTG





CAGCACAAGAAGGACCACCCCGACTACAAGTACCAGCCACGGCGCAGG





AAGAGCGCCAAAGCCGGCCACAGCGACTCCGACTCGGGCGCGGAGCTG





GGACCCCACCCTGGCGGCGGTGCCGTGTACAAGGCTGAAGCAGGGCTT





GGAGATGGGCACCACCATGGCGACCACACAGGGCAGACCCACGGGCCG





CCCACCCCGCCCACCACCCCCAAGACGGAGCTGCAGCAGGCGGGCGCC





AAGCCGGAGCTGAAGCTGGAGGGACGCCGGCCGGTGGACAGCGGGCGC





CAGAACATCGACTTCAGCAATGTGGACATCTCGGAGCTCAGCAGCGAG





GTCATGGGCACCATGGACGCCTTCGACGTCCACGAGTTCGACCAGTAC





CTGCCCCTGGGCGGCCCCGCCCCACCCGAGCCGGGCCAGGCCTATGGG





GGCGCCTACTTCCACGCCGGGGCGTCCCCCGTGTGGGCCCACAAGAGT





GCCCCGTCGGCCTCCGCGTCGCCCACCGAGACGGGTCCCCCACGGCCG





CACATCAAGACGGAGCAGCCGAGCCCCGGCCACTACGGCGACCAGCCC





CGAGGCTCGCCCGACTACGGTTCCTGCAGCGGCCAGTCCAGCGCCACC





CCGGCCGCCCCCGCCGGCCCCTTCGCCGGCTCACAGGGCGACTATGGC





GACCTGCAGGCCTCCAGCTACTATGGTGCCTACCCTGGCTACGCACCC





GGCCTCTACCAGTACCCCTGCTTCCACTCGCCGCGCCGGCCCTACGCC





TCACCCCTGCTCAACGGCCTGGCCCTGCCGCCCGCCCACAGCCCCACC





AGTCACTGGGACCAGCCGGTGTACACCACCCTGACCAGGCCC,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:146 under stringent hybridization conditions.


In some embodiments, SRY-box 9 (SOX9) comprises the amino acid sequence:









(SEQ ID NO: 147; NP_000337)


MNLLDPFMKMTDEQEKGLSGAPSPTMSEDSAGSPCPSGSGSDTENTRPQ





ENTFPKGEPDLKKESEEDKFPVCIREAVSQVLKGYDWTLVPMPVRVNGS





SKNKPHVKRPMNAFMVWAQAARRKLADQYPHLHNAELSKTLGKLWRLLN





ESEKRPFVEEAERLRVQHKKDHPDYKYQPRRRKSVKNGQAEAEEATEQT





HISPNAIFKALQADSPHSSSGMSEVHSPGEHSGQSQGPPTPPTTPKTDV





QPGKADLKREGRPLPEGGRQPPIDFRDVDIGELSSDVISNIETFDVNEF





DQYLPPNGHPGVPATHGQVTYTGSYGISSTAATPASAGHVWMSKQQAPP





PPPQQPPQAPPAPQAPPQPQAAPPQQPAAPPQQPQAHTLTTLSSEPGQS





QRTHIKTEQLSPSHYSEQQQHSPQQIAYSPFNLPHYSPSYPPITRSQYD





YTDHQNSSSYYSHAAGQGTGLYSTFTYMNPAQRPMYTPIADTSGVPSIP





QTHSPQHWEQPVYTQLTRP,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:147.


In some embodiments, the nucleic acid sequence encoding SOX9 comprises the nucleic acid sequence:









(SEQ ID NO: 148; NM_000346)


ATGAATCTCCTGGACCCCTTCATGAAGATGACCGACGAGCAGGAGAAGG





GCCTGTCCGGCGCCCCCAGCCCCACCATGTCCGAGGACTCCGCGGGCTC





GCCCTGCCCGTCGGGCTCCGGCTCGGACACCGAGAACACGCGGCCCCAG





GAGAACACGTTCCCCAAGGGCGAGCCCGATCTGAAGAAGGAGAGCGAGG





AGGACAAGTTCCCCGTGTGCATCCGCGAGGCGGTCAGCCAGGTGCTCAA





AGGCTACGACTGGACGCTGGTGCCCATGCCGGTGCGCGTCAACGGCTCC





AGCAAGAACAAGCCGCACGTCAAGCGGCCCATGAACGCCTTCATGGTGT





GGGCGCAGGCGGCGCGCAGGAAGCTCGCGGACCAGTACCCGCACTTGCA





CAACGCCGAGCTCAGCAAGACGCTGGGCAAGCTCTGGAGACTTCTGAAC





GAGAGCGAGAAGCGGCCCTTCGTGGAGGAGGCGGAGCGGCTGCGCGTGC





AGCACAAGAAGGACCACCCGGATTACAAGTACCAGCCGCGGCGGAGGAA





GTCGGTGAAGAACGGGCAGGCGGAGGCAGAGGAGGCCACGGAGCAGACG





CACATCTCCCCCAACGCCATCTTCAAGGCGCTGCAGGCCGACTCGCCAC





ACTCCTCCTCCGGCATGAGCGAGGTGCACTCCCCCGGCGAGCACTCGGG





GCAATCCCAGGGCCCACCGACCCCACCCACCACCCCCAAAACCGACGTG





CAGCCGGGCAAGGCTGACCTGAAGCGAGAGGGGCGCCCCTTGCCAGAGG





GGGGCAGACAGCCCCCTATCGACTTCCGCGACGTGGACATCGGCGAGCT





GAGCAGCGACGTCATCTCCAACATCGAGACCTTCGATGTCAACGAGTTT





GACCAGTACCTGCCGCCCAACGGCCACCCGGGGGTGCCGGCCACGCACG





GCCAGGTCACCTACACGGGCAGCTACGGCATCAGCAGCACCGCGGCCAC





CCCGGCGAGCGCGGGCCACGTGTGGATGTCCAAGCAGCAGGCGCCGCCG





CCACCCCCGCAGCAGCCCCCACAGGCCCCGCCGGCCCCGCAGGCGCCCC





CGCAGCCGCAGGCGGCGCCCCCACAGCAGCCGGCGGCACCCCCGCAGCA





GCCACAGGCGCACACGCTGACCACGCTGAGCAGCGAGCCGGGCCAGTCC





CAGCGAACGCACATCAAGACGGAGCAGCTGAGCCCCAGCCACTACAGCG





AGCAGCAGCAGCACTCGCCCCAACAGATCGCCTACAGCCCCTTCAACCT





CCCACACTACAGCCCCTCCTACCCGCCCATCACCCGCTCACAGTACGAC





TACACCGACCACCAGAACTCCAGCTCCTACTACAGCCACGCGGCAGGCC





AGGGCACCGGCCTCTACTCCACCTTCACCTACATGAACCCCGCTCAGCG





CCCCATGTACACCCCCATCGCCGACACCTCTGGGGTCCCTTCCATCCCG





CAGACCCACAGCCCCCAGCACTGGGAACAACCCGTCTACACACAGCTCA





CTCGACCT,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:148 under stringent hybridization conditions.


In some embodiments, SRY-box 10 (SOX10) comprises the amino acid sequence:









(SEQ ID NO: 149; NP_008872)


MAEEQDLSEVELSPVGSEEPRCLSPGSAPSLGPDGGGGGSGLRASPGPG





ELGKVKKEQQDGEADDDKFPVCIREAVSQVLSGYDWTLVPMPVRVNGAS





KSKPHVKRPMNAFMVWAQAARRKLADQYPHLHNAELSKTLGKLWRLLNE





SDKRPFIEEAERLRMQHKKDHPDYKYQPRRRKNGKAAQGEAECPGGEAE





QGGTAAIQAHYKSAHLDHRHPGEGSPMSDGNPEHPSGQSHGPPTPPTTP





KTELQSGKADPKRDGRSMGEGGKPHIDFGNVDIGEISHEVMSNMETFDV





AELDQYLPPNGHPGHVSSYSAAGYGLGSALAVASGHSAWISKPPGVALP





TVSPPGVDAKAQVKTETAGPQGPPHYTDQPSTSQIAYTSLSLPHYGSAF





PSISRPQFDYSDHQPSGPYYGHSGQASGLYSAFSYMGPSQRPLYTAISD





PSPSGPQSHSPTHWEQPVYTTLSRP,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:149.


In some embodiments, the nucleic acid sequence encoding SOX10 comprises the nucleic acid sequence:









(SEQ ID NO: 150; NM_006941)


ATGGCGGAGGAGCAGGACCTATCGGAGGTGGAGCTGAGCCCCGTGGGCT





CGGAGGAGCCCCGCTGCCTGTCCCCGGGGAGCGCGCCCTCGCTAGGGCC





CGACGGCGGCGGCGGCGGATCGGGCCTGCGAGCCAGCCCGGGGCCAGGC





GAGCTGGGCAAGGTCAAGAAGGAGCAGCAGGACGGCGAGGCGGACGATG





ACAAGTTCCCCGTGTGCATCCGCGAGGCCGTCAGCCAGGTGCTCAGCGG





CTACGACTGGACGCTGGTGCCCATGCCCGTGCGCGTCAACGGCGCCAGC





AAAAGCAAGCCGCACGTCAAGCGGCCCATGAACGCCTTCATGGTGTGGG





CTCAGGCAGCGCGCAGGAAGCTCGCGGACCAGTACCCGCACCTGCACAA





CGCTGAGCTCAGCAAGACGCTGGGCAAGCTCTGGAGGCTGCTGAACGAA





AGTGACAAGCGCCCCTTCATCGAGGAGGCTGAGCGGCTCCGTATGCAGC





ACAAGAAAGACCACCCGGACTACAAGTACCAGCCCAGGCGGCGGAAGAA





CGGGAAGGCCGCCCAGGGCGAGGCGGAGTGCCCCGGTGGGGAGGCCGAG





CAAGGTGGGACCGCCGCCATCCAGGCCCACTACAAGAGCGCCCACTTGG





ACCACCGGCACCCAGGAGAGGGCTCCCCCATGTCAGATGGTAACCCCGA





GCACCCCTCAGGCCAGAGCCATGGCCCACCCACCCCTCCAACCACCCCG





AAGACAGAGCTGCAGTCGGGCAAGGCAGACCCGAAGCGGGACGGGCGCT





CCATGGGGGAGGGCGGGAAGCCTCACATCGACTTCGGCAACGTGGACAT





TGGTGAGATCAGCCACGAGGTAATGTCCAACATGGAGACCTTTGATGTG





GCTGAGTTGGACCAGTACCTGCCGCCCAATGGGCACCCAGGCCATGTGA





GCAGCTACTCAGCAGCCGGCTATGGGCTGGGCAGTGCCCTGGCCGTGGC





CAGTGGACACTCCGCCTGGATCTCCAAGCCACCAGGCGTGGCTCTGCCC





ACGGTCTCACCACCTGGTGTGGATGCCAAAGCCCAGGTGAAGACAGAGA





CCGCGGGGCCCCAGGGGCCCCCACACTACACCGACCAGCCATCCACCTC





ACAGATCGCCTACACCTCCCTCAGCCTGCCCCACTATGGCTCAGCCTTC





CCCTCCATCTCCCGCCCCCAGTTTGACTACTCTGACCATCAGCCCTCAG





GACCCTATTATGGCCACTCGGGCCAGGCCTCTGGCCTCTACTCGGCCTT





CTCCTATATGGGGCCCTCGCAGCGGCCCCTCTACACGGCCATCTCTGAC





CCCAGCCCCTCAGGGCCCCAGTCCCACAGCCCCACACACTGGGAGCAGC





CAGTATATACGACACTGTCCCGGCCC,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:150 under stringent hybridization conditions.


In some embodiments, SRY-box 7 (SOX7) comprises the amino acid sequence:









(SEQ ID NO: 151; NP_113627)


MASLLGAYPWPEGLECPALDAELSDGQSPPAVPRPPGDKGSESRIRRPM





NAFMVWAKDERKRLAVQNPDLHNAELSKMLGKSWKALTLSQKRPYVDEA





ERLRLQHMQDYPNYKYRPRRKKQAKRLCKRVDPGFLLSSLSRDQNALPE





KRSGSRGALGEKEDRGEYSPGTALPSLRGCYHEGPAGGGGGGTPSSVDT





YPYGLPTPPEMSPLDVLEPEQTFFSSPCQEEHGHPRRIPHLPGHPYSPE





YAPSPLHCSHPLGSLALGQSPGVSMMSPVPGCPPSPAYYSPATYHPLHS





NLQAHLGQLSPPPEHPGFDALDQLSQVELLGDMDRNEFDQYLNTPGHPD





SATGAMALSGHVPVSQVTPTGPTETSLISVLADATATYYNSYSVS,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:151.


In some embodiments, the nucleic acid sequence encoding SOX7 comprises the nucleic acid sequence:









(SEQ ID NO: 152; NM_031439)


ATGGCTTCGCTGCTGGGAGCCTACCCTTGGCCCGAGGGTCTCGAGTGCC





CGGCCCTGGACGCCGAGCTGTCGGATGGACAATCGCCGCCGGCCGTCCC





CCGGCCCCCGGGGGACAAGGGCTCCGAGAGCCGTATCCGGCGGCCCATG





AACGCCTTCATGGTTTGGGCCAAGGACGAGAGGAAACGGCTGGCAGTGC





AGAACCCGGACCTGCACAACGCCGAGCTCAGCAAGATGCTGGGAAAGTC





GTGGAAGGCGCTGACGCTGTCCCAGAAGAGGCCGTACGTGGACGAGGCG





GAGCGGCTGCGCCTGCAGCACATGCAGGACTACCCCAACTACAAGTACC





GGCCGCGCAGGAAGAAGCAGGCCAAGCGGCTGTGCAAGCGCGTGGACCC





GGGCTTCCTTCTGAGCTCCCTCTCCCGGGACCAGAACGCCCTGCCGGAG





AAGAGAAGCGGCAGCCGGGGGGCGCTGGGGGAGAAGGAGGACAGGGGTG





AGTACTCCCCCGGCACTGCCCTGCCCAGCCTCCGGGGCTGCTACCACGA





GGGGCCGGCTGGTGGTGGCGGCGGCGGCACCCCGAGCAGTGTGGACACG





TACCCGTACGGGCTGCCCACACCTCCTGAAATGTCTCCCCTGGACGTGC





TGGAGCCGGAGCAGACCTTCTTCTCCTCCCCCTGCCAGGAGGAGCATGG





CCATCCCCGCCGCATCCCCCACCTGCCAGGGCACCCGTACTCACCGGAG





TACGCCCCAAGCCCTCTCCACTGTAGCCACCCCCTGGGCTCCCTGGCCC





TTGGCCAGTCCCCCGGCGTCTCCATGATGTCCCCTGTACCCGGCTGTCC





CCCATCTCCTGCCTATTACTCCCCGGCCACCTACCACCCACTCCACTCC





AACCTCCAAGCCCACCTGGGCCAGCTTTCCCCGCCTCCTGAGCACCCTG





GCTTCGACGCCCTGGATCAACTGAGCCAGGTGGAACTCCTGGGGGACAT





GGATCGCAATGAATTCGACCAGTATTTGAACACTCCTGGCCACCCAGAC





TCCGCCACAGGGGCCATGGCCCTCAGTGGGCATGTTCCGGTCTCCCAGG





TGACACCAACGGGTCCCACAGAGACCAGCCTCATCTCCGTCCTGGCTGA





TGCCACGGCCACGTACTACAACAGCTACAGTGTGTCA,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:152 under stringent hybridization conditions.


In some embodiments, SRY-box 17 (SOX17) comprises the amino acid sequence:









(SEQ ID NO: 153; NP_071899)


MSSPDAGYASDDQSQTQSALPAVMAGLGPCPWAESLSPIGDMKVKGEAP





ANSGAPAGAAGRAKGESRIRRPMNAFMVWAKDERKRLAQQNPDLHNAEL





SKMLGKSWKALTLAEKRPFVEEAERLRVQHMQDHPNYKYRPRRRKQVKR





LKRVEGGFLHGLAEPQAAALGPEGGRVAMDGLGLQFPEQGFPAGPPLLP





PHMGGHYRDCQSLGAPPLDGYPLPTPDTSPLDGVDPDPAFFAAPMPGDC





PAAGTYSYAQVSDYAGPPEPPAGPMHPRLGPEPAGPSIPGLLAPPSALH





VYYGAMGSPGAGGGRGFQMQPQHQHQHQHQHHPPGPGQPSPPPEALPCR





DGTDPSQPAELLGEVDRTEFEQYLHFVCKPEMGLPYQGHDSGVNLPDSH





GAISSVVSDASSAVYYCNYPDV,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:153.


In some embodiments, the nucleic acid sequence encoding SOX17 comprises the nucleic acid sequence:









(SEQ ID NO: 154; NM_022454)


ATGAGCAGCCCGGATGCGGGATACGCCAGTGACGACCAGAGCCAGACCC





AGAGCGCGCTGCCCGCGGTGATGGCCGGGCTGGGCCCCTGCCCCTGGGC





CGAGTCGCTGAGCCCCATCGGGGACATGAAGGTGAAGGGCGAGGCGCCG





GCGAACAGCGGAGCACCGGCCGGGGCCGCGGGCCGAGCCAAGGGCGAGT





CCCGTATCCGGCGGCCGATGAACGCTTTCATGGTGTGGGCTAAGGACGA





GCGCAAGCGGCTGGCGCAGCAGAATCCAGACCTGCACAACGCCGAGTTG





AGCAAGATGCTGGGCAAGTCGTGGAAGGCGCTGACGCTGGCGGAGAAGC





GGCCCTTCGTGGAGGAGGCAGAGCGGCTGCGCGTGCAGCACATGCAGGA





CCACCCCAACTACAAGTACCGGCCGCGGCGGCGCAAGCAGGTGAAGCGG





CTGAAGCGGGTGGAGGGCGGCTTCCTGCACGGCCTGGCTGAGCCGCAGG





CGGCCGCGCTGGGCCCCGAGGGCGGCCGCGTGGCCATGGACGGCCTGGG





CCTCCAGTTCCCCGAGCAGGGCTTCCCCGCCGGCCCGCCGCTGCTGCCT





CCGCACATGGGCGGCCACTACCGCGACTGCCAGAGTCTGGGCGCGCCTC





CGCTCGACGGCTACCCGTTGCCCACGCCCGACACGTCCCCGCTGGACGG





CGTGGACCCCGACCCGGCTTTCTTCGCCGCCCCGATGCCCGGGGACTGC





CCGGCGGCCGGCACCTACAGCTACGCGCAGGTCTCGGACTACGCTGGCC





CCCCGGAGCCTCCCGCCGGTCCCATGCACCCCCGACTCGGCCCAGAGCC





CGCGGGTCCCTCGATTCCGGGCCTCCTGGCGCCACCCAGCGCCCTTCAC





GTGTACTACGGCGCGATGGGCTCGCCCGGGGCGGGCGGCGGGCGCGGCT





TCCAGATGCAGCCGCAACACCAGCACCAGCACCAGCACCAGCACCACCC





CCCGGGCCCCGGACAGCCGTCGCCCCCTCCGGAGGCACTGCCCTGCCGG





GACGGCACGGACCCCAGTCAGCCCGCCGAGCTCCTCGGGGAGGTGGACC





GCACGGAATTTGAACAGTATCTGCACTTCGTGTGCAAGCCTGAGATGGG





CCTCCCCTACCAGGGGCATGACTCCGGTGTGAATCTCCCCGACAGCCAC





GGGGCCATTTCCTCGGTGGTGTCCGACGCCAGCTCCGCGGTATATTACT





GCAACTATCCTGACGTG,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:154 under stringent hybridization conditions.


In some embodiments, SRY-box 18 (SOX18) comprises the amino acid sequence:









(SEQ ID NO: 155; NP_060889)


MQRSPPGYGAQDDPPARRDCAWAPGHGAAADTRGLAAGPAALAAPAAPA





SPPSPQRSPPRSPEPGRYGLSPAGRGERQAADESRIRRPMNAFMVWAKD





ERKRLAQQNPDLHNAVLSKMLGKAWKELNAAEKRPFVEEAERLRVQHLR





DHPNYKYRPRRKKQARKARRLEPGLLLPGLAPPQPPPEPFPAASGSARA





FRELPPLGAEFDGLGLPTPERSPLDGLEPGEAAFFPPPAAPEDCALRPF





RAPYAPTELSRDPGGCYGAPLAEALRTAPPAAPLAGLYYGTLGTPGPYP





GPLSPPPEAPPLESAEPLGPAADLWADVDLTEFDQYLNCSRTRPDAPGL





PYHVALAKLGPRAMSCPEESSLISALSDASSAVYYSACISGSGP,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:155.


In some embodiments, the nucleic acid sequence encoding SOX18 comprises the nucleic acid sequence:









(SEQ ID NO: 156; NM_018419)


ATGCAGAGATCGCCGCCCGGCTACGGCGCACAGGACGACCCGCCCGCCC





GCCGCGACTGTGCATGGGCCCCGGGACACGGGGCCGCCGCTGACACGCG





CGGCCTCGCCGCCGGCCCCGCCGCCCTCGCCGCGCCCGCCGCGCCCGCC





TCGCCGCCCAGCCCGCAGCGCAGTCCCCCGCGCAGCCCCGAGCCGGGGC





GCTATGGCCTCAGCCCGGCCGGCCGCGGGGAACGCCAGGCGGCAGACGA





GTCGCGCATCCGGCGGCCCATGAACGCCTTCATGGTGTGGGCAAAGGAC





GAGCGCAAGCGGCTGGCTCAGCAGAACCCGGACCTGCACAACGCGGTGC





TCAGCAAGATGCTGGGCAAAGCGTGGAAGGAGCTGAACGCGGCGGAGAA





GCGGCCCTTCGTGGAGGAAGCCGAACGGCTGCGCGTGCAGCACTTGCGC





GACCACCCCAACTACAAGTACCGGCCGCGCCGCAAGAAGCAGGCGCGCA





AGGCCCGGCGGCTGGAGCCCGGCCTCCTGCTCCCGGGATTAGCGCCCCC





GCAGCCACCGCCCGAGCCTTTCCCCGCGGCGTCTGGCTCGGCTCGCGCC





TTCCGCGAGCTGCCCCCGCTGGGCGCCGAGTTCGACGGCCTGGGGCTGC





CCACGCCCGAGCGCTCGCCTCTGGACGGCCTGGAGCCCGGCGAGGCTGC





CTTCTTCCCACCGCCCGCGGCGCCCGAGGACTGCGCGCTGCGGCCCTTC





CGCGCGCCCTACGCGCCCACCGAGTTGTCGCGGGACCCCGGCGGTTGCT





ACGGGGCTCCCCTGGCGGAGGCGCTCAGGACCGCGCCCCCCGCGGCGCC





GCTCGCTGGCCTGTACTACGGCACCCTGGGCACGCCCGGCCCGTACCCC





GGCCCGCTGTCGCCGCCGCCCGAGGCCCCGCCGCTGGAGAGCGCCGAGC





CGCTGGGGCCCGCCGCCGATCTGTGGGCCGACGTGGACCTCACCGAGTT





CGACCAGTACCTCAACTGCAGCCGGACTCGGCCCGACGCCCCCGGGCTC





CCGTACCACGTGGCACTGGCCAAACTGGGCCCGCGCGCCATGTCCTGCC





CAGAGGAGAGCAGCCTGATCTCCGCGCTGTCGGACGCCAGCAGCGCGGT





CTATTACAGCGCGTGCATCTCCGGCAGCGGACCG,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:156 under stringent hybridization conditions.


In some embodiments, SRY-box 15 (SOX15) comprises the amino acid sequence:









(SEQ ID NO: 157; NP_008873)


MALPGSSQDQAWSLEPPAATAAASSSSGPQEREGAGSPAAPGTLPLEKV





KRPMNAFMVWSSAQRRQMAQQNPKMHNSEISKRLGAQWKLLDEDEKRPF





VEEAKRLRARHLRDYPDYKYRPRRKAKSSGAGPSRCGQGRGNLASGGPL





WGPGYATTQPSRGFGYRPPSYSTAYLPGSYGSSHCKLEAPSPCSLPQSD





PRLQGELLPTYTHYLPPGSPTPYNPPLAGAPMPLTHL,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:157.


In some embodiments, the nucleic acid sequence encoding SOX15 comprises the nucleic acid sequence:









(SEQ ID NO: 158; NM_006942)


ATGGCGCTACCAGGCTCCTCACAGGACCAGGCCTGGAGCCTGGAGCCTC





CGGCTGCCACGGCTGCTGCCTCCTCATCTTCGGGACCCCAGGAGCGGGA





GGGCGCTGGGAGCCCCGCGGCCCCCGGGACGCTGCCCCTGGAGAAGGTG





AAGCGGCCGATGAACGCGTTCATGGTGTGGAGCTCCGCTCAGCGCCGCC





AGATGGCGCAGCAGAACCCCAAGATGCACAACTCCGAGATCTCCAAGCG





CCTGGGCGCGCAGTGGAAGCTGCTGGACGAGGACGAGAAGCGGCCCTTC





GTGGAGGAGGCCAAGCGGCTCCGCGCCCGACACCTGCGCGACTACCCCG





ACTACAAGTACCGGCCTCGGCGCAAGGCCAAGAGCTCGGGCGCCGGACC





TTCCCGCTGCGGACAGGGAAGAGGCAACCTGGCCAGCGGCGGCCCGCTC





TGGGGGCCGGGGTACGCGACCACCCAACCGAGCAGAGGCTTTGGGTACA





GACCCCCCAGCTACTCGACAGCCTACCTGCCTGGCAGCTATGGCTCTTC





CCACTGCAAACTGGAAGCCCCCTCACCGTGCTCCCTCCCTCAGAGTGAC





CCTAGGCTCCAGGGGGAACTGCTGCCCACCTATACCCACTACCTGCCCC





CTGGCTCTCCCACTCCATACAACCCTCCCCTTGCTGGTGCCCCCATGCC





CCTAACCCACCTC,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:158 under stringent hybridization conditions.


In some embodiments, SRY-box 30 (SOX30) comprises the amino acid sequence:









(SEQ ID NO: 159; NP_848511)


MERARPEPPPQPRPLRPAPPPLPVEGTSFWAAAMEPPPSSPTLSAAASA





TLASSCGEAVASGLQPAVRRLLQVKPEQVLLLPQPQAQNEEAAASSAQA





RLLQFRPDLRLLQPPTASDGATSRPELHPVQPLALHVKAKKQKLGPSLD





QSVGPRGAVETGPRASRVVKLEGPGPALGYFRGDEKGKLEAEEVMRDSM





QGGAGKSPAAIREGVIKTEEPERLLEDCRLGAEPASNGLVHGSAEVILA





PTSGAFGPHQQDLRIPLTLHTVPPGARIQFQGAPPSELIRLTKVPLTPV





PTKMQSLLEPSVKIETKDVPLTVLPSDAGIPDTPFSKDRNGHVKRPMNA





FMVWARIHRPALAKANPAANNAEISVQLGLEWNKLSEEQKKPYYDEAQK





IKEKHREEFPGWVYQPRPGKRKRFPLSVSNVFSGTTKNIISTNPTTVYP





YRSPTYSVVIPSLQNPITHPVGETSPAIQLPTPAVQSPSPVTLFQPSVS





SAAQVAVQDPSLPVYPALPPQRFTGPSQTDTHQLHSEATHTVKQPTPVS





LESANRISSSASTAHARFATSTIQPPREYSSVSPCPRSAPIPQASPIPH





PHVYQPPPLGHPATLFGTPPRFSFHHPYFLPGPHYFPSSTCPYSRPPFG





YGNFPSSMPECLSYYEDRYPKHEGIFSTLNRDYSFRDYSSECTHSENSR





SCENMNGTSYYNSHSHSGEENLNPVPQLDIGTLENVFTAPTSTPSSIQQ





VNVTDSDEEEEEKVLRDL,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:159.


In some embodiments, the nucleic acid sequence encoding SOX30 comprises the nucleic acid sequence:









(SEQ ID NO: 160; NM_178424)


ATGGAGAGAGCCAGACCCGAGCCGCCGCCTCAGCCGCGCCCGTTGCGTC





CCGCTCCGCCCCCGCTGCCGGTCGAGGGCACCTCCTTTTGGGCAGCAGC





CATGGAGCCCCCTCCGTCGTCTCCCACACTGAGCGCGGCAGCCAGTGCG





ACCTTGGCCTCGTCGTGCGGGGAGGCAGTGGCGTCCGGCTTACAGCCCG





CGGTGCGGCGGCTGCTGCAGGTGAAGCCAGAGCAGGTGTTGCTGCTACC





ACAGCCTCAGGCCCAGAACGAGGAAGCCGCTGCCTCGTCCGCGCAGGCG





CGGCTGTTGCAGTTCAGGCCCGACCTGCGGCTCCTGCAGCCGCCGACAG





CGTCAGACGGCGCCACCTCCAGGCCCGAGTTGCACCCGGTGCAGCCCCT





GGCGCTGCATGTCAAGGCCAAGAAGCAGAAGCTGGGGCCCAGCCTGGAT





CAGTCAGTGGGGCCTCGAGGGGCCGTCGAAACCGGTCCTAGAGCCTCCA





GGGTGGTCAAGTTGGAAGGCCCCGGGCCGGCCCTCGGCTACTTCCGAGG





GGACGAGAAGGGCAAGCTGGAGGCGGAGGAGGTCATGAGAGACTCGATG





CAAGGCGGGGCAGGCAAAAGCCCGGCAGCCATCCGAGAAGGTGTGATCA





AAACGGAGGAACCCGAGAGACTCCTCGAGGACTGCAGGCTCGGCGCGGA





GCCCGCGTCCAATGGCCTGGTTCATGGCAGCGCGGAGGTCATCTTGGCC





CCAACGTCCGGTGCCTTTGGGCCGCACCAGCAAGACCTTAGGATCCCTT





TGACGCTCCACACGGTCCCCCCTGGGGCCCGGATCCAGTTTCAGGGAGC





TCCGCCTTCAGAGCTGATAAGATTGACCAAGGTCCCCCTGACACCAGTG





CCTACTAAAATGCAGTCCCTACTGGAGCCTTCTGTAAAAATTGAAACCA





AAGATGTCCCGCTCACCGTGTTGCCCTCAGATGCAGGCATACCAGATAC





TCCCTTCAGTAAGGACAGAAATGGTCATGTGAAGCGACCCATGAACGCA





TTTATGGTTTGGGCAAGGATCCACCGACCAGCACTAGCCAAAGCTAACC





CAGCAGCCAACAATGCAGAAATCAGTGTCCAGCTTGGGTTAGAGTGGAA





CAAACTTAGTGAAGAACAAAAGAAACCCTATTACGATGAAGCACAAAAG





ATTAAGGAAAAGCACAGAGAGGAATTTCCTGGTTGGGTTTATCAGCCTC





GTCCAGGGAAGCGAAAACGATTCCCTCTAAGTGTTTCCAATGTATTTTC





TGGTACCACAAAGAATATCATCTCTACAAATCCTACAACAGTTTATCCT





TACCGCTCACCTACGTACTCTGTGGTAATTCCCAGCCTACAGAATCCCA





TCACTCATCCAGTTGGTGAAACCTCACCTGCTATCCAGCTGCCCACACC





TGCAGTCCAGAGCCCAAGCCCTGTCACACTTTTCCAGCCCAGCGTCTCC





AGTGCTGCTCAGGTGGCTGTCCAGGATCCAAGTCTACCTGTCTATCCAG





CACTCCCACCCCAACGCTTTACTGGGCCTTCCCAAACAGACACTCATCA





GCTGCATTCTGAAGCCACTCACACTGTGAAGCAACCCACTCCTGTCTCT





CTAGAGAGCGCCAACAGGATTTCAAGTAGTGCAAGTACTGCCCATGCCA





GATTTGCAACTTCGACCATCCAACCTCCTAGGGAGTATTCCAGCGTTTC





CCCTTGTCCCAGAAGTGCTCCAATCCCCCAGGCTTCTCCCATTCCACAC





CCACATGTCTACCAGCCCCCTCCCCTTGGCCATCCAGCCACACTGTTCG





GGACACCACCAAGATTCTCTTTTCATCACCCTTACTTCCTACCCGGACC





TCACTACTTCCCATCAAGTACATGCCCTTACAGTCGGCCTCCCTTTGGC





TATGGAAATTTTCCGAGTTCAATGCCAGAATGCCTTAGTTATTATGAAG





ACAGGTACCCAAAACATGAGGGTATCTTTTCAACTTTAAATAGAGACTA





TTCTTTTAGAGACTACTCAAGTGAATGCACACACAGTGAAAATTCTCGG





AGTTGTGAGAACATGAATGGAACTTCTTACTATAACAGTCATAGCCACA





GTGGGGAAGAAAACTTAAACCCTGTGCCTCAGCTGGACATTGGAACCTT





GGAGAATGTCTTCACAGCCCCGACATCAACTCCTTCTAGCATCCAGCAA





GTCAATGTCACCGACAGTGATGAGGAGGAAGAAGAAAAAGTGCTCAGGG





ATTTA,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:160 under stringent hybridization conditions.


In some embodiments, Notochord Homeobox (NOTO) comprises the amino acid sequence:









(SEQ ID NO: 161; NP_001127934)


MPSPRPRGSPPPAPSGSRVRPPRSGRSPAPRSPTGPNTPRAPGRFESPF





SVEAILARPDPCAPAASQPSGSACVHPAFWTAASLCATGGLPWACPTSW





LPAYLSVGFYPVPGPRVAPVCGLLGFGVTGLELAHCSGLWAFPDWAPTE





DLQDTERQQKRVRTMFNLEQLEELEKVFAKQHNLVGKKRAQLAARLKLT





ENQVRVWFQNRRVKYQKQQKLRAAVTSAEAASLDEPSSSSIASIQSDDA





ESGVDG,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:161.


In some embodiments, the nucleic acid sequence encoding NOTO comprises the nucleic acid sequence:









(SEQ ID NO: 162; NM_001134462)


ATGCCTAGCCCCAGGCCGCGAGGCAGCCCGCCACCCGCTCCCTCGGGCTC





TCGGGTCCGACCTCCGCGCTCTGGCCGCTCTCCGGCGCCCAGGTCCCCTA





CTGGCCCGAACACGCCCCGCGCTCCCGGACGCTTCGAGTCCCCTTTCTCG





GTCGAGGCCATCCTGGCGAGGCCCGACCCCTGCGCGCCGGCGGCCTCCCA





GCCGTCGGGCTCCGCCTGCGTCCACCCGGCCTTCTGGACCGCTGCTTCCC





TGTGCGCCACCGGGGGTCTGCCCTGGGCTTGCCCGACATCGTGGCTGCCC





GCCTACCTGAGCGTAGGTTTTTACCCTGTGCCAGGGCCGCGCGTGGCTCC





CGTCTGCGGCCTGCTGGGCTTCGGCGTCACAGGGTTGGAGCTGGCTCACT





GCTCAGGACTCTGGGCCTTCCCAGACTGGGCCCCAACGGAGGACCTACAG





GACACTGAGAGACAGCAAAAGAGAGTCCGAACTATGTTTAACTTGGAGCA





GCTGGAAGAGTTGGAGAAAGTGTTTGCAAAACAGCACAATCTGGTGGGGA





AGAAGAGAGCCCAGCTGGCAGCTCGGCTCAAACTTACAGAGAACCAGGTG





AGAGTCTGGTTCCAGAACCGCAGGGTCAAGTATCAGAAGCAGCAAAAGCT





GAGGGCAGCAGTTACATCTGCCGAGGCTGCCTCCCTGGATGAGCCTTCCA





GCAGCTCCATCGCCAGTATCCAGAGTGATGATGCCGAGTCAGGAGTGGAC





GGC,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:162 under stringent hybridization conditions.


In some embodiments, Tenomodulin (TNMD) comprises the amino acid sequence:









(SEQ ID NO: 163; NP_071427)


MAKNPPENCEDCHILNAEAFKSKKICKSLKICGLVFGILTLTLIVLFWGS





KHFWPEVPKKAYDMEHTFYSSGEKKKIYMEIDPVTRTEIFRSGNGTDETL





EVHDFKNGYTGIYFVGLQKCFIKTQIKVIPEFSEPEEEIDENEEITTTFE





QSVIWVPAEKPIENRDFLKNSKILEICDNVTMYWINPTLISVSELQDFEE





EGEDLHFPANEKKGIEQNEQWVVPQVKVEKTRHARQASEEELPINDYTEN





GIEFDPMLDERGYCCIYCRRGNRYCRRVCEPLLGYYPYPYCYQGGRVICR





VIMPCNWWVARMLGRV,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:163.


In some embodiments, the nucleic acid sequence encoding TNMD comprises the nucleic acid sequence:









(SEQ ID NO: 164; NM_022144)


ATGGCAAAGAATCCTCCAGAGAATTGTGAAGACTGTCACATTCTAAATGC





AGAAGCTTTTAAATCCAAGAAAATATGTAAATCACTTAAGATTTGTGGAC





TGGTGTTTGGTATCCTGACCCTAACTCTAATTGTCCTGTTTTGGGGGAGC





AAGCACTTCTGGCCGGAGGTACCCAAAAAAGCCTATGACATGGAGCACAC





TTTCTACAGCAGTGGAGAGAAGAAGAAGATTTACATGGAAATTGATCCTG





TGACCAGAACTGAAATATTCAGAAGCGGAAATGGCACTGATGAAACATTG





GAAGTACACGACTTTAAAAACGGATACACTGGCATCTACTTCGTGGGTCT





TCAAAAATGTTTTATCAAAACTCAGATTAAAGTGATTCCTGAATTTTCTG





AACCAGAAGAGGAAATAGATGAGAATGAAGAAATTACCACAACTTTCTTT





GAACAGTCAGTGATTTGGGTCCCAGCAGAAAAGCCTATTGAAAACCGAGA





TTTTCTTAAAAATTCCAAAATTCTGGAGATTTGTGATAACGTGACCATGT





ATTGGATCAATCCCACTCTAATATCAGTTTCTGAGTTACAAGACTTTGAG





GAGGAGGGAGAAGATCTTCACTTTCCTGCCAACGAAAAAAAAGGGATTGA





ACAAAATGAACAGTGGGTGGTCCCTCAAGTGAAAGTAGAGAAGACCCGTC





ACGCCAGACAAGCAAGTGAGGAAGAACTTCCAATAAATGACTATACTGAA





AATGGAATAGAATTTGATCCCATGCTGGATGAGAGAGGTTATTGTTGTAT





TTACTGCCGTCGAGGCAACCGCTATTGCCGCCGCGTCTGTGAACCTTTAC





TAGGCTACTACCCATATCCATACTGCTACCAAGGAGGACGAGTCATCTGT





CGTGTCATCATGCCTTGTAACTGGTGGGTGGCCCGCATGCTGGGGAGGGT





C,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:164 under stringent hybridization conditions.


In some embodiments, Human nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 (NFATc1) comprises the amino acid sequence:









(SEQ ID NO: 165; NP_765978)


MPSTSFPVPSKFPLGPAAAVFGRGETLGPAPRAGGTMKSAEEEHYGYASS





NVSPALPLPTAHSTLPAPCHNLQTSTPGIIPPADHPSGYGAALDGGPAGY





FLSSGHTRPDGAPALESPRIEITSCLGLYHNNNQFFHDVEVEDVLPSSKR





SPSTATLSLPSLEAYRDPSCLSPASSLSSRSCNSEASSYESNYSYPYASP





QTSPWQSPCVSPKTTDPEEGFPRGLGACTLLGSPRHSPSTSPRASVTEES





WLGARSSRPASPCNKRKYSLNGRQPPYSPHHSPTPSPHGSPRVSVTDDSW





LGNTTQYTSSAIVAAINALTTDSSLDLGDGVPVKSRKTTLEQPPSVALKV





EPVGEDLGSPPPPADFAPEDYSSFQHIRKGGFCDQYLAVPQHPYQWAKPK





PLSPTSYMSPTLPALDWQLPSHSGPYELRIEVQPKSHHRAHYETEGSRGA





VKASAGGHPIVQLHGYLENEPLMLQLFIGTADDRLLRPHAFYQVHRITGK





TVSTTSHEAILSNTKVLEIPLLPENSMRAVIDCAGILKLRNSDIELRKGE





TDIGRKNTRVRLVFRVHVPQPSGRTLSLQVASNPIECSQRSAQELPLVEK





QSTDSYPVVGGKKMVLSGHNFLQDSKVIFVEKAPDGHHVWEMEAKTDRDL





CKPNSLVVEIPPFRNQRITSPVHVSFYVCNGKRKRSQYQRFTYLPANGNA





IFLTVSREHERVGCFF,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:165.


In some embodiments, the nucleic acid sequence encoding NFATc1 comprises the nucleic acid sequence:









(SEQ ID NO: 166; NM_172390)


ATGCCAAGCACCAGCTTTCCAGTCCCTTCCAAGTTTCCACTTGGCCCTGC





GGCTGCGGTCTTCGGGAGAGGAGAAACTTTGGGGCCCGCGCCGCGCGCCG





GCGGCACCATGAAGTCAGCGGAGGAAGAACACTATGGCTATGCATCCTCC





AACGTCAGCCCCGCCCTGCCGCTCCCCACGGCGCACTCCACCCTGCCGGC





CCCGTGCCACAACCTTCAGACCTCCACACCGGGCATCATCCCGCCGGCGG





ATCACCCCTCGGGGTACGGGGCAGCTTTGGACGGTGGGCCCGCGGGCTAC





TTCCTCTCCTCCGGCCACACCAGGCCTGATGGGGCCCCTGCCCTGGAGAG





TCCTCGCATCGAGATAACCTCGTGCTTGGGCCTGTACCACAACAATAACC





AGTTTTTCCACGATGTGGAGGTGGAAGACGTCCTCCCTAGCTCCAAACGG





TCCCCCTCCACGGCCACGCTGAGTCTGCCCAGCCTGGAGGCCTACAGAGA





CCCCTCGTGCCTGAGCCCGGCCAGCAGCCTGTCCTCCCGGAGCTGCAACT





CAGAGGCCTCCTCCTACGAGTCCAACTACTCGTACCCGTACGCGTCCCCC





CAGACGTCGCCATGGCAGTCTCCCTGCGTGTCTCCCAAGACCACGGACCC





CGAGGAGGGCTTTCCCCGCGGGCTGGGGGCCTGCACACTGCTGGGTTCCC





CGCGGCACTCCCCCTCCACCTCGCCCCGCGCCAGCGTCACTGAGGAGAGC





TGGCTGGGTGCCCGCTCCTCCAGACCCGCGTCCCCGTGCAACAAGAGGAA





GTACAGCCTCAACGGCCGGCAGCCGCCCTACTCACCCCACCACTCGCCCA





CGCCGTCCCCGCACGGCTCCCCGCGGGTCAGCGTGACCGACGACTCGTGG





TTGGGCAACACCACCCAGTACACCAGCTCGGCCATCGTGGCCGCCATCAA





CGCGCTGACCACCGACAGCAGCCTGGACCTGGGAGATGGCGTCCCTGTCA





AGTCCCGCAAGACCACCCTGGAGCAGCCGCCCTCAGTGGCGCTCAAGGTG





GAGCCCGTCGGGGAGGACCTGGGCAGCCCCCCGCCCCCGGCCGACTTCGC





GCCCGAAGACTACTCCTCTTTCCAGCACATCAGGAAGGGCGGCTTCTGCG





ACCAGTACCTGGCGGTGCCGCAGCACCCCTACCAGTGGGCGAAGCCCAAG





CCCCTGTCCCCTACGTCCTACATGAGCCCGACCCTGCCCGCCCTGGACTG





GCAGCTGCCGTCCCACTCAGGCCCGTATGAGCTTCGGATTGAGGTGCAGC





CCAAGTCCCACCACCGAGCCCACTACGAGACGGAGGGCAGCCGGGGGGCC





GTGAAGGCGTCGGCCGGAGGACACCCCATCGTGCAGCTGCATGGCTACTT





GGAGAATGAGCCGCTGATGCTGCAGCTTTTCATTGGGACGGCGGACGACC





GCCTGCTGCGCCCGCACGCCTTCTACCAGGTGCACCGCATCACAGGGAAG





ACCGTGTCCACCACCAGCCACGAGGCCATCCTCTCCAACACCAAAGTCCT





GGAGATCCCACTCCTGCCGGAGAACAGCATGCGAGCCGTCATTGACTGTG





CCGGAATCCTGAAACTCAGAAACTCCGACATTGAACTTCGGAAAGGAGAG





ACGGACATCGGGAGGAAGAACACACGGGTACGGCTGGTGTTCCGCGTTCA





CGTCCCGCAACCCAGCGGCCGCACGCTGTCCCTGCAGGTGGCCTCCAACC





CCATCGAATGCTCCCAGCGCTCAGCTCAGGAGCTGCCTCTGGTGGAGAAG





CAGAGCACGGACAGCTATCCGGTCGTGGGCGGGAAGAAGATGGTCCTGTC





TGGCCACAACTTCCTGCAGGACTCCAAGGTCATTTTCGTGGAGAAAGCCC





CAGATGGCCACCATGTCTGGGAGATGGAAGCGAAAACTGACCGGGACCTG





TGCAAGCCGAATTCTCTGGTGGTTGAGATCCCGCCATTTCGGAATCAGAG





GATAACCAGCCCCGTTCACGTCAGTTTCTACGTCTGCAACGGGAAGAGAA





AGCGAAGCCAGTACCAGCGTTTCACCTACCTTCCCGCCAACGGTAACGCC





ATCTTTCTAACCGTAAGCCGTGAACATGAGCGCGTGGGGTGCTTTTTC,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:166 under stringent hybridization conditions.


In some embodiments, Human nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 (NFATc2) comprises the amino acid sequence:









(SEQ ID NO: 167; NP_036472)


MNAPERQPQPDGGDAPGHEPGGSPQDELDFSILFDYEYLNPNEEEPNAHK





VASPPSGPAYPDDVLDYGLKPYSPLASLSGEPPGRFGEPDRVGPQKFLSA





AKPAGASGLSPRIEITPSHELIQAVGPLRMRDAGLLVEQPPLAGVAASPR





FTLPVPGFEGYREPLCLSPASSGSSASFISDTFSPYTSPCVSPNNGGPDD





LCPQFQNIPAHYSPRTSPIMSPRTSLAEDSCLGRHSPVPRPASRSSSPGA





KRRHSCAEALVALPPGASPQRSRSPSPQPSSHVAPQDHGSPAGYPPVAGS





AVIMDALNSLATDSPCGIPPKMWKTSPDPSPVSAAPSKAGLPRHIYPAVE





FLGPCEQGERRNSAPESILLVPPTWPKPLVPAIPICSIPVTASLPPLEWP





LSSQSGSYELRIEVQPKPHHRAHYETEGSRGAVKAPTGGHPVVQLHGYME





NKPLGLQIFIGTADERILKPHAFYQVHRITGKTVTTTSYEKIVGNTKVLE





IPLEPKNNMRATIDCAGILKLRNADIELRKGETDIGRKNTRVRLVFRVHI





PESSGRIVSLQTASNPIECSQRSAHELPMVERQDTDSCLVYGGQQMILTG





QNFTSESKVVFTEKTTDGQQIWEMEATVDKDKSQPNMLFVEIPEYRNKHI





RTPVKVNFYVINGKRKRSQPQHFTYHPVPAIKTEPTDEYDPTLICSPTHG





GLGSQPYYPQHPMVAESPSCLVATMAPCQQFRTGLSSPDARYQQQNPAAV





LYQRSKSLSPSLLGYQQPALMAAPLSLADAHRSVLVHAGSQGQSSALLHP





SPTNQQASPVIHYSPTNQQLRCGSHQEFQHIMYCENFAPGTTRPGPPPVS





QGQRLSPGSYPTVIQQQNATSQRAAKNGPPVSDQKEVLPAGVTIKQEQNL





DQTYLDDELIDTHLSWIQNIL,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:167.


In some embodiments, the nucleic acid sequence encoding NFATc2 comprises the nucleic acid sequence:









ATGAACGCCCCCGAGCGGCAGCCCCAACCCGACGGCGGGGACGCCCCAGG





CCACGAGCCTGGGGGCAGCCCCCAAGACGAGCTTGACTTCTCCATCCTCT





TCGACTATGAGTATTTGAATCCGAACGAAGAAGAGCCGAATGCACATAAG





GTCGCCAGCCCACCCTCCGGACCCGCATACCCCGATGATGTCCTGGACTA





TGGCCTCAAGCCATACAGCCCCCTTGCTAGTCTCTCTGGCGAGCCCCCCG





GCCGATTCGGAGAGCCGGATAGGGTAGGGCCGCAGAAGTTTCTGAGCGCG





GCCAAGCCAGCAGGGGCCTCGGGCCTGAGCCCTCGGATCGAGATCACTCC





GTCCCACGAACTGATCCAGGCAGTGGGGCCCCTCCGCATGAGAGACGCGG





GCCTCCTGGTGGAGCAGCCGCCCCTGGCCGGGGTGGCCGCCAGCCCGAGG





TTCACCCTGCCCGTGCCCGGCTTCGAGGGCTACCGCGAGCCGCTTTGCTT





GAGCCCCGCTAGCAGCGGCTCCTCTGCCAGCTTCATTTCTGACACCTTCT





CCCCCTACACCTCGCCCTGCGTCTCGCCCAATAACGGCGGGCCCGACGAC





CTGTGTCCGCAGTTTCAAAACATCCCTGCTCATTATTCCCCCAGAACCTC





GCCAATAATGTCACCTCGAACCAGCCTCGCCGAGGACAGCTGCCTGGGCC





GCCACTCGCCCGTGCCCCGTCCGGCCTCCCGCTCCTCATCGCCTGGTGCC





AAGCGGAGGCATTCGTGCGCCGAGGCCTTGGTTGCCCTGCCGCCCGGAGC





CTCACCCCAGCGCTCCCGGAGCCCCTCGCCGCAGCCCTCATCTCACGTGG





CACCCCAGGACCACGGCTCCCCGGCTGGGTACCCCCCTGTGGCTGGCTCT





GCCGTGATCATGGATGCCCTGAACAGCCTCGCCACGGACTCGCCTTGTGG





GATCCCCCCCAAGATGTGGAAGACCAGCCCTGACCCCTCGCCGGTGTCTG





CCGCCCCATCCAAGGCCGGCCTGCCTCGCCACATCTACCCGGCCGTGGAG





TTCCTGGGGCCCTGCGAGCAGGGCGAGAGGAGAAACTCGGCTCCAGAATC





CATCCTGCTGGTTCCGCCCACTTGGCCCAAGCCGCTGGTGCCTGCCATTC





CCATCTGCAGCATCCCAGTGACTGCATCCCTCCCTCCACTTGAGTGGCCG





CTGTCCAGTCAGTCAGGCTCTTACGAGCTGCGGATCGAGGTGCAGCCCAA





GCCACATCACCGGGCCCACTATGAGACAGAAGGCAGCCGAGGGGCTGTCA





AAGCTCCAACTGGAGGCCACCCTGTGGTTCAGCTCCATGGCTACATGGAA





AACAAGCCTCTGGGACTTCAGATCTTCATTGGGACAGCTGATGAGCGGAT





CCTTAAGCCGCACGCCTTCTACCAGGTGCACCGAATCACGGGGAAAACTG





TCACCACCACCAGCTATGAGAAGATAGTGGGCAACACCAAAGTCCTGGAG





ATACCCTTGGAGCCCAAAAACAACATGAGGGCAACCATCGACTGTGCGGG





GATCTTGAAGCTTAGAAACGCCGACATTGAGCTGCGGAAAGGCGAGACGG





ACATTGGAAGAAAGAACACGCGGGTGAGACTGGTTTTCCGAGTTCACATC





CCAGAGTCCAGTGGCAGAATCGTCTCTTTACAGACTGCATCTAACCCCAT





CGAGTGCTCCCAGCGATCTGCTCACGAGCTGCCCATGGTTGAAAGACAAG





ACACAGACAGCTGCCTGGTCTATGGCGGCCAGCAAATGATCCTCACGGGG





CAGAACTTTACATCCGAGTCCAAAGTTGTGTTTACTGAGAAGACCACAGA





TGGACAGCAAATTTGGGAGATGGAAGCCACGGTGGATAAGGACAAGAGCC





AGCCCAACATGCTTTTTGTTGAGATCCCTGAATATCGGAACAAGCATATC





CGCACACCTGTAAAAGTGAACTTCTACGTCATCAATGGGAAGAGAAAACG





AAGTCAGCCTCAGCACTTTACCTACCACCCAGTCCCAGCCATCAAGACGG





AGCCCACGGATGAATATGACCCCACTCTGATCTGCAGCCCCACCCATGGA





GGCCTGGGGAGCCAGCCTTACTACCCCCAGCACCCGATGGTGGCCGAGTC





CCCCTCCTGCCTCGTGGCCACCATGGCTCCCTGCCAGCAGTTCCGCACGG





GGCTCTCATCCCCTGACGCCCGCTACCAGCAACAGAACCCAGCGGCCGTA





CTCTACCAGCGGAGCAAGAGCCTGAGCCCCAGCCTGCTGGGCTATCAGCA





GCCGGCCCTCATGGCCGCCCCGCTGTCCCTTGCGGACGCTCACCGCTCTG





TGCTGGTGCACGCCGGCTCCCAGGGCCAGAGCTCAGCCCTGCTCCACCCC





TCTCCGACCAACCAGCAGGCCTCGCCTGTGATCCACTACTCACCCACCAA





CCAGCAGCTGCGCTGCGGAAGCCACCAGGAGTTCCAGCACATCATGTACT





GCGAGAATTTCGCACCAGGCACCACCAGACCTGGCCCGCCCCCGGTCAGT





CAAGGTCAGAGGCTGAGCCCGGGTTCCTACCCCACAGTCATTCAGCAGCA





GAATGCCACGAGCCAAAGAGCCGCCAAAAACGGACCCCCGGTCAGTGACC





AAAAGGAAGTATTACCTGCGGGGGTGACCATTAAACAGGAGCAGAACTTG





GACCAGACCTACTTGGATGATGAGCTGATAGACACACACCTTAGCTGGAT





ACA















(SEQ ID NO: 168; NM_012340)



AAACATATTA,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:168 under stringent hybridization conditions.


In some embodiments, Human nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 (NFATc3) comprises the amino acid sequence:









(SEQ ID NO: 169; NP_004546)


MTTANCGAHDELDFKLVFGEDGAPAPPPPGSRPADLEPDDCASIYIFNVD





PPPSTLTTPLCLPHHGLPSHSSVLSPSFQLQSHKNYEGTCEIPESKYSPL





GGPKPFECPSIQITSISPNCHQELDAHEDDLQINDPEREFLERPSRDHLY





LPLEPSYRESSLSPSPASSISSRSWFSDASSCESLSHIYDDVDSELNEAA





ARFTLGSPLTSPGGSPGGCPGEETWHQQYGLGHSLSPRQSPCHSPRSSVT





DENWLSPRPASGPSSRPTSPCGKRRHSSAEVCYAGSLSPHHSPVPSPGHS





PRGSVTEDTWLNASVHGGSGLGPAVFPFQYCVETDIPLKTRKTSEDQAAI





LPGKLELCSDDQGSLSPARETSIDDGLGSQYPLKKDSCGDQFLSVPSPFT





WSKPKPGHTPIFRTSSLPPLDWPLPAHFGQCELKIEVQPKTHHRAHYETE





GSRGAVKASTGGHPVVKLLGYNEKPINLQMFIGTADDRYLRPHAFYQVHR





ITGKTVATASQEIIIASTKVLEIPLLPENNMSASIDCAGILKLRNSDIEL





RKGETDIGRKNTRVRLVFRVHIPQPSGKVLSLQIASIPVECSQRSAQELP





HIEKYSINSCSVNGGHEMVVTGSNFLPESKIIFLEKGQDGRPQWEVEGKI





IREKCQGAHIVLEVPPYHNPAVTAAVQVHFYLCNGKRKKSQSQRFTYTPV





LMKQEHREEIDLSSVPSLPVPHPAQTQRPSSDSGCSHDSVLSGQRSLICS





IPQTYASMVTSSHLPQLQCRDESVSKEQHMIPSPIVHQPFQVTPTPPVGS





SYQPMQTNVVYNGPTCLPINAASSQEFDSVLFQQDATLSGLVNLGCQPLS





SIPFHSSNSGSTGHLLAHTPHSVHTLPHLQSMGYHCSNTGQRSLSSPVAD





QITGQPSSQLQPITYGPSHSGSATTASPAASHPLASSPLSGPPSPQLQPM





PYQSPSSGTASSPSPATRMHSGQHSTQAQSTGQGGLSAPSSLICHSLCDP





ASFPPDGATVSIKPEPEDREPNFATIGLQDITLDDDQFISDLEHQPSGSA





EKWPNHSVLSCPAPFWRI,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:169.


In some embodiments, the nucleic acid sequence encoding NFATc3 comprises the nucleic acid sequence:









(SEQ ID NO: 170; NM_004555)


ATGACTACTGCAAACTGTGGCGCCCACGACGAGCTCGACTTCAAACTCGT





CTTTGGCGAGGACGGGGCGCCGGCGCCGCCGCCCCCGGGCTCGCGGCCTG





CAGATCTTGAGCCAGATGATTGTGCATCCATTTACATCTTTAATGTAGAT





CCACCTCCATCTACTTTAACCACACCACTTTGCTTACCACATCATGGATT





ACCGTCTCACTCTTCTGTTTTGTCACCATCGTTTCAGCTCCAAAGTCACA





AAAACTATGAAGGAACTTGTGAGATTCCTGAATCTAAATATAGCCCATTA





GGTGGTCCCAAACCCTTTGAGTGCCCAAGTATTCAAATTACATCTATCTC





TCCTAACTGTCATCAAGAATTAGATGCACATGAAGATGACCTACAGATAA





ATGACCCAGAACGGGAATTTTTGGAAAGGCCTTCTAGAGATCATCTCTAT





CTTCCTCTTGAGCCATCCTACCGGGAGTCTTCTCTTAGTCCTAGTCCTGC





CAGCAGCATCTCTTCTAGGAGTTGGTTCTCTGATGCATCTTCTTGTGAAT





CGCTTTCACATATTTATGATGATGTGGACTCAGAGTTGAATGAAGCTGCA





GCCCGATTTACCCTTGGATCCCCTCTGACTTCTCCTGGTGGCTCTCCAGG





GGGCTGCCCTGGAGAAGAAACTTGGCATCAACAGTATGGACTTGGACACT





CATTATCACCCAGGCAATCTCCTTGCCACTCTCCTAGATCCAGTGTCACT





GATGAGAATTGGCTGAGCCCCAGGCCAGCCTCAGGACCCTCATCAAGGCC





CACATCCCCCTGTGGGAAACGGAGGCACTCCAGTGCTGAAGTTTGTTATG





CTGGGTCCCTTTCACCCCATCACTCACCTGTTCCTTCACCTGGTCACTCC





CCCAGGGGAAGTGTGACAGAAGATACGTGGCTCAATGCTTCTGTCCATGG





TGGGTCAGGCCTTGGCCCTGCAGTTTTTCCATTTCAGTACTGTGTAGAGA





CTGACATCCCTCTCAAAACAAGGAAAACTTCTGAAGATCAAGCTGCCATA





CTACCAGGAAAATTAGAGCTGTGTTCAGATGACCAAGGGAGTTTATCACC





AGCCCGGGAGACTTCAATAGATGATGGCCTTGGATCTCAGTATCCTTTAA





AGAAAGATTCATGTGGTGATCAGTTTCTTTCAGTTCCTTCACCCTTTACC





TGGAGCAAACCAAAGCCTGGCCACACCCCTATATTTCGCACATCTTCATT





ACCTCCACTAGACTGGCCTTTACCAGCTCATTTTGGACAATGTGAACTGA





AAATAGAAGTGCAACCTAAAACTCATCATCGAGCCCATTATGAAACTGAA





GGTAGCCGAGGGGCAGTAAAAGCATCTACTGGGGGACATCCTGTTGTGAA





GCTCCTGGGCTATAACGAAAAGCCAATAAATCTACAAATGTTTATTGGGA





CAGCAGATGATCGATATTTACGACCTCATGCATTTTACCAGGTGCATCGA





ATCACTGGGAAGACAGTCGCTACTGCAAGCCAAGAGATAATAATTGCCAG





TACAAAAGTTCTGGAAATTCCACTTCTTCCTGAAAATAATATGTCAGCCA





GTATTGATTGTGCAGGTATTTTGAAACTCCGCAATTCAGATATAGAACTT





CGAAAAGGAGAAACTGATATTGGCAGAAAGAATACTAGAGTACGACTTGT





GTTTCGTGTACACATCCCACAGCCCAGTGGAAAAGTCCTTTCTCTGCAGA





TAGCCTCTATACCCGTTGAGTGCTCCCAGCGGTCTGCTCAAGAACTTCCT





CATATTGAGAAGTACAGTATCAACAGTTGTTCTGTAAATGGAGGTCATGA





AATGGTTGTGACTGGATCTAATTTTCTTCCAGAATCCAAAATCATTTTTC





TTGAAAAAGGACAAGATGGACGACCTCAGTGGGAGGTAGAAGGGAAGATA





ATCAGGGAAAAATGTCAAGGGGCTCACATTGTCCTTGAAGTTCCTCCATA





TCATAACCCAGCAGTTACAGCTGCAGTGCAGGTGCACTTTTATCTTTGCA





ATGGCAAGAGGAAAAAAAGCCAGTCTCAACGTTTTACTTATACACCAGTT





TTGATGAAGCAAGAACACAGAGAAGAGATTGATTTGTCTTCAGTTCCATC





TTTGCCTGTGCCTCATCCTGCTCAGACCCAGAGGCCTTCCTCTGATTCAG





GGTGTTCACATGACAGTGTACTGTCAGGACAGAGAAGTTTGATTTGCTCC





ATCCCACAAACATATGCATCCATGGTGACCTCATCCCATCTGCCACAGTT





GCAGTGTAGAGATGAGAGTGTTAGTAAAGAACAGCATATGATTCCTTCTC





CAATTGTACACCAGCCTTTTCAAGTCACACCAACACCTCCTGTGGGGTCT





TCCTATCAGCCTATGCAAACTAATGTTGTGTACAATGGACCAACTTGTCT





TCCTATTAATGCTGCCTCTAGTCAAGAATTTGATTCAGTTTTGTTTCAGC





AGGATGCAACTCTTTCTGGTTTAGTGAATCTTGGCTGTCAACCACTGTCA





TCCATACCATTTCATTCTTCAAATTCAGGCTCAACAGGACATCTCTTAGC





CCATACACCTCATTCTGTGCATACCCTGCCTCATCTGCAATCAATGGGAT





ATCATTGTTCAAATACAGGACAAAGATCTCTTTCTTCTCCAGTGGCTGAC





CAGATTACAGGTCAGCCTTCGTCTCAGTTACAACCTATTACATATGGTCC





TTCACATTCAGGGTCTGCTACAACAGCTTCCCCAGCAGCTTCTCATCCCT





TGGCTAGTTCACCGCTTTCTGGGCCACCATCTCCTCAGCTTCAGCCTATG





CCTTACCAATCTCCTAGCTCAGGAACTGCCTCATCACCGTCTCCAGCCAC





CAGAATGCATTCTGGACAGCACTCAACTCAAGCACAAAGTACGGGCCAGG





GGGGTCTTTCTGCACCTTCATCCTTAATATGTCACAGTTTGTGTGATCCA





GCGTCATTTCCACCTGATGGGGCAACTGTGAGCATTAAACCTGAACCAGA





AGATCGAGAGCCTAACTTTGCAACCATTGGTCTGCAGGACATCACTTTAG





ATGATGACCAATTTATATCTGACTTGGAACACCAGCCATCAGGTTCAGCA





GAGAAATGGCCTAACCACAGTGTGCTCTCATGTCCAGCTCCTTTCTGGAG





AATC,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:170 under stringent hybridization conditions.


In some embodiments, Human nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4 (NFATc4) comprises the amino acid sequence:









(SEQ ID NO: 171; NP_001129494)


MITTLPSLLPASLASISHRVTNLPSNSLSHNPGLSKPDFPGNSSPGLPSS





SSPGRDLGAPAGSMGAASCEDEELEFKLVFGEEKEAPPLGAGGLGEELDS





EDAPPCCRLALGEPPPYGAAPIGIPRPPPPRPGMHSPPPRPAPSPGTWES





QPARSVRLGGPGGGAGGAGGGRVLECPSIRITSISPTPEPPAALEDNPDA





WGDGSPRDYPPPEGFGGYREAGGQGGGAFFSPSPGSSSLSSWSFFSDASD





EAALYAACDEVESELNEAASRFGLGSPLPSPRASPRPVVTPEDPWSLYGP





SPGGRGPEDSWLLLSAPGPTPASPRPASPCGKRRYSSSGTPSSASPALSR





RGSLGEEGSEPPPPPPLPLARDPGSPGPFDYVGAPPAESIPQKTRRTSSE





QAVALPRSEEPASCNGKLPLGAEESVAPPGGSRKEVAGMDYLAVPSPLAW





SKARIGGHSPIFRTSALPPLDWPLPSQYEQLELRIEVQPRAHHRAHYETE





GSRGAVKAAPGGHPVVKLLGYSEKPLTLQMFIGTADERNLRPHAFYQVHR





ITGKMVATASYEAVVSGTKVLEMTLLPENNMAANIDCAGILKLRNSDIEL





RKGETDIGRKNTRVRLVFRVHVPQGGGKVVSVQAASVPIECSQRSAQELP





QVEAYSPSACSVRGGEELVLTGSN FLPDSKVVFIERGPDGKLQWEEEAT





VNRLQSNEVTLTLTVPEYSNKRVSRPVQVYFYVSNGRRKRSPTQSFRFLP





VICKEEPLPDSSLRGFPSASATPFGTDMDFSPPRPPYPSYPHEDPACETP





YLSEGFGYGMPPLYPQTGPPPSYRPGLRMFPETRGTTGCAQPPAVSFLPR





PFPSDPYGGRGSSFSLGLPFSPPAPFRPPPLPASPPLEGPFPSQSDVHPL





PAEGYNKVGPGYGPGEGAPEQEKSRGGYSSGFRDSVPIQGITLEEGGCGT





GGCECECVQEIALHVC,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:171.


In some embodiments, the nucleic acid sequence encoding NFATc4 comprises the nucleic acid sequence:









(SEQ ID NO: 172; NM_001136022)


ATGATAACCACCCTCCCATCTCTCCTACCCGCCAGCCTCGCCAGTATCTC





CCACCGAGTCACGAATCTCCCATCTAACTCCCTCTCACACAACCCAGGCC





TCTCCAAGCCTGACTTTCCCGGAAACTCCAGTCCAGGTCTTCCTTCCTCC





TCCAGCCCAGGCCGGGACCTGGGGGCTCCTGCCGGATCCATGGGGGCGGC





CAGCTGCGAGGATGAGGAGCTGGAATTTAAGCTGGTGTTCGGGGAGGAAA





AGGAGGCCCCCCCGCTGGGCGCGGGGGGATTGGGGGAAGAACTGGACTCA





GAGGATGCCCCGCCATGCTGCCGTCTGGCCTTGGGAGAGCCCCCTCCCTA





TGGCGCTGCACCTATCGGTATTCCCCGACCTCCACCCCCTCGGCCTGGCA





TGCATTCGCCACCGCCGCGACCAGCCCCCTCACCTGGCACCTGGGAGAGC





CAGCCCGCCAGGTCGGTGAGGCTGGGAGGACCAGGAGGGGGTGCTGGGGG





TGCTGGGGGTGGCCGTGTTCTCGAGTGTCCCAGCATCCGCATCACCTCCA





TCTCTCCCACGCCGGAGCCGCCAGCAGCGCTGGAGGACAACCCTGATGCC





TGGGGGGACGGCTCTCCTAGAGATTACCCCCCACCAGAAGGCTTTGGGGG





CTACAGAGAAGCAGGGGGCCAGGGTGGGGGGGCCTTCTTCAGCCCAAGCC





CTGGCAGCAGCAGCCTGTCCTCGTGGAGCTTCTTCTCCGATGCCTCTGAC





GAGGCAGCCCTGTATGCAGCCTGCGACGAGGTGGAGTCTGAGCTAAATGA





GGCGGCCTCCCGCTTTGGCCTGGGCTCCCCGCTGCCCTCGCCCCGGGCCT





CCCCTCGGCCATGGACCCCCGAAGATCCCTGGAGCCTGTATGGTCCAAGC





CCCGGAGGCCGAGGGCCAGAGGATAGCTGGCTACTCCTCAGTGCTCCTGG





GCCCACCCCAGCCTCCCCGCGGCCTGCCTCTCCATGTGGCAAGCGGCGCT





ATTCCAGCTCGGGAACCCCATCTTCAGCCTCCCCAGCTCTGTCCCGCCGT





GGCAGCCTGGGGGAAGAGGGGTCTGAGCCACCTCCACCACCCCCATTGCC





TCTGGCCCGGGACCCGGGCTCCCCTGGTCCCTTTGACTATGTGGGGGCCC





CACCAGCTGAGAGCATCCCTCAGAAGACACGGCGGACTTCCAGCGAGCAG





GCAGTGGCTCTGCCTCGGTCTGAGGAGCCTGCCTCATGCAATGGGAAGCT





GCCCTTGGGAGCAGAGGAGTCTGTGGCTCCTCCAGGAGGTTCCCGGAAGG





AGGTGGCTGGCATGGACTACCTGGCAGTGCCCTCCCCACTCGCTTGGTCC





AAGGCCCGGATTGGGGGACACAGCCCTATCTTCAGGACCTCTGCCCTACC





CCCACTGGACTGGCCTCTGCCCAGCCAATATGAGCAGCTGGAGCTGAGGA





TCGAGGTACAGCCTAGAGCCCACCACCGGGCCCACTATGAGACAGAAGGC





AGCCGTGGAGCTGTCAAAGCTGCCCCTGGCGGTCACCCCGTAGTCAAGCT





CCTAGGCTACAGTGAGAAGCCACTGACCCTACAGATGTTCATCGGCACTG





CAGATGAAAGGAACCTGCGGCCTCATGCCTTCTATCAGGTGCACCGTATC





ACAGGCAAGATGGTGGCCACGGCCAGCTATGAAGCCGTAGTCAGTGGCAC





CAAGGTGTTGGAGATGACTCTGCTGCCTGAGAACAACATGGCGGCCAACA





TTGACTGCGCGGGAATCCTGAAGCTTCGGAATTCAGACATTGAGCTTCGG





AAGGGTGAGACGGACATCGGGCGCAAAAACACACGTGTACGGCTGGTGTT





CCGGGTACACGTGCCCCAGGGCGGCGGGAAGGTCGTCTCAGTACAGGCAG





CATCGGTGCCCATCGAGTGCTCCCAGCGCTCAGCCCAGGAGCTGCCCCAG





GTGGAGGCCTACAGCCCCAGTGCCTGCTCTGTGAGAGGAGGCGAGGAACT





GGTACTGACTGGCTCCAACTTCCTGCCAGACTCCAAGGTGGTGTTCATTG





AGAGGGGTCCTGATGGGAAGCTGCAATGGGAGGAGGAGGCCACAGTGAAC





CGACTGCAGAGCAACGAGGTGACGCTGACCCTGACTGTCCCCGAGTACAG





CAACAAGAGGGTTTCCCGGCCAGTCCAGGTCTACTTTTATGTCTCCAATG





GGCGGAGGAAACGCAGTCCTACCCAGAGTTTCAGGTTTCTGCCTGTGATC





TGCAAAGAGGAGCCCCTACCGGACTCATCTCTGCGGGGTTTCCCTTCAGC





ATCGGCAACCCCCTTTGGCACTGACATGGACTTCTCACCACCCAGGCCCC





CCTACCCCTCCTATCCCCATGAAGACCCTGCTTGCGAAACTCCTTACCTA





TCAGAAGGCTTCGGCTATGGCATGCCCCCTCTGTACCCCCAGACGGGGCC





CCCACCATCCTACAGACCGGGCCTGCGGATGTTCCCTGAGACTAGGGGTA





CCACAGGTTGTGCCCAACCACCTGCAGTTTCCTTCCTTCCCCGCCCCTTC





CCTAGTGACCCGTATGGAGGGCGGGGCTCCTCTTTCTCCCTGGGGCTGCC





ATTCTCTCCGCCAGCCCCCTTTCGGCCGCCTCCTCTTCCTGCATCCCCAC





CGCTTGAAGGCCCCTTCCCTTCCCAGAGTGATGTGCATCCCCTACCTGCT





GAGGGATACAATAAGGTAGGGCCAGGCTATGGCCCTGGGGAGGGGGCTCC





GGAGCAGGAGAAATCCAGGGGTGGCTACAGCAGCGGCTTCCGAGACAGTG





TCCCTATCCAGGGTATCACGCTGGAGGAAGGTGGGTGTGGGACTGGGGGC





TGTGAGTGTGAGTGTGTGCAAGAGATTGCTCTGCATGTTTGC,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:172 under stringent hybridization conditions.


In some embodiments, Human v-ets erythroblastosis virus E26 oncogene homolog (ERG, C-1-1 is a variant) comprises the amino acid sequence:









(SEQ ID NO: 173; NP_001129626)


IQTVPDPAAHIKEALSVVSEDQSLFECAYGTPHLAKTEMTASSSSDYGQT





SKMSPRVPQQDWLSQPPARVTIKMECNPSQVNGSRNSPDECSVAKGGKMV





GSPDTVGMNYGSYMEEKHMPPPNMTTNERRVIVPADPTLWSTDHVRQWLE





WAVKEYGLPDVNILLFQNIDGKELCKMTKDDFQRLTPSYNADILLSHLHY





LRETPLPHLTSDDVDKALQNSPRLMHARNTGGAAFIFPNTSVYPEATQRI





TTRPDLPYEPPRRSAWTGHGHPTPQSKAAQPSPSTVPKTEDQRPQLDPYQ





ILGPTSSRLANPGSGQIQLWQFLLELLSDSSNSSCITWEGTNGEFKMTDP





DEVARRWGERKSKPNMNYDKLSRALRYYYDKNIMTKVHGKRYAYKFDFHG





IAQALQPHPPESSLYKYPSDLPYMGSYHAHPQKMNFVAPHPPALPVTSSS





FFAAPNPYWNSPTGGIYPNTRLPTSHMPSHLGTYY,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:173.


In some embodiments, the nucleic acid sequence encoding ERG comprises the nucleic acid sequence









(SEQ ID NO: 174; NM_001136154)


ATGATTCAGACTGTCCCGGACCCAGCAGCTCATATCAAGGAAGCCTTAT





CAGTTGTGAGTGAGGACCAGTCGTTGTTTGAGTGTGCCTACGGAACGCC





ACACCTGGCTAAGACAGAGATGACCGCGTCCTCCTCCAGCGACTATGGA





CAGACTTCCAAGATGAGCCCACGCGTCCCTCAGCAGGATTGGCTGTCTC





AACCCCCAGCCAGGGTCACCATCAAAATGGAATGTAACCCTAGCCAGGT





GAATGGCTCAAGGAACTCTCCTGATGAATGCAGTGTGGCCAAAGGCGGG





AAGATGGTGGGCAGCCCAGACACCGTTGGGATGAACTACGGCAGCTACA





TGGAGGAGAAGCACATGCCACCCCCAAACATGACCACGAACGAGCGCAG





AGTTATCGTGCCAGCAGATCCTACGCTATGGAGTACAGACCATGTGCGG





CAGTGGCTGGAGTGGGCGGTGAAAGAATATGGCCTTCCAGACGTCAACA





TCTTGTTATTCCAGAACATCGATGGGAAGGAACTGTGCAAGATGACCAA





GGACGACTTCCAGAGGCTCACCCCCAGCTACAACGCCGACATCCTTCTC





TCACATCTCCACTACCTCAGAGAGACTCCTCTTCCACATTTGACTTCAG





ATGATGTTGATAAAGCCTTACAAAACTCTCCACGGTTAATGCATGCTAG





AAACACAGGGGGTGCAGCTTTTATTTTCCCAAATACTTCAGTATATCCT





GAAGCTACGCAAAGAATTACAACTAGGCCAGATTTACCATATGAGCCCC





CCAGGAGATCAGCCTGGACCGGTCACGGCCACCCCACGCCCCAGTCGAA





AGCTGCTCAACCATCTCCTTCCACAGTGCCCAAAACTGAAGACCAGCGT





CCTCAGTTAGATCCTTATCAGATTCTTGGACCAACAAGTAGCCGCCTTG





CAAATCCAGGCAGTGGCCAGATCCAGCTTTGGCAGTTCCTCCTGGAGCT





CCTGTCGGACAGCTCCAACTCCAGCTGCATCACCTGGGAAGGCACCAAC





GGGGAGTTCAAGATGACGGATCCCGACGAGGTGGCCCGGCGCTGGGGAG





AGCGGAAGAGCAAACCCAACATGAACTACGATAAGCTCAGCCGCGCCCT





CCGTTACTACTATGACAAGAACATCATGACCAAGGTCCATGGGAAGCGC





TACGCCTACAAGTTCGACTTCCACGGGATCGCCCAGGCCCTCCAGCCCC





ACCCCCCGGAGTCATCTCTGTACAAGTACCCCTCAGACCTCCCGTACAT





GGGCTCCTATCACGCCCACCCACAGAAGATGAACTTTGTGGCGCCCCAC





CCTCCAGCCCTCCCCGTGACATCTTCCAGTTTTTTTGCTGCCCCAAACC





CATACTGGAATTCACCAACTGGGGGTATATACCCCAACACTAGGCTCCC





CACCAGCCATATGCCTTCTCATCTGGGCACTTACTAC,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:174 under stringent hybridization conditions.


In some embodiments, PGC1α comprises the amino acid sequence: MAWDMCNQDSESVWSDIECAALVGEDQPLCPDLPELDLSELDVNDLDTDSFLGGLKW CSDQSEIISNQYNNEPSNIFEKIDEENEANLLAVLTETLDSLPVDEDGLPSFDALTDGDV









(SEQ ID NO: 175; NP_037393)


TTDNEASPSSMPDGTPPPQEAEEPSLLKKLLLAPANTQLSYNECSGLST





QNHANHNHRIRTNPAIVKTENSWSNKAKSICQQQKPQRRPCSELLKYLT





TNDDPPHTKPTENRNSSRDKCTSKKKSHTQSQSQHLQAKPTTLSLPLTP





ESPNDPKGSPFENKTIERTLSVELSGTAGLTPPTTPPHKANQDNPFRAS





PKLKSSCKTVVPPPSKKPRYSESSGTQGNNSTKKGPEQSELYAQLSKSS





VLTGGHEERKTKRPSLRLFGDHDYCQSINSKTEILINISQELQDSRQLE





NKDVSSDWQGQICSSTDSDQCYLRETLEASKQVSPCSTRKQLQDQEIRA





ELNKHFGHPSQAVFDDEADKTSELRDSDFSNEQFSKLPMFINSGLAMDG





LFDDSEDESDKLSYPWDGTQSYSLFNVSPSCSSFNSPCRDSVSPPKSLF





SQRPQRMRSRSRSFSRHRSCSRSPYSRSRSRSPGSRSSSRSCYYYESSH





YRHRTHRNSPLYVRSRSRSPYSRRPRYDSYEEYQHERLKREEYRREYEK





RESERAKQRERQRQKAIEERRVIYVGKIRPDTTRTELRDRFEVFGEIEE





CTVNLRDDGDSYGFITYRYTCDAFAALENGYTLRRSNETDFELYFCGRK





QFFKSNYADLDSNSDDFDPASTKSKYDSLDFDSLLKEAQRSLRR,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:175.


In some embodiments, the nucleic acid sequence encoding PGC1a comprises the nucleic acid sequence:









(SEQ ID NO: 176; NM_013261)


ATGGCGTGGGACATGTGCAACCAGGACTCTGAGTCTGTATGGAGTGACA





TCGAGTGTGCTGCTCTGGTTGGTGAAGACCAGCCTCTTTGCCCAGATCT





TCCTGAACTTGATCTTTCTGAACTAGATGTGAACGACTTGGATACAGAC





AGCTTTCTGGGTGGACTCAAGTGGTGCAGTGACCAATCAGAAATAATAT





CCAATCAGTACAACAATGAGCCTTCAAACATATTTGAGAAGATAGATGA





AGAGAATGAGGCAAACTTGCTAGCAGTCCTCACAGAGACACTAGACAGT





CTCCCTGTGGATGAAGACGGATTGCCCTCATTTGATGCGCTGACAGATG





GAGACGTGACCACTGACAATGAGGCTAGTCCTTCCTCCATGCCTGACGG





CACCCCTCCACCCCAGGAGGCAGAAGAGCCGTCTCTACTTAAGAAGCTC





TTACTGGCACCAGCCAACACTCAGCTAAGTTATAATGAATGCAGTGGTC





TCAGTACCCAGAACCATGCAAATCACAATCACAGGATCAGAACAAACCC





TGCAATTGTTAAGACTGAGAATTCATGGAGCAATAAAGCGAAGAGTATT





TGTCAACAGCAAAAGCCACAAAGACGTCCCTGCTCGGAGCTTCTCAAAT





ATCTGACCACAAACGATGACCCTCCTCACACCAAACCCACAGAGAACAG





AAACAGCAGCAGAGACAAATGCACCTCCAAAAAGAAGTCCCACACACAG





TCGCAGTCACAACACTTACAAGCCAAACCAACAACTTTATCTCTTCCTC





TGACCCCAGAGTCACCAAATGACCCCAAGGGTTCCCCATTTGAGAACAA





GACTATTGAACGCACCTTAAGTGTGGAACTCTCTGGAACTGCAGGCCTA





ACTCCACCCACCACTCCTCCTCATAAAGCCAACCAAGATAACCCTTTTA





GGGCTTCTCCAAAGCTGAAGTCCTCTTGCAAGACTGTGGTGCCACCACC





ATCAAAGAAGCCCAGGTACAGTGAGTCTTCTGGTACACAAGGCAATAAC





TCCACCAAGAAAGGGCCGGAGCAATCCGAGTTGTATGCACAACTCAGCA





AGTCCTCAGTCCTCACTGGTGGACACGAGGAAAGGAAGACCAAGCGGCC





CAGTCTGCGGCTGTTTGGTGACCATGACTATTGCCAGTCAATTAATTCC





AAAACGGAAATACTCATTAATATATCACAGGAGCTCCAAGACTCTAGAC





AACTAGAAAATAAAGATGTCTCCTCTGATTGGCAGGGGCAGATTTGTTC





TTCCACAGATTCAGACCAGTGCTACCTGAGAGAGACTTTGGAGGCAAGC





AAGCAGGTCTCTCCTTGCAGCACAAGAAAACAGCTCCAAGACCAGGAAA





TCCGAGCCGAGCTGAACAAGCACTTCGGTCATCCCAGTCAAGCTGTTTT





TGACGACGAAGCAGACAAGACCAGTGAACTGAGGGACAGTGATTTCAGT





AATGAACAATTCTCCAAACTACCTATGTTTATAAATTCAGGACTAGCCA





TGGATGGCCTGTTTGATGACAGCGAAGATGAAAGTGATAAACTGAGCTA





CCCTTGGGATGGCACACAATCCTATTCATTGTTCAATGTGTCTCCTTCT





TGTTCTTCTTTTAACTCTCCATGTAGAGATTCTGTGTCACCACCCAAAT





CCTTATTTTCTCAAAGACCCCAAAGGATGCGCTCTCGTTCAAGGTCCTT





TTCTCGACACAGGTCGTGTTCCCGATCACCATATTCCAGGTCAAGATCA





AGGTCTCCAGGCAGTAGATCCTCTTCAAGATCCTGCTATTACTATGAGT





CAAGCCACTACAGACACCGCACGCACCGAAATTCTCCCTTGTATGTGAG





ATCACGTTCAAGATCGCCCTACAGCCGTCGGCCCAGGTATGACAGCTAC





GAGGAATATCAGCACGAGAGGCTGAAGAGGGAAGAATATCGCAGAGAGT





ATGAGAAGCGAGAGTCTGAGAGGGCCAAGCAAAGGGAGAGGCAGAGGCA





GAAGGCAATTGAAGAGCGCCGTGTGATTTATGTCGGTAAAATCAGACCT





GACACAACACGGACAGAACTGAGGGACCGTTTTGAAGTTTTTGGTGAAA





TTGAGGAGTGCACAGTAAATCTGCGGGATGATGGAGACAGCTATGGTTT





CATTACCTACCGTTATACCTGTGATGCTTTTGCTGCTCTTGAAAATGGA





TACACTTTGCGCAGGTCAAACGAAACTGACTTTGAGCTGTACTTTTGTG





GACGCAAGCAATTTTTCAAGTCTAACTATGCAGACCTAGATTCAAACTC





AGATGACTTTGACCCTGCTTCCACCAAGAGCAAGTATGACTCTCTGGAT





TTTGATAGTTTACTGAAAGAAGCTCAGAGAAGCTTGCGCAGG,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:176 under stringent hybridization conditions.


In some embodiments, Osterix (SP7) comprises the amino acid sequence:









(SEQ ID NO: 177; NP_690599)


MASSLLEEEVHYGSSPLAMLTAACSKFGGSSPLRDSTTLGKAGTKKPYS





VGSDLSASKTMGDAYPAPFTSTNGLLSPAGSPPAPTSGYANDYPPFSHS





FPGPTGTQDPGLLVPKGHSSSDCLPSVYTSLDMTHPYGSWYKAGIHAGI





SPGPGNTPTPWWDMHPGGNWLGGGQGQGDGLQGTLPTGPAQPPLNPQLP





TYPSDFAPLNPAPYPAPHLLQPGPQHVLPQDVYKPKAVGNSGQLEGSGG





AKPPRGASTGGSGGYGGSGAGRSSCDCPNCQELERLGAAAAGLRKKPIH





SCHIPGCGKVYGKASHLKAHLRWHTGERPFVCNWLFCGKRFTRSDELER





HVRTHTREKKFTCLLCSKRFTRSDHLSKHQRTHGEPGPGPPPSGPKELG





EGRSTGEEEASQTPRPSASPATPEKAPGGSPEQSNLLEI,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:177.


In some embodiments, the nucleic acid sequence encoding Osterix comprises the nucleic acid sequence:









(SEQ ID NO: 178; NM_152860)


ATGGCGTCCTCCCTGCTTGAGGAGGAAGTTCACTATGGCTCCAGTCCCC





TGGCCATGCTGACGGCAGCGTGCAGCAAATTTGGTGGCTCTAGCCCTCT





GCGGGACTCAACAACTCTGGGCAAAGCAGGCACAAAGAAGCCGTACTCT





GTGGGCAGTGACCTTTCAGCCTCCAAAACCATGGGGGATGCTTATCCAG





CCCCCTTTACAAGCACTAATGGGCTCCTTTCACCTGCAGGCAGTCCTCC





AGCACCCACCTCAGGCTATGCTAATGATTACCCTCCCTTTTCCCACTCA





TTCCCTGGGCCCACAGGCACCCAGGACCCTGGGCTACTAGTGCCCAAGG





GGCACAGCTCTTCTGACTGTCTGCCCAGTGTCTACACCTCTCTGGACAT





GACACACCCCTATGGCTCCTGGTACAAGGCAGGCATCCATGCAGGCATT





TCACCAGGCCCAGGCAACACTCCTACTCCATGGTGGGATATGCACCCTG





GAGGCAACTGGCTAGGTGGTGGGCAGGGCCAGGGTGATGGGCTGCAAGG





GACACTGCCCACAGGTCCAGCTCAGCCTCCACTGAACCCCCAGCTGCCC





ACCTACCCATCTGACTTTGCTCCCCTTAATCCAGCCCCCTACCCAGCTC





CCCACCTCTTGCAACCAGGGCCCCAGCATGTCTTGCCCCAAGATGTCTA





TAAACCCAAGGCAGTGGGAAATAGTGGGCAGCTAGAAGGGAGTGGTGGA





GCCAAACCCCCACGGGGTGCAAGCACTGGGGGTAGTGGTGGATATGGGG





GCAGTGGGGCAGGGCGCTCCTCCTGCGACTGCCCTAATTGCCAGGAGCT





AGAGCGGCTGGGAGCAGCAGCGGCTGGGCTGCGGAAGAAGCCCATCCAC





AGCTGCCACATCCCTGGCTGCGGCAAGGTGTATGGCAAGGCTTCGCACC





TGAAGGCCCACTTGCGCTGGCACACAGGCGAGAGGCCCTTCGTCTGCAA





CTGGCTCTTCTGCGGCAAGAGGTTCACTCGTTCGGATGAGCTGGAGCGT





CATGTGCGCACTCACACCCGGGAGAAGAAGTTCACCTGCCTGCTCTGCT





CCAAGCGCTTTACCCGAAGTGACCACCTGAGCAAACACCAGCGCACCCA





CGGAGAACCAGGCCCGGGTCCCCCTCCCAGTGGCCCCAAGGAGCTGGGG





GAGGGCCGCAGCACGGGGGAAGAGGAGGCCAGTCAGACGCCCCGACCTT





CTGCCTCGCCAGCAACCCCAGAGAAAGCCCCTGGAGGCAGCCCTGAGCA





GAGCAACTTGCTGGAGATC,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:178 under stringent hybridization conditions.


In some embodiments, myocyte enhancer factor 2C (MEF2C) comprises the amino acid sequence:









(SEQ ID NO: 179; NP_002388)


MGRKKIQITRIMDERNRQVTFTKRKFGLMKKAYELSVLCDCEIALIIFN





STNKLFQYASTDMDKVLLKYTEYNEPHESRTNSDIVETLRKKGLNGCDS





PDPDADDSVGHSPESEDKYRKINEDIDLMISRQRLCAVPPPNFEMPVSI





PVSSHNSLVYSNPVSSLGNPNLLPLAHPSLQRNSMSPGVTHRPPSAGNT





GGLMGGDLTSGAGTSAGNGYGNPRNSPGLLVSPGNLNKNMQAKSPPPMN





LGMNNRKPDLRVLIPPGSKNTMPSVSEDVDLLLNQRINNSQSAQSLATP





VVSVATPTLPGQGMGGYPSAISTTYGTEYSLSSADLSSLSGFNTASALH





LGSVTGWQQQHLHNMPPSALSQLGACTSTHLSQSSNLSLPSTQSLNIKS





EPVSPPRDRTTTPSRYPQHTRHEAGRSPVDSLSSCSSSYDGSDREDHRN





EFHSPIGLTRPSPDERESPSVKRMRLSEGWAT,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:179.


In some embodiments, the nucleic acid sequence encoding MEF2C comprises the nucleic acid sequence:









(SEQ ID NO: 180; NM_002397)


ATGGGGAGAAAAAAGATTCAGATTACGAGGATTATGGATGAACGTAACA





GACAGGTGACATTTACAAAGAGGAAATTTGGGTTGATGAAGAAGGCTTA





TGAGCTGAGCGTGCTGTGTGACTGTGAGATTGCGCTGATCATCTTCAAC





AGCACCAACAAGCTGTTCCAGTATGCCAGCACCGACATGGACAAAGTGC





TTCTCAAGTACACGGAGTACAACGAGCCGCATGAGAGCCGGACAAACTC





AGACATCGTGGAGACGTTGAGAAAGAAGGGCCTTAATGGCTGTGACAGC





CCAGACCCCGATGCGGACGATTCCGTAGGTCACAGCCCTGAGTCTGAGG





ACAAGTACAGGAAAATTAACGAAGATATTGATCTAATGATCAGCAGGCA





AAGATTGTGTGCTGTTCCACCTCCCAACTTCGAGATGCCAGTCTCCATC





CCAGTGTCCAGCCACAACAGTTTGGTGTACAGCAACCCTGTCAGCTCAC





TGGGAAACCCCAACCTATTGCCACTGGCTCACCCTTCTCTGCAGAGGAA





TAGTATGTCTCCTGGTGTAACACATCGACCTCCAAGTGCAGGTAACACA





GGTGGTCTGATGGGTGGAGACCTCACGTCTGGTGCAGGCACCAGTGCAG





GGAACGGGTATGGCAATCCCCGAAACTCACCAGGTCTGCTGGTCTCACC





TGGTAACTTGAACAAGAATATGCAAGCAAAATCTCCTCCCCCAATGAAT





TTAGGAATGAATAACCGTAAACCAGATCTCCGAGTTCTTATTCCACCAG





GCAGCAAGAATACGATGCCATCAGTGTCTGAGGATGTCGACCTGCTTTT





GAATCAAAGGATAAATAACTCCCAGTCGGCTCAGTCATTGGCTACCCCA





GTGGTTTCCGTAGCAACTCCTACTTTACCAGGACAAGGAATGGGAGGAT





ATCCATCAGCCATTTCAACAACATATGGTACCGAGTACTCTCTGAGTAG





TGCAGACCTGTCATCTCTGTCTGGGTTTAACACCGCCAGCGCTCTTCAC





CTTGGTTCAGTAACTGGCTGGCAACAGCAACACCTACATAACATGCCAC





CATCTGCCCTCAGTCAGTTGGGAGCTTGCACTAGCACTCATTTATCTCA





GAGTTCAAATCTCTCCCTGCCTTCTACTCAAAGCCTCAACATCAAGTCA





GAACCTGTTTCTCCTCCTAGAGACCGTACCACCACCCCTTCGAGATACC





CACAACACACGCGCCACGAGGCGGGGAGATCTCCTGTTGACAGCTTGAG





CAGCTGTAGCAGTTCGTACGACGGGAGCGACCGAGAGGATCACCGGAAC





GAATTCCACTCCCCCATTGGACTCACCAGACCTTCGCCGGACGAAAGGG





AAAGTCCCTCAGTCAAGCGCATGCGACTTTCTGAAGGATGGGCAACA,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:180 under stringent hybridization conditions.


In some embodiments, Mohawk (MKX) comprises the amino acid sequence:









(SEQ ID NO: 181; NP_775847)


MNTIVFNKLSSAVLFEDGGASERERGGRPYSGVLDSPHARPEVGIPDGP





PLKDNLGLRHRRTGARQNGGKVRHKRQALQDMARPLKQWLYKHRDNPYP





TKTEKILLALGSQMTLVQVSNWFANARRRLKNTVRQPDLSWALRIKLYN





KYVQGNAERLSVSSDDSCSEDGENPPRTHMNEGGYNTPVHHPVIKSENS





VIKAGVRPESRASEDYVAPPKYKSSLLNRYLNDSLRHVMATNTTMMGKT





RQRNHSGSFSSNEFEEELVSPSSSETEGNFVYRTDTLENGSNKGESAAN





RKGPSKDDTYWKEINAAMALTNLAQGKDKLQGTTSCIIQKSSHIAEVKT





VKVPLVQQF,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:181.


In some embodiments, the nucleic acid sequence encoding MKX comprises the nucleic acid sequence:









(SEQ ID NO: 182; NM_173576)


ATGAACACCATCGTCTTCAACAAGCTCAGCTCTGCGGTGCTGTTTGAGG





ACGGAGGCGCCTCGGAGCGGGAGCGGGGTGGCCGGCCCTACAGCGGTGT





CCTGGACAGTCCTCACGCCCGCCCCGAGGTGGGCATTCCCGACGGCCCG





CCCCTCAAGGACAACCTCGGCCTGAGACACCGGAGGACCGGCGCCCGGC





AGAATGGCGGGAAGGTGAGGCACAAGCGGCAGGCCCTGCAAGACATGGC





GCGACCCCTCAAGCAGTGGCTTTACAAGCACCGTGACAACCCGTACCCC





ACCAAGACCGAGAAGATACTCTTGGCCCTCGGCTCGCAGATGACGCTAG





TGCAGGTGTCAAATTGGTTTGCTAATGCAAGACGTCGGCTTAAGAATAC





CGTTCGACAGCCAGATTTAAGCTGGGCTTTGAGAATAAAGTTATACAAC





AAGTATGTTCAAGGCAATGCTGAACGGCTTAGCGTAAGCAGTGATGACT





CATGTTCTGAAGATGGAGAAAATCCTCCAAGAACCCACATGAACGAAGG





GGGCTATAATACCCCAGTTCACCATCCTGTGATTAAAAGTGAGAATTCG





GTCATCAAAGCGGGAGTGAGGCCAGAGTCACGGGCCAGTGAGGACTACG





TGGCACCCCCCAAATACAAGAGCAGCTTGTTGAACCGTTACCTTAATGA





CTCTTTGAGACATGTCATGGCCACGAACACTACCATGATGGGAAAAACA





AGGCAAAGAAACCACTCGGGATCTTTTAGCTCCAATGAATTTGAGGAAG





AATTAGTGTCTCCATCGTCATCAGAAACTGAAGGCAACTTTGTCTATCG





CACAGACACTCTGGAAAATGGATCCAATAAGGGTGAAAGCGCAGCTAAC





AGAAAAGGACCAAGCAAGGATGACACGTATTGGAAGGAGATCAACGCAG





CTATGGCCTTAACAAATCTTGCACAGGGAAAGGACAAACTGCAGGGAAC





TACCAGCTGCATCATCCAGAAGTCGTCCCATATAGCAGAAGTAAAGACT





GTCAAAGTGCCGCTGGTGCAGCAGTTT,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:182 under stringent hybridization conditions.


In some embodiments, Iroquois homeobox 1 (IRX1) comprises the amino acid sequence:









(SEQ ID NO: 183; NP_077313)


MSFPQLGYPQYLSAAGPGAYGGERPGVLAAAAAAAAAASSGRPGAAELG





GGAGAAAVTSVLGMYAAAGPYAGAPNYSAFLPYAADLSLFSQMGSQYEL





KDNPGVHPATFAAHTAPAYYPYGQFQYGDPGRPKNATRESTSTLKAWLN





EHRKNPYPTKGEKIMLAIITKMTLTQVSTWFANARRRLKKENKVTWGAR





SKDQEDGALFGSDTEGDPEKAEDDEEIDLESIDIDKIDEHDGDQSNEDD





EDKAEAPHAPAAPSALARDQGSPLAAADVLKPQDSPLGLAKEAPEPGST





RLLSPGAAAGGLQGAPHGKPKIWSLAETATSPDGAPKASPPPPAGHPGA





HGPSAGAPLQHPAFLPSHGLYTCHIGKFSNVVTNSAFLAQGSLLNMRSF





LGVGAPHAAPHGPHLPAPPPPQPPVAIAPGALNGDKASVRSSPTLPERD





LVPRPDSPAQQLKSPFQPVRDNSLAPQEGTPRILAALPSA,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:183.


In some embodiments, the nucleic acid sequence encoding IRX1 comprises the nucleic acid sequence:









(SEQ ID NO: 184; NM_024337)


ATGTCCTTCCCGCAGCTGGGCTACCCGCAGTACCTGAGCGCCGCGGGGC


CGGGCGCCTACGGCGGCGAGCGCCCGGGGGTGCTGGCCGCGGCCGCTGC


GGCGGCTGCCGCCGCCTCGTCGGGCCGACCGGGGGCCGCGGAGCTGGGC


GGCGGGGCAGGCGCGGCTGCAGTCACCTCGGTGCTGGGCATGTACGCGG


CGGCGGGGCCGTACGCGGGCGCGCCCAACTACAGCGCCTTCCTGCCCTA





CGCCGCGGATCTCAGCCTCTTCTCGCAGATGGGCTCGCAGTATGAACTG





AAGGACAACCCTGGGGTGCACCCCGCCACCTTCGCAGCCCACACGGCGC





CGGCTTATTACCCCTACGGCCAGTTCCAATACGGGGACCCCGGGCGGCC





CAAGAACGCCACCCGCGAGAGCACCAGCACGCTCAAGGCCTGGCTCAAC





GAGCACCGCAAGAATCCCTACCCCACCAAGGGCGAGAAGATCATGCTGG





CCATCATCACCAAGATGACCCTCACGCAGGTCTCCACCTGGTTCGCCAA





CGCGCGCCGGCGCCTCAAGAAGGAGAACAAGGTGACATGGGGAGCGCGC





AGCAAGGACCAGGAAGATGGAGCGCTCTTCGGCAGCGACACCGAGGGCG





ACCCGGAGAAGGCCGAGGACGACGAGGAGATCGACCTGGAAAGCATCGA





CATTGACAAGATCGACGAGCACGATGGCGACCAGAGCAACGAGGATGAC





GAGGACAAGGCCGAGGCTCCGCACGCGCCCGCAGCCCCTTCTGCTCTTG





CCCGGGACCAAGGCTCGCCGCTGGCAGCAGCCGACGTTCTCAAGCCCCA





GGACTCGCCCTTGGGCCTGGCAAAGGAGGCCCCAGAGCCGGGCAGCACG





CGCCTGCTGAGCCCCGGCGCTGCAGCGGGCGGCCTGCAGGGTGCGCCGC





ACGGCAAGCCCAAGATCTGGTCGCTGGCGGAGACAGCCACGAGCCCCGA





CGGTGCGCCCAAGGCTTCGCCACCACCACCCGCGGGCCACCCCGGCGCG





CACGGGCCCTCCGCCGGGGCGCCGCTGCAACACCCCGCCTTCCTGCCTA





GCCACGGACTGTACACCTGCCACATCGGCAAGTTCTCCAACTGGACCAA





CAGCGCATTCCTCGCACAGGGCTCCCTGCTCAACATGCGCTCCTTCCTG





GGCGTTGGCGCTCCCCACGCCGCGCCCCATGGCCCTCACCTTCCTGCAC





CTCCACCACCGCAGCCGCCGGTCGCTATTGCCCCGGGGGCACTCAATGG





AGACAAGGCCTCGGTCCGCAGCAGCCCCACGCTCCCAGAGAGAGACCTC





GTCCCCAGGCCAGATTCGCCGGCACAGCAGTTAAAGTCGCCCTTCCAGC





CGGTACGCGACAACTCTCTGGCCCCGCAGGAGGGAACGCCGCGGATCCT





AGCAGCCCTCCCGTCCGCC,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:184 under stringent hybridization conditions.


In some embodiments, iroquois homeobox 2 (IRX2) comprises the amino acid sequence:









(SEQ ID NO: 185; NP_150366)


MSYPQGYLYQAPGSLALYSCPAYGASALAAPRSEELARSASGSAFSPYP





GSAAFTAQAATGFGSPLQYSADAAAAAAGFPSYMGAPYDAHTTGMTGAI





SYHPYGSAAYPYQLNDPAYRKNATRDATATLKAWLNEHRKNPYPTKGEK





IMLAIITKMTLTQVSTWFANARRRLKKENKMTWAPRNKSEDEDEDEGDA





TRSKDESPDKAQEGTETSAEDEGISLHVDSLTDHSCSAESDGEKLPCRA





GDPLCESGSECKDKYDDLEDDEDDDEEGERGLAPPKPVTSSPLTGLEAP





LLSPPPEAAPRGGRKTPQGSRTSPGAPPPASKPKLWSLAEIATSDLKQP





SLGPGCGPPGLPAAAAPASTGAPPGGSPYPASPLLGRPLYYTSPFYGNY





TNYGNLNAALQGQGLLRYNSAAAAPGEALHTAPKAASDAGKAGAHPLES





HYRSPGGGYEPKKDASEGCTVVGGGVQPYL,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:185.


In some embodiments, the nucleic acid sequence encoding IRX2 comprises the nucleic acid sequence:









(SEQ ID NO: 186; NM_033267)


ATGTCCTACCCGCAGGGCTACCTGTACCAGGCGCCCGGCTCGCTGGCGC





TCTACTCGTGCCCGGCCTACGGCGCGTCGGCTTTGGCGGCTCCGCGCAG





CGAGGAGCTGGCGCGCTCGGCGTCGGGCTCGGCGTTCAGCCCCTACCCG





GGCTCGGCGGCCTTCACGGCGCAGGCGGCCACCGGCTTCGGGAGCCCGC





TGCAGTACTCGGCCGACGCCGCCGCCGCCGCCGCCGGCTTCCCGTCCTA





CATGGGCGCACCCTACGACGCGCACACCACCGGCATGACCGGCGCCATC





AGCTACCACCCGTACGGCAGCGCGGCCTACCCGTACCAGCTCAACGACC





CCGCGTACCGCAAGAACGCCACGCGGGACGCCACGGCCACTCTCAAGGC





CTGGCTCAACGAGCACCGCAAGAACCCCTACCCCACCAAGGGCGAGAAG





ATCATGCTAGCCATCATCACCAAGATGACCCTCACCCAGGTCTCCACCT





GGTTCGCCAACGCGCGCCGGCGCCTCAAGAAGGAGAACAAGATGACCTG





GGCCCCGAGAAACAAAAGCGAAGATGAGGACGAGGACGAGGGCGACGCT





ACCAGAAGCAAGGACGAGAGTCCCGACAAGGCGCAGGAGGGCACGGAGA





CCTCGGCAGAGGACGAAGGGATCAGCCTGCACGTGGACTCGCTCACGGA





TCACTCGTGCTCGGCCGAGTCGGACGGGGAGAAGCTTCCGTGCCGCGCC





GGGGACCCCCTGTGCGAATCGGGCTCGGAGTGCAAGGACAAGTATGACG





ACCTGGAGGACGACGAGGACGACGACGAGGAGGGCGAGCGGGGCCTGGC





GCCGCCCAAGCCCGTGACCTCGTCGCCGCTTACCGGCTTGGAGGCGCCG





CTGCTGAGCCCCCCGCCCGAGGCCGCGCCCCGCGGTGGCCGCAAGACGC





CCCAGGGCAGCCGGACGTCTCCGGGCGCGCCGCCCCCCGCCAGCAAGCC





CAAGCTGTGGTCGCTGGCCGAGATCGCCACGTCGGACCTCAAGCAGCCG





AGCCTGGGCCCGGGCTGCGGGCCACCGGGGCTGCCCGCGGCCGCCGCGC





CGGCCTCAACCGGGGCACCGCCAGGAGGCTCGCCCTACCCTGCCTCGCC





GCTGCTGGGCCGCCCCCTCTACTACACGTCGCCCTTCTACGGCAACTAC





ACAAACTACGGGAACTTGAACGCGGCGCTGCAGGGCCAGGGTCTCCTGC





GGTACAACTCTGCGGCCGCGGCCCCCGGCGAGGCCCTGCACACCGCGCC





AAAGGCGGCCAGCGACGCGGGCAAGGCGGGCGCGCACCCGCTCGAGTCC





CACTACCGGTCCCCGGGCGGCGGCTACGAGCCCAAGAAAGATGCCAGCG





AGGGCTGCACCGTGGTTGGCGGGGGCGTCCAGCCCTACCTA,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:186 under stringent hybridization conditions.


In some embodiments, iroquois homeobox 3 (IRX3) comprises the amino acid sequence:









(SEQ ID NO: 187; NP_077312)


MSFPQLGYQYIRPLYPSERPGAAGGSGGSAGARGGLGAGASELNASGSL





SNVLSSVYGAPYAAAAAAAAAQGYGAFLPYAAELPIFPQLGAQYELKDS





PGVQHPAAAAAFPHPHPAFYPYGQYQFGDPSRPKNATRESTSTLKAWLN





EHRKNPYPTKGEKIMLAIITKMTLTQVSTWFANARRRLKKENKMTWAPR





SRTDEEGNAYGSEREEEDEEEDEEDGKRELELEEEELGGEEEDTGGEGL





ADDDEDEEIDLENLDGAATEPELSLAGAARRDGDLGLGPISDSKNSDSE





DSSEGLEDRPLPVLSLAPAPPPVAVASPSLPSPPVSLDPCAPAPAPASA





LQKPKIWSLAETATSPDNPRRSPPGAGGSPPGAAVAPSALQLSPAAAAA





AAHRLVSAPLGKFPAWTNRPFPGPPPGPRPHPLSLLGSAPPHLLGLPGA





AGHPAAAAAFARPAEPEGGTDRCSALEVEKKLLKTAFQPVPRRPQNHLD





AALVLSALSSS,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:187.


In some embodiments, the nucleic acid sequence encoding IRX3 comprises the nucleic acid sequence









(SEQ ID NO: 188; NM_024336)


ATGTCCTTCCCCCAGCTGGGATACCAATACATCCGCCCGCTTTACCCGT





CCGAGCGCCCGGGGGCCGCTGGCGGCAGCGGCGGCAGCGCGGGGGCCCG





GGGCGGCCTGGGTGCCGGAGCCTCGGAGCTGAACGCCTCGGGGTCCCTG





TCCAACGTGCTCTCGTCCGTGTACGGGGCGCCCTACGCCGCGGCCGCTG





CGGCCGCCGCCGCCCAAGGCTACGGCGCCTTCCTGCCCTACGCCGCGGA





GCTGCCCATCTTCCCGCAGCTGGGCGCGCAGTATGAGCTGAAGGACAGC





CCCGGGGTGCAGCATCCGGCCGCGGCTGCCGCGTTTCCGCACCCGCACC





CCGCCTTCTACCCGTATGGCCAGTACCAGTTCGGGGACCCGTCCCGTCC





CAAGAACGCCACCAGGGAGAGCACCAGCACGCTGAAGGCCTGGCTCAAC





GAGCACCGCAAGAACCCCTACCCCACCAAGGGCGAGAAGATCATGCTGG





CCATCATCACCAAGATGACCCTCACCCAGGTGTCCACCTGGTTCGCCAA





CGCGCGCCGGCGCCTCAAGAAGGAGAATAAGATGACTTGGGCGCCTCGC





AGCCGCACTGACGAGGAGGGAAACGCTTATGGGAGCGAGCGCGAGGAGG





AAGACGAAGAGGAGGACGAGGAGGACGGCAAACGCGAGCTAGAGCTGGA





GGAGGAGGAGCTCGGGGGGGAGGAGGAGGACACGGGGGGCGAGGGCCTG





GCTGACGACGACGAGGACGAGGAGATCGATTTGGAGAACTTAGACGGCG





CGGCCACCGAGCCTGAGCTGTCCCTGGCTGGGGCGGCGCGCAGGGATGG





CGACCTAGGCCTGGGACCCATTTCGGACTCCAAAAATAGCGACTCGGAA





GATAGCTCTGAGGGCTTAGAGGACCGGCCACTACCGGTCCTGAGTCTGG





CTCCAGCGCCACCACCAGTGGCCGTGGCCTCGCCGTCTCTGCCGTCGCC





CCCCGTGAGCCTGGACCCCTGCGCTCCCGCACCAGCCCCCGCCTCCGCC





CTGCAGAAGCCCAAGATCTGGTCCCTCGCGGAGACTGCCACAAGCCCGG





ACAACCCGCGCCGCTCGCCTCCCGGCGCGGGGGGGTCTCCACCGGGGGC





AGCGGTCGCGCCTTCCGCCCTGCAGCTCTCTCCGGCCGCCGCCGCCGCC





GCCGCTCACAGACTGGTCTCAGCGCCGCTGGGCAAGTTCCCGGCTTGGA





CCAACCGGCCGTTTCCAGGCCCACCGCCCGGCCCCCGCCCGCACCCGCT





CTCCCTGCTGGGCTCTGCCCCTCCGCACCTGCTGGGACTTCCCGGAGCC





GCGGGCCACCCGGCTGCCGCCGCCGCCTTCGCTCGGCCAGCGGAGCCCG





AAGGCGGAACAGATCGCTGTAGTGCCTTGGAAGTGGAGAAAAAGTTACT





CAAGACAGCTTTCCAGCCCGTGCCCAGGCGGCCCCAGAACCATCTGGAC





GCCGCCCTGGTCTTATCGGCTCTCTCCTCATCC,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:188 under stringent hybridization conditions.


In some embodiments, iroquois homeobox 4 (IRX4) comprises the amino acid sequence:









(SEQ ID NO: 189; NP_057442)


MSYPQFGYPYSSAPQFLMATNSLSTCCESGGRTLADSGPAASAQAPVYC





PVYESRLLATARHELNSAAALGVYGGPYGGSQGYGNYVTYGSEASAFYS





LNSFDSKDGSGSAHGGLAPATAAYYPYEPALGQYPYDRYGTMDSGTRRK





NATRETTSTLKAWLQEHRKNPYPTKGEKIMLAIITKMTLTQVSTWFANA





RRRLKKENKMTWPPRNKCADEKRPYAEGEEEEGGEEEAREEPLKSSKNA





EPVGKEEKELELSDLDDFDPLEAEPPACELKPPFHSLDGGLERVPAAPD





GPVKEASGALRMSLAAGGGAALDEDLERARSCLRSAAAGPEPLPGAEGG





PQVCEAKLGFVPAGASAGLEAKPRIWSLAHTATAAAAAATSLSQTEFPS





CMLKRQGPAAPAAVSSAPATSPSVALPHSGALDRHQDSPVTSLRNWVDG





VFHDPILRHSTLNQAWATAKGALLDPGPLGRSLGAGANVLTAPLARAFP





PAVPQDAPAAGAARELLALPKAGGKPFCA,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:189.


In some embodiments, the nucleic acid sequence encoding IRX4 comprises the nucleic acid sequence:









(SEQ ID NO: 190: NM_016358)


ATGTCCTACCCGCAGTTTGGATACCCCTACTCCTCGGCTCCCCAGTTCT





TGATGGCCACCAACTCCCTGAGCACGTGCTGCGAGTCCGGAGGCCGCAC





GCTGGCGGACTCCGGGCCCGCCGCCTCGGCCCAGGCGCCGGTCTACTGC





CCGGTCTACGAGAGCCGGCTGCTGGCCACCGCGCGCCACGAGCTCAACT





CGGCCGCGGCGCTGGGCGTCTATGGGGGTCCCTATGGCGGATCGCAGGG





CTATGGCAACTACGTGACCTACGGCTCGGAGGCGTCCGCCTTCTACTCG





CTGAACAGCTTTGATTCCAAGGATGGTTCGGGATCTGCGCATGGGGGCC





TGGCACCAGCCACTGCCGCCTACTACCCTTACGAGCCAGCTCTGGGCCA





GTACCCCTATGACAGGTATGGAACCATGGACAGCGGCACGCGGCGCAAG





AACGCCACGCGCGAGACCACCAGCACGCTCAAGGCCTGGCTGCAGGAGC





ACCGCAAGAACCCCTACCCCACCAAGGGCGAGAAGATCATGCTGGCCAT





CATCACCAAGATGACCCTCACACAGGTCTCCACCTGGTTCGCCAACGCG





CGCCGGCGCCTCAAGAAGGAGAACAAGATGACGTGGCCGCCGCGGAACA





AGTGCGCAGACGAGAAGCGGCCCTACGCGGAGGGCGAGGAGGAGGAGGG





GGGCGAGGAGGAGGCGCGGGAGGAGCCCCTCAAGAGCTCCAAGAACGCA





GAGCCCGTGGGCAAAGAGGAGAAGGAGCTGGAGCTTAGTGACTTGGACG





ACTTCGACCCGCTGGAAGCAGAGCCGCCGGCGTGCGAGCTGAAGCCGCC





CTTCCACTCCCTGGACGGCGGTCTGGAGCGCGTCCCCGCCGCGCCCGAC





GGCCCGGTCAAGGAGGCCTCAGGCGCGCTCCGGATGTCTCTGGCCGCGG





GTGGCGGAGCTGCTCTGGACGAGGACCTGGAGAGGGCCCGGAGCTGTCT





CCGCAGCGCGGCGGCCGGGCCGGAGCCACTGCCGGGCGCAGAGGGCGGC





CCTCAGGTCTGCGAGGCCAAGCTGGGGTTTGTGCCGGCGGGGGCGTCGG





CAGGCCTGGAGGCTAAGCCGCGCATCTGGTCCCTGGCCCACACAGCCAC





CGCCGCCGCCGCCGCCGCCACCTCCCTGAGCCAGACTGAGTTTCCGTCG





TGCATGCTCAAGCGCCAAGGTCCCGCGGCCCCTGCGGCTGTGTCCTCCG





CGCCCGCCACGTCCCCGTCTGTGGCCCTTCCCCACTCTGGCGCCCTGGA





CAGGCACCAGGACTCCCCGGTAACCAGTCTCAGAAACTGGGTGGACGGG





GTCTTCCACGACCCCATCCTCAGGCACAGCACTTTGAACCAGGCCTGGG





CCACCGCCAAGGGCGCCCTCCTGGACCCCGGGCCTCTGGGACGCTCGCT





GGGGGCGGGCGCGAACGTGCTGACTGCACCCCTGGCCCGCGCCTTTCCG





CCTGCCGTGCCCCAGGACGCCCCAGCTGCAGGCGCCGCCAGGGAGCTGC





TCGCCCTGCCCAAGGCCGGCGGCAAACCCTTCTGCGCC,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:190 under stringent hybridization conditions.


In some embodiments, iroquois homeobox 5 (IRX5) comprises the amino acid sequence:









(SEQ ID NO: 191; NP_005844)


MSYPQGYLYQPSASLALYSCPAYSTSVISGPRTDELGRSSSGSAFSPYA





GSTAFTAPSPGYNSHLQYGADPAAAAAAAFSSYVGSPYDHTPGMAGSLG





YHPYAAPLGSYPYGDPAYRKNATRDATATLKAWLNEHRKNPYPTKGEKI





MLAIITKMTLTQVSTWFANARRRLKKENKMTWTPRNRSEDEEEEENIDL





EKNDEDEPQKPEDKGDPEGPEAGGAEQKAASGCERLQGPPTPAGKETEG





SLSDSDFKEPPSEGRLDALQGPPRTGGPSPAGPAAARLAEDPAPHYPAG





APAPGPHPAAGEVPPGPGGPSVIHSPPPPPPPAVLAKPKLWSLAEIATS





SDKVKDGGGGNEGSPCPPCPGPIAGQALGGSRASPAPAPSRSPSAQCPF





PGGTVLSRPLYYTAPFYPGYTNYGSFGHLHGHPGPGPGPTTGPGSHFNG





LNQTVLNRADALAKDPKMLRSQSQLDLCKDSPYELKKGMSDI,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:191.


In some embodiments, the nucleic acid sequence encoding IRX5 comprises the nucleic acid sequence:









(SEQ ID NO: 192; NM_005853)


ATGTCCTATCCGCAGGGCTACTTGTACCAGCCGTCCGCCTCGCTGGCGC





TCTACTCGTGCCCGGCGTACAGCACCAGCGTCATTTCGGGGCCCCGCAC





GGATGAGCTCGGCCGCTCTTCTTCGGGCTCCGCGTTCTCGCCCTACGCT





GGCTCGACTGCCTTCACGGCGCCCTCGCCGGGCTACAACTCGCACCTCC





AGTACGGCGCCGACCCCGCGGCCGCCGCCGCCGCCGCCTTCTCCTCGTA





CGTGGGCTCTCCCTACGACCACACACCCGGCATGGCGGGCTCCTTGGGG





TACCATCCTTACGCGGCGCCCCTGGGATCGTACCCTTACGGGGACCCAG





CGTACCGGAAGAACGCCACAAGGGACGCCACGGCTACCCTCAAGGCCTG





GCTCAACGAGCACCGCAAGAACCCCTACCCCACCAAGGGCGAGAAGATC





ATGCTGGCCATCATCACCAAGATGACCCTCACCCAGGTGTCCACCTGGT





TCGCCAACGCGCGCCGGCGCCTCAAGAAAGAGAATAAAATGACGTGGAC





GCCGCGGAACCGCAGCGAGGACGAGGAAGAGGAGGAGAACATTGACCTG





GAGAAGAACGACGAGGACGAGCCCCAGAAGCCCGAGGACAAGGGCGACC





CCGAGGGCCCCGAAGCAGGAGGAGCTGAGCAGAAGGCGGCTTCGGGCTG





CGAACGGCTTCAGGGACCACCCACCCCTGCAGGCAAGGAGACGGAGGGC





AGCCTCAGCGACTCGGATTTTAAGGAGCCGCCCTCGGAGGGCCGCCTCG





ACGCGCTGCAGGGCCCCCCCCGCACCGGCGGGCCCTCCCCGGCTGGGCC





AGCGGCGGCGCGGCTGGCGGAGGACCCGGCCCCTCACTACCCCGCCGGA





GCGCCGGCGCCCGGCCCGCATCCAGCCGCGGGCGAGGTGCCTCCGGGTC





CCGGCGGGCCCTCGGTTATCCATTCGCCGCCTCCGCCGCCGCCTCCTGC





GGTGCTCGCCAAGCCCAAACTGTGGTCTTTGGCAGAGATCGCCACATCG





TCGGACAAGGTCAAGGACGGGGGCGGCGGGAACGAGGGCTCTCCATGCC





CACCGTGTCCCGGGCCCATAGCCGGGCAAGCCCTAGGAGGCAGCCGGGC





GTCGCCGGCCCCGGCGCCGTCACGCTCGCCCTCGGCGCAGTGTCCTTTT





CCAGGCGGGACGGTGCTGTCCCGGCCTCTCTACTACACCGCGCCCTTCT





ATCCCGGCTACACGAACTATGGCTCCTTCGGACACCTTCATGGCCACCC





GGGGCCCGGGCCAGGCCCCACAACCGGTCCGGGGTCTCATTTCAATGGA





TTAAACCAGACCGTGTTGAACCGAGCGGACGCTTTGGCTAAAGACCCGA





AAATGTTGCGGAGCCAGTCTCAGCTAGACCTGTGCAAAGACTCTCCCTA





TGAATTGAAGAAAGGTATGTCCGACATT,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:192 under stringent hybridization conditions.


In some embodiments, iroquois homeobox 6 (IRX6) comprises the amino acid sequence









(SEQ ID NO: 193; NP_077311)


MSFPHFGHPYRGASQFLASASSSTTCCESTQRSVSDVASGSTPAPALCC





APYDSRLLGSARPELGAALGIYGAPYAAAAAAQSYPGYLPYSPEPPSLY





GALNPQYEFKEAAGSFTSSLAQPGAYYPYERTLGQYQYERYGAVELSGA





GRRKNATRETTSTLKAWLNEHRKNPYPTKGEKIMLAIITKMTLTQVSTW





FANARRRLKKENKMTWAPKNKGGEERKAEGGEEDSLGCLTADTKEVTAS





QEARGLRLSDLEDLEEEEEEEEEAEDEEVVATAGDRLTEFRKGAQSLPG





PCAAAREGRLERRECGLAAPRFSFNDPSGSEEADFLSAETGSPRLTMHY





PCLEKPRIWSLAHTATASAVEGAPPARPRPRSPECRMIPGQPPASARRL





SVPRDSACDESSCIPKAFGNPKFALQGLPLNCAPCPRRSEPVVQCQYPS





GAEAG,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:193.


In some embodiments, the nucleic acid sequence encoding IRX6 comprises the nucleic acid sequence:









(SEQ ID NO: 194; NM_024335)


ATGTCCTTCCCACACTTTGGACACCCGTACCGCGGCGCTTCCCAGTTTC





TGGCGTCGGCAAGTTCCAGCACCACATGCTGCGAATCTACCCAACGCTC





TGTCTCAGATGTGGCATCAGGCTCCACCCCAGCGCCCGCTCTCTGCTGC





GCACCCTACGATAGTCGACTGCTGGGCAGTGCGCGACCGGAGCTGGGCG





CCGCCTTGGGCATCTATGGAGCACCCTATGCGGCCGCTGCAGCTGCCCA





GAGCTACCCTGGCTACCTGCCCTATAGCCCAGAGCCCCCCTCACTGTAT





GGGGCACTGAATCCACAGTATGAATTTAAGGAGGCTGCAGGGAGTTTTA





CATCCAGCCTGGCACAACCAGGAGCCTATTATCCCTATGAGCGGACTCT





GGGGCAGTACCAATATGAACGGTATGGCGCAGTGGAATTGAGTGGCGCC





GGTCGCCGAAAGAACGCGACCCGGGAGACCACCAGTACACTCAAGGCCT





GGCTCAACGAGCACCGCAAAAACCCCTACCCCACTAAGGGTGAGAAGAT





CATGCTGGCCATCATCACCAAGATGACCCTCACCCAGGTGTCCACCTGG





TTCGCCAACGCACGCCGGCGCCTCAAGAAAGAGAACAAAATGACATGGG





CGCCCAAGAACAAAGGTGGGGAGGAGAGGAAGGCAGAGGGAGGAGAGGA





GGACTCACTAGGCTGCCTAACTGCTGACACCAAAGAAGTTACTGCTAGC





CAGGAGGCCCGGGGGCTCCGGCTGAGTGACCTGGAAGACCTGGAGGAAG





AGGAGGAGGAGGAGGAGGAAGCTGAAGACGAGGAGGTAGTGGCCACAGC





TGGGGACAGGCTGACGGAGTTCCGAAAGGGCGCGCAGTCACTGCCTGGG





CCGTGCGCTGCAGCTCGAGAGGGCCGATTGGAGCGCAGGGAGTGCGGCC





TGGCTGCGCCCCGCTTCTCCTTCAATGACCCTTCCGGATCGGAAGAAGC





TGACTTCCTCTCGGCGGAGACAGGCAGCCCTAGGTTGACCATGCACTAC





CCATGCTTGGAGAAACCGCGCATCTGGTCTCTGGCGCACACCGCGACAG





CCAGCGCTGTTGAAGGTGCACCCCCAGCCCGGCCTAGGCCACGAAGTCC





TGAGTGCCGTATGATTCCTGGACAGCCTCCTGCCTCTGCCCGGCGACTC





TCAGTCCCCAGAGACTCCGCGTGCGACGAGTCTTCCTGCATACCCAAAG





CCTTTGGAAACCCCAAGTTTGCCCTGCAGGGACTACCGCTGAACTGTGC





GCCGTGCCCGCGGAGGAGCGAGCCTGTAGTGCAGTGCCAGTACCCGTCT





GGAGCAGAAGCAGGT,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:194 under stringent hybridization conditions.


In some embodiments, Scleraxis (SCX) comprises the amino acid sequence:









(SEQ ID NO: 195; NP_001073983)


MSFATLRPAPPGRYLYPEVSPLSEDEDRGSDSSGSDEKPCRVHAARCGL





QGARRRAGGRRAGGGGPGGRPGREPRQRHTANARERDRTNSVNTAFTAL





RTLIPTEPADRKLSKIETLRLASSYISHLGNVLLAGEACGDGQPCHSGP





AFFHAARAGSPPPPPPPPPARDGENTQPKQICTFCLSNQRKLSKDRDRK





TAIRS,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:195.


In some embodiments, the nucleic acid sequence encoding SCX comprises the nucleic acid sequence:









(SEQ ID NO: 196; NM_001080514)


ATGTCCTTCGCCACGCTGCGCCCGGCGCCGCCGGGCCGCTACCTGTACC





CCGAGGTGAGCCCGCTGTCGGAGGACGAGGACCGCGGCAGCGACAGCTC





GGGCTCCGACGAGAAACCCTGTCGCGTGCACGCGGCGCGCTGCGGCCTC





CAGGGCGCCCGGCGGAGGGCGGGGGGCCGGCGGGCCGGGGGCGGGGGGC





CAGGGGGCCGGCCAGGCCGTGAGCCCCGGCAGCGGCACACGGCGAACGC





GCGCGAGCGAGACCGCACCAACAGCGTGAACACGGCCTTCACGGCGCTG





CGCACGCTGATCCCCACCGAGCCCGCCGACCGCAAGCTCTCCAAGATTG





AGACGCTGCGCCTGGCCTCCAGCTACATCTCGCACCTGGGCAACGTGCT





GCTGGCGGGCGAGGCCTGCGGCGACGGACAGCCCTGCCACTCCGGGCCC





GCCTTCTTCCACGCGGCGCGCGCCGGCAGCCCCCCGCCGCCGCCCCCGC





CGCCTCCCGCCCGCGACGGCGAGAACACCCAGCCCAAACAGATCTGCAC





CTTCTGCCTCAGCAACCAGAGAAAGTTGAGCAAGGACCGCGACAGAAAG





ACAGCGATTCGCAGT,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:196 under stringent hybridization conditions.


In some embodiments, runt-related transcription factor 1 (RUNX1) comprises the amino acid sequence:









(SEQ ID NO: 197; NP_001745)


MASDSIFESFPSYPQCFMRECILGMNPSRDVHDASTSRRFTPPSTALSP





GKMSEALPLGAPDAGAALAGKLRSGDRSMVEVLADHPGELVRTDSPNFL





CSVLPTHWRCNKTLPIAFKVVALGDVPDGTLVTVMAGNDENYSAELRNA





TAAMKNQVARFNDLRFVGRSGRGKSFTLTITVFTNPPQVATYHRAIKIT





VDGPREPRRHRQKLDDQTKPGSLSFSERLSELEQLRRTAMRVSPHHPAP





TPNPRASLNHSTAFNPQPQSQMQDTRQIQPSPPWSYDQSYQYLGSIASP





SVHPATPISPGRASGMTTLSAELSSRLSTAPDLTAFSDPRQFPALPSIS





DPRMHYPGAFTYSPTPVTSGIGIGMSAMGSATRYHTYLPPPYPGSSQAQ





GGPFQASSPSYHLYYGASAGSYQFSMVGGERSPPRILPPCTNASTGSAL





LNPSLPNQSDVVEAEGSHSNSPTNMAPSARLEEAVWRPY,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:197.


In some embodiments, the nucleic acid sequence encoding RUNX1 comprises the nucleic acid sequence:









(SEQ ID NO: 198; NM_001754)


ATGGCTTCAGACAGCATATTTGAGTCATTTCCTTCGTACCCACAGTGCT





TCATGAGAGAATGCATACTTGGAATGAATCCTTCTAGAGACGTCCACGA





TGCCAGCACGAGCCGCCGCTTCACGCCGCCTTCCACCGCGCTGAGCCCA





GGCAAGATGAGCGAGGCGTTGCCGCTGGGCGCCCCGGACGCCGGCGCTG





CCCTGGCCGGCAAGCTGAGGAGCGGCGACCGCAGCATGGTGGAGGTGCT





GGCCGACCACCCGGGCGAGCTGGTGCGCACCGACAGCCCCAACTTCCTC





TGCTCCGTGCTGCCTACGCACTGGCGCTGCAACAAGACCCTGCCCATCG





CTTTCAAGGTGGTGGCCCTAGGGGATGTTCCAGATGGCACTCTGGTCAC





TGTGATGGCTGGCAATGATGAAAACTACTCGGCTGAGCTGAGAAATGCT





ACCGCAGCCATGAAGAACCAGGTTGCAAGATTTAATGACCTCAGGTTTG





TCGGTCGAAGTGGAAGAGGGAAAAGCTTCACTCTGACCATCACTGTCTT





CACAAACCCACCGCAAGTCGCCACCTACCACAGAGCCATCAAAATCACA





GTGGATGGGCCCCGAGAACCTCGAAGACATCGGCAGAAACTAGATGATC





AGACCAAGCCCGGGAGCTTGTCCTTTTCCGAGCGGCTCAGTGAACTGGA





GCAGCTGCGGCGCACAGCCATGAGGGTCAGCCCACACCACCCAGCCCCC





ACGCCCAACCCTCGTGCCTCCCTGAACCACTCCACTGCCTTTAACCCTC





AGCCTCAGAGTCAGATGCAGGATACAAGGCAGATCCAACCATCCCCACC





GTGGTCCTACGATCAGTCCTACCAATACCTGGGATCCATTGCCTCTCCT





TCTGTGCACCCAGCAACGCCCATTTCACCTGGACGTGCCAGCGGCATGA





CAACCCTCTCTGCAGAACTTTCCAGTCGACTCTCAACGGCACCCGACCT





GACAGCGTTCAGCGACCCGCGCCAGTTCCCCGCGCTGCCCTCCATCTCC





GACCCCCGCATGCACTATCCAGGCGCCTTCACCTACTCCCCGACGCCGG





TCACCTCGGGCATCGGCATCGGCATGTCGGCCATGGGCTCGGCCACGCG





CTACCACACCTACCTGCCGCCGCCCTACCCCGGCTCGTCGCAAGCGCAG





GGAGGCCCGTTCCAAGCCAGCTCGCCCTCCTACCACCTGTACTACGGCG





CCTCGGCCGGCTCCTACCAGTTCTCCATGGTGGGCGGCGAGCGCTCGCC





GCCGCGCATCCTGCCGCCCTGCACCAACGCCTCCACCGGCTCCGCGCTG





CTCAACCCCAGCCTCCCGAACCAGAGCGACGTGGTGGAGGCCGAGGGCA





GCCACAGCAACTCCCCCACCAACATGGCGCCCTCCGCGCGCCTGGAGGA





GGCCGTGTGGAGGCCCTAC,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:198 under stringent hybridization conditions.


In some embodiments, runt-related transcription factor 2 (RUNX2) comprises the amino acid sequence:









(SEQ ID NO: 199; NP_001019801)


MLHSPHKQPQNHKCGANFLQEDSKKSLVFKWLISAGHYQPPRPTESFKA





ASSIYNRGYKFYLKKKGGTMASNSLFSTVTPCQQNFFWDPSTSRRFSPP





SSSLQPGKMSDVSPVVAAQQQQQQQQQQQQQQQQQQQQQQQEAAAAAAA





AAAAAAAAAAVPRLRPPHDNRTMVEIIADHPAELVRTDSPNFLCSVLPS





HWRCNKTLPVAFKVVALGEVPDGTVVTVMAGNDENYSAELRNASAVMKN





QVARFNDLRFVGRSGRGKSFTLTITVFTNPPQVATYHRAIKVTVDGPRE





PRRHRQKLDDSKPSLFSDRLSDLGRIPHPSMRVGVPPQNPRPSLNSAPS





PFNPQGQSQITDPRQAQSSPPWSYDQSYPSYLSQMTSPSIHSTTPLSST





RGTGLPAITDVPRRISDDDTATSDFCLWPSTLSKKSQAGASELGPFSDP





RQFPSISSLTESRFSNPRMHYPATFTYTPPVTSGMSLGMSATTHYHTYL





PPPYPGSSQSQSGPFQTSSTPYLYYGTSSGSYQFPMVPGGDRSPSRMLP





PCTTTSNGSTLLNPNLPNQNDGVDADGSHSSSPTVLNSSGRMDESVWRP





Y,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:199.


In some embodiments, the nucleic acid sequence encoding RUNX2 comprises the nucleic acid sequence









(SEQ ID NO: 200; NM_001024630)


ATGCTTCATTCGCCTCACAAACAACCACAGAACCACAAGTGCGGTGCAA





ACTTTCTCCAGGAGGACAGCAAGAAGTCTCTGGTTTTTAAATGGTTAAT





CTCCGCAGGTCACTACCAGCCACCGAGACCAACAGAGTCATTTAAGGCT





GCAAGCAGTATTTACAACAGAGGGTACAAGTTCTATCTGAAAAAAAAAG





GAGGGACTATGGCATCAAACAGCCTCTTCAGCACAGTGACACCATGTCA





GCAAAACTTCTTTTGGGATCCGAGCACCAGCCGGCGCTTCAGCCCCCCC





TCCAGCAGCCTGCAGCCCGGCAAAATGAGCGACGTGAGCCCGGTGGTGG





CTGCGCAACAGCAGCAGCAACAGCAGCAGCAGCAACAGCAGCAGCAGCA





GCAGCAACAGCAGCAGCAGCAGCAGGAGGCGGCGGCGGCGGCTGCGGCG





GCGGCGGCGGCTGCGGCGGCGGCAGCTGCAGTGCCCCGGTTGCGGCCGC





CCCACGACAACCGCACCATGGTGGAGATCATCGCCGACCACCCGGCCGA





ACTCGTCCGCACCGACAGCCCCAACTTCCTGTGCTCGGTGCTGCCCTCG





CACTGGCGCTGCAACAAGACCCTGCCCGTGGCCTTCAAGGTGGTAGCCC





TCGGAGAGGTACCAGATGGGACTGTGGTTACTGTCATGGCGGGTAACGA





TGAAAATTATTCTGCTGAGCTCCGGAATGCCTCTGCTGTTATGAAAAAC





CAAGTAGCAAGGTTCAACGATCTGAGATTTGTGGGCCGGAGTGGACGAG





GCAAGAGTTTCACCTTGACCATAACCGTCTTCACAAATCCTCCCCAAGT





AGCTACCTATCACAGAGCAATTAAAGTTACAGTAGATGGACCTCGGGAA





CCCAGAAGGCACAGACAGAAGCTTGATGACTCTAAACCTAGTTTGTTCT





CTGACCGCCTCAGTGATTTAGGGCGCATTCCTCATCCCAGTATGAGAGT





AGGTGTCCCGCCTCAGAACCCACGGCCCTCCCTGAACTCTGCACCAAGT





CCTTTTAATCCACAAGGACAGAGTCAGATTACAGACCCCAGGCAGGCAC





AGTCTTCCCCGCCGTGGTCCTATGACCAGTCTTACCCCTCCTACCTGAG





CCAGATGACGTCCCCGTCCATCCACTCTACCACCCCGCTGTCTTCCACA





CGGGGCACTGGGCTTCCTGCCATCACCGATGTGCCTAGGCGCATTTCAG





ATGATGACACTGCCACCTCTGACTTCTGCCTCTGGCCTTCCACTCTCAG





TAAGAAGAGCCAGGCAGGTGCTTCAGAACTGGGCCCTTTTTCAGACCCC





AGGCAGTTCCCAAGCATTTCATCCCTCACTGAGAGCCGCTTCTCCAACC





CACGAATGCACTATCCAGCCACCTTTACTTACACCCCGCCAGTCACCTC





AGGCATGTCCCTCGGTATGTCCGCCACCACTCACTACCACACCTACCTG





CCACCACCCTACCCCGGCTCTTCCCAAAGCCAGAGTGGACCCTTCCAGA





CCAGCAGCACTCCATATCTCTACTATGGCACTTCGTCAGGATCCTATCA





GTTTCCCATGGTGCCGGGGGGAGACCGGTCTCCTTCCAGAATGCTTCCG





CCATGCACCACCACCTCGAATGGCAGCACGCTATTAAATCCAAATTTGC





CTAACCAGAATGATGGTGTTGACGCTGATGGAAGCCACAGCAGTTCCCC





AACTGTTTTGAATTCTAGTGGCAGAATGGATGAATCTGTTTGGCGACCA





TAT,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:200 under stringent hybridization conditions.


In some embodiments, runt-related transcription factor 3 (RUNX3) comprises the amino acid sequence:









(SEQ ID NO: 201; NP_001026850)


MASNSIFDSFPTYSPTFIRDPSTSRRFTPPSPAFPCGGGGGKMGENSGA





LSAQAAVGPGGRARPEVRSMVDVLADHAGELVRTDSPNFLCSVLPSHWR





CNKTLPVAFKVVALGDVPDGTVVTVMAGNDENYSAELRNASAVMKNQVA





RFNDLRFVGRSGRGKSFTLTITVFTNPTQVATYHRAIKVTVDGPREPRR





HRQKLEDQTKPFPDRFGDLERLRMRVTPSTPSPRGSLSTTSHFSSQPQT





PIQGTSELNPFSDPRQFDRSFPTLPTLTESRFPDPRMHYPGAMSAAFPY





SATPSGTSISSLSVAGMPATSRFHHTYLPPPYPGAPQNQSGPFQANPSP





YHLYYGTSSGSYQFSMVAGSSSGGDRSPTRMLASCTSSAASVAAGNLMN





PSLGGQSDGVEADGSHSNSPTALSTPGRMDEAVWRPY,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:201.


In some embodiments, the nucleic acid sequence encoding RUNX3 comprises the nucleic acid sequence:









(SEQ ID NO: 202; NM_001031680)


ATGGCATCGAACAGCATCTTCGACTCCTTCCCGACCTACTCGCCGACCT





TCATCCGCGACCCAAGCACCAGCCGCCGCTTCACACCTCCCTCCCCGGC





CTTCCCCTGCGGCGGCGGCGGCGGCAAGATGGGCGAGAACAGCGGCGCG





CTGAGCGCGCAGGCGGCCGTGGGGCCCGGAGGGCGCGCCCGGCCCGAGG





TGCGCTCGATGGTGGACGTGCTGGCGGACCACGCAGGCGAGCTCGTGCG





CACCGACAGCCCCAACTTCCTCTGCTCCGTGCTGCCCTCGCACTGGCGC





TGCAACAAGACGCTGCCCGTCGCCTTCAAGGTGGTGGCATTGGGGGACG





TGCCGGATGGTACGGTGGTGACTGTGATGGCAGGCAATGACGAGAACTA





CTCCGCTGAGCTGCGCAATGCCTCGGCCGTCATGAAGAACCAGGTGGCC





AGGTTCAACGACCTTCGCTTCGTGGGCCGCAGTGGGCGAGGGAAGAGTT





TCACCCTGACCATCACTGTGTTCACCAACCCCACCCAAGTGGCGACCTA





CCACCGAGCCATCAAGGTGACCGTGGACGGACCCCGGGAGCCCAGACGG





CACCGGCAGAAGCTGGAGGACCAGACCAAGCCGTTCCCTGACCGCTTTG





GGGACCTGGAACGGCTGCGCATGCGGGTGACACCGAGCACACCCAGCCC





CCGAGGCTCACTCAGCACCACAAGCCACTTCAGCAGCCAGCCCCAGACC





CCAATCCAAGGCACCTCGGAACTGAACCCATTCTCCGACCCCCGCCAGT





TTGACCGCTCCTTCCCCACGCTGCCAACCCTCACGGAGAGCCGCTTCCC





AGACCCCAGGATGCATTATCCCGGGGCCATGTCAGCTGCCTTCCCCTAC





AGCGCCACGCCCTCGGGCACGAGCATCAGCAGCCTCAGCGTGGCGGGCA





TGCCGGCCACCAGCCGCTTCCACCATACCTACCTCCCGCCACCCTACCC





GGGGGCCCCGCAGAACCAGAGCGGGCCCTTCCAGGCCAACCCGTCCCCC





TACCACCTCTACTACGGGACATCCTCTGGCTCCTACCAGTTCTCCATGG





TGGCCGGCAGCAGCAGTGGGGGCGACCGCTCACCTACCCGCATGCTGGC





CTCTTGCACCAGCAGCGCTGCCTCTGTCGCCGCCGGCAACCTCATGAAC





CCCAGCCTGGGCGGCCAGAGTGATGGCGTGGAGGCCGACGGCAGCCACA





GCAACTCACCCACGGCCCTGAGCACGCCAGGCCGCATGGATGAGGCCGT





GTGGCGGCCCTAC,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:202 under stringent hybridization conditions.


In some embodiments, Paired box 9 (PAX9) comprises the amino acid sequence:









(SEQ ID NO: 203; NP_001359005.1)


MEPAFGEVNQLGGVFVNGRPLPNAIRLRIVELAQLGIRPCDISRQLRVS





HGCVSKILARYNETGSILPGAIGGSKPRVTTPTVVKHIRTYKQRDPGIF





AWEIRDRLLADGVCDKYNVPSVSSISRILRNKIGNLAQQGHYDSYKQHQ





PTPQPALPYNHIYSYPSPITAAAAKVPTPPGVPAIPGSVAMPRTWPSSH





SVTDILGIRSITDQVSDSSPYHSPKVEEWSSLGRNNFPAAAPHAVNGLE





KGALEQEAKYGQAPNGLPAVGSFVSASSMAPYPTPAQVSPYMTYSAAPS





GYVAGHGWQHAGGTSLSPHNCDIPASLAFKGMQAAREGSHSVTASAL.,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:203.


In some embodiments, the nucleic acid sequence encoding PAX9 comprises the nucleic acid sequence:









(SEQ ID NO: 204; NM_001372076.1)


AGCCCAGCCCACGTTGCTGCTTAGATTGAAATGCAGAACTCAAGCCTCT





TTCATCGGGGCACAGACTTCCTTTTACTTCTTCCTTTTGCCCTCTCGCC





TCCTCCTCCTGGGAAGAAGCGGAGGCGCCGGCGGTCGGCCGGGATAGCA





ACAGGCCGGGCCACTGAGGCGGTGCGGAAAGTTTCTGTCTGGGAGTGCG





GAACTGGGGCCGGGTTGGTGTACTGCTCGGAGCAATGGAGCCAGCCTTC





GGGGAGGTGAACCAGCTGGGAGGAGTGTTCGTGAACGGGAGGCCGCTGC





CCAACGCCATCCGGCTTCGCATCGTGGAACTGGCCCAACTGGGCATCCG





ACCGTGTGACATCAGCCGCCAGCTACGGGTCTCGCACGGCTGCGTCAGC





AAGATCCTGGCGCGATACAACGAGACGGGCTCGATCTTGCCAGGAGCCA





TCGGGGGCAGCAAGCCCCGGGTCACTACCCCCACCGTGGTGAAACACAT





CCGGACCTACAAGCAGAGAGACCCCGGCATCTTCGCCTGGGAGATCCGG





GACCGCCTGCTGGCGGACGGCGTGTGCGACAAGTACAATGTGCCCTCCG





TGAGCTCCATCAGCCGCATTCTGCGCAACAAGATCGGCAACTTGGCCCA





GCAGGGTCATTACGACTCATACAAGCAGCACCAGCCGACGCCGCAGCCA





GCGCTGCCCTACAACCACATCTACTCGTACCCCAGCCCTATCACGGCGG





CGGCCGCCAAGGTGCCCACGCCACCCGGGGTGCCTGCCATCCCCGGTTC





GGTGGCCATGCCGCGCACCTGGCCCTCCTCGCACTCCGTCACCGACATC





CTGGGCATCCGCTCCATCACCGACCAAGTGAGCGACAGCTCCCCCTACC





ACAGCCCCAAGGTGGAGGAGTGGAGCAGCCTGGGCCGCAACAACTTCCC





CGCCGCCGCCCCGCACGCGGTGAACGGGTTGGAGAAGGGAGCCCTGGAG





CAGGAAGCCAAGTACGGTCAGGCACCAAATGGTCTCCCAGCTGTGGGCA





GTTTTGTGTCAGCATCCAGCATGGCTCCTTACCCTACCCCAGCCCAAGT





GTCGCCTTACATGACCTACAGTGCTGCTCCTTCTGGTTATGTTGCTGGA





CATGGGTGGCAACATGCTGGGGGCACCTCATTGTCTCCCCACAACTGTG





ACATTCCGGCATCGCTGGCGTTCAAGGGAATGCAGGCAGCCAGAGAAGG





TAGTCATTCTGTCACGGCTTCCGCGCTCTGATGGGAAATTCCGTCTCCA





GCAGCTTCACCCGGGTCTCCCTGTCTCAGCACCTCCTCCCCCAATTCCC





AGGTCTCACATCCCACCCCTCCTGCCCTCCAACCCTTCTGCCTTGAAAG





CTGGCTGTACGGACTCACATCCTTTGTGCTAATGACACTTACATATTTC





TTGCCATAACTTTTCTCTTGCAGAAAAACTGACATGACTTTAGGATTTA





AAAACAAGAGCAACAATAAGCATTGAATGAGACATTTGTGTTGCCCACA





TACTGTCTTAACATAACAAAGAAACCTACACCCCTCAAAGGGTTTAAGG





AACTTTACAAACTAGTCTTTGGTAAAACCACATGTGTATATTTATTCTA





AATCAACCTGAACTTTTGAAATGTGCAATTGTTGAGATTTTGCAAAATC





AATAAAGGAAAATACTTATAGAAAAAATTATGCTACACCCTCTAATCAA





ATATGGTAACCAAGTAAGCTTTAATTCATCATTAGGAAACAAATCAATA





AGTGACTTGTTTGAGTGATCCTTTGTTTAAGACATGACCTATTTTGTTG





AAAAATATATGTAGAACCCAAGCAATATCTGAATCTAGCTCTCCCTGGT





GTTTTGACTTGGTTCCAAATACAATAATGTTTATATTTTCTATTAGTTT





GTAAATACGGACTCTGGATGGTGCATTTGTGTCTTCATTCCATAAGATA





TTCCCCTCCCCTCAGCCCCACCCCCTCTCTATTTTTTTCTTTCTTTTTT





GCAAAGGTGACTTTCTGGCAACGTCTTTGTCTCTGTTTGGTGGTGGGCT





GCTCGGGCTCCTGGACCTGGACTTGCCCCCAAATTTTGTGTATGCAGTG





AAGGCTTCAACATCTCATGAAGGACACTTTATTTCTACAGCAGAGGACA





CGAAAAACAGATAAAACAAGCCAGTCTCCCATTTTGTACCTAATCAAAC





AACACACATGCTAAGCATATAAAGACAAGAGGGTGGAAAATATCTGAAC





AAGAAGGCTCTAAAGGAAGTCACTTAGAAACTTAAGTTTAATGTGAAAT





GTTTTGCAAAGATGCTTAAAATGAACTTTGTGTTAAGAAAACCACTGTG





AAACTAAATTGTCCTATTATTGTTGGCTTACCTGTGTGTTCAGCAATCT





CAGCCCCAAATAATGTTGTAATTTAAAGAAAATGGAAAATTCTGCTCTA





ATGAATGTAACAATGGCTTGCTGTGAAGTTTACATTGTTGTACAGAAGC





ATGTTTCGCATGTAGGTAAACTGGTGGTGGTACTAGAAATACAATGTTA





TTTAATTTTAACAAATTCCCTTTATTCATTTCTGAAATTACAGGACACA





GTTTAACTCATAAACCTTTCTAGACCAATTTATTTTTCACTTTAATGTT





AATAACAGTTGTGGAGTATATGTGTGTGTGAGCATGTGAGTATGTGTTG





TATTTTAAAACAATTGATTTTCTGGGGCAAAATTCTACAGTTTTTAATC





CCTTCTGTTTAGGAAGTTCTTCCTGTTTGGCAATATAGGCTTAAAAATA





TGTTTTTAGGACATTGGTACAATTCAGCTGTTGGAAAATTAATATATTG





AGGGTTTTTTGGTACTAATTCTGTGCAATAACTAAAAGAGCACCTCACT





GGATATGGATGTTGAAGATGGATTCCCTAGGTGATTTTAATTTCTTCCG





GTCTGTGCTGTGCACAGTCTACATGGCAATGCGGTTCCACCACATCGGT





TTCGTGGCTTCGTTTAAAACTCAGATGGCTAGATTAGTTAGGTTTTCAA





ATCACTAGGATGTAAACAGTAAGCAGATTTCTGACACACAAATTATGTT





AGAGTGACTGCTTTTTTCAGACAGCAGATATCTTATAGAGAGCTTTGAA





CTGCATTTATTTCTAAAGCAACCGAAATTCAGTGCTACAAATAGAGGAT





TATAACTTCAGGAGAAGAATAAGCAGAAGGAGCAGATGAACTCTCAGGG





CCATAGTCTTCCTTTGATCTTGTAAAACTTCCATTGACATCTGGAGTTC





CCAGTCTGGTGAGAAAATAGACTATAAACTGAATGGAACAAAGATCCAA





TCCAATATTTTGGTGGAGACTTCTTTAAAACCATACCATACAGGGACTC





TCCTGTCATCTGAAAAACTGATGTAAGGTACAGAACTATTCTTTATCAA





ATGTTTTTAGGTGGCTGTTAGGGGGCTTTAAAAAATATTACTTGCTTGT





GTGGAAATGCAAATAATGTTATTTTCTTTATCTAAATTAAGAAATCTCT





TGTTATTGTGCTATTTATAATTTTTTTCTGGTTCTTGTATTTTAAAAAA





TCTAATATTAATGGTATTGAAGTTTCCTTTTCTCCCTCTAGGTCTTAAC





AGTGAATTCACATGGAGTAATTTTTAAAAGATATCAGATACAATTTGCT





ATTCAAAGAAAATTATGATTTAAAGCCACTTTTTAAAATACGAGAAGGA





AAATAGGATGGATTAAAGGGTTAACTTTTAAAGATTATTATTGGTTAAT





GTTGACATATTTCCTCTATCTCATAGATGGTAAAAGTGTTGCTTTTAAA





CTGGCAAATGCACTCTTCAGAAATCCTTTTCTATCTGATCCACATGGAG





AGGTTAAAGGTTCAATTTCATGACCTCTATGCAGGCAGCGCTCTCATTG





GATGTAAGAATATTACCTGCAAGGATAGAATGCAGTTGTGCAACAGAGA





CACATTCTTATTTCTTTTTTTTCACAATTTTGTTTTGTTTTTAATGACC





CTTTTATTGAATATTGGACTGAAATATAAATTTTAAAAAACACGTTGGA





AAGGATGTACAACAGAAGGCTATGTATGTATATACAGTATGTCAAAAGC





CTTTTATTTTTATACTTCAAATGCTCTAAATTAATAAAAAGTAATAATT





A.,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:204 under stringent hybridization conditions.


In some embodiments, Homeobox Protein Nkx-3.2 (Nkx-3.2) comprises the amino acid sequence:









(SEQ ID NO: 205; NP_001180.1)


MAVRGANTLTSFSIQAILNKKEERGGLAAPEGRPAPGGTAASVAAAPAV





CCWRLFGERDAGALGGAEDSLLASPAGTRTAAGRTAESPEGWDSDSALS





EENESRRRCADARGASGAGLAGGSLSLGQPVCELAASKDLEEEAAGRSD





SEMSASVSGDRSPRTEDDGVGPRGAHVSALCSGAGGGGGSGPAGVAEEE





EEPAAPKPRKKRSRAAFSHAQVFELERRFNHQRYLSGPERADLAASLKL





TETQVKIWFQNRRYKTKRRQMAADLLASAPAAKKVAVKVLVRDDQRQYL





PGEVLRPPSLLPLQPSYYYPYYCLPGWALSTCAAAAGTQ.,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:205


In some embodiments, the nucleic acid sequence encoding Nkx-3.2 comprises the nucleic acid sequence:









(SEQ ID NO: 206; NM_001189.4)


ACTCGCGCTGCGGCCGCCGGCGCTCTCTGTCCCGCTCGGAGCTGCTCGG





CGCCCCAGCTGCCCGCCCCGCCGGCCGCTCCTGCCCGCGGCGCAGATGG





CTGTGCGCGGCGCCAACACCTTGACGTCCTTCTCCATCCAGGCGATCCT





CAACAAGAAAGAGGAGCGCGGCGGGCTGGCCGCGCCAGAGGGGCGCCCG





GCGCCCGGGGGCACAGCGGCATCGGTGGCCGCGGCTCCCGCTGTCTGCT





GTTGGCGGCTCTTTGGGGAGAGGGACGCGGGCGCGTTGGGGGGCGCCGA





GGACTCTCTGCTGGCGTCTCCTGCCGGTACCAGAACAGCTGCGGGGCGG





ACTGCGGAGAGCCCGGAAGGCTGGGACTCGGACTCCGCGCTCAGCGAGG





AGAACGAGAGCAGGCGGCGCTGCGCGGACGCGCGGGGGGCCAGCGGGGC





CGGCCTTGCGGGGGGATCCTTGAGCCTCGGCCAGCCGGTCTGTGAGCTG





GCCGCTTCCAAAGACCTAGAGGAGGAAGCCGCGGGCCGGAGCGACAGCG





AGATGTCCGCCAGCGTCTCAGGCGACCGCAGCCCAAGGACCGAGGACGA





CGGTGTTGGCCCCAGAGGTGCACACGTGTCCGCGCTGTGCAGCGGGGCC





GGCGGCGGGGGCGGCAGCGGGCCGGCAGGCGTCGCGGAGGAGGAGGAGG





AGCCGGCGGCGCCCAAGCCACGCAAGAAGCGCTCGCGGGCCGCTTTCTC





CCACGCGCAGGTCTTCGAGCTGGAGCGCCGCTTTAACCACCAGCGCTAC





CTGTCCGGGCCCGAGCGCGCAGACCTGGCCGCGTCGCTGAAGCTCACCG





AGACGCAGGTGAAAATCTGGTTCCAGAACCGTCGCTACAAGACAAAGCG





CCGGCAGATGGCAGCCGACCTGCTGGCCTCGGCGCCCGCCGCCAAGAAG





GTGGCCGTAAAGGTGCTGGTGCGCGACGACCAGAGACAATACCTGCCCG





GCGAAGTGCTGCGGCCACCCTCGCTTCTGCCACTGCAGCCCTCCTACTA





TTACCCGTACTACTGCCTCCCAGGCTGGGCGCTCTCCACCTGCGCAGCT





GCCGCAGGCACCCAGTGAACCCGCTTGGGCTGAGGCAGCGAGTGATTCC





CGCGCTCCGGCTCCGGACCGGCGCTGACAGCTGTAGGCTGTAGCCTGCA





CGGGGCGCCCCGCCAAGGAGGCACCTGGAGGTGAAACCCAGCTCCAGCT





CCCGTTAGCCAGGACTTGTCCCCTGGCAGCTGGGCTGAGTCTGCCCTGA





GGGGGCGCCTTTTTCTAATTTGAACAGAGGCACCCTATGGCCTAGGGGC





CCTGATCGCCCACCTGCCTGGAAGCCCCTGGGCTCTATTTATTATCATG





ACAATGTTGGAATTAAATTTTGATTCGAATATGTCTGCCTGGGGGTGGG





GTTTTCCCTGAGCGGCAACTCCTGGAGACCACATAGCCTGAATCCTCAG





AATTTCAGGCCTGCTGGGAGCTTTCTGCACTAGGCCACACTAGTTCATG





GTATCCATGCTACCAATCTATGTGTATCTACATATCTTTTATTTTTGGA





AATTGCATTTGTAACCAAGGGGTGCGAAACCCTGGCAGTCCCAGGCAGC





ACCAGGCCAGGGGTTGATTTGAAACGTGAAGGATTGGGTTTTCAGGCCC





TCTGCTCCACCCCTCCTGTGTGTCAGAGCTAGGGTGGGGGTGCCCGATT





CGGGTGCTGAATGTAAGGAGGGGAGCCTCCAAGTGTGGTGCAAGCCGGG





GGTCTCCACATCTTCCTTCTCTGAAGTCCAGGTACCTGCACAAGCAGGA





AGCGCCTGGGAGTCCCGGAAGGAGGAGAGCGCACACCCAGGCAGCCCTC





TGCGGAAACTTTCCTTGGTTTCTTTTTATTTGTGTAAAGGAGGTTAAGA





CGTGTCGCACTTTTCAGTTGTTTGTATTCAAATGACGATTATTTTTCTA





CTCAATGTGAATATCCCTGGCCAGCCTTTCCACGGCGCCCACCGCAGTG





CCGCTGCCTGGCCCTCAGTGTCTACCTTCTGCCCTCTGCGACTCCAGTG





CTCTGGCCCGGGACTCCCCTATCCGCCCCTCACTTACCCTTAAACAGGT





GATCCCACCTGTCTTGTCAACCTCGCCGCTTTTCGCCTCCTTAATGGCA





CTGTGCACTCAACTAGAGTATTAACTGTAAAAAGATTTGTGAAGTTTGG





AAGCTCTATTCGCTGTATTTTTTCTTTAATTTATAAACTTTTAGTTTAA





CATGC.,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:206 under stringent hybridization conditions.


In some embodiments, AP-1 transcription factor (FOS, C-FOX, AP-1, p55) comprises the amino acid sequence:









(SEQ ID NO: 207; NP_005243.1)


MMFSGFNADYEASSSRCSSASPAGDSLSYYHSPADSFSSMGSPVNAQDF





CTDLAVSSANFIPTVTAISTSPDLQWLVQPALVSSVAPSQTRAPHPFGV





PAPSAGAYSRAGVVKTMTGGRAQSIGRRGKVEQLSPEEEEKRRIRRERN





KMAAAKCRNRRRELTDTLQAETDQLEDEKSALQTEIANLLKEKEKLEFI





LAAHRPACKIPDDLGFPEEMSVASLDLTGGLPEVATPESEEAFTLPLLN





DPEPKPSVEPVKSISSMELKTEPFDDFLFPASSRPSGSETARSVPDMDL





SGSFYAADWEPLHSGSLGMGPMATELEPLCTPVVTCTPSCTAYTSSFVF





TYPEADSFPSCAAAHRKGSSSNEPSSDSLSSPTLLAL.,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:207)


In some embodiments, the nucleic acid sequence encoding FOS comprises the nucleic acid sequence:









(SEQ ID NO: 208; NM_005252.4)


AACCGCATCTGCAGCGAGCATCTGAGAAGCCAAGACTGAGCCGGCGGCC





GCGGCGCAGCGAACGAGCAGTGACCGTGCTCCTACCCAGCTCTGCTCCA





CAGCGCCCACCTGTCTCCGCCCCTCGGCCCCTCGCCCGGCTTTGCCTAA





CCGCCACGATGATGTTCTCGGGCTTCAACGCAGACTACGAGGCGTCATC





CTCCCGCTGCAGCAGCGCGTCCCCGGCCGGGGATAGCCTCTCTTACTAC





CACTCACCCGCAGACTCCTTCTCCAGCATGGGCTCGCCTGTCAACGCGC





AGGACTTCTGCACGGACCTGGCCGTCTCCAGTGCCAACTTCATTCCCAC





GGTCACTGCCATCTCGACCAGTCCGGACCTGCAGTGGCTGGTGCAGCCC





GCCCTCGTCTCCTCCGTGGCCCCATCGCAGACCAGAGCCCCTCACCCTT





TCGGAGTCCCCGCCCCCTCCGCTGGGGCTTACTCCAGGGCTGGCGTTGT





GAAGACCATGACAGGAGGCCGAGCGCAGAGCATTGGCAGGAGGGGCAAG





GTGGAACAGTTATCTCCAGAAGAAGAAGAGAAAAGGAGAATCCGAAGGG





AAAGGAATAAGATGGCTGCAGCCAAATGCCGCAACCGGAGGAGGGAGCT





GACTGATACACTCCAAGCGGAGACAGACCAACTAGAAGATGAGAAGTCT





GCTTTGCAGACCGAGATTGCCAACCTGCTGAAGGAGAAGGAAAAACTAG





AGTTCATCCTGGCAGCTCACCGACCTGCCTGCAAGATCCCTGATGACCT





GGGCTTCCCAGAAGAGATGTCTGTGGCTTCCCTTGATCTGACTGGGGGC





CTGCCAGAGGTTGCCACCCCGGAGTCTGAGGAGGCCTTCACCCTGCCTC





TCCTCAATGACCCTGAGCCCAAGCCCTCAGTGGAACCTGTCAAGAGCAT





CAGCAGCATGGAGCTGAAGACCGAGCCCTTTGATGACTTCCTGTTCCCA





GCATCATCCAGGCCCAGTGGCTCTGAGACAGCCCGCTCCGTGCCAGACA





TGGACCTATCTGGGTCCTTCTATGCAGCAGACTGGGAGCCTCTGCACAG





TGGCTCCCTGGGGATGGGGCCCATGGCCACAGAGCTGGAGCCCCTGTGC





ACTCCGGTGGTCACCTGTACTCCCAGCTGCACTGCTTACACGTCTTCCT





TCGTCTTCACCTACCCCGAGGCTGACTCCTTCCCCAGCTGTGCAGCTGC





CCACCGCAAGGGCAGCAGCAGCAATGAGCCTTCCTCTGACTCGCTCAGC





TCACCCACGCTGCTGGCCCTGTGAGGGGGCAGGGAAGGGGAGGCAGCCG





GCACCCACAAGTGCCACTGCCCGAGCTGGTGCATTACAGAGAGGAGAAA





CACATCTTCCCTAGAGGGTTCCTGTAGACCTAGGGAGGACCTTATCTGT





GCGTGAAACACACCAGGCTGTGGGCCTCAAGGACTTGAAAGCATCCATG





TGTGGACTCAAGTCCTTACCTCTTCCGGAGATGTAGCAAAACGCATGGA





GTGTGTATTGTTCCCAGTGACACTTCAGAGAGCTGGTAGTTAGTAGCAT





GTTGAGCCAGGCCTGGGTCTGTGTCTCTTTTCTCTTTCTCCTTAGTCTT





CTCATAGCATTAACTAATCTATTGGGTTCATTATTGGAATTAACCTGGT





GCTGGATATTTTCAAATTGTATCTAGTGCAGCTGATTTTAACAATAACT





ACTGTGTTCCTGGCAATAGTGTGTTCTGATTAGAAATGACCAATATTAT





ACTAAGAAAAGATACGACTTTATTTTCTGGTAGATAGAAATAAATAGCT





ATATCCATGTACTGTAGTTTTTCTTCAACATCAATGTTCATTGTAATGT





TACTGATCATGCATTGTTGAGGTGGTCTGAATGTTCTGACATTAACAGT





TTTCCATGAAAACGTTTTATTGTGTTTTTAATTTATTTATTAAGATGGA





TTCTCAGATATTTATATTTTTATTTTATTTTTTTCTACCTTGAGGTCTT





TTGACATGTGGAAAGTGAATTTGAATGAAAAATTTAAGCATTGTTTGCT





TATTGTTCCAAGACATTGTCAATAAAAGCATTTAAGTTGAATGCGA.,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:208 under stringent hybridization conditions.


In some embodiments, FosB proto-oncogene (FosB, GOS3, G0S3, GOSB) comprises the amino acid sequence:


MFQAFPGDYDSGSRCSSSPSAESQYLSSVDSFGSPPTAAASQECAGLGEMPGSFVPT VTAITTSQDLQWLVQPTLISSMAQSQGQPLASQPPVVDPYDMPGTSYSTPGMSGYSS GGASGSGGPSTSGTTSGPGPARPARARPRRPREETETDQLEEEKAELESEIAELQKEK ERLEFVLVAHKPGCKIPYEEGPGPGPLAEVRDLPGSAPAKEDGFSWLLPPPPPPPLPF QTSQDAPPNLTASLFTHSEVQVLGDPFPVVNPSYTSSFVLTCPEVSAFAGAQRTSGSD QPSDPLNSPSLLAL. (SEQ ID NO:209; NP_001107643.1), or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:209)


In some embodiments, the nucleic acid sequence encoding FosB comprises the nucleic acid sequence:









(SEQ ID NO: 210; NM_001114171.2)


ATTCATAAGACTCAGAGCTACGGCCACGGCAGGGACACGCGGAACCAAG





ACTTGGAAACTTGATTGTTGTGGTTCTTCTTGGGGGTTATGAAATTTCA





TTAATCTTTTTTTTTCCGGGGAGAAAGTTTTTGGAAAGATTCTTCCAGA





TATTTCTTCATTTTCTTTTGGAGGACCGACTTACTTTTTTTGGTCTTCT





TTATTACTCCCCTCCCCCCGTGGGACCCGCCGGACGCGTGGAGGAGACC





GTAGCTGAAGCTGATTCTGTACAGCGGGACAGCGCTTTCTGCCCCTGGG





GGAGCAACCCCTCCCTCGCCCCTGGGTCCTACGGAGCCTGCACTTTCAA





GAGGTACAGCGGCATCCTGTGGGGGCCTGGGCACCGCAGGAAGACTGCA





CAGAAACTTTGCCATTGTTGGAACGGGACGTTGCTCCTTCCCCGAGCTT





CCCCGGACAGCGTACTTTGAGGACTCGCTCAGCTCACCGGGGACTCCCA





CGGCTCACCCCGGACTTGCACCTTACTTCCCCAACCCGGCCATAGCCTT





GGCTTCCCGGCGACCTCAGCGTGGTCACAGGGGCCCCCCTGTGCCCAGG





GAAATGTTTCAGGCTTTCCCCGGAGACTACGACTCCGGCTCCCGGTGCA





GCTCCTCACCCTCTGCCGAGTCTCAATATCTGTCTTCGGTGGACTCCTT





CGGCAGTCCACCCACCGCCGCCGCCTCCCAGGAGTGCGCCGGTCTCGGG





GAAATGCCCGGTTCCTTCGTGCCCACGGTCACCGCGATCACAACCAGCC





AGGACCTCCAGTGGCTTGTGCAACCCACCCTCATCTCTTCCATGGCCCA





GTCCCAGGGGCAGCCACTGGCCTCCCAGCCCCCGGTCGTCGACCCCTAC





GACATGCCGGGAACCAGCTACTCCACACCAGGCATGAGTGGCTACAGCA





GTGGCGGAGCGAGTGGCAGTGGTGGGCCTTCCACCAGCGGAACTACCAG





TGGGCCTGGGCCTGCCCGCCCAGCCCGAGCCCGGCCTAGGAGACCCCGA





GAGGAGACGGAGACAGATCAGTTGGAGGAAGAAAAAGCAGAGCTGGAGT





CGGAGATCGCCGAGCTCCAAAAGGAGAAGGAACGTCTGGAGTTTGTGCT





GGTGGCCCACAAACCGGGCTGCAAGATCCCCTACGAAGAGGGGCCCGGG





CCGGGCCCGCTGGCGGAGGTGAGAGATTTGCCGGGCTCAGCACCGGCTA





AGGAAGATGGCTTCAGCTGGCTGCTGCCGCCCCCGCCACCACCGCCCCT





GCCCTTCCAGACCAGCCAAGACGCACCCCCCAACCTGACGGCTTCTCTC





TTTACACACAGTGAAGTTCAAGTCCTCGGCGACCCCTTCCCCGTTGTTA





ACCCTTCGTACACTTCTTCGTTTGTCCTCACCTGCCCGGAGGTCTCCGC





GTTCGCCGGCGCCCAACGCACCAGCGGCAGTGACCAGCCTTCCGATCCC





CTGAACTCGCCCTCCCTCCTCGCTCTGTGAACTCTTTAGACACACAAAA





CAAACAAACACATGGGGGAGAGAGACTTGGAAGAGGAGGAGGAGGAGGA





GAAGGAGGAGAGAGAGGGGAAGAGACAAAGTGGGTGTGTGGCCTCCCTG





GCTCCTCCGTCTGACCCTCTGCGGCCACTGCGCCACTGCCATCGGACAG





GAGGATTCCTTGTGTTTTGTCCTGCCTCTTGTTTCTGTGCCCCGGCGAG





GCCGGAGAGCTGGTGACTTTGGGGACAGGGGGTGGGAAGGGGATGGACA





CCCCCAGCTGACTGTTGGCTCTCTGACGTCAACCCAAGCTCTGGGGATG





GGTGGGGAGGGGGGCGGGTGACGCCCACCTTCGGGCAGTCCTGTGTGAG





GATTAAGGGACGGGGGTGGGAGGTAGGCTGTGGGGTGGGCTGGAGTCCT





CTCCAGAGAGGCTCAACAAGGAAAAATGCCACTCCCTACCCAATGTCTC





CCACACCCACCCTTTTTTTGGGGTGCCTAGGTTGGTTTCCCCTGCACTC





CCGACCTTAGCTTATTGATCCCACATTTCCATGGTGTGAGATCCTCTTT





ACTCTGGGCAGAAGTGAGCCCCCCCCTTAAAGGGAATTCGATGCCCCCC





TAGAATAATCTCATCCCCCCACCCGACTTCTTTTGAAATGTGAACGTCC





TTCCTTGACTGTCTAGCCACTCCCTCCCAGAAAAACTGGCTCTGATTGG





AATTTCTGGCCTCCTAAGGCTCCCCACCCCGAAATCAGCCCCCAGCCTT





GTTTCTGATGACAGTGTTATCCCAAGACCCTGCCCCCTGCCAGCCGACC





CTCCTGGCCTTCCTCGTTGGGCCGCTCTGATTTCAGGCAGCAGGGGCTG





CTGTGATGCCGTCCTGCTGGAGTGATTTATACTGTGAAATGAGTTGGCC





AGATTGTGGGGTGCAGCTGGGTGGGGCAGCACACCTCTGGGGGGATAAT





GTCCCCACTCCCGAAAGCCTTTCCTCGGTCTCCCTTCCGTCCATCCCCC





TTCTTCCTCCCCTCAACAGTGAGTTAGACTCAAGGGGGTGACAGAACCG





AGAAGGGGGTGACAGTCCTCCATCCACGTGGCCTCTCTCTCTCTCCTCA





GGACCCTCAGCCCTGGCCTTTTTCTTTAAGGTCCCCCGACCAATCCCCA





GCCTAGGACGCCAACTTCTCCCACCCCTTGGCCCCTCACATCCTCTCCA





GGAAGGGAGTGAGGGGCTGTGACATTTTTCCGGAGAAGATTTCAGAGCT





GAGGCTTTGGTACCCCCAAACCCCCAATATTTTTGGACTGGCAGACTCA





AGGGGCTGGAATCTCATGATTCCATGCCCGAGTCCGCCCATCCCTGACC





ATGGTTTTGGCTCTCCCACCCCGCCGTTCCCTGCGCTTCATCTCATGAG





GATTTCTTTATGAGGCAAATTTATATTTTTTAATATCGGGGGGTGGACC





ACGCCGCCCTCCATCCGTGCTGCATGAAAAACATTCCACGTGCCCCTTG





TCGCGCGTCTCCCATCCTGATCCCAGACCCATTCCTTAGCTATTTATCC





CTTTCCTGGTTTCCGAAAGGCAATTATATCTATTATGTATAAGTAAATA





TATTATATATGGATGTGTGTGTGTGCGTGCGCGTGAGTGTGTGAGCGCT





TCTGCAGCCTCGGCCTAGGTCACGTTGGCCCTCAAAGCGAGCCGTTGAA





TTGGAAACTGCTTCTAGAAACTCTGGCTCAGCCTGTCTCGGGCTGACCC





TTTTCTGATCGTCTCGGCCCCTCTGATTGTTCCCGATGGTCTCTCTCCC





TCTGTCTTTTCTCCTCCGCCTGTGTCCATCTGACCGTTTTCACTTGTCT





CCTTTCTGACTGTCCCTGCCAATGCTCCAGCTGTCGTCTGACTCTGGGT





TCGTTGGGGACATGAGATTTTATTTTTTGTGAGTGAGACTGAGGGATCG





TAGATTTTTACAATCTGTATCTTTGACAATTCTGGGTGCGAGTGTGAGA





GTGTGAGCAGGGCTTGCTCCTGCCAACCACAATTCAATGAATCCCCGAC





CCCCCTACCCCATGCTGTACTTGTGGTTCTCTTTTTGTATTTTGCATCT





GACCCCGGGGGGCTGGGACAGATTGGCAATGGGCCGTCCCCTCTCCCCT





TGGTTCTGCACTGTTGCCAATAAAAAGCTCTTAAAAACGCA,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:210 under stringent hybridization conditions.


In some embodiments, FOS like 1, AP-1 transcription factor subunit (FRA, FRA1, FOSL1) comprises the amino acid sequence:









(SEQ ID NO: 211; NP_001287773.1)


MFRDFGEPGPSSGNGGGYGGPAQPPAAAQAAQQKFHLVPSINTMSGSQE





LQWMVQPHFLGPSSYPRPLTYPQYSPPQPRPGVIRALGPPPGVRRRPCE





QETDKLEDEKSGLQREIEELQKQKERLELVLEAHRPICKIPEGAKEGDT





GSTSGTSSPPAPCRPVPCISLSPGPVLEPEALHTPTLMTTPSLTPFTPS





LVFTYPSTPEPCASAHRKSSSSSGDPSSDPLGSPTLLAL.,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:211)


In some embodiments, the nucleic acid sequence encoding FRA comprises the nucleic acid sequence:









(SEQ ID NO: 212; NM_001300844.2)


GAGTCAGAACCCAGCAGCCGTGTACCCCGCAGAGCCGCCAGCCCCGGGC





ATGTTCCGAGACTTCGGGGAACCCGGCCCGAGCTCCGGGAACGGCGGCG





GGTACGGCGGCCCCGCGCAGCCCCCGGCCGCAGCGCAGGCAGCCCAGCA





GAAGTTCCACCTGGTGCCAAGCATCAACACCATGAGTGGCAGTCAGGAG





CTGCAGTGGATGGTACAGCCTCATTTCCTGGGGCCCAGCAGTTACCCCA





GGCCTCTGACCTACCCTCAGTACAGCCCCCCACAACCCCGGCCAGGAGT





CATCCGGGCCCTGGGGCCGCCTCCAGGGGTACGTCGAAGGCCTTGTGAA





CAGGAGACTGACAAACTGGAAGATGAGAAATCTGGGCTGCAGCGAGAGA





TTGAGGAGCTGCAGAAGCAGAAGGAGCGCCTAGAGCTGGTGCTGGAAGC





CCACCGACCCATCTGCAAAATCCCGGAAGGAGCCAAGGAGGGGGACACA





GGCAGTACCAGTGGCACCAGCAGCCCACCAGCCCCCTGCCGCCCTGTAC





CTTGTATCTCCCTTTCCCCAGGGCCTGTGCTTGAACCTGAGGCACTGCA





CACCCCCACACTCATGACCACACCCTCCCTAACTCCTTTCACCCCCAGC





CTGGTCTTCACCTACCCCAGCACTCCTGAGCCTTGTGCCTCAGCTCATC





GCAAGAGTAGCAGCAGCAGCGGAGACCCATCCTCTGACCCCCTTGGCTC





TCCAACCCTCCTCGCTTTGTGAGGCGCCTGAGCCCTACTCCCTGCAGAT





GCCACCCTAGCCAATGTCTCCTCCCCTTCCCCCACCGGTCCAGCTGGCC





TGGACAGTATCCCACATCCAACTCCAGCAACTTCTTCTCCATCCCTCTA





ATGAGACTGACCATATTGTGCTTCACAGTAGAGCCAGCTTGGGGCCACC





AAAGCTGCCCACTGTTTCTCTTGAGCTGGCCTCTCTAGCACAATTTGCA





CTAAATCAGAGACAAAATATTTCCCATTTGTGCCAGAGGAATCCTGGCA





GCCCAGAGACTTTGTAGATCCTTAGAGGTCCTCTGGAGCCCTAACCCCT





TCCAGATCACTGCCACACTCTCCATCACCCTCTTCCTGTGATCCACCCA





ACCCTATCTCCTGACAGAAGGTGCCACTTTACCCACCTAGAACACTAAC





TCACCAGCCCCACTGCCAGCAGCAGCAGGTGATTGGACCAGGCCATTCT





GCCGCCCCCTCCTGAACCGCACAGCTCAGGAGGCGCCCTTGGCTTCTGT





GATGAGCTGATCTGCGGATCTCAGCTTTGAGAAGCCTTCAGCTCCAGGG





AATCCAAGCCTCCACAGCGAGGGCAGCTGCTATTTATTTTCCTAAAGAG





AGTATTTTTATACAAACCTACCAAAATGGAATAAAAGGCTTGAAGCTGT





GGCCTGAGTGCCTCACTGGACCCAGAGGCCAATGGGAGAGTATTTGGAG





CCCTAGGTCCCAGCCTTAGCTCTACAGACTCACTGCATGACCTTGGACA





AATTCTTTGATATTTTTGGACTTTGTCTTATCTGACAAGTGGGGCTACA





TCCGCTCGGCCTCATCTCCGGGACTG,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:212 under stringent hybridization conditions.


In some embodiments, FOS like 2, AP-1 transcription factor subunit (FRA2, FOSL2) comprises the amino acid sequence:









(SEQ ID NO: 213; NP_005244.1)


MYQDYPGNFDTSSRGSSGSPAHAESYSSGGGGQQKFRVDMPGSGSAFIP





TINAITTSQDLQWMVQPTVITSMSNPYPRSHPYSPLPGLASVPGHMALP





RPGVIKTIGTTVGRRRRDEQLSPEEEEKRRIRRERNKLAAAKCRNRRRE





LTEKLQAETEELEEEKSGLQKEIAELQKEKEKLEFMLVAHGPVCKISPE





ERRSPPAPGLQPMRSGGGSVGAVVVKQEPLEEDSPSSSSAGLDKAQRSV





IKPISIAGGFYGEEPLHTPIVVTSTPAVTPGTSNLVFTYPSVLEQESPA





SPSESCSKAHRRSSSSGDQSSDSLNSPTLLAL.,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:213) In some embodiments, the nucleic acid sequence encoding FRA2 comprises the nucleic acid sequence:









(SEQ ID NO: 214; NM_0052534)


GTAGTGACTCATCTCGGGCAGAGCGCTAGGGCTCCGAGCGAACCAGCGA





GCGAGCGAACGAGCGGCGCTCGGCGGGGACAGAAAGAGGGAGAGAGAGA





GAGAGAGAGAGGGAGAGGCGCGGCCGGGCGAGGCGGGCCCGTCCGGGAG





CGGGCTCCGGGGAAGGGGTGCGGGTCTGGGCGCCGGAGCGGGGAGCGGG





GCCGCGTCCCTCTCAGCGCCAGCTCTACTTGAGCCCCACGAGCCGCTGT





CCCCCTGGCGCGCTCGGGGCCGCGGGACGGGCGCACGCCGCCTTCTCCT





AGTCAAGTATCCGAGCCGCCCCGAAACTCGGGCGGCGAGTCGGCCACGG





GAAGTTTATTCTCCGGCTCCTTTTCTAAAAGGAAGAAACAGAAGTTTCT





CCCAGCGGACAGCTTTTCTTTCCGCCTTTTTGGCCCTGTCTGAAATCGG





GGGTCCCCAGGGCTGGCAGGCCAGGCTCGCTGGGCTCCTAATCTTTTTT





TTAATTTCCAATTTTTGATTGGGCCGTGGGTCCCCGCTGAGCTCCGGCT





GCGCGCGGGGGCGGGAGGGCGCGCGCAGGGGAGGGACCGAGAGACGCGC





CGACTTTTTAGAGGGAGGGATCGGGTGGACAACTGGTCCCGCGGCGCTC





GCAGAGCCGGAAAGAAGTGCTGTAAGGGACGCTCGGGGGACGCTGTTCC





TGAGGTGTCGCCGCCTCCCTGTCCTCGCCCTCCGCGGTGGGGGAGAAAC





CCAGGAGCGAAGCCCAGAGCCCGCGGCGCGGCCGGCGGACGAACGAGCG





CGCAGCAGCCGGTGCGCGGCCGCGGCGAGGGCGGGGGAAGAAAAACACC





CTGTTTCCTCTCCGGCCCCCACCGCGGATCATGTACCAGGATTATCCCG





GGAACTTTGACACCTCGTCCCGGGGCAGCAGCGGCTCTCCTGCGCACGC





CGAGTCCTACTCCAGCGGCGGCGGCGGCCAGCAGAAATTCCGGGTAGAT





ATGCCTGGCTCAGGCAGTGCATTCATCCCCACCATCAACGCCATCACGA





CCAGCCAGGACCTGCAGTGGATGGTGCAGCCCACAGTGATCACCTCCAT





GTCCAACCCATACCCTCGCTCGCACCCCTACAGCCCCCTGCCGGGCCTG





GCCTCTGTCCCTGGACACATGGCCCTCCCAAGACCTGGCGTGATCAAGA





CCATTGGCACCACCGTGGGCCGCAGGAGGAGAGATGAGCAGCTGTCTCC





TGAAGAGGAGGAGAAGCGTCGCATCCGGCGGGAGAGGAACAAGCTGGCT





GCAGCCAAGTGCCGGAACCGACGCCGGGAGCTGACAGAGAAGCTGCAGG





CGGAGACAGAGGAGCTGGAGGAGGAGAAGTCAGGCCTGCAGAAGGAGAT





TGCTGAGCTGCAGAAGGAGAAGGAGAAGCTGGAGTTCATGTTGGTGGCT





CACGGCCCAGTGTGCAAGATTAGCCCCGAGGAGCGCCGATCGCCCCCAG





CCCCTGGGCTGCAGCCCATGCGCAGTGGGGGTGGCTCGGTGGGCGCTGT





AGTGGTGAAACAGGAGCCCCTGGAAGAGGACAGCCCCTCGTCCTCGTCG





GCGGGGCTGGACAAGGCCCAGCGCTCTGTCATCAAGCCCATCAGCATTG





CTGGGGGCTTCTACGGTGAGGAGCCCCTGCACACCCCCATCGTGGTGAC





CTCCACACCTGCTGTCACTCCGGGCACCTCGAACCTCGTCTTCACCTAT





CCTAGCGTCCTGGAGCAGGAGTCACCCGCATCTCCCTCCGAATCCTGCT





CCAAGGCTCACCGCAGAAGCAGTAGCAGCGGGGACCAATCATCAGACTC





CTTGAACTCCCCCACTCTGCTGGCTCTGTAACCCAGTGCACCTCCCTCC





CCAGCTCCGGAGGGGGTCCTCCTCGCTCCTCCTTCCCAGGGACCAGCAC





CTTCAAGCGCTCCAGGGCCGTGAGGGCAAGAGGGGGACCTGCCACCAGG





GAGCTTCCTGGCTCTGGGGGACCCAGGTGGGACTTAGCAGTGAGTATTG





GAAGACTTGGGTTGATCTCTTAGAAGCCATGGGACCTCCTCCCTCATTC





ATCTTGCAAGCAAATCCCATTTCTTGAAAAGCCTTGGAGAACTCGGTTT





GGTAGACTTGGACATCTCTCTGGCTTCTGAAGAGCCTGAAGCTGGCCTG





GACCATTCCTGTCCCTTTGTTACCATACTGTCTCTGGAGTGATGGTGTC





CTTCCCTGCCCCACCACGCATGCTCAGTGCCTTTTGGTTTCACCTTCCC





TCGACTTGACCCTTTCCTCCCCCAGCGTCAGTTTCACTCCCTCTTGGTT





TTTATCAAATTTGCCATGACATTTCATCTGGGTGGTCTGAATATTAAAG





CTCTTCATTTCTGGAGATGGGGCAGCAGGTGGCTCTTCTGCTGGGGCTG





ACTTGTCCAGAAGGGGACAAAGTGCAATACAGAGCCTTCCCTACCCTGA





CGCCTCCCAGTCATCATCTCCAGAACTCCCAGCGGGGCTCCCTGAGCTC





TCAAGGAGATGCTGCCATCACTGGGAGGCTCAGAGGACCCTTCCTGCCC





ACCTTCGGAGACGGCTTCTGGAGGAACGGCTTGGCCAGAAGACAGGGTG





TGAGTGAGACAGTGGGGCACAGGTTGGGTTTGCCAAACGCCTAATTACC





AGGCCAGGAAGCATGCCAACAAAGCCACACGGGTGTCCTAGCCAGCTTC





CCTTCACCTGGTGTCTTGAGTAGGGCGTCTCCTGTAATTACTGCCTTGC





CATTCTGCCCCTGGACCCTTCTCTCCGGACCAGGGAGGCGTCCCTCCCT





AGGAGCCACACATTATACTCCAAGTCCCTGCCGGGCTCCGCCTTTCCCC





CACCCTGGCTCTCAGGGTGACGCCACCCACAGAGATTTAATGAGCGTGG





GCCTGGACCTTCCCCAGATGCTGCCAGGCAGCCCCTCCCCAAGCCTCAA





AGAAGCATTTGCTGAGGATGGAGAGGCAGGGGAGGGAGGCGGGAGGCCG





TCACTGGAGTGGCGTCTGCAGCAGCTGCTGCCCCAGCACCCGCTCAGCC





TGTCCTGGCTGCTCACCTCCCCGCAGGGCACCGGGCCTTTCCTGCCCTC





TGTGGTCATCTGCCACCTGCTGGATCAAGTGCTTTCTCTTTTACACTCC





CCTGTCCCCACCCCAGTGCACTCTTCTGGCCCAGGCAGCAAGCAAGCTG





TGAACAGCTGGCCTGAGCTGTCGCTGTGGCTTGTGGCTCATGCGCCATT





CCTGGTTGTCTGTTGAATCTTTCTGGCTGCTGGAATTGGAGATAGGATG





TTTTGCTTCCCACTGCAGGAGAGCTGCCCCCTTTCACGGGGTTGGGGAA





GGGTCCCCCTGGCCTCCAGCAGGAGCACAGCTCAGCAGGGTCCCTGCTG





CCCACCCCTCTGAGCCTTTTCTCCCCAGGGTATGGCTCCTGCTGAGTTT





CTTGTCCAGCAGGGCCTTGACAGGAATCCAGGGAGTAGCTCCTGGCCAG





AACCAGCCTCTGCGGGGCTTGTGCTCTGCAAAGACTCTGCTGCTGGGGA





TTCAGCTCTAGAGGTCACAGTATCCTCGTTTGAAAGATAATTAGATCCC





CCGTGGAGAAAGCAGTGACACATTCACACAGCTGTTCCCTCGCATGTTA





TTTCATGAACATGCCTGTTTTCGTGCACTAGACACACAGAGTGGAACAG





CCGTATGCTTAAAGTACATGGGCCAGTGGGACTGGAAGTGACCTGTACA





AGTGATGCAGAAAGGAGGGTTTCAAAGAAAAAGGATTTTGTTTAAAATA





CTTTAAAAATGTTATTTCCTGCATCCCTTGGCTGTGATGCCCCTCTCCC





GATTTCCCAGGGGCTCTGGGAGGGACCCTTCTAAGAAGATTGGGCAGTT





GGGTTTCTGGCTTGAGATGAATCCAAGCAGCAGAATGAGCCAGGAGTAG





CAGGAGATGGGCAAAGAAAACTGGGGTGCACTCAGCTCTCACAGGGGTA





ATCATCTCAAGTGGTATTTGTAGCCAAGTGGGAGCTATTTTCTTTTTTG





TGCATATAGATATTTCTTAAATGAAGCTGCTTTCTTGTCTTTTATTTCT





AAAAGCCCCCTTATACCCCACTTTGTGCAGCAAAGATCCCCGTGCAGGT





CACAGCCTGATTTGTGGCCAGGCTGGACAAATTCCTGAGGCACAACTTG





GCTTCAGTTCAGATTTCAAGCTGTGTTGGTGTTGGGACCAGCAGAAGGC





AAACGTCCAGCCAACACACAGGACTGTAAGAGGACTCTGAGCTACGTGC





CCTGTGAAGACCCCCAGGCTTTGTCATAGGAGGTCGTTCAGCTTCCCCA





AAGTCAGAGGTGATTTGATTTGGGGAAGACTGAATATTCACACCTAAGT





CGTGAGCATATCCTGAGTTTTACTTCCTTATGGCTTGCCCTCCAAGTTC





TCTCTCTCATACACACACACACCCTTGCTCCAGAATCACCAGACACCTC





CATGGCTCCAGCTATGGGAACAGCTGCATTGGGGCTGCCTTTCTGTTTG





GCTTAGGAACTTCTGTGCTTCTTGTGGCTCCACTCGCGAGGCAGCTCGG





AGGTGTGGACTCCGATTGGGCTGCAGGCAGCTCTGGGACGGCACAGGGC





GGGCGCTCTGATCAGCTCGTGTAAAACACACCGTCTTCTTGGCCTCCTG





GCCAGTCTTTCTGCGAATAGTCCTCTCCCTGGCCAGTTGAATGGGGGAA





GCTGCTGGCACAGGAAGGAGAGGCGATCCCGGCTGAGGCTTAGGAAATT





GCTGGAGCCGGCTCCAAGCAGATAATTCACTGGGGAGGTTTTCAGAGTC





AAACATCATTCTGCCTGTGTTGGGGGCCAGGTGTGTCACACAAGCATCT





CAAAGTCAAAAGCCATCTGGGGCTGCTGCTTCTGTTTCTCAGGCTCTGG





GGAAAGGAATCTCCCTCTCCTCTCACTTGATTCCAAGTGTGGTTGAATT





GTCTGGAGCACTGGGACTTTTTTTCTCTTTTCCTTGATGGACCAACAGT





GCAAATGCAATCTCGCCATTTAACTTTCAGGTCGATTTCCTTTCCTGAT





CAGACATCTTTGTGCCCCCTTTAGGAAGGAAAAGAATACACCTACGATG





TGCCAGGCACTGTGTTAGGCGCTTTTATATAGATCCTCGTTAGGATGAG





ACTAAGGGATGAGGACATCTCTTTATAAAAGGCCCCTAAGTAATGGATA





AACAGAAACACTTAGAGGTGAGAAGGTCTGTCTTCAAGATCCAAGGTAA





GATTGCCTTCAGTCTGATGTTTGTTCTCAAGGACTTATCCCCTACAATA





TTCTCCCACTCCATACTTCTCCTTCTACCCCACCATGTGCTCCCGTGCA





CTCCTCAGATGGTCAGAGGGGTAACCCAAGTCCTTAGAGAATTTGGGGA





CCAATAGAATATGTGATGTGTGAATTTTCTTTAAAAAACTTAAGGAGTC





TTTGCTACCTTCTGCTTGTTGAGTTGTTTTGGCATTCATATTAAAAGCC





AGCATCTCACTATTTATTGACAGGTTGGGCTGTGTGTGTGCGCATGTGT





GTATACATTTCCAGGCGTGCCTGTGTCCTGTAGCTTTTTAAAAGGAAAC





CCAGTCATCCCACTATGAATCTGGCATCTTCTTATGCTTCTAGTGTTTT





GGCCATACATCAACCAAGGGGTTTAATTTATCCAATGCTTGACGACATG





TTCAGGAGGGGCTGGATCAAATTTTGAGAGGGTTATGGGAAAGGGAGGG





GGAGAAGAAATTGACATTTATTTTATTATTTATTTTAAATGTTTACATC





TTCTTTATGTTGTATCAAGCCTGAATAGAAACTGATAGCATTAAAATAC





TCCGTTCCTCTCTCTCTTCTCGCTTCCTTTTTTTTTTTTTTTTTAAATT





TAGGATAACACATTTTTGTTTCTAAAGTGATTTGTGATTTGTGCTGTAT





AAACTGTATAAAAGGTTCTGTTTTTAAAGGTGGATTTTCATTCCTCTGG





GGACAGTGGTCGCCAAGACATCTACATTGTAAGAGAACACAGTGGAAGA





TCCTGTCCTGATTCTCAAAAATTATTTTCTCTGTATGATTAAAAGTTTA





TTCCATTTATTTTAGTTTGTGTTTACTTGATTTTGAGGAAGAAAATATT





TGACTTTGTGTAAAGAGTAGGGTATCAGGGTGTCTTTTCTGCCGTGGGA





GATGTGTATATATATAGTATTTTGGTGTATAGTAGAAAATAAGCTTTGT





GCATCTGTATTTGAGATATGTTAATGACGTGGAGTAAAGTCAGCTGTAA





GACTCTGGAGGCAAACAAGTTGTATATGGTTCATATGGCTCTATGGGGA





ATTTAATTACCTTTCTGGGCACTTTTTTTTTTTTTTTTTTTTTAAGTAA





TGGTGAAATGGTCCCATTGGAGAGTCTCCTAAATAGACCTTCCAGGCAG





AACCGCAAGCTCAAAATCTTTGTATAGTTTTGAAAATTGAGGAGTAGCT





TTGTTTGGAAGCCTTTCTGGTGGTGGTTTTTGTTGTTGTTGTTGTTTTG





TTGTTTTACTATATGTAATACAAGCCTACAGTATTTGCACTAAAGAAAG





CTTGTTAGAAAAAGCTTGCTGCTATGGAAGAAAGAACATATTAAAACTT





CTTTCCCTTGCGATTTTTTTGGGGGAGGGGGGTTAGCATTTCCACTTTC





AGTTGAGTAGCATTTTGTAGAATAAAATGAATTAAGATTGAAGAGCC.,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:214 under stringent hybridization conditions.


In some embodiments Jun proto-oncogene, AP-1 transcription factor subunit (JUN, p39, cJUN) comprises the amino acid sequence:









MTAKMETTFYDDALNASFLPSESGPYGYSNPKILKQSMTLNLADPVGSLK





PHLRAKNSDLLTSPDVGLLKLASPELERLIIQSSNGHITTTPTPTQFLCP





KNVTDEQEGFAEGFVRALAELHSQNTLPSVTSAAQPVNGAGMVAPAVASV





AGGSGSGGFSASLHSEPPVYANLSNFNPGALSSGGGAPSYGAAGLAFPAQ





PQQQQQPPHHLPQQMPVQHPRLQALKEEPQTVPEMPGETPPLSPIDMESQ





ERIKAERKRMRNRIAASKCRKRKLERIARLEEKVKTLKAQNSELASTANM





LREQVAQLKQKVMNHVNSGCQLMLTQQLQTF.(SEQ ID NO: 215; N





NP_002219.1),







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:215)


In some embodiments, the nucleic acid sequence encoding JUN comprises the nucleic acid sequence:










GCTCAGAGTTGCACTGAGTGTGGCTGAAGCAGCGAGGCGGGAGTGGAGGTGCGC






GGAGTCAGGCAGACAGACAGACACAGCCAGCCAGCCAGGTCGGCAGTATAGTCC





GAACTGCAAATCTTATTTTCTTTTCACCTTCTCTCTAACTGCCCAGAGCTAGCGCCT





GTGGCTCCCGGGCTGGTGTTTCGGGAGTGTCCAGAGAGCCTGGTCTCCAGCCGC





CCCCGGGAGGAGAGCCCTGCTGCCCAGGCGCTGTTGACAGCGGCGGAAAGCAGC





GGTACCCACGCGCCCGCCGGGGGAAGTCGGCGAGCGGCTGCAGCAGCAAAGAAC





TTTCCCGGCTGGGAGGACCGGAGACAAGTGGCAGAGTCCCGGAGCCAACTTTTGC





AAGCCTTTCCTGCGTCTTAGGCTTCTCCACGGCGGTAAAGACCAGAAGGCGGCGG





AGAGCCACGCAAGAGAAGAAGGACGTGCGCTCAGCTTCGCTCGCACCGGTTGTTG





AACTTGGGCGAGCGCGAGCCGCGGCTGCCGGGCGCCCCCTCCCCCTAGCAGCGG





AGGAGGGGACAAGTCGTCGGAGTCCGGGCGGCCAAGACCCGCCGCCGGCCGGC





CACTGCAGGGTCCGCACTGATCCGCTCCGCGGGGAGAGCCGCTGCTCTGGGAAG





TGAGTTCGCCTGCGGACTCCGAGGAACCGCTGCGCACGAAGAGCGCTCAGTGAGT





GACCGCGACTTTTCAAAGCCGGGTAGCGCGCGCGAGTCGACAAGTAAGAGTGCGG





GAGGCATCTTAATTAACCCTGCGCTCCCTGGAGCGAGCTGGTGAGGAGGGCGCAG





CGGGGACGACAGCCAGCGGGTGCGTGCGCTCTTAGAGAAACTTTCCCTGTCAAAG





GCTCCGGGGGGCGCGGGTGTCCCCCGCTTGCCACAGCCCTGTTGCGGCCCCGAA





ACTTGTGCGCGCAGCCCAAACTAACCTCACGTGAAGTGACGGACTGTTCTATGACT





GCAAAGATGGAAACGACCTTCTATGACGATGCCCTCAACGCCTCGTTCCTCCCGTC





CGAGAGCGGACCTTATGGCTACAGTAACCCCAAGATCCTGAAACAGAGCATGACC





CTGAACCTGGCCGACCCAGTGGGGAGCCTGAAGCCGCACCTCCGCGCCAAGAAC





TCGGACCTCCTCACCTCGCCCGACGTGGGGCTGCTCAAGCTGGCGTCGCCCGAG





CTGGAGCGCCTGATAATCCAGTCCAGCAACGGGCACATCACCACCACGCCGACCC





CCACCCAGTTCCTGTGCCCCAAGAACGTGACAGATGAGCAGGAGGGCTTCGCCGA





GGGCTTCGTGCGCGCCCTGGCCGAACTGCACAGCCAGAACACGCTGCCCAGCGT





CACGTCGGCGGCGCAGCCGGTCAACGGGGCAGGCATGGTGGCTCCCGCGGTAGC





CTCGGTGGCAGGGGGCAGCGGCAGCGGCGGCTTCAGCGCCAGCCTGCACAGCG





AGCCGCCGGTCTACGCAAACCTCAGCAACTTCAACCCAGGCGCGCTGAGCAGCGG





CGGCGGGGCGCCCTCCTACGGCGCGGCCGGCCTGGCCTTTCCCGCGCAACCCCA





GCAGCAGCAGCAGCCGCCGCACCACCTGCCCCAGCAGATGCCCGTGCAGCACCC





GCGGCTGCAGGCCCTGAAGGAGGAGCCTCAGACAGTGCCCGAGATGCCCGGCGA





GACACCGCCCCTGTCCCCCATCGACATGGAGTCCCAGGAGCGGATCAAGGCGGA





GAGGAAGCGCATGAGGAACCGCATCGCTGCCTCCAAGTGCCGAAAAAGGAAGCTG





GAGAGAATCGCCCGGCTGGAGGAAAAAGTGAAAACCTTGAAAGCTCAGAACTCGG





AGCTGGCGTCCACGGCCAACATGCTCAGGGAACAGGTGGCACAGCTTAAACAGAA





AGTCATGAACCACGTTAACAGTGGGTGCCAACTCATGCTAACGCAGCAGTTGCAAA





CATTTTGAAGAGAGACCGTCGGGGGCTGAGGGGCAACGAAGAAAAAAAATAACAC





AGAGAGACAGACTTGAGAACTTGACAAGTTGCGACGGAGAGAAAAAAGAAGTGTCC





GAGAACTAAAGCCAAGGGTATCCAAGTTGGACTGGGTTGCGTCCTGACGGCGCCC





CCAGTGTGCACGAGTGGGAAGGACTTGGCGCGCCCTCCCTTGGCGTGGAGCCAG





GGAGCGGCCGCCTGCGGGCTGCCCCGCTTTGCGGACGGGCTGTCCCCGCGCGAA





CGGAACGTTGGACTTTTCGTTAACATTGACCAAGAACTGCATGGACCTAACATTCGA





TCTCATTCAGTATTAAAGGGGGGAGGGGGAGGGGGTTACAAACTGCAATAGAGAC





TGTAGATTGCTTCTGTAGTACTCCTTAAGAACACAAAGCGGGGGGAGGGTTGGGGA





GGGGCGGCAGGAGGGAGGTTTGTGAGAGCGAGGCTGAGCCTACAGATGAACTCT





TTCTGGCCTGCCTTCGTTAACTGTGTATGTACATATATATATTTTTTAATTTGATGAA





AGCTGATTACTGTCAATAAACAGCTTCATGCCTTTGTAAGTTATTTCTTGTTTGTTTG





TTTGGGTATCCTGCCCAGTGTTGTTTGTAAATAAGAGATTTGGAGCACTCTGAGTTT





ACCATTTGTAATAAAGTATATAATTTTTTTATGTTTTGTTTCTGAAAATTCCAGAAAGG





ATATTTAAGAAAATACAATAAACTATTGGAAAGTACTCCCCTAACCTCTTTTCTGCAT





CATCTGTAGATACTAGCTATCTAGGTGGAGTTGAAAGAGTTAAGAATGTCGATTAAA





ATCACTCTCAGTGCTTCTTACTATTAAGCAGTAAAAACTGTTCTCTATTAGACTTTAG





AAATAAATGTACCTGATGTACCTGATGCTATGGTCAGGTTATACTCCTCCTCCCCCA





GCTATCTATATGGAATTGCTTACCAAAGGATAGTGCGATGTTTCAGGAGGCTGGAG





GAAGGGGGGTTGCAGTGGAGAGGGACAGCCCACTGAGAAGTCAAACATTTCAAAG





TTTGGATTGTATCAAGTGGCATGTGCTGTGACCATTTATAATGTTAGTAGAAATTTTA





CAATAGGTGCTTATTCTCAAAGCAGGAATTGGTGGCAGATTTTACAAAAGATGTATC





CTTCCAATTTGGAATCTTCTCTTTGACAATTCCTAGATAAAAAGATGGCCTTTGCTTA





TGAATATTTATAACAGCATTCTTGTCACAATAAATGTATTCAAATACCAA. (SEQ ID





NO: 216; NM_002228.4),







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:216 under stringent hybridization conditions.


In some embodiments, JunB proto-oncogene, AP-1 transcription factor subunit (JUNB) comprises the amino acid sequence:









MCTKMEQPFYHDDSYTATGYGRAPGGLSLHDYKLLKPSLAVNLADPYRSL





KAPGARGPGPEGGGGGSYFSGQGSDTGASLKLASSELERLIVPNSNGVIT





TTPTPPGQYFYPRGGGSGGGAGGAGGGVTEEQEGFADGFVKALDDLHKMN





HVTPPNVSLGATGGPPAGPGGVYAGPEPPPVYTNLSSYSPASASSGGAGA





AVGTGSSYPTTTISYLPHAPPFAGGHPAQLGLGRGASTFKEEPQTVPEAR





SRDATPPVSPINMEDQERIKVERKRLRNRLAATKCRKRKLERIARLEDKV





KTLKAENAGLSSTAGLLREQVAQLKQKVMTHVSNGCQLLLGVKGHAF





(SEQ ID NO: 217; NP_0022201),







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:217)


In some embodiments, the nucleic acid sequence encoding JUNB comprises the nucleic acid sequence:









GGGACCTTGAGAGCGGCCAGGCCAGCCTCGGAGCCAGCAGGGAGCTGGGA





GCTGGGGGAAACGACGCCAGGAAAGCTATCGCGCCAGAGAGGGCGACGGG





GGCTCGGGAAGCCTGACAGGGCTTTTGCGCACAGCTGCCGGCTGGCTGCT





ACCCGCCCGCGCCAGCCCCCGAGAACGCGCGACCAGGCACCCAGTCCGGT





CACCGCAGCGGAGAGCTCGCCGCTCGCTGCAGCGAGGCCCGGAGCGGCCC





CGCAGGGACCCTCCCCAGACCGCCTGGGCCGCCCGGATGTGCACTAAAAT





GGAACAGCCCTTCTACCACGACGACTCATACACAGCTACGGGATACGGCC





GGGCCCCTGGTGGCCTCTCTCTACACGACTACAAACTCCTGAAACCGAGC





CTGGCGGTCAACCTGGCCGACCCCTACCGGAGTCTCAAAGCGCCTGGGGC





TCGCGGACCCGGCCCAGAGGGCGGCGGTGGCGGCAGCTACTTTTCTGGTC





AGGGCTCGGACACCGGCGCGTCTCTCAAGCTCGCCTCTTCGGAGCTGGAA





CGCCTGATTGTCCCCAACAGCAACGGCGTGATCACGACGACGCCTACACC





CCCGGGACAGTACTTTTACCCCCGCGGGGGTGGCAGCGGTGGAGGTGCAG





GGGGCGCAGGGGGCGGCGTCACCGAGGAGCAGGAGGGCTTCGCCGACGGC





TTTGTCAAAGCCCTGGACGATCTGCACAAGATGAACCACGTGACACCCCC





CAACGTGTCCCTGGGCGCTACCGGGGGGCCCCCGGCTGGGCCCGGGGGCG





TCTACGCCGGCCCGGAGCCACCTCCCGTTTACACCAACCTCAGCAGCTAC





TCCCCAGCCTCTGCGTCCTCGGGAGGCGCCGGGGCTGCCGTCGGGACCGG





GAGCTCGTACCCGACGACCACCATCAGCTACCTCCCACACGCGCCGCCCT





TCGCCGGTGGCCACCCGGCGCAGCTGGGCTTGGGCCGCGGCGCCTCCACC





TTCAAGGAGGAACCGCAGACCGTGCCGGAGGCGCGCAGCCGGGACGCCAC





GCCGCCGGTGTCCCCCATCAACATGGAAGACCAAGAGCGCATCAAAGTGG





AGCGCAAGCGGCTGCGGAACCGGCTGGCGGCCACCAAGTGCCGGAAGCGG





AAGCTGGAGCGCATCGCGCGCCTGGAGGACAAGGTGAAGACGCTCAAGGC





CGAGAACGCGGGGCTGTCGAGTACCGCCGGCCTCCTCCGGGAGCAGGTGG





CCCAGCTCAAACAGAAGGTCATGACCCACGTCAGCAACGGCTGTCAGCTG





CTGCTTGGGGTCAAGGGACACGCCTTCTGAACGTCCCCTGCCCCTTTACG





GACACCCCCTCGCTTGGACGGCTGGGCACACGCCTCCCACTGGGGTCCAG





GGAGCAGGCGGTGGGCACCCACCCTGGGACCTAGGGGCGCCGCAAACCAC





ACTGGACTCCGGCCCTCCTACCCTGCGCCCAGTCCTTCCACCTCGACGTT





TACAAGCCCCCCCTTCCACTTTTTTTTGTATGTTTTTTTTCTGCTGGAAA





CAGACTCGATTCATATTGAATATAATATATTTGTGTATTTAACAGGGAGG





GGAAGAGGGGGCGATCGCGGCGGAGCTGGCCCCGCCGCCTGGTACTCAAG





CCCGCGGGGACATTGGGAAGGGGACCCCCGCCCCCTGCCCTCCCCTCTCT





GCACCGTACTGTGGAAAAGAAACACGCACTTAGTCTCTAAAGAGTTTATT





TTAAGACGTGTTTGTGTTTGTGTGTGTTTGTTCTTTTTATTGAATCTATT





TAAGTAAAAAAAAAATTGGTTCTTTATTAA. (SEQ ID NO: 218;





NM_002229.3),







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:218 under stringent hybridization conditions.


In some embodiments, JunD proto-oncogene, AP-1 transcription factor subunit (JunD) comprises the amino acid sequence:









MMKKDALTLSLSEQVAAALKPAAAPPPTPLRADGAPSAAPPDGLLASPDL





GLLKLASPELERLIIQSNGLVTTTPTSSQFLYPKVAASEEQEFAEGFVKA





LEDLHKQNQLGAGAAAAAAAAAAGGPSGTATGSAPPGELAPAAAAPEAPV





YANLSSYAGGAGGAGGAATVAFAAEPVPFPPPPPPGALGPPRLAALKDEP





QTVPDVPSFGESPPLSPIDMDTQERIKAERKRLRNRIAASKCRKRKLERI





SRLEEKVKTLKSQNTELASTASLLREQVAQLKQKVLSHVNSGCQLLPQHQ





VPAY.(SEQ ID NO: 219; NP_001273897.1),







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:219)


In some embodiments, the nucleic acid sequence encoding JUND comprises the nucleic acid sequence:









AGGAGCCGCCGCCAGTGGAGGGCCGGGCGCTGCGGCCGCGGCCGGGGCGG





GCGCAGGGCCGAGCGGACGGGGGGGCGCGGGCCCCCCGGGAGGCCGCGGC





CACTCCCCCCCGGGCCGGCGCGGCGGGGGAGGCGGAGGATGGAAACACCC





TTCTACGGCGATGAGGCGCTGAGCGGCCTGGGCGGCGGCGCCAGTGGCAG





CGGCGGCAGCTTCGCGTCCCCGGGCCGCTTGTTCCCCGGGGCGCCCCCGA





CGGCCGCGGCCGGCAGCATGATGAAGAAGGACGCGCTGACGCTGAGCCTG





AGTGAGCAGGTGGCGGCAGCGCTCAAGCCTGCGGCCGCGCCGCCTCCTAC





CCCCCTGCGCGCCGACGGCGCCCCCAGCGCGGCACCCCCCGACGGCCTGC





TCGCCTCTCCCGACCTGGGGCTGCTGAAGCTGGCCTCCCCCGAGCTCGAG





CGCCTCATCATCCAGTCCAACGGGCTGGTCACCACCACGCCGACGAGCTC





ACAGTTCCTCTACCCCAAGGTGGCGGCCAGCGAGGAGCAGGAGTTCGCCG





AGGGCTTCGTCAAGGCCCTGGAGGATTTACACAAGCAGAACCAGCTCGGC





GCGGGCGCGGCCGCTGCCGCCGCCGCCGCCGCCGCCGGGGGGCCCTCGGG





CACGGCCACGGGCTCCGCGCCCCCCGGCGAGCTGGCCCCGGCGGCGGCCG





CGCCCGAAGCGCCTGTCTACGCGAACCTGAGCAGCTACGCGGGCGGCGCC





GGGGGCGCGGGGGGCGCCGCGACGGTCGCCTTCGCTGCCGAACCTGTGCC





CTTCCCGCCGCCGCCACCCCCAGGCGCGTTGGGGCCGCCGCGCCTGGCTG





CGCTCAAGGACGAGCCACAGACGGTGCCCGACGTGCCGAGCTTCGGCGAG





AGCCCGCCGTTGTCGCCCATCGACATGGACACGCAGGAGCGCATCAAGGC





GGAGCGCAAGCGGCTGCGCAACCGCATCGCCGCCTCCAAGTGCCGCAAGC





GCAAGCTGGAGCGCATCTCGCGCCTGGAAGAGAAAGTGAAGACCCTCAAG





AGTCAGAACACGGAGCTGGCGTCCACGGCGAGCCTGCTGCGCGAGCAGGT





GGCGCAGCTCAAGCAGAAAGTCCTCAGCCACGTCAACAGCGGCTGCCAGC





TGCTGCCCCAGCACCAGGTGCCCGCGTACTGAGTCCGCGCGCGGGGCGCA





TGCGCGGCCACCCTCCCCAAGGGGCGGGCTCGCGGGGGGGTGTCGTGGGC





GCCCCGGACTTGGAGAGGGTGCGGCCCTGGGGACCCCCCCTCCCCGAGTG





TGCCCAGGAACTCAGAGAGGGCGCGGCCCCCGGGGATTCCCCCCCCCCGA





GGGTGCCCAGGACTCGACAAGCTGGACCCCCTGCTCCCGGGGGGGCGAGC





GCATGACCCCCCCGCCCTCGCGCTGCCTCTTTCCCCCGCGCGGCCGCCCC





GTGTTGCACAAACCCGCGCGTCTCGGCTGCCCCTTTGTACACCGCGCCGC





GGAAGGGGGCTCCGAGGGGGCGCAGCCTCAAACCCTGCCTTTCCTTTACT





TTTACTTTTTTTTTTTTTTCTTTGGAAGAGAGAAGAACAGAGTGTTCGAT





TCTGCCCTATTTATGTTTCTACTCGGGAACAAACGTTGGTTGTGTGTGTG





TGTGTTTTCTTGTGTTGGTTTTTTAAAGAAATGGGAAGAAGAAAAAAAAA





TTCTCCGCCCCTTTCCTCGATCTCGCTCCCCCCTTCGGTTCTTTCGACCG





GTCCCCCCTCCCTTTTTTGTTCTGTTTTGTTTTGTTTTGCTACGAGTCCA





CATTCCTGTTTGTAATCCTTGGTTCGCCCGGTTTTCTGTTTTCAGTAAAG





TCTCGTTACGCCAGCTCGGCTCTCCGCCTCCTTCTTCCCCCGCCGGGGCC





TGGCGGGCTGGGCGGGGCCTGGTTCGCTT.(SEQ ID NO: 220;





NM_001286968.2),







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:220 under stringent hybridization conditions.


In some embodiments, ZFP36 ring finger protein (ZFP36, TTP) comprises the amino acid sequence:









MDLTAIYESLLSLSPDVPVPSDHGGTESSPGWGSSGPWSLSPSDSSPSGV





TSRLPGRSTSLVEGRSCGWVPPPPGFAPLAPRLGPELSPSPTSPTATSTT





PSRYKTELCRTFSESGRCRYGAKCQFAHGLGELRQANRHPKYKTELCHKF





YLQGRCPYGSRCHFIHNPSEDLAAPGHPPVLRQSISFSGLPSGRRTSPPP





PGLAGPSLSSSSFSPSSSPPPPGDLPLSPSAFSAAPGTPLARRDPTPVCC





PSCRRATPISVWGPLGGLVRTPSVQSLGSDPDEYASSGSSLGGSDSPVFE





AGVFAPPQPVAAPRRLPIFNRISVSE.(SEQ ID NO: 221;





NP_003398.3),







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:221)


In some embodiments, the nucleic acid sequence encoding ZFP36 comprises the nucleic acid sequence:









AGCCTGACTTCAGCGCTCCCACTCTCGGCCGACACCCCTCATGGCCAACC





GTTACACCATGGATCTGACTGCCATCTACGAGAGCCTCCTGTCGCTGAGC





CCTGACGTGCCCGTGCCATCCGACCATGGAGGGACTGAGTCCAGCCCAGG





CTGGGGCTCCTCGGGACCCTGGAGCCTGAGCCCCTCCGACTCCAGCCCGT





CTGGGGTCACCTCCCGCCTGCCTGGCCGCTCCACCAGCCTAGTGGAGGGC





CGCAGCTGTGGCTGGGTGCCCCCACCCCCTGGCTTCGCACCGCTGGCTCC





CCGCCTGGGCCCTGAGCTGTCACCCTCACCCACTTCGCCCACTGCAACCT





CCACCACCCCCTCGCGCTACAAGACTGAGCTATGTCGGACCTTCTCAGAG





AGTGGGCGCTGCCGCTACGGGGCCAAGTGCCAGTTTGCCCATGGCCTGGG





CGAGCTGCGCCAGGCCAATCGCCACCCCAAATACAAGACGGAACTCTGTC





ACAAGTTCTACCTCCAGGGCCGCTGCCCCTACGGCTCTCGCTGCCACTTC





ATCCACAACCCTAGCGAAGACCTGGCGGCCCCGGGCCACCCTCCTGTGCT





TCGCCAGAGCATCAGCTTCTCCGGCCTGCCCTCTGGCCGCCGGACCTCAC





CACCACCACCAGGCCTGGCCGGCCCTTCCCTGTCCTCCAGCTCCTTCTCG





CCCTCCAGCTCCCCACCACCACCTGGGGACCTTCCACTGTCACCCTCTGC





CTTCTCTGCTGCCCCTGGCACCCCCCTGGCTCGAAGAGACCCCACCCCAG





TCTGTTGCCCCTCCTGCCGAAGGGCCACTCCTATCAGCGTCTGGGGGCCC





TTGGGTGGCCTGGTTCGGACCCCCTCTGTACAGTCCCTGGGATCCGACCC





TGATGAATATGCCAGCAGCGGCAGCAGCCTGGGGGGCTCTGACTCTCCCG





TCTTCGAGGCGGGAGTTTTTGCACCACCCCAGCCCGTGGCAGCCCCCCGG





CGACTCCCCATCTTCAATCGCATCTCTGTTTCTGAGTGACAAAGTGACTG





CCCGGTCAGATCAGCTGGATCTCAGCGGGGAGCCACGTCTCTTGCACTGT





GGTCTCTGCATGGACCCCAGGGCTGTGGGGACTTGGGGGACAGTAATCAA





GTAATCCCCTTTTCCAGAATGCATTAACCCACTCCCCTGACCTCACGCTG





GGGCAGGTCCCCAAGTGTGCAAGCTCAGTATTCATGATGGTGGGGGATGG





AGTGTCTTCCGAGGTTCTTGGGGGAAAAAAAATTGTAGCATATTTAAGGG





AGGCAATGAACCCTCTCCCCCACCTCTTCCCTGCCCAAATCTGTCTCCTA





GAATCTTATGTGCTGTGAATAATAGGCCTTCACTGCCCCTCCAGTTTTTA





TAGACCTGAGGTTCCAGTGTCTCCTGGTAACTGGAACCTCTCCTGAGGGG





GAATCCTGGTGCTCAAATTACCCTCCAAAAGCAAGTAGCCAAAGCCGTTG





CCAAACCCCACCCATAAATCAATGGGCCCTTTATTTATGACGACTTTATT





TATTCTAATATGATTTTATAGTATTTATATATATTGGGTCGTCTGCTTCC





CTTGTATTTTTCTTCCTTTTTTTGTAATATTGAAAACGACGATATAATTA





TTATAAGTAGACTATAATATATTTAGTAATATATATTATTACCTTAAAAG





TCTATTTTTGTGTTTTGGGCATTTTTAAATAAACAATCTGAGTGTAA.





(SEQ ID NO: 222; NM_003407.5),







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:222 under stringent hybridization conditions.


In some embodiments, EBF transcription factor 1 (EBF1, EBF, COE1, OL1)) comprises the amino acid sequence:









MFGIQESIQRSGSSMKEEPLGSGMNAVRTWMQGAGVLDANTAAQSGVGLA





RAHFEKQPPSNLRKSNFFHFVLALYDRQGQPVEIERTAFVGFVEKEKEAN





SEKTNNGIHYRLQLLYSNGIRTEQDFYVRLIDSMTKQAIVYEGQDKNPEM





CRVLLTHEIMCSRCCDKKSCGNRNETPSDPVIIDRFFLKFFLKCNQNCLK





NAGNPRDMRRFQVVVSTTVNVDGHVLAVSDNMFVHNNSKHGRRARRLDPS





EGTPSYLEHAATPCIKAISPSEGVVTTGGATVIIIGDNFFDGLQVIFGTM





LVWSELITPHAIRVQTPPRHIPGVVEVTLSYKSKQFCKGTPGRFIYTALN





EPTIDYGFQRLQKVIPRHPGDPERLPKEVILKRAADLVEALYGMPHNNQE





IILKRAADIAEALYSVPRNHNQLPALANTSVHAGMMGVNSFSGQLAVNVS





EASQATNQGFTRNSSSVSPHGYVPSTTPQQTNYNSVTTSMNGYGSAAMSN





LGGSPTFLNGSAANSPYAIVPSSPTMASSTSLPSNCSSSSGIFSFSPANM





VSAVKQKSAFAPVVRPQTSPPPTCTSTNGNSLQAISGMIVPPM.(SEQ





ID NO: 223; NP_001277289.1),







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:223)


In some embodiments, the nucleic acid sequence encoding EBF1 comprises the nucleic acid sequence:










CCTGCTTCTTCAAGTGAAGGGTACCTCTACAAAAGGAAACTCCAGCCCCTCCTGTC






CTCCACCGGCCTGTGATCATTACAAAAAAAAAAAAAAAAAAGCAAAAAAAAAAAAAA





AGCACCCAAACCAAAAATCAACCAACCAAACAACCCCCAACAGCCAAGCATACATC





TCTAATTTTATTATTTTGGTCTTTTCGTTGGATTTTCCCTTTCTTCTTTTTTTCGGGTT





ATCGCTCAGTTTTGAGCAGAGGTTTACATTTTTTAAAAATTTGCTTTCCAGCCCGCC





TTGATCTTCTAAGTGCGAGTTCATCGTCTGAGAAAAAAAAAAATCTCTGGTTGGCGT





TTTTGTTTCTTTTCTTTTCTTTCTTTTCTTTCCTTTTTTTTTTTTTTTAATTTTTTTCAAG





GGGGAGGAGATTTTCCACAAGAAAAGGTTGTTTTCATGTTTGGGATTCAGGAAAGC





ATCCAACGGAGTGGAAGCAGCATGAAGGAAGAGCCGCTGGGCAGCGGCATGAAC





GCGGTGCGGACGTGGATGCAGGGCGCCGGGGTGCTGGACGCCAACACGGCGGC





GCAGAGCGGGGTGGGTCTGGCCCGGGCTCACTTTGAGAAGCAGCCGCCTTCCAAT





CTGCGGAAATCCAACTTCTTCCACTTCGTCCTGGCCCTCTACGACAGACAGGGCCA





GCCCGTGGAGATCGAGAGGACAGCGTTTGTGGGGTTCGTGGAGAAGGAAAAAGAA





GCCAACAGCGAAAAGACCAATAACGGAATTCACTACCGGCTTCAGCTTCTCTACAG





CAATGGGATAAGGACGGAGCAGGATTTCTACGTGCGCCTCATTGACTCCATGACAA





AACAAGCCATAGTGTATGAAGGCCAAGACAAGAACCCAGAAATGTGCCGAGTCTTG





CTCACACATGAGATCATGTGCAGCCGCTGTTGTGACAAGAAAAGCTGTGGCAACCG





AAATGAGACTCCCTCAGATCCAGTGATAATTGACAGGTTCTTCTTGAAATTTTTCCT





CAAATGTAACCAAAATTGCCTAAAGAATGCGGGAAACCCACGTGACATGCGGAGAT





TCCAGGTCGTGGTGTCTACGACAGTCAATGTGGATGGCCATGTCCTGGCAGTCTCT





GATAACATGTTTGTCCATAATAATTCCAAGCATGGGCGGAGGGCTCGGAGGCTTGA





CCCCTCGGAAGGTACGCCCTCTTATCTGGAACATGCAGCTACTCCCTGTATCAAAG





CCATCAGCCCGAGTGAAGGATGGACGACGGGAGGTGCGACTGTGATCATCATAGG





GGACAATTTCTTTGATGGGTTACAGGTCATATTCGGTACCATGCTGGTCTGGAGTG





AGTTGATCACTCCTCATGCCATCCGTGTGCAGACCCCTCCTCGGCACATCCCTGGT





GTTGTGGAAGTCACACTGTCCTACAAATCTAAGCAGTTCTGCAAAGGAACACCAGG





CAGATTCATTTATACAGCGCTCAACGAACCCACCATCGATTATGGTTTCCAGAGGTT





ACAGAAGGTCATTCCTCGGCACCCTGGTGACCCTGAGCGTTTGCCAAAGGAAGTAA





TACTCAAAAGGGCTGCGGATCTGGTAGAAGCACTGTATGGGATGCCACACAACAAC





CAGGAAATCATTCTGAAGAGAGCGGCCGACATTGCCGAGGCCCTGTACAGTGTTC





CCCGCAACCACAACCAACTCCCGGCCCTTGCTAACACCTCGGTCCACGCAGGGAT





GATGGGCGTGAATTCGTTCAGTGGACAACTGGCCGTGAATGTCTCCGAGGCATCA





CAAGCCACCAATCAGGGTTTCACCCGCAACTCAAGCAGCGTATCACCACACGGGTA





CGTGCCGAGCACCACTCCCCAGCAGACCAACTATAACTCCGTCACCACGAGCATG





AACGGATACGGCTCTGCCGCAATGTCCAATTTGGGCGGCTCCCCCACCTTCCTCAA





CGGCTCAGCTGCCAACTCCCCCTATGCCATAGTGCCATCCAGCCCCACCATGGCC





TCCTCCACAAGCCTCCCCTCCAACTGCAGCAGCTCCTCGGGCATCTTCTCCTTCTC





ACCAGCCAACATGGTCTCAGCCGTGAAACAGAAGAGTGCTTTCGCACCAGTCGTCA





GACCCCAGACCTCCCCACCTCCCACCTGCACCAGCACCAACGGGAACAGCCTGCA





AGCGATATCTGGCATGATTGTTCCTCCTATGTGAAAGAATTGCCTTGAAGAATTGTA





TTAATGAAGAGGTTGGATTCTGCTACAGAGAGTAATCTGATACAAGTCCCAGAGTG





GAACTTTTAACTCAGGCCTTTTTAAGAGGAATCACAATAACTGCAGATTTTTAAACAA





ACAAAATCACCGACCTTGCAAATACTGAAATTGGAAGAGGGATCTGCAAGTGCAGG





GTGTTGGTTAAAGTTGTACCTCCCAAGTATTTGGGGGATATATTTATTCTGTATTGA





CAAAAGCAAATCCACTTTTTCTTTTTCTTTTTTTTTTTTAAGCTTAATTCTGCAATCATT





TGTCTTTTATAAACCGTAAAGCTCTATACAAGGGACACTATAAATAAGACTCCATGTT





TTAATTTATGATGTTTTTAAAGCTGTGTAAAGGAAGAATGAAGTGGTGATATTTACAA





AAAAGTAAAAAAAAAAAAAAAGAAAAAAAGGAAAAAAAAAAAAGCTTGTATGGGACA





GAATAGGAATGCCAGTTAGATTTTTTAGAAAAACTAAGGGTCGGCTTTTGCGCCTTA





AAGCATATCAAATGGTAGTTAGCTCAGACAGTGCATTTTCAATATCTAACTTAACATG





CCACCCCTTAGCAGTGCAAGCTTATTTATCTCTTTTGTATTGTTGTCTTAAGCAACTG





TGTAAATAAATGCAGCCTGGAAAGTTAAAACGCGATGTAAGTGATCACATTTTTCCC





TCTACTCGAAAATCCAGTGCCTCTAGACAGATTGTTAAAACTGCATATTTAAATCTGA





TCTCATTCTCTCCTTTTACTTAAGTCAGTTTCTTCTGAAGCCGATGGCCTCTCGAGA





GCTTGGTGGCACACATACTGTGTGAGAATCTCCTTTGAGACTTCATGGAACAGGGT





CCAGGCACAGAATTCCACACTCTGCCCTCCAGTTAACAAGCCAAAACCTCACGTAC





GCTCCCCCATTTGCAAGTTTAAAGTTTACTCGTCCTAAATGCAGACTTCATACCTAT





CTTCCAAAAGTTGATAAAAGCAACGTGGCAGGTATTTTCGATTTTCCCATTCCAGAT





ACTGCCTCTATCAGTCGACCCTTACCATTTGTAACATAATAGATTGAAACAACAGGT





TAAGTGCTTTGGAATTAAGAGTTAAAGGGAACCGGGGGTGGAGAAAGGAAAAGAA





GGTTGAGACCTCCAAAACATAGTTTTCTGTTCTATGGGAATTTTTGCTCTCATTATCT





GGGAAGTGTTCTTAAAAATAAGAATTAATAGCAAAGATGCAGCAAAGCTCTGAGGAT





GCATTTGCCTGATATTTTTTTCTTTGCTCTTGTGTTTTTGTATGTAGTTATAAATACTG





TAGATTTTTTTTTTGTGATTTTTTGCCAAAGTTGTTGTTCTATTTATACATTTTAATGTC





TTAAGACATTTTTTCAATATCACAAAAAGATTTTACTGCGTATTTTGCAAAGAAAAAA





AGCTCACTACCTTTAGCTTGCACATACTTGCAAAGTTAATTAAAAGGCTTTTTGTTTT





AAAGGGGATTTTGTAAAATATCCATATAAATAATGTATTTATCTTTCGAATTTGTACAT





TGCTTTTCCCTTCTTCCTCTTCCTTCCACCCCCAATTTATTTTATTGTGTATGTTTGCT





ACGTGAAAAGTGCGTATTTGTTTGGTCACCTACACTTGTATTAGCTGTTTCAATGTG





ATTTTTAAACATTTCATTTATAGTTATTTTTAGTATTGTTATAAACCATGCTTCAGTTTT





TTTAATTTCCACCCAAAAGTCATTGTCTATTTTTGTATTATTTGTAAGTTAAGAAGTTT





TTTCCAATATATGGCAAAAAAAAAAAAATAGTAGCATATTATTCTTGTAGTATTTAGTT





CAGTAGATTTAAAAAAAAATGTATCCTTTGCTTTGGAAGCTTACAAAACAACCCTAAT





GCTGTTTTACTCTATTAATATGCATGGAATCTCTCCCTTTGGAGTGACGCATTTTGT





GCATTAAATTCTAGGGAGAAACTTCATAGAAATCAATGAACATACTTTCTTTCTTAAG





TCTGCTTGTATATTTCCTCTGTCTTTCACATAAATATAAACCAGCAGATTGGATGCCT





TAACAATGCAAATCATATTCATTTCACTTGTACATTGTAACTGTGCACCAGAACTGTC





AGTCATCACTAACATTCTAAGAAAAAAGAAAAAGAAAAAAAGAAAAAAAAAAAAACAA





AGAAATCGAAAAGCACAAAAGAACTGTTTTGTTACCTTAAGACAATGTAACTTTTTCT





AGTAGAGCAAGAAATCATTTACAACAATGCTGCAACTGTGCATGCCCCCATATGGAT





TTTGCAATGGTTTTCACTAGGCTGTCAAGAGTGCGATTTTTATGGGTTGGGGTGGG





TGGGGGAGGGGAGTTGTGGGAGGGTAGGGGAGGGAGGAAAGCTGTTTTTCATGG





TGAGAAATAATAATGATGACTAATAATAATAAAAAAAACTGGAAAATGTAAGCAAGGT





GGACGCATTGCTTCTCGGTACTCAGAAAGGTTATCTGAATTTGCGTGGTAAGCGCT





GGCCTGAAGATGTACACAAGTTAAAGCCATATTTTATCTGGTGAGCCCCTTAACTGT





TTCTGAAGGAATGAACGGTCAGCCGGGAAGGTGTCCGGCTTAGACCTTGACAACA





GACACTACCCATCTGTCAGCCATGTGCAGTGGTTAGAACTCTTCTTGAAAGTCCAAA





GAGCCTTTAAAATGTGTATAATTTGTGTTTTGTTGCTTCTATTTCTATTGATTAGATGA





AAAGACATTCTGGCCCTCTGATCCTCTTTCTTCTCCACAAAAGTTTTACAAATAAAAG





ATGTTCCCCTAAATACAGAATATGGCTTTAAGAAGAAAATGAAATGAAGAATTAAATT





AAGATTTCAGTGTTGGGGGAAAAAATACAGCTTCTGGATGACTGGATTGCATAACAT





TGCCCTGGCCTCACATTGTACTAGGATGCAGCTTAAATGAAGTCATCTCTAAATCTA





CTAACCTTTCACCTTCTTATCAAAACTTTTTGAATAGACACACACTGTACAGTTCAAT





TGTTAGAGAACCTAACTACTGTAGAGATTGTTAAATTTTTTTTTTTTTTTTGCAAAAAT





TCAAGCTGTAAAAACTTTTCAACTTTCACAATATTTAATTAAAGTTACTTCCTGTCTGT





GA. (SEQ ID NO: 224; NM_001290360.3),







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:224 under stringent hybridization conditions.


In some embodiments, EBF transcription factor 3 (EBF3, COE3, OE2, HADDS) comprises the amino acid sequence:









MFGIQENIPRGGTTMKEEPLGSGMNPVRSWMHTAGVVDANTAAQSGVGLA





RAHFEKQPPSNLRKSNFFHFVLALYDRQGQPVEIERTAFVDFVEKEKEPN





NEKTNNGIHYKLQLLYSNGVRTEQDLYVRLIDSMTKQAIVYEGQDKNPEM





CRVLLTHEIMCSRCCDKKSCGNRNETPSDPVIIDRFFLKFFLKCNQNCLK





NAGNPRDMRRFQVVVSTTVNVDGHVLAVSDNMFVHNNSKHGRRARRLDPS





EATPCIKAISPSEGVVTTGGATVIIIGDNFFDGLQVVFGTMLVWSELITP





HAIRVQTPPRHIPGVVEVTLSYKSKQFCKGAPGRFVYTALNEPTIDYGFQ





RLQKVIPRHPGDPERLPKEVLLKRAADLVEALYGMPHNNQEIILKRAADI





AEALYSVPRNHNQIPTLGNNPAHTGMMGVNSFSSQLAVNVSETSQANDQV





GYSRNTSSVSPRGYVPSSTPQQSNYNTVSTSMNGYGSGAMASLGVPGSPG





FLNGSSANSPYGMKQKSAFAPVVRPQASPPPSCTSANGNGLQAMSGLVVP





PM.(SEQ ID NO: 225; NP_001005463.1),







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:225)


In some embodiments, the nucleic acid sequence encoding EBF3 comprises the nucleic acid sequence:










ATTCCTCGGGGAGAGAGGGCTGAGTTTTGTGCGCCTCCGTCCGCTGCGCGCGCC






GCTCCAGGCCCCGCCGCGCCCCGCCTGCGCCCGGGACTGCGCCGCAGCACTCAC





TGCCCCGTTTATTTGTCTTTGGAGCAGGCGGGCCGCGCCAGAAGCGGGCGATCCC





GCAGTGTCCTGCAGCCGCGGACGCCGCCTGGCTAGGATGACACCACGTTGAGCG





CGCCTGCAAACAACAACAACAACAAGCGCCGCCGCGGCCACCGCGTCCTGCTCCT





TCGAAGCGCCGCCGCCGCCGGTGGAGCCGCCTCCGCGCCCCTGGCCGTCCGGA





GCGCCCGGCCGCTGGTGTATGTCGCGCCTGCCCGGGACGGGCTGAAGCCGGCG





GCGGGGCCGGACCGCAGGCGCCGAGCAGGGCGAGGGCGGCCAGGGCAGCCGC





CTGCCGCCAAGCCCCGAGCGCCGCTGCTCGAGGAAACGCTTTCGGCCGGGAGCT





GCGGCCGCCGCCAGCAGTTTTCATGTTTGGGATTCAGGAGAATATTCCGCGCGGG





GGGACGACCATGAAGGAGGAGCCGCTGGGCAGCGGCATGAACCCGGTGCGCTCG





TGGATGCACACGGCGGGCGTGGTGGACGCCAACACGGCCGCCCAGAGCGGCGTG





GGGCTGGCGCGGGCGCACTTCGAGAAGCAGCCGCCTTCCAACCTCCGGAAATCC





AATTTCTTCCACTTCGTGCTGGCGCTCTACGATAGGCAGGGGCAGCCGGTGGAGA





TTGAAAGGACCGCTTTTGTGGACTTTGTGGAGAAAGAGAAAGAGCCAAACAACGAG





AAAACCAACAACGGCATCCACTATAAACTCCAGTTATTGTACAGCAACGGAGTCAG





AACAGAGCAAGATCTGTATGTTCGCCTCATAGATTCAATGACCAAACAGGCCATCG





TCTACGAGGGCCAGGACAAGAACCCGGAGATGTGCCGTGTGCTGCTGACCCACGA





GATCATGTGCAGCCGGTGCTGTGACAAGAAAAGTTGTGGCAATAGAAACGAAACGC





CCTCAGACCCTGTAATCATTGACAGATTCTTTCTAAAGTTTTTCCTCAAGTGCAATCA





GAACTGTTTGAAGAATGCAGGCAACCCTCGAGATATGCGGAGATTCCAGGTTGTTG





TATCGACAACAGTCAACGTGGACGGCCACGTGCTGGCCGTGTCAGACAACATGTTT





GTGCACAACAATTCCAAACACGGGAGGCGGGCCCGCCGCCTAGACCCGTCAGAAG





CCACTCCGTGCATCAAGGCCATCAGTCCCAGTGAAGGCTGGACCACGGGGGGTGC





CACCGTCATCATAATTGGCGACAACTTCTTTGACGGGCTGCAAGTTGTATTCGGAA





CTATGTTGGTGTGGAGCGAGCTGATAACTCCCCATGCCATCCGAGTCCAGACCCC





GCCGAGGCACATTCCTGGCGTCGTCGAAGTGACCCTCTCCTACAAATCCAAGCAGT





TCTGCAAAGGTGCTCCTGGGCGCTTTGTCTACACCGCCCTTAATGAACCAACCATA





GATTACGGCTTTCAGAGGTTGCAGAAAGTGATCCCAAGACATCCGGGTGATCCCGA





AAGGTTACCCAAGGAGGTGTTACTGAAGCGGGCGGCGGACCTGGTGGAAGCCTTA





TACGGAATGCCTCACAACAACCAGGAGATCATCTTGAAGCGAGCGGCGGACATCG





CCGAGGCGCTGTACAGCGTTCCCCGCAATCACAACCAGATCCCCACCCTGGGCAA





CAACCCTGCACACACGGGCATGATGGGCGTCAACTCCTTCAGCAGCCAGCTAGCC





GTCAACGTGTCAGAGACGTCACAAGCCAACGACCAAGTCGGCTACAGTCGCAATA





CAAGCAGCGTGTCCCCGCGAGGCTACGTCCCCAGCAGTACTCCCCAGCAGTCCAA





TTACAACACAGTCAGCACTAGCATGAATGGATATGGAAGTGGCGCCATGGCCAGTC





TAGGGGTCCCTGGCTCGCCTGGATTTCTTAATGGCTCCTCCGCTAACTCTCCCTAC





GGCATGAAACAGAAGAGCGCCTTCGCGCCCGTGGTCCGGCCCCAAGCCTCTCCTC





CTCCTTCCTGCACCAGCGCCAACGGGAATGGACTGCAAGCTATGTCTGGGCTGGT





AGTCCCGCCAATGTGAGGGACTTCTGTTTACCTTCCGCAGCACCCAGCATCAAAGG





ACGGACTTCAGGGGACACGTTTAGTATATTAAGACATGCTGATGGAAACAGTATCTT





CAAAAAAATCAGCAGCAATTGAAATGCTACAAAAGACTTTGTTTAAAGATTTTATTTA





AACTATTAAGAATCAACATGCAAACAGCCTACTTCTTCATGAACAATTCCATTTTATT





GACTGAACTTTTCTCATATTTTCACATTTCTCAGTCCTGAAGAATAAGGAAAACAAAG





CGACGCCTATTTTGTATAAAGTTTCCGACTCCGTCTTGGCCATGTCTAGTAATTGCT





ATGTGTTGGGAGAAACTTTGTGAATGCACCATTTTGATGATCATGAAACGCTGATGA





AAAATGCCTCCAAACATTTTTCTGTACTCATACTTAGATTCACAATGGTTGTGTATCT





CTATAATGTGAAATATTTTTTTGTGGTGATAAAAAGAGGGCCAAGGAGGTATGAGCC





ATCAGACTGGAAAAAAGGATGACTATATGATGAGGAGAAACTGGGGTGGCAGGGA





GGGAGGGAGGGTTTATCACTGCTTAACTTCATCTTCATGAAATGAAACTTTGTAACT





TATTGTAGTTAGAAATTGTAACTTTGATATTGAATTCTCTTGCCTTCAACAAGCACAC





TGACAGAGAAAAAATGCTACTGTCTGTTGGTTCCAATATTCTCCCACTGCTAGAGCT





TCCTGTTAAGCAAGTGTGATCTGCAACATTTTTTCAACTTTTGCTAGCACTGTATACT





ATTGCATTCTTAGGCTACTGTGAGGTCTATGTTTCTTGTACCAGAAATTGTCCTTTTG





ACTTCTAGATCCTTCTTCCCTAATGTGTTTTGTATGTGGTTATAAAATTGTAGACTTT





TGTGATTTTGCCAAAGTTGTAGCTAAATATTTATACACTTGTCTTGAATTTTTTTCAGA





TCCACTTAAAATATTTAGAAAAACAAGTTTTATTCCTTATGTGTCTTATAAGGAATAAA





ATGGTCTTCATTTGACACTTACTTTCCCATGAACACTTGCAGTTGCTAAGGGACTTT





ATTTTGTAACATATCAATTATAAATATTGTATTTATCTTTGAAATTTTGTACATTGCTTT





TCCCACCTTTTCCTTTTTCTTCTTTCTTGTCTGTATTGGTTTTTGATCACGGCCTGGT





GTTGTGATACTGGGAAGAGCATTAGCCAAGAACTTGTCTCTTTGATCTGTTTCGTTA





AGCTGAACCAGTGTCTTTACATTTCATTTGTACTTCAAAAAATATGCTATTGTTTAGA





CTTTCCATCCTTTTTTTTTTTATTTTGAGGAAAAGTCAAATTCATTGTTTATTTTTATAT





TATTTTTAAGTTATCTGAACAAATACTTTTGAAAAAAAAGTTTGTTGTATAGTCAAAAC





AAATCGGTGCCACCCGGCCGTGACAAATCCTAGTAGATTCTGTGCATGTGGAGCG





GCCGCGAAGAGGTGACACCGTTTGGGGCTGTGTCCTTATTTTATTTTATTTTTTTGT





AGAATGTAAAAAGTCATTTTAGATGCCACCCATTGACTTTGCCACATAGCTGAACTG





TGTTTACTGGAAAAATTCAGAGGCCTAAAGTTTAAAATAAAATTTACTTCTGATGTTT





TAATTAAAATGTTTGCCACATTAACTTTTCTGATGCCTTAAAAGTGAACTTCTTTAAA





GAACCTTTGTGCTATTTTATCACAGGCTTACACTACAATTGTTAATAAATACTTCATT





TGGAGATGTATGGTGTAAAACACACAAACACACACAAAAAAGCACAAGCCCGCTGC





ATGACCCGTCTCTCCTTTCTGGGACTATTTCTGCTGCGTCCTGCACCCTCCTGGGC





CCACCTCCGATTCACAGAGGTTTCAGGGGGACCCAAATCACTGCTGGTTTTCAATT





TTTTTTTAACAATACATTTTTGTGGTCAGTTCCAACAGCACTGTCCGTACTTTTAAAA





CTGGAATGACCTCCTTCAGATATCGTGCCTCTTAGTGCCAAACCCACAGTGAGACC





AAAAGTGTCAGGTGTTTTTTTTTTTTTCTTTCTCCTTTGCACTAAGTGCTTTGCAGAC





ACGGCACAGCAAACATTTTGCAAACTGCAGCAGAAATCGAATTTAAAACAAAAAGGA





GGGACTTTAAAATACCTTCTTGACAAAAATCAACAATGCACAACTTACAAAGTGTTC





ATTCTAGGGACAAAATTAAATAAACAGAATGTCCCCAGGAGTCAGCAGGTCACAGT





CTGGCTTTGTGATGGTTGACAAGGTCTAGCTACATGGGAAAGCCTGAGAAGTCACT





TTGGAACTAAATTGCCTCCATTTTATTTTGTACGAGTAAGGGTTTGATCTACAAAAGA





GCTCACATGGACGCACTGAGAACGCCTGCCAGCTTCCCCATGCCCTCACTTGGTTT





GTGTTTTAGGTTAAGTAGTCAATGCCCACATCACTTCACTGTCTCAAGACTGAGCAC





TTCACTAAATGGTAGATTTTACTGTTAAAGACCCTACAATAAGATTGTTTTATCTGTA





CATTTTTTCAGATATTTAACTGTATAAAAATGTTCATTTTACACAATATTTAATTAAAG





TATTTCTTGTCTGTGAATTTCACTTTTGGTAATTTTCTCTGTTTTTGATTATTAAAATG





ACTAAACACTAA. (SEQ ID NO: 226; NM_001005463.3),







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:226 under stringent hybridization conditions.


In some embodiments, MAF bZIP transcription factor (MAF, CCA4, AYGRP, c-MAF, CTRCT21) comprises the amino acid sequence:









MASELAMSNSDLPTSPLAMEYVNDFDLMKFEVKKEPVETDRIISQCGR





LIAGGSLSSTPMSTPCSSVPPSPSFSAPSPGSGSEQKAHLEDYYWMTG





YPQQLNPEALGFSPEDAVEALISNSHQLQGGFDGYARGAQQLAAAAGA





GAGASLGGSGEEMGPAAAVVSAVIAAAAAQSGAGPHYHHHHHHAAGHH





HHPTAGAPGAAGSAAASAGGAGGAGGGGPASAGGGGGGGGGGGGGGAA





GAGGALHPHHAAGGLHFDDRFSDEQLVTMSVRELNRQLRGVSKEEVIR





LKQKRRTLKNRGYAQSCRFKRVQQRHVLESEKNQLLQQVDHLKQEISR





LVRERDAYKEKYEKLVSSGFRENGSSSDNPSSPEFFM. (SEQ ID





NO: 227; NP_001026974.1),







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:227)


In some embodiments, the nucleic acid sequence encoding MAF comprises the nucleic acid sequence:










CTTGCTGGATCAGAGGCTTTAAAATCTTTTTTCATCTTCTAGCTGTAGCTCGGGCTG






CTTGTCGGCTTGGCCTCCCCCTCCCCCCTTTGCTCTCTGCCTCGTCTTTCCCCAGG





ACTTCGCTATTTTGCTTTTTTAAAAAAAGGCAAGAAAGAACTAAACTCCCCCCTCCC





TCTCCTCCAGTCGGGCTGCACCTCTGCCTTGCACTTTGCACAGAGGTAGAGAGCG





CGCGAGGGAGAGAGAGGAAAGAAAAAAAATAATAAAGAGAGCCAAGCAGAAGAGG





AGGCGAGAAGCATGAAGTGTTAACTCCCCCGTGCCAAGGCCCGCGCCGCCCGGA





CAGACGCCCGCCGCGCCTCCAGCCCCGAGCGGACGCCGCGCGCGCCCTGCCTG





CAGCCCGGGCCGGCGAGGCGAGCCCTTCCTTATGCAAAGCGCGCAGCGGAGCGG





CGAGCGGGGGACGCCGCGCACCGGGCCGGGCTCCTCCAGCTTCGCCGCCGCAG





CCACCACCGCCGCCACCGCAGCTCGCGGAGGATCTTCCCGAGCCTGAAGCCGCC





GGCTCGGCGCGCAAGGAGGCGAGCGAGCAAGGAGGGGCCGGGGCGAGCGAGG





GAGCACATTGGCGTGAGCAGGGGGGAGGGAGGGCGGGCGCGGGGGGCGCGGG





CAGGGCGGGGGGGTGTGTGTGTGAGCGCGCTCGGAGGTTTCGGGCCAGCCACCG





CCGCGCAAGCTAGAAGCGCCCCAGCCCGGCAAGCTGGCTCACCCGCTGGCCACC





CAGCACAGCCCGCTGGCCCCTCTCCTGCAGCCCATCTGGCGGAGCGGCGGCGGC





GGCGGCGGCGGCGGCAGGAGAATGGCATCAGAACTGGCAATGAGCAACTCCGAC





CTGCCCACCAGTCCCCTGGCCATGGAATATGTTAATGACTTCGATCTGATGAAGTTT





GAAGTGAAAAAGGAACCGGTGGAGACCGACCGCATCATCAGCCAGTGCGGCCGTC





TCATCGCCGGGGGCTCGCTGTCCTCCACCCCCATGAGCACGCCGTGCAGCTCGGT





GCCCCCTTCCCCCAGCTTCTCGGCGCCCAGCCCGGGCTCGGGCAGCGAGCAGAA





GGCGCACCTGGAAGACTACTACTGGATGACCGGCTACCCGCAGCAGCTGAACCCC





GAGGCGCTGGGCTTCAGCCCCGAGGACGCGGTCGAGGCGCTCATCAGCAACAGC





CACCAGCTCCAGGGCGGCTTCGATGGCTACGCGCGCGGGGCGCAGCAGCTGGCC





GCGGCGGCCGGGGCCGGTGCCGGCGCCTCCTTGGGCGGCAGCGGCGAGGAGAT





GGGCCCCGCCGCCGCCGTGGTGTCCGCCGTGATCGCCGCGGCCGCCGCGCAGA





GCGGCGCGGGCCCGCACTACCACCACCACCACCACCACGCCGCCGGCCACCACC





ACCACCCGACGGCCGGCGCGCCCGGCGCCGCGGGCAGCGCGGCCGCCTCGGCC





GGTGGCGCTGGGGGCGCGGGCGGCGGTGGCCCGGCCAGCGCTGGGGGCGGCG





GCGGCGGCGGCGGCGGCGGAGGCGGCGGGGGCGCGGCGGGGGCGGGGGGCG





CCCTGCACCCGCACCACGCCGCCGGCGGCCTGCACTTCGACGACCGCTTCTCCG





ACGAGCAGCTGGTGACCATGTCTGTGCGCGAGCTGAACCGGCAGCTGCGCGGGG





TCAGCAAGGAGGAGGTGATCCGGCTGAAGCAGAAGAGGCGGACCCTGAAAAACC





GCGGCTATGCCCAGTCCTGCCGCTTCAAGAGGGTGCAGCAGAGACACGTCCTGGA





GTCGGAGAAGAACCAGCTGCTGCAGCAAGTCGACCACCTCAAGCAGGAGATCTCC





AGGCTGGTGCGCGAGAGGGACGCGTACAAGGAGAAATACGAGAAGTTGGTGAGC





AGCGGCTTCCGAGAAAACGGCTCGAGCAGCGACAACCCGTCCTCTCCCGAGTTTT





TCATGTGAGTCTGACACGCGATTCCAGCTAGCCACCCTGATAAGTGCTCCGCGGG





GGTCCGGCTCGGGTGTGGGCTTGCTAGTTCTAGAGCCATGCTCGCCACCACCTCA





CCACCCCCACCCCCACCGAGTTTGGCCCCCTTGGCCCCCTACACACACACAAACC





CGCACGCACACACCACACACACACACACACACACACACACACCCCACACCCTGCT





CGAGTTTGTGGTGGTGGTGGCTGTTTTAAACTGGGGAGGGAATGGGTGTCTGGCT





CATGGATTGCCAATCTGAAATTCTCCATAACTTGCTAGCTTGTTTTTTTTTTTTTTTTA





CACCCCCCCGCCCCACCCCCGGACTTGCACAATGTTCAATGATCTCAGCAGAGTTC





TTCATGTGAAACGTTGATCACCTTTGAAGCCTGCATCATTCACATATTTTTTCTTCTT





CTTCCCCTTCAGTTCATGAACTGGTGTTCATTTTCTGTGTGTGTGTGTGTTTTATTTT





GTTTGGATTTTTTTTTTTAATTTTACTTTTAGAGCTTGCTGTGTTGCCCACCTTTTTTC





CAACCTCCACCCTCACTCCTTCTCAACCCATCTCTTCCGAGATGAAAGAAAAAAAAA





AGCAAAGTTTTTTTTTCTTCTCCTGAGTTCTTCATGTGAGATTGAGCTTGCAAAGGAA





AAAAAAATGTGAAATGTTATAGACTTGCAGCGTGCCGAGTTCCATCGGGTTTTTTTT





TTAGCATTGTTATGCTAAAATAGAGAAAAAAATCCTCATGAACCTTCCACAATCAAG





CCTGCATCAACCTTCTGGGTGTGACTTGTGAGTTTTGGCCTTGTGATGCCAAATCT





GAGAGTTTAGTCTGCCATTAAAAAAACTCATTCTCATCTCATGCATTATTATGCTTGC





TACTTTGTCTTAGCAACAATGAACTATAACTGTTTCAAAGACTTTATGGAAAAGAGAC





ATTATATTAATAAAAAAAAAAAGCCTGCATGCTGGACATGTATGGTATAATTATTTTT





TCCTTTTTTTTTCCTTTTGGCTTGGAAATGGACGTTCGAAGACTTATAGCATGGCATT





CATACTTTTGTTTTATTGCCTCATGACTTTTTTGAGTTTAGAACAAAACAGTGCAACC





GTAGAGCCTTCTTCCCATGAAATTTTGCATCTGCTCCAAAACTGCTTTGAGTTACTC





AGAACTTCAACCTCCCAATGCACTGAAGGCATTCCTTGTCAAAGATACCAGAATGG





GTTACACATTTAACCTGGCAAACATTGAAGAACTCTTAATGTTTTCTTTTTAATAAGA





ATGACGCCCCACTTTGGGGACTAAAATTGTGCTATTGCCGAGAAGCAGTCTAAAAT





TTATTTTTTAAAAAGAGAAACTGCCCCATTATTTTTGGTTTGTTTTATTTTTATTTTATA





TTTTTTGGCTTTTGGTCATTGTCAAATGTGGAATGCTCTGGGTTTCTAGTATATAATT





TAATTCTAGTTTTTATAATCTGTTAGCCCAGTTAAAATGTATGCTACAGATAAAGGAA





TGTTATAGATAAATTTGAAAGAGTTAGGTCTGTTTAGCTGTAGATTTTTTAAACGATT





GATGCACTAAATTGTTTACTATTGTGATGTTAAGGGGGGTAGAGTTTGCAAGGGGA





CTGTTTAAAAAAAGTAGCTTATACAGCATGTGCTTGCAACTTAAATATAAGTTGGGTA





TGTGTAGTCTTTGCTATACCACTGACTGTATTGAAAACCAAAGTATTAAGAGGGGAA





ACGCCCCTGTTTATATCTGTAGGGGTATTTTACATTCAAAAATGTATGTTTTTTTTTC





TTTTCAAAATTAAAGTATTTGGGACTGAATTGCACTAAGATATAACCTGCAAGCATAT





AATACAAAAAAAAATTGCAAAACTGTTTAGAACGCTAATAAAATTTATGCAGTTATAA





AAATGGCATTACTGCACAGTTTTAAGATGATGCAGATTTTTTTACAGTTGTATTGTGG





TGCAGAACTGGATTTTCTGTAACTTAAAAAAAAATCCACAGTTTTAAAGGCAATAATC





AGTAAATGTTATTTTCAGGGACTGACATCCTGTCTTTAAAAAGAAATGAAAAGTAAAT





CTTACCACAATAAATATAAAAAAATCTTGTCAGTTACTTTTCTTTTACATATTTTGCTG





TGCAAAATTGTTTTATATCTTGAGTTACTAACTAACCACGCGTGTTGTTCCTATGTGC





TTTTCTTTCATTTTCAATTCTGGTTATATCAAGAAAAGAATAATCTACAATAATAAACG





GCATTTTTTTTTGATTCTGTACTCAGTTTCTTAGTGTACAGTTTAACTGGGCCCAACA





ACCTCGTTAAAAGTGTAAAATGCATCCTTTTCTCCAGTGGAAGGATTCCTGGAGGAA





TAGGGAGACAGTAATTCAGGGTGAAATTATAGGCTGTTTTTTGAAGTGAGGAGGCT





GGCCCCATATACTGATTAGCAATATTTAATATAGATGTAAATTATGACCTCATTTTTT





TCTCCCCAAAGTTTTCAGTTTTCAAATGAGTTGAGCCATAATTGCCCTTGGTAGGAA





AAACAAAACAAAACAGTGGAACTAGGCTTCCTGAGCATGGCCCTACACTTCTGATC





AGGAGCAAAGCCATCCATAGACAGAGGAGCCGGACAAATATGGCGCATCAGAGGT





GGCTTGCGCACATATGCATTGAACGGTAAAGAGAAACAGCGCTTGCCTTTTCACTA





AAGTTGACTATTTTTCCTTCTTCTCTTACACACCGAGATTTTCTTGTTAGCAAGGCCT





GACAAGATTTAACATAAACATGACAAATCATAGTTGTTTGTTTTGTTTTGCTTTTCTCT





TTAACACTGAAGATCATTTGTCTTAAATAGGAAAAAGAAAATCCACTCCTTACTTCCA





TATTTCCAAGTACATATCTGGTTTAAACTATGTTATCAAATCATATTTCACCGTGAAT





ATTCAGTGGAGAACTTCTCTACCTGGATGAGCTAGTAATGATTTCAGATCATGCTAT





CCCCAGAAATAAAAGCAAAAAATAATACCTGTGTGGAATATAGGCTGTGCTTTGATT





TACTGGTATTTACCCCAAAATAGGCTGTGTATGGGGGCTGACTTAAAGATCCCTTG





GAAAGACTCAAAACTACCTTCACTAGTAGGACTCCTAAGCGCTGACCTATTTTTAAA





TGACACAAATTCATGAAACTAATGTTACAAATTCATGCAGTTTGCACTCTTAGTCATC





TTCCCCTAGCACACCAATAGAATGTTAGACAAAGCCAGCACTGTTTTGAAAATACAG





CCAAACACGATGACTTTTGTTTTGTTTTCTGCCGTTCTTAAAAGAAAAAAAGATAATA





TTGCAACTCTGACTGAAAGACTTATTTTTAAGAAAACAGGTTGTGTTTGGTGCTGCT





AAGTTCTGGCCAGTTTATCATCTGGCCTTCCTGCCTATTTTTTACAAAACACGAAGA





CAGTGTGTAACCTCGACATTTTGACCTTCCTTTATGTGCTAGTTTAGACAGGCTCCT





GAATCCACACTTAATTTTGCTTAACAAAAGTCTTAATAGTAAACCTCCCCTCATGAGC





TTGAAGTCAAGTGTTCTTGACTTCAGATATTTCTTTCCTTTTTTTTTTTTTTTCCTCAT





CACAACTAAGAGATACACAAACTCTGAAGAAGCAGAAATGGAGAGAATGCTTTTAAC





AAAAAAGCATCTGATGAAAGATTTTAGGCAAACATTCTCAAAATAAGAGTGATATTCT





GGATGTAGTTATTGCAGTTATCTCATGACAAATGAGGCCTGGATTGGAAGGAAAATA





TAGTTGTGTAGAATTAAGCATTTTGATAGGAATCTACAAGGTAGTTGAATATAATAAG





CAGGTTTGGGCCCCCAAACTTTAGAAAATCAAATGCAAAGGTGCTGGCAAAAATGA





GGTTTGAGTGGCTGGCTGTAAGAGAAGGTTAACTCCTAGTAAAAGGCATTTTTAGA





AATAACAATTACTGAAAACTTTGAAGTATAGTGGGAGTAGCAAACAAATACATGTTTT





TTTTTTCTTACAAAGAACTCCTAAATCCTGAGTAAGTGCCATTCATTACAATAAGTCT





CTAAATTTAAAAAAAAAAAAATCATATGAGGAAATCTAGCTTTCCCCTTTACGCTGCG





TTTGATCTTTGTCTAAATAGTGTTAAAATTCCTTTCATTCCAATTACAGAACTGAGCC





CACTCGCAAGTTGGAGCCATCAGTGGGATACGCCACATTTTGGAAGCCCCAGCATC





GTGTACTTACCAGTGTGTTCACAAAATGAAATTTGTGTGAGAGCTGTACATTAAAAA





AAATCATCATTATTATTATTATTTGCAGTCATGGAGAACCACCTACCCCTGACTTCTG





TTTAGTCTCCTTTTTAAATAAAAATTACTGTGTTAGAGAAGAAGGCTATTAAATGTAG





TAGTTAACTATGCCTCTTGTCTGGGGGTTTCATAGAGACCGGTAGGAAAGCGCACT





CCTGCTTTTCGATTTATGGTGTGTGCAAGTAAACAGGTGCATTGCTTTCAACCTGCC





ATACTAGTTTTAAAAATTCACTGAAATTACAAAGATACATATATATGCATATATATAAT





GGAAAGTTTCCCGGAATGCAACAATTAGCATTTTAAAATCATATATAGGCATGCACA





TTCTAAATAGTACTTTTTCATGCTTCATTGTTTCTCTGGCAGATAATTTTACTAAGAA





GAAAAATAGATATTCGACTCCCCTTCCCTAAACAAATCCACGGGCAGAGGCTCCAG





CGGAGCCGAGCCCCCTGGTTTTCTCGTAGGCCCTAGACGGTGTTGCATTTATCAGT





GATGTCAAACGTGCTCATTTGTCAGACATAGCTGTAAATGAAAACAATGTGTGGCAA





AATACAAAGTTAGTTAAATACA. (SEQ ID NO: 228; NM_001031804.3),







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:228 under stringent hybridization conditions.


In some embodiments, nuclear protein 1 (NUPR1, P8, COM1) comprises the amino acid sequence:









MATFPPATSAPQQPPGPEDEDSSLDESDLYSLAHSYLGPLIMPMPTSP





LTPALVTGGGGRKGRTKREAAANTNRPSPGGHERKLVTKLQNSERKKR





GARR. (SEQ ID NO: 229; NP_001035948.1),







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:229)


In some embodiments, the nucleic acid sequence encoding NUPR1 comprises the nucleic acid sequence:









GCCAGGAAAGCAGAGACAGACAAAGCGTTAGGAGAAGAAGAGAGGCAG





GGAAGACAAGCCAGGCACGATGGCCACCTTCCCACCAGCAACCAGCGC





CCCCCAGCAGCCCCCAGGCCCGGAGGACGAGGACTCCAGCCTGGATGA





ATCTGACCTCTATAGCCTGGCCCATTCCTACCTCGGGCCTCTCATCAT





GCCTATGCCCACTTCACCTCTGACTCCTGCCTTGGTTACAGGAGGTGG





AGGCCGGAAAGGTCGCACCAAGAGAGAAGCTGCTGCCAACACCAACCG





CCCCAGCCCTGGCGGGCACGAGAGGAAACTGGTGACCAAGCTGCAGAA





TTCAGAGAGGAAGAAGCGAGGGGCACGGCGCTGAGACAGAGCTGGAGA





TGAGGCCAGACCATGGACACTACACCCAGCAATAGAGACGGGACTGCG





GAGGAAGGAGGACCCAGGACAGGATCCAGGCCGGCTTGCCACACCCCC





CACCCCTAGGACTTATTCCCGCTGACTGAGTCTCTGAGGGGCTACCAG





GAAAGCGCCTCCAACCCTAGCAAAAGTGCAAGATGGGGAGTGAGAGGC





TGGGAATGGAGGGGCAGAGCCAGGAAGATCCCCCAGAAAAGAAAGCTA





CAGAAGAAACTGGGGCTCCTCCAGGGTGGCAGCAACAATAAATAGACA





CGCACGGCAGCCACAGCTTGGGTGTGTGTTCATCCTTGTTCTTTGTGT





GTTTTTGTTCGGGCATGTGTGTGCTTGCCTGTGCCTGCACATTCATGA





GCCTGAGAGAGCATCTTTGATGTGTATTTGTGTTTGGTGTATGTATCT





GGGGCAGGGAGTGTTCCTGCTCTTGCAGGGTCTACGCTGTGAATGCAG





CTTTTGGTTTGTTTGCTTTTGCTTGCATATATTTTAGTGCATACATTT





CTGTGGGCTCCTACGTAGTGGAAAGGAATTTCTTCTGCTTTTTTGCGA





TACTGCCCATGAAACACGGCCCTCCCCAGCACCTGTTTTTGTTGATTG





TGTCCTGTTCATAGACGGGAACGCTACTTATGAGTGCCATCTAAAAGT





CAGAGAAAACTGAGATTTAAAATATTAAAAGCCAGGGCCGGGGGCAGT





GGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGTGGGTGGAT





CACAAAGTCAGGAGTTCAAGACCAGCCTGACCAACATGGTGAAACCCC





ATCTCCACTAAAAATACCAAAAATTAGCCAAGCATGGTGGCAGGTGCC





TGTAATCCCAGCTGCTCAGGAGGCTGAGGCAGTAGAATCGCTTGAACC





CAGGAGGTAGAGGTTGCAGTGAGCCGACATCGTGCCATTGCACTCCAG





CCTGGGTGACAGAGGGAGACTCTGTCTCAAAACAAACAAACAAACAAA





AACTAAAGTCTGGGAGCAGTGGCTCATGCCTGTAATCACAGCAGTTTA





GGAGGCCGAAGTGGGAGGATTACTTGAGCCTAGGAGTTTGAGACCAGC





CTGAGCATCATAGTAAGACCCCATCTCTACAATTTTTTTTTTGAGACA





GAGTCTCACTCTGTTGCTCAGGTTAGAGTGCAGTGGCACCATCTTGGC





TCACTGCAACCTCTGCCTCCCGGGTTCAAGCAATTCTCGTGCCTACGC





CCCCTGAGTAGCTGGGATTACAGGTGAGCACCACCACGCCTGGCTAAT





TTTTGTTTTTTTGTTTTTTTGATACAGAGTCTCACTCTGTTGCTCAGG





CTGGAGTGCAGTGGCATGATCGCAGCTCACTGCAACCTCCGCCTCCTG





GGTTCAAGCTATTCTCCTGCTTCAGCCTCCTGAGTAGCTGGGACTACA





GGCACCTGCCACCATGCCTGGCTAATTTTTGTATTTTTAGTAGAAACA





GAGTTTCACCATGTTGGCCAGGATGGTCTCAATCTCTTGACCTCATGA





TCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAGGCGTCAGCCA





CCACGCCTGGCCAATTTTTGTATTTTTAGTAGAGATGGGGTTTCATCA





TGTTGGCCAGGCTGGTCTCAAACTCCTGGCCTCAAATGATCTGCCCAC





CTCAGCCTTCCAGCCTTTGGGAGGCCAAGGAGGGAGGATCGCTTGAGG





CCAGGAGTTCGAGACCAGCCTAGGCAACATACCAAGGCCCTGTCTCTA





CAAAAATTTAAAAATTAGCAAAGCATGGTGGCTCATGCCTGTAGTCCT





AGTTGCTCAGAGGCTGAAGTTGGAGGATCCCTTGAACCCAGTTGGAGG





CTACAGTAAGCCATGATGGTGCCACTGCACTGCAGCCTGAGCAATAGA





GTGAAACCATGTATTGAAAAAGAAAGAAAGAAAGAAAGAGAAAAAGAA





GGAAGGAAGGAAAAGAAAGGAAGGAAGAAAGAAAAGAAAGAGAGAAAG





GAGAGAAAAAGAAGAAAGAGAGAGAAAGAGAAGAAAGAAAGAAAGAAA





GAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGGAAGGAAGGAAAGAA





AGAAAGAAAGAAGGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAGAA





AGAAAAGAGCGAGCCCCGGCACAGTGGCTCACACCTGTAATCCCAGCA





CTTTGGGAGGCCAAGGCAGGCGGATCACCTGAGGTCAGTAGTTCGAGT





TCGAGGCAGAAGTTGTGGTGAGCCAAGATCACGCCATTGCACTCCAGC





CTGGGCAACAAGAGCAAAACTCCATCTCAAAAAAAGAAAAAGAGAGAG





AAAGAAAGAGAGAAGGAGGGAAAGAAAGAGGAAGGAAAGGAGGGAGGG





AAGGAGGGAAGGAGGAAAGGAGGGAAGGAAATATTAAGGGATTTGCCC





TAGCTCACTCAGGGCTCATATTCAGGGATCTTATTGTCTTCAGATATG





AGGTGGGTCCCCAGGCCAAGGGGGCTGTGGGACAGGGTTCTGGGAAGT





GAGATGGGGGAGGGAGATTCTTATTCAGTGCTATGTCTCAGGACCAGA





GTTGAAGAAAAATATGGGGCAAACAGGAAGTGTGGTTGGAGCTGAGAT





TATTTGTTGATTGAGATACAGGTTTGGGTTGCTATTATGAAGAATCAA





AACAGGATACAAAGTTACTCCTCTCTTACTTAGCCCCAAGTCCTCCTG





GGTTCAAATGGCAGCTCCATTGTGTTGAGGATTCCAGCTATTTTTACT





CACTGTTCTGCCACACCCAAAACATGGCTTCCACTTTGAGGCCCAAAA





TAGCTACTCCAATACCTGCCATCACGTTTGCATCTCAGCCTGTGGAAA





GAGTGTGGAAGAGACAGAGGAGGCCACACCTCTTCAATTTTAGGGCAT





AATCTAAAAGTAGAACACATCACATCTGCTCCGAATGTGGCTACATGG





CCACACCCAACTACGAGAGAGGTTGGGAAATGTAGCATTGAGCTGCTT





AGCCACGTGGTAGCCAAAACTTGGGCAACAGCAGGGTTTTATGATGAA





AGGGAACCAGAGAGAGTGAATACACGAAGAAGCTAGCAAGAAACATTG





CCCACATGCAGACTCAACAGATGTCGGGGGAGAAAACTCTGAGATTGG





GCCCCGGGCAGAGCCTGTTTCCTTTTCCCCTGTCCCTTTCACATAAGC





CCCACACTGCAGAACTTGGAGTCAGTGGTTCATGGGGACCCAAGGACA





TCCACAGAAGACCGAAGTACCTGATAGAGCAGGAACAGATGCACGTCA





GACTACGACCAGCTTGAACCCTTGGGGACCTGTATCCATCCCCTTCCC





TTGAGTCCAGCCTAATCACAGCCACAGAATGAATCCATGACCCGGAAG





GACATTTAAGGACCTCTGGCCCAACTCTCCCCACGCAACAGTGGGATT





GCCTCTGCTTGTTTGAATACCACTATGGAGGGGGAACTTGCTACATTT





AAAGGTTGCTGAATTTTTTTGTTTTGTTTTGGGAGATGGAGTCTCTCT





CTGTCGCCCAGGCTGGAGTGCAGTGGTGTGATCTCGACCCACTGCAAC





CTCCGCTTCCTGGGTTCAAGCGATTTTCATGCCTCAGCCTCCCTAGTA





GCTGGGACTACAGGTGTGGGCCACCACACCTGGCTAATTTTTGTATTT





TTAGTAGAGACGGGGTTTCACCATGTTGCCCAGGCTGGTCTCAAACTC





CCGACCTCAGGTGATCTGCCTGCCTTGGCCTCCCAAAGTGTTGGGATT





ACAGGCTTGAGCCACACCACCCGGCAAAGGTTGCCTAATTCTATCTCA





GGGCAAGTCTGTTCATGTGGGCTGAAATCTGTCTCTCATACCTGCCCT





TAAATAAGCTTCTGTTTTTCTGGTCCTTTCTGTCTGAGATGACTTTAA





TTCCTCCCCCGACCCCATCTCATGAGGCTCAGCTTAGATGTTTCCTTC





TCTTCCTCCCTGATGGCTGCGTGCAGAAGCTCATACCTGCAATCCCAG





CACTTTGGGAGGCCGAGGTGGGAGGATTGCTTGGGCCCAGGAGTTCTA





GGCCAGCCTAGCAACACAGCAAGACCCTCTCTCTACAAAAAATTAAAA





ATTAGCCAGGTGTGGTGGCTTGTGCCTGTGGGCCCACCTACTCAGGAG





GCTGAGGTGAGAGGATCTCTTGAGTCTGGGAGGTGGAGGCTGCAGTGA





GCCATGATCTCACTCCAGCCTGGGCGTCAGAGTGAGACCTGTCTCAAA





AAAACAAAAACCAAAGTTTTCCTTAACTTGCAATCCTCCACCCATCTC





CTGACCTCCACCCCAGGCCGACCCTCCTCTGGGATCACACGGAAGCCT





GGGCCCAGAATCTTACAGTCTACCTTGGAAATCCTTCAGATTTTGCCT





CCAACTCCTCTTTCCATACAAGTTACATATTAACTCAATCAATGCTTA





TTGGATGCCTTCTGAGTTACCAGGATGCTGCTGGAGGCCTGTGCTGCT





GAGAGGGACAAATAGAATCCTGATATGACTGGAACCAGGAATAGGGCC





ACCATCAGCTCTAGAACCCAGGGAGCAAATGGCAGGAGCAACACCAGG





CAGTCGGCCCTCAGCCCAGCACAGACCTGGTGTGTTGGCTTCAGAAAA





TCCTGGAAACATCTCTGCTGTGTTTGGAGCTCCTATTCTGTGAGAAGT





GTTTTATAGGCTTTGCTCCATTTAATCCTTACGATAACCCAATAGGAC





ATACTATTAATGATCCCCTTTTTTTCAGACCGGAAAACTGAGGTTCGG





AGACATTAAGTAATTTGCCTAAAGTCACACAGCCACATCCTGTAGGAC





TTGGAATTATGAACTCAGGTCTATCTGAATTTTAAAGCCTGGATTTTT





CCCCCTTTGCTACATGCCTGGGAAGAACCATGTATTGACAATGAAGAA





TCCTAAACTCTCGTTAA. (SEQ ID NO: 230;





NM_001042483.2),







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:230 under stringent hybridization conditions.


In some embodiments, twist family bHLH transcription factor 1 (TWIST1, CRS, CSP, SC3, ACS3, CRS1, BPES2/3, SWCOS, TWIST) comprises the amino acid sequence:









MMQDVSSSPVSPADDSLSNSEEEPDRQQPPSGKRGGRKRRSSRRSAGG





GAGPGGAAGGGVGGGDEPGSPAQGKRGKKSAGCGGGGGAGGGGGSSSG





GGSPQSYEELQTQRVMANVRERQRTQSLNEAFAALRKIIPTLPSDKLS





KIQTLKLAARYIDFLYQVLQSDELDSKMASCSYVAHERLSYAFSVWRM





EGAWSMSASH. (SEQ ID NO: 231; NP_000465.1),







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:231)


In some embodiments, the nucleic acid sequence encoding TWIST1 comprises the nucleic acid sequence:









AACTCCCAGACACCTCGCGGGCTCTGCAGCACCGGCACCGTTTCCAGG





AGGCCTGGCGGGGTGTGCGTCCAGCCGTTGGGCGCTTTCTTTTTGGAC





CTCGGGGCCATCCACACCGTCCCCTCCCCCTCCCGCCTCCCTCCCCGC





CTCCCCCGCGCGCCCTCCCCGCGGAGGTCCCTCCCGTCCGTCCTCCTG





CTCTCTCCTCCGCGGGCCGCATCGCCCGGGCCGGCGCCGCGCGCGGGG





GAAGCTGGCGGGCTGAGGCGCCCCGCTCTTCTCCTCTGCCCCGGGCCC





GCGAGGCCACGCGTCGCCGCTCGAGAGATGATGCAGGACGTGTCCAGC





TCGCCAGTCTCGCCGGCCGACGACAGCCTGAGCAACAGCGAGGAAGAG





CCAGACCGGCAGCAGCCGCCGAGCGGCAAGCGCGGGGGACGCAAGCGG





CGCAGCAGCAGGCGCAGCGCGGGCGGCGGCGCGGGGCCCGGCGGAGCC





GCGGGTGGGGGCGTCGGAGGCGGCGACGAGCCGGGCAGCCCGGCCCAG





GGCAAGCGCGGCAAGAAGTCTGCGGGCTGTGGGGCGGCGGCGGCGCGG





GCGGCGGCGGCGGCAGCAGCAGCGGCGGCGGGAGTCCGCAGTCTTACG





AGGAGCTGCAGACGCAGCGGGTCATGGCCAACGTGCGGGAGCGCCAGC





GCACCCAGTCGCTGAACGAGGCGTTCGCCGCGCTGCGGAAGATCATCC





CCACGCTGCCCTCGGACAAGCTGAGCAAGATTCAGACCCTCAAGCTGG





CGGCCAGGTACATCGACTTCCTCTACCAGGTCCTCCAGAGCGACGAGC





TGGACTCCAAGATGGCAAGCTGCAGCTATGTGGCTCACGAGCGGCTCA





GCTACGCCTTCTCGGTCTGGAGGATGGAGGGGGCCTGGTCCATGTCCG





CGTCCCACTAGCAGGCGGAGCCCCCCACCCCCTCAGCAGGGCCGGAGA





CCTAGATGTCATTGTTTCCAGAGAAGGAGAAAATGGACAGTCTAGAGA





CTCTGGAGCTGGATAACTAAAAATAAAAATATATGCCAAAGATTTTCT





TGGAAATTAGAAGAGCAAAATCCAAATTCAAAGAAACAGGGCGTGGGG





CGCACTTTTAAAAGAGAAAGCGAGACAGGCCCGTGGACAGTGATTCCC





AGACGGGCAGCGGCACCATCCTCACACCTCTGCATTCTGATAGAAGTC





TGAACAGTTGTTTGTGTTTTTTTTTTTTTTTTTTTTGACGAAGAATGT





TTTTATTTTTATTTTTTTCATGCATGCATTCTCAAGAGGTCGTGCCAA





TCAGCCACTGAAAGGAAAGGCATCACTATGGACTTTCTCTATTTTAAA





ATGGTAACAATCAGAGGAACTATAAGAACACCTTTAGAAATAAAAATA





CTGGGATCAAACTGGCCTGCAAAACCATAGTCAGTTAATTCTTTTTTT





CATCCTTCCTCTGAGGGGAAAAACAAAAAAAAACTTAAAATACAAAAA





ACAACATTCTATTTATTTATTGAGGACCCATGGTAAAATGCAAATAGA





TCCGGTGTCTAAATGCATTCATATTTTTATGATTGTTTTGTAAATATC





TTTGTATATTTTTCTGCAATAAATAAATATAAAAAATTTAGAGAA.





(SEQ ID NO: 232; NM_000474.4),







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:232 under stringent hybridization conditions


In some embodiments, twist family bHLH transcription factor 2 (TWIST2, AMS, FFDD3, BBRSAY, DERMO1, SETLSS) comprises the amino acid sequence:









MEEGSSSPVSPVDSLGTSEEELERQPKRFGRKRRYSKKSSEDGSPTPG





KRGKKGSPSAQSFEELQSQRILANVRERQRTQSLNEAFAALRKIIPTL





PSDKLSKIQTLKLAARYIDFLYQVLQSDEMDNKMTSCSYVAHERLSYA





FSVWRMEGAWSMSASH. (SEQ ID NO: 233;





NP_001258822.1),







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:233)


In some embodiments, the nucleic acid sequence encoding Fos comprises the nucleic acid sequence:









GCACAAGCCGGCCTTGAAATCAGAGCCTTTCCAGCAACTCCGAGAGCG





TGTGCTCGGCGACCGCGGGCTTGGCCAGCGGCGCGCGCTCGGCGCCCC





GGCGCCCCCAGCCCCACGCGCGCCGGGCGGGCGCCATGGAGGAGGGCT





CCAGCTCGCCCGTGTCCCCCGTGGACAGCCTGGGCACCAGCGAGGAGG





AGCTCGAGAGGCAGCCCAAGCGCTTCGGCCGGAAGCGGCGCTACAGCA





AGAAGTCGAGCGAAGATGGCAGCCCGACCCCGGGCAAGCGCGGCAAGA





AGGGCAGCCCCAGCGCGCAGTCCTTCGAGGAGCTGCAGAGCCAGCGCA





TCCTGGCCAACGTGCGCGAGCGCCAGCGCACCCAGTCGCTCAACGAGG





CCTTCGCGGCGCTGCGCAAGATCATCCCCACGCTGCCCTCTGACAAGC





TGAGCAAGATCCAGACGCTCAAGCTGGCCGCCAGGTACATAGACTTCC





TCTACCAGGTCCTGCAGAGCGACGAGATGGACAATAAGATGACCAGCT





GCAGCTACGTGGCCCACGAGCGCCTCAGCTACGCCTTCTCCGTGTGGC





GCATGGAGGGCGCGTGGTCCATGTCCGCCTCCCACTAGCGCCGCGCCA





CCCACCTCCGGACCGGCGCGCCAGGGCTGTCCGTCGCGTCGGCGGCGC





AAGTGGAATTGGGATGCATTCGAGTCTGTAACTTCTGAAACCTGAACA





ACCTCAGGAGGCCCCCACCTCTGCCCTCCACCAGCGTCGAGAGAAGGG





ACAGCAGTGACATCGGACAGAAGACCCGGGCTCCCGTCCTCCCCCAGG





ACGGTCCCCACATAGGAAGGGCACTCCCAGCCCTCTTGCTGGTGACAT





TGTCATGGTCATCTTGTTTCTGTTTGGATTTTTCTTCTGGGTCTTATG





TTTGGGGGGAGGTTTATTCTTTCTGAAAATGTCTAGATTCAGGAACAC





ATTTATGAGGATTTGGATTTTGAATTTGTATTTCCCTCTAAGTGCCTT





TTTTAATGTCTATTTTTTTAATAAAACAGAAATGCATTCTTGTACAAT





TCTGTTGAAACTGGACCAAGGCTCTCAGAAGAGGACCCCCGAGTTCCT





TCCCCTCCCCCGAGCCTCTGCATGATTGTTTCAAGTCAGCCTGGAATT





CTTACTTTCACGCCGCTATTCTTTTCCTTTCTCCGTGATTGCTTGGCT





AGCCATTTAAAAAAAAATATTCTCTGTTCAGTGTATATGTTGCTTGTT





TGTTTTATTTATTGAGATATTTTTACAAGCTAAGTGACTGCAGTGTGG





CTGTGTATCCTGCTCCCCACCCAGGAAAAATAAAGACGTCCGCGCA.





(SEQ ID NO: 234; NM_001271893.4),







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:234 under stringent hybridization conditions


In some embodiments, MAGE family member D1 (MAGED1, NRAGE, DLXIN-1) comprises the amino acid sequence:









MAQKMDCGAGLLGFQAEASVEDSALLMQTLMEAIQISEAPPTNQATAA





ASPQSSQPPTANEMADIQVSAAAARPKSAFKVQNATTKGPNGVYDFSQ





AHNAKDVPNTQPKAAFKSQNATPKGPNAAYDFSQAATTGELAANKSEM





AFKAQNATTKVGPNATYNFSQSLNANDLANSRPKTPFKAWNDTTKAPT





ADTQTQNVNQAKMATSQADIETDPGISEPDGATAQTSADGSQAQNLES





RTIIRGKRTRKINNLNVEENSSGDQRRAPLAAGTWRSAPVPVTTQNPP





GAPPNVLWQTPLAWQNPSGWQNQTARQTPPARQSPPARQTPPAWQNPV





AWQNPVIWPNPVIWQNPVIWPNPIVWPGPVVWPNPLAWQNPPGWQTPP





GWQTPPGWQGPPDWQGPPDWPLPPDWPLPPDWPLPTDWPLPPDWIPAD





WPIPPDWQNLRPSPNLRPSPNSRASQNPGAAQPRDVALLQERANKLVK





YLMLKDYTKVPIKRSEMLRDIIREYTDVYPEIIERACFVLEKKFGIQL





KEIDKEEHLYILISTPESLAGILGTTKDTPKLGLLLVILGVIFMNGNR





ASEAVLWEALRKMGLRPGVRHPLLGDLRKLLTYEFVKQKYLDYRRVPN





SNPPEYEFLWGLRSYHETSKMKVLRFIAEVQKRDPRDWTAQFMEAADE





ALDALDAAAAEAEARAEARTRMGIGDEAVSGPWSWDDIEFELLTWDEE





GDFGDPWSRIPFTFWARYHQNARSRFPQTFAGPIIGPGGTASANFAAN





FGAIGFFWVE. (SEQ ID NO: 235; NP_001005332.1),







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:235)


In some embodiments, the nucleic acid sequence encoding MAGED1 comprises the nucleic acid sequence:









AGCACTTCCGGTCACGCCATCGTTGCTGCCTTCTTCGTCAAGCCCCCA





GGCTCCGCTCTTGCCAGAGGGACAGGAGCCATGGCTCAGAAAATGGAC





TGTGGTGCGGGCCTCCTCGGCTTCCAGGCTGAGGCCTCCGTAGAAGAC





AGCGCCTTGCTTATGCAGACCTTGATGGAGGCCATCCAGATCTCAGAG





GCTCCACCTACTAACCAGGCCACCGCAGCTGCTAGTCCCCAGAGTTCA





CAGCCCCCAACTGCCAATGAGATGGCTGACATTCAGGTTTCAGCAGCT





GCCGCTAGGCCTAAGTCAGCCTTTAAAGTCCAGAATGCCACCACAAAA





GGCCCAAATGGTGTCTATGATTTCTCTCAGGCTCATAATGCCAAGGAT





GTGCCCAACACGCAGCCCAAGGCAGCCTTTAAGTCCCAAAATGCTACC





CCAAAGGGTCCAAATGCTGCCTATGATTTTTCCCAGGCAGCAACCACT





GGTGAGTTAGCTGCTAACAAGTCTGAGATGGCCTTCAAGGCCCAGAAT





GCCACTACTAAAGTGGGCCCAAATGCCACCTACAATTTCTCTCAGTCT





CTCAATGCCAATGACCTGGCCAACAGCAGGCCTAAGACCCCTTTCAAG





GCTTGGAATGATACCACTAAGGCCCCAACAGCTGATACCCAGACCCAG





AATGTAAATCAGGCCAAAATGGCCACTTCCCAGGCTGACATAGAGACC





GACCCAGGTATCTCTGAACCTGACGGTGCAACTGCACAGACATCAGCA





GATGGTTCCCAGGCTCAGAATCTGGAGTCCCGGACAATAATTCGGGGC





AAGAGGACCCGCAAGATTAATAACTTGAATGTTGAAGAGAACAGCAGT





GGGGATCAGAGGCGGGCCCCACTGGCTGCAGGGACCTGGAGGTCTGCA





CCAGTTCCAGTGACCACTCAGAACCCACCTGGCGCACCCCCCAATGTG





CTCTGGCAGACGCCATTGGCTTGGCAGAACCCCTCAGGCTGGCAAAAC





CAGACAGCCAGGCAGACCCCACCAGCACGTCAGAGCCCTCCAGCTAGG





CAGACCCCACCAGCCTGGCAGAACCCAGTCGCTTGGCAGAACCCAGTG





ATTTGGCCAAACCCAGTAATCTGGCAGAACCCAGTGATCTGGCCAAAC





CCCATTGTCTGGCCCGGCCCTGTTGTCTGGCCGAATCCACTGGCCTGG





CAGAATCCACCTGGATGGCAGACTCCACCTGGATGGCAGACCCCACCG





GGCTGGCAGGGTCCTCCAGACTGGCAAGGTCCTCCTGACTGGCCGCTA





CCACCCGACTGGCCACTGCCACCTGATTGGCCACTTCCCACTGACTGG





CCACTACCACCTGACTGGATCCCCGCTGATTGGCCAATTCCACCTGAC





TGGCAGAACCTGCGCCCCTCGCCTAACCTGCGCCCTTCTCCCAACTCG





CGTGCCTCACAGAACCCAGGTGCTGCACAGCCCCGAGATGTGGCCCTT





CTTCAGGAAAGAGCAAATAAGTTGGTCAAGTACTTGATGCTTAAGGAC





TACACAAAGGTGCCCATCAAGCGCTCAGAAATGCTGAGAGATATCATC





CGTGAATACACTGATGTTTATCCAGAAATCATTGAACGTGCATGCTTT





GTCCTAGAGAAGAAATTTGGGATTCAACTGAAAGAAATTGACAAAGAA





GAACACCTGTATATTCTCATCAGTACCCCCGAGTCCCTGGCTGGCATA





CTGGGAACGACCAAAGACACACCCAAGCTCGGTCTCCTCTTGGTGATT





CTGGGTGTCATCTTCATGAATGGCAACCGTGCCAGTGAGGCTGTCCTC





TGGGAGGCACTACGCAAGATGGGACTGCGTCCTGGGGTGAGACATCCC





CTCCTTGGAGATCTAAGGAAACTTCTCACCTATGAGTTTGTAAAGCAG





AAATACCTGGACTACAGACGAGTGCCCAACAGCAACCCCCCGGAGTAT





GAGTTCCTCTGGGGCCTCCGTTCCTACCATGAGACTAGCAAGATGAAA





GTGCTGAGATTCATTGCAGAGGTTCAGAAAAGAGACCCTCGTGACTGG





ACTGCACAGTTCATGGAGGCTGCAGATGAGGCCTTGGATGCTCTGGAT





GCTGCTGCAGCTGAGGCCGAAGCCCGGGCTGAAGCAAGAACCCGCATG





GGAATTGGAGATGAGGCTGTGTCTGGGCCCTGGAGCTGGGATGACATT





GAGTTTGAGCTGCTGACCTGGGATGAGGAAGGAGATTTTGGAGATCCC





TGGTCCAGAATTCCATTTACCTTCTGGGCCAGATACCACCAGAATGCC





CGCTCCAGATTCCCTCAGACCTTTGCCGGTCCCATTATTGGTCCTGGT





GGTACAGCCAGTGCCAACTTCGCTGCCAACTTTGGTGCCATTGGTTTC





TTCTGGGTTGAGTGAGATGTTGGATATTGCTATCAATCGCAGTAGTCT





TTCCCCTGTGTGAGGCTGAAGCCTCAGATTCCTTCTAAACACAGCTAT





CTAGAGAGCCACATCCTGTTGACTGAAAGTGGCATGCAAGATAAATTT





ATTTGCTGTTCCTTGTCTACTGCTTTTTTTCCCCTTGTGTGCTGTCAA





GTTTTGGTATCAGAAATAAACATTGAAATTGCAAAGTGAA. (SEQ





ID NO: 236; NM_001005332.2),







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:236 under stringent hybridization conditions


In some embodiments, SATB homeobox 2 (SATB2, GLSS) comprises the amino acid sequence:









MERRSESPCLRDSPDRRSGSPDVKGPPPVKVARLEQNGSPMGARGRPN





GAVAKAVGGLMIPVFCVVEQLDGSLEYDNREEHAEFVLVRKDVLFSQL





VETALLALGYSHSSAAQAQGIIKLGRWNPLPLSYVTDAPDATVADMLQ





DVYHVVTLKIQLQSCSKLEDLPAEQWNHATVRNALKELLKEMNQSTLA





KECPLSQSMISSIVNSTYYANVSATKCQEFGRVVYKKYKKIKVERVER





ENLSDYCVLGQRPMHLPNMNQLASLGKTNEQSPHSQIHHSTPIRNQVP





ALQPIMSPGLLSPQLSPQLVRQQIAMAHLINQQIAVSRLLAHQHPQAI





NQQFLNHPPIPRAVKPEPTNSSVEVSPDIYQQVRDELKRASVSQAVFA





RVAFNRTQGLLSEILRKEEDPRTASQSLLVNLRAMQNFLNLPEVERDR





IYQDERERSMNPNVSMVSSASSSPSSSRTPQAKTSTPTTDLPIKVDGA





NINITAAIYDEIQQEMKRAKVSQALFAKVAANKSQGWLCELLRWKENP





SPENRTLWENLCTIRRFLNLPQHERDVIYEEESRHHHSERMQHVVQLP





PEPVQVLHRQQSQPAKESSPPREEAPPPPPPTEDSCAKKPRSRTKISL





EALGILQSFIHDVGLYPDQEAIHTLSAQLDLPKHTIIKFFQNQRYHVK





HHGKLKEHLGSAVDVAEYKDEELLTESEENDSEEGSEEMYKVEAEEEN





ADKSKAAPAEIDQR. (SEQ ID NO: 237;





NP_001165980.1),







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:237)


In some embodiments, the nucleic acid sequence encoding SATB2 comprises the nucleic acid sequence:










GAGTCCGGCTCTGGCTGCTGGCAGAGGCGGCCGAGAGGGGAGAGGCTGGAGGT






GACAGCTTGGGCGGCCGCCGCGTTTCCTCCCGCGCGCGGTCCCGGGTCCCTGCG





TCTTCTCGGCTCTTGGTGTTACCGGTCCCACCGCTCTGGCCGCGCCTCCTCGCGA





GCTAGCCGCCCTGCGAACCAGCAGCCCCGGCTCGCCGCCGCCGCCGCCGCCTCC





GGGTTCTCAGCCCTTTCTCTCCAGAACGGGTCTCCTTCCCGAAGGTGTGAAAAGGC





TCTTTCAGCCTCCTTCTCTTCCCCCCTCCTCCGCCGTCCCCTCCCCCGCTCGCTCG





GGTGTCCCTTTGGAGGAGTCCTTTCCCTCTCCTCCTCCTCCCCCTCCTCCCTCCCC





CCATCATCATCATAACAACCATCTCCGCACCAGAAGAAGACACCCTGACCCAGGAC





CTTAAACATTAGGACCTGGGGAAGAGGGAAGGGGAAGGAGTAAAGAGGAAGACTA





GGAGAACACTGCAAAGCCAAGCACCAGAAACTTTCCACCCTGGATTCTCTACTTTT





GCTCCATGGACAGAGCCCCAGTCAGCCAAGTTTCAGACAGACCGTGAGCAGTCCC





TGTGCGTTTTATTGCGACCTGCCGGTGGGAACTTTGTCTCCGAGTCGGAGCAGCAT





GGAGCGGCGGAGCGAGAGCCCGTGTCTGCGGGACAGCCCCGACCGGCGGAGCG





GCAGCCCGGACGTCAAGGGGCCTCCCCCAGTGAAGGTGGCCCGGCTGGAGCAGA





ACGGCAGCCCCATGGGAGCCCGCGGGAGGCCCAACGGCGCCGTGGCCAAGGCC





GTGGGAGGTTTGATGATTCCTGTCTTTTGTGTCGTGGAGCAGTTGGACGGCTCTCT





TGAATATGACAACAGAGAAGAACACGCCGAGTTTGTCCTGGTGCGGAAAGATGTGC





TTTTTAGCCAGCTGGTGGAGACTGCGCTCCTGGCCCTGGGGTATTCTCACAGCTCT





GCGGCCCAGGCCCAAGGAATAATCAAGCTGGGAAGGTGGAACCCTCTCCCCCTCA





GTTATGTGACAGATGCACCCGACGCGACAGTGGCCGACATGCTACAAGATGTCTAT





CATGTTGTGACGTTGAAAATCCAATTACAAAGTTGTTCAAAGTTGGAAGACTTGCCT





GCGGAGCAGTGGAACCATGCCACAGTCCGCAATGCCTTAAAGGAACTGCTCAAAG





AGATGAACCAGAGCACATTAGCCAAAGAATGCCCTCTCTCCCAGAGTATGATTTCAT





CCATTGTAAATAGCACATATTATGCCAATGTGTCAGCAACCAAGTGCCAGGAGTTTG





GGAGATGGTATAAAAAGTACAAGAAGATTAAAGTGGAAAGAGTGGAACGAGAAAAC





CTTTCAGACTATTGTGTTCTGGGCCAGCGTCCAATGCATTTACCAAATATGAACCAG





CTGGCATCCCTGGGGAAAACCAACGAACAGTCTCCTCACAGCCAAATTCACCACAG





TACTCCAATCCGAAACCAAGTGCCCGCATTACAGCCCATCATGAGCCCTGGTCTTC





TTTCTCCCCAGCTTAGTCCACAACTTGTAAGGCAACAAATAGCCATGGCCCATCTGA





TAAACCAACAGATTGCCGTTAGCCGGCTCCTGGCTCACCAGCATCCTCAAGCCATC





AACCAGCAGTTCCTGAACCATCCACCCATCCCCAGAGCAGTTAAGCCAGAGCCAAC





CAACTCTTCCGTGGAAGTCTCTCCAGATATCTACCAGCAAGTCAGAGATGAGCTGA





AGAGGGCCAGTGTGTCCCAAGCTGTCTTTGCAAGAGTGGCATTCAACCGCACACA





GGGATTGTTGTCTGAGATTCTGCGTAAGGAAGAAGACCCTCGGACAGCCTCTCAGT





CTCTTCTAGTAAACCTGAGGGCCATGCAGAATTTCCTCAATCTGCCAGAAGTGGAG





CGAGATCGCATCTACCAGGATGAGAGGGAGCGGAGCATGAATCCCAATGTGAGCA





TGGTCTCCTCGGCCTCCAGCAGTCCCAGCTCCTCCCGAACCCCTCAGGCCAAAAC





CTCGACACCGACAACAGACCTCCCTATTAAGGTGGACGGCGCCAACATCAACATCA





CAGCTGCCATTTATGACGAGATCCAACAGGAGATGAAAAGGGCCAAGGTGTCTCAA





GCCCTGTTTGCCAAAGTGGCTGCAAATAAAAGTCAGGGCTGGCTGTGTGAACTGCT





CCGCTGGAAGGAGAACCCAAGCCCAGAAAACCGCACCCTCTGGGAAAACCTCTGT





ACCATCCGTCGCTTCCTGAACCTTCCCCAGCATGAGAGGGATGTCATCTATGAGGA





GGAGTCAAGGCATCACCACAGCGAACGCATGCAACACGTGGTCCAGCTTCCCCCT





GAGCCGGTGCAGGTACTTCATAGACAGCAGTCTCAGCCAGCCAAGGAGAGTTCCC





CTCCCAGAGAAGAAGCGCCTCCCCCACCTCCTCCGACTGAAGACAGTTGTGCCAA





AAAGCCCCGGTCTCGCACAAAGATCTCCTTAGAAGCCCTGGGGATCCTCCAAAGCT





TTATTCATGATGTAGGCCTGTACCCAGACCAGGAAGCCATCCACACTCTTTCGGCT





CAGCTGGATCTCCCCAAACACACCATCATCAAGTTCTTCCAGAACCAGCGGTACCA





CGTGAAGCACCACGGGAAGCTGAAAGAGCACCTGGGCTCCGCGGTGGACGTGGC





TGAATATAAGGACGAGGAGCTGCTGACCGAGTCAGAGGAGAACGACAGCGAGGAA





GGCTCCGAGGAGATGTACAAAGTGGAGGCTGAGGAGGAAAATGCTGACAAAAGCA





AGGCAGCACCTGCCGAAATTGACCAGAGATAATGTGAACTTCTACTAGGCAAAGCA





ATACATCGGTCCAAGGATTTTCTGCTTTCATTTCTTTAAAAGTTTTTTGTTAGTTTGTT





TTTTGTTTTTGTTTTTGGGTTTTTTTGGCTTTATTTTTGTCTTTTTATGTCTGTTTTGTT





TTTCTTACCCTTTTGGACATTTCTTTGTTGCACAGGATACACCTATAGACTGAATAAG





TTCAGTATTTCCGAATCAGACATCGCCTTGGCAAAGACACTAAAGCGTTACACTTTA





TCCCGTCTCTATGACTGGATCATAGTCATTATAATCACAGGAGACTCTGCCTTCATT





ATCCTTGCACTTAACGGAAGTTACATCAGGCAAGTACCAGGATGAAAAGAACTATG





AAATAAATGAAGGAAGCTACAAGTGTGTGTGTATATGTATATGTATATATCTCTATAT





TTACATATATATATTAAAATTGCATGGGACAGAGACTTTGCAATCCGAAAGAATAGA





CTGTGAAATGAGTTCTTAAAGAAAAGACTTGTTTATGTATTAAAAAAACCACTTCACA





GTGAGTCGCTTTGGCTTTTTGATAAACTGCGGCCTGCTCTCAGGGTGGGGTGACTA





TTTTTGAATTCCTATTTATTTTTTGTGTTTGTCCCTGATTTTTTTTTTTTAATTCTATGG





CTTCCTATCTGGCAGCTTAATGGGTAATTTTTGAGGTATGTATTTAACAAAATAAACG





ACACTGCCGAAAAAAAAAAAAGTGAAGTGAAAACAATCAGGGCACATTAAAATGATA





CAAGTCAAATAAATCTTAAAGACACAATGCACACTTAAAATGACTCAATAAAATGACT





TGCTACGTTCCGTTATTCAATTTGTCATTACTGTAGTGAACAGATGCATTTCTGTGG





AATTCCAAATAAGTAAAACTGAAATTCAGTGCAGAGAAAACTTTGTCCACTAGTGCA





AGTCTTGATCAAATGACATTTTGACATTGGACATATGGAATTCATAGTATGAGCCAC





ATTTTGTTGTGAAATTTATTTACCTGCTTGTGGCTTCAAATCTGAAAATTAATAAGCC





TGCTCGTTTAAAAGTTGTTTGTTGTTGCTGTTTTTTTGTCTTTTTGTTTTTTACTAGAA





AATAGTTCAGTGTAATATTAAGTTAGAAAAGAAGTTGCTGCCCAGTTAAAGGGGCTC





CCTCTCAAATAAATCTCCATCCTTCCCTCTCCCAAAAGACATTTCTGATTTCTGCTTC





ACTTTGGGCTTCCTCTTCTTCGTACACATTCCATCTACCTAATCAAACATTTTCAGTC





CCTGATCTCTCCTGTCCCTTTTCCTGGGATGACAGCCCTAACAAGAACTGTTTTTGA





ATCGTTGTGCAGCTCCAGGCAATAGAGTATGTGAAGCGATTTCAGTAGAATCACTTA





CTCATCCTAAAAGAAAACATTATCCCAGTTACCTACATCGCAATTACCTTATGTAAAG





CAGAACTAATGCTGACTGGATGTTTAATGGGATGAGCATTAAAGCTGCAATCTACTA





TAGTACTCCAGATCTCTTTCGGCTTCCTATGAGAAACACCAGAAGCATTACTTTCCA





CTTCTACTTACAGTAATTGCAAGAGGAGACCTCACATTCAGGACTGCCTAGTGAAC





GTAATCCATGCTTTAAACTGGCCATTAAACAGTCCCACATGGTTGGATTTTTTTTTTT





TTTTTGAGTTGTGCTTTCACAAAACCTTGTCAAAGACCTCATGCAATATCACTTTGAA





AGTTATTTTCTGTTTACTACACAAACATTGTAATATAACTGTTAATACTATTTATATAT





TTGAAAGGTATAAAAGGTAGGAGTTAAAAAAAAAACCTCTATGTGTAGATATTAACT





CAGAACTTACAATATACAGGGAGAAGACATGTTGCAATACAAGCTAATTCTAGCTGC





TCAGTAACCTCTGGAGTTTTTAAAGGGACATTTTCCTGTACTTTTTCAAATAATGATG





TTTAAAAATTATCTTGACATAAGCGTCATATACCTTTGCAAAAGGATGGTTGTTTGCA





GTTAGCCCTGGCCCCATCCTTCCTATTTCTGTAGTATGCTGCAGCTTTAATCAGAAA





GTCCATGGTTGCTGCTTCCTGATCTCCGAGTTACTCTTTCCAAATTGTCTTCTTACA





CTGTTGCTGAAGGTCACTCTGTACACGTAATGGAAACTGATTTTGCCAAGCTCTTAC





AAGGTGGTTCATCTATCGATGGCATCCGCATTTGGTATCTTTTACACTTCAACCAAA





AATTTATTAGGTATTTTTCAATGCTAAGTCTTGCCTTTTATTTTTTAATTTCACTGCCA





AGTTTGCAGTGGTTCTAAGTGAATCTGTGGGCATTTTAGCCTGTGGTCTTGCCAGAT





CTTTGCGAATTACAATGCATATATGTCTATTTATTCAATATCTGTCATATAATATCTAT





TTGGAAGAAGAAACTTTCTCTTGTAGTGCCTCTTGACAAAGCACAATTTCCCGCCTT





TTTTTTTTTTTGTGAAATGAAAAAAACAAATTGTGTTTTATTGCGGTATCAACAATGTG





AATAAGGATTAACATATTGTAAATGTTCTTTTTTCCATGTAAATCAACTATCTTTGTTA





TCACTAAGTGATAATTAATTTTTAACTTATGTGCATTGTTAGGCTGTTAGAATTTTTTG





GTTGTTAAAATAAACGCATTCAATAAA. (SEQ ID NO: 238; NM_001172509.2),







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:238 under stringent hybridization conditions


In some embodiments, PDZ and LIM domain 7 (LMP3, PDLIM7, LMP1) comprises the amino acid sequence:









MDSFKVVLEGPAPWGFRLQGGKDFNVPLSISRLTPGGKAAQAGVAVGDWV





LSIDGENAGSLTHIEAQNKIRACGERLSLGLSRAQPVQSKPQKASAPAAD





PPRYTFAPSVSLNKTARPFGAPPPADSAPQQNGQPLRPLVPDASKQRLME





NTEDWRPRPGTGQSRSFRILAHLTGTEFMQDPDEEHLKKSSQVPRTEAPA





PASSTPQEPWPGPTAPSPTSRPPWAVDPAFAERYAPDKTSTVLTRHSQPA





TPTPLQSRTSIVQAAAGGVPGGGSNNGKTPVCHQCHKVIRGRYLVALGHA





YHPEEFVCSQCGKVLEEGGFFEEKGAIFCPPCYDVRYAPSCAKCKKKITG





EIMHALKMTWHVHCFTCAACKTPIRNRAFYMEEGVPYCERDYEKMFGTKC





HGCDFKIDAGDRFLEALGFSWHDTCFVCAICQINLEGKTFYSKKDRPLCK





SHAFSHV (SEQ ID NO: 239; NP_005442.2),







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:239)


In some embodiments, the nucleic acid sequence encoding LMP3 comprises the nucleic acid sequence:









GTCAGAACACTGGCGGCCGATCCCAACGAGGCTCCCTGGAGCCCGACGCA





GAGCAGCGCCCTGGCCGGGCCAAGCAGGAGCCGGCATCATGGATTCCTTC





AAAGTAGTGCTGGAGGGGCCAGCACCTTGGGGCTTCCGGCTGCAAGGGGG





CAAGGACTTCAATGTGCCCCTCTCCATTTCCCGGCTCACTCCTGGGGGCA





AAGCGGCGCAGGCCGGAGTGGCCGTGGGTGACTGGGTGCTGAGCATCGAT





GGCGAGAATGCGGGTAGCCTCACACACATCGAAGCTCAGAACAAGATCCG





GGCCTGCGGGGAGCGCCTCAGCCTGGGCCTCAGCAGGGCCCAGCCGGTTC





AGAGCAAACCGCAGAAGGCCTCCGCCCCCGCCGCGGACCCTCCGCGGTAC





ACCTTTGCACCCAGCGTCTCCCTCAACAAGACGGCCCGGCCCTTTGGGGC





GCCCCCGCCCGCTGACAGCGCCCCGCAGCAGAATGGACAGCCGCTCCGAC





CGCTGGTCCCAGATGCCAGCAAGCAGCGGCTGATGGAGAACACAGAGGAC





TGGCGGCCGCGGCCGGGGACAGGCCAGTCGCGTTCCTTCCGCATCCTTGC





CCACCTCACAGGCACCGAGTTCATGCAAGACCCGGATGAGGAGCACCTGA





AGAAATCAAGCCAGGTGCCCAGGACAGAAGCCCCAGCCCCAGCCTCATCT





ACACCCCAGGAGCCCTGGCCTGGCCCTACCGCCCCCAGCCCTACCAGCCG





CCCGCCCTGGGCTGTGGACCCTGCGTTTGCCGAGCGCTATGCCCCGGACA





AAACGAGCACAGTGCTGACCCGGCACAGCCAGCCGGCCACGCCCACGCCG





CTGCAGAGCCGCACCTCCATTGTGCAGGCAGCTGCCGGAGGGGTGCCAGG





AGGGGGCAGCAACAACGGCAAGACTCCCGTGTGTCACCAGTGCCACAAGG





TCATCCGGGGCCGCTACCTGGTGGCGCTGGGCCACGCGTACCACCCGGAG





GAGTTTGTGTGTAGCCAGTGTGGGAAGGTCCTGGAAGAGGGTGGCTTCTT





TGAGGAGAAGGGCGCCATCTTCTGCCCACCATGCTATGACGTGCGCTATG





CACCCAGCTGTGCCAAGTGCAAGAAGAAGATTACAGGCGAGATCATGCAC





GCCCTGAAGATGACCTGGCACGTGCACTGCTTTACCTGTGCTGCCTGCAA





GACGCCCATCCGGAACAGGGCCTTCTACATGGAGGAGGGCGTGCCCTATT





GCGAGCGAGACTATGAGAAGATGTTTGGCACGAAATGCCATGGCTGTGAC





TTCAAGATCGACGCTGGGGACCGCTTCCTGGAGGCCCTGGGCTTCAGCTG





GCATGACACCTGCTTCGTCTGTGCGATATGTCAGATCAACCTGGAAGGAA





AGACCTTCTACTCCAAGAAGGACAGGCCTCTCTGCAAGAGCCATGCCTTC





TCTCATGTGTGAGCCCCTTCTGCCCACAGCTGCCGCGGTGGCCCCTAGCC





TGAGGGGCCTGGAGTCGTGGCCCTGCATTTCTGGGTAGGGCTGGCAATGG





TTGCCTTAACCCTGGCTCCTGGCCCGAGCCTGGGGCTCCCTGGGCCCTGC





CCCACCCACCTTATCCTCCCACCCCACTCCCTCCACCACCACAGCACACC





GGTGCTGGCCACACCAGCCCCCTTTCACCTCCAGTGCCACAATAAACCTG





TACCCAGCTGTG. (SEQ ID NO: 240; NM_005451.5),







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:240 under stringent hybridization conditions


In some embodiments, POU class 5 homeobox 1 (OCT3, OCT4, POU5F1) comprises the amino acid sequence:









MGVLFGKVFSQTTICRFEALQLSFKNMCKLRPLLQKWVEEADNNENLQEI





CKAETLVQARKRKRTSIENRVRGNLENLFLQCPKPTLQQISHIAQQLGLE





KDVVRVWFCNRRQKGKRSSSDYAQREDFEAAGSPFSGGPVSFPLAPGPHF





GTPGYGSPHFTALYSSVPFPEGEAFPPVSVTTLGSPMHSN. (SEQ ID





NO: 241; NP_001167002.1),







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:241)


In some embodiments, the nucleic acid sequence encoding OCT3 comprises the nucleic acid sequence:









GGAAAAAAGGAAAGTGCACTTGGAAGAGATCCAAGTGGGCAACTTGAAGA





ACAAGTGCCAAATAGCACTTCTGTCATGCTGGATGTCAGGGCTCTTTGTC





CACTTTGTATAGCCGCTGGCTTATAGAAGGTGCTCGATAAATCTCTTGAA





TTTAAAAATCAATTAGGATGCCTCTATAGTGAAAAAGATACAGTAAAGAT





GAGGGATAATCAATTTAAAAAATGAGTAAGTACACACAAAGCACTTTATC





CATTCTTATGACACCTGTTACTTTTTTGCTGTGTTTGTGTGTATGCATGC





CATGTTATAGTTTGTGGGACCCTCAAAGCAAGCTGGGGAGAGTATATACT





GAATTTAGCTTCTGAGACATGATGCTCTTCCTTTTTAATTAACCCAGAAC





TTAGCAGCTTATCTATTTCTCTAATCTCAAAACATCCTTAAACTGGGGGT





GATACTTGAGTGAGAGAATTTTGCAGGTATTAAATGAACTATCTTCTTTT





TTTTTTTTCTTTGAGACAGAGTCTTGCTCTGTCACCCAGGCTGGAGTGCA





GTGGCGTGATCTCAGCTCACTGCAACCTCCGCCTCCCGGGTTCAAGTGAT





TCTCCTGCCTCAGCCTCCTGAGTAGCTGGGATTACAGTCCCAGGACATCA





AAGCTCTGCAGAAAGAACTCGAGCAATTTGCCAAGCTCCTGAAGCAGAAG





AGGATCACCCTGGGATATACACAGGCCGATGTGGGGCTCACCCTGGGGGT





TCTATTTGGGAAGGTATTCAGCCAAACGACCATCTGCCGCTTTGAGGCTC





TGCAGCTTAGCTTCAAGAACATGTGTAAGCTGCGGCCCTTGCTGCAGAAG





TGGGTGGAGGAAGCTGACAACAATGAAAATCTTCAGGAGATATGCAAAGC





AGAAACCCTCGTGCAGGCCCGAAAGAGAAAGCGAACCAGTATCGAGAACC





GAGTGAGAGGCAACCTGGAGAATTTGTTCCTGCAGTGCCCGAAACCCACA





CTGCAGCAGATCAGCCACATCGCCCAGCAGCTTGGGCTCGAGAAGGATGT





GGTCCGAGTGTGGTTCTGTAACCGGCGCCAGAAGGGCAAGCGATCAAGCA





GCGACTATGCACAACGAGAGGATTTTGAGGCTGCTGGGTCTCCTTTCTCA





GGGGGACCAGTGTCCTTTCCTCTGGCCCCAGGGCCCCATTTTGGTACCCC





AGGCTATGGGAGCCCTCACTTCACTGCACTGTACTCCTCGGTCCCTTTCC





CTGAGGGGGAAGCCTTTCCCCCTGTCTCCGTCACCACTCTGGGCTCTCCC





ATGCATTCAAACTGAGGTGCCTGCCCTTCTAGGAATGGGGGACAGGGGGA





GGGGAGGAGCTAGGGAAAGAAAACCTGGAGTTTGTGCCAGGGTTTTTGGG





ATTAAGTTCTTCATTCACTAAGGAAGGAATTGGGAACACAAAGGGTGGGG





GCAGGGGAGTTTGGGGCAACTGGTTGGAGGGAAGGTGAAGTTCAATGATG





CTCTTGATTTTAATCCCACATCATGTATCACTTTTTTCTTAAATAAAGAA





GCCTGGGACACAGTAGATAGACACACTTAAAAAAAAAAA. (SEQ ID





NO: 242; NM_001173531.2),







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:242 under stringent hybridization conditions


In some embodiments, Kruppel like factor 4 (KLF4, EZF, GKLF) comprises the amino acid sequence:









MRQPPGESDMAVSDALLPSFSTFASGPAGREKTLRQAGAPNNRWREELSH





MKRLPPVLPGRPYDLAAATVATDLESGGAGAACGGSNLAPLPRRETEEFN





DLLDLDFILSNSLTHPPESVAATVSSSASASSSSSPSSSGPASAPSTCSF





TYPIRAGNDPGVAPGGTGGGLLYGRESAPPPTAPFNLADINDVSPSGGFV





AELLRPELDPVYIPPQQPQPPGGGLMGKFVLKASLSAPGSEYGSPSVISV





SKGSPDGSHPVVVAPYNGGPPRTCPKIKQEAVSSCTHLGAGPPLSNGHRP





AAHDFPLGRQLPSRTTPTLGLEEVLSSRDCHPALPLPPGFHPHPGPNYPS





FLPDQMQPQVPPLHYQGQSRGFVARAGEPCVCWPHFGTHGMMLTPPSSPL





ELMPPGSCMPEEPKPKRGRRSWPRKRTATHTCDYAGCGKTYTKSSHLKAH





LRTHTGEKPYHCDWDGCGWKFARSDELTRHYRKHTGHRPFQCQKCDRAFS





RSDHLALHMKRHF. (SEQ ID NO: 243; NP_001300981.1),







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:243)


In some embodiments, the nucleic acid sequence encoding KLF4 comprises the nucleic acid sequence:










GGCAGTTTCCCGACCAGAGAGAACGAACGTGTCTGCGGGCGCGCGGGGAGCAGA






GGCGGTGGCGGGCGGCGGCGGCACCGGGAGCCGCCGAGTGACCCTCCCCCGCC





CCTCTGGCCCCCCACCCTCCCACCCGCCCGTGGCCCGCGCCCATGGCCGCGCGC





GCTCCACACAACTCACCGGAGTCCGCGCCTTGCGCCGCCGACCAGTTCGCAGCTC





CGCGCCACGGCAGCCAGTCTCACCTGGCGGCACCGCCCGCCCACCGCCCCGGCC





ACAGCCCCTGCGCCCACGGCAGCACTCGAGGCGACCGCGACAGTGGTGGGGGAC





GCTGCTGAGTGGAAGAGAGCGCAGCCCGGCCACCGGACCTACTTACTCGCCTTGC





TGATTGTCTATTTTTGCGTTTACAACTTTTCTAAGAACTTTTGTATACAAAGGAACTTT





TTAAAAAAGACGCTTCCAAGTTATATTTAATCCAAAGAAGAAGGATCTCGGCCAATT





TGGGGTTTTGGGTTTTGGCTTCGTTTCTTCTCTTCGTTGACTTTGGGGTTCAGGTGC





CCCAGCTGCTTCGGGCTGCCGAGGACCTTCTGGGCCCCCACATTAATGAGGCAGC





CACCTGGCGAGTCTGACATGGCTGTCAGCGACGCGCTGCTCCCATCTTTCTCCAC





GTTCGCGTCTGGCCCGGCGGGAAGGGAGAAGACACTGCGTCAAGCAGGTGCCCC





GAATAACCGCTGGCGGGAGGAGCTCTCCCACATGAAGCGACTTCCCCCAGTGCTT





CCCGGCCGCCCCTATGACCTGGCGGCGGCGACCGTGGCCACAGACCTGGAGAGC





GGCGGAGCCGGTGCGGCTTGCGGCGGTAGCAACCTGGCGCCCCTACCTCGGAGA





GAGACCGAGGAGTTCAACGATCTCCTGGACCTGGACTTTATTCTCTCCAATTCGCT





GACCCATCCTCCGGAGTCAGTGGCCGCCACCGTGTCCTCGTCAGCGTCAGCCTCC





TCTTCGTCGTCGCCGTCGAGCAGCGGCCCTGCCAGCGCGCCCTCCACCTGCAGCT





TCACCTATCCGATCCGGGCCGGGAACGACCCGGGCGTGGCGCCGGGCGGCACG





GGCGGAGGCCTCCTCTATGGCAGGGAGTCCGCTCCCCCTCCGACGGCTCCCTTCA





ACCTGGCGGACATCAACGACGTGAGCCCCTCGGGCGGCTTCGTGGCCGAGCTCC





TGCGGCCAGAATTGGACCCGGTGTACATTCCGCCGCAGCAGCCGCAGCCGCCAG





GTGGCGGGCTGATGGGCAAGTTCGTGCTGAAGGCGTCGCTGAGCGCCCCTGGCA





GCGAGTACGGCAGCCCGTCGGTCATCAGCGTCAGCAAAGGCAGCCCTGACGGCA





GCCACCCGGTGGTGGTGGCGCCCTACAACGGCGGGCCGCCGCGCACGTGCCCCA





AGATCAAGCAGGAGGCGGTCTCTTCGTGCACCCACTTGGGCGCTGGACCCCCTCT





CAGCAATGGCCACCGGCCGGCTGCACACGACTTCCCCCTGGGGCGGCAGCTCCC





CAGCAGGACTACCCCGACCCTGGGTCTTGAGGAAGTGCTGAGCAGCAGGGACTGT





CACCCTGCCCTGCCGCTTCCTCCCGGCTTCCATCCCCACCCGGGGCCCAATTACC





CATCCTTCCTGCCCGATCAGATGCAGCCGCAAGTCCCGCCGCTCCATTACCAAGGT





CAGTCCCGGGGATTTGTAGCTCGGGCTGGGGAGCCCTGTGTGTGCTGGCCCCACT





TCGGGACACACGGGATGATGCTCACCCCACCTTCTTCACCCCTAGAGCTCATGCCA





CCCGGTTCCTGCATGCCAGAGGAGCCCAAGCCAAAGAGGGGAAGACGATCGTGG





CCCCGGAAAAGGACCGCCACCCACACTTGTGATTACGCGGGCTGCGGCAAAACCT





ACACAAAGAGTTCCCATCTCAAGGCACACCTGCGAACCCACACAGGTGAGAAACCT





TACCACTGTGACTGGGACGGCTGTGGATGGAAATTCGCCCGCTCAGATGAACTGA





CCAGGCACTACCGTAAACACACGGGGCACCGCCCGTTCCAGTGCCAAAAATGCGA





CCGAGCATTTTCCAGGTCGGACCACCTCGCCTTACACATGAAGAGGCATTTTTAAA





TCCCAGACAGTGGATATGACCCACACTGCCAGAAGAGAATTCAGTATTTTTTACTTT





TCACACTGTCTTCCCGATGAGGGAAGGAGCCCAGCCAGAAAGCACTACAATCATG





GTCAAGTTCCCAACTGAGTCATCTTGTGAGTGGATAATCAGGAAAAATGAGGAATC





CAAAAGACAAAAATCAAAGAACAGATGGGGTCTGTGACTGGATCTTCTATCATTCCA





ATTCTAAATCCGACTTGAATATTCCTGGACTTACAAAATGCCAAGGGGGTGACTGGA





AGTTGTGGATATCAGGGTATAAATTATATCCGTGAGTTGGGGGAGGGAAGACCAGA





ATTCCCTTGAATTGTGTATTGATGCAATATAAGCATAAAAGATCACCTTGTATTCTCT





TTACCTTCTAAAAGCCATTATTATGATGTTAGAAGAAGAGGAAGAAATTCAGGTACA





GAAAACATGTTTAAATAGCCTAAATGATGGTGCTTGGTGAGTCTTGGTTCTAAAGGT





ACCAAACAAGGAAGCCAAAGTTTTCAAACTGCTGCATACTTTGACAAGGAAAATCTA





TATTTGTCTTCCGATCAACATTTATGACCTAAGTCAGGTAATATACCTGGTTTACTTC





TTTAGCATTTTTATGCAGACAGTCTGTTATGCACTGTGGTTTCAGATGTGCAATAATT





TGTACAATGGTTTATTCCCAAGTATGCCTTAAGCAGAACAAATGTGTTTTTCTATATA





GTTCCTTGCCTTAATAAATATGTAATATAAATTTAAGCAAACGTCTATTTTGTATATTT





GTAAACTACAAAGTAAAATGAACATTTTGTGGAGTTTGTATTTTGCATACTCAAGGTG





AGAATTAAGTTTTAAATAAACCTATAATATTTTATCTGAA. (SEQ ID NO: 244;





NM_001314052.2),







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:244 under stringent hybridization conditions


In some embodiments, MYC proto-oncogene, bHLH transcription factor (MYC, MRTL, MYCC, c-MC) comprises the amino acid sequence:









MDFFRVVENQPPATMPLNVSFTNRNYDLDYDSVQPYFYCDEEENFYQQQQ





QSELQPPAPSEDIWKKFELLPTPPLSPSRRSGLCSPSYVAVTPFSLRGDN





DGGGGSFSTADQLEMVTELLGGDMVNQSFICDPDDETFIKNIIIQDCMWS





GFSAAAKLVSEKLASYQAARKDSGSPNPARGHSVCSTSSLYLQDLSAAAS





ECIDPSVVFPYPLNDSSSPKSCASQDSSAFSPSSDSLLSSTESSPQGSPE





PLVLHEETPPTTSSDSEEEQEDEEEIDVVSVEKRQAPGKRSESGSPSAGG





HSKPPHSPLVLKRCHVSTHQHNYAAPPSTRKDYPAAKRVKLDSVRVLRQI





SNNRKCTSPRSSDTEENVKRRTHNVLERQRRNELKRSFFALRDQIPELEN





NEKAPKVVILKKATAYILSVQAEEQKLISEEDLLRKRREQLKHKLEQLRN





SCA. (SEQ ID NO: 245; NP_001341799.1),







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:245)


In some embodiments, the nucleic acid sequence encoding MYC comprises the nucleic acid sequence:










GGAGTTTATTCATAACGCGCTCTCCAAGTATACGTGGCAATGCGTTGCTGGGTTATT






TTAATCATTCTAGGCATCGTTTTCCTCCTTATGCCTCTATCATTCCTCCCTATCTACA





CTAACATCCCACGCTCTGAACGCGCGCCCATTAATACCCTTCTTTCCTCCACTCTCC





CTGGGACTCTTGATCAAAGCGCGGCCCTTTCCCCAGCCTTAGCGAGGCGCCCTGC





AGCCTGGTACGCGCGTGGCGTGGCGGTGGGCGCGCAGTGCGTTCTCGGTGTGGA





GGGCAGCTGTTCCGCCTGCGATGATTTATACTCACAGGACAAGGATGCGGTTTGTC





AAACAGTACTGCTACGGAGGAGCAGCAGAGAAAGGGAGAGGGTTTGAGAGGGAG





CAAAAGAAAATGGTAGGCGCGCGTAGTTAATTCATGCGGCTCTCTTACTCTGTTTAC





ATCCTAGAGCTAGAGTGCTCGGCTGCCCGGCTGAGTCTCCTCCCCACCTTCCCCA





CCCTCCCCACCCTCCCCATAAGCGCCCCTCCCGGGTTCCCAAAGCAGAGGGCGTG





GGGGAAAAGAAAAAAGATCCTCTCTCGCTAATCTCCGCCCACCGGCCCTTTATAAT





GCGAGGGTCTGGACGGCTGAGGACCCCCGAGCTGTGCTGCTCGCGGCCGCCACC





GCCGGGCCCCGGCCGTCCCTGGCTCCCCTCCTGCCTCGAGAAGGGCAGGGCTTC





TCAGAGGCTTGGCGGGAAAAAGAACGGAGGGAGGGATCGCGCTGAGTATAAAAGC





CGGTTTTCGGGGCTTTATCTAACTCGCTGTAGTAATTCCAGCGAGAGGCAGAGGGA





GCGAGCGGGCGGCCGGCTAGGGTGGAAGAGCCGGGCGAGCAGAGCTGCGCTGC





GGGCGTCCTGGGAAGGGAGATCCGGAGCGAATAGGGGGCTTCGCCTCTGGCCCA





GCCCTCCCGCTGATCCCCCAGCCAGCGGTCCGCAACCCTTGCCGCATCCACGAAA





CTTTGCCCATAGCAGCGGGCGGGCACTTTGCACTGGAACTTACAACACCCGAGCA





AGGACGCGACTCTCCCGACGCGGGGAGGCTATTCTGCCCATTTGGGGACACTTCC





CCGCCGCTGCCAGGACCCGCTTCTCTGAAAGGCTCTCCTTGCAGCTGCTTAGACG





CTGGATTTTTTTCGGGTAGTGGAAAACCAGCCTCCCGCGACGATGCCCCTCAACGT





TAGCTTCACCAACAGGAACTATGACCTCGACTACGACTCGGTGCAGCCGTATTTCT





ACTGCGACGAGGAGGAGAACTTCTACCAGCAGCAGCAGCAGAGCGAGCTGCAGC





CCCCGGCGCCCAGCGAGGATATCTGGAAGAAATTCGAGCTGCTGCCCACCCCGCC





CCTGTCCCCTAGCCGCCGCTCCGGGCTCTGCTCGCCCTCCTACGTTGCGGTCACA





CCCTTCTCCCTTCGGGGAGACAACGACGGCGGTGGCGGGAGCTTCTCCACGGCC





GACCAGCTGGAGATGGTGACCGAGCTGCTGGGAGGAGACATGGTGAACCAGAGTT





TCATCTGCGACCCGGACGACGAGACCTTCATCAAAAACATCATCATCCAGGACTGT





ATGTGGAGCGGCTTCTCGGCCGCCGCCAAGCTCGTCTCAGAGAAGCTGGCCTCCT





ACCAGGCTGCGCGCAAAGACAGCGGCAGCCCGAACCCCGCCCGCGGCCACAGCG





TCTGCTCCACCTCCAGCTTGTACCTGCAGGATCTGAGCGCCGCCGCCTCAGAGTG





CATCGACCCCTCGGTGGTCTTCCCCTACCCTCTCAACGACAGCAGCTCGCCCAAGT





CCTGCGCCTCGCAAGACTCCAGCGCCTTCTCTCCGTCCTCGGATTCTCTGCTCTCC





TCGACGGAGTCCTCCCCGCAGGGCAGCCCCGAGCCCCTGGTGCTCCATGAGGAG





ACACCGCCCACCACCAGCAGCGACTCTGAGGAGGAACAAGAAGATGAGGAAGAAA





TCGATGTTGTTTCTGTGGAAAAGAGGCAGGCTCCTGGCAAAAGGTCAGAGTCTGGA





TCACCTTCTGCTGGAGGCCACAGCAAACCTCCTCACAGCCCACTGGTCCTCAAGAG





GTGCCACGTCTCCACACATCAGCACAACTACGCAGCGCCTCCCTCCACTCGGAAG





GACTATCCTGCTGCCAAGAGGGTCAAGTTGGACAGTGTCAGAGTCCTGAGACAGAT





CAGCAACAACCGAAAATGCACCAGCCCCAGGTCCTCGGACACCGAGGAGAATGTC





AAGAGGCGAACACACAACGTCTTGGAGCGCCAGAGGAGGAACGAGCTAAAACGGA





GCTTTTTTGCCCTGCGTGACCAGATCCCGGAGTTGGAAAACAATGAAAAGGCCCCC





AAGGTAGTTATCCTTAAAAAAGCCACAGCATACATCCTGTCCGTCCAAGCAGAGGA





GCAAAAGCTCATTTCTGAAGAGGACTTGTTGCGGAAACGACGAGAACAGTTGAAAC





ACAAACTTGAACAGCTACGGAACTCTTGTGCGTAAGGAAAAGTAAGGAAAACGATT





CCTTCTAACAGAAATGTCCTGAGCAATCACCTATGAACTTGTTTCAAATGCATGATC





AAATGCAACCTCACAACCTTGGCTGAGTCTTGAGACTGAAAGATTTAGCCATAATGT





AAACTGCCTCAAATTGGACTTTGGGCATAAAAGAACTTTTTTATGCTTACCATCTTTT





TTTTTTCTTTAACAGATTTGTATTTAAGAATTGTTTTTAAAAAATTTTAAGATTTACACA





ATGTTTCTCTGTAAATATTGCCATTAAATGTAAATAACTTTAATAAAACGTTTATAGCA





GTTACACAGAATTTCAATCCTAGTATATAGTACCTAGTATTATAGGTACTATAAACCC





TAATTTTTTTTATTTAAGTACATTTTGCTTTTTAAAGTTGATTTTTTTCTATTGTTTTTA





GAAAAAATAAAATAACTGGCAAATATATCATTGAGCCAAATCTTAAGTTGTGAATGTT





TTGTTTCGTTTCTTCCCCCTCCCAACCACCACCATCCCTGTTTGTTTTCATCAATTGC





CCCTTCAGAGGGTGGTCTTAAGAAAGGCAAGAGTTTTCCTCTGTTGAAATGGGTCT





GGGGGCCTTAAGGTCTTTAAGTTCTTGGAGGTTCTAAGATGCTTCCTGGAGACTAT





GATAACAGCCAGAGTTGACAGTTAGAAGGAATGGCAGAAGGCAGGTGAGAAGGTG





AGAGGTAGGCAAAGGAGATACAAGAGGTCAAAGGTAGCAGTTAAGTACACAAAGA





GGCATAAGGACTGGGGAGTTGGGAGGAAGGTGAGGAAGAAACTCCTGTTACTTTA





GTTAACCAGTGCCAGTCCCCTGCTCACTCCAAACCCAGGAATTCTGCCCAGTTGAT





GGGGACACGGTGGGAACCAGCTTCTGCTGCCTTCACAACCAGGCGCCAGTCCTGT





CCATGGGTTATCTCGCAAACCCCAGAGGATCTCTGGGAGGAATGCTACTATTAACC





CTATTTCACAAACAAGGAAATAGAAGAGCTCAAAGAGGTTATGTAACTTATCTGTAG





CCACGCAGATAATACAAAGCAGCAATCTGGACCCATTCTGTTCAAAACACTTAACCC





TTCGCTATCATGCCTTGGTTCATCTGGGTCTAATGTGCTGAGATCAAGAAGGTTTAG





GACCTAATGGACAGACTCAAGTCATAACAATGCTAAGCTCTATTTGTGTCCCAAGCA





CTCCTAAGCATTTTATCCCTAACTCTACATCAACCCCATGAAGGAGATACTGTTGAT





TTCCCCATATTAGAAGTAGAGAGGGAAGCTGAGGCACACAAAGACTCATCCACATG





CCCAAGATTCACTGATAGGGAAAAGTGGAAGCGAGATTTGAACCCAGGCTGTTTAC





TCCTAACCTGTCCAAGCCACCTCTCAGACGACGGTAGGAATCAGCTGGCTGCTTGT





GAGTACAGGAGTTACAGTCCAGTGGGTTATGTTTTTTAAGTCTCAACATCTAAGCCT





GGTCAGGCATCAGTTCCCCTTTTTTTGTGATTTATTTTGTTTTTATTTTGTTGTTCATT





GTTTAATTTTTCCTTTTACAATGAGAAGGTCACCATCTTGACTCCTACCTTAGCCATT





TGTTGAATCAGACTCATGACGGCTCCTGGGAAGAAGCCAGTTCAGATCATAAAATA





AAACATATTTATTCTTTGTCATGGGAGTCATTATTTTAGAAACTACAAACTCTCCTTG





CTTCCATCCTTTTTTACATACTCATGACACATGCTCATCCTGAGTCCTTGAAAAGGTA





TTTTTGAACATGTGTATTAATTATAAGCCTCTGAAAACCTATGGCCCAAACCAGAAAT





GATGTTGATTATATAGGTAAATGAAGGATGCTATTGCTGTTCTAATTACCTCATTGTC





TCAGTCTCAAAGTAGGTCTTCAGCTCCCTGTACTTTGGGATTTTAATCTACCACCAC





CCATAAATCAATAAATAATTACTTTCTTTGA. (SEQ ID NO: 246;





NM_001354870.1),







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:246 under stringent hybridization conditions


In some embodiments, distal-less homeobox 3 (DLX3, AI4, TDO) comprises the amino acid sequence:









MSGSFDRKLSSILTDISSSLSCHAGSKDSPTLPESSVTDLGYYSAPQHDY





YSGQPYGQTVNPYTYHHQFNLNGLAGTGAYSPKSEYTYGASYRQYGAYRE





QPLPAQDPVSVKEEPEAEVRMVNGKPKKVRKPRTIYSSYQLAALQRRFQK





AQYLALPERAELAAQLGLTQTQVKIWFQNRRSKFKKLYKNGEVPLEHSPN





NSDSMACNSPPSPALWDTSSHSTPAPARSQLPPPLPYSASPSYLDDPTNS





WYHAQNLSGPHLQQQPPQPATLHHASPGPPPNPGAVY (SEQ ID NO:





247; NP_005211.1),







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:247)


In some embodiments, the nucleic acid sequence encoding DLX3 comprises the nucleic acid sequence:









AGCATTTGATTGTGGCTTGGGACGCGAGGAGAGGCGCGCAGCGACCGCCT





GACGGCAGGCAATGGTGTAAGCGCCTCTCGGCCTCCCCCTCCCCCCAGAC





GCGGCCGGGTCCTCCCTTCGCCTTCTGGACACACACCCCTGCCTCGTCTC





TTCCGCCTCTCTCGCACTCCGGTCCGTTCCTGTCCTCTGCGGAGGCCAGC





CCTGGGGAGGTGCAGCGCCCGCCAGGATGAGTGGCTCCTTCGATCGCAAG





CTCAGCAGCATCCTCACCGACATCTCCAGCTCCCTTAGCTGCCATGCGGG





CTCCAAGGACTCGCCTACCCTGCCCGAGTCTTCTGTCACTGACCTGGGCT





ACTACAGCGCTCCCCAGCACGATTACTACTCGGGCCAGCCCTATGGCCAG





ACGGTGAACCCCTACACCTACCACCACCAATTCAATCTCAATGGGCTTGC





AGGCACGGGCGCTTACTCGCCCAAGTCGGAATATACCTACGGAGCCTCCT





ACCGGCAATACGGGGCGTATCGGGAGCAGCCGCTGCCAGCCCAGGACCCA





GTGTCGGTGAAGGAGGAGCCGGAAGCAGAGGTGCGCATGGTGAATGGGAA





GCCCAAGAAGGTCCGAAAGCCGCGTACGATCTACTCCAGCTACCAGCTGG





CCGCCCTGCAGCGCCGCTTCCAGAAGGCCCAGTACCTGGCGCTGCCCGAG





CGCGCCGAGCTGGCCGCGCAGCTGGGCCTCACGCAGACACAGGTGAAAAT





CTGGTTCCAGAACCGCCGTTCCAAGTTCAAGAAACTCTACAAGAACGGGG





AGGTGCCGCTGGAGCACAGTCCCAATAACAGTGATTCCATGGCCTGCAAC





TCACCACCATCACCCGCCCTCTGGGACACCTCTTCCCACTCCACTCCGGC





CCCTGCCCGCAGTCAGCTGCCCCCGCCGCTCCCATACAGTGCCTCCCCCA





GCTACCTGGACGACCCCACCAACTCCTGGTATCACGCACAGAACCTGAGT





GGACCCCACTTACAGCAGCAGCCGCCTCAGCCAGCCACCCTGCACCATGC





CTCTCCCGGGCCCCCGCCCAACCCTGGGGCTGTGTACTGAGCACCCATCT





GGCCTGCACCCTTGACAAAGGACCCCAGGACCAGGCAGAAGGCGCCTCCG





TCCTAGCCACTCAGGAATCATCGAGGAGCACAGGGAAAAGGAACTCCCTT





TCCCCCTCCCTTGCCCCTTCCTCCAGGGACCCAAGCGCTTCCAGATGACA





ATTGCATGGACCAAGGATGCCCCCTGAACCTCCCTCCCTCTGCCTAGACA





CTGGGGTACCCCTCCAGATGTGGGGACATTCCACCCCAGTGGGGACAGCC





ATTCCCCTACCTGCTCCAGGAGCCTGGATTGGCTTTAAATGGCTCATCAT





CTTCCAGCTTCTTAAACTTAGTGCCTGTTCCCAGACTGGAGACCTTGGGA





TGGGGGAGAGTGTGGAGGGTTTGCGGGTCCTGCCTGTGCTGGGGCACCTG





GCACCGTGGATCTTAAAACTTGCCAGGCCTAGTTCCTCCTGAGCCTCTGG





TGGTCTCCCCCTGCTCGAGCGGCCCCTCGGCCAATAAGACAGTGGACATC





ATGACGAGGACTCCGGGTGGGGACCTGAACTGGTCACCGCCCTGCACTTC





TAGCCCTCATTTAAGATTTGAGGGTGAAACCAAAGAAAACCCCCTAAGTG





AGGGAATCTTTTAATATTTGTGGCTTTAGAGGAAAGAACTAAAGGAGCCA





TCTCTCTCCCCTCTCCTCCGTTCCGAGAGGAGGGGTGGGTCTCAGACGTT





TTTCCTATGGACTTATTTCTTCCATGTCCAGGACTTTGCACAACTTTGGT





TTTAAAAGCTGTTGAAAAATAGGAAAACAAAGGGCATTGTTCACAGATAG





GGCCAAGTCTCCCCTTGCAAGGGTGCCTCTGTTCTGTCCCTGCCCCCACC





TCACCTTCTCTACTCCTCCAGTAAGTTGGCAGTTTTGGTGCCAAACCCCA





AATCTCCAAAGAGACATACCAGGCAAGACAAACCCCCAAACACCTCCTTT





CCGGTGGCCTTGGAAACAGATTGCTCCGAGCTGGAGAATGTCGGGTGAGG





TGTATGGGAGAGGAGGGGAGAGTTAGAACTTGTGCCTTTGGGAGTAAGGG





GTAACTGCCTGGAGGGCTGGTGGCACTGCCCCTCCCTGACCCAGACATCC





CACCAAAGCTAACTTTCCCCCACCCCTGATGCAGTAAAACATTGAAAAAA





AAAAAAAAGGAGAGGTAGAAGACTGTAGCTATATATATAAATATATAGTA





AGTTTTTTTTTTTTAAGAGCAACAGAGAGAAGCAGCCTCCTCCCTGCTGC





GGTTTCCTATTTATGTGGCCATGTTCCTCCTGGACGGATCTCCCTGTGTG





TTTCAAGCTGAGAGATGTGGGCTCCGGCTGGATTTGGGTTTTGTGGGAGG





TGCAGGGGCCAAGAGAGACGTGGTAGGTCTCCAAGAGTCCCACCCGGGGG





GGAAGAAGCAAAGCCATCTCCCACCCCCTCCCAGCCTTCTCATTTCTGCT





TTCTTACTGGACTCATCTTTATATATAATGTTAATAAAAAAGACGAAAAT





AA. (SEQ ID NO: 248; NM_005220.3),







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:248 under stringent hybridization conditions


In some embodiments, distal-less homeobox 5 (DLX5, SHFM1 D) comprises the amino acid sequence:









(SEQ ID NO: 249; NP_005212.1)


MTGVFDRRVPSIRSGDFQAPFQTSAAMHHPSQESPTLPESSATDSDYYS





PTGGAPHGYCSPTSASYGKALNPYQYQYHGVNGSAGSYPAKAYADYSYA





SSYHQYGGAYNRVPSATNQPEKEVTEPEVRMVNGKPKKVRKPRTIYSSF





QLAALQRRFQKTQYLALPERAELAASLGLTQTQVKIWFQNKRSKIKKIM





KNGEMPPEHSPSSSDPMACNSPQSPAVWEPQGSSRSLSHHPHAHPPTSN





QSPASSYLENSASVVYTSAASSINSHLPPPGSLQHPLALASGTLY.,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:249)


In some embodiments, the nucleic acid sequence encoding DLX5 comprises the nucleic acid sequence:









(SEQ ID NO: 250; NM_005221.6)


AGCAGTCAGCCGGCCGGAGACAGAGACTTCACGACTCCCAGTCTCCTCC





TCGCCGCGGCCGCCGCCTCCTCCTTCTCTCCTCCTCCTCTTCCTCCTCC





TCCCTCGCTCCCACAGCCATGTCTGCTTAGACCAGAGCAGCCCCACAGC





CAACTAGGGCAGCTGCCGCCGCCACAACAGCAAGGACAGCCGCTGCCGC





CGCCCGTGAGCGATGACAGGAGTGTTTGACAGAAGGGTCCCCAGCATCC





GATCCGGCGACTTCCAAGCTCCGTTCCAGACGTCCGCAGCTATGCACCA





TCCGTCTCAGGAATCGCCAACTTTGCCCGAGTCTTCAGCTACCGATTCT





GACTACTACAGCCCTACGGGGGGAGCCCCGCACGGCTACTGCTCTCCTA





CCTCGGCTTCCTATGGCAAAGCTCTCAACCCCTACCAGTATCAGTATCA





CGGCGTGAACGGCTCCGCCGGGAGCTACCCAGCCAAAGCTTATGCCGAC





TATAGCTACGCTAGCTCCTACCACCAGTACGGCGGCGCCTACAACCGCG





TCCCAAGCGCCACCAACCAGCCAGAGAAAGAAGTGACCGAGCCCGAGGT





GAGAATGGTGAATGGCAAACCAAAGAAAGTTCGTAAACCCAGGACTATT





TATTCCAGCTTTCAGCTGGCCGCATTACAGAGAAGGTTTCAGAAGACTC





AGTACCTCGCCTTGCCGGAACGCGCCGAGCTGGCCGCCTCGCTGGGATT





GACACAAACACAGGTGAAAATCTGGTTTCAGAACAAAAGATCCAAGATC





AAGAAGATCATGAAAAACGGGGAGATGCCCCCGGAGCACAGTCCCAGCT





CCAGCGACCCAATGGCGTGTAACTCGCCGCAGTCTCCAGCGGTGTGGGA





GCCCCAGGGCTCGTCCCGCTCGCTCAGCCACCACCCTCATGCCCACCCT





CCGACCTCCAACCAGTCCCCAGCGTCCAGCTACCTGGAGAACTCTGCAT





CCTGGTACACAAGTGCAGCCAGCTCAATCAATTCCCACCTGCCGCCGCC





GGGCTCCTTACAGCACCCGCTGGCGCTGGCCTCCGGGACACTCTATTAG





ATGGGCTGCTCTCTCTTACTCTCTTTTTTGGGACTACTGTGTTTTGCTG





TTCTAGAAAATCATAAAGAAAGGAATTCATATGGGGAAGTTCGGAAAAC





TGAAAAAGATTCATGTGTAAAGCTTTTTTTTGCATGTAAGTTATTGCAT





TTCAAAAGACCCCCCCTTTTTTTACAGAGGACTTTTTTTGCGCAACTGT





GGACACTTTCAATGGTGCCTTGAAATCTATGACCTCAACTTTTCAAAAG





ACTTTTTTCAATGTTATTTTAGCCATGTAAATAAGTGTAGATAGAGGAA





TTAAACTGTATATTCTGGATAAATAAAATTATTTCGACCATGAAAA.,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:250 under stringent hybridization conditions


In some embodiments, distal-less homeobox 6 (DLX6) comprises the amino acid sequence:









(SEQ ID NO: 251; NP_005213.3)


MMTMTTMADGLEGQDSSKSAFMEFGQQQQQQQQQQQQQQQQQQQPPPPP





PPPPQPHSQQSSPAMAGAHYPLHCLHSAAAAAAAGSHHHHHHQHHHHGS





PYASGGGNSYNHRSLAAYPYMSHSQHSPYLQSYHNSSAAAQTRGDDTDQ





QKTTVIENGEIRFNGKGKKIRKPRTIYSSLQLQALNHRFQQTQYLALPE





RAELAASLGLTQTQVKIWFQNKRSKFKKLLKQGSNPHESDPLQGSAALS





PRSPALPPVWDVSASAKGVSMPPNSYMPGYSHWYSSPHQDTMQRPQMM.,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:251)


In some embodiments, the nucleic acid sequence encoding DLX6 comprises the nucleic acid sequence:









(SEQ ID NO: 252; NM_005222.4)


ATTCGACTCGTGGCGTCTGCATCAAGTCTGAAAGCAGACGCGCAACTTT





CGCAGAATCCACCTTAAAATCTCTGCCTTAAACTGCACCAGCCCCCAAA





AAATCCAAGGGGGGAAAGCAGGCGGGGGGAGAGCAGATTCCCCCCTCCC





CCTCTCCTCTCCCATCCCTCCTCCTTCCTCCTCCCTTTGAGTTAACAAG





GCCCCGCTCACTATATCTCTTTATATTAAATATATATATATATTAGAGA





AGAGCGAGGGAGAGGGAGAACCACCTCCACCCCCCTCTTTAAATTCTTT





TTTTTTTTTTTTTTTTTTTTTGCAAGGATCCAAAGAGCTAAGGTGGCTG





CAGAGGGGAGAGCGGCGCGAGCCAAGTGGGGGAGGGTGGAGGAAACCCG





GGAGAAGGCTTTCTCCAGCCCCCAAAGTTTTTGATGATGACCATGACTA





CGATGGCTGACGGCTTGGAAGGCCAGGACTCGTCCAAATCCGCCTTCAT





GGAGTTCGGGCAGCAGCAGCAGCAGCAGCAGCAACAGCAGCAGCAGCAG





CAGCAGCAACAGCAACAGCCGCCGCCGCCGCCGCCGCCGCCGCCGCAGC





CGCACTCGCAGCAGAGCTCCCCGGCCATGGCAGGCGCGCACTACCCTCT





GCACTGCCTGCACTCGGCGGCGGCGGCGGCAGCGGCCGGCTCGCACCAC





CACCACCACCACCAGCACCACCACCACGGCTCGCCCTACGCGTCGGGCG





GAGGGAACTCCTACAACCACCGCTCGCTCGCCGCCTACCCCTACATGAG





CCACTCGCAGCACAGCCCTTACCTCCAGTCCTACCACAACAGCAGCGCA





GCCGCCCAGACGCGAGGGGACGACACAGATCAACAAAAAACTACAGTGA





TTGAAAACGGGGAAATCAGGTTCAATGGAAAAGGGAAAAAGATTCGGAA





GCCTCGGACCATTTATTCCAGCCTGCAGCTCCAGGCTTTAAACCATCGC





TTTCAGCAGACACAGTATCTGGCCCTTCCAGAGAGAGCCGAACTGGCAG





CTTCCTTAGGACTGACACAAACACAGGTGAAGATATGGTTTCAGAACAA





ACGCTCTAAGTTTAAGAAACTGCTGAAGCAGGGCAGTAATCCTCATGAG





AGCGACCCCCTCCAGGGCTCGGCGGCCCTGTCGCCACGCTCGCCAGCGC





TGCCTCCAGTCTGGGACGTTTCTGCCTCGGCCAAGGGTGTCAGTATGCC





CCCCAACAGCTACATGCCTGGCTATTCTCACTGGTACTCCTCTCCACAC





CAGGACACGATGCAGAGACCACAGATGATGTGAGTTGCCCAAGGGAACA





CCCTAGGGAAACGTCTGAACAAGGAAAAGAGGATCCGGGACCTGCTTGT





ATCTGCGAAAAGGAGCCAAAGGAGCAGGCTTAGGAGAGCTCATAAGTGT





GGCAAGAAGCCGACTAGGCTCATTCTCTCTCCCTCTCTCTCTCTCTCCC





TCTCCTTTCTTTTTACTTCTTCCTTTCCTCCATTCCTTCTTTCTTTCCT





TTTCCTTTCTACCTTTCTTTTCTTTTTGCCTTTCACCTTTTTTCTCATT





TACCTTCTCTCTTGAGCAACGTCAGTAATTGATCTTGCATCTCAGAGAG





AGAGAAAGAGCATGTGTGAGAGAGAAACTGGTTTCTATGCCAGCACTCC





TGAAACCCCTTACTGTAAGGATATTTTCTCTTACCCCTTGGGATCCAGG





CTCTGAGTCTCTTCTCTTTGGGAGTATCCATCAAAATGACTTTTTTTAA





AAACAGATTTTCCCCCAACCAGAAGAATCTGCACAAACTTGGCAGCGTT





TTTACTTGTTTAATGAGTTTAAGACATTACATGGTGAAAGAGAAGCATT





TTGGACTCCTGCATTTTTATTTACCATTCCCAGACTGACGAGAAAAAGA





AAATTCCTCACATAACAGCCCTTCTCTAAAGAAAAAGGAAAAAGTGGCT





TTGATTAAAAAAAAACAAAACAAAAACCACTCTTTCCCCACCCCACCCC





CCCAAACCCTGAACTGGAATCAGGAAAGACGGAGGAAACAATCAAAATC





ACCATTCTATTGCTTTGACACCTTTACTAGGTGAATTGGTGGCATTCAC





AAAGCTAATAGGGACGTTTATATCAAGAAACATTTCTGTATATATTGTT





GAATTTTAGTTGTACATATACTTTGTATGTTTTTGTCTTCTTTCATATA





TGGAGTAAAAGCCACAAAACGCTGA.,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:252 under stringent hybridization conditions


In some embodiments, HOP homeobox2 (OB1, HOD, HOPX, LAGY, TOTO, CAMEO, NECC1, SMAP31) comprises the amino acid sequence:









(SEQ ID NO: 253; NP_001138931.1)


MSAETASGPTEDQVEILEYNFNKVDKHPDSTTLCLIAAEAGLSEEETQK


WFKQRLAKWRRSEGLPSECRSVTD,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:253)


In some embodiments, the nucleic acid sequence encoding OB1 comprises the nucleic acid sequence:









(SEQ ID NO: 254; NM_001145459.1)


GAGACAGAAGGCCGCCTACCGGGGAGGCCGGAGGCCGGCTAGTCGCGGA





CTCGGGCGAACCCACCCTCGCGATCTGTCAAGTCTGTCCCCAGGGGAGG





TCCCCCTTTCGGGAGGAAGTTTTTAAGGGGATTTCTCAAAATCACCCCC





GCGCTTCCTTCACTCCTTCCTTAGAGCCGGAGGTCGGTGAGGGCCCGCG





GAATCATCTATCTCGCCCCCGTCGCAGCGCGCAGGGACCATGTCGGCGG





AGACCGCGAGCGGCCCCACAGAGGACCAGGTGGAAATCCTGGAGTACAA





CTTCAACAAGGTCGACAAGCACCCGGATTCCACCACGCTGTGCCTCATC





GCGGCCGAGGCAGGCCTTTCCGAGGAGGAGACCCAGAAATGGTTTAAGC





AGCGCCTGGCAAAGTGGCGGCGCTCAGAAGGCCTGCCCTCAGAGTGCAG





ATCCGTCACAGACTAAGGAGATGGCAGGCATTGACAGCTTCACTCCATG





AAGGCCATCTCTGTTTCTCTCCTCCGCTTAACCAAGCTGTTGTGGTTTT





TCAGCATAGTGTTGTATGTTCCATTGCTAGCTGTCCTGCTGTTTAACAC





AGTGTTGTATTTTTTTTCTAAATGTACATAATTAGAAAAGAAAATAACA





ATAGGAAGCTATGTGTATCTTCTGTGTAAAGCAGTGGCTTCACTGGAAA





AATGGTGTGGCTAGCATTTCCCTTTGAGTCATGATGACAGATGGTGTGA





AAACCATCTAAGTTTGCTTTTGACCATCACCTCCCAGTAGCAATTTGCT





TTCATAATCCATTTAGCAATCCAGGCCTCTGTTGAAAAGATAATATGAG





GGAGAAGGGAACACATTTCCTTCTGAACTTACTTCCCTAAGTCACTTTC





CTTATGTATCATCTAATACAATGATGGTTGAGTGAAAATACAGAAGGGG





TGTTTGAGTATTCAGATTTCATAAAACACTTCCTTGGAATATAGCTGCA





TTAACTTGGAAAGAAGCCTGTTGGGCCAGAAGACAGAAACTCCAACTGG





CAAAAAAGCAAGCATCTAAGAAAAAAAACCACCAAAGTTCTTGAATTTA





CTATATTTAAATGCATTGGTTAAGTTTATTTTGCTAAATAAAGTGAACT





GCTTTTTGTCTCTAAAATGATATTCTAAATAAAACCTTAACTTTTTGTT





GAAGATGCACTGAAAAAAAAAA.,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:254 under stringent hybridization conditions


In some embodiments, CCAAT enhancer binding protein alpha (CEBPA, CEBP C/EBP) comprises the amino acid sequence:









(SEQ ID NO: 255; NP_001272758.1)


MPGGAHGPPPGYGCAAAGYLDGRLEPLYERVGAPALRPLVIKQEPREED





EAKQLALAGLFPYQPPPPPPPSHPHPHPPPAHLAAPHLQFQIAHCGQTT





MHLQPGHPTPPPTPVPSPHPAPALGAAGLPGPGSALKGLGAAHPDLRAS





GGSGAGKAKKSVDKNSNEYRVRRERNNIAVRKSRDKAKQRNVETQQKVL





ELTSDNDRLRKRVEQLSRELDTLRGIFRQLPESSLVKAMGNCA.,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:255)


In some embodiments, the nucleic acid sequence encoding CEBP comprises the nucleic acid sequence:









(SEQ ID NO: 256; NM_001285829.1)


TATAAAAGCTGGGCCGGCGCGGGCCGGGCCATTCGCGACCCGGAGGTGC





GCGGGCGCGGGCGAGCAGGGTCTCCGGGTGGGCGGCGGCGACGCCCCGC





GCAGGCTGGAGGCCGCCGAGGCTCGCCATGCCGGGAGAACTCTAACTCC





CCCATGGAGTCGGCCGACTTCTACGAGGCGGAGCCGCGGCCCCCGATGA





GCAGCCACCTGCAGAGCCCCCCGCACGCGCCCAGCAGCGCCGCCTTCGG





CTTTCCCCGGGGCGCGGGCCCCGCGCAGCCTCCCGCCCCACCTGCCGCC





CCGGAGCCGCTGGGCGGCATCTGCGAGCACGAGACGTCCATCGACATCA





GCGCCTACATCGACCCGGCCGCCTTCAACGACGAGTTCCTGGCCGACCT





GTTCCAGCACAGCCGGCAGCAGGAGAAGGCCAAGGCGGCCGTGGGCCCC





ACGGGCGGCGGCGGCGGCGGCGACTTTGACTACCCGGGCGCGCCCGCGG





GCCCCGGCGGCGCCGTCATGCCCGGGGGAGCGCACGGGCCCCCGCCCGG





CTACGGCTGCGCGGCCGCCGGCTACCTGGACGGCAGGCTGGAGCCCCTG





TACGAGCGCGTCGGGGCGCCGGCGCTGCGGCCGCTGGTGATCAAGCAGG





AGCCCCGCGAGGAGGATGAAGCCAAGCAGCTGGCGCTGGCCGGCCTCTT





CCCTTACCAGCCGCCGCCGCCGCCGCCGCCCTCGCACCCGCACCCGCAC





CCGCCGCCCGCGCACCTGGCCGCCCCGCACCTGCAGTTCCAGATCGCGC





ACTGCGGCCAGACCACCATGCACCTGCAGCCCGGTCACCCCACGCCGCC





GCCCACGCCCGTGCCCAGCCCGCACCCCGCGCCCGCGCTCGGTGCCGCC





GGCCTGCCGGGCCCTGGCAGCGCGCTCAAGGGGCTGGGCGCCGCGCACC





CCGACCTCCGCGCGAGTGGCGGCAGCGGCGCGGGCAAGGCCAAGAAGTC





GGTGGACAAGAACAGCAACGAGTACCGGGTGCGGCGCGAGCGCAACAAC





ATCGCGGTGCGCAAGAGCCGCGACAAGGCCAAGCAGCGCAACGTGGAGA





CGCAGCAGAAGGTGCTGGAGCTGACCAGTGACAATGACCGCCTGCGCAA





GCGGGTGGAACAGCTGAGCCGCGAACTGGACACGCTGCGGGGCATCTTC





CGCCAGCTGCCAGAGAGCTCCTTGGTCAAGGCCATGGGCAACTGCGCGT





GAGGCGCGCGGCTGTGGGACCGCCCTGGGCCAGCCTCCGGCGGGGACCC





AGGGAGTGGTTTGGGGTCGCCGGATCTCGAGGCTTGCCCGAGCCGTGCG





AGCCAGGACTAGGAGATTCCGGTGCCTCCTGAAAGCCTGGCCTGCTCCG





CGTGTCCCCTCCCTTCCTCTGCGCCGGACTTGGTGCGTCTAAGATGAGG





GGGCCAGGCGGTGGCTTCTCCCTGCGAGGAGGGGAGAATTCTTGGGGCT





GAGCTGGGAGCCCGGCAACTCTAGTATTTAGGATAACCTTGTGCCTTGG





AAATGCAAACTCACCGCTCCAATGCCTACTGAGTAGGGGGAGCAAATCG





TGCCTTGTCATTTTATTTGGAGGTTTCCTGCCTCCTTCCCGAGGCTACA





GCAGACCCCCATGAGAGAAGGAGGGGAGCAGGCCCGTGGCAGGAGGAGG





GCTCAGGGAGCTGAGATCCCGACAAGCCCGCCAGCCCCAGCCGCTCCTC





CACGCCTGTCCTTAGAAAGGGGTGGAAACATAGGGACTTGGGGCTTGGA





ACCTAAGGTTGTTCCCCTAGTTCTACATGAAGGTGGAGGGTCTCTAGTT





CCACGCCTCTCCCACCTCCCTCCGCACACACCCCACCCCAGCCTGCTAT





AGGCTGGGCTTCCCCTTGGGGCGGAACTCACTGCGATGGGGGTCACCAG





GTGACCAGTGGGAGCCCCCACCCCGAGTCACACCAGAAAGCTAGGTCGT





GGGTCAGCTCTGAGGATGTATACCCCTGGTGGGAGAGGGAGACCTAGAG





ATCTGGCTGTGGGGCGGGCATGGGGGGTGAAGGGCCACTGGGACCCTCA





GCCTTGTTTGTACTGTATGCCTTCAGCATTGCCTAGGAACACGAAGCAC





GATCAGTCCATCCCAGAGGGACCGGAGTTATGACAAGCTTTCCAAATAT





TTTGCTTTATCAGCCGATATCAACACTTGTATCTGGCCTCTGTGCCCCA





GCAGTGCCTTGTGCAATGTGAATGTGCGCGTCTCTGCTAAACCACCATT





TTATTTGGTTTTTGTTTTGTTTTGGTTTTGCTCGGATACTTGCCAAAAT





GAGACTCTCCGTCGGCAGCTGGGGGAAGGGTCTGAGACTCCCTTTCCTT





TTGGTTTTGGGATTACTTTTGATCCTGGGGGACCAATGAGGTGAGGGGG





GTTCTCCTTTGCCCTCAGCTTTCCCCAGCCCCTCCGGCCTGGGCTGCCC





ACAAGGCTTGTCCCCCAGAGGCCCTGGCTCCTGGTCGGGAAGGGAGGTG





GCCTCCCGCCAACGCATCACTGGGGCTGGGAGCAGGGAAGGACGGCTTG





GTTCTCTTCTTTTGGGGAGAACGTAGAGTCTCACTCTAGATGTTTTATG





TATTATATCTATAATATAAACATATCAAAGTCAA.,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:256 under stringent hybridization conditions


In some embodiments, activating transcription factor 4 (ATF4, CREB2, TXREB) comprises the amino acid sequence:









(SEQ ID NO: 257; NP_001666.2)


MTEMSFLSSEVLVGDLMSPFDQSGLGAEESLGLLDDYLEVAKHFKPHGF





SSDKAKAGSSEWLAVDGLVSPSNNSKEDAFSGTDWMLEKMDLKEFDLDA





LLGIDDLETMPDDLLTTLDDTCDLFAPLVQETNKQPPQTVNPIGHLPES





LTKPDQVAPFTFLQPLPLSPGVLSSTPDHSFSLELGSEVDITEGDRKPD





YTAYVAMIPQCIKEEDTPSDNDSGICMSPESYLGSPQHSPSTRGSPNRS





LPSPGVLCGSARPKPYDPPGEKMVAAKVKGEKLDKKLKKMEQNKTAATR





YRQKKRAEQEALTGECKELEKKNEALKERADSLAKEIQYLKDLIEEVRK





ARGKKRVP.,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:257)


In some embodiments, the nucleic acid sequence encoding ATF4 comprises the nucleic acid sequence:









(SEQ ID NO: 258; NM_001675.4)


AGCCATTTCTACTTTGCCCGCCCACAGATGTAGTTTTCTCTGCGCGTGT





GCGTTTTCCCTCCTCCCCGCCCTCAGGGTCCACGGCCACCATGGCGTAT





TAGGGGCAGCAGTGCCTGCGGCAGCATTGGCCTTTGCAGCGGCGGCAGC





AGCACCAGGCTCTGCAGCGGCAACCCCCAGCGGCTTAAGCCATGGCGTG





AGTACCGGGGCGGGTCGTCCAGCTGTGCTCCTGGGGCCGGCGCGGGTTT





TGGATTGGTGGGGTGCGGCCTGGGGCCAGGGCGGTGCCGCCAAGGGGGA





AGCGATTTAACGAGCGCCCGGGACGCGTGGTCTTTGCTTGGGTGTCCCC





GAGACGCTCGCGTGCCTGGGATCGGGAAAGCGTAGTCGGGTGCCCGGAC





TGCTTCCCCAGGAGCCCTACAGCCCTCGGACCCCGAGCCCCGCAAGGGT





CCCAGGGGTCTTGGCTGTTGCCCCACGAAACGTGGCAGGAACCAAGATG





GCGGCGGCAGGGCGGCGGCGCGGGCGTGAGTCAAGGGCGGGCGGTGGGC





GGGGCGCGGCCGCCCTGGCCGTATTTGGACGTGGGGACGGAGCGCTTTC





CTCTTGGCGGCCGGTGGAAGAATCCCCTGGTCTCCGTGAGCGTCCATTT





TGTGGAACCTGAGTTGCAAGCAGGGAGGGGCAAATACAACTGCCCTGTT





CCCGATTCTCTAGATGGCCGATCTAGAGAAGTCCCGCCTCATAAGTGGA





AGGATGAAATTCTCAGAACAGCTAACCTCTAATGGGAGTTGGCTTCTGA





TTCTCATTCAGGCTTCTCACGGCATTCAGCAGCAGCGTTGCTGTAACCG





ACAAAGACACCTTCGAATTAAGCACATTCCTCGATTCCAGCAAAGCACC





GCAACATGACCGAAATGAGCTTCCTGAGCAGCGAGGTGTTGGTGGGGGA





CTTGATGTCCCCCTTCGACCAGTCGGGTTTGGGGGCTGAAGAAAGCCTA





GGTCTCTTAGATGATTACCTGGAGGTGGCCAAGCACTTCAAACCTCATG





GGTTCTCCAGCGACAAGGCTAAGGCGGGCTCCTCCGAATGGCTGGCTGT





GGATGGGTTGGTCAGTCCCTCCAACAACAGCAAGGAGGATGCCTTCTCC





GGGACAGATTGGATGTTGGAGAAAATGGATTTGAAGGAGTTCGACTTGG





ATGCCCTGTTGGGTATAGATGACCTGGAAACCATGCCAGATGACCTTCT





GACCACGTTGGATGACACTTGTGATCTCTTTGCCCCCCTAGTCCAGGAG





ACTAATAAGCAGCCCCCCCAGACGGTGAACCCAATTGGCCATCTCCCAG





AAAGTTTAACAAAACCCGACCAGGTTGCCCCCTTCACCTTCTTACAACC





TCTTCCCCTTTCCCCAGGGGTCCTGTCCTCCACTCCAGATCATTCCTTT





AGTTTAGAGCTGGGCAGTGAAGTGGATATCACTGAAGGAGATAGGAAGC





CAGACTACACTGCTTACGTTGCCATGATCCCTCAGTGCATAAAGGAGGA





AGACACCCCTTCAGATAATGATAGTGGCATCTGTATGAGCCCAGAGTCC





TATCTGGGGTCTCCTCAGCACAGCCCCTCTACCAGGGGCTCTCCAAATA





GGAGCCTCCCATCTCCAGGTGTTCTCTGTGGGTCTGCCCGTCCCAAACC





TTACGATCCTCCTGGAGAGAAGATGGTAGCAGCAAAAGTAAAGGGTGAG





AAACTGGATAAGAAGCTGAAAAAAATGGAGCAAAACAAGACAGCAGCCA





CTAGGTACCGCCAGAAGAAGAGGGCGGAGCAGGAGGCTCTTACTGGTGA





GTGCAAAGAGCTGGAAAAGAAGAACGAGGCTCTAAAAGAGAGGGCGGAT





TCCCTGGCCAAGGAGATCCAGTACCTGAAAGATTTGATAGAAGAGGTCC





GCAAGGCAAGGGGGAAGAAAAGGGTCCCCTAGTTGAGGATAGTCAGGAG





CGTCAATGTGCTTGTACATAGAGTGCTGTAGCTGTGTGTTCCAATAAAT





TATTTTGTAGGGAAAGTAAAAAAAAAAAAAAA,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:258 under stringent hybridization conditions


In some embodiments, SMAD family member 1 (SMAD1) comprises the amino acid sequence:









MNVTSLFSFTSPAVKRLLGWKQGDEEEKWAEKAVDALVKKLKKKKGAME





ELEKALSCPGQPSNCVTIPRSLDGRLQVSHRKGLPHVIYCRVWRWPDLQ





SHHELKPLECCEFPFGSKQKEVCINPYHYKRVESPVLPPVLVPRHSEYN





PQHSLLAQFRNLGQNEPHMPLNATFPDSFQQPNSHPFPHSPNSSYPNSP





GSSSSTYPHSPTSSDPGSPFQMPADTPPPAYLPPEDPMTQDGSQPMDTN





MMAPPLPSEINRGDVQAVAYEEPKHWCSIVYYELNNRVGEAFHASSTSV





LVDGFTDPSNNKNRFCLGLLSNVNRNSTIENTRRHIGKGVHLYYVGGEV





YAECLSDSSIFVQSRNCNYHHGFHPTTVCKIPSGCSLKIFNNQEFAQLL





AQSVNHGFETVYELTKMCTIRMSFVKGWGAEYHRQDVTSTPCWIEIHLH





GPLQWLDKVLTQMGSPHNPIS







SVS. (SEQ ID NO:259; NP_001003688.1), or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:259)


In some embodiments, the nucleic acid sequence encoding SMAD1 comprises the nucleic acid sequence:









(SEQ ID NO: 260; NM_001003688.1)


CACTGCATGTGTATTCGTGAGTTCGCGGTTGAACAACTGTTCCTTTACT





CTGCTCCCTGTCTTTGTGCTGACTGGGTTACTTTTTTAAACACTAGGAA





TGGTAATTTCTACTCTTCTGGACTTCAAACTAAGAAGTTAAAGAGACTT





CTCTGTAAATAAACAAATCTCTTCTGCTGTCCTTTTGCATTTGGAGACA





GCTTTATTTCACCATATCCAAGGAGTATAACTAGTGCTGTCATTATGAA





TGTGACAAGTTTATTTTCCTTTACAAGTCCAGCTGTGAAGAGACTTCTT





GGGTGGAAACAGGGCGATGAAGAAGAAAAATGGGCAGAGAAAGCTGTTG





ATGCTTTGGTGAAAAAACTGAAGAAAAAGAAAGGTGCCATGGAGGAACT





GGAAAAGGCCTTGAGCTGCCCAGGGCAACCGAGTAACTGTGTCACCATT





CCCCGCTCTCTGGATGGCAGGCTGCAAGTCTCCCACCGGAAGGGACTGC





CTCATGTCATTTACTGCCGTGTGTGGCGCTGGCCCGATCTTCAGAGCCA





CCATGAACTAAAACCACTGGAATGCTGTGAGTTTCCTTTTGGTTCCAAG





CAGAAGGAGGTCTGCATCAATCCCTACCACTATAAGAGAGTAGAAAGCC





CTGTACTTCCTCCTGTGCTGGTTCCAAGACACAGCGAATATAATCCTCA





GCACAGCCTCTTAGCTCAGTTCCGTAACTTAGGACAAAATGAGCCTCAC





ATGCCACTCAACGCCACTTTTCCAGATTCTTTCCAGCAACCCAACAGCC





ACCCGTTTCCTCACTCTCCCAATAGCAGTTACCCAAACTCTCCTGGGAG





CAGCAGCAGCACCTACCCTCACTCTCCCACCAGCTCAGACCCAGGAAGC





CCTTTCCAGATGCCAGCTGATACGCCCCCACCTGCTTACCTGCCTCCTG





AAGACCCCATGACCCAGGATGGCTCTCAGCCGATGGACACAAACATGAT





GGCGCCTCCCCTGCCCTCAGAAATCAACAGAGGAGATGTTCAGGCGGTT





GCTTATGAGGAACCAAAACACTGGTGCTCTATTGTCTACTATGAGCTCA





ACAATCGTGTGGGTGAAGCGTTCCATGCCTCCTCCACAAGTGTGTTGGT





GGATGGTTTCACTGATCCTTCCAACAATAAGAACCGTTTCTGCCTTGGG





CTGCTCTCCAATGTTAACCGGAATTCCACTATTGAAAACACCAGGCGGC





ATATTGGAAAAGGAGTTCATCTTTATTATGTTGGAGGGGAGGTGTATGC





CGAATGCCTTAGTGACAGTAGCATCTTTGTGCAAAGTCGGAACTGCAAC





TACCATCATGGATTTCATCCTACTACTGTTTGCAAGATCCCTAGTGGGT





GTAGTCTGAAAATTTTTAACAACCAAGAATTTGCTCAGTTATTGGCACA





GTCTGTGAACCATGGATTTGAGACAGTCTATGAGCTTACAAAAATGTGT





ACTATACGTATGAGCTTTGTGAAGGGCTGGGGAGCAGAATACCACCGCC





AGGATGTTACTAGCACCCCCTGCTGGATTGAGATACATCTGCACGGCCC





CCTCCAGTGGCTGGATAAAGTTCTTACTCAAATGGGTTCACCTCATAAT





CCTATTTCATCTGTATCTTAAATGGCCCCAGGCATCTGCCTCTGGAAAA





CTATTGAGCCTTGCATGTACTTGAAGGATGGATGAGTCAGACACGATTG





AGAACTGACAAAGGAGCCTTGATAATACTTGACCTCTGTGACCAACTGT





TGGATTCAGAAATTTAAACAAAAAAAAAAAAAAACACACACACCTTGGT





AACATACTGTTGATATCAAGAACCTGTTTAGTTTACATTGTAACATTCT





ATTGTAAAATCAACTAAAATTCAGACTTTTAGCAGGACTTTGTGTACAG





TTAAAGGAGAGATGGCCAAGCCAGGGACAAATTGTCTATTAGAAAACGG





TCCTAAGAGATTCTTTGGTGTTTGGCACTTTAAGGTCATCGTTGGGCAG





AAGTTTAGCATTAATAGTTGTTCTGAAACGTGTTTTATCAGGTTTAGAG





CCCATGTTGAGTCTTCTTTTCATGGGTTTTCATAATATTTTAAAACTAT





TTGTTTAGCGATGGTTTTGTTCGTTTAAGTAAAGGTTAATCTTGATGAT





ATACATAATAATCTTTCTAAAATTGTATGCTGACCATACTTGCTGTCAG





AATAATGCTAGGCATATGCTTTTTGCTAAATATGTATGTACAGAGTATT





TGGAAGTTAAGAATTGATTAGACTAGTGAATTTAGGAGTATTTGAGGTG





GGTGGGGGGAAGAGGGAAATGACAACTGCAAATGTAGACTATACTGTAA





AAATTCAGTTTGTTGCTTTAAAGAAACAAACTGATACCTGAATTTTGCT





GTGTTTCCATTTTTTAGAGATTTTTATCATTTTTTTCTCTCTCGGCATT





CTTTTTTCTCATACTCTTCAAAAAGCAGTTCTGCAGCTGGTTAATTCAT





GTAACTGTGAGAGCAAATGAATAATTCCTGCTATTCTGAAATTGCCTAC





ATGTTTCAATACCAGTTATATGGAGTGCTTGAATTTAATAAGCAGTTTT





TACGGAGTTTACAGTACAGAAATAGGCTTTAATTTTCAAGTGAATTTTT





TGCCAAACTTAGTAACTCTGTTAAATATTTGGAGGATTTAAAGAACATC





CCAGTTTGAATTCATTTCAAACTTTTTAAATTTTTTTGTACTATGTTTG





GTTTTATTTTCCTTCTGTTAATCTTTTGTATTCACTTATGCTCTCGTAC





ATTGAGTACTTTTATTCCAAAACTAGTGGGTTTTCTCTACTGGAAATTT





TCAATAAACCTGTCATTATTGCTTACTTTGATTAAAA.,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:260 under stringent hybridization conditions


In some embodiments, menin 1 (MEN1, MEAT, SCG2) comprises the amino acid sequence:









(SEQ ID NO: 261; NP_000235.2NP_001180.1)


MGLKAAQKTLFPLRSIDDVVRLFAAELGREEPDLVLLSLVLGFVEHFLA





VNRVIPTNVPELTFQPSPAPDPPGGLTYFPVADLSIIAALYARFTAQIR





GAVDLSLYPREGGVSSRELVKKVSDVIWNSLSRSYFKDRAHIQSLFSFI





TGWSPVGTKLDSSGVAFAVVGACQALGLRDVHLALSEDHAWVVFGPNGE





QTAEVTWHGKGNEDRRGQTVNAGVAERSWLYLKGSYMRCDRKMEVAFMV





CAINPSIDLHTDSLELLQLQQKLLWLLYDLGHLERYPMALGNLADLEEL





EPTPGRPDPLTLYHKGIASAKTYYRDEHIYPYMYLAGYHCRNRNVREAL





QAWADTATVIQDYNYCREDEEIYKEFFEVANDVIPNLLKEAASLLEAGE





ERPGEQSQGTQSQGSALQDPECFAHLLRFYDGICKWEEGSPTPVLHVGW





ATFLVQSLGRFEGQVRQKVRIVSREAEAAEAEEPWGEEAREGRRRGPRR





ESKPEEPPPPKKPALDKGLGTGQGAVSGPPRKPPGTVAGTARGPEGGST





AQVPAPAASPPPEGPVLTFQSEKMKGMKELLVATKINSSAIKLQLTAQS





QVQMKKQKVSTPSDYTLSFLKRQRKGL.,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:261)


In some embodiments, the nucleic acid sequence encoding MEN1 comprises the nucleic acid sequence:









(SEQ ID NO: 262; NM_000244.3)


GGTGTCCGGAGCCGCGGACCTAGAGATCCCAGAAGCCACAGCGCAGCGG





CCCGGCCCGCCACTATTTCCAGGCTCAGCGGGGCAGGGGCCGCCGCCCA





CCGCCCGCCGCCATGGGGCTGAAGGCCGCCCAGAAGACGCTGTTCCCGC





TGCGCTCCATCGACGACGTGGTGCGCCTGTTTGCTGCCGAGCTGGGCCG





AGAGGAGCCGGACCTGGTGCTCCTTTCCTTGGTGCTGGGCTTCGTGGAG





CATTTTCTGGCTGTCAACCGCGTCATCCCTACCAACGTTCCCGAGCTCA





CCTTCCAGCCCAGCCCCGCCCCCGACCCGCCTGGCGGCCTCACCTACTT





TCCCGTGGCCGACCTGTCTATCATCGCCGCCCTCTATGCCCGCTTCACC





GCCCAGATCCGAGGCGCCGTCGACCTGTCCCTCTATCCTCGAGAAGGGG





GTGTCTCCAGCCGTGAGCTGGTGAAGAAGGTCTCCGATGTCATATGGAA





CAGCCTCAGCCGCTCCTACTTCAAGGATCGGGCCCACATCCAGTCCCTC





TTCAGCTTCATCACAGGTTGGAGCCCAGTAGGCACCAAATTGGACAGCT





CCGGTGTGGCCTTTGCTGTGGTTGGGGCCTGCCAGGCCCTGGGTCTCCG





GGATGTCCACCTCGCCCTGTCTGAGGATCATGCCTGGGTAGTGTTTGGG





CCCAATGGGGAGCAGACAGCTGAGGTCACCTGGCACGGCAAGGGCAACG





AGGACCGCAGGGGCCAGACAGTCAATGCCGGTGTGGCTGAGCGGAGCTG





GCTGTACCTGAAAGGATCATACATGCGCTGTGACCGCAAGATGGAGGTG





GCGTTCATGGTGTGTGCCATCAACCCTTCCATTGACCTGCACACCGACT





CGCTGGAGCTTCTGCAGCTGCAGCAGAAGCTGCTCTGGCTGCTCTATGA





CCTGGGACATCTGGAAAGGTACCCCATGGCCTTAGGGAACCTGGCAGAT





CTAGAGGAGCTGGAGCCCACCCCTGGCCGGCCAGACCCACTCACCCTCT





ACCACAAGGGCATTGCCTCAGCCAAGACCTACTATCGGGATGAACACAT





CTACCCCTACATGTACCTGGCTGGCTACCACTGTCGCAACCGCAATGTG





CGGGAAGCCCTGCAGGCCTGGGCGGACACGGCCACTGTCATCCAGGACT





ACAACTACTGCCGGGAAGACGAGGAGATCTACAAGGAGTTCTTTGAAGT





AGCCAATGATGTCATCCCCAACCTGCTGAAGGAGGCAGCCAGCTTGCTG





GAGGCGGGCGAGGAGCGGCCGGGGGAGCAAAGCCAGGGCACCCAGAGCC





AAGGTTCCGCCCTCCAGGACCCTGAGTGCTTCGCCCACCTGCTGCGATT





CTACGACGGCATCTGCAAATGGGAGGAGGGCAGTCCCACGCCTGTGCTG





CACGTGGGCTGGGCCACCTTTCTTGTGCAGTCCCTAGGCCGTTTTGAGG





GACAGGTGCGGCAGAAGGTGCGCATAGTGAGCCGAGAGGCCGAGGCGGC





CGAGGCCGAGGAGCCGTGGGGCGAGGAAGCCCGGGAAGGCCGGCGGCGG





GGCCCACGGCGGGAGTCCAAGCCAGAGGAGCCCCCGCCGCCCAAGAAGC





CAGCACTGGACAAGGGCCTGGGCACCGGCCAGGGTGCAGTGTCAGGACC





CCCCCGGAAGCCTCCTGGGACTGTCGCTGGCACAGCCCGAGGCCCTGAA





GGTGGCAGCACGGCTCAGGTGCCAGCACCCGCAGCATCACCACCGCCGG





AGGGTCCAGTGCTCACTTTCCAGAGTGAGAAGATGAAGGGCATGAAGGA





GCTGCTGGTGGCCACCAAGATCAACTCGAGCGCCATCAAGCTGCAACTC





ACGGCACAGTCGCAAGTGCAGATGAAGAAGCAGAAAGTGTCCACCCCTA





GTGACTACACTCTGTCTTTCCTCAAGCGGCAGCGCAAAGGCCTCTGAAC





TACTGGGGACTTCGGACCGCTTGTGGGGACCCAGGCTCCGCCCTTAGTC





CCCCAACTCTGAGCCCATGTTCTGCCCCCAGCCCAAAGGGGACAGGCCT





CACCTCTACCCAAACCCTAGGTTCCCGGTCCCGAGTACAGTCTGTATCA





AACCCACGATTTTCTCCAGCTCAGAACCCAGGGCTCTGCCCCAGTCGTT





AGAATATAGGTCTCTTCTCCCAGAATCCCAGCCGGCCAATGGAAACCTC





ACGCTGGGTCCTAATTACCAGTCTTTAAAGGCCCAGCCCCTAGAAACCC





AAGCTCCTCCTCGGAACCGCTCACCTAGAGCCAGACCAACGTTACTCAG





GGCTCCTCCCAGCTTGTAGGAGCTGAGGTTTCACCCTTAACCCAAGGAG





CACAGGTCCCACCTCCAGCCCGGGAGCCTAGGACCACTCAGCCCCTAGG





AGTATATTTCCGCACTTCAGAATTCCATATCTTGCGAATCCAAGCTCCC





TGCCCCAAATAACTTCAGTCCTGCTCCAGAATTTGGAAATCCTAGTTTC





CTCTCCTTCGTATCCCGAGTCTGGGACACAAAACTCCGCCCCCAGCCTA





TGAGCATCCTGAGCCCCGCCCTCTTCCTGACGAAACTGGCCCCGGATCA





GAGCAGGACCTCCCTTCCGACCCTCTGGGAACCTCCCAGAGGTCCAGCC





CATCTCGGAGCATCCCGGAGGAAATCTGCAGAGGGTTAGGAGTGGGTGA





CAAGAGCCTGATCTCTTCCTGTTTTGTACATAGATTTATTTTTCAGTTC





CAAGAAAGATGAATACATTTTGTTAAAAAAAATAAAAAAAA.,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:262 under stringent hybridization conditions


In some embodiments, msh homeobox 1 (MSX1, HOX7, HYD1, ECTD3, SThaG1) comprises the amino acid sequence:









MAPAADMTSLPLGVKVEDSAFGKPAGGGAGQAPSAAAATAAAMGADEEGA





KPKVSPSLLPFSVEALMADHRKPGAKESALAPSEGVQAAGGSAQPLGVPP





GSLGAPDAPSSPRPLGHFSVGGLLKLPEDALVKAESPEKPERTPWMQSPR





FSPPPARRLSPPACTLRKHKTNRKPRTPFTTAQLLALERKFRQKQYLSIA





ERAEFSSSLSLTETQVKIWFQNRRAKAKRLQEAELEKLKMAAKPMLPPAA





FGLSFPLGGPAAVAAAAGASLYGASGPFQRAALPVAPVGLYTAHVGYSMY





HLT. (SEQ ID NO: 263; NP_002439.2),







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:263)


In some embodiments, the nucleic acid sequence encoding MSX comprises the nucleic acid sequence:









AGGGCCCGGAGCCGGCGAGTGCTCCCGGGAACTCTGCCTGCGCGGCGGCA





GCGACCGGAGGCCAGGCCCAGCACGCCGGAGCTGGCCTGCTGGGGAGGGG





CGGGAGGCGCGCGCGGGAGGGTCCGCCCGGCCAGGGCCCCGGGCGCTCGC





AGAGGCCGGCCGCGCTCCCAGCCCGCCCGGAGCCCATGCCCGGCGGCTGG





CCAGTGCTGCGGCAGAAGGGGGGGCCCGGCTCTGCATGGCCCCGGCTGCT





GACATGACTTCTTTGCCACTCGGTGTCAAAGTGGAGGACTCCGCCTTCGG





CAAGCCGGCGGGGGGAGGCGCGGGCCAGGCCCCCAGCGCCGCCGCGGCCA





CGGCAGCCGCCATGGGCGCGGACGAGGAGGGGGCCAAGCCCAAAGTGTCC





CCTTCGCTCCTGCCCTTCAGCGTGGAGGCGCTCATGGCCGACCACAGGAA





GCCGGGGGCCAAGGAGAGCGCCCTGGCGCCCTCCGAGGGCGTGCAGGCGG





CGGGTGGCTCGGCGCAGCCACTGGGCGTCCCGCCGGGGTCGCTGGGAGCC





CCGGACGCGCCCTCTTCGCCGCGGCCGCTCGGCCATTTCTCGGTGGGGGG





ACTCCTCAAGCTGCCAGAAGATGCGCTCGTCAAAGCCGAGAGCCCCGAGA





AGCCCGAGAGGACCCCGTGGATGCAGAGCCCCCGCTTCTCCCCGCCGCCG





GCCAGGCGGCTGAGCCCCCCAGCCTGCACCCTCCGCAAACACAAGACGAA





CCGTAAGCCGCGGACGCCCTTCACCACCGCGCAGCTGCTGGCGCTGGAGC





GCAAGTTCCGCCAGAAGCAGTACCTGTCCATCGCCGAGCGCGCGGAGTTC





TCCAGCTCGCTCAGCCTCACTGAGACGCAGGTGAAGATATGGTTCCAGAA





CCGCCGCGCCAAGGCAAAGAGACTACAAGAGGCAGAGCTGGAGAAGCTGA





AGATGGCCGCCAAGCCCATGCTGCCACCGGCTGCCTTCGGCCTCTCCTTC





CCTCTCGGCGGCCCCGCAGCTGTAGCGGCCGCGGCGGGTGCCTCGCTCTA





CGGTGCCTCTGGCCCCTTCCAGCGCGCCGCGCTGCCTGTGGCGCCCGTGG





GACTCTACACGGCCCATGTGGGCTACAGCATGTACCACCTGACATAGAGG





GTCCCAGGTCGCCCACCTGTGGGCCAGCCGATTCCTCCAGCCCTGGTGCT





GTACCCCCGACGTGCTCCCCTGCTCGGCACCGCCAGCCGCCTTCCCTTTA





ACCCTCACACTGCTCCAGTTTCACCTCTTTGCTCCCTGAGTTCACTCTCC





GAAGTCTGATCCCTGCCAAAAAGTGGCTGGAAGAGTCCCTTAGTACTCTT





CTAGCATTTAGATCTACACTCTCGAGTTAAAGATGGGGAAACTGAGGGCA





GAGAGGTTAACAGATTTATCTAAGGTCCCCAGCAGAATTGACAGTTGAAC





AGAGCTAGAGGCCATGTCTCCTGCATAGCTTTTCCCTGTCCTGACACCAG





GCAAGAAAAGCGCAGAGAAATCGGTGTCTGACGATTTTGGAAATGAGAAC





AATCTCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGAAAAGAG





AAAAAAAAGACTAGCCAGCCAGGAAGATGAATCCTAGCTTCTTCCATTGG





AAAATTTAAGACAAGTTCAACAACAAAACATTTGCTCTGGGGGGCAGGGA





AAACACAGATGTGTTGCAAAGGTAGGTTGAAGGGACCTCTCTCTTACCAG





TACCAGAAACACAATTGTAAAATTAAAAAAAAAAAAAAACTCTTTCTATT





TAACAGTACATTTGTGTGGCTCTCAAACATCCCTTTGGAAGGGATTGTGT





GTACTATGTAATATACTGTATATTTGAAATTTTATTATCATTTATATTAT





AGCTATATTTGTTAAATAAATTAATTTTAAGCTACAAAAA. (SEQ ID





NO: 264; NM_002448.3),







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:264 under stringent hybridization conditions


In some embodiments, msh homeobox 2 (MSX2, FPP, MSH, PFM, CRS2, HOX8, PFM1) comprises the amino acid sequence:









MASPSKGNDLFSPDEEGPAVVAGPGPGPGGAEGAAEERRVKVSSLPFSVE





ALMSDKKPPKEASPLPAESASAGATLRPLLLSGHGAREAHSPGPLVKPFE





TASVKSENSEDGAAWMQEPGRYSPPPSECAPGQE. (SEQ ID NO:





265; NP_001350555.1),







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:265)


In some embodiments, the nucleic acid sequence encoding MSX2 comprises the nucleic acid sequence:









GCAGCAAAAAAGTTTGAGTCGCCGCTGCCGGGTTGCCAGCGGAGTCGCGC





GTCGGGAGCTACGTAGGGCAGAGAAGTCATGGCTTCTCCGTCCAAAGGCA





ATGACTTGTTTTCGCCCGACGAGGAGGGCCCAGCAGTGGTGGCCGGACCA





GGCCCGGGGCCTGGGGGCGCCGAGGGGGCCGCGGAGGAGCGCCGCGTCAA





GGTCTCCAGCCTGCCCTTCAGCGTGGAGGCGCTCATGTCCGACAAGAAGC





CGCCCAAGGAGGCGTCCCCGCTGCCGGCCGAAAGCGCCTCGGCCGGGGCC





ACCCTGCGGCCACTGCTGCTGTCGGGGCACGGCGCTCGGGAAGCGCACAG





CCCCGGGCCGCTGGTGAAGCCCTTCGAGACCGCCTCGGTCAAGTCGGAAA





ATTCAGAAGATGGAGCGGCGTGGATGCAGGAACCCGGCCGATATTCGCCG





CCGCCAAGTGAGTGCGCGCCGGGGCAGGAGTAGGAGGACATATGAGCCCT





ACCACCTGCACCCTGAGGAAACACAAGACCAATCGGAAGCCGCGCACGCC





CTTTACCACATCCCAGCTCCTCGCCCTGGAGCGCAAGTTCCGTCAGAAAC





AGTACCTCTCCATTGCAGAGCGTGCAGAGTTCTCCAGCTCTCTGAACCTC





ACAGAGACCCAGGTCAAAATCTGGTTCCAGAACCGAAGGGCCAAGGCGAA





AAGACTGCAGGAGGCAGAACTGGAAAAGCTGAAAATGGCTGCAAAACCTA





TGCTGCCCTCCAGCTTCAGTCTCCCTTTCCCCATCAGCTCGCCCCTGCAG





GCAGCGTCCATATATGGAGCATCCTACCCGTTCCATAGACCTGTGCTTCC





CATCCCGCCTGTGGGACTCTATGCCACGCCAGTGGGATATGGCATGTACC





ACCTGTCCTAAGGAAGACCAGATCAATAGACTCCATGATGGATGCTTGTT





TCAAAGGGTTTCCTCTCCCTCTCCACGAAGGCAGTACCAGCCAGTACTCC





TGCTCTGCTAACCCTGCGTGCACCACCCTAAGCGGCTAGGCTGACAGGGC





CACACGACATAGCTGAAATTTGTTCTGTAGGCGGAGGCACCAAGCCCTGT





TTTCTTGGTGTAATCTTCCAGATGCCCCCTTTTCCTTTCACAAAGATTGG





CTCTGATGGTTTTTATGTATAAATATATATATATAATAAAATATAATACA





TTTTTATACAGCAGACGTAAAAATTCAAATTATTTTAAAAGGCAAAATTT





ATATACATATGTGCTTTTTTTCTATATCTCACCTTCCCAAAAGACACTGT





GTAAGTCCATTTGTTGTATTTTCTTAAAGAGGGAGACAAATTATTTGCAA





AATGTGCTAAAGTCAATGATTTTTACGGGATTATTGACTTCTGCTTATGG





AAAACAAAGAAACAGACACAATGCACACAGAAAATATTAGATATGGAGAG





ATTATTCAAAGTGAAGGGGACACATCATATTTCTGCATTTTACTTGCATT





AAAAGAAACCTCTTTATATACTACAGTTGTTCCTATCTCTCCCCCGCCCC





CCACCGCCCCACCACACACATATTTTTAAAGTTTTTCCTTTTTTAAGAAT





ATTTTTGTAAGACCAATACCTGGGATGAGAAGAATCCTGAGACTGCCTGG





AGGTGAGGTAGAAAATTAGAAATACTTCCTAATTCTTCTCAAGGCTGTTG





GTAACTTTATTTCAGATAATTGGAGAGTAAAATGTTAAAACCTGTTGAGA





GGAATTGATGGTTTCTGAGAAATACTAGGTACATTCATCCTCACAGATTG





CAAAGGTGATTTGGGTGGGGGTTTAGTAATTTTCTGCTTAAAAAATGAGT





ATCTTGTAACCATTACCTATATGCTAAATATTCTTGAACAATTAGTAGAT





CCAGAAAGAAAAAAAAATATGCTTTCTCTGTGTGTGTACCTGTTGTATGT





CCTAAACTTATTAGAAAATTTTATATACTTTTTTACATGTTGGGGGGCAG





AAGGTAAAGCCATGTTTTGACTTGGTGAAAATGGGATTGTCAAACAGCCC





ATTAAGTTCCCTGGTATTTCACCTTCCTGTCCATCTGTCCCCTCCCTCCG





GTATACCTTTATCCCTTTGAAAGGGTGCTTGTACAATTTGATATATTTTA





TTGAAGAGTTATCTCTTATTCTGAATTAAATTAAGCATTTGTTTTATTGC





AGTAAAGTTTGTCCAAACTCACAA (SEQ ID NO: 266; NM_





001363626.2),







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:266 under stringent hybridization conditions


In some embodiments, neurofibromin 1 (NF1, WSS, NFNS, VRNF) comprises the amino acid sequence:









MAAHRPVEWVQAVVSRFDEQLPIKTGQQNTHTKVSTEHNKECLINISKYK





FSLVISGLTTILKNVNNMRIFGEAAEKNLYLSQLIILDTLEKCLAGQPKD





TMRLDETMLVKQLLPEICHFLHTCREGNQHAAELRNSASGVLFSLSCNNF





NAVFSRISTRLQELTVCSEDNVDVHDIELLQYINVDCAKLKRLLKETAFK





FKALKKVAQLAVINSLEKAFWNWVENYPDEFTKLYQIPQTDMAECAEKLF





DLVDGFAESTKRKAAVWPLQIILLILCPEIIQDISKDVVDENNMNKKLFL





DSLRKALAGHGGSRQLTESAAIACVKLCKASTYINWEDNSVIFLLVQSMV





VDLKNLLFNPSKPFSRGSQPADVDLMIDCLVSCFRISPHNNQHFKICLAQ





NSPSTFHYVLVNSLHRIITNSALDWWPKIDAVYCHSVELRNMFGETLHKA





VQGCGAHPAIRMAPSLTFKEKVTSLKFKEKPTDLETRSYKYLLLSMVKLI





HADPKLLLCNPRKQGPETQGSTAELITGLVQLVPQSHMPEIAQEAMEALL





VLHQLDSIDLWNPDAPVETFWEISSQMLFYICKKLTSHQMLSSTEILKWL





REILICRNKFLLKNKQADRSSCHFLLFYGVGCDIPSSGNTSQMSMDHEEL





LRTPGASLRKGKGNSSMDSAAGCSGTPPICRQAQTKLEVALYMFLWNPDT





EAVLVAMSCFRHLCEEADIRCGVDEVSVHNLLPNYNTFMEFASVSNMMST





GRAALQKRVMALLRRIEHPTAGNTEAWEDTHAKWEQATKLILNYPKAKME





DGQAAESLHKTIVKRRMSHVSGGGSIDLSDTDSLQEWINMTGFLCALGGV





CLQQRSNSGLATYSPPMGPVSERKGSMISVMSSEGNADTPVSKFMDRLLS





LMVCNHEKVGLQIRTNVKDLVGLELSPALYPMLFNKLKNTISKFFDSQGQ





VLLTDTNTQFVEQTIAIMKNLLDNHTEGSSEHLGQASIETMMLNLVRYVR





VLGNMVHAIQIKTKLCQLVEVMMARRDDLSFCQEMKFRNKMVEYLTDWVM





GTSNQAADDDVKCLTRDLDQASMEAVVSLLAGLPLQPEEGDGVELMEAKS





QLFLKYFTLFMNLLNDCSEVEDESAQTGGRKRGMSRRLASLRHCTVLAMS





NLLNANVDSGLMHSIGLGYHKDLQTRATFMEVLTKILQQGTEFDTLAETV





LADRFERLVELVTMMGDQGELPIAMALANVVPCSQWDELARVLVTLFDSR





HLLYQLLWNMFSKEVELADSMQTLFRGNSLASKIMTFCFKVYGATYLQKL





LDPLLRIVITSSDWQHVSFEVDPTRLEPSESLEENQRNLLQMTEKFFHAI





ISSSSEFPPQLRSVCHCLYQVVSQRFPQNSIGAVGSAMFLRFINPAIVSP





YEAGILDKKPPPRIERGLKLMSKILQSIANHVLFTKEEHMRPFNDFVKSN





FDAARRFFLDIASDCPTSDAVNHSLSFISDGNVLALHRLLWNNQEKIGQY





LSSNRDHKAVGRRPFDKMATLLAYLGPPEHKPVADTHWSSLNLTSSKFEE





FMTRHQVHEKEEFKALKTLSIFYQAGTSKAGNPIFYYVARRFKTGQINGD





LLIYHVLLTLKPYYAKPYEIVVDLTHTGPSNRFKTDFLSKWFVVFPGFAY





DNVSAVYIYNCNSWVREYTKYHERLLTGLKGSKRLVFIDCPGKLAEHIEH





EQQKLPAATLALEEDLKVFHNALKLAHKDTKVSIKVGSTAVQVTSAERTK





VLGQSVFLNDIYYASEIEEICLVDENQFTLTIANQGTPLTFMHQECEAIV





QSIIHIRTRWELSQPDSIPQHTKIRPKDVPGTLLNIALLNLGSSDPSLRS





AAYNLLCALTCTFNLKIEGQLLETSGLCIPANNTLFIVSISKTLAANEPH





LTLEFLEECISGFSKSSIELKHLCLEYMTPWLSNLVRFCKHNDDAKRQRV





TAILDKLITMTINEKQMYPSIQAKIWGSLGQITDLLDVVLDSFIKTSATG





GLGSIKAEVMADTAVALASGNVKLVSSKVIGRMCKIIDKTCLSPTPTLEQ





HLMWDDIAILARYMLMLSFNNSLDVAAHLPYLFHVVTFLVATGPLSLRAS





THGLVINIIHSLCTCSQLHFSEETKQVLRLSLTEFSLPKFYLLFGISKVK





SAAVIAFRSSYRDRSFSPGSYERETFALTSLETVTEALLEIMEACMRDIP





TCKWLDQVVTELAQRFAFQYNPSLQPRALVVFGCISKRVSHGQIKQIIRI





LSKALESCLKGPDTYNSQVLIEATVIALTKLQPLLNKDSPLHKALFWVAV





AVLQLDEVNLYSAGTALLEQNLHTLDSLRIFNDKSPEEVFMAIRNPLEWH





CKQMDHFVGLNFNSNFNFALVGHLLKGYRHPSPAIVARTVRILHTLLTLV





NKHRNCDKFEVNTQSVAYLAALLTVSEEVRSRCSLKHRKSLLLTDISMEN





VPMDTYPIHHGDPSYRTLKETQPWSSPKGSEGYLAATYPTVGQTSPRARK





SMSLDMGQPSQANTKKLLGTRKSFDHLISDTKAPKRQEMESGITTPPKMR





RVAETDYEMETQRISSSQQHPHLRKVSVSESNVLLDEEVLTDPKIQALLL





TVLATLVKYTTDEFDQRILYEYLAEASVVFPKVFPVVHNLLDSKINTLLS





LCQDPNLLNPIFIGIVQSVVYHEESPPQYQTSYLQSFGFNGLWRFAGPFS





KQTQIPDYAELIVKFLDALIDTYLPGIDEETSEESLLTPTSPYPPALQSQ





LSITANLNLSNSMTSLATSQHSPGIDKENVELSPTTGHCNSGRTRHGSAS





QVQKQRSAGSFKRNSIKKIV. (SEQ ID NO: 267; NP_000258.





1),







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:267)


In some embodiments, the nucleic acid sequence encoding NF1 comprises the nucleic acid sequence:










AATCTCTAGCTCGCTCGCGCTCCCTCTCCCCGGGCCGTGGAAAGGATCCCACTTC






CGGTGGGGTGTCATGGCGGCGTCTCGGACTGTGATGGCTGTGGGGAGACGGCGC





TAGTGGGGAGAGCGACCAAGAGGCCCCCTCCCCTCCCCGGGTCCCCTTCCCCTAT





CCCCCTCCCCCCAGCCTCCTTGCCAACGCCCCCTTTCCCTCTCCCCCTCCCGCTC





GGCGCTGACCCCCCATCCCCACCCCCGTGGGAACACTGGGAGCCTGCACTCCACA





GACCCTCTCCTTGCCTCTTCCCTCACCTCAGCCTCCGCTCCCCGCCCTCTTCCCGG





CCCAGGGCGCCGGCCCACCCTTCCCTCCGCCGCCCCCCGGCCGCGGGGAGGAC





ATGGCCGCGCACAGGCCGGTGGAATGGGTCCAGGCCGTGGTCAGCCGCTTCGAC





GAGCAGCTTCCAATAAAAACAGGACAGCAGAACACACATACCAAAGTCAGTACTGA





GCACAACAAGGAATGTCTAATCAATATTTCCAAATACAAGTTTTCTTTGGTTATAAGC





GGCCTCACTACTATTTTAAAGAATGTTAACAATATGAGAATATTTGGAGAAGCTGCT





GAAAAAAATTTATATCTCTCTCAGTTGATTATATTGGATACACTGGAAAAATGTCTTG





CTGGGCAACCAAAGGACACAATGAGATTAGATGAAACGATGCTGGTCAAACAGTTG





CTGCCAGAAATCTGCCATTTTCTTCACACCTGTCGTGAAGGAAACCAGCATGCAGC





TGAACTTCGGAATTCTGCCTCTGGGGTTTTATTTTCTCTCAGCTGCAACAACTTCAA





TGCAGTCTTTAGTCGCATTTCTACCAGGTTACAGGAATTAACTGTTTGTTCAGAAGA





CAATGTTGATGTTCATGATATAGAATTGTTACAGTATATCAATGTGGATTGTGCAAAA





TTAAAACGACTCCTGAAGGAAACAGCATTTAAATTTAAAGCCCTAAAGAAGGTTGCG





CAGTTAGCAGTTATAAATAGCCTGGAAAAGGCATTTTGGAACTGGGTAGAAAATTAT





CCAGATGAATTTACAAAACTGTACCAGATCCCACAGACTGATATGGCTGAATGTGCA





GAAAAGCTATTTGACTTGGTGGATGGTTTTGCTGAAAGCACCAAACGTAAAGCAGC





AGTTTGGCCACTACAAATCATTCTCCTTATCTTGTGTCCAGAAATAATCCAGGATATA





TCCAAAGACGTGGTTGATGAAAACAACATGAATAAGAAGTTATTTCTGGACAGTCTA





CGAAAAGCTCTTGCTGGCCATGGAGGAAGTAGGCAGCTGACAGAAAGTGCTGCAA





TTGCCTGTGTCAAACTGTGTAAAGCAAGTACTTACATCAATTGGGAAGATAACTCTG





TCATTTTCCTACTTGTTCAGTCCATGGTGGTTGATCTTAAGAACCTGCTTTTTAATCC





AAGTAAGCCATTCTCAAGAGGCAGTCAGCCTGCAGATGTGGATCTAATGATTGACT





GCCTTGTTTCTTGCTTTCGTATAAGCCCTCACAACAACCAACACTTTAAGATCTGCC





TGGCTCAGAATTCACCTTCTACATTTCACTATGTGCTGGTAAATTCACTCCATCGAA





TCATCACCAATTCCGCATTGGATTGGTGGCCTAAGATTGATGCTGTGTATTGTCACT





CGGTTGAACTTCGAAATATGTTTGGTGAAACACTTCATAAAGCAGTGCAAGGTTGTG





GAGCACACCCAGCAATACGAATGGCACCGAGTCTTACATTTAAAGAAAAAGTAACA





AGCCTTAAATTTAAAGAAAAACCTACAGACCTGGAGACAAGAAGCTATAAGTATCTT





CTCTTGTCCATGGTGAAACTAATTCATGCAGATCCAAAGCTCTTGCTTTGTAATCCA





AGAAAACAGGGGCCCGAAACCCAAGGCAGTACAGCAGAATTAATTACAGGGCTCG





TCCAACTGGTCCCTCAGTCACACATGCCAGAGATTGCTCAGGAAGCAATGGAGGCT





CTGCTGGTTCTTCATCAGTTAGATAGCATTGATTTGTGGAATCCTGATGCTCCTGTA





GAAACATTTTGGGAGATTAGCTCACAAATGCTTTTTTACATCTGCAAGAAATTAACTA





GTCATCAAATGCTTAGTAGCACAGAAATTCTCAAGTGGTTGCGGGAAATATTGATCT





GCAGGAATAAATTTCTTCTTAAAAATAAGCAGGCAGATAGAAGTTCCTGTCACTTTC





TCCTTTTTTACGGGGTAGGATGTGATATTCCTTCTAGTGGAAATACCAGTCAAATGT





CCATGGATCATGAAGAATTACTACGTACTCCTGGAGCCTCTCTCCGGAAGGGAAAA





GGGAACTCCTCTATGGATAGTGCAGCAGGATGCAGCGGAACCCCCCCGATTTGCC





GACAAGCCCAGACCAAACTAGAAGTGGCCCTGTACATGTTTCTGTGGAACCCTGAC





ACTGAAGCTGTTCTGGTTGCCATGTCCTGTTTCCGCCACCTCTGTGAGGAAGCAGA





TATCCGGTGTGGGGTGGATGAAGTGTCAGTGCATAACCTCTTGCCCAACTATAACA





CATTCATGGAGTTTGCCTCTGTCAGCAATATGATGTCAACAGGAAGAGCAGCACTT





CAGAAAAGAGTGATGGCACTGCTGAGGCGCATTGAGCATCCCACTGCAGGAAACA





CTGAGGCTTGGGAAGATACACATGCAAAATGGGAACAAGCAACAAAGCTAATCCTT





AACTATCCAAAAGCCAAAATGGAAGATGGCCAGGCTGCTGAAAGCCTTCACAAGAC





CATTGTTAAGAGGCGAATGTCCCATGTGAGTGGAGGAGGATCCATAGATTTGTCTG





ACACAGACTCCCTACAGGAATGGATCAACATGACTGGCTTCCTTTGTGCCCTTGGG





GGAGTGTGCCTCCAGCAGAGAAGCAATTCTGGCCTGGCAACCTATAGCCCACCCA





TGGGTCCAGTCAGTGAACGTAAGGGTTCTATGATTTCAGTGATGTCTTCAGAGGGA





AACGCAGATACACCTGTCAGCAAATTTATGGATCGGCTGTTGTCCTTAATGGTGTGT





AACCATGAGAAAGTGGGACTTCAAATACGGACCAATGTTAAGGATCTGGTGGGTCT





AGAATTGAGTCCTGCTCTGTATCCAATGCTATTTAACAAATTGAAGAATACCATCAG





CAAGTTTTTTGACTCCCAAGGACAGGTTTTATTGACTGATACCAATACTCAATTTGTA





GAACAAACCATAGCTATAATGAAGAACTTGCTAGATAATCATACTGAAGGCAGCTCT





GAACATCTAGGGCAAGCTAGCATTGAAACAATGATGTTAAATCTGGCAGGTATGTTC





GTGTGCTTGGGAATATGGTCCATGCAATTCAAATAAAAACGAAACTGTGTCAATTAG





TTGAAGTAATGATGGCAAGGAGAGATGACCTCTCATTTTGCCAAGAGATGAAATTTA





GGAATAAGATGGTAGAATACCTGACAGACTGGGTTATGGGAACATCAAACCAAGCA





GCAGATGATGATGTAAAATGTCTTACAAGAGATTTGGACCAGGCAAGCATGGAAGC





AGTAGTTTCACTTCTAGCTGGTCTCCCTCTGCAGCCTGAAGAAGGAGATGGTGTGG





AATTGATGGAAGCCAAATCACAGTTATTTCTTAAATACTTCACATTATTTATGAACCT





TTTGAATGACTGCAGTGAAGTTGAAGATGAAAGTGCGCAAACAGGTGGCAGGAAAC





GTGGCATGTCTCGGAGGCTGGCATCACTGAGGCACTGTACGGTCCTTGCAATGTC





AAACTTACTCAATGCCAACGTAGACAGTGGTCTCATGCACTCCATAGGCTTAGGTTA





CCACAAGGATCTCCAGACAAGAGCTACATTTATGGAAGTTCTGACAAAAATCCTTCA





ACAAGGCACAGAATTTGACACACTTGCAGAAACAGTATTGGCTGATCGGTTTGAGA





GATTGGTGGAACTGGTCACAATGATGGGTGATCAAGGAGAACTCCCTATAGCGATG





GCTCTGGCCAATGTGGTTCCTTGTTCTCAGTGGGATGAACTAGCTCGAGTTCTGGT





TACTCTGTTTGATTCTCGGCATTTACTCTACCAACTGCTCTGGAACATGTTTTCTAAA





GAAGTAGAATTGGCAGACTCCATGCAGACTCTCTTCCGAGGCAACAGCTTGGCCAG





TAAAATAATGACATTCTGTTTCAAGGTATATGGTGCTACCTATCTACAAAAACTCCTG





GATCCTTTATTACGAATTGTGATCACATCCTCTGATTGGCAACATGTTAGCTTTGAA





GTGGATCCTACCAGGTTAGAACCATCAGAGAGCCTTGAGGAAAACCAGCGGAACC





TCCTTCAGATGACTGAAAAGTTCTTCCATGCCATCATCAGTTCCTCCTCAGAATTCC





CCCCTCAACTTCGAAGTGTGTGCCACTGTTTATACCAGGTGGTTAGCCAGCGTTTC





CCTCAGAACAGCATCGGTGCAGTAGGAAGTGCCATGTTCCTCAGATTTATCAATCC





TGCCATTGTCTCACCGTATGAAGCAGGGATTTTAGATAAAAAGCCACCACCTAGAAT





CGAAAGGGGCTTGAAGTTAATGTCAAAGATACTTCAGAGTATTGCCAATCATGTTCT





CTTCACAAAAGAAGAACATATGCGGCCTTTCAATGATTTTGTGAAAAGCAACTTTGA





TGCAGCACGCAGGTTTTTCCTTGATATAGCATCTGATTGTCCTACAAGTGATGCAGT





AAATCATAGTCTTTCCTTCATAAGTGACGGCAATGTGCTTGCTTTACATCGTCTACT





CTGGAACAATCAGGAGAAAATTGGGCAGTATCTTTCCAGCAACAGGGATCATAAAG





CTGTTGGAAGACGACCTTTTGATAAGATGGCAACACTTCTTGCATACCTGGGTCCT





CCAGAGCACAAACCTGTGGCAGATACACACTGGTCCAGCCTTAACCTTACCAGTTC





AAAGTTTGAGGAATTTATGACTAGGCATCAGGTACATGAAAAAGAAGAATTCAAGGC





TTTGAAAACGTTAAGTATTTTCTACCAAGCTGGGACTTCCAAAGCTGGGAATCCTAT





TTTTTATTATGTTGCACGGAGGTTCAAAACTGGTCAAATCAATGGTGATTTGCTGAT





ATACCATGTCTTACTGACTTTAAAGCCATATTATGCAAAGCCATATGAAATTGTAGTG





GACCTTACCCATACCGGGCCTAGCAATCGCTTTAAAACAGACTTTCTCTCTAAGTGG





TTTGTTGTTTTTCCTGGCTTTGCTTACGACAACGTCTCCGCAGTCTATATCTATAACT





GTAACTCCTGGGTCAGGGAGTACACCAAGTATCATGAGCGGCTGCTGACTGGCCT





CAAAGGTAGCAAAAGGCTTGTTTTCATAGACTGTCCTGGGAAACTGGCTGAGCACA





TAGAGCATGAACAACAGAAACTACCTGCTGCCACCTTGGCTTTAGAAGAGGACCTG





AAGGTATTCCACAATGCTCTCAAGCTAGCTCACAAAGACACCAAAGTTTCTATTAAA





GTTGGTTCTACTGCTGTCCAAGTAACTTCAGCAGAGCGAACAAAAGTCCTAGGGCA





ATCAGTCTTTCTAAATGACATTTATTATGCTTCGGAAATTGAAGAAATCTGCCTAGTA





GATGAGAACCAGTTCACCTTAACCATTGCAAACCAGGGCACGCCGCTCACCTTCAT





GCACCAGGAGTGTGAAGCCATTGTCCAGTCTATCATTCATATCCGGACCCGCTGGG





AACTGTCACAGCCCGACTCTATCCCCCAACACACCAAGATTCGGCCAAAAGATGTC





CCTGGGACACTGCTCAATATCGCATTACTTAATTTAGGCAGTTCTGACCCGAGTTTA





CGGTCAGCTGCCTATAATCTTCTGTGTGCCTTAACTTGTACCTTTAATTTAAAAATCG





AGGGCCAGTTACTAGAGACATCAGGTTTATGTATCCCTGCCAACAACACCCTCTTTA





TTGTCTCTATTAGTAAGACACTGGCAGCCAATGAGCCACACCTCACGTTAGAATTTT





TGGAAGAGTGTATTTCTGGATTTAGCAAATCTAGTATTGAATTGAAACACCTTTGTTT





GGAATACATGACTCCATGGCTGTCAAATCTAGTTCGTTTTTGCAAGCATAATGATGA





TGCCAAACGACAAAGAGTTACTGCTATTCTTGACAAGCTGATAACAATGACCATCAA





TGAAAAACAGATGTACCCATCTATTCAAGCAAAAATATGGGGAAGCCTTGGGCAGA





TTACAGATCTGCTTGATGTTGTACTAGACAGTTTCATCAAAACCAGTGCAACAGGTG





GCTTGGGATCAATAAAAGCTGAGGTGATGGCAGATACTGCTGTAGCTTTGGCTTCT





GGAAATGTGAAATTGGTTTCAAGCAAGGTTATTGGAAGGATGTGCAAAATAATTGAC





AAGACATGCTTATCTCCAACTCCTACTTTAGAACAACATCTTATGTGGGATGATATT





GCTATTTTAGCACGCTACATGCTGATGCTGTCCTTCAACAATTCCCTTGATGTGGCA





GCTCATCTTCCCTACCTCTTCCACGTTGTTACTTTCTTAGTAGCCACAGGTCCGCTC





TCCCTTAGAGCTTCCACACATGGACTGGTCATTAATATCATTCACTCTCTGTGTACT





TGTTCACAGCTTCATTTTAGTGAAGAGACCAAGCAAGTTTTGAGACTCAGTCTGACA





GAGTTCTCATTACCCAAATTTTACTTGCTGTTTGGCATTAGCAAAGTCAAGTCAGCT





GCTGTCATTGCCTTCCGTTCCAGTTACCGGGACAGGTCATTCTCTCCTGGCTCCTA





TGAGAGAGAGACTTTTGCTTTGACATCCTTGGAAACAGTCACAGAAGCTTTGTTGGA





GATCATGGAGGCATGCATGAGAGATATTCCAACGTGCAAGTGGCTGGACCAGTGG





ACAGAACTAGCTCAAAGATTTGCATTCCAATATAATCCATCCCTGCAACCAAGAGCT





CTTGTTGTCTTTGGGTGTATTAGCAAACGAGTGTCTCATGGGCAGATAAAGCAGATA





ATCCGTATTCTTAGCAAGGCACTTGAGAGTTGCTTAAAAGGACCTGACACTTACAAC





AGTCAAGTTCTGATAGAAGCTACAGTAATAGCACTAACCAAATTACAGCCACTTCTT





AATAAGGACTCGCCTCTGCACAAAGCCCTCTTTTGGGTAGCTGTGGCTGTGCTGCA





GCTTGATGAGGTCAACTTGTATTCAGCAGGTACCGCACTTCTTGAACAAAACCTGC





ATACTTTAGATAGTCTCCGTATATTCAATGACAAGAGTCCAGAGGAAGTATTTATGG





CAATCCGGAATCCTCTGGAGTGGCACTGCAAGCAAATGGATCATTTTGTTGGACTC





AATTTCAACTCTAACTTTAACTTTGCATTGGTTGGACACCTTTTAAAAGGGTACAGG





CATCCTTCACCTGCTATTGTTGCAAGAACAGTCAGAATTTTACATACACTACTAACTC





TGGTTAACAAACACAGAAATTGTGACAAATTTGAAGTGAATACACAGAGCGTGGCCT





ACTTAGCAGCTTTACTTACAGTGTCTGAAGAAGTTCGAAGTCGCTGCAGCCTAAAAC





ATAGAAAGTCACTTCTTCTTACTGATATTTCAATGGAAAATGTTCCTATGGATACATA





TCCCATTCATCATGGTGACCCTTCCTATAGGACACTAAAGGAGACTCAGCCATGGT





CCTCTCCCAAAGGTTCTGAAGGATACCTTGCAGCCACCTATCCAACTGTCGGCCAG





ACCAGTCCCCGAGCCAGGAAATCCATGAGCCTGGACATGGGGCAACCTTCTCAGG





CCAACACTAAGAAGTTGCTTGGAACAAGGAAAAGTTTTGATCACTTGATATCAGACA





CAAAGGCTCCTAAAAGGCAAGAAATGGAATCAGGGATCACAACACCCCCCAAAATG





AGGAGAGTAGCAGAAACTGATTATGAAATGGAAACTCAGAGGATTTCCTCATCACA





ACAGCACCCACATTTACGTAAAGTTTCAGTGTCTGAATCAAATGTTCTCTTGGATGA





AGAAGTACTTACTGATCCGAAGATCCAGGCGCTGCTTCTTACTGTTCTAGCTACACT





GGTAAAATATACCACAGATGAGTTTGATCAACGAATTCTTTATGAATACTTAGCAGA





GGCCAGTGTTGTGTTTCCCAAAGTCTTTCCTGTTGTGCATAATTTGTTGGACTCTAA





GATCAACACCCTGTTATCATTGTGCCAAGATCCAAATTTGTTAAATCCAATCCATGG





AATTGTGCAGAGTGTGGTGTACCATGAAGAATCCCCACCACAATACCAAACATCTTA





CCTGCAAAGTTTTGGTTTTAATGGCTTGTGGCGGTTTGCAGGACCGTTTTCAAAGCA





AACACAAATTCCAGACTATGCTGAGCTTATTGTTAAGTTTCTTGATGCCTTGATTGAC





ACGTACCTGCCTGGAATTGATGAAGAAACCAGTGAAGAATCCCTCCTGACTCCCAC





ATCTCCTTACCCTCCTGCACTGCAGAGCCAGCTTAGTATCACTGCCAACCTTAACCT





TTCTAATTCCATGACCTCACTTGCAACTTCCCAGCATTCCCCAGGAATCGACAAGGA





GAACGTTGAACTCTCCCCTACCACTGGCCACTGTAACAGTGGACGAACTCGCCACG





GATCCGCAAGCCAAGTGCAGAAGCAAAGAAGCGCTGGCAGTTTCAAACGTAATAG





CATTAAGAAGATCGTGTGAAGCTTGCTTGCTTTCTTTTTTAAAATCAACTTAACATGG





GCTCTTCACTAGTGACCCCTTCCCTGTCCTTGCCCTTTCCCCCCATGTTGTAATGCT





GCACTTCCTGTTTTATAATGAACCCATCCGGTTTGCCATGTTGCCAGATGATCAACT





CTTCGAAGCCTTGCCTAAATTTAATGCTGCCTTTTCTTTAACTTTTTTTCTTCTACTTT





TGGCGTGTATCTGGTATATGTAAGTGTTCAGAACAACTGCAAAGAAAGTGGGAGGT





CAGGAAACTTTTAACTGAGAAATCTCAATTGTAAGAGAGGATGAATTCTTGAATACT





GCTACTACTGGCCAGTGATGAAAGCCATTTGCACAGAGCTCTGCCTTCTGTGGTTT





TCCCTTCTTCATCCTACAGAGTAAAGTGTTAGTCCTATTTATACATTTTTCAAGATAC





AAGTTTATGAGAGAAATAGTATTATAACCCCAGTATGTTTAATCTTTTAGCTGTGGAC





TTTTTTTTTAACCGTACAAAACTGAAAGAACCATAGAGGTCAAGCCTCAGTGACTTG





ACACCATAAAGCCACAGACAAGGTACTTGGGGGGGAGGGCAGGGAAATTTCATATT





TTATAGTGGATTCTTAAGAAATACTAACACTTGAGTATTAGCAATAATTACAGGAAAA





TAAGTGCGACCACATATATCTTAACATTACTGAATTAAAACTATGGCTTCTAAGTCCT





TATCCAAACTCAGTCATCCAAACTAGTTTATTTTTTTCTCCAGTTGATTATCTTTTAAT





TTTTAATTTTGCTAAAGGTGGTTTTTTTGTGTTTTGTTTTTTGTAAACCAAAACTATAC





TAAGTATAGTAATTATATATATATATATATTTTTTCCCCTCCCCCTCTTCTTTCCTAAC





TAATTCTGAGCAGGGTAATCAGTGAACAAAGTGTTGAAAATTGTTCCCAGAAGGTAA





TTTTCATAGATGTTTGCATTAGCTCCATAGCAAAATGGAATGGTACGTGACATTTAG





GGTAGCTGATATTTTTATTTTGTTAAATAATTTCCAAGAATAGAGTATGGTGTATATT





ATAAATTTCTTTGATAAGATGTATTTTGAATGTCTTTTAATCTTCCTCCTCCTCTCCAA





AAAAATCAGAAACCTCTTTAAGAAAACATGTAGGTTATATATGCTAGAATTGCATTTA





ATCACTGTGAAAAGACTGGTCAGCCTGCATTAGTATGACAGTAGGGGGGCTGTTAG





AATTGCTGCTATACTGGTGGTATGGATTATCATGGCATTGGAATTTTCATAGTAATG





CAGATCCAATTTCTTTGTGGTACCTGCAGTTTACAAAATAATTTGACTTCAGTGAGC





ATATTGGTATCTGGATGTTCCAATTTAGAACTAAACCATATTTATTACAAAAAGATAT





TAATCCCTCTACTCCCAGGTTCCCTTTATATGTTAAGATATAATGGCTTTGAGGGGG





GAAAAAATAAACCTAGGGGAGAGGGGAGTTTCCTGTAGTGCTGTTTCATTAGAGGA





TTTCAGTAAATTAAATTCCACAGCTAATTCAATAAATAATGGTACATTTAAGTGTTCT





GATTTTAATAATATATTTCACATTTATCCACACAGTAACAATGTAATATGTTAATGTAA





ATAAAATTGGTTTTGATACTCAGAAATAACAAGAATTTAATTTTTTAAATTTGTTTACA





GTCCTGGGAAAAGTAAGAATTATTTGCCAAAATAAGAGGAAAGAAAACCTTAGTATT





ATTAATGAGTTTACCATAGAATTGTTGGAAATACTGAAGACAGGTGCAATTTACTAAA





CTTTTGTTTTTAAACTATTGTAGAGGCTGCATTAGAAGAAAATGTTTATAATGACAGA





GCAACTATGACTATATAAAAAAGCTGAAATTAGAACTGTGTTTAGAAATAGATCAGTA





ACCCAGTGCCAAGGATGCCAAGCTGCCACCATGGTCTTGGCTCTCCCACAACCCA





GTGTTTCTGGGGTAAGTTTCACAGTTTCTAGGCCCTGGAATAGCAGGCAGTGTAAG





CCTTTGATAACTTTAGTTCGATGTTTTTCTTGTTTTTGTTTGTTGGTTTGGTGCATATG





ATAGTGGGTGTTATGCTATTTTGCTCTTCCCATCAAAATAAAGAAACTTCCAGAGGT





TTACTGTTAAAAATACTGATATTTCCATAAACGGGTTTACCAAGGGTGTAGTATTTCA





TACCGCCTGAAATGATCAGCATTGGCACAAATCAAAATTCAGCCGCCTTTGAAATGC





AAAAATACCTTTGACTAGTAAGTACATCCTAGGAGTTTGAAAACTTAACTAAGGTTTA





AAATTTACCTTGTTTAAAGAACTTCTGACTTTTGAGGAAAATCTAGCTTTCCAAGTAA





CTAAAATGTACATGAGATAAACCTCTCACCACTATGTGTCCCTTGAGAAATGCAACA





CTTTTTTAGTCTTCATACTTGTAATCTATAAAAGAAATTCTGAAGTTTAGACCAAGTT





GCCCATTTCTGCGTAATTGACATAAGTTCTGTTAAAAATATTATAAGTAATTCGTTTC





GGTTTGTAGATGTTTCCCCTGACTTGTTAAAGAGGAAACCAGGAACTCAGTCATGTT





TTTGTCCTGGATAATCTACCTGTTATGCCAGTACTCCCATCCGAGGGGCATGCCCT





TAGTTGCCCAGATGGAGATGCAGTTCAGTAGATTTGGGGCAAAGTGGCTACAGCTC





TGTCTTCCATTCACTCAACACCTGTTCATGACTGAGCCAGGTGCCCAGGACACATC





CTAAACAGTCAGCTTCTATCCTGTGTCCTAGTTGGGGAGACAGAGTGCCAGCCAGC





AACCCTCCCAGGTTTGTAGGTTTTAGGGGTTTTCAGTTTTGTTTGGGTTTTTTGTTTT





TTGTTTTTGTTTCTACATCCTTCCCCGACTCCCAGGCATAATGAGGCATGTCTTACT





CAATGTTATGCAATGGATTTAGGCAAAAATTCATTCTTAGTGTCAGCCACACAATTTT





TTTTAATGCAGTATATTCACCTGTAAATAGTTTGTGTAAAATTTGACAAAAAAAGTAT





ATTTACTATACTGTAAATATATGTGATGATATATTGTATTATTTTGCTTTTTTGTAAAG





CAGTTAGTTGCTGCACATGGATAACAACAAAAATTTGATTATTCTCGTGTTAGTATTG





TTAACTTCTTTTTGCGACTGCGTTACATCATTTAAAGAAAATGCTGTGTATTGTAAAC





TTAAATTGTATATGATAACTTACTGTCCTTTCCATCCGGGCCTAAACTTTGGCAGTTC





CTTTGTCTACAACCTTGTTAATACTGTAAACAGTTGTACGCCAGCAGGAAAAATACT





GCCCAACAGACAAAATCGATCATTGTAGGGGAAAATCATAGAAATCCATTTCAGATC





TTTATTGTTCCTCACCCCATTTTCCTCCTTGTGTATGTACTTCCCCCACCCCCCTTTT





TTTAAGTAAAATGTAAATTCAATCTGCTCTAAGAAAAAAAAAAAAAAAAAAAA.





(SEQ ID NO: 268; NM_000267.3),







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:268 under stringent hybridization conditions


In some embodiments, early growth response 1 (EGR1, TIS8, AT225, KROX-24, NGFI-A, ZNF225) comprises the amino acid sequence:









MAAAKAEMQLMSPLQISDPFGSFPHSPTMDNYPKLEEMMLLSNGAPQFLG





AAGAPEGSGSNSSSSSSGGGGGGGGGSNSSSSSSTFNPQADTGEQPYEHL





TAESFPDISLNNEKVLVETSYPSQTTRLPPITYTGRFSLEPAPNSGNTLW





PEPLFSLVSGLVSMTNPPASSSSAPSPAASSASASQSPPLSCAVPSNDSS





PIYSAAPTFPTPNTDIFPEPQSQAFPGSAGTALQYPPPAYPAAKGGFQVP





MIPDYLFPQQQGDLGLGTPDQKPFQGLESRTQQPSLTPLSTIKAFATQSG





SQDLKALNTSYQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFS





RSDELTRHIRIHTGQKPFQCRICMRNFSRSDHLTTHIRTHTGEKPFACDI





CGRKFARSDERKRHTKIHLRQKDKKADKSVVASSATSSLSSYPSPVATSY





PSPVTTSYPSPATTSYPSPVPTSFSSPGSSTYPSPVHSGFPSPSVATTYS





SVPPAFPAQVSSFPSSAVTNSFSASTGLSDMTATFSPRTIEIC. (SEQ





ID NO: 269; NP_001955.1),







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:269)


In some embodiments, the nucleic acid sequence encoding Fos comprises the nucleic acid sequence:









GAGAGATCCCAGCGCGCAGAACTTGGGGAGCCGCCGCCGCCATCCGCCGC





CGCAGCCAGCTTCCGCCGCCGCAGGACCGGCCCCTGCCCCAGCCTCCGCA





GCCGCGGCGCGTCCACGCCCGCCCGCGCCCAGGGCGAGTCGGGGTCGCCG





CCTGCACGCTTCTCAGTGTTCCCCGCGCCCCGCATGTAACCCGGCCAGGC





CCCCGCAACTGTGTCCCCTGCAGCTCCAGCCCCGGGCTGCACCCCCCCGC





CCCGACACCAGCTCTCCAGCCTGCTCGTCCAGGATGGCCGCGGCCAAGGC





CGAGATGCAGCTGATGTCCCCGCTGCAGATCTCTGACCCGTTCGGATCCT





TTCCTCACTCGCCCACCATGGACAACTACCCTAAGCTGGAGGAGATGATG





CTGCTGAGCAACGGGGCTCCCCAGTTCCTCGGCGCCGCCGGGGCCCCAGA





GGGCAGCGGCAGCAACAGCAGCAGCAGCAGCAGCGGGGGCGGTGGAGGCG





GCGGGGGCGGCAGCAACAGCAGCAGCAGCAGCAGCACCTTCAACCCTCAG





GCGGACACGGGCGAGCAGCCCTACGAGCACCTGACCGCAGAGTCTTTTCC





TGACATCTCTCTGAACAACGAGAAGGTGCTGGTGGAGACCAGTTACCCCA





GCCAAACCACTCGACTGCCCCCCATCACCTATACTGGCCGCTTTTCCCTG





GAGCCTGCACCCAACAGTGGCAACACCTTGTGGCCCGAGCCCCTCTTCAG





CTTGGTCAGTGGCCTAGTGAGCATGACCAACCCACCGGCCTCCTCGTCCT





CAGCACCATCTCCAGCGGCCTCCTCCGCCTCCGCCTCCCAGAGCCCACCC





CTGAGCTGCGCAGTGCCATCCAACGACAGCAGTCCCATTTACTCAGCGGC





ACCCACCTTCCCCACGCCGAACACTGACATTTTCCCTGAGCCACAAAGCC





AGGCCTTCCCGGGCTCGGCAGGGACAGCGCTCCAGTACCCGCCTCCTGCC





TACCCTGCCGCCAAGGGTGGCTTCCAGGTTCCCATGATCCCCGACTACCT





GTTTCCACAGCAGCAGGGGGATCTGGGCCTGGGCACCCCAGACCAGAAGC





CCTTCCAGGGCCTGGAGAGCCGCACCCAGCAGCCTTCGCTAACCCCTCTG





TCTACTATTAAGGCCTTTGCCACTCAGTCGGGCTCCCAGGACCTGAAGGC





CCTCAATACCAGCTACCAGTCCCAGCTCATCAAACCCAGCCGCATGCGCA





AGTACCCCAACCGGCCCAGCAAGACGCCCCCCCACGAACGCCCTTACGCT





TGCCCAGTGGAGTCCTGTGATCGCCGCTTCTCCCGCTCCGACGAGCTCAC





CCGCCACATCCGCATCCACACAGGCCAGAAGCCCTTCCAGTGCCGCATCT





GCATGCGCAACTTCAGCCGCAGCGACCACCTCACCACCCACATCCGCACC





CACACAGGCGAAAAGCCCTTCGCCTGCGACATCTGTGGAAGAAAGTTTGC





CAGGAGCGATGAACGCAAGAGGCATACCAAGATCCACTTGCGGCAGAAGG





ACAAGAAAGCAGACAAAAGTGTTGTGGCCTCTTCGGCCACCTCCTCTCTC





TCTTCCTACCCGTCCCCGGTTGCTACCTCTTACCCGTCCCCGGTTACTAC





CTCTTATCCATCCCCGGCCACCACCTCATACCCATCCCCTGTGCCCACCT





CCTTCTCCTCTCCCGGCTCCTCGACCTACCCATCCCCTGTGCACAGTGGC





TTCCCCTCCCCGTCGGTGGCCACCACGTACTCCTCTGTTCCCCCTGCTTT





CCCGGCCCAGGTCAGCAGCTTCCCTTCCTCAGCTGTCACCAACTCCTTCA





GCGCCTCCACAGGGCTTTCGGACATGACAGCAACCTTTTCTCCCAGGACA





ATTGAAATTTGCTAAAGGGAAAGGGGAAAGAAAGGGAAAAGGGAGAAAAA





GAAACACAAGAGACTTAAAGGACAGGAGGAGGAGATGGCCATAGGAGAGG





AGGGTTCCTCTTAGGTCAGATGGAGGTTCTCAGAGCCAAGTCCTCCCTCT





CTACTGGAGTGGAAGGTCTATTGGCCAACAATCCTTTCTGCCCACTTCCC





CTTCCCCAATTACTATTCCCTTTGACTTCAGCTGCCTGAAACAGCCATGT





CCAAGTTCTTCACCTCTATCCAAAGAACTTGATTTGCATGGATTTTGGAT





AAATCATTTCAGTATCATCTCCATCATATGCCTGACCCCTTGCTCCCTTC





AATGCTAGAAAATCGAGTTGGCAAAATGGGGTTTGGGCCCCTCAGAGCCC





TGCCCTGCACCCTTGTACAGTGTCTGTGCCATGGATTTCGTTTTTCTTGG





GGTACTCTTGATGTGAAGATAATTTGCATATTCTATTGTATTATTTGGAG





TTAGGTCCTCACTTGGGGGAAAAAAAAAAAAGAAAAGCCAAGCAAACCAA





TGGTGATCCTCTATTTTGTGATGATGCTGTGACAATAAGTTTGAACCTTT





TTTTTTGAAACAGCAGTCCCAGTATTCTCAGAGCATGTGTCAGAGTGTTG





TTCCGTTAACCTTTTTGTAAATACTGCTTGACCGTACTCTCACATGTGGC





AAAATATGGTTTGGTTTTTCTTTTTTTTTTTTTTTGAAAGTGTTTTTTCT





TCGTCCTTTTGGTTTAAAAAGTTTCACGTCTTGGTGCCTTTTGTGTGATG





CGCCTTGCTGATGGCTTGACATGTGCAATTGTGAGGGACATGCTCACCTC





TAGCCTTAAGGGGGGCAGGGAGTGATGATTTGGGGGAGGCTTTGGGAGCA





AAATAAGGAAGAGGGCTGAGCTGAGCTTCGGTTCTCCAGAATGTAAGAAA





ACAAAATCTAAAACAAAATCTGAACTCTCAAAAGTCTATTTTTTTAACTG





AAAATGTAAATTTATAAATATATTCAGGAGTTGGAATGTTGTAGTTACCT





ACTGAGTAGGCGGCGATTTTTGTATGTTATGAACATGCAGTTCATTATTT





TGTGGTTCTATTTTACTTTGTACTTGTGTTTGCTTAAACAAAGTGACTGT





TTGGCTTATAAACACATTGAATGCGCTTTATTGCCCATGGGATATGTGGT





GTATATCCTTCCAAAAAATTAAAACGAAAATAAAGTA. (SEQ ID NO:





270; NM_001964.3),







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:270 under stringent hybridization conditions


In some embodiments, early growth response 2 (EGR2, CHN1, AT591, CMT1D, CMT4E, KROX20) comprises the amino acid sequence:









MMTAKAVDKIPVTLSGFVHQLSDNIYPVEDLAATSVTIFPNAELGGPFDQ





MNGVAGDGMINIDMTGEKRSLDLPYPSSFAPVSAPRNQTFTYMGKFSIDP





QYPGASCYPEGIINIVSAGILQGVTSPASTTASSSVTSASPNPLATGPLG





VCTMSQTQPDLDHLYSPPPPPPPYSGCAGDLYQDPSAFLSAATTSTSSSL





AYPPPPSYPSPKPATDPGLFPMIPDYPGFFPSQCQRDLHGTAGPDRKPFP





CPLDTLRVPPPLTPLSTIRNFTLGGPSAGVTGPGASGGSEGPRLPGSSSA





AAAAAAAAAYNPHHLPLRPILRPRKYPNRPSKTPVHERPYPCPAEGCDRR





FSRSDELTRHIRIHTGHKPFQCRICMRNFSRSDHLTTHIRTHTGEKPFAC





DYCGRKFARSDERKRHTKIHLRQKERKSSAPSASVPAPSTASCSGGVQPG





GTLCSSNSSSLGGGPLAPCSSRTRTP. (SEQ ID NO: 271; NP_





000390.2),







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:271)


In some embodiments, the nucleic acid sequence encoding EGR2 comprises the nucleic acid sequence:









(SEQ ID NO: 272; NM_000399.5)


AACTGAGCGAGGAGCAATTGATTAATAGCTCGGCGAGGGGACTCACTGA





CTGTTATAATAACACTACACCAGCAACTCCTGGCTTCCCAGCAGCCGGA





ACACAGACAGGAGAGAGTCAGTGGCAAATAGACATTTTTCTTATTTCTT





AAAAAACAGCAACTTGTTTGCTACTTTTATTTCTGTTGATTTTTTTTTC





TTGGTGTGTGTGGTGGTTGTTTTTAAGTGTGGAGGGCAAAAGGAGATAC





CATCCCAGGCTCAGTCCAACCCCTCTCCAAAACGGCTTTTCTGACACTC





CAGGTAGCGAGGGAGTTGGGTCTCCAGGTTGTGCGAGGAGCAAATGATG





ACCGCCAAGGCCGTAGACAAAATCCCAGTAACTCTCAGTGGTTTTGTGC





ACCAGCTGTCTGACAACATCTACCCGGTGGAGGACCTCGCCGCCACGTC





GGTGACCATCTTTCCCAATGCCGAACTGGGAGGCCCCTTTGACCAGATG





AACGGAGTGGCCGGAGATGGCATGATCAACATTGACATGACTGGAGAGA





AGAGGTCGTTGGATCTCCCATATCCCAGCAGCTTTGCTCCCGTCTCTGC





ACCTAGAAACCAGACCTTCACTTACATGGGCAAGTTCTCCATTGACCCT





CAGTACCCTGGTGCCAGCTGCTACCCAGAAGGCATAATCAATATTGTGA





GTGCAGGCATCTTGCAAGGGGTCACTTCCCCAGCTTCAACCACAGCCTC





ATCCAGCGTCACCTCTGCCTCCCCCAACCCACTGGCCACAGGACCCCTG





GGTGTGTGCACCATGTCCCAGACCCAGCCTGACCTGGACCACCTGTACT





CTCCGCCACCGCCTCCTCCTCCTTATTCTGGCTGTGCAGGAGACCTCTA





CCAGGACCCTTCTGCGTTCCTGTCAGCAGCCACCACCTCCACCTCTTCC





TCTCTGGCCTACCCACCACCTCCTTCCTATCCATCCCCCAAGCCAGCCA





CGGACCCAGGTCTCTTCCCAATGATCCCAGACTATCCTGGATTCTTTCC





ATCTCAGTGCCAGAGAGACCTACATGGTACAGCTGGCCCAGACCGTAAG





CCCTTTCCCTGCCCACTGGACACCCTGCGGGTGCCCCCTCCACTCACTC





CACTCTCTACAATCCGTAACTTTACCCTGGGGGGCCCCAGTGCTGGGGT





GACCGGACCAGGGGCCAGTGGAGGCAGCGAGGGACCCCGGCTGCCTGGT





AGCAGCTCAGCAGCAGCAGCAGCCGCCGCCGCCGCCGCCTATAACCCAC





ACCACCTGCCACTGCGGCCCATTCTGAGGCCTCGCAAGTACCCCAACAG





ACCCAGCAAGACGCCGGTGCACGAGAGGCCCTACCCGTGCCCAGCAGAA





GGCTGCGACCGGCGGTTCTCCCGCTCTGACGAGCTGACACGGCACATCC





GAATCCACACTGGGCATAAGCCCTTCCAGTGTCGGATCTGCATGCGCAA





CTTCAGCCGCAGTGACCACCTCACCACCCATATCCGCACCCACACCGGT





GAGAAGCCCTTCGCCTGTGACTACTGTGGCCGAAAGTTTGCCCGGAGTG





ATGAGAGGAAGCGCCACACCAAGATCCACCTGAGACAGAAAGAGCGGAA





AAGCAGTGCCCCCTCTGCATCGGTGCCAGCCCCCTCTACAGCCTCCTGC





TCTGGGGGCGTGCAGCCTGGGGGTACCCTGTGCAGCAGTAACAGCAGCA





GTCTTGGCGGAGGGCCGCTCGCCCCTTGCTCCTCTCGGACCCGGACACC





TTGAGATGAGACTCAGGCTGATACACCAGCTCCCAAAGGTCCCGGAGGC





CCTTTGTCCACTGGAGCTGCACAACAAACACTACCACCCTTTCCTGTCC





CTCTCTCCCTTTGTTGGGCAAAGGGCTTTGGTGGAGCTAGCACTGCCCC





CTTTCCACCTAGAAGCAGGTTCTTCCTAAAACTTAGCCCATTCTAGTCT





CTCTTAGGTGAGTTGACTATCAACCCAAGGCAAAGGGGAGGCTCAGAAG





GAGGTGGTGTGGGGACCCCTGGCCAAGAGGGCTGAGGTCTGACCCTGCT





TTAAAGGGTTGTTTGACTAGGTTTTGCTACCCCACTTCCCCTTATTTTG





ACCCATCACAGGTTTTTGACCCTGGATGTCAGAGTTGATCTAAGACGTT





TTCTACAATAGGTTGGGAGATGCTGATCCCTTCAAGTGGGGACAGCAAA





AAGACAAGCAAAACTGATGTGCACTTTATGGCTTGGGACTGATTTGGGG





GACATTGTACAGTGAGTGAAGTATAGCCTTTATGCCACACTCTGTGGCC





CTAAAATGGTGAATCAGAGCATATCTAGTTGTCTCAACCCTTGAAGCAA





TATGTATTATAAACTCAGAGAACAGAAGTGCAATGTGATGGGAGGAACA





TAGCAATATCTGCTCCTTTTCGAGTTGTTTGAGAAATGTAGGCTATTTT





TTCAGTGTATATCCACTCAGATTTTGTGTATTTTTGATGTACACTGTTC





TCTAAATTCTGAATCTTTGGGAAAAAATGTAAAGCATTTATGATCTCAG





AGGTTAACTTATTTAAGGGGGATGTACATATATTCTCTGAAACTAGGAT





GCATGCAATTGTGTTGGAAGTGTCCTTGGTGCCTTGTGTGATGTAGACA





ATGTTACAAGGTCTGCATGTAAATGGGTTGCCTTATTATGGAGAAAAAA





AATCACTCCCTGAGTTTAGTATGGCTGTATATTTCTGCCTATTAATATT





TGGAATTTTTTTTAGAAAGTATATTTTTGTATGCTTTGTTTTGTGACTT





AAAAGTGTTACCTTTGTAGTCAAATTTCAGATAAGAATGTACATAATGT





TACCGGAGCTGATTTGTTTGGTCATTAGCTCTTAATAGTTGTGAAAAAA





TAAATCTATTCTAACGCAAAACCACTAACTGAAGTTCAGATAATGGATG





GTTTGTGACTATAGTGTAAATAAATACTTTTCAACAATA.,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:272 under stringent hybridization conditions


In some embodiments, Sp3 transcription factor (SP3, SPR2) comprises the amino acid sequence:









(SEQ ID NO: 273; NP_001017371.3)


MGPPSPGDDEEEAAAAAGAPAAAGATGDLASAQLGGAPNRWEVLSATPT





TIKDEAGNLVQIPSAATSSGQYVLPLQNLQNQQIFSVAPGSDSSNGTVS





SVQYQVIPQIQSADGQQVQIGFTGSSDNGGINQESSQIQIIPGSNQTLL





ASGTPSANIQNLIPQTGQVQVQGVAIGGSSFPGQTQVVANVPLGLPGNI





TFVPINSVDLDSLGLSGSSQTMTAGINADGHLINTGQAMDSSDNSERTG





ERVSPDINETNTDTDLFVPTSSSSQLPVTIDSTGILQQNTNSLTTSSGQ





VHSSDLQGNYIQSPVSEETQAQNIQVSTAQPVVQHLQLQESQQPTSQAQ





IVQGITPQTIHGVQASGQNISQQALQNLQLQLNPGTFLIQAQTVTPSGQ





VTWQTFQVQGVQNLQNLQIQNTAAQQITLTPVQTLTLGQVAAGGAFTST





PVSLSTGQLPNLQTVTVNSIDSAGIQLHPGENADSPADIRIKEEEPDPE





EWQLSGDSTLNTNDLTHLRVQVVDEEGDQQHQEGKRLRRVACTCPNCKE





GGGRGTNLGKKKQHICHIPGCGKVYGKTSHLRAHLRWHSGERPFVCNWM





YCGKRFTRSDELQRHRRTHTGEKKFVCPECSKRFMRSDHLAKHIKTHQN





KKGIHSSSTVLASVEAARDDTLITAGGTTLILANIQQGSVSGIGTVNTS





ATSNQDILTNTEIPLQLVTVSGNETME.,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:273)


In some embodiments, the nucleic acid sequence encoding SP3 comprises the nucleic acid sequence:









(SEQ ID NO: 274; NM_001017371.5)


ACTCAGCCGTCACCGCTCGCTCTGCTGGCCGCTACCTGCAGCAAGATAG





GGCCGCCATCGCCGGGCGACGACGAGGAGGAGGCGGCCGCCGCAGCCGG





GGCCCCCGCCGCCGCCGGAGCGACAGGTGATTTGGCTTCTGCACAGTTA





GGAGGAGCACCAAACCGATGGGAGGTTTTGTCAGCCACACCTACAACTA





TAAAAGATGAAGCTGGTAATCTAGTCCAGATTCCAAGTGCTGCTACTTC





AAGTGGGCAGTATGTTCTTCCCCTTCAGAATTTGCAGAATCAACAAATA





TTTTCCGTTGCACCAGGATCAGATTCATCAAATGGTACAGTGTCCAGTG





TTCAATTCAAGTGATACCACAGATCCAGTCAGCAGATGGTCAGCAGGTT





CAAATTGGTTTCACAGGCTCTTCAGATAATGGGGGTATAAATCAAGAAA





GCAGTCAAATTCAGATCATTCCTGGCTCTAATCAAACCTTACTTGCCTC





TGGAACACCTTCTGCTAACATCCAGAATCTCATACCACAGACTGGTCAA





GTCCAGGTTCAGGGAGTTGCAATTGGTGGTTCATCTTTTCCTGGTCAAA





CCCAAGTAGTTGCTAATGTGCCTCTTGGTCTGCCAGGAAATATTACGTT





TGTACCAATCAATAGTGTCGATCTAGATTCTTTGGGACTCTCGGGCAGT





TCTCAGACAATGACTGCAGGCATTAATGCCGACGGACATTTGATAAACA





CAGGACAAGCTATGGATAGTTCAGACAATTCAGAAAGGACTGGTGAGCG





GGTTTCTCCTGATATTAATGAAACTAATACTGATACAGATTTATTTGTG





CCAACATCCTCTTCATCACAGTTGCCTGTTACGATAGATAGTACAGGTA





TATTACAACAAAACACAAATAGCTTGACTACATCTAGTGGGCAGGTTCA





TTCTTCAGATCTTCAGGGAAATTATATCCAGTCGCCTGTTTCTGAAGAG





ACACAGGCACAGAATATTCAGGTTTCTACAGCACAGCCTGTTGTACAGC





ATCTACAACTTCAAGAGTCTCAGCAGCCAACCAGTCAAGCCCAAATTGT





GCAAGGTATTACACCACAGACAATCCATGGTGTGCAAGCCAGTGGTCAA





AATATATCACAACAGGCTTTGCAAAATCTTCAGTTGCAGCTGAATCCTG





GAACCTTTTTAATTCAGGCACAGACAGTGACCCCTTCTGGACAGGTAAC





TTGGCAAACGTTTCAAGTACAAGGGGTCCAGAACTTGCAGAATTTGCAA





ATACAGAATACTGCTGCCCAACAAATAACTTTGACGCCTGTTCAAACCC





TCACACTTGGTCAAGTTGCGGCAGGTGGAGCCTTCACTTCAACTCCAGT





TAGTCTAAGCACTGGTCAGTTGCCAAATCTACAAACAGTTACAGTGAAC





TCTATAGATTCTGCTGGTATACAGCTACATCCAGGAGAGAATGCTGACA





GTCCTGCAGATATTAGGATCAAGGAAGAAGAACCTGATCCTGAAGAGTG





GCAGCTCAGTGGTGATTCTACCTTGAATACCAATGACCTAACACACTTA





AGAGTACAGGTGGTAGATGAAGAAGGGGACCAACAACATCAAGAAGGAA





AAAGACTTCGGAGGGTAGCTTGCACCTGTCCCAACTGTAAAGAAGGTGG





TGGAAGAGGTACCAATCTTGGGAAAAAGAAGCAACACATTTGTCATATA





CCAGGATGTGGTAAAGTCTATGGGAAGACCTCACATCTGAGAGCTCATC





TGCGTTGGCATTCTGGAGAACGCCCTTTTGTTTGTAACTGGATGTACTG





TGGTAAAAGATTTACTCGAAGTGATGAATTACAGAGGCACAGAAGAACA





CATACAGGTGAGAAGAAATTTGTTTGTCCAGAATGTTCAAAACGCTTTA





TGAGAAGTGACCACCTTGCCAAACATATTAAAACACACCAGAATAAAAA





AGGTATTCACTCTAGCAGTACAGTGCTGGCATCTGTGGAAGCTGCGCGA





GATGATACTTTGATTACTGCAGGAGGAACAACGCTTATCCTTGCAAATA





TTCAACAAGGTTCTGTTTCAGGGATAGGAACTGTTAATACTTCCGCCAC





CAGCAATCAAGATATCCTTACCAACACTGAAATACCTTTACAGCTTGTC





ACAGTTTCTGGAAATGAGACAATGGAGTAAATATTACACAAATACTTAT





TCATTGTGGTTATTTTTATACAGTAGTGAGAAGAATATTGTTCCTAAGT





TCTTAGATATCTTTTTATTGATGTGCAAAAATTTTTGGATTGACAGTAA





CTTGGTTATACATGACACTGAAATGCCTTACTTTGTATGATATTCCATA





GTATATTAAAAATGGTAAAATTGCATGGGTTTTGTAGGTACTTTTGGAA





TCTAGAAGAAATGAAATTTTACCAAGTTATATAAAGAGAAAATTGAATT





TAACAATGCGAATGGTAGTCTAACCAAATGCATCAATCCTGTGTGGTTT





AGTGTAAAAATGAGAACATGTTGGTATTTATCTATTGTAAGATAAAAAA





GCTGGTGGGTGAAAGAAATCATGTTATGATAAAAAATTTTGTAATTTTC





TTGATGACTGGAATTTTTATTATGCATAACTGACAAATCAAGTTTCCAA





GCAAATGTTACATAGTGTAGGCTTTACTTAGCTTATCAATTTGTCATTT





TGAAGCTAATTATTTTAATTAGGTTAACTATGTACAATATTTTAAGCAT





TACTCTTGTAAGATTTTGAAAACTACATTTTAACATGGAACTCTAGGGA





TAGTCACCTTTTAAATCCTGTTGAAAAGCCATGTTTAAGATTTAATTTG





CCAAAATAATGTCTTGTTAATATTCTTTCAATAACGAAGTTGGGCAATA





TAACCAATGTTTAAAAAAGTTTAAAATGTATAAGTTGAGGCATTTGGGT





GGTAAGAGAATGTTATAGTGAATTATCCCTTTTCTTGACTATTGGAGGA





CCAAAAAAATAAGGTGTATTGCGTCTTAGCAGTGATTTTTATCCAATCT





TGTTTCCAAAAACCATGTCTCCCAGGGCCTTAAAAGCCATCATGTAAAT





TACCAGTAAAGTGTAACATATGCAAACATAACAAAATCACTTCCATAGT





GACGATACTCCAACCATATGGATATTAGTCATAGAAGAACTAGAGGTTT





TATGATATTTTTTTAAGTCTTTTTTTTTTTTGTCTAGGTAGTCAGTCTG





CACTTAAATATCAATCATTTTCCTTTTTTGCTTCTTCCCTTAAAATTTA





TATGTATCCAGTACATTTAATTGAGAAGCGTATGTTTTTTATTATGCTG





TATTTTCTTTTTATTTTTTAATTATTGTTTATATTTTCAATTCAAAAAT





GTACAAAATAAAGTTACATTGCTGGTCTTGTAAGAGCTATACAGTTTTC





CTAAATGTATACCTGTAACTGCAGCAGTTCACCTATTTCAAAAATTTGG





AATTCTGTTCATTTGTTATTCTTAAGACCACCTCAAATTTAAAGGCTAC





CTTATTGTACGTTTAAAGTGTATTATAACAGTGTGGTAGTTAATAAAAC





ACTATTTTTTTTTCTTTTGAGTTTGTTGTATTCCTATGCATAAAAAATA





TTGCAGTGGTATGGGGTAAGAATTGGTGGTTTATTTTTCTTCAACTTGG





CTTTTTATTTTTAGATTCTTGATTTTAGACACTGAATTGTAAACAGGCA





TTTATTTGAAGAAGAGATATATAGAGACACTGGTCATTTACTAATTTTT





TACCTAGAGTAAATAAGAATGAGCTTATTAAATAAAATTTTTGAAAAAA





AGTCTTAGCCCTTAGCCCACATTGATTCATATCAGTTTTATCAGTACCA





TTTTGCAATTTTTTTGTTTTCCGTTTTAAAGCAATGCAGAATATTTTGA





TTTATCGAAAACCTGAATTTACATTAAGACTCCTGAAAATGATAAGACA





AGCGTTGGTAACCATGGCAGGAGTTACTTGAAAAAGTTGCCTTTGAATT





TGCATGTGTTTCATCATTATAAAGGCAGAGTAGGAGGAAAGAGTATTAA





TGTGATTGTGTATTGTAGATGTTTTAAAGTAAAAATCAAGTTTCTTAAC





ACATGTATACAGTGGGGGTAAAGATGTCCATTTTCTGTTTTCCAGGCCC





AGTCTGACTCTGTCTGTAATACCTGATTGCATTGGAGAACTCTAGACAC





GCATAAACATGGACAGTTTTTCTAAATGTGAGACTTAAGCCTGTGATGT





AAAATAGGAAGTTCTACTTGGAATAATATAAAGGAACCACTAGAATTTA





CAATTATTTTGAAGTTACAGGGATTAGATTTTGAATCTTAAAATCCTTT





AGGTAATTTTTAGAATTTTTAAATTAAGATTAATGTGAAGAGAATTAAG





TGAGCAGCAGGTGGTTCACTTGAGCAAACTGCCCATTAAGTCAGATTAA





ACCATTTGAATGATAGTAGAGATGTTTTAAGTAATACTGGATTTTTACA





GTAAGTTTATGGTGTACTTTGAATCGATAGGTGTCCATGCATATTTTAT





GAATTCGTGGAGAATGAATGCAATGAAGAAAGTAAGTAGTCTTGAAAAT





TATTTAAATAAAGTTGTAGATTTTTTTAGTGCCCCCTAGGAATATATTA





GTGAACTTTGGAACTTTTACCAAAGTTATGTAACCTCAGTGTAGATAAT





TTTAAATATTTCTATTTTTATATTTTAAAATGTTGAATATACTCTGGAA





ACAACATTTGAAGATTTGCTCTGATGTCAACTTTTTCTGGTTATAAAAC





CTATTAGTATTGTGTATAATTCTCAGGGTAGGTATACTCTAATAGGTGT





TTTGTCAATTGCTTTATTTTTGTAAAGGCTAGAGTTAGTGCATATTGAA





TATATTTATGTACAAATAATTCCTGTTGTAACATTTAGTGGACGCGATT





ATCTGTATACCTCAAATTTTAATTTAAGAAAGTATCACTTAAAGAGCAT





CTCATTTTCTATAGATTGAGGCTTAATTACTGAAAAGTGACTCAACCAA





AAAGCACATAACCTTTTAAAGGAGCTACACCTACCGCAGAAAGTCAGAT





GCCCTGTAAATAACTTTGGTCTTTCAAAATAGTGGCAATGCTTAAGATA





CTTAAAAATACACATACATATAAGCTGAAAGCATGTCAAGCCTATTTCA





TAGAAAATAGTTCTTAAACAGTATTGTTCATTAGAAATTGCTGGGGAGC





ATTTTAGAGATTCCATAGGCCTGGTAGCCACCTCAGCTTACTAAATCAA





CATCTCTGGAGATGGAGTGTATATGTGTTTTGAAACAGCTGCTCAAGTG





GTTCTGTTAAACACTCCTGCGTTACAATCACTTAAAATAGAGCAAGCAT





CCCCTTAGGCTCTTAATTGTAGTTTAAATTCCAGTACTGCCTACTCAGA





CCCAAAAGTTTTGTTTTATGAAAAATTTGTATTGTGTTCAATATTGTTT





GAAATTTGGGGTTGTTGCATAAATGATTATGGAATAACATTTGGTTTTA





AAATAATATAAACTGACATGTTATGCTACCTGTTACACAATTTGGTTTT





CAGTTTTAATTATATGAAGCTGGTAACAATCGTTTTTGTTGTAAAAGAA





TTATTTTTCACTAAACAGTATGTTTAAAACTGACTGCCATGAATGAGTA





CTAAGTCTTTTGTTGTCTGACAATAAGCACAAAACAAATTAATTGATAT





CTTTGGTACAAATTTGATATTTTTGTGAAATCACCTCATAATTTTATTT





AGTGTTGAAGAAACAACATTGGCCCCTTGCCTTGTTCAGACAGATTTGC





GTATAATGTAAATATATATATTAGTGGCAGAAACAAAGTACTGTAGAAA





CCTAGAAGAGGGAGAATTCTGCATGAAGTCTGGGAAACTCAGCAGAAAT





GGCGTTTGCAAAGGTACAGTGTGGTATGTTGGGTGATGGGGGACTTTGT





GAGGGACAGAGTGGAAAAATTTTTAAGAGGGGCTGCCAAATTGCAAAAG





AGAAGAATTTTTTTTGTCAGTGATTCCTAGTCTTTTTGGAATCCTACAC





CTTCTCCCCAGAAAAATTCATTCTAGTCCAGGGTTTATTGTTTGTTTTT





TCCCTATATTTGACAGGGTCTGTCTCTGTCACACAGTGCAGTGGTGCAA





TCATGGCTTACTGCAGACTCCACTTACTGGTCTCAAGCAATCCTCCCCA





CTTCGGCCTCTTAAGTAGCTTGGACCACAGGTGCACACCACCATGCTCA





GTTAATTTTAATTTGTTTTGTAGAGATGGGGTCTCACTATATTGCCTAG





GCTGGTCTTGAATTCCTGGGCTCAAGTGATCCTTCCACCTCTGCCTCCC





AAAGTGTTGGGATTATAGGCGTGAGCCACCACGCTTGGCCAAATCTGGA





GTCTAAAGGGTATACAAGGTTTTTTTTTTTCCCATGTTGGCTTTTATTT





GATGTTATAAAGTCTTCATGATATGAATATATTTTTTAAAAAGGTGTCA





TGTATATTGTCATGTAACATGATTCATGCCACTTCATTGTATTAAATAC





GTTTAAGATACAGTTTTTGATGTTAAGAATGATATCCTGAGAAGGCCTA





TCTCCTTCAGTCCTTTTCCCCATTTTTCACCTTTTAACTCTTGCTTCTG





AATCTATGCTAAGCTACTTACTAGATGTGTGATATTGGTAGTTTTCTTA





CCTTAAAACCTCATTTTCATCATCCATGAAGAGGCTAACAATAGTACTC





CCTGTTGATAGGATTGTTGTATTAAAATATAAGCATTCAGCATAGTGCC





TGACTTAACGGTAGAGATTCAAATGGTAACCTCCTTCCAATGCCTTCCT





CCCCCCTTAACTCTGGAGATTCCATTTTTCTGTAGTGAAGTGTTTTAGA





ATTTTCATTGTTTGACTATGGTTCATACATTGATTTTTCCAAAATGAGA





AGAAGTCTTATTTCTAATGCAAAAATGTGAAAAGAACAGTTGGAACCTA





AAGTGATAGTGGATGAAGTGTCTGAAGTGACTGCCCTATCAGAAAAGGA





TGGAATAAGAAGAAAAGACTGAAGCACCTAAATGTGTATTTTCTTGAGG





AAATTACACCCCTGTGTAAGAGTCTATCCTATTTGAACATTTCTAAAAA





CCAGCCGAAGAATCTTCAGGTTCATTGCGACTGAAAGATAAAGTCTAGC





ACTGAAGTGGTTTTTAAGATTAGGAAAGGCCATCAGAGAAATGCAGTTA





TTTCTCCCCTCCATCCTTCCCCCACAAAAAAAAGTCTAAGCCTCCGATT





AATCGACAACAACGAAATACAGGAAGTATTGGCTTAGTGACCTTTTAGG





ATATCTGTCCGACTTACATCCCTTCTCTGAGCATTACTTTCTGCCACCT





TCCGTGAGGAGCTGTTCAGAAATCAGACAAGGAGTGGACATCTGGTCAA





AGTTGAGCCAATTAGATGATTTCTCCTGAGAATTTGGAATTGGAAAACT





GATGTCTTGGGAGGTCACATCTGGAACATACATGGGAGGCAGAGAAAGC





AAAGATGACATTCAACCCCAGAAGAAAAAGAAAATGGCTTTCTTGATTC





CTGATAACTTGGCAGTGTTTGTTCCAGTGTCTTGCATTTCACTATCTGC





ATTTCATCCTCCTGGGGTTCCACAAGATAGCCTTAAAACCTTACAGAGA





GACTCCCCAACTTAGTTTTTTCTTAAGTCAGAAGGCTGTTACTTGCTAC





CAAATAATGCCAACTAAGACAACTGAGGTACAGTATATTCTCTCGTAAA





ACACCATAGAGTTGATGACTTGATCCTATAGAAAAGGGTCCCCAACCCC





TGGGCCACAGACCGGTACTGGTCCCTGGTCTGTGAGGAACCACCTGGGC





CACAGACTGGTCCTGGTCCCTGGTCTGTGAGGAACCAGGCCATACAGCA





GGAGGTAAGCGAGCATTCCTGCCTGAGCTCTGCCTCCTGTCAGATGAGC





CACAACATTAGATTCTCATAGGAGTGCGAACCCCGTTGTGAACCCCGCA





TGCGAGGGATCTAGGTAGTGCCCTCCTTAAGAGAATCTAATGTCTGATG





ATCTGAGGTAGAGCAGTTTCATCCTACAACCATCCCCACCCCCCGACCC





CCATCCATGAAAAAATTGTCTTCCTCAAAACTAGTCCCTGGTGCCAAAA





AGTTTGGGGACCGCCGTCCTAGGAAATACCAACAAAAAGTCACGTTTAT





TGCCTGCCAAGTGAGTCAGGTTTAGACAAGGCAGAACTTAGTATATAGC





TTGGATGAATCAGAAAGGGTGGGCCTTGAAAGACTGGTAGAATGTGTCC





AAGAAAACTGATTAAAAGCCTTAGAAGTCCCTCTACAGTTTCAGGACGC





CCTCTTAACAGATGGCTGTATCTTTATCTGTGGTTGGTCTTGTGGAATA





CTGACTTTCTGCCAGCATTAGCCTGTGTTTCTATGTCACACCAAGTCAC





GTATATTTTCATTGTGTGTTAGGACTCAGAATAGGTTTGGGTCTTTCTT





TTAATTATGTATACCCAATTACTTAGTCCTCCTCACACCCTGATCCTTT





AAAAATTCTTAAGTTGTGTTAATTGCATTTTTCTCAATTCTACTCCTAG





TAACTCTGTGTGTTTTTTTCCATCTTTATTCATTTAGTAAAGTTGAAAC





CTTTCATAGCATAATATAGTGATTAAGTGCATAGGTTTGGGACTTAGAC





ACACATGGGCTTGCTTGTCTCCCAGTTCTGCCGCTTACCACCTATGTGA





CCTTTCACTCTTTACCTTTCCACTCTTAGCCTGTTCTCTAACTATAAAA





TGAGAATGATGCTAGCGTCATCTTCATAGAGTGATTATGGAGATAAATA





AGTTAATGCATGTAAACCACTTTCCATAATGCCTGGCACATATTATATT





ATGTATTAGTAAATGTAAGCACTGGAAGAATCAGTAGTCTTCCTACACT





TGAAAATAGTTGTCTTCAACTATTGTTGTATTAATGAGTTAATTCACCT





TGTTAAGTCACCTTGATCCACCTAATTGTCAGCCAACATTTATTAACGA





AACTGCTAGTATTCGTATTGTGCCTTTTTTATTATGAAACATTTCAAGA





ATACAGAAAAATGCAGAAAACAATGTAACAAATACCTAAGTATCTATCA





CCCAACTTTTATAGTCTTATTTTTACCTATATATTTTTTCTTTTAGAAA





GGAATGATCACAGTTGTGCCTGAAATCTGTATAGCCCTGTCTCATTTCA





TTTGTCTCCCTTTACCCACATAAGTAATTGCAGCTCTGAATTTGATGTT





TATCAGAATGATACCATGAGTGGTTTTATATCCTTATTATATGTATGCA





TACCTAGGATTGTTTTTCTGATTTTGAAACTTCATATAAATGGTATCAT





TCTGTACAAAACCTTCTGGGACTTGTTTTACCACTCATGTTTTTGAGAT





GTATCCACACTACCATCTTTCTCTAAATCATTCATTTAAATGCTGTAGT





TCATTGAATAAGTTTATCACAATGTATCCATTTTCTTCTTGATGAGCAT





CTCAGTTATTTCCAATTTTTGACTTATAAACAATGCTGCAATGAAATAA





TTGACATATTTCCTTGTGTACATGTGAGCATTTCTTGAGATATGTATCT





AGAACTTGAATCACTGGCCAACAGGATATTCTTAATCTTCAGTTTCACC





AGATACTTCCAAATTGATCTCCATAACATGCATACCAAATTATATTCCT





ACCAGCCATTTATAGGAGTTCACATTTTTTCCATACCCTCCCAATCCTG





CCTTGGCAGATATGTTTTTTCCAATGAATAACAATGAAATTTTGTTTTG





GGATTTGACAAAATGATTCTAGATTCATCTGGAAGAAAAGCAAGTATAA





GTAAGAAATTTAAAAGGGACCTGAAAAACTAAGCAATGGATATATTTAA





AAATTGGTACCAGTAGGGATAACCAAATATTTGTTAACTGTAGCAGAAA





CAATGCATGTTTTTCTCACTGGTTCCACCTTCTATCTCTCAGTCAAGCC





CTGCCCAGGTGTGGTAGTCCTCATAGTCTCTCACTGTAGGGGTCTTCTC





ACATAGTAGACCACTCTCTTGAGTTGAATATTGAAAAGAAGGCTTGGCC





GGGGGCAGTGGCTCATGCCTGTGGTCCCAGCACTTTGGGAAGCTGAGTC





GAGCGGATTGCTTGAGGTCAGCAGTTCGAGAGCAGCCTGACTAACATGG





TGATGAAAAGTACAAAATTAGCTGGGGGTGGTGGCGCATGCCTGCAATC





CCAGCTACTCGGGAGGCTGAGGCACGAGAATCGCTTGAACGCAGGAGGC





ATAGGTTGCAGTGAGCCGAGATTGCACCACTGCACTCCAGCCTGGGCGA





CAGAGCAAGATTTCGTCTCAAAAAAAAAAAAAAAAAAAAAAAAGGCTTA





AGTCCAACTAACTGTTTCCCTGCTGTTCATTTTATCCAACGGCTGGGGA





TATAGGCTACTGCACATGATGGGTTGATGGATGTGAAATGATAACTCAT





GACTTTAATTCTAATTTTTCTATATTCTGGTGAGGTTGAGCATATTTTT





ACAAGTTCATAATCCATTTTCCTCTGATGGGAGTTGCCTGTTTGAATCC





TTTGCCCACTTGCTTTTTGGGGTTATTTGCAATTTTTTGCATTGATCTT





CAAACATTCTTAATTAATCCCAGGTACATATTATTTTATATATAAGATA





TATTTTAGAGATATATAGGCTGATAGTATCTTTTCTCAGTCTAAGGCTT





ATCTTTTAATTTTGTTTATGGTGTTTTGTGTGTGTTGTTTTGCAGAAGT





TTTATTGTATCTGAATTGTGGCTTTTGTGTCTTAAGAAATTCTTTACCT





ACTGTCATAAAAATTTTTGTCTAAAAATTTTATGATTTTGCCTTTCTAT





TTATCTTGTTAATTCACTTTGAAATTACTTTTGTTTATGGCATAAAGTC





CATTATTTTCCATATGGATAATCAGTTGTCTTAGCAGTTTATTGAATGG





TCCAACGTTTCCCTGCTGATTATAATGCCCTCTCTGTTATTTATCCTAA





ATTCTTGACATCCGGTAAGGAAGTCTCCTCTGCCCACCCTTCTCTGTAT





TTCAAAATGGTTTTGACTGTTCTTGACCCCTTGCTCTTTCTGTGAACTT





TAGGATTAAATGATTATGTAGAATTAAACAATCGGGTTAAGGTTTTTTA





TTAGAATTACATTGAATCTATAGATTAATTTGGGGAAAGAATGTTATCT





TTCTATCCATGATAATTCTGTATCTCTCCATTAATTCAAGTCTTTAATG





GTTTTTAAAAATAAATTATTGTCTCTTTGAAAA.,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:274 under stringent hybridization conditions


In some embodiments, SIX homeobox 1 (SIX1, BOS3, TIP39, DFNA23)) comprises the amino acid sequence:









(SEQ ID NO: 275; NP_005973.1)


MSMLPSFGFTQEQVACVCEVLQQGGNLERLGRFLWSLPACDHLHKNESV





LKAKAVVAFHRGNFRELYKILESHQFSPHNHPKLQQLWLKAHYVEAEKL





RGRPLGAVGKYRVRRKFPLPRTIWDGEETSYCFKEKSRGVLREVVYAHN





PYPSPREKRELAEATGLTTTQVSNWFKNRRQRDRAAEAKERENTENNNS





SSNKQNQLSPLEGGKPLMSSSEEEFSPPQSPDQNSVLLLQGNMGHARSS





NYSLPGLTASQPSHGLQTHQHQLQDSLLGPLTSSLVDLGS.,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:275)


In some embodiments, the nucleic acid sequence encoding SIX1 comprises the nucleic acid sequence:









(SEQ ID NO: 276; NM_005982.4)


AAGTTCCCCGGCAACTAGCAGCATCCACCGGGCGGGAGGTCGGAGGCAG





CAAGGCCTTAAAGGCTACTGAGTGCGCCGGCCGTTCCGTGTCCAGAACC





TCCCCTACTCCTCCGCCTTCTCTTCCTTGGCCGCCCACCGCCAAGTTCC





GACTCCGGTTTTCGCCTTTGCAAAGCCTAAGGAGGAGGTTAGGAACAGC





CGCGCCCCCCTCCCTGCGGCCGCCGCCCCCTGCCTCTCGGCTCTGCTCC





CTGCCGCGTGCGCCTGGGCCGTGCGCCCCGGCAGGCCCCAGCCATGTCG





ATGCTGCCGTCGTTTGGCTTTACGCAGGAGCAAGTGGCGTGCGTGTGCG





AGGTTCTGCAGCAAGGCGGAAACCTGGAGCGCCTGGGCAGGTTCCTGTG





GTCACTGCCCGCCTGCGACCACCTGCACAAGAACGAGAGCGTACTCAAG





GCCAAGGCGGTGGTCGCCTTCCACCGCGGCAACTTCCGTGAGCTCTACA





AGATCCTGGAGAGCCACCAGTTCTCGCCTCACAACCACCCCAAACTGCA





GCAACTGTGGCTGAAGGCGCATTACGTGGAGGCCGAGAAGCTGCGCGGC





CGACCCCTGGGCGCCGTGGGCAAATATCGGGTGCGCCGAAAATTTCCAC





TGCCGCGCACCATCTGGGACGGCGAGGAGACCAGCTACTGCTTCAAGGA





GAAGTCGAGGGGTGTCCTGCGGGAGTGGTACGCGCACAATCCCTACCCA





TCGCCGCGTGAGAAGCGGGAGCTGGCCGAGGCCACCGGCCTCACCACCA





CCCAGGTCAGCAACTGGTTTAAGAACCGGAGGCAAAGAGACCGGGCCGC





GGAGGCCAAGGAAAGGGAGAACACCGAAAACAATAACTCCTCCTCCAAC





AAGCAGAACCAACTCTCTCCTCTGGAAGGGGGCAAGCCGCTCATGTCCA





GCTCAGAAGAGGAATTCTCACCTCCCCAAAGTCCAGACCAGAACTCGGT





CCTTCTGCTGCAGGGCAATATGGGCCACGCCAGGAGCTCAAACTATTCT





CTCCCGGGCTTAACAGCCTCGCAGCCCAGTCACGGCCTGCAGACCCACC





AGCATCAGCTCCAAGACTCTCTGCTCGGCCCCCTCACCTCCAGTCTGGT





GGACTTGGGGTCCTAAGTGGGGAGGGACTGGGGCCTCGAAGGGATTCCT





GGAGCAGCAACCACTGCAGCGACTAGGGACACTTGTAAATAGAAATCAG





GAACATTTTTGCAGCTTGTTTCTGGAGTTGTTTGCGCATAAAGGAATGG





TGGACTTTCACAAATATCTTTTTAAAAATCAAAACCAACAGCGATCTCA





AGCTTAATCTCCTCTTCTCTCCAACTCTTTCCACTTTTGCATTTTCCTT





CCCAATGCAGAGATCAGGGAAAAAAAAAAAAAAAAACCCAAACAAACAA





AAGCACCCAGGCACCCAGTCTGAGTTCTGGGCAACTGATACGCCTGTTT





CAGCAGCCTTTCTTTTTTTTCAATGAATGGGAATTGCAAATCAACTGGA





TTTTCATTATTTCCTTTTAATTTATATATGGAGAAATGTGAAGAGGGAA





AGGAAATGGAAAGAGAAAGAGAAAGGGAGATAAAAATAGTGAAAATAAG





AGCCTCCAGGCTCAGAAGAACTGATTACATTCTTAAGGTGAACAGGAAA





AATACAATCTATAACTTTCTTTGATGAGGAAAAATTAAGTTTACATTTT





TCATATTTAGTGTTAAACAATTTAATGTAGATTAAAATAAAAGACCAGT





ATTAGGAGGAAAAAACAAGTGCCTAAATGTCTTAATGCTCTCTATGTGA





GACAGAAATAGACGTGACCATTAGTAATGCAACTATTTTTGTCAAATTT





AGTGGGATTTTTTGGTTGTTGTTTGTTTTCTTGGGTTTTTTTTTTTTAA





ATGACAAACTCTAAAAATGTACCAATGTGAAAAAACACTTTCCTGAATG





CCATTACTCATGCCCTCAAAGCTTTCATATCTGTAGCCTACTCCTGTAA





AGGGTTTCTCCTGTTTCTAGTTTCTAGTTTGCAAAGGTATGCCAACGAA





TCTGGCAACCTGGTATTTGTTACTAAAACAGCATGTGTTTTCAGGTTTC





TTTTCTATTGTACCTAAAGCAGTCTAAATTAAAACTTAGTAGAACACCA





GGAGTATGATTCTGTTTCTGAAAGGTGAGTGGTGTATTGCTGTCATTGG





GCCCTATTTTTTTTTTTAAATATATTTTTCTTTCTTACTTAATGGTGGC





TGTGAATTGCAGGGTACTTTGAAGGCCATCATCTGAACCAAGAGTAGTA





ACTAGATTAATTATATGACAGAAAGAGTGAATTTAGCCTTGGGGTATTT





ATTAACTTCTATTATTTAGATATGCAATTTTGTTTACCACTATCTCTTC





ACAGCATTCATATGTTAACTAAGCTCTTTTGTGTTAACAAGTTTATGAC





AAGACTGTGAAAGTAAAAATAATTTATCTGCTTGAAGACAAAAAAGGGA





AGGAGAACAAGGATAGAAACATTGTGAATTAATTTGTACAAATAGAAAG





CAGACCAGCAGGACAGGAGCTCTTTTGCAGTGCTGCCGGATGGTGTCTA





GAAAAATCCCAGTAATCATGTAGGCTCCATATTATTTTTGCCTGGGGCA





AAATGATGTATCTTCTGTATTTAGCTTTTAAAATTAGTGAAACAAATGG





CATTATTTATTAAAATTCTACTCAGGATAACAGGATTGGCTTGCTTGTG





CTTTGTAAAATATTGTTCCCCAGGGAGAATCTATTTATTTTCTGACATG





ACAGTTTCATAATTTTGATTTTTTCCCATCTATAATTGTCACCATTAAT





ATATTATTTCTTTCTTACTCTTTCCTATTTCTGTTCTGGTCTAGAAAAC





TGAGGTGTGCTTGGGGAAATCAAGGCCTTATTTTTTAAAACTGTCAAAT





AGCTTTGAGTTCCAGGGAGAAATGGTCACTGTACTTAACTGTACACACT





TTTACTTATAAAGTCGTTTTTCCCCCTCAGTGATGGACAGATGTGCACA





CAGCCACTCAGAGACCATCATTTGGTTTGGGAGCTCAGGGTCCCAATCT





CCCTTGTTAGTGTTTTGGATCATTAAGTCGGTGTTTATTTAAGTCACTA





GGGTGTTTATTCTCCCTGTCTTGGGCCACGGAGAAATGCCACCCTCTGC





AGGAGGGGCTCTCACAGGGAATCTCCTCACATTCTTCACATTCACTCCC





CAAAACAAACACCCTGCACAAAGATAGCTTTCAATGACCCTGACAGGCT





TCAAAGGACGCTGCGGAAATCTCTCTGGAAAATAGGAAGGGCCAATTAC





TTTAATTTCTTACATGCCGTCTCTTCCTACTCCGGTGACTACCCTCCAC





TCTCCCAGCTCCGCCTGGGATAATTTTAGGCTCGTGGAAGTTGTGTCTC





GCAGGGCGCCCCGGCCCACTTCCTGCTCCCTTAGTTGGTGAATCTTGGA





AATGTCTGCAGATCCGGCGAGGAGCAAGAGCGCTGGTCCTGTAAAAGCC





CCCGTGATTACTGCTTGTAAACTTGTTAAAAGGACAATTTTCTGTCACA





GTCATAAACTCTTTGTAAAACCCCTGGCACTAAATCCAGAGCGCGCATA





TTCCAGATGTGTTTAATAAGAAATTGCACAATGTGCCTCCTTCCGCCAT





CCTCGGCTCAGTCTGGGTAAAAGGGGCGAGCAGGAGGAGGCGAGAAAGC





TGGATATTGCTTTGAGTTTTTTTGGCAATCATTTCAGAGAGATCATTAG





GGGAAACTAACCATATTTTTTTCTTCCCTCGAGGAAATCTTCGAGAACC





AGCTGTTAAGGGACCTCCAGTTTACCTTCTGGGCGTCGCAGTTTAACTG





AATCTAAAGCCACTTTTCGTTTCTCCTCTACAGATGTCATAACGGTAGC





CAAAAGTAATGAACAACGGCTTATAAATAGTTTGTAGGACGAAACCATA





CAGCATTGTGCCAAGTGAAATGAAAAAAAAAAAAAA.,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:276 under stringent hybridization conditions


In some embodiments, SIX homeobox 2 (SIX2) comprises the amino acid sequence:









(SEQ ID NO: 277; NP_058628.3)


MSMLPTFGFTQEQVACVCEVLQQGGNIERLGRFLWSLPACEHLHKNESV





LKAKAVVAFHRGNFRELYKILESHQFSPHNHAKLQQLWLKAHYIEAEKL





RGRPLGAVGKYRVRRKFPLPRSIWDGEETSYCFKEKSRSVLREVVYAHN





PYPSPREKRELAEATGLTTTQVSNWFKNRRQRDRAAEAKERENNENSNS





NSHNPLNGSGKSVLGSSEDEKTPSGTPDHSSSSPALLLSPPPPGLPSLH





SLGHPPGPSAVPVPVPGGGGADPLQHHHGLQDSILNPMSANLVDLGS.,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:277)


In some embodiments, the nucleic acid sequence encoding SIX2 comprises the nucleic acid sequence:









(SEQ ID NO: 278; NM_016932.5)


AAGAAAGCTGAGAGCCAGCTAGACGGGAGGGAGAACGAGTGAGAAGCGA





GCGAGGGAACGGCGGGCGGGCGCGGAGCATGCGGAGCGGCGCCCCGGGC





GGCCCCCGGGCTTGGGCGAGGGCTTGGGCCAGGCGCGCGGGCCGTTGGG





GTTCGGAGCTTCGTGGGACCCGCGGCCGGCGCGGGGACGTACGGCAGTG





ACTCGGGGCTCACCGGGGGCCAGTGCCGGGCCAGGGGGCCAGCCCCGCC





CGCGTCTCGGCCCGGACGGCCCGGCGAGGAAGCTCCCATGCGGGACCGC





GCGGCCCGGTGAGGGCGCGCGCGGGCGGGCGGGGACGCAGCCGGCACCA





TGTCCATGCTGCCCACCTTCGGCTTCACGCAGGAGCAAGTGGCGTGCGT





GTGCGAGGTGCTGCAGCAGGGCGGCAACATCGAGCGGCTGGGCCGCTTC





CTGTGGTCGCTGCCCGCCTGCGAGCACCTTCACAAGAATGAAAGCGTGC





TCAAGGCCAAGGCCGTGGTGGCCTTCCACCGCGGCAACTTCCGCGAGCT





CTACAAGATCCTGGAGAGCCACCAGTTCTCGCCGCACAACCACGCCAAG





CTGCAGCAGCTGTGGCTCAAGGCACACTACATCGAGGCGGAGAAGCTGC





GCGGCCGACCCCTGGGCGCCGTGGGCAAATACCGCGTGCGCCGCAAATT





CCCGCTGCCGCGCTCCATCTGGGACGGCGAGGAGACCAGCTACTGCTTC





AAGGAAAAGAGTCGCAGCGTGCTGCGCGAGTGGTACGCGCACAACCCCT





ACCCTTCACCCCGCGAGAAGCGTGAGCTGGCGGAGGCCACGGGCCTCAC





CACCACACAGGTCAGCAACTGGTTCAAGAACCGGCGGCAGCGCGACCGG





GCGGCCGAGGCCAAGGAAAGGGAGAACAACGAGAACTCCAATTCTAACA





GCCACAACCCGCTGAATGGCAGCGGCAAGTCGGTGTTAGGCAGCTCGGA





GGATGAGAAGACTCCATCGGGGACGCCAGACCACTCATCATCCAGCCCC





GCACTGCTCCTCAGCCCGCCGCCCCCTGGGCTGCCGTCCCTGCACAGCC





TGGGCCACCCTCCGGGCCCCAGCGCAGTGCCAGTGCCGGTGCCAGGCGG





AGGTGGAGCGGACCCACTGCAACACCACCATGGCCTGCAGGACTCCATC





CTCAACCCCATGTCAGCCAACCTCGTGGACCTGGGCTCCTAGAACCCAT





TTGCCTTGATGAGCTTGCCTTTTGTGACTTGACACTGGGGACGTGGAGT





GGCGGTGTCCAGGGGCGCCCCGCCCCTGCGGCCCCACCAGGTACTGAAA





GACCCGCAGGCTGAGCGGGTAGAACAGCCGGGTAGGGCAGATAGCTGTC





TATGTTGGTTCTTGTTTGGGATTTATTTTCAACAAGTTACTTTTAGGAT





CCTTTTGGGGCTGGAGACTGAGTCTTGAACCACAGAAGGGAATAAATTA





TACACCACTGTCATTCTCTCTCTCCCTCTGTCTCTTCCTTTTACCCTCT





CTTGTCTTGCCTTTTCCCCCTTTCCTCTTCCTTTCCCTTCCTTCTCTTT





TCTTTTTTCTGCTTTCTGTCTTTCTCCCTCTCCTTGTATTGCTTTCCTT





CTAGATTTCTAGCTTGCCACCGTTCATTCTCTCCTTCTGTCTCTCCCTT





TCTCTCTCCTTCTCTGTTTCTCCTCTCTTCTCTCCTGCCAGTCTCTTGT





ACTCTGTGTCCTGGTCCCTCCGTATGTACCCCTGTCTTTCTCCTCCTGA





CTGGTGGTCTATCTGCCCCTACCTCTGGCCCTCGCTTTACCGGAGTAGG





GGGTGGGAGAGGGAAGAGGAGAGAAAATACAGGGACTTTGAACCTAGGC





CATCTCCTGAGGCCTTTTCCCTCGCCCATGTGGGTCAGTGGGAGCTGCA





GGTGTCAGCTTTTCGTCTAGTAACTTAAGTGAGAGAGAAAGGGCAGCGC





CACAGAAGCCCCTAAACGCCGCCTCGTCATACGCCCCTCCTCCTTCTCT





CTTGGCGAGGCCCCGCCACACCGCGCTCTTCCTCCCGGGACTGTGACTA





CAGCGCTCCCGGCTGAGCGCGCCCCCCGAGCCGCCGACTTGCCGTCTCC





CCGTAATGCCCTCATGTGAATGTTCTTCGGGAAATATTTCTGCTTTTAT





TTTATAATAAAATTAGAAATCATAAATATATAAATGGTTATATGCCACA





A.,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:278 under stringent hybridization conditions


In some embodiments, EYA transcriptional coactivator and phosphatase 1 (EYA1, BOP, BOR, BOS1, OFC1) comprises the amino acid sequence:









(SEQ ID NO: 279; NP_000494.2)


MEMQDLTSPHSRLSGSSESPSGPKLGNSHINSNSMTPNGTEVKTEPMSS





SETASTTADGSLNNFSGSAIGSSSFSPRPTHQFSPPQIYPSNRPYPHIL





PTPSSQTMAAYGQTQFTTGMQQATAYATYPQPGQPYGISSYGALWAGIK





TEGGLSQSQSPGQTGFLSYGTSFSTPQPGQAPYSYQMQGSSFTTSSGIY





TGNNSLTNSSGFNSSQQDYPSYPSFGQGQYAQYYNSSPYPAHYMTSSNT





SPTTPSTNATYQLQEPPSGITSQAVTDPTAEYSTIHSPSTPIKDSDSDR





LRRGSDGKSRGRGRRNNNPSPPPDSDLERVFIWDLDETIIVFHSLLTGS





YANRYGRDPPTSVSLGLRMEEMIFNLADTHLFFNDLEECDQVHIDDVSS





DDNGQDLSTYNFGTDGFPAAATSANLCLATGVRGGVDWMRKLAFRYRRV





KEIYNTYKNNVGGLLGPAKREAWLQLRAEIEALTDSWLTLALKALSLIH





SRTNCVNILVTTTQLIPALAKVLLYGLGIVFPIENIYSATKIGKESCFE





RIIQRFGRKVVYVVIGDGVEEEQGAKKHAMPFWRISSHSDLMALHHALE





LEYL.,







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:279)


In some embodiments, the nucleic acid sequence encoding EYA1 comprises the nucleic acid sequence:









(SEQ ID NO: 280; NM_000503.6)


CTCAGATGCTATCTGCCGCTGCTGTTTGGTGGGGAAGGAGCGCTGGGCG





CAAAGCTGTTACCAAACAGAACGGTGGGAGCTGATGGCTCCGAGTTTGG





GGCGAGGTAGAAACTCTCCAGTGCCACTTCCGACTTTAAGCCTTCCTGT





TGCCGTCCACTGTGGCGGGTTTCTTCCTGGGGAACACGTTTTCGCTCAG





TCGCTCGGCAGCCCGAGCCTGCGGCAGCGGCCAGGCGCCTGCCCCCTGC





GCCGAGCTTTCCCCTGCAGAGGCGCTCCACTCCCAGAAGCGCCGCGGCT





GCACCAGAGCGCCTGAGAGCCCCCGCGCGTACCCATCCAGGAGCAAAAC





TATGTCAGGAATGGAGGTTTGCTAACCCAGAAAATTCGAAGGAACACAT





TAAACTGGTGGATGCAGCAGATGTAAGCGCTGTGCAAACATCTCAAGCC





AGTTCAGATGTTGCTGTTTCCTCAAGTTGCAGGTCTATGGAAATGCAGG





ATCTAACCAGCCCGCATAGCCGTCTGAGTGGTAGTAGTGAATCCCCCAG





TGGCCCCAAACTCGGTAACTCTCATATAAATAGTAATTCCATGACTCCC





AATGGCACCGAAGTTAAAACAGAGCCAATGAGCAGCAGTGAAACAGCTT





CAACGACAGCCGACGGGTCTTTAAACAATTTCTCAGGTTCAGCAATTGG





GAGCAGTAGTTTCAGCCCACGACCAACTCACCAGTTCTCTCCACCACAG





ATTTACCCTTCCAACAGACCATACCCACATATTCTCCCTACCCCTTCCT





CACAAACTATGGCTGCATATGGGCAAACACAGTTTACCACAGGAATGCA





ACAAGCTACAGCCTATGCCACGTACCCACAGCCAGGACAGCCGTACGGC





ATTTCCTCATATGGTGCATTGTGGGCAGGCATCAAGACTGAAGGTGGAT





TGTCACAGTCTCAGTCACCTGGACAGACAGGATTTCTCAGCTATGGCAC





AAGCTTCAGTACCCCTCAACCTGGACAGGCACCATACAGCTACCAGATG





CAAGGTAGCAGTTTTACAACATCATCAGGAATATATACAGGAAATAATT





CACTCACAAATTCCTCTGGATTTAATAGTTCACAGCAGGACTATCCGTC





TTATCCCAGTTTTGGCCAGGGTCAGTACGCACAGTATTATAACAGCTCA





CCGTATCCAGCACATTATATGACCAGCAGCAACACCAGCCCAACGACAC





CATCCACCAATGCCACTTACCAGCTTCAAGAACCGCCATCTGGCATCAC





CAGCCAAGCAGTTACAGATCCCACAGCAGAGTACAGCACAATCCACAGC





CCATCAACACCCATTAAAGATTCAGATTCTGATCGATTGCGTCGAGGTT





CAGATGGGAAATCACGTGGACGGGGCCGAAGAAACAATAATCCTTCACC





TCCCCCAGATTCTGATCTTGAGAGAGTGTTCATCTGGGACTTGGATGAG





ACAATCATTGTTTTCCACTCCTTGCTTACTGGGTCCTACGCCAACAGAT





ATGGGAGGGATCCACCCACTTCAGTTTCCCTTGGACTGCGAATGGAAGA





AATGATTTTCAACTTGGCAGACACACATTTATTTTTTAATGACTTAGAA





GAATGTGACCAAGTCCATATAGATGATGTTTCTTCAGATGATAACGGAC





AGGACCTAAGCACATATAACTTTGGAACAGATGGCTTTCCTGCTGCAGC





AACCAGTGCTAACTTATGTTTGGCAACTGGTGTACGGGGCGGTGTGGAC





TGGATGAGAAAGTTGGCCTTCCGCTACAGACGGGTAAAAGAGATCTACA





ACACCTACAAAAATAATGTTGGAGGTCTGCTTGGTCCAGCTAAGAGGGA





AGCCTGGCTGCAGTTGAGGGCCGAAATTGAAGCCCTGACCGACTCCTGG





TTGACACTGGCCCTGAAAGCACTCTCGCTCATTCACTCCCGGACAAACT





GTGTGAATATTTTAGTAACAACTACTCAGCTCATCCCAGCATTGGCGAA





AGTCCTGCTGTATGGGTTAGGAATTGTATTTCCAATAGAAAATATTTAC





AGTGCAACTAAAATAGGAAAAGAAAGCTGTTTTGAGAGAATAATTCAAA





GGTTTGGAAGAAAAGTGGTGTATGTTGTTATAGGAGATGGTGTAGAAGA





AGAACAAGGAGCAAAAAAGCACGCGATGCCCTTCTGGAGGATCTCCAGC





CACTCGGACCTCATGGCCCTGCACCATGCCTTGGAACTGGAGTACCTGT





AACAGCGCTCGGCACTTTGACAGCGCACAGCTGCTCTGTGACCAGGGAC





AGATCCAGCAGGCCCCAGTCTCGCATCAGCGCCGGCCTCCAGAACTTAG





CAATTTCCGCCTGGTGATGCGCAGTTGCTGTCAGTCTTGACCTCTGCCT





TTGTGGTGAATGGAGGACCACGTCTATTTCATCAGAACAGCTGTTGACT





CTAGTACTGTGAATCCAGTGAAAATAAGCCATGAGAATGTTTTAGCACA





GCGTTATGTGTCTGCCACATTAACTACACGGTTCAAACCTGTGAAGAAA





GGACCTGCAAACGCTTCAGTTGTTAGCATTTTCAATGTGATATAAACAG





CTTCTCCAATACAGCAAACCTAATTGCACAACAGAGACTGAAATGTGTT





TCCTGAATACCAGTGGAGGAATTTTCTTGTAAAGAAGGTTTACTTTTTG





GTGTCTCATACCCAGGGTAATCTGTACATCTCTACTTATTTATGAACAG





ACTTTTTTTAAAAAGATAAAAAAACAGCTTTATTGAGGTATAATTCACC





CACCAGACTTTTTTAAACATCAAATAATTGAAGAGACAATAGCATTAGA





AATAAGTGATTAAAGGCCTCTGCCTCACAACATGGCAAGTACAGTACTT





TGAATTTTAGCACATTGCATAGTAGTTTTAAGTATGTCTAATTTAAACG





TATAATATGTACATCACTGAGACAATCATGTACAGAAAGAATTTTTGGT





GTAAATTTGTAATAATGGATAATTCTTTTACATATTGTTTAGGGAAATG





ATATTGAAAGGTAGCAATGCCTGGATAGTGAAGCATGAGGCAGCACGTG





CACAAATTCATGTGCCGTGCCTTATCTGAGTTTTCGGTATAAATATGTA





GATAATGGATTTTTTTTTTTTAGATAATGTTGTCAAGACCAAAAGCATG





GATGTCAAGTGTCAGTAAGGATTTTGTTTTCTAAAATTTTTTCCTGCAT





CAGTTCTTCTGAGGGCCTTGATGAAATAACACAGCAGTTTCTTAAACAA





TTTGAAACAAAATGAGCTCTCCTACCACCTCACTTTTTCATTTCCACAC





TAATGTATTATATGTAACTACTTGGAAAAAATAATTATTCAAATGCTTC





TTCCCACAAAGAATATAGATGATAGTAGATATATTTTATTAATAAAATG





GTTCATGAATCGGAGACTAACAAAGTTTTCATGTGCTCAGAATTATTAA





TTATCGTGTCTGCATTTTCTTTCGATAAAGGAAGACACACGATGCTAAT





CCGGAAATCAGCAAACTTTGCATTACTCCCTATGTGCGTATTTTCTCTT





TCTTCCTGTCACCCTGAGGAAGGTTCATTGCCATTGTCATCACCATGGA





AACAACGTTCCTCTCCACCTGCATTATGTACTACATGACAGGCATCAAT





CTGGGGAAATAATAAAATTATCACCTTTGTCAGACCATAAGAGTTTCTC





CAAAAGTGGTCAGTTTGGCTGGGCAATATTTTCTCTCATCTAACAAACA





CAATCCATTGTCATGAAATTACCCTTAGGATGAGTCTTCTTTAATCAAT





CATATATTGGGCGGGAAAAACACCAGCTTTGACCCGAAGTAGTTGAAGA





GCTACTTCATTCTTTTCTGAAGTTGTGTGTTGCTGCTAGAAATAGTCAT





TTGTGAATTATCCAAATTGTTTAAATTCACAATTGAATTAGTTTTTTCT





TCCTTTTTGCTTGAAGCAAACAGTTGACAATTTTTAACCTTTTCATTTT





ATGTTTTTGTACTCTGCAGACTGAAAAGACAAAGTTTATCTTGGCCTTA





CTGTATAAAGGTGTGCTGTGTCCACCGTTGTGTACAGAATTTTTCTTCA





TTAATTTTGTGTTTAAGTTAATAAAATTTATTTGTGATGTACTGTAA.,







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:280 under stringent hybridization conditions


In some embodiments, EYA transcriptional coactivator and phosphatase 2 (EYA2, EAB1) comprises the amino acid sequence:









MVELVISPSLTVNSDCLDKLKFNRADAAVWTLSDRQGITKSAPLRVSQLF





SRSCPRVLPRQPSTAMAAYGQTQYSAGIQQATPYTAYPPPAQAYGIPSYS





IKTEDSLNHSPGQSGFLSYGSSFSTSPTGQSPYTYQMHGTTGFYQGGNGL





GNAAGFGSVHQDYPSYPGFPQSQYPQYYGSSYNPPYVPASSICPSPLSTS





TYVLQEASHNVPNQSSESLAGEYNTHNGPSTPAKEGDTDRPHRASDGKLR





GRSKRSSDPSPAGDNEIERVFVWDLDETIIIFHSLLTGTFASRYGKDTTT





SVRIGLMMEEMIFNLADTHLFFNDLEDCDQIHVDDVSSDDNGQDLSTYNF





SADGFHSSAPGANLCLGSGVHGGVDWMRKLAFRYRRVKEMYNTYKNNVGG





LIGTPKRETWLQLRAELEALTDLWLTHSLKALNLINSRPNCVNVLVTTTQ





LIPALAKVLLYGLGSVFPIENIYSATKTGKESCFERIMQRFGRKAVYVVI





GDGVEEEQGAKKHNMPFWRISCHADLEALRHALELEYL. (SEQ ID





NO: 281; NP_005235.3),







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:281)


In some embodiments, the nucleic acid sequence encoding EYA2 comprises the nucleic acid sequence:










AGCAGCCGCGGCAGCCCAGGAGGCGGAGGCAGCGGCAACGGCAGAGACAGCAA






CGTGCCCGCCGCAGTCAGCCCGGCCTCGTCGGACCCGCACCGGCCCGCCCGCCC





GCCCGCACCGCGTCGGGGCGCCCTCTCCACTGCGCGCGGTACAAGGAAATGGTA





GAACTAGTGATCTCACCCAGCCTCACTGTAAACAGCGATTGTCTGGATAAACTGAA





GTTTAACCGTGCTGACGCTGCTGTGTGGACTCTGAGTGACAGACAAGGCATCACCA





AATCGGCCCCCCTGAGAGTGTCCCAGCTCTTCTCCAGATCTTGCCCACGTGTCCTC





CCCCGCCAGCCTTCCACAGCCATGGCAGCCTACGGCCAGACGCAGTACAGTGCG





GGGATCCAGCAGGCTACCCCCTATACAGCTTACCCACCTCCAGCACAAGCCTATG





GAATCCCTTCCTACAGCATCAAGACAGAAGACAGCTTGAACCATTCCCCTGGCCAG





AGTGGATTCCTCAGCTATGGCTCCAGCTTCAGCACCTCACCCACTGGACAGAGCCC





ATACACCTACCAGATGCACGGCACAACAGGGTTCTATCAAGGAGGAAATGGACTGG





GCAACGCAGCCGGTTTCGGGAGTGTGCACCAGGACTATCCTTCCTACCCCGGCTT





CCCCCAGAGCCAGTACCCCCAGTATTACGGCTCATCCTACAACCCTCCCTACGTCC





CGGCCAGCAGCATCTGCCCTTCGCCCCTCTCCACGTCCACCTACGTCCTCCAGGA





GGCATCTCACAACGTCCCCAACCAGAGTTCCGAGTCACTTGCTGGTGAATACAACA





CACACAATGGACCTTCCACACCAGCGAAAGAGGGAGACACAGACAGGCCGCACCG





GGCCTCCGACGGGAAGCTCCGAGGCCGGTCTAAGAGGAGCAGTGACCCGTCCCC





GGCAGGGGACAATGAGATTGAGCGTGTGTTCGTGTGGGACTTGGATGAGACAATA





ATTATTTTTCACTCCTTACTCACGGGGACATTTGCATCCAGATACGGGAAGGACACC





ACGACGTCCGTGCGCATTGGCCTTATGATGGAAGAGATGATCTTCAACCTTGCAGA





TACACATCTGTTCTTCAATGACCTGGAGGATTGTGACCAGATCCACGTTGATGACGT





CTCATCAGATGACAATGGCCAAGATTTAAGCACATACAACTTCTCCGCTGACGGCTT





CCACAGTTCGGCCCCAGGAGCCAACCTGTGCCTGGGCTCTGGCGTGCACGGCGG





CGTGGACTGGATGAGGAAGCTGGCCTTCCGCTACCGGCGGGTGAAGGAGATGTAC





AATACCTACAAGAACAACGTTGGTGGGTTGATAGGCACTCCCAAAAGGGAGACCTG





GCTACAGCTCCGAGCTGAGCTGGAAGCTCTCACAGACCTCTGGCTGACCCACTCC





CTGAAGGCACTAAACCTCATCAACTCCCGGCCCAACTGTGTCAATGTGCTGGTCAC





CACCACTCAACTAATTCCTGCCCTGGCCAAAGTCCTGCTATATGGCCTGGGGTCTG





TGTTTCCTATTGAGAACATCTACAGTGCAACCAAGACAGGGAAGGAGAGCTGCTTC





GAGAGGATAATGCAGAGATTCGGCAGAAAAGCTGTCTACGTGGTGATCGGTGATG





GTGTGGAAGAGGAGCAAGGAGCGAAAAAGCACAACATGCCTTTCTGGCGGATATC





CTGCCACGCAGACCTGGAGGCACTGAGGCACGCCCTGGAGCTGGAGTATTTATAG





CAGGATCAGCAGCATCTCCACCTGCCATCTCACCCTCAGACCCCCTCGCCTTCCCC





ACCTCCCCACCGAGAACTCCAGAGACCCAGATGTTGGACACCAGGAAGGGGCCCC





ACAGCCGAGACGACGTGTCCAGTGACCATCTCAGAAGCCGTCCATCAGTCCAAAT





GGGGGTTCTGAGAAGGAAAGTACCCAACATTGGCTTCGGAGTATTTGACTTTGGGG





AAAAGGGCTGGCTCGGAGTCTAGACTCTTCTGTAAGACTCACAGAACAAAAGCAAG





GAATTGCTGATTTGGGGGGTGCCTGGTGATGAGGAGGGGATGGGTTTGTCTTGTC





TTCTTTTTAATTTATGGACTAGTCTCATTACTCCGGAATTATGCTCTTGTACCTGTGT





GGCTGGGTTTCTTAGTCGTTGGTTTGGTTTGGTTTTTTGAACTGGTATGTGGGGTG





GTTCACAGTTCTAATGTAAGCACTCTATTCTCCAAGTTGTGCTTTGTGGGGACAATC





ATTCTTTGAACATTAGAGAGGAAGGCAGTTCAAGCTGTTGAAAAGACTATTGCTTAT





TTTTGTTTTTAAAGACCTACTTGACGTCATGTGGACAGTGCACGTGCCTTACGCTAC





ATCTTGTTTTCTAGGAAGAGGGGGATGCTGGGAAGGAATGGGTGCTTTGTGATGGA





TAAAAGGCATTAAATAAAACCACGTTTACATTTTGAA (SEQ ID NO: 282;





NM_005244.5),







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:282 under stringent hybridization conditions


In some embodiments, ETS variant transcription factor 4 (PEA3, ETV4, E1AF, PEAS3) comprises the amino acid sequence:









MERRMKAGYLDQQVPYTFSSKSPGNGSLREALIGPLGKLMDPGSLPPLDS





EDLFQDLSHFQETWLAEAQVPDSDEQFVPDFHSENLAFHSPTTRIKKEPQ





SPRTDPALSCSRKPPLPYHHGEQCLYSSAYDPPRQIAIKSPAPGALGQSP





LQPFPRAEQRNFLRSSGTSQPHPGHGYLGEHSSVFQQPLDICHSFTSQGG





GREPLPAPYQHQLSEPCPPYPQQSFKQEYHDPLYEQAGQPAVDQGGVNGH





RYPGAGVVIKQEQTDFAYDSDVTGCASMYLHTEGFSGPSPGDGAMGYGYE





KPLRPFPDDVCVVPEKFEGDIKQEGVGAFREGPPYQRRGALQLWQFLVAL





LDDPTNAHFIAWTGRGMEFKLIEPEEVARLWGIQKNRPAMNYDKLSRSLR





YYYEKGIMQKVAGERYVYKFVCEPEALFSLAFPDNQRPALKAEFDRPVSE





EDTVPLSHLDESPAYLPELAGPAQPFGPKGGYSY. (SEQ ID NO:





283; NP_001073143.1),







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:283)


In some embodiments, the nucleic acid sequence encoding PEA3 comprises the nucleic acid sequence:









GCTCACAACTGTCTGCTGCGCCCGAAAAACAAGTCGGTGCGCTGGGGACC





CGGGGCCGGGGCCGCCTTACTCCGGCCTAGCCCCGCGGCCCTCGGTGCGG





GCTCCAGGGCATGCTCGGGACCCCCCGCGGCTCCAGCCCAGACGCCCCGG





CCTCAGGTCTCGGCCCCCGCTTGGGGCCCCGGCCGTGCGGCCGGAGGGAG





CGGCCGGATGGAGCGGAGGATGAAAGCCGGATACTTGGACCAGCAAGTGC





CCTACACCTTCAGCAGCAAATCGCCCGGAAATGGGAGCTTGCGCGAAGCG





CTGATCGGCCCGCTGGGGAAGCTCATGGACCCGGGCTCCCTGCCGCCCCT





CGACTCTGAAGATCTCTTCCAGGATCTAAGTCACTTCCAGGAGACGTGGC





TCGCTGAAGCTCAGGTACCAGACAGTGATGAGCAGTTTGTTCCTGATTTC





CATTCAGAAAACCTAGCTTTCCACAGCCCCACCACCAGGATCAAGAAGGA





GCCCCAGAGTCCCCGCACAGACCCGGCCCTGTCCTGCAGCAGGAAGCCGC





CACTCCCCTACCACCATGGCGAGCAGTGCCTTTACTCCAGTGCCTATGAC





CCCCCCAGACAAATCGCCATCAAGTCCCCTGCCCCTGGTGCCCTTGGACA





GTCGCCCCTACAGCCCTTTCCCCGGGCAGAGCAACGGAATTTCCTGAGAT





CCTCTGGCACCTCCCAGCCCCACCCTGGCCATGGGTACCTCGGGGAACAT





AGCTCCGTCTTCCAGCAGCCCCTGGACATTTGCCACTCCTTCACATCTCA





GGGAGGGGGCCGGGAACCCCTCCCAGCCCCCTACCAACACCAGCTGTCGG





AGCCCTGCCCACCCTATCCCCAGCAGAGCTTTAAGCAAGAATACCATGAT





CCCCTGTATGAACAGGCGGGCCAGCCAGCCGTGGACCAGGGTGGGGTCAA





TGGGCACAGGTACCCAGGGGCGGGGGTGGTGATCAAACAGGAACAGACGG





ACTTCGCCTACGACTCAGATGTCACCGGGTGCGCATCAATGTACCTCCAC





ACAGAGGGCTTCTCTGGGCCCTCTCCAGGTGACGGGGCCATGGGCTATGG





CTATGAGAAACCTCTGCGACCATTCCCAGATGATGTCTGCGTTGTCCCTG





AGAAATTTGAAGGAGACATCAAGCAGGAAGGGGTCGGTGCATTTCGAGAG





GGGCCGCCCTACCAGCGCCGGGGTGCCCTGCAGCTGTGGCAATTTCTGGT





GGCCTTGCTGGATGACCCAACAAATGCCCATTTCATTGCCTGGACGGGCC





GGGGAATGGAGTTCAAGCTCATTGAGCCTGAGGAGGTCGCCAGGCTCTGG





GGCATCCAGAAGAACCGGCCAGCCATGAATTACGACAAGCTGAGCCGCTC





GCTCCGATACTATTATGAGAAAGGCATCATGCAGAAGGTGGCTGGTGAGC





GTTACGTGTACAAGTTTGTGTGTGAGCCCGAGGCCCTCTTCTCTTTGGCC





TTCCCGGACAATCAGCGTCCAGCTCTCAAGGCTGAGTTTGACCGGCCTGT





CAGTGAGGAGGACACAGTCCCTTTGTCCCACTTGGATGAGAGCCCCGCCT





ACCTCCCAGAGCTGGCTGGCCCCGCCCAGCCATTTGGCCCCAAGGGTGGC





TACTCTTACTAGCCCCCAGCGGCTGTTCCCCCTGCCGCAGGTGGGTGCTG





CCCTGTGTACATATAAATGAATCTGGTGTTGGGGAAACCTTCATCTGAAA





CCCACAGATGTCTCTGGGGCAGATCCCCACTGTCCTACCAGTTGCCCTAG





CCCAGACTCTGAGCTGCTCACCGGAGTCATTGGGAAGGAAAAGTGGAGAA





ATGGCAAGTCTAGAGTCTCAGAAACTCCCCTGGGGGTTTCACCTGGGCCC





TGGAGGAATTCAGCTCAGCTTCTTCCTAGGTCCAAGCCCCCCACACCTTT





TCCCCAACCACAGAGAACAAGAGTTTGTTCTGTTCTGGGGGACAGAGAAG





GCGCTTCCCAACTTCATACTGGCAGGAGGGTGAGGAGGTTCACTGAGCTC





CCCAGATCTCCCACTGCGGGGAGACAGAAGCCTGGACTCTGCCCCACGCT





GTGGCCCTGGAGGGTCCCGGTTTGTCAGTTCTTGGTGCTCTGTGTTCCCA





GAGGCAGGCGGAGGTTGAAGAAAGGAACCTGGGATGAGGGGTGCTGGGTA





TAAGCAGAGAGGGATGGGTTCCTGCTCCAAGGGACCCTTTGCCTTTCTTC





TGCCCTTTCCTAGGCCCAGGCCTGGGTTTGTACTTCCACCTCCACCACAT





CTGCCAGACCTTAATAAAGGCCCCCACTTCTCCCA. (SEQ ID NO:





284; NM_001079675.5),







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:284 under stringent hybridization conditions


In some embodiments, nuclear factor of activated T cells 5 (NFAT5, NFATZ, OREBP, NF-ATS, NFATL1, TONEBP) comprises the amino acid sequence:









MPSDFISLLSADLDLESPKSLYSRDSLKLHPSQNFHRAGLLEESVYDLLP





KELQLPPSRETSVASMSQTSGGEAGSPPPAVVAADASSAPSSSSMGGACS





SFTTSSSPTIYSTSVTDSKAMQVESCSSAVGVSNRGVSEKQLTSNTVQQH





PSTPKRHTVLYISPPPEDLLDNSRMSCQDEGCGLESEQSCSMWMEDSPSN





FSNMSTSSYNDNTEVPRKSRKRNPKQRPGVKRRDCEESNMDIFDADSAKA





PHYVLSQLTTDNKGNSKAGNGTLENQKGTGVKKSPMLCGQYPVKSEGKEL





KIVVQPETQHRARYLTEGSRGSVKDRTQQGFPTVKLEGHNEPVVLQVFVG





NDSGRVKPHGFYQACRVTGRNTTPCKEVDIEGTTVIEVGLDPSNNMTLAV





DCVGILKLRNADVEARIGIAGSKKKSTRARLVFRVNIMRKDGSTLTLQTP





SSPILCTQPAGVPEILKKSLHSCSVKGEEEVFLIGKNFLKGTKVIFQENV





SDENSWKSEAEIDMELFHQNHLIVKVPPYHDQHITLPVSVGIYVVTNAGR





SHDVQPFTYTPDPAAGALNVNVKKEISSPARPCSFEEAMKAMKTTGCNLD





KVNIIPNALMTPLIPSSMIKSEDVTPMEVTAEKRSSTIFKTTKSVGSTQQ





TLENISNIAGNGSFSSPSSSHLPSENEKQQQIQPKAYNPETLTTIQTQDI





SQPGTFPAVSASSQLPNSDALLQQATQFQTRETQSREILQSDGTVVNLSQ





LTEASQQQQQSPLQEQAQTLQQQISSNIFPSPNSVSQLQNTIQQLQAGSF





TGSTASGSSGSVDLVQQVLEAQQQLSSVLFSAPDGNENVQEQLSADIFQQ





VSQIQSGVSPGMFSSTEPTVHTRPDNLLPGRAESVHPQSENTLSNQQQQQ





QQQQQVMESSAAMVMEMQQSICQAAAQIQSELFPSTASANGNLQQSPVYQ





QTSHMMSALSTNEDMQMQCELFSSPPAVSGNETSTTTTQQVATPGTTMFQ





TSSSGDGEETGTQAKQIQNSVFQTMVQMQHSGDNQPQVNLFSSTKSMMSV





QNSGTQQQGNGLFQQGNEMMSLQSGNFLQQSSHSQAQLFHPQNPIADAQN





LSQETQGSLFHSPNPIVHSQTSTTSSEQMQPPMFHSQSTIAVLQGSSVPQ





DQQSTNIFLSQSPMNNLQTNTVAQEAFFAAPNSISPLQSTSNSEQQAAFQ





QQAPISHIQTPMLSQEQAQPPQQGLFQPQVALGSLPPNPMPQSQQGTMFQ





SQHSIVAMQSNSPSQEQQQQQQQQQQQQQQQQQSILFSNQNTMATMASPK





QPPPNMIFNPNQNPMANQEQQNQSIFHQQSNMAPMNQEQQPMQFQSQSTV





SSLQNPGPTQSESSQTPLFHSSPQIQLVQGSPSSQEQQVTLFLSPASMSA





LQTSINQQDMQQSPLYSPQNNMPGIQGATSSPQPQATLFHNTAGGTMNQL





QNSPGSSQQTSGMFLFGIQNNCSQLLTSGPATLPDQLMAISQPGQPQNEG





QPPVTTLLSQQMPENSPLASSINTNQNIEKIDLLVSLQNQGNNLTGSF.





(SEQ ID NO: 285; NP_001106649.1),







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:285)


In some embodiments, the nucleic acid sequence encoding NFAT5 comprises the nucleic acid sequence:










AGATTCCTGTCAGCGGCGGCGGCGGTGGCGGCGACCGTCAGTTTTCGCTGAGGA






GAAACACGAAACGGACCCTTTGGCTCTCCCCCTTCCCCTTCCCCGTCCTGAACCCC





TCTCCTGGTCACCGAGAATCAGTCCCCGTGGAGTTCCCCCTCCACCTCGCCATCGT





TTCCTCGGTCCTCGGCCCAGTGGAAGTCACTACCCTCGAGGAGGAGGCAGCGGCA





GCCGCCCTCGCGTCGCCGCCCCCGGTTCGGTGCCCGCGGTCCCGGAGAGGAGGT





GCCGCCGCCACCGCCGCTCCCCCCCTCCCGCTGCCCTCGGGCCGGGCTGGGTCG





AGCTGCGATGCCCTCGGACTTCATCTCATTGCTCAGCGCGGACCTAGACCTGGAAT





CGCCCAAGTCCCTCTACTCGCGAGATTCTCTGAAGTTACACCCATCACAGAATTTTC





ATAGAGCTGGACTATTGGAAGAATCTGTCTATGATCTTCTCCCAAAGGAGTTACAGT





TACCTCCATCTAGAGAAACATCTGTAGCATCAATGAGTCAGACAAGCGGTGGTGAG





GCAGGCTCGCCTCCTCCAGCTGTTGTTGCTGCTGATGCTTCTTCAGCTCCCTCCTC





TTCCTCCATGGGCGGTGCTTGCAGCTCCTTTACCACCTCTTCCAGCCCTACCATTTA





TTCTACCTCAGTCACCGACAGCAAGGCTATGCAAGTGGAGAGCTGCTCCTCAGCC





GTGGGGGTAAGTAACAGAGGGGTAAGTGAAAAGCAGTTAACCAGTAACACAGTTCA





GCAGCATCCATCAACACCGAAGAGGCACACAGTCTTGTACATCTCACCACCACCTG





AGGACTTGCTGGATAACAGTCGGATGTCCTGCCAGGATGAGGGGTGTGGATTGGA





ATCTGAGCAGAGCTGCAGTATGTGGATGGAGGATTCCCCCTCCAACTTCAGTAACA





TGAGCACCAGTTCCTACAATGATAACACTGAGGTACCTCGTAAATCACGAAAACGA





AATCCAAAGCAGAGGCCGGGGGTCAAACGACGAGATTGTGAAGAATCTAATATGGA





TATATTTGATGCCGACAGTGCCAAAGCACCTCACTATGTGCTTTCTCAGCTTACCAC





GGACAACAAAGGCAACTCAAAAGCGGGAAATGGAACATTGGAAAACCAAAAAGGAA





CTGGAGTAAAGAAGAGCCCTATGTTGTGTGGACAATATCCTGTTAAAAGTGAGGGA





AAGGAGCTGAAGATAGTTGTACAACCTGAGACACAGCACCGAGCTCGGTACCTGA





CTGAGGGCAGCCGTGGCTCAGTGAAAGATAGAACACAGCAAGGCTTTCCTACAGT





AAAGCTGGAAGGCCATAATGAACCTGTAGTGTTGCAAGTGTTTGTGGGCAACGACT





CTGGACGAGTGAAACCACATGGATTTTATCAGGCCTGCAGAGTAACTGGACGAAAT





ACAACTCCTTGCAAAGAAGTGGACATTGAAGGCACTACTGTTATAGAAGTCGGCCT





TGATCCTAGCAACAACATGACACTGGCGGTGGACTGCGTAGGGATATTGAAATTGA





GGAATGCTGATGTCGAAGCCAGAATAGGAATTGCTGGTTCCAAGAAGAAAAGCACT





CGTGCCAGATTGGTTTTTCGAGTTAATATCATGAGGAAAGATGGCTCCACTTTGACA





CTGCAAACACCCTCTTCTCCAATTTTGTGTACTCAGCCAGCAGGAGTGCCAGAAAT





CTTAAAGAAAAGCTTGCATAGCTGTTCAGTGAAAGGAGAAGAAGAAGTGTTTTTAAT





CGGCAAGAACTTTCTGAAAGGAACTAAAGTTATTTTCCAAGAAAATGTTTCTGATGA





AAACTCTTGGAAGTCAGAAGCTGAAATTGATATGGAACTATTTCATCAGAATCATCT





TATTGTGAAGGTTCCTCCCTATCATGACCAACATATAACTTTGCCTGTGTCAGTGGG





AATATATGTAGTGACAAATGCTGGAAGATCTCATGATGTTCAACCATTCACTTACAC





TCCAGACCCAGCAGCTGGTGCTTTGAATGTAAATGTGAAGAAGGAAATATCTAGTC





CAGCAAGACCTTGCTCTTTTGAAGAGGCCATGAAAGCAATGAAAACTACTGGATGT





AATTTAGATAAGGTAAATATTATCCCTAATGCCCTGATGACTCCACTCATACCAAGC





AGTATGATTAAGAGTGAAGATGTTACTCCAATGGAAGTAACAGCAGAAAAAAGATCT





TCCACTATTTTTAAGACTACAAAGTCTGTTGGATCAACTCAGCAAACATTAGAAAACA





TCTCAAACATAGCAGGAAATGGCTCTTTTTCATCACCATCATCTTCCCACCTACCTT





CTGAAAATGAAAAACAGCAGCAGATTCAGCCCAAGGCATACAACCCAGAGACCCTG





ACAACTATTCAAACCCAGGACATCTCACAGCCTGGTACTTTTCCAGCAGTTTCTGCT





TCTAGTCAGCTGCCCAACAGCGATGCACTATTGCAGCAGGCTACACAGTTTCAGAC





AAGAGAAACTCAGTCTAGAGAGATATTACAGTCAGATGGTACAGTGGTTAATTTGTC





ACAACTGACTGAGGCATCACAACAACAGCAGCAGTCACCACTACAAGAACAAGCAC





AGACTTTACAGCAGCAGATTTCATCAAATATTTTTCCATCACCAAATAGTGTGAGTCA





GCTTCAGAATACTATTCAGCAGCTGCAAGCAGGGAGTTTCACAGGCAGTACTGCTA





GTGGCAGCAGTGGAAGTGTTGACTTGGTCCAACAAGTTTTAGAGGCACAGCAGCA





GTTATCTTCAGTTTTATTTTCTGCTCCAGATGGTAATGAGAATGTTCAAGAGCAGCTT





AGTGCAGATATTTTTCAACAAGTCAGTCAAATTCAGAGTGGTGTAAGCCCTGGAATG





TTTTCCTCAACAGAGCCAACAGTCCATACCAGACCAGATAATTTATTACCTGGAAGA





GCTGAAAGTGTTCATCCACAGTCTGAAAACACGTTATCTAATCAACAGCAGCAGCA





GCAGCAGCAACAGCAAGTGATGGAATCTTCAGCCGCAATGGTGATGGAGATGCAA





CAGAGTATCTGCCAGGCAGCTGCCCAGATTCAGTCAGAGTTATTCCCTTCAACTGC





TTCAGCAAATGGAAACCTTCAGCAATCGCCAGTTTACCAGCAGACTTCTCACATGAT





GAGTGCATTGTCTACCAATGAGGATATGCAAATGCAGTGTGAATTGTTTTCTTCTCC





TCCTGCAGTTTCTGGAAATGAAACTTCTACAACTACCACACAGCAGGTTGCAACCC





CTGGCACTACCATGTTTCAGACATCAAGTTCAGGAGATGGAGAAGAAACTGGAACA





CAAGCAAAACAGATTCAGAACAGTGTCTTTCAGACCATGGTCCAAATGCAACATAGT





GGGGACAATCAACCTCAAGTTAACCTTTTTTCATCCACAAAAAGTATGATGAGTGTT





CAGAATAGTGGTACCCAACAACAAGGTAATGGTTTATTCCAGCAAGGGAATGAGAT





GATGTCACTTCAATCTGGAAATTTTTTGCAGCAGTCTTCTCATTCACAGGCCCAACT





TTTTCATCCTCAAAATCCTATTGCCGATGCTCAGAACCTTTCCCAGGAAACTCAAGG





TTCTCTCTTTCATAGTCCAAATCCTATTGTCCACAGTCAGACTTCTACAACCTCCTCT





GAACAAATGCAGCCTCCAATGTTTCACTCTCAAAGTACCATTGCTGTGTTACAGGGC





TCTTCAGTTCCTCAAGACCAGCAGTCAACCAACATATTTCTTTCCCAGAGTCCCATG





AATAATCTTCAGACTAACACAGTAGCCCAAGAAGCATTTTTTGCAGCACCGAACTCA





ATTTCTCCACTTCAGTCAACATCAAACAGTGAACAACAAGCTGCTTTCCAACAGCAA





GCTCCAATATCACACATCCAGACTCCTATGCTTTCCCAAGAACAGGCACAACCCCC





GCAGCAGGGTTTATTTCAGCCTCAGGTGGCCCTGGGCTCCCTTCCACCTAATCCAA





TGCCTCAAAGCCAACAAGGAACCATGTTCCAGTCACAGCACTCAATAGTTGCCATG





CAGAGTAACTCTCCATCCCAGGAACAGCAGCAGCAGCAGCAACAGCAGCAGCAAC





AGCAGCAGCAACAACAACAGAGCATTTTATTCAGTAATCAGAATACCATGGCTACAA





TGGCGTCTCCAAAGCAACCACCACCAAACATGATATTCAACCCAAATCAAAATCCAA





TGGCTAATCAGGAGCAACAGAACCAGTCAATTTTTCACCAACAAAGTAACATGGCC





CCAATGAATCAAGAGCAACAGCCCATGCAATTTCAGAGTCAGTCCACAGTTTCCTC





ACTTCAGAACCCAGGTCCTACCCAGTCGGAATCATCACAGACCCCCTTGTTCCATA





GCTCTCCTCAGATTCAGTTGGTACAAGGGTCACCTAGTTCTCAAGAGCAGCAAGTA





ACTCTCTTCTTATCTCCAGCATCCATGTCTGCCTTGCAGACCAGTATAAATCAACAA





GATATGCAACAGTCTCCTCTTTATTCCCCTCAGAACAACATGCCTGGAATTCAAGGA





GCCACATCTTCGCCTCAACCACAGGCTACTTTATTTCACAACACAGCAGGAGGCAC





AATGAACCAACTGCAGAATTCTCCTGGCTCATCTCAGCAGACATCAGGAATGTTCTT





ATTTGGCATTCAAAATAACTGTAGTCAGCTTTTAACCTCTGGACCAGCTACATTGCC





TGATCAGTTGATGGCCATAAGTCAGCCAGGCCAACCACAAAACGAGGGCCAGCCA





CCTGTGACAACACTTCTTTCTCAGCAAATGCCAGAGAATTCTCCACTGGCATCCTCT





ATAAACACCAACCAGAACATCGAAAAGATTGATTTGCTTGTTTCATTGCAAAACCAA





GGGAACAACTTGACTGGCTCCTTTTAACTGGATATAAATTCCACGAAGAAAATCCTG





ATTCCAAGATGTCCTGAGATCTTGTGGTTCCATGAGAATTATTACTTTAAAAACAAAA





CAAAATATAAAAAACTGTGTTTGAGTAAACTGATAGATTTTACTCTGACTGCAAAAGA





GCACACCTATGCTGCTTGTTGCAGTAACTAACCACCAATGTTAACATCTTCATATTTT





ATATTCCTAATAACAGTGATGACTGAGAATCTATTTGAGTTTCCAGCTGGCAGAATT





AATTGTTATTATTTTCCTAGGCGCAATTTCCTTAAACGTACAGTTTAAATTCAAGGCT





GGACCACTCAGTTATTATTGCTATTAGAAAATAATATATCATGTTTACTTTTGTTCTTC





ATTATTTTCTTTCCTGCATTGTTTTAGTCAAGTAATGGCTTTTGAAAAAGTAAAGTTC





AATAATAACTAAGGCTGTGATTTTTTTCAATATAAAAGGCACAGCTGTTGGCCAAAG





TGAAGGAATCTTTTTTCAGTTTTATTGGAGAAACTGAAGGGTAACATTCTAACAAGTA





AACTGTATGTGCAGATAAAAGTACTCTTGATTTAACACAAAGGCAGATGATACACTT





ATAAAACTGGGAACAGCTGGAATGCTTCTTGATTTTATTTTTTCAGAGAGTTGTTAGT





TCTCTGGGTTTCTACTAAGGGGTTTAGCCATAACTGTGCATAGAAAAATAATTATCT





GTAAAAAATGAAGGGGATAATATATGATAAATTATGTTCTGATATCCTCCTACAGTAG





TTTAAATTGACAGAAAAATTTGAATGTTTTCTTCTTAACCCAGTCTTAGGCTGGTATT





CCCTTTTTATATATATCTATATTACTTTTCACCTCTTTTTCACTTTACTTTAGAGAACT





ATTAATATACTACTGGCTTCATGACCCTGTAGCATCTTTGGCCACTTTAATCTAGGG





TGACCTAGCAATCCTGCAGCACAGGGCAGAGAGTACTGTCTTAGGAATTATTAGGA





GTTGATTCCTGAGAAACAACACATTTTTCCCCATGAACGGTGCTGTTCTGAAGTCTT





CAAATTTTTCCCTCTAATAGGAAACAGTATAAATTTTAATTAAAAAAAAAAGGCAAAC





TAAAATTTCTTGAAATATCACTTCTCCCTGATCTGCAGTGAGTATAAATTCACTTGTC





ACCTCAGTGCTTTACAGTTTGAAGTGGTCACTTACCTGATGGTTCCCACAAGCCTTA





GGCTTTACAGGGTTGTATCATTGACTTAAAATGAAGAATTAACTTGTGTTACATCTAT





AAAGAGCAAAATAACACACTCCAGAACTTGGCAGTTGTAGCATTAGTTATACAGTTT





TGGGTGTTCTTGCCACCCGTGGGATGCCTGCTTCTCACTACCACCTGTGTCTGGAC





ACATGCTTATGTCTCATTTTCCTTTTGGCATGTGGAAAGCTGTCAATGCAGTGTAAG





GCCAACGTGTGTGTGGCTTCTATGTGTTGAGATAATGTTTTGGTATCCTTGTCCGTT





TCATTTATTTTTTAAGTGTACAAAAAATAACCTGTTAATTGTTGAAGGCTACTTTTCTG





TTCTTTTTTTTTTTTTTTTTCTATCCTGTACATTTAGTTGAACTGTGCGGAATTGTGGT





GTTGGTTTTGTTTACACAGCCAGATTTTTCCTTCTTTTTGTTTTGTGATGATCTTCCTT





TGTTCTTTGAATGTGCTCTTTTGTCTTTTTCTCTTTTTTCTCATGTTTTCTTCCCTCCA





CCTCCACCCCTTTCTTTCTTTCTCTCTCTGATTGAGAGGCATTGAATTACGTTTTCAG





TAGTACAGGCTTCTTGCCGATATGAAGGGAACTTTTCAGAAAGAGACCTACTCTGG





GTCATTTAATTTTGAATACAGTTTTCAATCGTTCAAGTTTTGGATGGTTTATATCTAAT





GTGTGTTTCATTTTTTTGGAAAGCTATATTTTGTATTTAGGAAATGGTATACTATTTTG





CTATTTGTACTGAGTGAGTACATTGGCATAAATATAGAAATTTATATATATACATATAT





ATAAACTATTCTTTTTTGCCACACATTTTTGTGGTAAATTTGTGAGTTTGTCTGATGTT





CTACCACAACGTGGCGTCTGATAACAGTGAGGGGGGGTGGGGTTTGTTATGTCTTT





ATTGAGTATTTAAGTATCTTTTGAAACAAATGACCTGTTCATCTGTGGCCATTCCATC





AGGCAGTTAGTTCCTTGATGTCAGTAGTGGGCTAAAGGCAGCTTACTGTGTGTTTG





CTGGAGCTTTCACTCAGCCAAGTGTTAGAGTCAGGAAACCCATTGAGGCAATGGCG





TCAAATGGTGTTTCACAAGAATGAGCCATTCAGTCTTTGCTCACTATATATTTAATAT





TTTATTATTGTTGTTATTGTTATTATTAATTGGCTTTCTGTATTCTATGCCTTTTATTTA





TAAAGACACTAAGAAAACCCATGTTTGTAATTTTAATAACATTTTTCCCATCTTGTAAT





ATCCAGAGCTACTTTATAAATTCTCTGAACCAAAAGTATTTTCCTCAGTGTATCTCTT





CTCCCCCAGCCCCTATTGGGAAAAATTACCCAGTATAGTTCAGGTTATGAGGAGGA





TCAGCCACACAATCCAGTGCTTCAGTTTGAAAATGTAAAATTCTAACCCTAAAGTAG





GGTTGGTTGAAATTTCAGACAAAGCAAACCCAGCAGGTATAAAAAGTAGTATAAATA





CAAATCTGTAAGTTATTTTTGAATTTTCTGAACTTTTTTCTAAGAGATTACATAGGAG





ACTAAAGAAATCTATCTGTTCAAGTTCTAATTAGGATGATTGTTAATACTGCACTGTG





GATGAAGTGGCGACTGGCTTGTGTGCTGACTTCTGTGGTTTAGCAAGAGGTTTATT





GTTATCAAATGCTAATTGGCAATGCCAAGTCACTGGGACCAATTTTCTGTTTTATAAT





ATCTAAGTTTAGAACAGAATATATACCTGAACTGTAGTGGTTTGATCGGATGGAGAC





AGAAAACCCGATTTTTATTCTCATAAATTTTGTGGTTATTTATACAAGGGCTGTGCTA





TGCTACCATATTCTTGTTCAATAATAATAGGTTTGTTGTTTTTTTTACATTGTTAAATG





TTCCTTACCCCTAAAGGTCAATGTTAAGTACAACATTCTGAAAATACAATTTGGCTAC





GAAGAGTATTCATCTTCTTTGAAGCTCAGTGGTTGATATTTGTGCTAATAATGCAATT





TCCTGATTACTGTTACAAGTTATAGCTACATATGGGAGAGACTCAGTGAGCCAGCAA





AGGCCATAGAAACAACAATTTATTAAATGTATTTATGGCAGAAGGACCTAAATAAAC





TGTGAGCCACCTTTTCTTCTTTATATTGTTACATTTAAGTGTTCTTGCTTTCAGCAAC





TCACATTAATGCTTGGAGCTTATCTCTTTCTCTCTCTCTCTCTCTCTCTCTGTGTGTG





TGTGTGTATGTGTGTGTGTGTGTGTGTGTGTTTCCTTATTGTCATTCCATTATATATC





CACACCAACATGGGTGACGATAATTCAAAGTCATATTTTGCCTCTAAGCTTGATCAT





GTTACCTTTATGATTAAAGTATCATGTTATTTAGCCAATGCAAATCTGTTTTAAAACA





AATAGTTTAAAAAAAGAACAAGTTTTTAAGGGCTTTATTATAGAAGAAGTATTAATGA





AGGACTTTCCTTCCTCCCTCCCTTTCCTCCCCTCCCTGCCTCCCTTCTTCCCTTCCA





TCTCCCCCTCCTCCCTGCCTTCTTTGTTTCTCCTTCCCTTATTCCTCCCTCCCTCCTT





TCTCCCTTCCTTCCTTTCTTCCATTCATCCTTCCTTGCCTTTTATTTTTATTTTTTGTA





ATATCACATGTGCTGTAGTTTGGAATTTTATTCTAGTGCATTTCTTGCTCATCAGAAC





CTCAGCTAATCTACCTAGGAAAAATAGTATCAAAGGAAATGAGAAAGTTGTATCTGA





GTCCCTCCAGAACTAAGATAATTCTTTTTGACCATTTAAGCCTTTATAAATGCGTTTT





GACCATTTAAGCCTTTATAAATGCTTGTTTTAGGAAAGTGAATCTGTTAGATGCATCA





ACAAATAATGACCAGGACAAAACGATTTAATAATTAAAGTCTCAAATCACCATGGTTA





TACATTTTCACCAGAAATAGTAATCTTACAATTTTTCATTTTTCTGATGAAGATTTCTG





TTCCAATATCTGTTTCCTAATAGATTTTTTAAATTAATTAGCTTTCCTCTGCTTTATGA





CCACAGGTTTTATCCCTAACCGAGACAGCTGTCTTATATCTGCATGCCTTAGACTGT





GTGGAGGGACTCCATGAAGAAAGACCATAGGTTAGAAAAATAACTCATAGTATATAC





CCTAGTAAGTGGGTTAGTAGAATCTCATAACATGTATTAAAAAGAGGTTTTCTTCTCT





GCTTGTTTGTGTCACTAGAGCAAAATTGTAGAGATAATGCTCATAATGCAGTAAATA





TCAGAATAATATCTACAATATCATTTGTGGATGGTCCCAGGTCCCAGTGCTCTAGTT





ACTTTACTTCTTTTTTTTTTTTTGAGATGGAGTCTTGCTCTGTCTCTCAGGCTAGAGC





AGTGTGCGATCTCAGCTCACTGCAGCCTCCACCTCCCAGGTTCAAGCGATTCTCCT





GCCTCAGCCTCCCAAGTAGCCAGGATTACAGGCACCCTCCACTAGGCCCGGCTAA





TTTTTTTTGTATTTTTTTAGTAGAGATGGGGTTTTGCCATGTTGGCCAGGCTGGTTTC





GAACTCCTAACCTCCAGTGATCCACCTGCCTCGGCGTCCCAAAGTGCTAGGATTAC





AGGCATGAGCCACCACATCCGGCCTAATTACTTCTTTAATCCCCATTTATTTTTATG





CCATTCTAGCCTCATTTATTAATAAAATTATGTTTTTACTTTCTCTTTCAGGAAATTTT





TTAAATTAATATTTTATATCTAGATCTAATGCTATGGAAAAGTGCCTTTTTATCATTTA





TAATTTCATTTTTCACTATTTCCAAAAACACATAAACAAATAGTTTCAGTAGGTCCCA





GCTTTTACTTTTTCCATTTAAACCTTCTTTTCTCCATTTCTTCCCTTTGGCTTAAGAAT





AAAAGAAAAGGTACATTGCTAGAATTGTTTCTTTGGGAGAGGGTAAAAGATTACAGA





ATTAGACTGTTCAGCCTTTATATAAACTAAATTTGTCTTCATCTCAACCAGCTAATGG





TAGGTCTTATCTGAATACTCATGAGAATTTTAGCATCTGTGAAACTCCATGCACCAG





ATGTGTGTAAATTTCAGGAAGAAAGTGTTGAAAGCATTTTCTCTGATGTTAATTAGAT





GGAAATAAATCACTAAAACATAGTTTAGGTAAAGCCTGATTATGCCACTTTTTTTTAA





CTAGACAGGGCAAAGTTGTTTATGTTAGTGTACTTCTTGTCTATCCTCAGTTAATTTA





CCTAGACAAAAAGTGTCAAAGGAAATGAGAAAAAGGTTATATCTGACTCCCTCCAGA





CCTAAGATAATTCCTTTGATCAGATACAGTCAGATGGAGTGCCTTGGTTTTTGTTAA





TTTTGCCTCTATTCCAGCTCCTTACCACAGCGGTGGTGCTTAAAGAAAGGATCATCA





GCAACAGGTCAGGATAGTTCTACCTTTGGGATAGGGCTGCTTTCCCCGTGCTAGTA





TTTCTGTGACTGTTAGTGGCACTGAGGACTGCAAACTTTTATGCAATATTCTTAATAC





CCTATTGATATTATGCACTTTAATCATTCCAAAGAAGCCAAGAATGCTGTATAGTGAT





GATTCCTTCCTAATGAATTCATCTTAACTATTTAGAATGTTATGTCCCTTTTCTTTTGG





ATAGCCAACTTGGTATAAATGTTATATGGATTTTTCTAAAATGACTATATAGGACTTA





AGACTTTGAAATGTAATTTACTTATAAGGGGAAATAATTATGCTTTAGCACATCATTT





TAGAAACGTCACATTTTAGAAACATTCAGCTTGCTAACCTACATGTTTGGGAATTCAT





TAAAACCAGTTGTCTATATATTTTGTGCCATGTATATAAGAACATTACAATATATCTTT





TTCTACATATGTAGTATGTGCAACCAGTGGTTCTCAGAGTATGGTTCTCAGCCCACC





AGCTAGTATCAGTATCACCTGGGAACTAGTTAGAAATGTAAATTCTTTGGCCCCATC





CCAGACATACTGAGTCAGAAACTCTGGAATAGGGCCCCCGCAATCTGTTTTCACAA





GCCCTCCAGGTGATTCTGATGCACACTTTAAAGTTTAGGAACCACTGGGCTAAGAC





TCTGTTGAGATATAGAGTTTTTCTTCCACTCAGACTGATATAGTTATACATTGTTCTT





CATGTAAATTCAGCTTAACCTGGTTATCTATAATCTTTTATTGGCAAAAGTTAATTCT





CAGTACTGCCTATAGAGATACAGTGTATTTTATGTACATACACAATTAGTCTAATTCT





TGATAATTCAGTTAATTTAGTTTGGCATTTTCCTACCACTTACTAAAAGGTTTACATTA





AATGACTGATTTAAATATATAGGTGCAATGTTCTATGTTTATTTTAATTGTTATGACAT





TTAAGTAGCTAATATAATTGACCGGTGCTAAAGTCTCCTGTTTATCCATAAAATGGG





TACATTATGGGCAGTGTAATACAAGCTTTCTTTTCATTGCCTAGTACTTTACCAGCA





GACCACAGTTTTGCCCTGGCTAGACCAACCCTCAGAACAAAATCATCATTCCTTGTA





TTTATATTTGTATCTGAGATAGTAAACAAGATGGCTGGCCAGGTCAACATGGCACCT





TAACTTATTTTTTTAATAGGTAAAACTTCTTCAAAAGTAGCTTGCTTTGTATAAGAACT





AAGCTATCAGTATAGATATAGCTATCCTTGGAGCTTATGTTTCAGACAAGAATTATTT





ACTAAAATAAATAATAAACAAGATAATGCATTATACAATTTGGGCATTTCTCGTTTCT





CAAGTGTATGCATCATGGTAAATATAAACTAACCACAAGATAGGTAGATTGATTCAT





TTCATTTTAATCTCCTTGTGTAATTCAGTACCTCCATAATTGTTCTAATCTTCTTCCCA





CTGTTTACAAATTACCAGTTAATTAACTCGTGAAAGAAAAATTCACATATCAGAATAA





AAATAAATGTATACTCACTTTATAAAAATCACCACTGCTGTCTTTCCTTAATACTAGC





AGTGGAAATGTAAGTGGCTTACTCTACAAATTTTGGTGCTGGCAAATACATAGGCAA





ACTGTTGGGAGCTGCTCTAGTTACATTCCTCCCTTCTTATTCCCTTTTTCTCTTCCTC





ACTTTATTGCATAACATATTCCTGTACCCAAAGCATTCTACCACAGTTCTATTTGACT





CCCACTTGTAATAACTCCTTTAAAAAATTCCATGTTTAACCATATGACCCTGCTTGCT





TACTCATATTCTCCCTCCCTCTCCCCTTCCTTTCTCTCTCTTCCAGAAGTCATTTGCC





TGGTTTGAAATATTTTGTAGGGATTGCTTATTATATTATTTTAGCTGATGAACCTCAG





GACAACGTCTACACACACACACATACATACACGCACACAAAATCTCAGCTGTTGAA





GAGTGGGCTTGGAATCAGACTTCTGTGTCCAGTAAAAAACTCCTGCACTGAAGTCA





TTGTGACTTGAGTAGTTACAGACTGATTCCAGTGAACTTGATCTAATTTCTTTTGATC





TAATGAATGTGTCTGCTTACCTTGTTTCCTTTTAATTGATAAGCTCCAAGTAGTTGCT





AATTTTTTGACAACTTTAAATGAGTTTCATTCACTTCTTTTACTTAATGTTTTAAGTAT





AGTACCAATAATTTCATTAACCTGTTCTCAAGTGGTTTAGCTACCATTCTGCCATTTT





TAATTTTTATTTAATTTTATTTGCTTGAGCACACTGATCAACCACTGAACTGCCTTCTT





CCATTGTCCTGCAATGATATAAGGGTTACATTTTTGTGTATATGGCTTTCATAGTTGG





GATTTCAGAGCACTGATACCAGATATTTTCAGTTTGTTCTCTGGGGGAATTTCATTT





GCATCTATGTTTTTAGCTATCTGTGATAACTTGTTAAATATTAAAAAGATATTTTGCTT





CTATTGGAACATTTGTATACTCGCAACTATATTTCTGTAAACAGCTGCAGTCAAAAAT





AAAACACTGAAAGTTTTCA. (SEQ ID NO: 286; NM_001113178.3),







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:286 under stringent hybridization conditions


In some embodiments, BCL6 transcription repressor (BCL6, BCL5, LAZ3, BCL6A, ZNF51, ZBTB27) comprises the amino acid sequence:









MASPADSCIQFTRHASDVLLNLNRLRSRDILTDVVIVVSREQFRAHKTVL





MACSGLFYSIFTDQLKCNLSVINLDPEINPEGFCILLDFMYTSRLNLREG





NIMAVMATAMYLQMEHVVDTCRKFIKASEAEMVSAIKPPREEFLNSRMLM





PQDIMAYRGREVVENNLPLRSAPGCESRAFAPSLYSGLSTPPASYSMYSH





LPVSSLLFSDEEFRDVRMPVANPFPKERALPCDSARPVPGEYSRPTLEVS





PNVCHSNIYSPKETIPEEARSDMHYSVAEGLKPAAPSARNAPYFPCDKAS





KEEERPSSEDEIALHFEPPNAPLNRKGLVSPQSPQKSDCQPNSPTESCSS





KNACILQASGSPPAKSPTDPKACNWKKYKFIVLNSLNQNAKPEGPEQAEL





GRLSPRAYTAPPACQPPMEPENLDLQSPTKLSASGEDSTIPQASRLNNIV





NRSMTGSPRSSSESHSPLYMHPPKCTSCGSQSPQHAEMCLHTAGPTFPEE





MGETQSEYSDSSCENGAFFCNECDCRFSEEASLKRHTLQTHSDKPYKCDR





CQASFRYKGNLASHKTVHTGEKPYRCNICGAQFNRPANLKTHTRIHSGEK





PYKCETCGARFVQVAHLRAHVLIHTGEKPYPCEICGTRFRHLQTLKSHLR





IHTGEKPYHCEKCNLHFRHKSQLRLHLRQKHGAITNTKVQYRVSATDLPP





ELPKAC. (SEQ ID NO: 287; NP_001124317.1),







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:287)


In some embodiments, the nucleic acid sequence encoding BCL6 comprises the nucleic acid sequence:










ACAAGCGAGCTGGTGGTTGAAGCTGGTTAAAGAACAGCCTAGGTATTCCAGAAGTG






TTTGAGGATCCCTTCCATGAAGGAAGAGAGGAAAGTTTTTAAGTAAACCTCCCACTC





CCATGTGTCTTCAGCTTTCTTTTGCAAAGGAGAAAATCCTTGAAGTTTGGTAAAGAC





CGAGTTAGTCTATCTCTCTTTGCCTATCTCGAGTTGGGCTGGGGAGAGGAGGAGAT





AGGTTCTTTTGTCTTTTTCTGTCTTCTCCCTTCCCCACTTCCTTCCCTCCAGTCCCCA





CTCACTCACATGCACACACTAACCTTGGAGCCGATGGGATTGAGTGACTGGCACTT





GGGACCACAGAGAAATGTCAGAGTGTTTGGTTACAGACTCAAGGAAACCTCTCATT





TTAGAGTGCTCATTTGGTTTTGAGCAAAATTTTGGACTGTGAAGCAAGGCATTGGTG





AAGACAAAATGGCCTCGCCGGCTGACAGCTGTATCCAGTTCACCCGCCATGCCAG





TGATGTTCTTCTCAACCTTAATCGTCTCCGGAGTCGAGACATCTTGACTGATGTTGT





CATTGTTGTGAGCCGTGAGCAGTTTAGAGCCCATAAAACGGTCCTCATGGCCTGCA





GTGGCCTGTTCTATAGCATCTTTACAGACCAGTTGAAATGCAACCTTAGTGTGATCA





ATCTAGATCCTGAGATCAACCCTGAGGGATTCTGCATCCTCCTGGACTTCATGTACA





CATCTCGGCTCAATTTGCGGGAGGGCAACATCATGGCTGTGATGGCCACGGCTAT





GTACCTGCAGATGGAGCATGTTGTGGACACTTGCCGGAAGTTTATTAAGGCCAGTG





AAGCAGAGATGGTTTCTGCCATCAAGCCTCCTCGTGAAGAGTTCCTCAACAGCCGG





ATGCTGATGCCCCAAGACATCATGGCCTATCGGGGTCGTGAGGTGGTGGAGAACA





ACCTGCCACTGAGGAGCGCCCCTGGGTGTGAGAGCAGAGCCTTTGCCCCCAGCCT





GTACAGTGGCCTGTCCACACCGCCAGCCTCTTATTCCATGTACAGCCACCTCCCTG





TCAGCAGCCTCCTCTTCTCCGATGAGGAGTTTCGGGATGTCCGGATGCCTGTGGC





CAACCCCTTCCCCAAGGAGCGGGCACTCCCATGTGATAGTGCCAGGCCAGTCCCT





GGTGAGTACAGCCGGCCGACTTTGGAGGTGTCCCCCAATGTGTGCCACAGCAATA





TCTATTCACCCAAGGAAACAATCCCAGAAGAGGCACGAAGTGATATGCACTACAGT





GTGGCTGAGGGCCTCAAACCTGCTGCCCCCTCAGCCCGAAATGCCCCCTACTTCC





CTTGTGACAAGGCCAGCAAAGAAGAAGAGAGACCCTCCTCGGAAGATGAGATTGC





CCTGCATTTCGAGCCCCCCAATGCACCCCTGAACCGGAAGGGTCTGGTTAGTCCA





CAGAGCCCCCAGAAATCTGACTGCCAGCCCAACTCGCCCACAGAGTCCTGCAGCA





GTAAGAATGCCTGCATCCTCCAGGCTTCTGGCTCCCCTCCAGCCAAGAGCCCCACT





GACCCCAAAGCCTGCAACTGGAAGAAATACAAGTTCATCGTGCTCAACAGCCTCAA





CCAGAATGCCAAACCAGAGGGGCCTGAGCAGGCTGAGCTGGGCCGCCTTTCCCCA





CGAGCCTACACGGCCCCACCTGCCTGCCAGCCACCCATGGAGCCTGAGAACCTTG





ACCTCCAGTCCCCAACCAAGCTGAGTGCCAGCGGGGAGGACTCCACCATCCCACA





AGCCAGCCGGCTCAATAACATCGTTAACAGGTCCATGACGGGCTCTCCCCGCAGC





AGCAGCGAGAGCCACTCACCACTCTACATGCACCCCCCGAAGTGCACGTCCTGCG





GCTCTCAGTCCCCACAGCATGCAGAGATGTGCCTCCACACCGCTGGCCCCACGTT





CCCTGAGGAGATGGGAGAGACCCAGTCTGAGTACTCAGATTCTAGCTGTGAGAAC





GGGGCCTTCTTCTGCAATGAGTGTGACTGCCGCTTCTCTGAGGAGGCCTCACTCAA





GAGGCACACGCTGCAGACCCACAGTGACAAACCCTACAAGTGTGACCGCTGCCAG





GCCTCCTTCCGCTACAAGGGCAACCTCGCCAGCCACAAGACCGTCCATACCGGTG





AGAAACCCTATCGTTGCAACATCTGTGGGGCCCAGTTCAACCGGCCAGCCAACCT





GAAAACCCACACTCGAATTCACTCTGGAGAGAAGCCCTACAAATGCGAAACCTGCG





GAGCCAGATTTGTACAGGTGGCCCACCTCCGTGCCCATGTGCTTATCCACACTGGT





GAGAAGCCCTATCCCTGTGAAATCTGTGGCACCCGTTTCCGGCACCTTCAGACTCT





GAAGAGCCACCTGCGAATCCACACAGGAGAGAAACCTTACCATTGTGAGAAGTGTA





ACCTGCATTTCCGTCACAAAAGCCAGCTGCGACTTCACTTGCGCCAGAAGCATGGC





GCCATCACCAACACCAAGGTGCAATACCGCGTGTCAGCCACTGACCTGCCTCCGG





AGCTCCCCAAAGCCTGCTGAAGCATGGAGTGTTGATGCTTTCGTCTCCAGCCCCTT





CTCAGAATCTACCCAAAGGATACTGTAACACTTTACAATGTTCATCCCATGATGTAG





TGCCTCTTTCATCCACTAGTGCAAATCATAGCTGGGGGTTGGGGGTGGTGGGGGT





CGGGGCCTGGGGGACTGGGAGCCGCAGCAGCTCCCCCTCCCCCACTGCCATAAA





ACATTAAGAAAATCATATTGCTTCTTCTCCTATGTGTAAGGTGAACCATGTCAGCAA





AAAGCAAAATCATTTTATATGTCAAAGCAGGGGAGTATGCAAAAGTTCTGACTTGAC





TTTAGTCTGCAAAATGAGGAATGTATATGTTTTGTGGGAACAGATGTTTCTTTTGTAT





GTAAATGTGCATTCTTTTAAAAGACAAGACTTCAGTATGTTGTCAAAGAGAGGGCTT





TAATTTTTTTAACCAAAGGTGAAGGAATATATGGCAGAGTTGTAAATATATAAATATA





TATATATATAAAATAAATATATATAAACCTAAAAAAGATATATTAAAAATATAAAACTG





CGTTAAAGGCTCGATTTTGTATCTGCAGGCAGACACGGATCTGAGAATCTTTATTGA





GAAAGAGCACTTAAGAGAATATTTTAAGTATTGCATCTGTATAAGTAAGAAAATATTT





TGTCTAAAATGCCTCAGTGTATTTGTATTTTTTTGCAAGTGAAGGTTTACAATTTACA





AAGTGTGTATTAAAAAAAACAAAAAGAACAAAAAAATCTGCAGAAGGAAAAATGTGT





AATTTTGTTCTAGTTTTCAGTTTGTATATACCCGTACAACGTGTCCTCACGGTGCCTT





TTTTCACGGAAGTTTTCAATGATGGGCGAGCGTGCACCATCCCTTTTTGAAGTGTAG





GCAGACACAGGGACTTGAAGTTGTTACTAACTAAACTCTCTTTGGGAATGTTTGTCT





CATCCCATTCTGCGTCATGCTTGTGTTATAACTACTCCGGAGACAGGGTTTGGCTG





TGTCTAAACTGCATTACCGCGTTGTAAAATATAGCTGTACAAATATAAGAATAAAATG





TTGAAAAGTCAAA. (SEQ ID NO: 288; NM_001130845.2),







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:288 under stringent hybridization conditions


In some embodiments, myogenic differentiation 1 (MYOD1, PUM, MYF3, MYOD, bHLHc1) comprises the amino acid sequence:









MELLSPPLRDVDLTAPDGSLCSFATTDDFYDDPCFDSPDLRFFEDLDPRL





MHVGALLKPEEHSHFPAAVHPAPGAREDEHVRAPSGHHQAGRCLLWACKA





CKRKTTNADRRKAATMRERRRLSKVNEAFETLKRCTSSNPNQRLPKVEIL





RNAIRYIEGLQALLRDQDAAPPGAAAAFYAPGPLPPGRGGEHYSGDSDAS





SPRSNCSDGMMDYSGPPSGARRRNCYEGAYYNEAPSEPRPGKSAAVSSLD





CLSSIVERISTESPAAPALLLADVPSESPPRRQEAAAPSEGESSGDPTQS





PDAAPQCPAGANPNPIYQVL. (SEQ ID NO: 289; NP_





002469.2),







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:289)


In some embodiments, the nucleic acid sequence encoding MYOD comprises the nucleic acid sequence:









AGGGGTGAGGAAGCCCTGGGGCGCTGCCGCCGCTTTCCTTAACCACAAAT





CAGGCCGGACAGGAGAGGGAGGGGTGGGGGACAGTGGGTGGGCATTCAGA





CTGCCAGCACTTTGCTATCTACAGCCGGGGCTCCCGAGCGGCAGAAAGTT





CCGGCCACTCTCTGCCGCTTGGGTTGGGCGAAGCCAGGACCGTGCCGCGC





CACCGCCAGGATATGGAGCTACTGTCGCCACCGCTCCGCGACGTAGACCT





GACGGCCCCCGACGGCTCTCTCTGCTCCTTTGCCACAACGGACGACTTCT





ATGACGACCCGTGTTTCGACTCCCCGGACCTGCGCTTCTTCGAAGACCTG





GACCCGCGCCTGATGCACGTGGGCGCGCTCCTGAAACCCGAAGAGCACTC





GCACTTCCCCGCGGCGGTGCACCCGGCCCCGGGCGCACGTGAGGACGAGC





ATGTGCGCGCGCCCAGCGGGCACCACCAGGCGGGCCGCTGCCTACTGTGG





GCCTGCAAGGCGTGCAAGCGCAAGACCACCAACGCCGACCGCCGCAAGGC





CGCCACCATGCGCGAGCGGCGCCGCCTGAGCAAAGTAAATGAGGCCTTTG





AGACACTCAAGCGCTGCACGTCGAGCAATCCAAACCAGCGGTTGCCCAAG





GTGGAGATCCTGCGCAACGCCATCCGCTATATCGAGGGCCTGCAGGCTCT





GCTGCGCGACCAGGACGCCGCGCCCCCTGGCGCCGCAGCCGCCTTCTATG





CGCCGGGCCCGCTGCCCCCGGGCCGCGGCGGCGAGCACTACAGCGGCGAC





TCCGACGCGTCCAGCCCGCGCTCCAACTGCTCCGACGGCATGATGGACTA





CAGCGGCCCCCCGAGCGGCGCCCGGCGGCGGAACTGCTACGAAGGCGCCT





ACTACAACGAGGCGCCCAGCGAACCCAGGCCCGGGAAGAGTGCGGCGGTG





TCGAGCCTAGACTGCCTGTCCAGCATCGTGGAGCGCATCTCCACCGAGAG





CCCTGCGGCGCCCGCCCTCCTGCTGGCGGACGTGCCTTCTGAGTCGCCTC





CGCGCAGGCAAGAGGCTGCCGCCCCCAGCGAGGGAGAGAGCAGCGGCGAC





CCCACCCAGTCACCGGACGCCGCCCCGCAGTGCCCTGCGGGTGCGAACCC





CAACCCGATATACCAGGTGCTCTGAGGGGATGGTGGCCGCCCACCCGCCC





GAGGGATGGTGCCCCTAGGGTCCCTCGCGCCCAAAAGATTGAACTTAAAT





GCCCCCCTCCCAACAGCGCTTTAAAAGCGACCTCTCTTGAGGTAGGAGAG





GCGGGAGAACTGAAGTTTCCGCCCCCGCCCCACAGGGCAAGGACACAGCG





CGGTTTTTTCCACGCAGCACCCTTCTCGGAGACCCATTGCGATGGCCGCT





CCGTGTTCCTCGGTGGGCCAGAGCTGAACCTTGAGGGGCTAGGTTCAGCT





TTCTCGCGCCCTCCCCCATGGGGGTGAGACCCTCGCAGACCTAAGCCCTG





CCCCGGGATGCACCGGTTATTTGGGGGGGCGTGAGACCCAGTGCACTCCG





GTCCCAAATGTAGCAGGTGTAACCGTAACCCACCCCCAACCCGTTTCCCG





GTTCAGGACCACTTTTTGTAATACTTTTGTAATCTATTCCTGTAAATAAG





AGTTGCTTTGCCAGAGCAGGAGCCCCTGGGGCTGTATTTATCTCTGAGGC





ATGGTGTGTGGTGCTACAGGGAATTTGTACGTTTATACCGCAGGCGGGCG





AGCCGCGGGCGCTCGCTCAGGTGATCAAAATAAAGGCGCTAATTTATACC





GCC. (SEQ ID NO: 290; NM_002478.5),







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:290 under stringent hybridization conditions


In some embodiments, myogenic factor 5 (MYF5, EORVA, bHLHc2) comprises the amino acid sequence:









MDVMDGCQFSPSEYFYDGSCIPSPEGEFGDEFVPRVAAFGAHKAELQGSDE





DEHVRAPTGHHQAGHCLMWACKACKRKSTTMDRRKAATMRERRRLKKVNQA





FETLKRCTTTNPNQRLPKVEILRNAIRYIESLQELLREQVENYYSLPGQSC





SEPTSPTSNCSDGMPECNSPVWSRKSSTFDSIYCPDVSNVYATDKNSLSSL





DCLSNIVDRITSSEQPGLPLQDLASLSPVASTDSQPATPGASSSRLIYHV





L. (SEQ ID NO: 291; NP_005584.2),







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:291)


In some embodiments, the nucleic acid sequence encoding MYF5 comprises the nucleic acid sequence:









ACCCAGGCCAACAGGCGTCTGCCCTTGTTAATTACCGGAGCGACAGACTAG





GGAGCTCCGCCCGGGATTTGCCCATCGGCGGAGGCGCCAGGCTCCCGTTTC





TCCCCATCCCTCTCGCTGCCGTCCAGGTGCACCGCCTGCCTCTCAGCAGGA





TGGACGTGATGGATGGCTGCCAGTTCTCACCTTCTGAGTACTTCTACGACG





GCTCCTGCATACCGTCCCCCGAGGGTGAATTTGGGGACGAGTTTGTGCCGC





GAGTGGCTGCCTTCGGAGCGCACAAAGCAGAGCTGCAGGGCTCAGATGAGG





ACGAGCACGTGCGAGCGCCTACCGGCCACCACCAGGCTGGTCACTGCCTCA





TGTGGGCCTGCAAAGCCTGCAAGAGGAAGTCCACCACCATGGATCGGCGGA





AGGCAGCCACTATGCGCGAGCGGAGGCGCCTGAAGAAGGTCAACCAGGCTT





TCGAAACCCTCAAGAGGTGTACCACGACCAACCCCAACCAGAGGCTGCCCA





AGGTGGAGATCCTCAGGAATGCCATCCGCTACATCGAGAGCCTGCAGGAGT





TGCTGAGAGAGCAGGTGGAGAACTACTATAGCCTGCCGGGACAGAGCTGCT





CGGAGCCCACCAGCCCCACCTCCAACTGCTCTGATGGCATGCCCGAATGTA





ACAGTCCTGTCTGGTCCAGAAAGAGCAGTACTTTTGACAGCATCTACTGTC





CTGATGTATCAAATGTATATGCCACAGATAAAAACTCCTTATCCAGCTTGG





ATTGCTTATCCAACATAGTGGACCGGATCACCTCCTCAGAGCAACCTGGGT





TGCCTCTCCAGGATCTGGCTTCTCTCTCTCCAGTTGCCAGCACCGATTCAC





AGCCTGCAACTCCAGGGGCTTCTAGTTCCAGGCTTATCTATCATGTGCTAT





GAACTAATTTTCTGGTCTATATGACTTCTTCCAGGAGGGCCTAATACACAG





GAAGAAGAAGGCTTCAAAAAGTCCCAAACCAAGACAACATGTACATAAAGA





TTTCTTTTCAGTTGTAAATTTGTAAAGATTACCTTGCCACTTTATAAGAAA





GTGTATTTAACTAAAAAGTCATCATTGCAAATAATACTTTCTTCTTCTTTA





TTATTCTTTGCTTAGATATTAATACATAGTTCCAGTAATACTATTTCTGAT





AGGGGGCCATTGATTGAGGGTAGCTTGTTGCAATGCTTAACTTATATATAC





ATATATATATATTATAAATATTGCTCATCAAAATGTCTCTGGTGTTTAGAG





CTTTATTTTTTTCTTTAAAACATTAAAACAGCTGAGAATCAGTTAAATGGA





ATTTTAAATATATTTAACTATTTCTTTTCTCTTTAATCCTTTAGTTATATT





GTATTAAATAAAAATATAATACTGCCTAATGTATATATTTTGATCTTTTCT





TGTAAGAAATGTATCTTTTAAATGTAAGCACAAAATAGTACTTTGTGGATC





ATTTCAAGATATAAGAAATTTTGGAAATTCCACCATAAATAAAATTTTTTA





CTACAAGAAA. (SEQ ID NO: 292; NM_005593.3),







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:292 under stringent hybridization conditions


In some embodiments, myogenin (MYOG, MYF5, bHLHc3) comprises the amino acid sequence:









MELYETSPYFYQEPRFYDGENYLPVHLQGFEPPGYERTELTLSPEAPGPLE





DKGLGTPEHCPGQCLPWACKVCKRKSVSVDRRRAATLREKRRLKKVNEAFE





ALKRSTLLNPNQRLPKVEILRSAIQYIERLQALLSSLNQEERDLRYRGGGG





PQPGVPSECSSHSASCSPEWGSALEFSANPGDHLLTADPTDAHNLHSLTSI





VDSITVEDVSVAFPDETMPN. (SEQ ID NO: 293;





NP_002470.2),







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:293)


In some embodiments, the nucleic acid sequence encoding MYOG comprises the nucleic acid sequence:









GGGCTGCTGGAGCTTGGGGGCTGGTGGCAGGAACAAGCCTTTTCCGACCCC





ATGGAGCTGTATGAGACATCCCCCTACTTCTACCAGGAACCCCGCTTCTAT





GATGGGGAAAACTACCTGCCTGTCCACCTCCAGGGCTTCGAACCACCAGGC





TACGAGCGGACGGAGCTCACCCTGAGCCCCGAGGCCCCAGGGCCCCTTGAG





GACAAGGGGCTGGGGACCCCCGAGCACTGTCCAGGCCAGTGCCTGCCGTGG





GCGTGTAAGGTGTGTAAGAGGAAGTCGGTGTCCGTGGACCGGCGGCGGGCG





GCCACACTGAGGGAGAAGCGCAGGCTCAAGAAGGTGAATGAGGCCTTCGAG





GCCCTGAAGAGAAGCACCCTGCTCAACCCCAACCAGCGGCTGCCCAAGGTG





GAGATCCTGCGCAGTGCCATCCAGTACATCGAGCGCCTCCAGGCCCTGCTC





AGCTCCCTCAACCAGGAGGAGCGTGACCTCCGCTACCGGGGCGGGGGCGGG





CCCCAGCCAGGGGTGCCCAGCGAATGCAGCTCTCACAGCGCCTCCTGCAGT





CCAGAGTGGGGCAGTGCACTGGAGTTCAGCGCCAACCCAGGGGATCATCTG





CTCACGGCTGACCCTACAGATGCCCACAACCTGCACTCCCTCACCTCCATC





GTGGACAGCATCACAGTGGAAGATGTGTCTGTGGCCTTCCCAGATGAAACC





ATGCCCAACTGAGATTGTCTTCCAAGCCGGGCATCCTTGCGAGCCCCCCAA





GCTGGCCACAGATGCCACTACTTCTGTAGCAGGGGCCTCCTAAGCCAGGCT





GCCCTGATGCTAGGAAGCCAGCTCTGGGGTGCCATAGGCCAGACTATCCCC





TTCCTCATCCATGTAAGGTTAACCCACCCCCCAGCAAGGGACTGGACGCCC





TCATTCAGCTGCCTCCTTAGAGGAGAGGGCATCCCCTTTCCAGGGAGGTAA





AGCAGGGGACCAGAGCGCCCCCTCGTGTATGCCCCAGCTCAGGGGGCAAAC





TCAGGAGCTTCCTTTTTATCATAACGCGGCCTCTAATTCCACCCCCCAAGT





GAAACGGTTTGAGAGACGCAGTGCCCTGACCTGGACAAGCTGTGCACGTCT





CCTGTTCTGGTCTCTTCCCGATGCCAGTGGCTGGGCTGGGCCTGCCCTGAA





TTGAGAGAGAAGAAGGGGAGAGGAACAGCCCTCTGTTCCCAAGTCCCTGGG





GGGCCAAACTTTTGCAGTGAATATTGGGAACCTTCCAGTGGTTTTATGTTT





TGTTTTGTTTCGTGTGTTGTTTGTAAAGCTGCCATCCGACCAAGGTCTCCT





GTGCTGAAGTTGCCGGGGACAGGCAGGGAAAAGGGGTTGGGGCCTCTTGGG





GGTGATTTCTTTTGTTAACAAAGCATTGTGTGGTTTTGCCATTGTTTTGTA





TTTTTTTTTTTTTTTTTTTTTTTTGCTAACTTATTTGGATTTCCTTTTTTA





AAAAATGAATAAAGACTGGTTGCCAGAA. (SEQ ID NO: 294;





NM_002479.6),







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:294 under stringent hybridization conditions


In some embodiments, Spi-1 proto-oncogene (SPI1, OF, PU.1, SFPI1, SPI-A) comprises the amino acid sequence:









MLQACKMEGFPLVPPQPSEDLVPYDTDLYQRQTHEYYPYLSSDGESHSDHY





WDFHPHHVHSEFESFAENNFTELQSVQPPQLQQLYRHMELEQMHVLDTPMV





PPHPSLGHQVSYLPRMCLQYPSLSPAQPSSDEEEGERQSPPLEVSDGEADG





LEPGPGLLPGETGSKKKIRLYQFLLDLLRSGDMKDSIWWVDKDKGTFQFSS





KHKEALAHRWGIQKGNRKKMTYQKMARALRNYGKTGEVKKVKKKLTYQFSG





EVLGRGGLAERRHPPH. (SEQ ID NO: 295; NP_001074016.1),







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:295)


In some embodiments, the nucleic acid sequence encoding PU.1 comprises the nucleic acid sequence:









AAAATCAGGAACTTGTGCTGGCCCTGCAATGTCAAGGGAGGGGGCTCACCC





AGGGCTCCTGTAGCTCAGGGGGCAGGCCTGAGCCCTGCACCCGCCCCACGA





CCGTCCAGCCCCTGACGGGGCACCCCATCCTGAGGGGCTCTGCATTGGCCC





CCACCGAGGCAGGGGATCTGACCGACTCGGAGCCCGGCTGGATGTTACAGG





CGTGCAAAATGGAAGGGTTTCCCCTCGTCCCCCCTCAGCCATCAGAAGACC





TGGTGCCCTATGACACGGATCTATACCAACGCCAAACGCACGAGTATTACC





CCTATCTCAGCAGTGATGGGGAGAGCCATAGCGACCATTACTGGGACTTCC





ACCCCCACCACGTGCACAGCGAGTTCGAGAGCTTCGCCGAGAACAACTTCA





CGGAGCTCCAGAGCGTGCAGCCCCCGCAGCTGCAGCAGCTCTACCGCCACA





TGGAGCTGGAGCAGATGCACGTCCTCGATACCCCCATGGTGCCACCCCATC





CCAGTCTTGGCCACCAGGTCTCCTACCTGCCCCGGATGTGCCTCCAGTACC





CATCCCTGTCCCCAGCCCAGCCCAGCTCAGATGAGGAGGAGGGCGAGCGGC





AGAGCCCCCCACTGGAGGTGTCTGACGGCGAGGCGGATGGCCTGGAGCCCG





GGCCTGGGCTCCTGCCTGGGGAGACAGGCAGCAAGAAGAAGATCCGCCTGT





ACCAGTTCCTGTTGGACCTGCTCCGCAGCGGCGACATGAAGGACAGCATCT





GGTGGGTGGACAAGGACAAGGGCACCTTCCAGTTCTCGTCCAAGCACAAGG





AGGCGCTGGCGCACCGCTGGGGCATCCAGAAGGGCAACCGCAAGAAGATGA





CCTACCAGAAGATGGCGCGCGCGCTGCGCAACTACGGCAAGACGGGCGAGG





TCAAGAAGGTGAAGAAGAAGCTCACCTACCAGTTCAGCGGCGAAGTGCTGG





GCCGCGGGGGCCTGGCCGAGCGGCGCCACCCGCCCCACTGAGCCCGCAGCC





CCCGCCGGGCCCCGCCAGGCCTCCCCGCTGGCCATAGCATTAAGCCCTCGC





CCGGCCCGGACACAGGGAGGACGCTCCCGGGGCCCAGAGGCAGGACTGTGG





CGGGCCGGGCCTCGCCTCACCCGCCCCCTCCCCCCACTCCAGGCCCCCTCC





ACATCCCGCTTCGCCTCCCTCCAGGACTCCACCCCGGCTCCCGGACGCCAG





CTGGGCGTCAGACCCCACCGGGGCAACCTTGCAGAGGACGACCCGGGGTAC





TGCCTTGGGAGTCTCAAGTCCGTATGTAAATCAGATCTCCCCTCTCACCCC





TCCCACCCATTAACCTCCTCCCAAAAAACAAGTAAAGTTATTCTCAATCC





A. (SEQ ID NO: 296; NM_001080547.2),







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:296 under stringent hybridization conditions


In some embodiments, colony stimulating factor 1 receptor (CSF1R, FMS, CSFR, FIM2, HDLS, CD115, CSF-1R, BANDDOS, M-CSF-R) comprises the amino acid sequence:









MGPGVLLLLLVATAWHGQGIPVIEPSVPELVVKPGATVTLRCVGNGSVEWD





GPPSPHWTLYSDGSSSILSTNNATFQNTGTYRCTEPGDPLGGSAAIHLYVK





DPARPWNVLAQEVVVFEDQDALLPCLLTDPVLEAGVSLVRVRGRPLMRHTN





YSFSPWHGFTIHRAKFIQSQDYQCSALMGGRKVMSISIRLKVQKVIPGPPA





LTLVPAELVRIRGEAAQIVCSASSVDVNFDVFLQHNNTKLAIPQQSDFHNN





RYQKVLTLNLDQVDFQHAGNYSCVASNVQGKHSTSMFFRVVESAYLNLSSE





QNLIQEVTVGEGLNLKVMVEAYPGLQGFNWTYLGPFSDHQPEPKLANATTK





DTYRHTFTLSLPRLKPSEAGRYSFLARNPGGWRALTFELTLRYPPEVSVIW





TFINGSGTLLCAASGYPQPNVTWLQCSGHTDRCDEAQVLQVWDDPYPEVLS





QEPFHKVTVQSLLTVETLEHNQTYECRAHNSVGSGSWAFIPISAGAHTHPP





DEFLFTPVVVACMSIMALLLLLLLLLLYKYKQKPKYQVRWKIIESYEGNSY





TFIDPTQLPYNEKWEFPRNNLQFGKTLGAGAFGKVVEATAFGLGKEDAVLK





VAVKMLKSTAHADEKEALMSELKIMSHLGQHENIVNLLGACTHGGPVLVIT





EYCCYGDLLNFLRRKAEAMLGPSLSPGQDPEGGVDYKNIHLEKKYVRRDSG





FSSQGVDTYVEMRPVSTSSNDSFSEQDLDKEDGRPLELRDLLHFSSQVAQG





MAFLASKNCIHRDVAARNVLLTNGHVAKIGDFGLARDIMNDSNYIVKGNAR





LPVKWMAPESIFDCVYTVQSDVWSYGILLWEIFSLGLNPYPGILVNSKFYK





LVKDGYQMAQPAFAPKNIYSIMQACWALEPTHRPTFQQICSFLQEQAQEDR





RERDYTNLPSSSRSGGSGSSSSELEEESSSEHLTCCEQGDIAQPLLQPNNY





QFC. (SEQ ID NO: 297; NP_001275634.1),







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:297)


In some embodiments, the nucleic acid sequence encoding CSFR comprises the nucleic acid sequence:









AAACAGCCAGTGCAGAGGAGAGGAACGTGTGTCCAGTGTCCCGATCCCTGC





GGAGCTAGTAGCTGAGAGCTCTGTGCCCTGGGCACCTTGCAGCCCTGCACC





TGCCTGCCACTTCCCCACCGAGGCCATGGGCCCAGGAGTTCTGCTGCTCCT





GCTGGTGGCCACAGCTTGGCATGGTCAGGGAATCCCAGTGATAGAGCCCAG





TGTCCCTGAGCTGGTCGTGAAGCCAGGAGCAACGGTGACCTTGCGATGTGT





GGGCAATGGCAGCGTGGAATGGGATGGCCCCCCATCACCTCACTGGACCCT





GTACTCTGATGGCTCCAGCAGCATCCTCAGCACCAACAACGCTACCTTCCA





AAACACGGGGACCTATCGCTGCACTGAGCCTGGAGACCCCCTGGGAGGCAG





CGCCGCCATCCACCTCTATGTCAAAGACCCTGCCCGGCCCTGGAACGTGCT





AGCACAGGAGGTGGTCGTGTTCGAGGACCAGGACGCACTACTGCCCTGTCT





GCTCACAGACCCGGTGCTGGAAGCAGGCGTCTCGCTGGTGCGTGTGCGTGG





CCGGCCCCTCATGCGCCACACCAACTACTCCTTCTCGCCCTGGCATGGCTT





CACCATCCACAGGGCCAAGTTCATTCAGAGCCAGGACTATCAATGCAGTGC





CCTGATGGGTGGCAGGAAGGTGATGTCCATCAGCATCCGGCTGAAAGTGCA





GAAAGTCATCCCAGGGCCCCCAGCCTTGACACTGGTGCCTGCAGAGCTGGT





GCGGATTCGAGGGGAGGCTGCCCAGATCGTGTGCTCAGCCAGCAGCGTTGA





TGTTAACTTTGATGTCTTCCTCCAACACAACAACACCAAGCTCGCAATCCC





TCAACAATCTGACTTTCATAATAACCGTTACCAAAAAGTCCTGACCCTCAA





CCTCGATCAAGTAGATTTCCAACATGCCGGCAACTACTCCTGCGTGGCCAG





CAACGTGCAGGGCAAGCACTCCACCTCCATGTTCTTCCGGGTGGTAGAGAG





TGCCTACTTGAACTTGAGCTCTGAGCAGAACCTCATCCAGGAGGTGACCGT





GGGGGAGGGGCTCAACCTCAAAGTCATGGTGGAGGCCTACCCAGGCCTGCA





AGGTTTTAACTGGACCTACCTGGGACCCTTTTCTGACCACCAGCCTGAGCC





CAAGCTTGCTAATGCTACCACCAAGGACACATACAGGCACACCTTCACCCT





CTCTCTGCCCCGCCTGAAGCCCTCTGAGGCTGGCCGCTACTCCTTCCTGGC





CAGAAACCCAGGAGGCTGGAGAGCTCTGACGTTTGAGCTCACCCTTCGATA





CCCCCCAGAGGTAAGCGTCATATGGACATTCATCAACGGCTCTGGCACCCT





TTTGTGTGCTGCCTCTGGGTACCCCCAGCCCAACGTGACATGGCTGCAGTG





CAGTGGCCACACTGATAGGTGTGATGAGGCCCAAGTGCTGCAGGTCTGGGA





TGACCCATACCCTGAGGTCCTGAGCCAGGAGCCCTTCCACAAGGTGACGGT





GCAGAGCCTGCTGACTGTTGAGACCTTAGAGCACAACCAAACCTACGAGTG





CAGGGCCCACAACAGCGTGGGGAGTGGCTCCTGGGCCTTCATACCCATCTC





TGCAGGAGCCCACACGCATCCCCCGGATGAGTTCCTCTTCACACCAGTGGT





GGTCGCCTGCATGTCCATCATGGCCTTGCTGCTGCTGCTGCTCCTGCTGCT





ATTGTACAAGTATAAGCAGAAGCCCAAGTACCAGGTCCGCTGGAAGATCAT





CGAGAGCTATGAGGGCAACAGTTATACTTTCATCGACCCCACGCAGCTGCC





TTACAACGAGAAGTGGGAGTTCCCCCGGAACAACCTGCAGTTTGGTAAGAC





CCTCGGAGCTGGAGCCTTTGGGAAGGTGGTGGAGGCCACGGCCTTTGGTCT





GGGCAAGGAGGATGCTGTCCTGAAGGTGGCTGTGAAGATGCTGAAGTCCAC





GGCCCATGCTGATGAGAAGGAGGCCCTCATGTCCGAGCTGAAGATCATGAG





CCACCTGGGCCAGCACGAGAACATCGTCAACCTTCTGGGAGCCTGTACCCA





TGGAGGCCCTGTACTGGTCATCACGGAGTACTGTTGCTATGGCGACCTGCT





CAACTTTCTGCGAAGGAAGGCTGAGGCCATGCTGGGACCCAGCCTGAGCCC





CGGCCAGGACCCCGAGGGAGGCGTCGACTATAAGAACATCCACCTCGAGAA





GAAATATGTCCGCAGGGACAGTGGCTTCTCCAGCCAGGGTGTGGACACCTA





TGTGGAGATGAGGCCTGTCTCCACTTCTTCAAATGACTCCTTCTCTGAGCA





AGACCTGGACAAGGAGGATGGACGGCCCCTGGAGCTCCGGGACCTGCTTCA





CTTCTCCAGCCAAGTAGCCCAGGGCATGGCCTTCCTCGCTTCCAAGAATTG





CATCCACCGGGACGTGGCAGCGCGTAACGTGCTGTTGACCAATGGTCATGT





GGCCAAGATTGGGGACTTCGGGCTGGCTAGGGACATCATGAATGACTCCAA





CTACATTGTCAAGGGCAATGCCCGCCTGCCTGTGAAGTGGATGGCCCCAGA





GAGCATCTTTGACTGTGTCTACACGGTTCAGAGCGACGTCTGGTCCTATGG





CATCCTCCTCTGGGAGATCTTCTCACTTGGGCTGAATCCCTACCCTGGCAT





CCTGGTGAACAGCAAGTTCTATAAACTGGTGAAGGATGGATACCAAATGGC





CCAGCCTGCATTTGCCCCAAAGAATATATACAGCATCATGCAGGCCTGCTG





GGCCTTGGAGCCCACCCACAGACCCACCTTCCAGCAGATCTGCTCCTTCCT





TCAGGAGCAGGCCCAAGAGGACAGGAGAGAGCGGGACTATACCAATCTGCC





GAGCAGCAGCAGAAGCGGTGGCAGCGGCAGCAGCAGCAGTGAGCTGGAGGA





GGAGAGCTCTAGTGAGCACCTGACCTGCTGCGAGCAAGGGGATATCGCCCA





GCCCTTGCTGCAGCCCAACAACTATCAGTTCTGCTGAGGAGTTGACGACAG





GGAGTACCACTCTCCCCTCCCACAAACTTCAACTCCTCCATGGATGGGGCG





ACACGGGGAGAACATACAAACTCTGCCTTCGGTCATTTCACTCAACAGCTC





GGCCCAGCTCTGAAACTTGGGAAGGTGAGGGATTCAGGGGAGGTCAGAGGA





TCCCACTTCCTGAGCATGGGCCATCACTGCCAGTCAGGGGCTGGGGGCTGA





GCCCTCACCCCCCCCTCCCCTACTGTTCTCATGGTGTTGGCCTCGTGTTTG





CTATGCCAACTAGTAGAACCTTCTTTCCTAATCCCCTTATCTTCATGGAAA





TGGACTGACTTTATGCCTATGAAGTCCCCAGGAGCTACACTGATACTGAGA





AAACCAGGCTCTTTGGGGCTAGACAGACTGGCAGAGAGTGAGATCTCCCTC





TCTGAGAGGAGCAGCAGATGCTCACAGACCACACTCAGCTCAGGCCCCTTG





GAGCAGGATGGCTCCTCTAAGAATCTCACAGGACCTCTTAGTCTCTGCCCT





ATACGCCGCCTTCACTCCACAGCCTCACCCCTCCCACCCCCATACTGGTAC





TGCTGTAATGAGCCAAGTGGCAGCTAAAAGTTGGGGGTGTTCTGCCCAGTC





CCGTCATTCTGGGCTAGAAGGCAGGGGACCTTGGCATGTGGCTGGCCACAC





CAAGCAGGAAGCACAAACTCCCCCAAGCTGACTCATCCTAACTAACAGTCA





CGCCGTGGGATGTCTCTGTCCACATTAAACTAACAGCATTAATGCA.





(SEQ ID NO: 298; NM_001288705.3),







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:298 under stringent hybridization conditions


In some embodiments, serum response factor (SRF, MCMI) comprises the amino acid sequence:









MITSETGKALIQTCLNSPDSPPRSDPTTDQRMSATGFEETDLTYQVSESDS





SGETKDTLKPAFTVTNLPGTTSTIQTAPSTSTTMQVSSGPSFPITNYLAPV





SASVSPSAVSSANGTVLKSTGSGPVSSGGLMQLPTSFTLMPGGAVAQQVPV





QAIQVHQAPQQASPSRDSSTDLTQTSSSGTVTLPATIMTSSVPTTVGGHMM





YPSPHAVMYAPTSGLGDGSLTVLNAFSQAPSTMQVSHSQVQEPGGVPQVFL





TASSGTVQIPVSAVQLHQMAVIGQQAGSSSNLTELQVVNLDTAHSTKSE.





(SEQ ID NO: 299; NP_001278930.1







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:299)


In some embodiments, the nucleic acid sequence encoding SRF comprises the nucleic acid sequence:









GCAGAGGTGGGAGTGACCGGCGCCAGAGAGGAAGAGGGCCCTTGCTGAGTG





AAGGGGCCTATGAGCTGTCCACGCTGACAGGGACACAGGTGCTGTTGCTGG





TGGCCAGTGAGACAGGCCATGTGTATACCTTTGCCACCCGAAAACTGCAGC





CCATGATCACCAGTGAGACCGGCAAGGCACTGATTCAGACCTGCCTCAACT





CGCCAGACTCTCCACCCCGTTCAGACCCCACAACAGACCAGAGAATGAGTG





CCACTGGCTTTGAAGAGACAGATCTCACCTACCAGGTGTCGGAGTCTGACA





GCAGTGGGGAGACCAAGGACACACTGAAGCCGGCGTTCACAGTCACCAACC





TGCCGGGTACAACCTCCACCATCCAAACAGCACCTAGCACCTCTACCACCA





TGCAAGTCAGCAGCGGCCCCTCCTTTCCCATCACCAACTACCTGGCACCAG





TGTCTGCTAGTGTCAGCCCCAGTGCTGTCAGCAGTGCCAATGGGACTGTGC





TGAAGAGTACAGGCAGCGGCCCTGTCTCCTCTGGGGGCCTTATGCAGCTGC





CTACCAGCTTCACCCTCATGCCTGGTGGGGCAGTGGCCCAGCAGGTCCCAG





TGCAGGCCATTCAAGTGCACCAGGCCCCACAGCAAGCGTCTCCCTCCCGTG





ACAGCAGCACAGACCTCACGCAGACCTCCTCCAGCGGGACAGTGACGCTGC





CCGCCACCATCATGACGTCATCCGTGCCCACAACTGTGGGTGGCCACATGA





TGTACCCTAGCCCGCATGCGGTGATGTATGCCCCCACCTCGGGCCTGGGTG





ATGGCAGCCTCACCGTGCTGAATGCCTTCTCCCAGGCACCATCCACCATGC





AGGTGTCACACAGCCAGGTCCAGGAGCCAGGTGGCGTCCCCCAGGTGTTCC





TGACAGCATCATCTGGGACAGTGCAGATCCCTGTTTCAGCAGTTCAGCTCC





ACCAGATGGCTGTGATAGGGCAGCAGGCCGGGAGCAGCAGCAACCTCACCG





AGCTACAGGTGGTGAACCTGGACACCGCCCACAGCACCAAGAGTGAATGAT





CCGCCCGCCGCCCTGGACAGATGGCCCAAGGGATGGCACCACTTATTTATT





GTTGCCTTTTCACGTTTTCTTTACACACACGTTGACGGGCCGCAGGAGGGA





GGCGGGGAGGAGGAACGGGCAGCCACAGGACTGAGCCCTCTCACTCCAGCC





AAAGAAATGGGCCTGCCTGCCTCCACCCGTCCTCCCTCAGCCTCCCCTTCT





TCCCGCCCCACCTCCCATTTCTGTTGCTGGAGGGGCTGTCCTCCTTCCTGG





GACCCCCTCGCCAGCTTGGCTCGATGTTTGCCATGAGTATTAGCTTACCCA





ATGGGACCGTGCCCCACCTCCCCACACACAGGCCTTCTGTGGGGCTGGGCA





CCGTGTCCTCCTCTGAGGAAGCAGTTGGGGCCCTCTTGCCAGCCTCCTTGC





TGACCCCAGGTCAGCCCTGTGTCTGTCACAGGCTGGGTCAAAAGAGCCCTG





GCTCTGCCCCTCAGGGGGCCAGCTGGGGAGATGGGGGCTTCTTCCTCACAC





TGCTGTCCTCTCCCCCTTCAGCTCCTGAGTAGCTGGGCCTGTGCACTGGGC





AGGTTCCTGGGGCCGCCTGCCCTGCCTTGCCGCTCCCCTTGGACCTCCAGG





GGCTCCTGGGTTGGAGGGAACCACCAGCGTTCCCTTCTCCCCCTTGTCTTC





CCCCCTCTCCTCCCAGCTGCTTTACTTAAAGTTGATTTTGAACTTTTTATT





TGAGGAGACGAAGTGAAAACAAATCTATAAATATATATTTTTAAAATATTT





AACTTTTTTTTATGGCGTTTTTCTCGTCCCCCTCCCTGCCCAAACTCCCCT





TCCCTGGGGAGCCCTCAGGCTCCCCAGAACTGGCTGGGCCCCTGGGGACAG





AGCCACCCCATGAGCTCGGGGTCCACCAGTGTGTGGGGGAGATTCTGGGTT





TGCCCAGTCCTGGGTTGTTTCCAGGAGAAAGCCGGGGGAGGGGCCCTCAGG





CCATTCCCCAACGGGGTGGGGAGGGTGACCCACAGCTCTGGGCCTCTTTTT





GCCCTTTAGGGCTGTTGCTAGGGAGAGGGAAGAGGGAGACCAAATGTCGGG





GTTGGGGTGGGAGGGCGTCAGGCAGAGGCAACTGACTTCATTTGTGCCACA





CGCATGGGCATTGCAGCCTTGCGCTGTCCCAGGCATGCAGCTGCCTGGGGC





CCAAGTTGCAGTGAGCAGGGTGGGGTCTGGGAGGGGGTGAGAGGCAGGAAT





GGGGGTCAGAAGAAGTGGGAGCAGCTTCTTGGGCTGAGTGCAGCCAAAGGG





GAGCCAGAAATGGGCAGTTCTCCCAGGGAGTGAGCAGCTACTGTAACTTTT





TTAAATTAAGACAAAAAGCCTTGAAGAAAATGACTTTATTTTTCTAAGTGT





AACCTCAGTATTTATGTAATTTGTACAGGGGCCATGCCCCACCCCCCTCCT





CCCCCTTTGGGGTAGACCTTGAGGGTGGGCCAGCATAGGGGGGAGGGTCTT





TTACCCTGTGTCAGAGCCTACCTTCACCACCTATATCCAGAAGGGGAGCTT





TTTCAGAAACAGGGCAGCAGTGGGGTGAAATTTTCTTAACCCCTAAGACTG





CCTTCAGTAGGAACAAGCTGGCTTCTGTGATTAGGTGAAGGGATGGGGGAA





GATTTTATGCACAGCCTAGTTATCAAGGGGATGATTTGCCGACATGTTTGA





GAACCCCCTAACCTCTAACCCTCATTGCTGTCTTGCCCCAGTTTGGGGTGC





CAAGATGGAAGTCACCTTTCTGGGCTTTCTCCTGGAGATAGCTGGGGCTTA





TGGGTGGCTTTCAAGGCTGGGGCATGGCAAATCAGGGGCCAGAGAGCAGGG





GAGCTTGGGACTCAGGTCTGTAACTGCCCAGCCCCTTTTCTCTGCTCTTGT





TTCACTCCACCATCACTCACTCACTCCCCACTCCCCCACCCATGGGGAGGA





GACCTTTGATGAATTCTTCCTCTCCTTCCCACAAAAGACAGACCCAGTGAG





TGAATCAGGCAAAGTGCTTATAATGTGTGTTGTGTGAGCGTGGCCTTGGGA





GGACATGCGTGTGTCAGGGATGAGTTGAGGTGATATTTTTATGTGCAGCGA





CCCTTGGTGTTTCCCTTCCTCGGTGGCTCTGGGGTATGTGTGTGTGGGTGT





GTGCGCCTGAGTGAGTGTGTGTGCTTGAATGTGAGTGTGTATGTCAGTGGT





TTCTACTTCCCCTGGGATGCTGACCCAGGAATAGTGGACATGGTCACAGTC





CTATGTACAGAGCTTTCTTTTGTATTAAAAAAAAATACTCTTTCAATAAAT





GTATCATTTTTGTGCACAGA. (SEQ ID NO: 300;





NM_001292001.2),







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:300 under stringent hybridization conditions


In some embodiments, GLI family zinc finger 2 (GLI2, CJS, HPE9, PHS2, THP1, TH P2) comprises the amino acid sequence:









METSASATASEKQEAKSGILEAAGFPDPGKKASPLVVAAAAAAAVAAQGVP





QHLLPPFHAPLPIDMRHQEGRYHYEPHSVHGVHGPPALSGSPVISDISLIR





LSPHPAGPGESPFNAPHPYVNPHMEHYLRSVHSSPTLSMISAARGLSPADV





AQEHLKERGLFGLPAPGTTPSDYYHQMTLVAGHPAPYGDLLMQSGGAASAP





HLHDYLNPVDVSRFSSPRVTPRLSRKRALSISPLSDASLDLQRMIRTSPNS





LVAYINNSRSSSAASGSYGHLSAGALSPAFTFPHPINPVAYQQILSQQRGL





GSAFGHTPPLIQPSPTFLAQQPMALTSINATPTQLSSSSNCLSDTNQNKQS





SESAVSSTVNPVAIHKRSKVKTEPEGLRPASPLALTQGQVSGHGSCGCALP





LSQEQLADLKEDLDRDDCKQEAEVVIYETNCHWEDCTKEYDTQEQLVHHIN





NEHIHGEKKEFVCRWQACTREQKPFKAQYMLVVHMRRHTGEKPHKCTFEGC





SKAYSRLENLKTHLRSHTGEKPYVCEHEGCNKAFSNASDRAKHQNRTHSNE





KPYICKIPGCTKRYTDPSSLRKHVKTVHGPDAHVTKKQRNDVHLRTPLLKE





NGDSEAGTEPGGPESTEASSTSQAVEDCLHVRAIKTESSGLCQSSPGAQSS





CSSEPSPLGSAPNNDSGVEMPGTGPGSLGDLTALDDTPPGADTSALAAPSA





GGLQLRKHMTTMHRFEQLKKEKLKSLKDSCSWAGPTPHTRNTKLPPLPGSG





SILENFSGSGGGGPAGLLPNPRLSELSASEVTMLSQLQERRDSSTSTVSSA





YTVSRRSSGISPYFSSRRSSEASPLGAGRPHNASSADSYDPISTDASRRSS





EASQCSGGSGLLNLTPAQQYSLRAKYAAATGGPPPTPLPGLERMSLRTRLA





LLDAPERTLPAGCPRPLGPRRGSDGPTYGHGHAGAAPAFPHEAPGGGARRA





SDPVRRPDALSLPRVQRFHSTHNVNPGPLPPCADRRGLRLQSHPSTDGGLA





RGAYSPRPPSISENVAMEAVAAGVDGAGPEADLGLPEDDLVLPDDVVQYIK





AHASGALDEGTGQVYPTESTGFSDNPRLPSPGLHGQRRMVAADSNVGPSAP





MLGGCQLGFGAPSSLNKNNMPVQWNEVSSGTVDALASQVKPPPFPQGNLAV





VQQKPAFGQYPGYSPQGLQASPGGLDSTQPHLQPRSGAPSQGIPRVNYMQQ





LRQPVAGSQCPGMTTTMSPHACYGQVHPQLSPSTISGALNQFPQSCSNMPA





KPGHLGHPQQTEVAPDPTTMGNRHRELGVPDSALAGVPPPHPVQSYPQQSH





HLAASMSQEGYHQVPSLLPARQPGFMEPQTGPMGVATAGFGLVQPRPPLEP





SPTGRHRGVRAVQQQLAYARATGHAMAAMPSSQETAEAVPKGAMGNMGSVP





PQPPPQDAGGAPDHSMLYYYGQIHMYEQDGGLENLGSCQVMRSQPPQPQAC





QDSIQPQPLPSPGVNQVSSTVDSQLLEAPQIDFDAIMDDGDHSSLFSGALS





PSLLHSLSQNSSRLTTPRNSLTLPSIPAGISNMAVGDMSSMLTSLAEESKF





LNMMT. (SEQ ID NO: 301; NP_001358200.1),







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:301)


In some embodiments, the nucleic acid sequence encoding GLI2 comprises the nucleic acid sequence:









GCTGATGGATTGCAGAAGTGCCGGCGCTTGCCAGCCGAGGCAGCACGGCTC





CGCGGACTTTTTTTCAAACTCCCATCAATGAGACTTCGAGGAGGAGCGGGC





GGCGGCGGCGGCTGCGACTGCGAACGCGGAGGAAGGCCAGGAGCCGCAGGA





GGAGCCGGAGGAAAGAGCTTGGGCCGCGCGGCGCGCCGCAGCCTCGGGGAG





CCGCCTGCTCGCCGGCGGTAGGGGCTGCGCGGCGCCCGCCCGCCTCTCGGT





CCCCTCTCTTGCCTGGCCCGCCCCGCCCCGGCTGGCTGGAGCCCCGGCACA





AGGCAGCCAGCCGAGGGTCGCCGCGCCAGCCAAGGTGGGATGGGGGCCCAC





AGCCACCGCCCGGCGCCCGAGAGGCCACCTGCGTGCTAGAGGCAAACTTTT





GTCTCTCTCGGATTGCCACCCAGGACGATGAGCGGCTGAGATGGAGACGTC





TGCCTCAGCCACTGCCTCCGAGAAGCAAGAAGCCAAAAGTGGGATCCTGGA





GGCCGCTGGCTTCCCCGACCCGGGTAAAAAGGCCTCTCCTTTGGTGGTGGC





TGCAGCGGCAGCAGCAGCGGTAGCTGCCCAAGGAGTGCCGCAGCATCTCTT





GCCACCATTCCATGCGCCCCTACCGATTGACATGCGACACCAGGAAGGAAG





GTACCATTACGAGCCTCATTCTGTCCACGGTGTGCACGGGCCCCCTGCCCT





CAGCGGCAGCCCTGTCATCTCTGACATCTCCTTGATCCGGCTTTCCCCGCA





CCCGGCTGGCCCTGGGGAGTCCCCCTTCAACGCCCCCCACCCGTACGTGAA





CCCCCACATGGAGCACTACCTCCGTTCTGTGCACAGCAGCCCCACGCTCTC





CATGATCTCTGCAGCCAGGGGCCTCAGCCCCGCTGATGTGGCCCAGGAGCA





CCTTAAGGAGAGGGGACTGTTTGGCCTTCCTGCTCCAGGCACCACCCCCTC





AGACTATTACCACCAGATGACCCTCGTGGCAGGCCACCCCGCGCCCTACGG





GGACCTGCTGATGCAGAGCGGGGGCGCTGCCAGCGCACCCCATCTCCACGA





CTACCTCAACCCCGTGGACGTGTCCCGTTTCTCCAGCCCGCGGGTGACGCC





CCGCCTGAGCCGCAAGCGGGCGCTGTCCATCTCCCCACTCTCAGACGCCAG





CCTGGACCTGCAGCGGATGATCCGCACCTCACCCAACTCGCTAGTGGCCTA





CATCAACAACTCCCGAAGCAGCTCGGCGGCCAGCGGTTCCTACGGGCATCT





GTCAGCGGGTGCCCTCAGCCCAGCCTTCACCTTCCCCCACCCCATCAACCC





CGTGGCCTACCAGCAGATTCTGAGCCAGCAGAGGGGTCTGGGGTCAGCCTT





TGGACACACACCACCCCTGATCCAGCCCTCACCCACCTTCCTGGCCCAGCA





GCCCATGGCCCTCACCTCCATCAATGCCACGCCCACCCAGCTCAGCAGCAG





CAGCAACTGTCTGAGTGACACCAACCAGAACAAGCAGAGCAGTGAGTCGGC





CGTCAGCAGCACCGTCAACCCTGTCGCCATTCACAAGCGCAGCAAGGTCAA





GACCGAGCCTGAGGGCCTGCGGCCGGCCTCCCCTCTGGCGCTGACGCAGGG





CCAGGTGTCTGGACACGGCTCATGTGGGTGTGCCCTTCCCCTCTCCCAGGA





GCAGCTGGCTGACCTCAAGGAAGATCTGGACAGGGATGACTGTAAGCAGGA





GGCTGAGGTGGTCATCTATGAGACCAACTGCCACTGGGAAGACTGCACCAA





GGAGTACGACACCCAGGAGCAGCTGGTGCATCACATCAACAACGAGCACAT





CCACGGGGAGAAGAAGGAGTTTGTGTGCCGCTGGCAGGCCTGCACGCGGGA





GCAGAAGCCCTTCAAGGCGCAGTACATGCTGGTGGTGCACATGCGGCGACA





CACGGGCGAGAAGCCCCACAAGTGCACGTTCGAGGGCTGCTCGAAGGCCTA





CTCCCGCCTGGAGAACCTGAAGACACACCTGCGGTCCCACACCGGGGAGAA





GCCATATGTGTGTGAGCACGAGGGCTGCAACAAAGCCTTCTCCAACGCCTC





GGACCGCGCCAAGCACCAGAATCGCACCCACTCCAACGAGAAACCCTACAT





CTGCAAGATCCCAGGCTGCACCAAGAGATACACAGACCCCAGCTCTCTCCG





GAAGCATGTGAAAACGGTCCACGGCCCAGATGCCCACGTCACCAAGAAGCA





GCGCAATGACGTGCACCTCCGCACACCGCTGCTCAAAGAGAATGGGGACAG





TGAGGCCGGCACGGAGCCTGGCGGCCCAGAGAGCACCGAGGCCAGCAGCAC





CAGCCAGGCCGTGGAGGACTGCCTGCACGTCAGAGCCATCAAGACCGAGAG





CTCCGGGCTGTGTCAGTCCAGCCCCGGGGCCCAGTCGTCCTGCAGCAGCGA





GCCCTCTCCTCTGGGCAGTGCCCCCAACAATGACAGTGGCGTGGAGATGCC





GGGGACGGGGCCCGGGAGCCTGGGAGACCTGACGGCACTGGATGACACACC





CCCAGGGGCCGACACCTCAGCCCTGGCTGCCCCCTCCGCTGGTGGCCTCCA





GCTGCGCAAACACATGACCACCATGCACCGGTTCGAGCAGCTCAAGAAGGA





GAAGCTCAAGTCACTCAAGGATTCCTGCTCATGGGCCGGGCCGACTCCACA





CACGCGGAACACCAAGCTGCCTCCCCTCCCGGGAAGTGGCTCCATCCTGGA





AAACTTCAGTGGCAGTGGGGGCGGCGGGCCCGCGGGGCTGCTGCCGAACCC





GCGGCTGTCGGAGCTGTCCGCGAGCGAGGTGACCATGCTGAGCCAGCTGCA





GGAGCGCCGCGACAGCTCCACCAGCACGGTCAGCTCGGCCTACACCGTGAG





CCGCCGCTCCTCCGGCATCTCCCCCTACTTCTCCAGCCGCCGCTCCAGCGA





GGCCTCGCCCCTGGGCGCCGGCCGCCCGCACAACGCGAGCTCCGCTGACTC





CTACGACCCCATCTCCACGGACGCGTCGCGGCGCTCGAGCGAGGCCAGCCA





GTGCAGCGGCGGCTCCGGGCTGCTCAACCTCACGCCGGCGCAGCAGTACAG





CCTGCGGGCCAAGTACGCGGCAGCCACTGGCGGCCCCCCGCCCACTCCGCT





GCCGGGCCTGGAGCGCATGAGCCTGCGGACCAGGCTGGCGCTGCTGGACGC





GCCCGAGCGCACGCTGCCCGCCGGCTGCCCACGCCCACTGGGGCCGCGGCG





TGGCAGCGACGGGCCGACCTATGGCCACGGCCACGCGGGGGCTGCGCCCGC





CTTCCCCCACGAGGCTCCAGGCGGCGGAGCCAGGCGGGCCAGCGACCCTGT





GCGGCGGCCCGATGCCCTGTCCCTGCCGCGGGTGCAGCGCTTCCACAGCAC





CCACAACGTGAACCCCGGCCCGCTGCCGCCCTGTGCCGACAGGCGAGGCCT





CCGCCTGCAGAGCCACCCGAGCACCGACGGCGGCCTGGCCCGCGGCGCCTA





CTCGCCCCGGCCGCCTAGCATCAGCGAGAACGTGGCGATGGAGGCCGTGGC





GGCAGGAGTGGACGGCGCGGGGCCCGAGGCCGACCTGGGGCTGCCGGAGGA





CGACCTGGTGCTTCCAGACGACGTGGTGCAGTACATCAAGGCGCACGCCAG





TGGCGCTCTGGACGAGGGCACCGGGCAGGTGTATCCCACGGAAAGCACTGG





CTTCTCTGACAACCCCAGACTACCCAGCCCGGGGCTGCACGGCCAGCGCAG





GATGGTGGCTGCGGACTCCAACGTGGGCCCCTCCGCCCCTATGCTGGGAGG





ATGCCAGTTAGGCTTTGGGGCGCCCTCCAGCCTGAACAAAAATAACATGCC





TGTGCAGTGGAATGAGGTGAGCTCCGGCACCGTAGACGCCCTGGCCAGCCA





GGTGAAGCCTCCACCCTTTCCTCAGGGCAACCTGGCGGTGGTGCAGCAGAA





GCCTGCCTTTGGCCAGTACCCGGGCTACAGTCCGCAAGGCCTACAGGCTAG





CCCTGGGGGCCTGGACAGCACGCAGCCACACCTGCAGCCCCGCAGCGGAGC





CCCCTCCCAGGGCATCCCCAGGGTAAACTACATGCAGCAGCTGCGACAGCC





AGTGGCAGGCAGCCAGTGTCCTGGCATGACTACCACTATGAGCCCCCATGC





CTGCTATGGCCAAGTCCACCCCCAGCTGAGCCCCAGCACCATCAGTGGGGC





CCTCAACCAGTTCCCCCAATCCTGCAGCAACATGCCAGCCAAGCCAGGGCA





TCTGGGGCACCCTCAGCAGACAGAAGTGGCACCTGACCCCACCACGATGGG





CAATCGCCACAGGGAACTTGGGGTCCCCGATTCAGCCCTGGCTGGAGTGCC





ACCACCTCACCCAGTCCAGAGCTACCCACAGCAGAGCCATCACCTGGCAGC





CTCCATGAGCCAGGAGGGCTACCACCAGGTCCCCAGCCTTCTGCCTGCCCG





CCAGCCTGGCTTCATGGAGCCCCAAACAGGCCCGATGGGGGTGGCTACAGC





AGGCTTTGGCCTAGTGCAGCCCCGGCCTCCCCTCGAGCCCAGCCCCACTGG





CCGCCACCGTGGGGTACGTGCTGTGCAGCAGCAGCTGGCCTACGCCAGGGC





CACAGGCCATGCCATGGCTGCCATGCCGTCCAGTCAGGAAACAGCAGAGGC





TGTGCCCAAGGGAGCGATGGGCAACATGGGGTCGGTGCCTCCCCAGCCGCC





TCCGCAGGACGCAGGTGGGGCCCCGGACCACAGCATGCTCTACTACTACGG





CCAGATCCACATGTACGAACAGGATGGAGGCCTGGAGAACCTCGGGAGCTG





CCAGGTCATGCGGTCCCAGCCACCACAGCCACAGGCCTGTCAGGACAGCAT





CCAGCCCCAGCCCTTGCCCTCACCAGGGGTCAACCAGGTGTCCAGCACTGT





GGACTCCCAGCTCCTGGAGGCCCCCCAGATTGACTTCGATGCCATCATGGA





TGATGGCGATCACTCGAGTTTGTTCTCGGGTGCTCTGAGCCCCAGCCTCCT





CCACAGCCTCTCCCAGAACTCCTCCCGCCTCACCACCCCCCGAAACTCCTT





GACCCTGCCCTCCATCCCCGCAGGCATCAGCAACATGGCTGTCGGGGACAT





GAGCTCCATGCTCACCAGCCTCGCCGAGGAGAGCAAGTTCCTGAACATGAT





GACCTAGAGGCCCGAGCGCCTGGTGCTGAGTGCACCCGGAGGGGTCATCGC





TGCCCAGAGCCTGGGGATTCCAGCTGTCTTGTCTTTTTCCAAAAAAGTGTT





AAATAGGCTTGAGGGGTTGTTGCGCAATGGCCGCTTCAGATGACAGATGTT





GTAAGAGAAGGTTTATGGGCATCCTCTCTGGTCTTTTGGATTATTCCTCAG





AACAATGAAAAAAGTCTCCATAGGACAGGAAGGAATGCAAAACTCATTTAC





ACAGTGCTTTCCAGCCTTTGGTGCTTACAGGACCGCGCTGTTCCGGCTTCT





TCACGGCTGACATTCGGCTAACGAGGGATTACTTTGGCCAAAACCTTTCAA





AGGATATGCAGAAAGATGGTAGGGAGCATTTGGGTTTGAATCTGAATGCTA





TACTGGATACTCTGCTCCGGAAAGATGAGCTTTTTATTCTACTACTTGGAA





GGAAAAGGAATTCCTGGTCCACCTGAATTCCTCTATGAAGCCTAACTCTTG





AGGTCTCTAACATACCTTGTCATAGAGGAAAAGCACAGATTATACCTGGAT





GATTCAGGAGCACATTCTGATTCCAGGTTTGGTAGAGCTGGCTCTTCTACT





CCGTAAAGCCGAGTCTGGGACTGGCAGCCCATCCAAGTGTATATGAATGAA





TAAAGCATCCAAGTATATATGAATGAATAAAGTATGTAAGTATCACCAGAA





AAAGGAAAGAAAAAATGTACTCCTTGGGGCAAGCCCAGAAGCTGCCCTGGC





CTCTCCAGACCGTGTTTACAGTGTTTGCATGTAGAATGTAGCCCTTCCTGA





AAAGAAGACTTGTTTCTAAATACCTCGGGGCTGCTGGAGCCGCTGTGGGTT





AGGGATGGACTGAGGCCTCGAGGAGTGAGGGTGCACCCGGGGCCCAGCCTC





AGGCTGCCCTAGGGATCTCTCAGTAGGAAGAGGAAGTTGCGTGTTTACCCA





ATCCTGTTTCTCCAATGCAACGTCCACCCACTTTACCACCAAAAACTCCAG





GGCCTGACGGCAGCCCGGTCCCCCAGCACTCACCAGCAGCCCAGTGTTCTC





CACCAAGCCACAGTGTGCATGCCTGGTATCCTCCGGATTCCCTTCCTTCTG





CCCGCTGAGTCACTGGGCAGAGAATGATGACATGTGTAGGTGGTGTGGTTG





GGGGTGGAAAGGGGAAGGGGTTGATCCTCAGGACTCTGAGGGAGCATCGTT





GAATTTTCCTGTTCAGTGTGACCAAGACCCACCTGGAAATGGAATTTGGAA





CTGGCTTCAGGAGACATCATTCCTGAACACACTGTAGGGTGAATTGGTGCA





TCTTCCCCACCATACACACACACACACACACACACACACACACACACACAC





ACACACCCCAAACCTTTTCATGGGGAATGTGTGGCAACCTTGCCAAACAGC





ACCACTCAGAGTGTGACTCTGACTGTGACCTTGGCCTTAATGAGGAACTTC





TTAGGAGAGTTTGAGGACAAGGCCAACATCGTCATCTGGGCTCGCTGCGTC





CCAGCACATCAAACTCTGTCCAGAGACAAGGCCAACTGCAAATGAAAGCCA





GGGAACATTGCTAAGGGTCTGTGGCTCTGTGGTGGTGTTCATCGCCTTCCT





GAGATAGGATTTCCCTTGCCAGTCCCAACCTGTATATATTCTGTACAGAAG





ACATCCCTGAATATACTGTAGGTGAGTCGTCCAGCCAAATTTATATCTCCA





AAACATTTTTAGCTTTTTCTACATGCTATGAATTGAGATGACATGCTCAAC





TTGTAAATAAGTCTTTTTGTACATTAAAAAAGTAATTTTTTCATAATTTAT





CTTGTCTATCTGCTTCCCCCTTGACAGTAGTTAATGAGAACCTGGGCAGTA





AATTTGGTGCATTCGAGCAGAAATTAGGCTGTATTTTTTCTTAACAGTGTC





AAAATTGACTATCCCGCCTTTGCCAAGAAATGTTTAATGCTGAGGCA.





(SEQ ID NO: 302; NM 001371271.1),







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:302 under stringent hybridization conditions


In some embodiments, Sp4 transcription factor (SP4, HF1B, SPR-1) comprises the amino acid sequence:












MATEGGKTSEPENNNKKPKTSGSQDSQPSPLALLAATCSKIGTPGENQAT





GQQQIIIDPSQGLVQLQNQPQQLELVTTQLAGNAWQLVASTPPASKENNV





SQPASSSSSSSSSNNGSASPTKTKSGNSSTPGQFQVIQVQNPSGSVQYQV





IPQLQTVEGQQIQINPTSSSSLQDLQGQIQLISAGNNQAILTAANRTASG





NILAQNLANQTVPVQIRPGVSIPLQLQTLPGTQAQVVTTLPINIGGVTLA





LPVINNVAAGGGTGQVGQPAATADSGTSNGNQLVSTPTNTTTSASTMPES





PSSSTTCTTTASTSLTSSDTLVSSADTGQYASTSASSSERTIEESQTPAA





TESEAQSSSQLQPNGMQNAQDQSNSLQQVQIVGQPILQQIQIQQPQQQII





QAIPPQSFQLQSGQTIQTIQQQPLQNVQLQAVNPTQVLIRAPTLTPSGQI





SWQTVQVQNIQSLSNLQVQNAGLSQQLTITPVSSSGGTTLAQIAPVAVAG





APITLNTAQLASVPNLQTVSVANLGAAGVQVQGVPVTITSVAGQQQGQDG





VKVQQATIAPVTVAVGGIANATIGAVSPDQLTQVHLQQGQQTSDQEVQPG





KRLRRVACSCPNCREGEGRGSNEPGKKKQHICHIEGCGKVYGKTSHLRAH





LRWHTGERPFICNWMFCGKRFTRSDELQRHRRTHTGEKRFECPECSKRFM





RSDHLSKHVKTHQNKKGGGTALAIVTSGELDSSVTEVLGSPRIVTVAAIS





QDSNPATPNVSTNMEEF. (SEQ ID NO: 303; NP_001313471.





1),







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:303)


In some embodiments, the nucleic acid sequence encoding SP4 comprises the nucleic acid sequence:










ACAGCCCAGCGGCGGCCATTCGCGGAAAAAGAGGCAGAGCCTGTGCCAGCTACA






GCCTCCTCCGAGCCACCGCGGGCGGGCGGGACCGGCCTCTCCTCCCGCCTCGCC





CCCACCCCCACCCACCTCTATCCCAGTGTCTCCGTCTGAGGGTTTGTCCTGTTAAT





GCGGGATGAGCGAAGAAGGAGGAGGAGGAGGAGGCGGCAGCGGCAGCGGCGAT





GGCTACAGAAGGAGGGAAAACCTCTGAGCCAGAGAATAACAATAAAAAACCCAAAA





CCTCAGGCTCCCAGGACTCTCAGCCCTCTCCTCTGGCTTTACTGGCAGCTACTTGC





AGCAAAATAGGGACTCCTGGTGAAAATCAAGCAACTGGACAACAACAAATTATTATA





GATCCAAGTCAAGGATTGGTGCAACTTCAAAATCAACCACAACAGCTAGAACTGGT





AACAACGCAACTTGCTGGAAACGCTTGGCAACTTGTTGCCTCCACTCCTCCTGCTT





CAAAAGAGAATAACGTTTCTCAACCAGCCTCTAGTTCGTCTAGTTCTTCCAGCAGTA





ATAACGGGAGTGCATCTCCTACAAAAACTAAATCAGGTAATTCTTCCACCCCTGGTC





AATTTCAAGTCATACAAGTACAAAATCCAAGTGGTAGTGTACAGTACCAAGTAATTC





CACAACTTCAGACAGTGGAAGGTCAACAAATTCAAATCAATCCAACTAGTAGTTCAT





CTCTACAGGATTTGCAGGGTCAAATTCAGCTCATTTCTGCAGGTAATAATCAAGCTA





TACTCACAGCTGCTAACAGGACAGCTTCTGGGAATATTCTTGCTCAAAACCTGGCA





AATCAGACAGTTCCGGTCCAAATTAGACCTGGTGTTTCAATACCACTGCAGTTACAG





ACTCTTCCTGGTACTCAGGCTCAAGTTGTAACAACCCTACCAATTAACATTGGAGGA





GTGACTCTAGCTTTGCCAGTGATAAACAACGTGGCTGCCGGAGGAGGGACTGGGC





AGGTTGGCCAGCCTGCTGCTACTGCTGATAGTGGGACTTCCAATGGGAATCAATTA





GTTTCCACACCCACCAACACCACTACTTCTGCCAGTACTATGCCAGAATCTCCCTCC





TCCTCCACTACCTGCACAACCACTGCTTCAACGTCTTTGACAAGCAGTGACACATTA





GTGAGCTCAGCAGATACTGGCCAGTATGCAAGCACATCAGCCAGTAGTTCTGAACG





CACCATTGAAGAATCTCAAACACCTGCTGCTACTGAGTCTGAAGCCCAGAGCTCCA





GTCAGCTTCAGCCTAATGGAATGCAGAATGCACAGGATCAATCAAATTCTCTTCAGC





AGGTGCAAATTGTAGGCCAACCTATCTTACAGCAGATCCAGATCCAACAGCCTCAG





CAACAGATCATTCAGGCTATTCCACCACAGTCGTTTCAACTCCAGTCAGGGCAGAC





GATTCAGACCATCCAGCAGCAGCCTTTACAGAATGTTCAACTTCAAGCAGTAAATCC





GACTCAGGTGCTTATCAGGGCTCCAACTTTAACACCTTCAGGGCAAATCAGTTGGC





AAACTGTACAGGTTCAGAATATTCAGAGTCTTTCAAATTTGCAAGTTCAGAATGCTG





GGTTATCCCAACAATTAACCATCACCCCAGTGTCTTCAAGTGGTGGCACAACTCTTG





CTCAGATTGCTCCTGTGGCTGTTGCTGGTGCCCCAATAACTTTGAATACTGCCCAG





CTTGCATCAGTGCCTAACCTTCAGACAGTGAGCGTTGCCAACCTGGGTGCTGCAG





GTGTTCAAGTGCAGGGAGTTCCCGTTACAATCACTAGTGTTGCAGGTCAGCAGCAA





GGACAAGATGGAGTAAAAGTCCAGCAAGCTACTATAGCTCCTGTAACTGTAGCAGT





TGGAGGAATTGCTAATGCCACGATAGGTGCTGTTAGTCCTGACCAACTCACACAAG





TGCATTTGCAGCAAGGCCAGCAGACTTCTGATCAAGAGGTACAACCTGGCAAGAG





GCTTCGAAGAGTTGCCTGTTCCTGTCCTAATTGTAGGGAAGGAGAAGGAAGAGGCA





GTAATGAACCAGGAAAAAAGAAGCAGCATATCTGTCATATTGAAGGATGTGGTAAA





GTTTATGGCAAAACATCTCATTTACGAGCACATCTTCGCTGGCATACTGGAGAAAGA





CCTTTTATATGCAACTGGATGTTTTGTGGCAAAAGATTCACACGGAGTGATGAGCTC





CAGAGACATAGAAGAACCCATACAGGTGAAAAGAGATTTGAATGCCCGGAATGTTC





TAAAAGGTTTATGCGGAGTGATCATCTCTCCAAACATGTCAAAACGCACCAGAATAA





AAAAGGTGGTGGGACAGCTCTTGCCATTGTTACCTCGGGAGAACTGGACTCATCTG





TTACAGAGGTGCTTGGCTCCCCAAGAATTGTCACAGTTGCAGCCATTTCTCAAGATT





CGAATCCAGCAACTCCCAATGTTTCAACCAACATGGAAGAATTCTGAAAAGTTATTT





ATAACAGAGACCTCTAGTGCTGCACTTGTTTACACACCTTTGAAAATCTGGAAATGG





GCTGGTCAAGTGGATTACAGAGTAGGAAATTATGTTTTCATTCTTGGCTTCTTTAAG





TATTCCAGGGTTTGGGGTCAACACGTGAAGTGTTGAATTTTAAAAAATACAAAAAGC





AGACTGATGTACTGGAAACAGAAAAGTATTTCCTCCATACTATAAGTTGTAGTTGTTT





GGAAATATATCACATAACCTTTATACAGAATCTTCCCATCTCTTAATATCATGTGTTA





ACATGTTTAAAAAGACCTTAGTAGTTTGCAGGCTGGACCTTAATTGGACTTATTTTCT





TTGAAAGTACTTTGTTATAAATTCAGTCAGTAATAATTTACGTGTATTCTTTTTCTCTA





TAGCACAGAAAACAGATAGTTAACTGATGATAGGGATAATACTGTATTTCCTTAGCT





TGATTTTTGGAAAATCAACCGAAAATAGTTTGGCCGTCTTTTCTAAATGTTAGAAATT





CTTCAACAGTTGAATTAGGTAAGTTCCAAAACAGTAATCTGAGATGCATCTCAGATC





TTTATTACCACTACATTATAGTAGTGTGTATGCAGACAATCAGTGAAGTCCAATTACT





TTCTCCATTTGGAGACACAAGAGGAACATAGAGTTAAATCTTAGGTTAAATTTTAGG





TTGACACCTTAGGAAAATGCTGGGAAAAAAATGGTTAAAACAAAACTCATCATAGCT





TCAGAAAAATAAAATGAGGCATCTTAACATGCAATGTTCTAAAGTTAGGATTGATTAT





ATTCCTAACCCTAGGTTGAACCACAAAATTTCATTTAAAATGTTTATATTTGGAAATA





TTTGCATAGAGTGTAAATTGTTCTGTAGTTTCATATTTTGTAAATATGAGTTATGTTG





ACAATGTGCAGAATTCTTTATGCTTTGATGTGGTAGCCAAAGAAAGAATTACACTTTT





TTCCAAGGCCAGCAGAAAATTCTCTTTTAACTACATTGTAATTCTTGTTTTCCTCTAC





TAAAAATTGGCCAGTCCCATTTTATTTCTAGTGCTATGTAAGAAGGTAATTAGGAATT





ATAACACAGTAATGTTTTTATGTTACATCAATAACTGAATTTTCCCTAAAAATTAGCCT





AATATATAATAGATATATTATGAAGCAAAACTTTTATTTTTGAAAAGGCAGAATAATTT





TCAGTGAAGTAAGTGACTAAAGAAAAAAACTATATTATTGTTTATGCAAGGGTCTTAC





AGGAAAGGGTCTTTTTTTTTTTTTTTTTGAGATGGAGTCTCGCTCTCTTGCCCAGGC





TGGAGTGCAATGGCACGATCTCAGCTTACTGCAACCGCCGCCTCCCAGGTTCAAG





CGATTCTCCTGTCTTAGCCTCCTGAGTAGCTGGGATTAACAGGCGCCTGCCACCAT





GCCTGGCTAATTTTTGTATTTTTAGTAGAGACAGGGTTTCGCCATGTTGGCCAGGCT





GGTTTCAAACTCCTGACCTCAGGTGATCTGCCCACCTCGGCCTCCCAGAGTGCTG





GGATTACAGGCATGAGCCACCATGCCCGGCTAGGAAAGGGTCTTACTAGGAAAGA





TGGCCAAAAGTTTCATATGAAAAAAATTGGATTATAAACCAGTAACTTAAATATTAAT





AAGGATATTTTATGTTTTAAAAAAGTATTTACACAGAATCATAATCAGTGAAATTGAC





CATTTGAAAACTAAAAGTTTTTACCTACCTGCTCAATTTATTAACATCATTGCTTTGG





GGACTGTTTGAATATAGGTACGTGTTTTCTTGTGCATTCTCTATAATTTCAGGAAAAG





TACTAATGCGAATTCTCTTCCAAAATTGTGATGTTTCTTGTATTTTTGATGAAGGAGA





AATACTGTAATGATCACTGTTTACACTATGTACACTTTAGGCCAGCCCTTTGTAGCG





TTATATAAAACTGAAGGTCTTTTGTGCTTTCAGTTTGTATAAAAAAGCTTTGAGATTA





AAGGAAAAAAAAAATTTTTACACTGTGGTTATAAATTTCAAGTTTCTTAAAGCTTTTGT





AGACTTGTAACAGAGTCTTTAAATTTAAGTTGGATTTTGTAAATTGTTTTGTATATTTT





ATTTAATGTACTCTTAACAACTGATGTATCTGGCTTTAAAACATCAGAATTGGTTTGT





TGTTTTGTTTGGTACAGAGGAGCATTTGGTAGTGTTCATTTTAATTTTATTATATAGG





AGCTGAAACATCAAATATATATTTTATCTATCATTATGCTACACAATCAGTGCTATAA





ATTTTTTTATGCAAAGAAACTTTCTTAATGTTTTAATCATGTTTCCTCAGAGTGACACT





TTTTGTTGTTGTTAATACCAAGTATGAACACTCTGCATCATTATTCCATGAACCAGTT





CTAATGCAAACCTATGTATGTCCATTAGAAATGGAAGTTATTTTTTAATCAACAATGA





GGCCTATTATAAATTTATCAGATGAATCTAGATAGCTTTATAGCATATAAAATATGTT





AATTTGTGTTAGCAGGTGCACATTTCACCACTGAAATTAGAAATATTTTGACAGTCT





GTTCTGCATACCATTCTGAGTCTACTTTTCTGTCTTTAGAAGAATCGTAAATTTCAGT





GTCCTTTATTTGACTCAGTGGGATATAGCTGTTATAAGTAATAGGGCACAGATGTGC





AGTAGAGTCTTGTTTAATGGCATTTCACTGTTCATTCCCTTTACCACCGTTATAAAAC





TTTTCTTTATTGTAATTATCAGTGCAAAGCTATGTATTTATCATGGTAAAACTCCAGT





GTTAGAATAGTTTTTTCTTACAGTATACTTTCTTTGGTTAGGTTTGTGTATGTGTTGC





TGATTACATTAGAACTTGATGTTAAGTCATTTATCACACTCTCATGAGAGCAGTAATA





AAAGTGTGTAATCTAGGAGAAAAAGTTAATTTGTCAAACTTAGATAAGCATGATGTTT





AGGTCCTATTTTTCAATTTTATAACTGTTTTATTGCAACAATATTTGTATTTAAGTCTC





CATTTTAATGCCTTGTGGTGTTTTTTTATGCATGTCACTAAGTTGTCATCCCACATAA





ATTGATGTGCAGCATAGGGTATTAAATCTACATAATGATTTTAAAACAGAAATAGTTG





ATGGTAAAATGTAAATGTTTTGCAAAAATTCCTTATAAAAAGTTTTGTAGTAACATTTC





ACTTGTAAATTTTTTTTGTAAAAAAAAAAAAATGAAAAAAAAAGATGAATCCAGAAAA





AAACCTGTTTCCCATATTCTAGAATTTAGACAATTATTCTGCCAGCAAAGCCTCTGG





GGCTGTAATTGACATTTTTACAGTGCTGATTTGTATAAAATTTGTTTTTTGTGGATTT





GGAAATAAAATCATGTACAAGTTGTTGCCTGCAATAACAATTGCAAGTAACCTATTA





AAAATTCCCTTGAGTTTAACATGTTTCATTTAATTATGTATACTATAAAGCAGCAATAA





ATTATTTGAACTATCAACCTA. (SEQ ID NO: 304; NM_001326542.2),







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:304 under stringent hybridization conditions


In some embodiments, activating transcription factor 2 (ATF2, HB16, CREB2, TREB7, CRE-BP1) comprises the amino acid sequence:









MKFKLHVNSARQYKDLWNMSDDKPFLCTAPGCGQRFTNEDHLAVHKHKHE





MTLKFGPARNDSVIVADQTPTPTRFLKNCEEVGLFNELASPFENEFKKAS





EDDIKKMPLDLSPLATPIIRSKIEEPSVVETTHQDSPLPHPESTTSDEKE





VPLAQTAQPTSAIVRPASLQVPNVLLTSSDSSVIIQQAVPSPTSSTVITQ





APSSNRPIVPVPGPFPLLLHLPNGQTMPVAIPASITSSNVHVPAAVPLVR





PVTMVPSVPGIPGPSSPQPVQSEAKMRLKAALTQQHPPVTNGDTVKGHGS





GLVRTQSEESRPQSLQQPATSTTETPASPAHTTPQTQSTSGRRRRAANED





PDEKRRKFLERNRAAASRCRQKRKVWVQSLEKKAEDLSSLNGQLQSEVTL





LRNEVAQLKQLLLAHKDCPVTAMQKKSGYHTADKDDSSEDISVPSSPHTE





AIQHSSVSTSNGVSSTSKAEAVATSVLTQMADQSTEPALSQIVMAPSSQS





QPSGS. (SEQ ID NO: 305; NP_001243019.1),







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:305)


In some embodiments, the nucleic acid sequence encoding ATF2 comprises the nucleic acid sequence:










GTCAGTCCGATCTCGCGAGAGAGGACGGAAGCCTGTGGGAGCCCGTGGCCTTTAA






AGTGCCGTTCAGCCTTTTCCTCCAGGGGTGCTTTGTAAACACGGCTGTGCTCAGGG





CTCGCGGGTGACCGAAAGGATCATGAACTAGTGACCTGGAAAGGGTACTAGATGG





AAACTTGAGAAAGGACTGCTTATTGATAACAGCTAAGGTATTCCTGGAAGCAGAGTA





AATAAAGCTCATGGCCCACCAGCTAGAAAGATTTCCTGAAGAGGTAGTCTGATTGG





CTTAACTCGTATTCTTGCCATGAGAAAAAGAATGTGATAAGTTATTCAACTTATGAAA





TTCAAGTTACATGTGAATTCTGCCAGGCAATACAAGGACCTGTGGAATATGAGTGAT





GACAAACCCTTTCTATGTACTGCGCCTGGATGTGGCCAGCGTTTTACCAACGAGGA





TCATTTGGCTGTCCATAAACATAAACATGAGATGACACTGAAATTTGGTCCAGCACG





TAATGACAGTGTCATTGTGGCTGATCAGACCCCAACACCAACAAGATTCTTGAAAAA





CTGTGAAGAAGTGGGTTTGTTTAATGAGTTGGCGAGTCCATTTGAGAATGAATTCAA





GAAAGCTTCAGAAGATGACATTAAAAAAATGCCTCTAGATTTATCCCCTCTTGCAAC





ACCTATCATAAGAAGCAAAATTGAGGAGCCTTCTGTTGTAGAAACAACTCACCAGGA





TAGTCCTTTACCTCACCCAGAGTCTACTACCAGTGATGAGAAGGAAGTACCATTGG





CACAAACTGCACAGCCCACATCAGCTATTGTTCGTCCAGCATCATTACAGGTTCCC





AATGTGCTGCTTACAAGTTCTGACTCAAGTGTAATTATTCAGCAGGCAGTACCTTCA





CCAACCTCAAGTACTGTAATCACCCAGGCACCATCCTCTAACAGGCCAATTGTCCC





TGTACCAGGCCCATTTCCTCTTCTGTTACATCTTCCTAATGGACAAACCATGCCTGT





TGCTATTCCTGCATCAATTACAAGTTCTAATGTGCATGTTCCAGCTGCAGTCCCACT





CGTTCGACCAGTCACCATGGTGCCTAGTGTTCCAGGAATCCCAGGTCCTTCCTCTC





CCCAACCAGTACAGTCAGAAGCAAAAATGAGATTAAAAGCTGCTTTGACCCAGCAA





CATCCTCCAGTTACCAATGGTGATACTGTCAAAGGTCATGGTAGCGGATTGGTTAG





GACTCAGTCAGAGGAATCTCGACCGCAGTCATTACAACAGCCAGCCACATCCACTA





CAGAAACTCCGGCTTCTCCAGCTCACACAACTCCACAGACCCAAAGTACAAGTGGT





CGTCGGAGAAGAGCAGCTAACGAAGATCCTGATGAAAAAAGGAGAAAGTTTTTAGA





GCGAAATAGAGCAGCAGCTTCAAGATGCCGACAAAAAAGGAAAGTCTGGGTTCAGT





CTTTAGAGAAGAAAGCTGAAGACTTGAGTTCATTAAATGGTCAGCTGCAGAGTGAA





GTCACCCTGCTGAGAAATGAAGTGGCACAGCTGAAACAGCTTCTTCTGGCTCATAA





AGATTGCCCTGTAACCGCCATGCAGAAGAAATCTGGCTATCATACTGCTGATAAAG





ATGATAGTTCAGAAGACATTTCAGTGCCGAGTAGTCCACATACAGAAGCTATACAG





CATAGTTCGGTCAGCACATCCAATGGAGTCAGTTCAACCTCCAAGGCAGAAGCTGT





AGCCACTTCAGTCCTCACCCAGATGGCGGACCAGAGTACAGAGCCTGCTCTTTCAC





AGATCGTTATGGCTCCTTCCTCCCAGTCACAGCCCTCAGGAAGTTGATTAAAAACCT





GCAGTACAACAGTTTTAGATACTCATTAGTGACTTCAAAGGGAAATCAAGGAAAGAC





CAGTTTCCATTTATGCGAAATCTGTGGTTGTAAATTTTTTTTTTTTACTTGAAATTAAA





TTTGGCTCTAAAGTTGGTGTAGCAGCAGTTGATCAGACTGAAAAACGGTTTTTAGTC





TCTGGAAAAAGACTGATTTTGCTTTTTTTATAAATATTATTAGATTTATTAATTTTTCT





GTGCTCAATGTGTAAATTGTATTATAATTCATTGTGATTTATTTCACTTTTAATTTGCT





GGTGTTTTAATAAATGGGGGTGTTACTGAATCTTTCTTCCCACTTCCATTTCTTTTGA





CCACCCCTTAACCCTCAACTGTGACGGTAGTAGTATTATCATTTATACCAAAGTTTT





GCATAGTCCCTGTTGACTTTGTAATGTTAACGGAGTCATAAAAGCACTAGGCAAGA





GAAAGATAGAAATTTGCTTTTAATCTTTTTGCCTTTTATTTTGCACATTATGCAAAAG





GAAAAACATTAAAGAACACTTTTTTTTAAGTGAGTGAAAACATGGTAAAGACATACA





GTGCTTTTATGCACATTGTTAAGCTAAATCAAGGTCATTTATAATCATTTTCCTTTTTT





ATTTAAGATTTTAAGTAAACAAATTTTAGAATTTTCAGCATTTCAAAAATGATTTTATT





TTTCAAGTCTTAAATTCAATATTTTACACCTATGTTTTGAGGCTAAAAATATGAAATTA





TATAATGTATGATACAGGGTTATCAAATATCTAATAATTTTTGAAATTAGCTCTTGTTT





TTGGTTTTTTTGTTGTTGTTTTTACAGATTTCAGGTTACAAACTGCAAAGTTTATGCA





TAATTAAGTATGGTATGGTTGCCAGAAAAGCCTAAAATTACTACTTAGAAAATTTAAG





ACTGTTTACCCCCATTGTCTTGTACTTGCGAGCTAACTTGTACTATTCTTGTGAAAG





CACTGTCATCTTTTAGTAGCAAATTTTGATAATGTTTCTCGTGGAAAAAAAAATCAGT





ATCTATCTTTAGAACAATGTAATTATAATGTGGGAAGTGTGCATGAATGAGAGAGAG





TGTGTGTGTATCTGTGTGTGTGTGCGCGTGTGTGTGTGTCTTTTAATAGTTTATGCC





AGCAATCTTTGCTTGAATGTTTAACGATGCCTTCAGTGTGATGCTGGCCAATAGATG





ATTGCAGTTTAAAATGTCATTATTGTGCAGGCTTGGATAACTAACATTCCATGATGTA





GCTTGTTTCTGATGAGATGATTGTAGGTACATTTTTCTCATTATCCAATCATCTGTGG





GATACTTAGTTTTCTAATGTGCCATTATCTATTTTTATTCTGCAGTTATGTTCAAAATA





CAGTACATATTTTAAAATAGAATAAATTGTTAAACATAAAATTTTAAAAGTAGTAGATG





TGCGTAAGAAAACTTTGTAAAATAGTTATGAGTCCTACCCAGTAGCAACTTCTGGCA





TTCAAGCAGGATTCCACTATGTAAATATCTGTAATGCATTTATAATAAGTTGTGTAGT





TTGTCCTGCATCCATACTACACTATTTGCTAAAGTCTCAGTGCCATCTCCTAATGAG





ACTGACATTTTAAAAGTCTGTATGGAATATCCTTGATAATTCAAGGAAATATCCCTCC





TGCCTAAGTTCCAAACTGGGAAACATTCAAATTATATAAATGACATTTCAGGACTTTA





AGTATGAAGATAATGGGAATTTTATTGTTTTGCTTTTTAAAATGAGAGCATTTTTATTT





GATAATTTTTTTTAAATTTTTAATTTTTAACTAATTTCATTATTTTAAAGTAATCAGTTTT





TCAAATCATGATTTTGATATCATTATTCTAAGGAGTTATCTCAAAGGCACAAAATATG





AATTCTGCAAGAAGGCTATTTTTTATTGTAGTTTGAATGGGTTAGGAAAAGCCTCAA





TTTTTCACTCTTAAGTCCTTCAGTACATTTTTCTTTCATCTTATTACTTATGCAAGTTA





AGGTTCTTTGGTAACAGAATTCTTGCAACTGTAAAATAAAACTACATAGATGTAAGAA





GTCATGTAAACGGTTAACAAGCTTACCAAGGTTAGCAAAACTTTCATTGTAAATCAG





TCTGTACTGAGCAAATAAAAATCATTATTAGTTGTATAAACACAAATTCCATTTTGAC





TTTCAGGATGTCATACTACTTCTGTACCTAGCATTTTCAGTCCTTATATTTGCAATGT





TACACAAACTGTACTATTTTCTTTTATGTGCAGTTTGCATGAGTAAACCATCAGAGAA





TAAATTCTATCTTTAAATTA. (SEQ ID NO: 306; NM_001256090.2),







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:306 under stringent hybridization conditions


In some embodiments, activating transcription factor 3 (ATF3) comprises the amino acid sequence:









MMLQHPGQVSASEVSASAIVPCLSPPGSLVFEDFANLTPFVKEELRFAIQ





NKHLCHRMSSALESVTVSDRPLGVSITKAEVAPEEDERKKRRRERNKIAA





AKCRNKKKEKTECLQKESEKLESVNAELKAQIEELKNEKQHLIYMLNLHR





PTCIVRAQNGRTPEDERNLFIQQIKEGTLQS. (SEQ ID NO: 307;





NP_001025458.1),







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:307)


In some embodiments, the nucleic acid sequence encoding ATF3 comprises the nucleic acid sequence:









GGCGGAGGTGGGGTTAGCTTCAGTTGACCAACCATGCCTTGAGGATAAAT





TGGATGGGATCAGATGGGAAGATGTGACAAGAAGAGAAATCCTCCTCTAT





ATAGGATGCTCTGCTGTTTCCTAAGGATTTTCAGCACCTTGCCCCAAAAT





CAAAATGATGCTTCAACACCCAGGCCAGGTCTCTGCCTCGGAAGTGAGTG





CTTCTGCCATCGTCCCCTGCCTGTCCCCTCCTGGGTCACTGGTGTTTGAG





GATTTTGCTAACCTGACGCCCTTTGTCAAGGAAGAGCTGAGGTTTGCCAT





CCAGAACAAGCACCTCTGCCACCGGATGTCCTCTGCGCTGGAATCAGTCA





CTGTCAGCGACAGACCCCTCGGGGTGTCCATCACAAAAGCCGAGGTAGCC





CCTGAAGAAGATGAAAGGAAAAAGAGGCGACGAGAAAGAAATAAGATTGC





AGCTGCAAAGTGCCGAAACAAGAAGAAGGAGAAGACGGAGTGCCTGCAGA





AAGAGTCGGAGAAGCTGGAAAGTGTGAATGCTGAACTGAAGGCTCAGATT





GAGGAGCTCAAGAACGAGAAGCAGCATTTGATATACATGCTCAACCTTCA





TCGGCCCACGTGTATTGTCCGGGCTCAGAATGGGAGGACTCCAGAAGATG





AGAGAAACCTCTTTATCCAACAGATAAAAGAAGGAACATTGCAGAGCTAA





GCAGTCGTGGTATGGGGGCGACTGGGGAGTCCTCATTGAATCCTCATTTT





ATACCCAAAACCCTGAAGCCATTGGAGAGCTGTCTTCCTGTGTACCTCTA





GAATCCCAGCAGCAGAGAACCATCAAGGCGGGAGGGCCTGCAGTGATTCA





GCAGGCCCTTCCCATTCTGCCCCAGAGTGGGTCTTGGACCAGGGCAAGTG





CATCTTTGCCTCAACTCCAGGATTTAGGCCTTAACACACTGGCCATTCTT





ATGTTCCAGATGGCCCCCAGCTGGTGTCCTGCCCGCCTTTCATCTGGATT





CTACAAAAAACCAGGATGCCCACCGTTAGGATTCAGGCAGCAGTGTCTGT





ACCTCGGGTGGGAGGGATGGGGCCATCTCCTTCACCGTGGCTACCATTGT





CACTCGTAGGGGATGTGGAGTGAGAACAGCATTTAGTGAAGTTGTGCAAC





GGCCAGGGTTGTGCTTTCTAGCAAATATGCTGTTATGTCCAGAAATTGTG





TGTGCAAGAAAACTAGGCAATGTACTCTTCCGATGTTTGTGTCACACAAC





ACTGATGTGACTTTTATATGCTTTTTCTCAGATCTGGTTTCTAAGAGTTT





TGGGGGGCGGGGCTGTCACCACGTGCAGTATCTCAAGATATTCAGGTGGC





CAGAAGAGCTTGTCAGCAAGAGGAGGACAGAATTCTCCCAGCGTTAACAC





AAAATCCATGGGCAGTATGATGGCAGGTCCTCTGTTGCAAACTCAGTTCC





AAAGTCACAGGAAGAAAGCAGAAAGTTCAACTTCCAAAGGGTTAGGACTC





TCCACTCAATGTCTTAGGTCAGGAGTTGTGTCTAGGCTGGAAGAGCCAAA





GAATATTCCATTTTCCTTTCCTTGTGGTTGAAAACCACAGTCAGTGGAGA





GATGTTTGGAAACCACAGTCAGTGGAGCCTGGGTGGTACCCAGGCTTTAG





CATTATTGGATGTCAATAGCATTGTTTTTGTCATGTAGCTGTTTTAAGAA





ATCTGGCCCAGGGTGTTTGCAGCTGTGAGAAGTCACTCACACTGGCCACA





AGGACGCTGGCTACTGTCTATTAAAATTCTGATGTTTCTGTGAAATTCTC





AGAGTGTTTAATTGTACTCAATGGTATCATTACAATTTTCTGTAAGAGAA





AATATTACTTATTTATCCTAGTATTCCTAACCTGTCAGAATAATAAATAT





TGGAACCAAGACATGGTAAACAAAAAAAAAAAAAA. (SEQ ID NO:





308; NM_001030287.3),







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:308 under stringent hybridization conditions


In some embodiments, ETS variant transcription factor 5 (ETV5, ERM) comprises the amino acid sequence:









MDGFYDQQVPFMVPGKSRSEECRGRPVIDRKRKFLDTDLAHDSEELFQDL





SQLQEAWLAEAQVPDDEQFVPDFQSDNLVLHAPPPTKIKRELHSPSSELS





SCSHEQALGANYGEKCLYNYCAYDRKPPSGFKPLTPPTTPLSPTHQNPLF





PPPQATLPTSGHAPAAGPVQGVGPAPAPHSLPEPGPQQQTFAVPRPPHQP





LQMPKMMPENQYPSEQRFQRQLSEPCHPFPPQPGVPGDNRPSYHRQMSEP





IVPAAPPPPQGFKQEYHDPLYEHGVPGMPGPPAHGFQSPMGIKQEPRDYC





VDSEVPNCQSSYMRGGYFSSSHEGFSYEKDPRLYFDDTCVVPERLEGKVK





QEPTMYREGPPYQRRGSLQLWQFLVTLLDDPANAHFIAWTGRGMEFKLIE





PEEVARRWGIQKNRPAMNYDKLSRSLRYYYEKGIMQKVAGERYVYKFVCD





PDALFSMAFPDNQRPFLKAESECHLSEEDTLPLTHFEDSPAYLLDMDRCS





SLPYAEGFAY. (SEQ ID NO: 309; NP_004445.1),







or an amino acid sequence that has at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:309)


In some embodiments, the nucleic acid sequence encoding ETV5 comprises the nucleic acid sequence:










AGAGTCCAGCCGCTGGTGCGCGGAGCGGTTCACCGTCTTCGGAGCGGTTCGGCC






CAGCCTTTCGCCCAGGCGCCCAGGCCCGCTGCGCGCGTGCGTGAGCGCGCCTGC





GCCGCCGGGGCCGCTGCAAGGGGAGGAGAGAGGCCGCCTCAGGAGGATCCCTTT





TCCCCCAGAAATTACTCAATGCTGAAACCTCTCAAAGTGGTATTAGAGACGCTGAAA





GCACCATGGACGGGTTTTATGATCAGCAAGTCCCTTTTATGGTCCCAGGGAAATCT





CGATCTGAGGAATGCAGAGGGCGGCCTGTGATTGACAGAAAGAGGAAGTTTTTGG





ACACAGATCTGGCTCACGATTCTGAAGAGCTATTTCAGGATCTCAGTCAACTTCAAG





AGGCTTGGTTAGCTGAAGCACAAGTTCCTGATGATGAACAGTTTGTCCCAGATTTTC





AGTCTGATAACCTGGTGCTTCATGCCCCACCTCCAACCAAGATCAAACGGGAGCTG





CACAGCCCCTCCTCTGAGCTGTCGTCTTGTAGCCATGAGCAGGCTCTTGGTGCTAA





CTATGGAGAAAAGTGCCTCTACAACTATTGTGCCTATGATAGGAAGCCTCCCTCTG





GGTTCAAGCCATTAACCCCTCCTACAACCCCCCTCTCACCCACCCATCAGAATCCC





CTATTTCCCCCACCTCAGGCAACTCTGCCCACCTCAGGGCATGCCCCTGCAGCTG





GCCCAGTTCAAGGTGTGGGCCCCGCCCCCGCCCCCCATTCGCTTCCAGAGCCTGG





ACCACAGCAGCAAACATTTGCGGTCCCCCGACCACCACATCAGCCCCTGCAGATG





CCAAAGATGATGCCTGAAAACCAGTATCCATCAGAACAGAGATTTCAGAGACAACT





GTCTGAACCCTGCCACCCCTTCCCTCCTCAGCCAGGAGTTCCTGGAGATAATCGCC





CCAGTTACCATCGGCAAATGTCAGAACCTATTGTCCCTGCAGCTCCCCCGCCCCCT





CAGGGATTCAAACAAGAATACCATGACCCACTCTATGAACATGGGGTCCCGGGCAT





GCCAGGGCCCCCAGCACACGGGTTCCAGTCACCAATGGGAATCAAGCAGGAGCCT





CGGGATTACTGCGTCGATTCAGAAGTGCCTAACTGCCAGTCATCCTACATGAGAGG





GGGTTATTTCTCCAGCAGCCATGAAGGTTTTTCATATGAAAAAGATCCCCGATTATA





CTTTGACGACACTTGTGTTGTGCCTGAGAGACTGGAAGGCAAAGTCAAACAGGAGC





CTACCATGTATCGAGAGGGGCCCCCTTACCAGAGGCGAGGTTCCCTTCAGCTGTG





GCAGTTCCTGGTCACCCTTCTTGATGACCCAGCCAATGCCCACTTCATTGCCTGGA





CAGGTCGAGGCATGGAGTTCAAGCTGATAGAACCGGAAGAGGTTGCTCGGCGCTG





GGGCATCCAGAAGAACCGGCCAGCCATGAACTATGACAAGCTGAGCCGCTCTCTC





CGCTATTACTATGAAAAGGGCATCATGCAGAAGGTGGCTGGAGAGCGATACGTCTA





CAAATTTGTCTGTGACCCAGATGCCCTCTTCTCCATGGCTTTCCCGGATAACCAGC





GTCCGTTCCTGAAGGCAGAGTCCGAGTGCCACCTCAGCGAGGAGGACACCCTGCC





GCTGACCCACTTTGAAGACAGCCCCGCTTACCTCCTGGACATGGACCGCTGCAGC





AGCCTCCCCTATGCCGAAGGCTTTGCTTACTAAGTTTCTGAGTGGCGGAGTGGCCA





AACCCTAGAGCTAGCAGTTCCCATTCAGGCAAACAAGGGCAGTGGTTTTGTTTGTG





TTTTTGGTTGTTCCTAAAGCTTGCCCTTTGAGTATTATCTGGAGAACCCAAGCTGTC





TCTGGATTGGCACCCTTAAAGACAGATACATTGGCTGGGGAGTGGGAACAGGGAG





GGGCAGAAAACCACCAAAAGGCCAGTGCCTCAACTCTTGATTCTGATGAGGTTTCT





GGGAAGAGATCAAAATGGAGTCTCCTTACCATGGACAATACATGCAAAGCAATATC





TTGTTCAGGTTAGTACCCGCAAAACGGGACATAGTATGTGACAATCTGCATCGATC





ATGGACTACTAAATGCCTTTACATAGAAGGGCTCTGATTTGCACAATTTGTTGAAAA





ATCACAAACCCATAGAAAAGTAAGTAGGCTAAGTTGGGGAGGCTCAAACCATTAAG





GGTTAAAAATACATCTTAAACATTGGAAAGCTCTTCTAGCTGAATCTGAAATATTACC





CCTTGTCTAGAAAAAGGGGGGCAGTCAGAACAGCTGTTCCCCACTCCGTGGTTCTC





AAAATCATAAACCATGGCTACTCTTGGGAACCACCCGGCCATGTGGTCGCCAAGTA





GAGCAAGCCCCCTTTCTCTTCCCAATCACGTGGCTGAGTGTGGATGACTTTTATTTT





AGGAGAAGGGCGATTAACACTTTTGACAGTATTTTGTTTTGCCCTGATTTGGGGGAT





TGTTTTGTTTTGGTGGTTGTTTTGGAAAAACAGTTTATAAACTGATTTTTGTAGTTTT





GGTATTTAAAGCAAAAAAACGAAAAACAAAAAACAAAAACAAACCTTTTGGTAACTG





TGCACTGTGTCCTTTAGCCAGGGCCGTGCCAACTTATGAAGACACTGCAGCTTGAG





AGGGGCTTTGCTGAGGCTTCCCCTTGGCCATGTGAAAGCCCGCCTTGTTGCCTGC





TTTGTGCTTTCTGCACCAGACAACCTGATGGAACATTTGCACCTGAGTTGTACATTT





TTGAAGTGTGCAGGGCAGCCTGGACACAAGCTTAGATTCTCTATGTATAGTTCCCC





GTGTTCACTAACATGCCCTCTCTGGAAAGCATATGTATATAACATGTGTCATGTCCT





TTGGAAACCTGGTCACCTGGTGAAAACCCTTGGGATTCTTCCCTGGGCATGACTGA





TGACAATTTCCATTTCATCAGTTTGTTTTGTTTTCCTTTTTCTTTAAATCTTGGACTTT





AAACCCTACCTGTGTGATTCAGTAGGGTTTGAGACTTACGTGTGATACTGACAGGT





AAGCAACAGTGCTAGCATTCTAGATTCCTGCCTTTTTTTAAAAAGAAATTATTCTCAT





TGCTGTATTATATTGGAAAAGTTTTAAACAACCAAGCTAAAGCTATGTGAAAGTTGA





GCTCAAAGTAGAGGAAAAGTTACTGGTGGTACCTTGCTGCCTGCTCTGCTGGTAGA





ATTCTGTGCTCCCCGTGACACTTAGTACATTAAGAATGACTACACTGTTCCTCGTAT





GTGAAGGAGGCAGTGCTGACTCCGTGAGTGTGAGACACGTGCTTTGAACTGCTTTT





CTATTCATGGAGCACTCCATAGTCTCAAACTGTCCCCCTTATGACCAACAGCACATT





TGTGAAGAGGTTCGCAGGGATAAGGGGTGCACTTTATAGCTATGGAAACATGAGAT





TCTCCTCTATTGGAAGCTAATTAGCCCACAAAGGTGGTAAACCTGTAGATTGGGCC





TTAATTAGCATTGTACTCTAATCAAAGGACTCTTTCTAAACCATATTTATAGCTTTCTT





AACCTACACATAGTCTATACATAGATGCATATTTTACCCCCAGCTGGCTAGAGATTT





ATTTGTTGTAAATGCTGTATAGATTTGGTTTTCCTTTCTTTACTTACCCTGGTTTGGA





TTTTTTTTTTTTTTCTTTTGAATGGATTTATGCTGTCTTAGCAATATGACAATAATCCT





CTGTAGCTTGAGCTACCCCTCCCCTGCTGTAACTTACGTGACCTGTGCTGTCACTG





GGCATAGGACAGCGGCATCACGGTTGCATTCCCATTGGACTCATGCACCTCCCGG





ATGGTTTTTGTTTTTTTCGGGGGTTCTTTGGGGTTTGTTTGTTTGCTTCTTTTCCAGA





GTGTGGAAAGTCTACAGTGCAGAAAGGCTTGAACCTGCCAGCTGATTTGAAATACT





TTCCCCTGCGCAGGGCCGTATGCATCCTGCCAAGCTGCGTTATATTCTGTACTGTG





TACAATAAAGAAGTTTGCTTTTCGTTTACCAAGCA. (SEQ ID NO: 310; NM_004454.3),







or a nucleic acid sequence that hybridizes to a nucleic acid sequence consisting of SEQ ID NO:310 under stringent hybridization conditions. In order to express a polypeptide or functional nucleic acid, the nucleotide coding sequence may be inserted into appropriate expression vector. Therefore, also disclosed is a non-viral vector comprising a polynucleotide comprising one or more nucleic acid sequences encoding the disclosed transcription factors, wherein the one or more nucleic acid sequences are operably linked to an expression control sequence. In some embodiments, the nucleic acid sequences are operably linked to a single expression control sequence. In other embodiments, the nucleic acid sequences are operably linked to two or more separate expression control sequences. In some embodiments, the non-viral vector comprises a plasmid selected from the group pIRES-hrGFP-21, pAd-IRES-GFP, pCMV6-AC-GFP, and pCDNA3.0.


Methods to construct expression vectors containing genetic sequences and appropriate transcriptional and translational control elements are well known in the art. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. Such techniques are described in Sambrook et al., Molecular Cloning, A Laboratory Manual (Cold Spring Harbor Press, Plainview, N.Y., 1989), and Ausubel et al., Current Protocols in Molecular Biology (John Wiley & Sons, New York, N.Y., 1989).


Expression vectors generally contain regulatory sequences necessary elements for the translation and/or transcription of the inserted coding sequence. For example, the coding sequence is preferably operably linked to a promoter and/or enhancer to help control the expression of the desired gene product.


The “control elements” or “regulatory sequences” are those non-translated regions of the vector—enhancers, promoters, 5′ and 3′ untranslated regions—which interact with host cellular proteins to carry out transcription and translation. Such elements may vary in their strength and specificity.


A “promoter” is generally a sequence or sequences of DNA that function when in a relatively fixed location in regard to the transcription start site. A “promoter” contains core elements required for basic interaction of RNA polymerase and transcription factors and can contain upstream elements and response elements.


“Enhancer” generally refers to a sequence of DNA that functions at no fixed distance from the transcription start site and can be either 5′ or 3′ to the transcription unit. Furthermore, enhancers can be within an intron as well as within the coding sequence itself. They are usually between 10 and 300 bp in length, and they function in cis. Enhancers function to increase transcription from nearby promoters. Enhancers, like promoters, also often contain response elements that mediate the regulation of transcription. Enhancers often determine the regulation of expression.


An “endogenous” enhancer/promoter is one which is naturally linked with a given gene in the genome. An “exogenous” or “heterologous” enhancer/promoter is one which is placed in juxtaposition to a gene by means of genetic manipulation (i.e., molecular biological techniques) such that transcription of that gene is directed by the linked enhancer/promoter.


Promoters used in biotechnology are of different types according to the intended type of control of gene expression. They can be generally divided into constitutive promoters, tissue-specific or development-stage-specific promoters, inducible promoters, and synthetic promoters.


Constitutive promoters direct expression in virtually all tissues and are largely, if not entirely, independent of environmental and developmental factors. As their expression is normally not conditioned by endogenous factors, constitutive promoters are usually active across species and even across kingdoms. Examples of constitutive promoters include CMV, EF1a, SV40, PGK1, Ubc, Human beta actin, and CAG.


Tissue-specific or development-stage-specific promoters direct the expression of a gene in specific tissue(s) or at certain stages of development. For plants, promoter elements that are expressed or affect the expression of genes in the vascular system, photosynthetic tissues, tubers, roots and other vegetative organs, or seeds and other reproductive organs can be found in heterologous systems (e.g. distantly related species or even other kingdoms) but the most specificity is generally achieved with homologous promoters (i.e. from the same species, genus or family). This is probably because the coordinate expression of transcription factors is necessary for regulation of the promoters activity.


The performance of inducible promoters is not conditioned to endogenous factors but to environmental conditions and external stimuli that can be artificially controlled. Within this group, there are promoters modulated by abiotic factors such as light, oxygen levels, heat, cold and wounding. Since some of these factors are difficult to control outside an experimental setting, promoters that respond to chemical compounds, not found naturally in the organism of interest, are of particular interest. Along those lines, promoters that respond to antibiotics, copper, alcohol, steroids, and herbicides, among other compounds, have been adapted and refined to allow the induction of gene activity at will and independently of other biotic or abiotic factors.


The two most commonly used inducible expression systems for research of eukaryote cell biology are named Tet-Off and Tet-On. The Tet-Off system makes use of the tetracycline transactivator (tTA) protein, which is created by fusing one protein, TetR (tetracycline repressor), found in Escherichia coli bacteria, with the activation domain of another protein, VP16, found in the Herpes Simplex Virus. The resulting tTA protein is able to bind to DNA at specific TetO operator sequences. In most Tet-Off systems, several repeats of such TetO sequences are placed upstream of a minimal promoter such as the CMV promoter. The entirety of several TetO sequences with a minimal promoter is called a tetracycline response element (TRE), because it responds to binding of the tetracycline transactivator protein tTA by increased expression of the gene or genes downstream of its promoter. In a Tet-Off system, expression of TRE-controlled genes can be repressed by tetracycline and its derivatives. They bind tTA and render it incapable of binding to TRE sequences, thereby preventing transactivation of TRE-controlled genes. A Tet-On system works similarly, but in the opposite fashion. While in a Tet-Off system, tTA is capable of binding the operator only if not bound to tetracycline or one of its derivatives, such as doxycycline, in a Tet-On system, the rtTA protein is capable of binding the operator only if bound by a tetracycline. Thus the introduction of doxycycline to the system initiates the transcription of the genetic product. The Tet-On system is sometimes preferred over Tet-Off for its faster responsiveness.


In some embodiments, the nucleic acid sequences encoding the disclosed transcription factors are operably linked to the same expression control sequence. Alternatively, internal ribosome entry sites (IRES) elements can be used to create multigene, or polycistronic, messages. IRES elements are able to bypass the ribosome scanning model of 5′ methylated Cap dependent translation and begin translation at internal sites. IRES elements can be linked to heterologous open reading frames. Multiple open reading frames can be transcribed together, each separated by an IRES, creating polycistronic messages. By virtue of the IRES element, each open reading frame is accessible to ribosomes for efficient translation. Multiple genes can be efficiently expressed using a single promoter/enhancer to transcribe a single message.


Disclosed are non-viral vectors containing one or more polynucleotides disclosed herein operably linked to an expression control sequence. Examples of such non-viral vectors include the oligonucleotide alone or in combination with a suitable protein, polysaccharide or lipid formulation. Non-viral methods present certain advantages over viral methods, with simple large scale production and low host immunogenicity being just two. Previously, low levels of transfection and expression of the gene held non-viral methods at a disadvantage; however, recent advances in vector technology have yielded molecules and techniques with transfection efficiencies similar to those of viruses.


Examples of suitable non-viral vectors include, but are not limited to pIRES-hrGFP-2a, pAd-IRES-GFP, and pCDNA3.0.


The compositions disclosed can be used therapeutically in combination with a pharmaceutically acceptable carrier. By “pharmaceutically acceptable” is meant a material that is not biologically or otherwise undesirable, i.e., the material may be administered to a subject, along with the nucleic acid or vector, without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained. The carrier would naturally be selected to minimize any degradation of the active ingredient and to minimize any adverse side effects in the subject, as would be well known to one of skill in the art.


The materials may be in solution, suspension (for example, incorporated into microparticles, liposomes, or cells). These may be targeted to a particular cell type via antibodies, receptors, or receptor ligands. The following references are examples of the use of this technology to target specific proteins to tumor tissue (Senter, et al., Bioconjugate Chem., 2:447-451, (1991); Bagshawe, K. D., Br. J. Cancer, 60:275-281, (1989); Bagshawe, et al., Br. J. Cancer, 58:700-703, (1988); Senter, et al., Bioconjugate Chem., 4:3-9, (1993); Battelli, et al., Cancer Immunol. Immunother., 35:421-425, (1992); Pietersz and McKenzie, Immunolog. Reviews, 129:57-80, (1992); and Roffler, et al., Biochem. Pharmacol, 42:2062-2065, (1991)). Vehicles such as “stealth” and other antibody conjugated liposomes (including lipid mediated drug targeting to colonic carcinoma), receptor mediated targeting of DNA through cell specific ligands, lymphocyte directed tumor targeting, and highly specific therapeutic retroviral targeting of murine glioma cells in vivo. The following references are examples of the use of this technology to target specific proteins to tumor tissue (Hughes et al., Cancer Research, 49:6214-6220, (1989); and Litzinger and Huang, Biochimica et Biophysica Acta, 1104:179-187, (1992)). In general, receptors are involved in pathways of endocytosis, either constitutive or ligand induced. These receptors cluster in clathrin-coated pits, enter the cell via clathrin-coated vesicles, pass through an acidified endosome in which the receptors are sorted, and then either recycle to the cell surface, become stored intracellularly, or are degraded in lysosomes. The internalization pathways serve a variety of functions, such as nutrient uptake, removal of activated proteins, clearance of macromolecules, opportunistic entry of viruses and toxins, dissociation and degradation of ligand, and receptor-level regulation. Many receptors follow more than one intracellular pathway, depending on the cell type, receptor concentration, type of ligand, ligand valency, and ligand concentration. Molecular and cellular mechanisms of receptor-mediated endocytosis has been reviewed (Brown and Greene, DNA and Cell Biology 10:6, 399-409 (1991)).


Suitable carriers and their formulations are described in Remington: The Science and Practice of Pharmacy (19th ed.) ed. A. R. Gennaro, Mack Publishing Company, Easton, Pa. 1995. Typically, an appropriate amount of a pharmaceutically-acceptable salt is used in the formulation to render the formulation isotonic. Examples of the pharmaceutically-acceptable carrier include, but are not limited to, saline, Ringer's solution and dextrose solution. The pH of the solution is preferably from about 5 to about 8, and more preferably from about 7 to about 7.5. Further carriers include sustained release preparations such as semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, liposomes or microparticles. It will be apparent to those persons skilled in the art that certain carriers may be more preferable depending upon, for instance, the route of administration and concentration of composition being administered.


Pharmaceutical carriers are known to those skilled in the art. These most typically would be standard carriers for administration of drugs to humans, including solutions such as sterile water, saline, and buffered solutions at physiological pH. The compositions can be administered intramuscularly or subcutaneously. Other compounds will be administered according to standard procedures used by those skilled in the art.


Pharmaceutical compositions may include carriers, thickeners, diluents, buffers, preservatives, surface active agents and the like in addition to the molecule of choice. Pharmaceutical compositions may also include one or more active ingredients such as antimicrobial agents, antiinflammatory agents, anesthetics, and the like.


Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringers dextrose, dextrose and sodium chloride, lactated Ringers, or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringers dextrose), and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, anti-oxidants, chelating agents, and inert gases and the like.


Formulations for topical administration may include ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.


Compositions for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets, or tablets. Thickeners, flavorings, diluents, emulsifiers, dispersing aids or binders may be desirable.


Some of the compositions may potentially be administered as a pharmaceutically acceptable acid- or base-addition salt, formed by reaction with inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, and phosphoric acid, and organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, and fumaric acid, or by reaction with an inorganic base such as sodium hydroxide, ammonium hydroxide, potassium hydroxide, and organic bases such as mono-, di-, trialkyl and aryl amines and substituted ethanolamines.


The herein disclosed compositions, including pharmaceutical composition, may be administered in a number of ways depending on whether local or systemic treatment is desired, and on the area to be treated. For example, the disclosed compositions can be administered intravenously, intraperitoneally, intramuscularly, subcutaneously, intracavity, or transdermally. The compositions may be administered orally, parenterally (e.g., intravenously), by intramuscular injection, by intraperitoneal injection, transdermally, extracorporeally, ophthalmically, vaginally, rectally, intranasally, topically or the like, including topical intranasal administration or administration by inhalant.


Methods

Also disclosed are methods of reprogramming diseased musculoskeletal cells that involve delivering intracellularly into the somatic cells a polynucleotide comprising one or more nucleic acid sequences encoding the disclosed transcription factors. In some embodiments, the nucleic acid sequences are present in non-viral vectors. In some embodiments, the nucleic acid sequences are operably linked to an expression control sequence. In other embodiments the nucleic acids are operably linked to two or more expression control sequences.


A variety of methods are known in the art and suitable for introduction of nucleic acid into a cell, including viral and non-viral mediated techniques. Examples of typical non-viral mediated techniques include, but are not limited to, electroporation, calcium phosphate mediated transfer, nucleofection, sonoporation, heat shock, magnetofection, liposome mediated transfer, microinjection, microprojectile mediated transfer (nanoparticles), cationic polymer mediated transfer (DEAE-dextran, polyethylenimine, polyethylene glycol (PEG) and the like) or cell fusion.


In some embodiments, after transfecting target cells with the disclosed polynucleotides, the cells can then pack the transfected genes (e.g. cDNA) into EVs, which can then induce endothelium in other somatic cells. Therefore, also disclosed is a method of reprogramming diseased musculoskeletal cells that involves exposing the cells with an extracellular vesicle produced from a cell containing or expressing the disclosed transcription factors.


Therefore, disclosed are methods of reprogramming diseased musculoskeletal cells that involve exposing the cells to extracellular vesicles (EVs) isolated from cells expressing or containing exogenous polynucleotides comprising one or more nucleic acid sequences encoding the disclosed transcription factors. For example, in some embodiments, the donor cells are transfected with the one or more disclosed polynucleotides and cultured in vitro. EVs secreted by the donor cells can then collected from the culture medium. These EVs can then be administered to the diseased musculoskeletal to reprogram them into healthy cells. In some embodiments, the donor cells can be any viable musculoskeletal cells or skin cells, including (but not limited to) NP, AF, CEPs, Articular Chondrocytes, tenocytes, and osteoblasts.


Exosomes and microvesicles are EVs that differ based on their process of biogenesis and biophysical properties, including size and surface protein markers. Exosomes are homogenous small particles ranging from 40 to 150 nm in size and they are normally derived from the endocytic recycling pathway. In endocytosis, endocytic vesicles form at the plasma membrane and fuse to form early endosomes. These mature and become late endosomes where intraluminal vesicles bud off into an intra-vesicular lumen. Instead of fusing with the lysosome, these multivesicular bodies directly fuse with the plasma membrane and release exosomes into the extracellular space. Exosome biogenesis, protein cargo sorting, and release involve the endosomal sorting complex required for transport (ESCRT complex) and other associated proteins such as Alix and Tsg101. In contrast, microvesicles, are produced directly through the outward budding and fission of membrane vesicles from the plasma membrane, and hence, their surface markers are largely dependent on the composition of the membrane of origin. Further, they tend to constitute a larger and more heterogeneous population of extracellular vesicles, ranging from 150 to 1000 nm in diameter. However, both types of vesicles have been shown to deliver functional mRNA, miRNA and proteins to recipient cells.


In some embodiments, the polynucleotides are delivered to the somatic cells, or the donor cells for EVs, intracellularly via a gene gun, a microparticle or nanoparticle suitable for such delivery, transfection by electroporation, three-dimensional nanochannel electroporation, a tissue nanotransfection device, a liposome suitable for such delivery, or a deep-topical tissue nanoelectroinjection device. In some embodiments, a viral vector can be used. However, in other embodiments, the polynucleotides are not delivered virally.


Electroporation is a technique in which an electrical field is applied to cells in order to increase permeability of the cell membrane, allowing cargo (e.g., reprogramming factors) to be introduced into cells. Electroporation is a common technique for introducing foreign DNA into cells.


Tissue nanotransfection allows for direct cytosolic delivery of cargo (e.g., reprogramming factors) into cells by applying a highly intense and focused electric field through arrayed nanochannels, which benignly nanoporates the juxtaposing tissue cell members, and electrophoretically drives cargo into the cells.


In one embodiment, the disclosed compositions are administered in a dose equivalent to parenteral administration of about 0.1 ng to about 100 g per kg of body weight, about 10 ng to about 50 g per kg of body weight, about 100 ng to about 1 g per kg of body weight, from about 1 μg to about 100 mg per kg of body weight, from about 1 μg to about 50 mg per kg of body weight, from about 1 mg to about 500 mg per kg of body weight; and from about 1 mg to about 50 mg per kg of body weight. Alternatively, the amount of the disclosed compositions administered to achieve a therapeutic effective dose is about 0.1 ng, 1 ng, 10 ng, 100 ng, 1 μg, 10 μg, 100 μg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 500 mg per kg of body weight or greater.


In some embodiments, the disclosed compositions and methods are used to create a vasculature that can serve as a scaffolding structure. This scaffolding structure can then be used, for example, to aid in the repair of nerve tissue. Applications of this include peripheral nerve injuries, and pathological/injurious insults to the central nervous system such as traumatic brain injury or stroke. In some embodiments, the created vasculature can be used to nourish composite tissue transplants, or any tissue graft.


In some embodiments, the disclosed compositions and methods are used to convert “unwanted” tissue (e.g., fat, scar tissue) into vasculature. Such newly formed vasculature is expected to “resorb” under non-ischemic conditions.


A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, other embodiments are within the scope of the following claims.


EXAMPLES
Example 1: FOXF1 Transfection for Trans-Differentiation of Diseased Intervertebral Disc Cells into a Healthy Phenotype

Low back pain affects 70-85% of the world's population and is the leading cause of disability worldwide with over $100 billion in medical expenses in the U.S.A Alone. Intervertebral Disc degeneration is a main contributor of low back pain but current therapies do not target the underlying disease.


Such treatments include surgical interventions and medication which can result in non-unions, nerve injuries, ect. Some proposed treatments include tissue engineering, cell therapy, and even injectable hydrogel constructs. However, those treatments are under desired by clinicians and lack mechanical integrity of the IVD.


A native healthy IVD is gelatinous in the middle (Nucleus Pulposus) with surrounding fibers (Annulus Fibrosus). It's the largest avascular organ in the body. However, with aging, increased mechanical loads, and unknown disease pathologies, the disc degenerates. This degeneration has shown to cause pain due to pressure on the spinal cord along with unwarranted neurovascular invasion.


The overarching goal of this technology is to use the combination of transcription factor and TNT/Evs to revert diseased intervertebral disc cells to a healthy phenotype (FIG. 1).


Methods


Transcription factor plasmid expansion via transformation into DH5a E. coli cells, selectivity via ampicillin resistance and plasmid DNA isolated


NP cells isolated from IVD tissue of human patients (n=5) undergoing spinal surgery and cadaveric tissue and expanded in monolayer until 80% confluent.


FOX Family transcription factor or non-transcription factor containing vector (SHAM) transfected in NP cells via bulk electroporation Neon™ Transfection System MPK5000 (V=1425 Volts, t=30 msec, 1 Pulse). Cells expanded and seeded in 2% Agarose Gels (Ø=8 mm, H=4 mm).


Gels taken down for analysis at Day 0, Week 2, and week 4 and analyzed for: cell viability (Live/Dead Assay Calcein/Ethidium), gene expression (qPCR) and Glycosaminoglycan (GAG) content (Dimethyl methylene Blue Assay (DMMB) normalized to DNA (Hoechst Assay).


Mann Whitney statistical tests used to evaluate significance at α=0.05.


Thompson Grading is a standard grade for disc degeneration where 1=healthy and 5=degenerate. Autopsy samples are graded as they do not come directly from diseased tissue. Surgical samples are diseased tissue removed from patients during routine spinal surgery. Table 2 shows human surgical and autopsy NP cells expanded 2 weeks.









TABLE 2







Human autopsy and surgical specimen demographic with level


Thompson grade for Autopsy and level for Surgical








Autopsy
Surgical

















Age




Age



ID
Sex
(years)
Level
Grade
ID
Sex
(years)
Level


















Hu-4
Female
49
L2-L3
2.5
Hs-2
Male
26
L5-S1


Hu-6
Male
45
L2-L3
3
Hs-11
Male
28
L5-S1


Hu-7
Female
56
L2-L3
2.5
Hs-29
Female
70
L5-S1


Hu-9
Female
58
L4-L5
2.5
Hs-34
Female
19
L5-S1


Hu-16
Female
19
L1-L2
1.5
Hs-39
Male
60
L5-S1










FIG. 2 is a schematic of DNA bulk electroporation into NP cells then seeded in Agarose Gel.


Results



FIG. 3 is a graph showing qPCR Gene expression data validating that the transcription factor was successfully transmitted. X-axis=type of tissue and transcription factor. Colors indicate the gene being tested for.



FIG. 4 contains representative viability images (4× Stitched) of Gels at day 0 and 4 Weeks. (Green=Live, Red=Dead).



FIGS. 5A and 5B are graphs showing Brachyury T expression in autopsy (FIG. 5A) and surgical (FIG. 5B) nucleus pulposus cells after sham or FOXF1 treatment. FIGS. 5C and 5D are graphs showing FOXF1 (FIG. 5C) and KRT19 (FIG. 5D) expression in healthy nucleus pulposus cells after sham or FOXF1 treatment.



FIGS. 6A and 6B are graphs showing ACAN (FIG. 6A) and COL2 (FIG. 6B) expression in healthy nucleus pulposus cells after sham or FOXF1 treatment.



FIGS. 7A and 7B are graphs showing NGF expression in autopsy (FIG. 7A) and surgical (FIG. 7B) nucleus pulposus cells after sham or FOXF1 treatment.



FIGS. 8A and 8B are graphs showing IL1-8 expression in autopsy (FIG. 8A) and surgical (FIG. 8B) nucleus pulposus cells after sham or FOXF1 treatment. FIG. 8C is a graph showing IL6 expression in nucleus pulposus cells after sham or FOXF1 treatment.



FIGS. 9A and 9B are graphs showing MMP12 expression in autopsy (FIG. 9A) and surgical (FIG. 9B) nucleus pulposus cells after sham or FOXF1 treatment. FIGS. 9C and 9D are graphs showing MMP13 expression in autopsy (FIG. 9C) and surgical (FIG. 9D) nucleus pulposus cells after sham or FOXF1 treatment.



FIGS. 10A and 10B are bar graphs showing GAG content in autopsy (FIG. 10A) and surgical (FIG. 10B) nucleus pulposus cells after sham or FOXF1 treatment.


CONCLUSION

This study demonstrates: (i) the ability to transfect degenerate cells using bulk electroporation, (ii) transfected cell maintained viability over 4 weeks of culture in 3D constructs, (iii) introduction of FOX family gene into the cytosolic environment of the cell induces proteoglycan (GAG) production critical for IVD function and (iv) inhibition of inflammatory and neuron growth factor.


Example 2: Non-Viral Transfection of Human Intervertebral Disc Cells with Developmental Factors Induces Reprogramming to a Healthy Anti-Catabolic/Inflammatory Phenotype with Enhanced Extracellular Matrix Accumulation

Low back pain (LBP) is the leading cause of disability worldwide with an associated socioeconomic burden of over $100 billion annually in the U.S alone [Katz, J. et al, 2006]. Intervertebral disc (IVD) degeneration is a major contributor to LBP and is characterized by decreases in cellularity and proteoglycan synthesis, upregulation of matrix degrading enzymes (MMPs), and increases in pro-inflammatory factors with neurovascular invasion[Rodriques-Pinto R. et al, 2014; Freemont A. J. et al, 2009]. Current treatment strategies are highly invasive and fail to target the underlying pathology or promote tissue repair. Pro-anabolic approaches have been proposed which includes gene therapy through viral infection, but this has raised safety concerns due to mutagenesis and unwarranted immune responses. To avoid such safety risks, electroporation of plasmids carrying DNA for transcription factors can be introduced into endogenous cells without alteration of native DNA to stimulate IVD repair. The transcription factor, Brachyury (BrachT), is expressed in the developing notochord and is associated with maintaining a healthy immature nucleus pulposus (NP) phenotype [Vujovic, S. et al, 2006; Tang, R. et al, 2018]. As disclosed herein, delivery of BrachT into degenerate human IVD cells can reprogram diseased NP cells into healthy cells with increased proteoglycan and decreased inflammatory, catabolic and pain associated factors which are critical for maintaining the structure and function of the healthy IVD. Thus, the overall objective of this study was to examine the effects of BrachT transfection on human NP cell phenotype and function.


Methods


BrachT transcription factor plasmids (OriGene Tech, Cat: SC303281) were expanded via transformation into DH5a E. coli cells with ampicillin resistance and plasmid DNA isolated for downstream electroporation. Human NP cells were isolated from non-degenerate (ND) cadaveric IVDs from autopsy (n=5, 19-58 y.o) or from the painful-degenerate (PD) IVD tissue of human patients with back pain (n=5, 19-70 y.o, IRB: 2015H0385) undergoing microdiscectomy (2 mg/mL Pronase-1 hour, 2 mg/mL Collagenase 11-4 hours). NP cells were expanded in monolayer (p2) until 80% confluent before bulk electroporation with empty plasmids (SHAM) or BrachT plasmids via Neon™ Transfection System MPK5000 (V=1425 Volts, t=30 msec, 1 Pulse). Successful transfection was verified with RT-qPCR at 48 hours. Transfected cells were then expanded in disc cell media (High glucose DMEM, 10% FBS, 1% P/S, 50 μg/ml ascorbic acid fresh) and seeded in 2% 3D agarose gel constructs at 20E6 cells/mL. Dependent variables were examined at day 0, week 2 and week 4 for cell viability (Calcein/Ethidium staining), extracellular matrix, phenotypic marker and inflammatory/catabolic gene expression (RT-qPCR) and proteoglycan/GAG content (Dimethylmethylene Blue Assay with DNA/Hoechst normalization). Non-parametric statistical tests were used (Mann-Whitney Tests, α=0.05).


Results


Cell viability remained high for all groups and BrachT gene expression was maintained over 4 weeks in both ND and PD cells with a decline in PD cells at week 4 only (fold change >100).


Expression of NP marker KRT19 was significantly increased in BrachT transfected PD cells at 2 weeks compared to SHAM controls while ND cells showed significant increases at all time-points (FIGS. 11A and 11B, p<0.05).


Expression of matrix protein ACAN was increased at 2 weeks in transfected ND and PD cells (significant for PD cells) with significant decreases at 4 weeks for both groups (FIGS. 12A and 12B).


Expression of MMP13 was significantly decreased in transfected ND cells at all time points and demonstrated a significant decrease at week 4 for transfected PD cells (FIGS. 13A and 13B).


Pro-inflammatory cytokines IL-1β (FIGS. 14A and 14B) and IL-6 (FIGS. 15A and 15B) demonstrated decreased expression at 2 weeks for transfected ND samples but showed an initial increase for transfected PD samples that decreased with time.


Nerve growth factor (NGF) showed a significant decrease in expression at week 2 for transfected PD cells but significant decreases at 2 and 4 weeks in transfected ND cells (FIGS. 16A and 16B).


PD cells demonstrated a significant increase in GAG content in BrachT transfected groups at 2 weeks compared to their respective SHAM and this was observed to a lesser extent at week 4 (FIGS. 17A and 17B). Autopsy samples demonstrated an increase in GAG at 4 weeks in SHAM groups with no significant differences in BrachT transfected groups.


DISCUSSION

These results demonstrate that human NP cells can be successfully transfected with transcription factor BrachT and reprogrammed to a healthy NP phenotype with up-regulation of key phenotypic markers, enhanced proteoglycan synthesis and down-regulation of inflammatory, catabolic and pain-related markers. High expression of BrachT was maintained over 4 weeks in 3D culture without any detrimental effects on cell viability. ND cells transfected with BrachT demonstrated increases in gene expression for healthy NP marker KRT19, decreases in MMP13 suggesting a decrease in catabolism, decreases in pro-inflammatory and pain genes IL-1β, IL-6, and NGF which all suggest reprogramming towards a ‘healthier’ IVD phenotype. While similar effects were observed in PD cells this was considered more temporal with peak anabolic effects observed at 2 weeks. Temporal effects suggest further optimization of the delivery system as bulk electroporation involves disruption of the cellular membrane and is less efficient compared to techniques such as engineered vesicles or tissue nanotransfection [Gallego-Perez et al, 2017]. The same temporal effects are seen at week 2 in GAG content with significant increases in GAG compared to the SHAM group at 2 weeks only. In conclusion, this study demonstrated the potential of BrachT to promote a healthy IVD phenotype via transfection into human ND and PD NP cells with increased GAG accumulation.


This is the first study to demonstrate successful reprogramming of diseased human NP cells into healthy NP cells using non-viral transfection of transcription factor BrachT. Further development of this treatment in conjunction with novel, minimally invasive tissue nanotransfection methods has high potential as a regenerative strategy for the treatment of LBP and other musculoskeletal diseases.


Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of skill in the art to which the disclosed invention belongs. Publications cited herein and the materials for which they are cited are specifically incorporated by reference.


Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.


Example 3: Extracellular Vesicle Delivery of Transcription Factors to Reprogram Cells In-Vitro

Methods:


FOXF1 plasmids were expanded and transfected into NP as in cells with culture media collected at 48 hours and extracellular vesicles isolated (Total exosome Isolation Kit). Exosomes were introduced to separate NP cells in monolayer with FOXF1 gene expression assessed at 2 and 7 days. Non-parametric statistical tests were used (Mann-Whitney Tests, α=0.05).


Results: When human EVs labelled with membrane dye PKH26 (red) were incubated with human NP cells in-vitro, uptake of labelled EVs was observed for SHAM and FOXF1 groups (FIG. 19A). In addition, >1000 fold increases in FOXF1 gene expression in FOXF1-EVs compared to SHAM-EVs was also observed. When human NP cells were treated with FOXF1-EVs they demonstrated significant upregulation of FOXF1 at both 2 and 7 days in culture compared to SHAM-EV controls (FIG. 18B,C) Conclusion:


Tagged EVs showed high efficiency in microscopic images and high expression of FOXF1 gene packaged within EVs. Significant upregulation of FOXF1 in FOXF1 EV treated cells implies successful transfection of NP cells using generated EVs. This study demonstrated the potential of FOXF1 to promote a healthy IVD phenotype via transfection into degenerate human NP cells using EVs as a delivery mechanism.


Example 4: Extracellular Vesicle Delivery of Transcription Factors to Reprogram Cells In-Vivo

Method: EVs were generated as before and injected into mice lumbar intervertebral disc in-vivo and accessed for 7 days (N=3). In an ongoing study, mice discs were punctured and will be accessed biweekly over 12 and 24 weeks.


Results: Viability staining of Mouse disc showed no cytotoxicity compared to non-injected control discs and injected discs showed upregulation of FOXF1 along with healthy NP marker brachyury (FIG. 20)


Conclusion: This experiment shows the non-cytotoxic effects of transcription factor delivery via EVs and that the transcription factor successfully integrates into the intervertebral disc space along with upregulation of a healthy marker that was not Injected into the disc. Furthermore, ongoing studies show behavioral differences between injured untreated mice compared to foxfl treated mice as seen in FIG. 21 where treated mice exhibit longer grip time (indicative of axial strength) compared to injured groups.

Claims
  • 1. A method for treating a musculoskeletal disease in a subject, comprising (a) non-virally delivering intracellularly into musculoskeletal cells of the subject one or more transcription factor proteins selected from the group comprising HIF-1α, HIF-2α, T-box family protein, a Forkhead-box (FOX) family protein, a Mohawk family protein, Scleraxis, NFAT Family protein, C-1-1, PGC1α, Osterix, MEF2C, Sonic hedgehog pathway protein, PAX family protein, SOX family protein, notochord homeobox, Tenomodulin, Nkx3-2, RUNX2, API family proteins, Afp36, Ebf family proteins, MAF, NUPR1, Twist family protein, MAGED1, SATB2, LMP3, Oct family protein, Dlx family proteins, C/ECPs, ATF family proteins, SMADs, MEN family proteins, MSX family proteins, NF-1, SP3, Ob1, EGR family proteins, SIX family proteins, EYA family proteins, PEA3, BCL6, Myo family Proteins, CSFR pathway proteins, SRG, GLI2, Sp4, ATF family proteins, ETV family proteins, and REST or polynucleotides encoding the one or more transcription factor proteins;(b) exposing the musculoskeletal cells to an extracellular vesicle produced from a cell containing or expressing the one or more transcription factor proteins, or polynucleotides encoding the one or more transcription factor proteins.
  • 2. The method of claim 1, wherein the musculoskeletal cells comprises diseased nucleus pulposus (NP) cells, and wherein the one or more transcription factor proteins comprises HIF-1α, HIF-2α, a T-box family protein, a Sonic Hedgehod signalong pathway, PAX1, SOX family protein, NOTO, a Forkhead-box (FOX) family protein, or any combination thereof.
  • 3. The method of claim 1, wherein the musculoskeletal cells comprises annulus fibrosis (AF) cells, and wherein the one or more transcription factor proteins comprises a Mohawk family protein, Tenomodulin, PAX9, Scleraxis, or any combination thereof.
  • 4. The method of claim 1, wherein the musculoskeletal cells comprises cartilage endplate cells, and wherein the one or more transcription factor proteins comprises NFAT Family protein, C-1-1, PGC1α, Osterix, SOX family protein, Nkx3-2, MEF2C, or any combination thereof.
  • 5. The method of claim 1, wherein the musculoskeletal cells comprises Osteocytes, Osteoclasts, Osteoblasts, and wherein the one or more transcription factor proteins comprises RUNX2, Fox family proteins, API complex proteins, Afp36, Ebf famil proteins, Naf, Nef2c, Twist family proteins, MAGED1, SATB2, LMP3, OCT family proteins, KLF4, MYC, DLX family proteins, C/EBPs, ATF family proteins, NFATc, SMADS, Menin, Msx family proteins, SP3, Ob-1, NF-1, or any combination thereof.
  • 6. The method of claim 1, wherein the musculoskeletal cells comprises Tenocytes and Ligament cells, and wherein the one or more transcription factor proteins comprises EGR family proteins, Scleraxis, NKx, SIX family proteins, EYA family proteins, PEA3 and Mohawk.
  • 7. The method of claim 1, wherein the musculoskeletal cells comprises Synoviocytes, and wherein the one or more transcription factor proteins comprises SOX family proteins, NFAT5, BCL-6, HIF-1a, and HIF-2a.
  • 8. The method of claim 1, wherein the musculoskeletal cells comprises Monocytes and Myofibroblasts, and wherein the one or more transcription factor proteins comprises Myo family proteins, PU.1, CSFR Pathway proteins, EBPA, SRF, GLI2
  • 9. The method of claim 1, wherein the musculoskeletal cells comprises Dorsal Root Ganglion Cells, and wherein the one or more transcription factor proteins comprises FOXO, SP4, ATF family proteins, ETV family proteins, SOX11, REST, RUNX1, and RUNX3.
  • 10. A non-viral vector comprising a polynucleotide comprising a nucleic acid sequence encoding two or more transcription factors selected from the group comprising Forkhead-box (FOX) family protein, a Mohawk family protein, Scleraxis, NFAT Family protein, C-1-1, PGC1α, Osterix, and MEF2C, and factors from Table 1 operably linked to an expression control sequence, wherein the non-viral vector is encapsulated in a liposome, microparticle, or nanoparticle suitable for intracellular delivery.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims benefit of U.S. Provisional Application No. 62/782,734, filed Dec. 20, 2018, which is hereby incorporated herein by reference in its entirety.

PCT Information
Filing Document Filing Date Country Kind
PCT/US2019/067448 12/19/2019 WO 00
Provisional Applications (1)
Number Date Country
62782734 Dec 2018 US